PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chow, CW; Rincon, M; Cavanagh, J; Dickens, M; Davis, RJ				Chow, CW; Rincon, M; Cavanagh, J; Dickens, M; Davis, RJ			Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway	SCIENCE			English	Article							KINASE; FAMILY; MORPHOGENESIS; CALCINEURIN; ACTIVATION; DROSOPHILA; INDUCTION; RECEPTOR; DOMAIN; MEMBER	The nuclear factor of activated T cells (NFAT) group of transcription factors is retained in the cytoplasm of quiescent cells, NFAT activation is mediated in part, by induced nuclear import, This process requires calcium-dependent dephosphorylation of NFAT caused by the phosphatase calcineurin, The c-Jun amino-terminal kinase (JNK) phosphorylates NFAT4 on two sites, Mutational removal of the JNK phosphorylation sites caused constitutive nuclear localization of NFAT4, in contrast, JNK activation in calcineurin-stimulated cells caused nuclear exclusion of NFAT4. These findings show that the nuclear accumulation of NFAT4 promoted by calcineurin is opposed by the JNK signal transduction pathway.	UNIV MASSACHUSETTS, SCH MED,HOWARD HUGHES MED INST,PROGRAM MOL MED, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01605 USA; UNIV VERMONT, DEPT MED, PROGRAM IMMUNOBIOL, BURLINGTON, VT 05405 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Vermont			Dickens, Martin/B-2001-2012		NCI NIH HHS [CA58396, CA65831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHOW CW, UNPUB; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; RAPP UR, 1994, ONCOGENE, V9, P3493; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	28	297	305	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 28	1997	278	5343					1638	1641		10.1126/science.278.5343.1638	http://dx.doi.org/10.1126/science.278.5343.1638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374467				2022-12-28	WOS:A1997YJ87400046
J	Furberg, CD; Psaty, BM				Furberg, CD; Psaty, BM			JNC VI: Timing is everything	LANCET			English	Editorial Material									UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Furberg, CD (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27109, USA.							Byington RP, 1997, LANCET, V350, P1075, DOI 10.1016/S0140-6736(05)70455-4; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Garber AM, 1997, CIRCULATION, V95, P1642; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; *JOINT NAT COMM DE, IN PRESS ARCH INTERN; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; PEARCE KA, 1997, IN PRESS AM J HYPERT; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TATTI P, 1997, CIRCULATION S, V96	10	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1413	1414		10.1016/S0140-6736(05)64202-X	http://dx.doi.org/10.1016/S0140-6736(05)64202-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371160				2022-12-28	WOS:A1997YF95300003
J	Yarnold, J				Yarnold, J			Benefits of post-mastectomy radiotherapy	LANCET			English	Editorial Material							BREAST-CANCER; TRIALS				Yarnold, J (corresponding author), INST CANC RES,DEPT RADIOTHERAPY,SUTTON SM2 5PT,SURREY,ENGLAND.			Yarnold, John/0000-0002-9010-1854				AUQUIER A, 1992, EUR J CANCER, V28A, P433, DOI 10.1016/S0959-8049(05)80070-X; CUZICK J, 1987, CANCER TREAT REP, V71, P15; *EARL BREAST CANC, 1995, NEW ENGL J MED, V333, P1444; *EARL BREAST CANC, 1996, NEW ENGL J MED, V334, P1003; FISHER B, 1980, CANCER-AM CANCER SOC, V46, P1009, DOI 10.1002/1097-0142(19800815)46:4+<1009::AID-CNCR2820461326>3.0.CO;2-H; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402	7	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1415	1416		10.1016/S0140-6736(05)64204-3	http://dx.doi.org/10.1016/S0140-6736(05)64204-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371162				2022-12-28	WOS:A1997YF95300005
J	Prigge, ST; Kolhekar, AS; Eipper, BA; Mains, RE; Amzel, LM				Prigge, ST; Kolhekar, AS; Eipper, BA; Mains, RE; Amzel, LM			Amidation of bioactive peptides: The structure of peptidylglycine alpha-hydroxylating monooxygenase	SCIENCE			English	Article							DOPAMINE-BETA-HYDROXYLASE; ENZYME-BOUND COPPER; MACROMOLECULAR STRUCTURES; PROTEIN; SITE; STEREOCHEMISTRY; IDENTIFICATION; BIOSYNTHESIS; INTERMEDIATE; SPECTROSCOPY	Many neuropeptides and peptide hormones require amidation at the carboxyl terminus for activity. Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the amidation of these diverse physiological regulators. The amino-terminal domain of the bifunctional PAM protein is a peptidylglycine alpha-hydroxylating monooxygenase (PHM) with two coppers that cycle through cupric and cuprous oxidation states. The anomalous signal of the endogenous coppers was used to determine the structure of the catalytic core of oxidized rat PHM with and without bound peptide substrate. These structures strongly suggest that the PHM reaction proceeds via activation of substrate by a copper-bound oxygen species. The mechanistic and structural insight gained from the PHM structures can be directly extended to dopamine beta-monooxygenase.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Prigge, Sean/GVS-9197-2022	Prigge, Sean/0000-0001-9684-1733; Amzel, L. Mario/0000-0002-0129-9572	NIDDK NIH HHS [DK32949] Funding Source: Medline; NIGMS NIH HHS [GM44692] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032949, R37DK032949, R56DK032949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044692] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BATTERSBY AR, 1976, J CHEM SOC PERK T 1, P1056, DOI 10.1039/p19760001056; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Boswell JS, 1996, BIOCHEMISTRY-US, V35, P12241, DOI 10.1021/bi960742y; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; EVANS SV, 1993, J MOL GRAPHICS, V11, P268; FITZPATRICK PF, 1986, J BIOL CHEM, V261, P4510; FREEMAN JC, 1993, J AM CHEM SOC, V115, P4923, DOI 10.1021/ja00064a077; Grimmelikhuijzen CJP, 1996, INT REV CYTOL, V167, P37, DOI 10.1016/S0074-7696(08)61345-5; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P4541, DOI 10.1021/bi00471a006; KIZER JS, 1986, ENDOCRINOLOGY, V118, P2262, DOI 10.1210/endo-118-6-2262; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MERKLER DJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P93, DOI 10.1006/abbi.1995.1140; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; MILLER SM, 1985, BIOCHEMISTRY-US, V24, P2114, DOI 10.1021/bi00330a004; NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007; NEWTON MD, 1997, J ELECTROANAL CHEM, V5025, P1; NOGUCHI M, 1992, BIOCHEM J, V283, P883, DOI 10.1042/bj2830883; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PING DS, 1992, J AM CHEM SOC, V114, P3998, DOI 10.1021/ja00036a071; RAMER SE, 1988, J AM CHEM SOC, V110, P8526, DOI 10.1021/ja00233a032; REEDY BJ, 1994, J AM CHEM SOC, V116, P1924, DOI 10.1021/ja00084a037; SCOTT RA, 1988, BIOCHEMISTRY-US, V27, P5411, DOI 10.1021/bi00415a005; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; SUZUKI K, 1993, EUR J BIOCHEM, V213, P93, DOI 10.1111/j.1432-1033.1993.tb17738.x; Yonekura H, 1996, BIOCHEM BIOPH RES CO, V218, P495, DOI 10.1006/bbrc.1996.0088; ZABRISKIE TM, 1991, J CHEM SOC CHEM COMM, P571, DOI 10.1039/c39910000571	40	291	293	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1300	1305		10.1126/science.278.5341.1300	http://dx.doi.org/10.1126/science.278.5341.1300			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360928				2022-12-28	WOS:A1997YG04300047
J	Johnston, C				Johnston, C			Cervical adenocarcinoma in situ: a persistent clinical dilemma	LANCET			English	Editorial Material							UTERINE CERVIX; IN-SITU; INSITU; CONIZATION; MANAGEMENT				Johnston, C (corresponding author), UNIV MICHIGAN,MED CTR,DEPT OBSTET & GYNAECOL,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.							AYER B, 1987, ACTA CYTOL, V31, P397; BERTRAND M, 1987, AM J OBSTET GYNECOL, V157, P21, DOI 10.1016/S0002-9378(87)80338-1; CULLIMORE JE, 1992, BRIT J OBSTET GYNAEC, V99, P314, DOI 10.1111/j.1471-0528.1992.tb13730.x; Denehy TR, 1997, OBSTET GYNECOL, V90, P1, DOI 10.1016/S0029-7844(97)00122-1; HOPKINS MP, 1988, OBSTET GYNECOL, V71, P842; IM DD, 1995, GYNECOL ONCOL, V59, P179; MUNTZ HG, 1992, OBSTET GYNECOL, V80, P935; NICKLIN JL, 1991, AUST NZ J OBSTET GYN, V31, P179, DOI 10.1111/j.1479-828X.1991.tb01814.x; POYNOR EA, 1995, GYNECOL ONCOL, V57, P158, DOI 10.1006/gyno.1995.1118; WILDRICH T, 1996, GYNECOL ONCOL, V61, P304	10	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1337	1338		10.1016/S0140-6736(05)65129-X	http://dx.doi.org/10.1016/S0140-6736(05)65129-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365443				2022-12-28	WOS:A1997YE87200003
J	Levine, MM; Levine, OS				Levine, MM; Levine, OS			Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use	LANCET			English	Article							ENTERIC-COATED CAPSULES; ORAL CHOLERA VACCINE; CONJUGATE VACCINE; FIELD TRIAL; PNEUMOCOCCAL DISEASE; PROTECTIVE EFFICACY; ESCHERICHIA-COLI; RURAL BANGLADESH; TYPHOID VACCINE; SEROGROUP	The development, implementation, and continued use of new vaccines depends on several factors. Although disease burden seems like an obvious quantitative measure for setting priorities for new vaccine development and use, resources are not always allocated proportionately. This is particularly evident for diseases that are unique (or largely limited) to people in developing countries. Public pressure based on perceptions of the risks associated with a disease or vaccine, the cost of new vaccines, and the ability to incorporate them into existing vaccination programmes also need to be considered in the decision to introduce new vaccines. Vaccine manufacturers play an important part in development of new vaccines, and therefore, the issues that are important to them, namely, production, intellectual property rights, and product liability, must be addressed. By advocating rational decisions, supported by accurate information, scientists and public-health professionals can have an important role in transforming the potential of new vaccines into the reality of new vaccine-preventable diseases.	CTR DIS CONTROL & PREVENT, RESP DIS BRANCHE, DIV BACTERIAL & MYCOT DIS, NATL CTR INFECT DIS, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	Levine, MM (corresponding author), UNIV MARYLAND, SCH MED, CTR VACCINE DEV, BALTIMORE, MD 21201 USA.							Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; BATSON A, 1994, VACCINE, V12, P963, DOI 10.1016/0264-410X(94)90328-X; BERNIER RH, 1984, REV INFECT DIS, V6, pS371; BLACK RE, 1980, J INFECT DIS, V142, P660, DOI 10.1093/infdis/142.5.660; BLACK RE, 1989, AM J EPIDEMIOL, V129, P785, DOI 10.1093/oxfordjournals.aje.a115193; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; *COMM ISS PRIOR NE, 1985, NEW VACC DEV EST PRI, V2; *COMM ISS PRIOR NE, 1985, NEW VACC DEV EST PRI, V1; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; DEMORAES JC, 1992, LANCET, V340, P1074; Douglas R G Jr, 1994, Curr Clin Top Infect Dis, V14, P192; EDELMAN R, 1997, NEW GENERATION VACCI, P897; FERRECCIO C, 1989, J INFECT DIS, V159, P766, DOI 10.1093/infdis/159.4.766; FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075; Guibourdenche M, 1996, EPIDEMIOL INFECT, V116, P115, DOI 10.1017/S095026880005233X; GUPTA A, 1994, PEDIATR INFECT DIS J, V13, P134, DOI 10.1097/00006454-199402000-00011; Lagos R, 1996, PEDIATR INFECT DIS J, V15, P216, DOI 10.1097/00006454-199603000-00008; Lanata CF, 1996, J INFECT DIS, V174, P268, DOI 10.1093/infdis/174.2.268; LEVINE MM, 1993, AM J EPIDEMIOL, V138, P849, DOI 10.1093/oxfordjournals.aje.a116788; LEVINE MM, 1990, LANCET, V336, P891; LEVINE MM, 1989, PEDIATR INFECT DIS J, V8, P374, DOI 10.1097/00006454-198906000-00010; Levine MM, 1995, B I PASTEUR, V93, P243, DOI 10.1016/0020-2452(96)85758-7; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; Miller MA, 1996, JAMA-J AM MED ASSOC, V276, P967, DOI 10.1001/jama.276.12.967; NAIR GB, 1994, J INFECT DIS, V169, P1029, DOI 10.1093/infdis/169.5.1029; ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010; POLLARD R, 1980, LANCET, V1, P1180; ROBBINS A, 1993, PEDIATR INFECT DIS J, V12, P523, DOI 10.1097/00006454-199306000-00012; ROMANUS V, 1987, PEDIATR INFECT DIS J, V6, P364, DOI 10.1097/00006454-198704000-00005; RYDER RW, 1976, LANCET, V1, P659; SCHONBERGER LB, 1976, AM J EPIDEMIOL, V104, P202, DOI 10.1093/oxfordjournals.aje.a112290; SENCER DJ, 1967, PUBLIC HEALTH REP, V82, P253, DOI 10.2307/4592985; SNIADACK DH, 1995, PEDIATR INFECT DIS J, V14, P503, DOI 10.1097/00006454-199506000-00007; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; TACKET CO, 1992, J INFECT DIS, V166, P837, DOI 10.1093/infdis/166.4.837; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; WENGER JD, 1997, HAEMOPHILUS INFLUENZ, P489; *WHO, 1996, UN CHILDR FUND STAT; Zangwill KM, 1996, J INFECT DIS, V174, P752, DOI 10.1093/infdis/174.4.752	41	44	44	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	1997	350	9088					1386	1392		10.1016/S0140-6736(97)03253-4	http://dx.doi.org/10.1016/S0140-6736(97)03253-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365466				2022-12-28	WOS:A1997YE87200048
J	Skov, L; Clemmensen, O; Baadsgaard, O				Skov, L; Clemmensen, O; Baadsgaard, O			Thin cutaneous malignant melanoma and the MIN terminology	LANCET			English	Editorial Material							CRITERIA		ODENSE UNIV HOSP,DEPT DERMATOL,DK-5000 ODENSE,DENMARK	University of Southern Denmark; Odense University Hospital	Skov, L (corresponding author), UNIV COPENHAGEN,GENTOFTE HOSP,DEPT DERMATOL,DK-2900 HELLERUP,DENMARK.		Skov, Lone/W-3575-2018	Skov, Lone/0000-0002-4784-9680				Cook MG, 1996, HISTOPATHOLOGY, V28, P497, DOI 10.1046/j.1365-2559.1996.d01-464.x; *CRC MEL PATH PAN, 1997, J CLIN PATHOL, V50, P202; DEWIT PEJ, 1993, EUR J CANCER, V29A, P831, DOI 10.1016/S0959-8049(05)80419-8; Farmer ER, 1996, HUM PATHOL, V27, P528, DOI 10.1016/S0046-8177(96)90157-4; HASTRUP N, 1994, HISTOPATHOLOGY, V24, P503; THORN M, 1994, BRIT J CANCER, V70, P743, DOI 10.1038/bjc.1994.388	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1264	1265		10.1016/S0140-6736(05)62469-5	http://dx.doi.org/10.1016/S0140-6736(05)62469-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357402				2022-12-28	WOS:A1997YD68900004
J	Thel, MC; Armstrong, AL; McNulty, SE; Califf, RM; OConnor, CM				Thel, MC; Armstrong, AL; McNulty, SE; Califf, RM; OConnor, CM			Randomised trial of magnesium in in-hospital cardiac arrest	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; INTRAVENOUS-MAGNESIUM; CARDIOPULMONARY-RESUSCITATION; CALCIUM BLOCKERS; SULFATE; SURVIVAL	Background The apparent benefit of magnesium in acute myocardial infarction, and the persistently poor outcome after cardiac arrest, have led to use of magnesium in cardiopulmonary resuscitation. Because few data on its use in cardiac arrest were available, we undertook a randomised placebo-controlled trial (MAGIC trial). Methods Patients treated for cardiac arrest by the Duke Hospital code team were randomly assigned intravenous magnesium (2 g [8 mmoles] bolus, followed by 8 g [32 mmoles] over 24 h; 76 patients) or placebo (80 patients). Only patients in intensive care or general wards were eligible; those whose cardiac arrest occurred in emergency, operating, or recovery rooms were excluded. The primary endpoint was return of spontaneous circulation, defined as attainment of any measurable blood pressure or palpable pulse for at least 1 h after cardiac arrest. The secondary endpoints were survival to 24 h, survival to hospital discharge, and neurological outcome. Analysis was by intention to treat. Findings There were no significant differences between the magnesium and placebo groups in the proportion with return of spontaneous circulation (41 [54%] vs 48 [60%], p=0.44), survival to 24 h (33 [43%] vs 40 [50%], p=0.41), survival to hospital discharge (16 [21%] vs 17 [21%], p=0.98), or Glasgow coma score (median 15 in both). Interpretation Empirical magnesium supplementation did not improve the rate of successful resuscitation, survival to 24 h, or survival to hospital discharge overall or in any subpopulation of patients with in-hospital cardiac arrest.	DUKE UNIV,MED CTR,DEPT INTERNAL MED,DUKE CLIN RES INST,DIV CARDIOL,DURHAM,NC 27710	Duke University								*AHA, 1992, JAMA-J AM MED ASSOC, V268, P2171; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; CASAGRANDE JT, 1978, BIOMETRICS, V34, P482; CASPI J, 1995, ANN THORAC SURG, V59, P942, DOI 10.1016/0003-4975(95)00050-U; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; *DEP HLTH HUM SERV, 1995, FED REGISTER, V60, P49086; EISENBERG MS, 1991, AM J EMERG MED, V9, P544, DOI 10.1016/0735-6757(91)90108-V; GETTES LS, 1992, CIRCULATION S1, V85, P170; HAMBURG RS, 1995, CIRCULATION, V92, P149, DOI 10.1161/01.CIR.92.2.149; HILTON TC, 1992, CLIN CARDIOL, V15, P176, DOI 10.1002/clc.4960150308; HORNER SM, 1992, CIRCULATION, V86, P774, DOI 10.1161/01.CIR.86.3.774; *ISIS 4, 1995, LANCET, V345, P669; JAFFE AS, 1993, NEUROLOGY, V43, P2173, DOI 10.1212/WNL.43.11.2173; KARMYJONES R, 1995, ANN THORAC SURG, V59, P502, DOI 10.1016/0003-4975(94)00895-E; Karnofsky D, 1949, EVALUATION CHEMOTHER, P196; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; MILLER B, 1995, RESUSCITATION, V30, P3, DOI 10.1016/0300-9572(95)00868-T; ROFFE C, 1994, BRIT HEART J, V71, P141; SACK JB, 1992, CIRCULATION, V86, P1692, DOI 10.1161/01.CIR.86.6.1692; SAKLAYEN M, 1995, MEDICINE, V74, P163, DOI 10.1097/00005792-199507000-00001; Schneider A P 2nd, 1993, J Am Board Fam Pract, V6, P91; SCHWARTZ AC, 1985, AM J EMERG MED, V3, P1, DOI 10.1016/0735-6757(85)90002-6; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; STIELL IG, 1995, ACAD EMERG MED, V2, P264, DOI 10.1111/j.1553-2712.1995.tb03220.x; SUETA CA, 1994, CIRCULATION, V89, P660, DOI 10.1161/01.CIR.89.2.660; TEASDALE G, 1974, LANCET, V2, P81; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; Thel MC, 1995, CORONARY ARTERY DIS, V6, P831, DOI 10.1097/00019501-199510000-00012; THEL MC, 1993, J AM COLL CARDIOL, V21, pA104; WHITE BC, 1983, J TRAUMA, V23, P788, DOI 10.1097/00005373-198309000-00003; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; WOODS KL, 1991, BRIT J CLIN PHARMACO, V32, P3, DOI 10.1111/j.1365-2125.1991.tb05605.x	32	112	111	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1272	1276		10.1016/S0140-6736(97)05048-4	http://dx.doi.org/10.1016/S0140-6736(97)05048-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357406				2022-12-28	WOS:A1997YD68900008
J	Marques, G; Musacchio, M; Shimell, MJ; WunnenbergStapleton, K; Cho, KWY; OConnor, MB				Marques, G; Musacchio, M; Shimell, MJ; WunnenbergStapleton, K; Cho, KWY; OConnor, MB			Production of a DPP activity gradient in the early Drosophila embryo through the opposing actions of the SOG and TLD proteins	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-1; TGF-BETA FAMILY; PROCOLLAGEN C-PROTEINASE; SHORT GASTRULATION GENE; DORSAL-VENTRAL PATTERN; XENOPUS CHORDIN; ASTACIN FAMILY; GROWTH-FACTOR; TOLLOID GENE; CELL FATES	During early Drosophila embryogenesis, several zygotic gene products act to establish a posttranscriptional activity gradient of the morphogen DPP. Among these molecules, Tolloid, a putative metalloprotease related to BMP-1, enhances DPP function, while SOG, an ortholog of the Xenopus organizer Chordin, inhibits DPP function. Using epistasis tests and a Xenopus secondary axis induction assay, we show that TLD negates the inhibitory effects of SOG/CHD on DPP/BMP-type ligands. In transient transfection assays, we demonstrate that TLD cleaves SOG and that cleavage is stimulated by DPP. We propose that formation of the embryonic DPP activity gradient involves the opposing effects of SOG inhibiting DPP and TLD processing SOG to release DPP from the inhibitory complex.	UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92697; UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities			O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K02HD001158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054704, K04GM000599] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01158] Funding Source: Medline; NIGMS NIH HHS [GM00599, GM54704] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CHERBAS L, 1994, METHOD CELL BIOL, V44, P161, DOI 10.1016/S0091-679X(08)60912-7; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Faber J., 1994, NORMAL TABLE XENOPUS, P2; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GELBART WM, 1989, DEVELOPMENT, V107, P65; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Hoffmann FM, 1991, CURR OPIN CELL BIOL, V3, P947, DOI 10.1016/0955-0674(91)90112-C; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KIROV N, 1994, MOL CELL BIOL, V14, P713, DOI 10.1128/MCB.14.1.713; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Marques G., 1997, ASTACINS STRUCTURE F, P191; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; PIROTTA V, 1986, DROSOPHILA PRACTICAL, P83; RAY RP, 1991, DEVELOPMENT, V113, P35; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; Sarras MP, 1996, BIOESSAYS, V18, P439, DOI 10.1002/bies.950180604; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	52	297	311	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					417	426		10.1016/S0092-8674(00)80425-0	http://dx.doi.org/10.1016/S0092-8674(00)80425-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363950	Bronze			2022-12-28	WOS:A1997YD94100015
J	Piccolo, S; Agius, E; Lu, B; Goodman, S; Dale, L; DeRobertis, EM				Piccolo, S; Agius, E; Lu, B; Goodman, S; Dale, L; DeRobertis, EM			Cleavage of chordin by Xolloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROCOLLAGEN C-PROTEINASE; DORSAL-VENTRAL PATTERN; DROSOPHILA EMBRYO; SHORT GASTRULATION; XENOPUS EMBRYO; GENE; BMP-4; INDUCTION; RECEPTOR	The Xolloid secreted metalloprotease, a tolloid-related protein, was found to cleave Chordin and Chordin/ BMP-4 complexes at two specific sites in biochemical experiments. Xolloid mRNA blocks secondary axes caused by chordin, but not by noggin, follistatin, or dominant-negative BMP receptor, mRNA injection. Xolloid-treated Chordin protein was unable to antagonize BMP activity. Furthermore, Xolloid digestion released biologically active BMPs from Chordin/BMP inactive complexes. Injection of dominant-negative Xolloid mRNA indicated that the in vivo function of Xolloid is to limit the extent of Spemann's organizer field. We propose that Xolloid regulates organizer function by a novel proteolytic mechanism involving a double inhibition pathway required to pattern the dorsoventral axis: XOLL inverted left perpendicular CHD inverted inverted perpendicular BMPs --> BMPR.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of London; University College London			Dale, Leslie/C-6709-2008; agius, Eric/AHC-9705-2022	Agius, Eric/0000-0003-2123-9283; De Robertis, Edward/0000-0002-7843-1869; PICCOLO, STEFANO/0000-0002-2037-0004	NICHD NIH HHS [R37 HD021502-13, R37 HD021502, R37 HD21502-11] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; DALE L, 1992, DEVELOPMENT, V115, P573; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Dosch R, 1997, DEVELOPMENT, V124, P2325; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; GOODMAN S, 1997, IN PRESS DEV BIOL; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; JONES CM, 1992, DEVELOPMENT, V115, P639; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Lin JJ, 1997, DEV GROWTH DIFFER, V39, P43; MAENO M, 1993, GENE, V134, P257, DOI 10.1016/0378-1119(93)90103-A; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Moon RT, 1997, CELL, V88, P725, DOI 10.1016/S0092-8674(00)81915-7; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STOCKER W, 1995, PROTEIN SCI, V4, P823; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	45	332	348	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					407	416		10.1016/S0092-8674(00)80424-9	http://dx.doi.org/10.1016/S0092-8674(00)80424-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363949	Green Accepted, Bronze			2022-12-28	WOS:A1997YD94100014
J	Grotta, J				Grotta, J			Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA - The best current option for most patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TISSUE-PLASMINOGEN-ACTIVATOR; URGENT THERAPY; MINUTES				Grotta, J (corresponding author), UNIV TEXAS,SCH MED,DEPT NEUROL,6431 FANNIN,SUITE 7044,HOUSTON,TX 77030, USA.		Grotta, James/AAH-7423-2021					Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; [Anonymous], 1996, NEUROLOGY, V47, P835; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1993, THROMBOLYTIC THERAPY, V2, P59; DONMAN GA, 1995, LANCET, V345, P578; *EUR COOP AC STROK, 1995, JAMA-J AM MED ASSOC, V274, P1017; HALEY EC, 1992, STROKE, V23, P641, DOI 10.1161/01.STR.23.5.641; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; *MULT AC STROK TRI, 1996, NEW ENGL J MED, V335, P145; *MULT AC STROK TRI, 1995, LANCET, V346, P1509; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581	13	42	42	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1310	1313						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345085				2022-12-28	WOS:A1997YC92000013
J	Muroi, N; Nishibori, M; Fujii, T; Yamagata, M; Hosoi, S; Nakaya, N; Saeki, K; Henmi, K				Muroi, N; Nishibori, M; Fujii, T; Yamagata, M; Hosoi, S; Nakaya, N; Saeki, K; Henmi, K			Anaphylaxis from the carboxymethylcellulose component of barium sulfate suspension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERSENSITIVITY REACTION; ALLERGIC REACTIONS; CONTRAST MATERIALS; LATEX ALLERGY; ENEMA		OKAYAMA UNIV,SCH MED,DEPT PHARMACOL,OKAYAMA 700,JAPAN; AKO MUNICIPAL HOSP,AKO,JAPAN	Okayama University								ALMUDALLAL R, 1990, AM J MED, V89, P251, DOI 10.1016/0002-9343(90)90312-2; BRENNER JS, 1990, AM J ROENTGENOL, V154, P199, DOI 10.2214/ajr.154.1.2104710; dePaulis A, 1996, J ALLERGY CLIN IMMUN, V98, P152, DOI 10.1016/S0091-6749(96)70237-3; FECZKO PJ, 1989, AM J ROENTGENOL, V153, P275, DOI 10.2214/ajr.153.2.275; FECZKO PJ, 1990, RADIOLOGY, V174, P367, DOI 10.1148/radiology.174.2.2136954; GELFAND DW, 1985, AM J ROENTGENOL, V144, P405, DOI 10.2214/ajr.144.2.405; ITOH Y, 1992, J NEUROCHEM, V58, P884, DOI 10.1111/j.1471-4159.1992.tb09339.x; JANOWER ML, 1990, RADIOLOGY, V177, P287, DOI 10.1148/radiology.177.1.2399333; JANOWER ML, 1986, RADIOLOGY, V161, P139, DOI 10.1148/radiology.161.1.3763856; JHOYT TS, 1985, AJR AM J ROENTGENOL, V145, P653; LEEMANN W, 1969, NATURE, V223, P621, DOI 10.1038/223621a0; MCAVOY M, 1985, AM J ROENTGENOL, V144, P1316, DOI 10.2214/ajr.144.6.1316-a; MISSELBECK WJA, 1994, AM J EMERG MED, V12, P445, DOI 10.1016/0735-6757(94)90058-2; MURRIETAAGUTTES M, 1991, J ASTHMA, V28, P329, DOI 10.3109/02770909109089460; NAGI B, 1988, ALLERGY, V43, P473, DOI 10.1111/j.1398-9995.1988.tb00922.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; PATTERSON DL, 1995, ANN ALLERG ASTHMA IM, V74, P163; SCHWARTZ EE, 1984, AM J ROENTGENOL, V143, P103, DOI 10.2214/ajr.143.1.103; SHAFFER HA, 1988, GASTROINTEST RADIOL, V13, P221, DOI 10.1007/BF01889065; STRINGER DA, 1993, PEDIATR RADIOL, V23, P587, DOI 10.1007/BF02014970; TARLO SM, 1995, J ALLERGY CLIN IMMUN, V95, P933, DOI 10.1016/S0091-6749(95)70091-9; WARPINSKI JR, 1991, AM J MED, V90, P769	22	47	48	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1275	1277		10.1056/NEJM199710303371804	http://dx.doi.org/10.1056/NEJM199710303371804			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345076				2022-12-28	WOS:A1997YC92000004
J	Haigney, E; Morgan, R; King, D; Spencer, B				Haigney, E; Morgan, R; King, D; Spencer, B			Breast examinations in older women: questionnaire survey of attitudes of patients and doctors	BRITISH MEDICAL JOURNAL			English	Article									WIRRAL HOSP,DEPT MED ELDERLY,WIRRAL L49 5PE,MERSEYSIDE,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool								ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; AMSTERDAM E, 1987, J SURG ONCOL, V180, P183; Ries LAB, 1989, NIH PUBLICATION; SHELDON T, 1996, EFFECTIVE HLTH CARE, V2, P1	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1058	1059		10.1136/bmj.315.7115.1058	http://dx.doi.org/10.1136/bmj.315.7115.1058			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366734	Green Published			2022-12-28	WOS:A1997YD44500024
J	DeRisi, JL; Iyer, VR; Brown, PO				DeRisi, JL; Iyer, VR; Brown, PO			Exploring the metabolic and genetic control of gene expression on a genomic scale	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATOR; MESSENGER-RNAS; ENCODING GENE; PROTEIN; COMPLEX; GLUCOSE; PATHWAY; CARBON; HYBRIDIZATION	DNA microarrays containing virtually every gene of Saccharomyces cerevisiae were used to carry out a comprehensive investigation of the temporal program of gene expression accompanying the metabolic shift from fermentation to respiration. The expression profiles observed for genes with known metabolic functions pointed to features of the metabolic reprogramming that occur during the diauxic shift, and the expression patterns of many previously uncharacterized genes provided clues to their possible functions. The same DNA microarrays were also used to identify genes whose expression was affected by deletion of the transcriptional co-repressor TUP1 or overexpression of the transcriptional activator YAP1. These results demonstrate the feasibility and utility of this approach to genomewide exploration of gene expression patterns.	STANFORD UNIV,HOWARD HUGHES MED INST,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000450, T32HG000044, R21HG000450] Funding Source: NIH RePORTER; NHGRI NIH HHS [T32 HG00044, HG00450] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DeRisi J, 1996, NAT GENET, V14, P457; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FERNANDEZ M, 1994, MOL GEN GENET, V242, P727; Fondrat C, 1996, COMPUT APPL BIOSCI, V12, P363; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GUTIERREZ A, 1994, APPL ENVIRON MICROB, V60, P1783; HARTIG A, 1992, NUCLEIC ACIDS RES, V20, P5677, DOI 10.1093/nar/20.21.5677; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HERRERO P, 1995, YEAST, V11, P137, DOI 10.1002/yea.320110205; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; KOWALSKI LR, 1995, MOLMICROBIOL, V115, P341; KRATZER S, 1995, GENE, V161, P75, DOI 10.1016/0378-1119(95)00289-I; LASHKARI D, IN PRESS P NATL ACAD; Lesage P, 1996, MOL CELL BIOL, V16, P1921, DOI 10.1128/mcb.16.5.1921; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MARTINEZ PM, 1996, EMBO J, V15, P2227; MOORE PA, 1991, MOL CELL BIOL, V11, P5330, DOI 10.1128/MCB.11.10.5330; MUHEIM A, 1991, EUR J BIOCHEM, V195, P369, DOI 10.1111/j.1432-1033.1991.tb15715.x; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; PLANTA RJ, 1988, TRENDS GENET, V4, P64, DOI 10.1016/0168-9525(88)90042-X; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; ROSENKRANTZ M, 1994, MOL MICROBIOL, V13, P119, DOI 10.1111/j.1365-2958.1994.tb00407.x; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHOLER A, 1994, MOL CELL BIOL, V14, P3613, DOI 10.1128/MCB.14.6.3613; SCHOLER A, 1993, CURR GENET, V23, P375, DOI 10.1007/BF00312621; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; VISWANATHAN M, 1994, GENE, V148, P149, DOI 10.1016/0378-1119(94)90249-6; VNDENBERG MA, 1996, J BIOL CHEM, V271, P28953; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717; Yin ZK, 1996, MOL MICROBIOL, V20, P751, DOI 10.1111/j.1365-2958.1996.tb02514.x	41	3448	3688	2	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					680	686		10.1126/science.278.5338.680	http://dx.doi.org/10.1126/science.278.5338.680			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381177				2022-12-28	WOS:A1997YC32300053
J	Tatusov, RL; Koonin, EV; Lipman, DJ				Tatusov, RL; Koonin, EV; Lipman, DJ			A genomic perspective on protein families	SCIENCE			English	Article							ARCHAEON METHANOSARCINA-THERMOPHILA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PHYLOGENETIC TREES; CARBONIC-ANHYDRASE; BACTERIAL GENOMES; SEQUENCE-ANALYSIS; BINDING; GENES; SIMILARITY	In order to extract the maximum amount of information from the rapidly accumulating genome sequences, all conserved genes need to be classified according to their homologous relationships. Comparison of proteins encoded in seven complete genomes from five major phylogenetic lineages and elucidation of consistent patterns of sequence similarities allowed the delineation of 720 clusters of orthologous groups (COGs). Each COG consists of individual orthologous proteins or orthologous sets of paralogs from at least three lineages. Orthologs typically have the same function, allowing transfer of functional information from one member to an entire COG. This relation automatically yields a number of functional predictions for poorly characterized genomes. The COGs comprise a framework for functional and evolutionary genome analysis.	NIH, NATL CTR BIOTECHNOL INFORMAT, NATL LIB MED, BETHESDA, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)			Peng, Bo/A-6920-2009; Puigbò, Pere/A-2214-2008	Peng, Bo/0000-0001-8225-2284; 				ALBER BE, 1994, P NATL ACAD SCI USA, V91, P6909, DOI 10.1073/pnas.91.15.6909; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bork P, 1996, PROTEIN SCI, V5, P1421, DOI 10.1002/pro.5560050720; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chanfreau G, 1996, SCIENCE, V274, P1511, DOI 10.1126/science.274.5292.1511; Clayton RA, 1997, NATURE, V387, P459, DOI 10.1038/387459a0; COLBEAU A, 1993, MOL MICROBIOL, V8, P15, DOI 10.1111/j.1365-2958.1993.tb01199.x; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; FITCH WM, 1995, PHILOS T ROY SOC B, V349, P93, DOI 10.1098/rstb.1995.0095; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GOGARTEN JP, 1996, EVOLUTION MICROBIAL, P267; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; HAMA H, 1994, J BIOCHEM-TOKYO, V115, P1135, DOI 10.1093/oxfordjournals.jbchem.a124469; Himmelreich R, 1997, NUCLEIC ACIDS RES, V25, P701, DOI 10.1093/nar/25.4.701; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; Kaneko T, 1996, DNA Res, V3, P109; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; KOBAYASHI T, 1985, J BIOCHEM-TOKYO, V98, P1017, DOI 10.1093/oxfordjournals.jbchem.a135347; Koonin EV, 1996, CURR BIOL, V6, P404, DOI 10.1016/S0960-9822(02)00508-0; KOONIN EV, 1995, PROTEIN SCI, V4, P1608, DOI 10.1002/pro.5560040819; Koonin EV, 1996, METHOD ENZYMOL, V266, P295; Koonin EV, 1997, GENOME RES, V7, P418, DOI 10.1101/gr.7.5.418; Koonin EV, 1996, CURR OPIN GENET DEV, V6, P757, DOI 10.1016/S0959-437X(96)80032-3; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; Koonin EV, 1996, TRENDS GENET, V12, P334, DOI 10.1016/0168-9525(96)20010-1; KOONIN EV, UNPUB; LIN ECC, 1996, CELLULAR MOL BIOL, P307; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; MORRIS TW, 1995, J BACTERIOL, V177, P1; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; NEUHARD J, 1996, CELLULAR MOL BIOL, P580; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; RICHTER D, 1992, MOL GEN GENET, V231, P194, DOI 10.1007/BF00279791; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; ROZANOV MN, UNPUB; Rudd Kevin, COMMUNICATION; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Stumpf G, 1996, SCIENCE, V274, P1517, DOI 10.1126/science.274.5292.1517; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Walker DR, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P333; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATANABE H, 1995, COMPUT APPL BIOSCI, V11, P159; Weiser JN, 1997, INFECT IMMUN, V65, P943, DOI 10.1128/IAI.65.3.943-950.1997; Woese CR, 1996, CURR BIOL, V6, P1060, DOI 10.1016/S0960-9822(02)70664-7; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOLFSBERG TJ, COMMUNICATION; Wolter R, 1996, MOL GEN GENET, V250, P162, DOI 10.1007/s004380050063; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	63	2639	2771	5	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					631	637		10.1126/science.278.5338.631	http://dx.doi.org/10.1126/science.278.5338.631			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381173	Green Published, Green Submitted			2022-12-28	WOS:A1997YC32300041
J	Clark, F; Azen, SP; Zemke, R; Jackson, J; Carlson, M; Mandel, D; Hay, J; Josephson, K; Cherry, B; Hessel, C; Palmer, J; Lipson, L				Clark, F; Azen, SP; Zemke, R; Jackson, J; Carlson, M; Mandel, D; Hay, J; Josephson, K; Cherry, B; Hessel, C; Palmer, J; Lipson, L			Occupational therapy for independent-living older adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH SURVEY SF-36; QUALITY-OF-LIFE; SATISFACTION; PERFORMANCE; POPULATION; MACARTHUR; VALIDITY; OUTCOMES; SCIENCE; SERVICE	Context.-Preventive health programs may mitigate against the health risks of older adulthood. Objective.-To evaluate the effectiveness of preventive occupational therapy (OT) services specifically tailored for multiethnic, independent-living older adults. Design.-A randomized controlled trial. Setting.-Two government subsidized apartment complexes for independent-living older adults. Subjects.-A total of 361 culturally diverse volunteers aged 60 years or older. Intervention.-An OT group, a social activity control group, and a nontreatment control group, The period of treatment was 9 months. Main Outcome Measures.-A battery of self-administered questionnaires designed to measure physical and social function, self-rated health, life satisfaction, and depressive symptoms, Results.-Benefit attributable to OT treatment was found for the quality of interaction scale on the Functional Status Questionnaire (P=.03), Life Satisfaction Index-Z (P=.03), Medical Outcomes Study Health Perception Survey (P=.05), and for 7 of 8 scales on the RAND 36-item Health Status Survey, Short Form: bodily pain (P=.03), physical functioning (P=.008), role limitations attributable to health problems (P=.02), vitality (P=.004), social functioning (P=.05), role limitations attributable to emotional problems (P=.05), and general mental health (P=.02). Conclusions.-Significant benefits for the OT preventive treatment group were found across various health, function, and quality-of-life domains. Because the control groups tended to decline over the study interval, our results suggest that preventive health programs based on OT may mitigate against the health risks of older adulthood.	UNIV SO CALIF,SCH MED,STAT CONSULTAT & RES CTR,DEPT PREVENT MED,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH PHARM,DEPT PHARMACEUT ECON & POLICY,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH MED,DEPT MED,DIV GERIATR MED,LOS ANGELES,CA 90033	University of Southern California; University of Southern California; University of Southern California	Clark, F (corresponding author), UNIV SO CALIF,DEPT OCCUPAT SCI & OCCUPAT THERAPY,1540 ALCAZAR,CHP 133,LOS ANGELES,CA 90033, USA.			Jackson, Jeanne/0000-0001-5290-7382	NATIONAL INSTITUTE ON AGING [R01AG011810] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG11810] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BACHELDER JM, 1993, AM J OCCUP THER, V48, P73; BERKMAN LF, 1993, J CLIN EPIDEMIOL, V46, P1129, DOI 10.1016/0895-4356(93)90112-E; BURCKHARDT CS, 1989, RES NURS HEALTH, V12, P347, DOI 10.1002/nur.4770120604; Carlson M, 1996, AM J OCCUP THER, V50, P89, DOI 10.5014/ajot.50.2.89; CLARK F, 1993, AM J OCCUP THER, V47, P1067, DOI 10.5014/ajot.47.12.1067; Clark F, 1996, AM J OCCUP THER, V50, P99, DOI 10.5014/ajot.50.2.99; Clark F., 1993, WILLARD SPACKMANS OC, P44; CLARK FA, 1991, AM J OCCUP THER, V45, P300, DOI 10.5014/ajot.45.4.300; Cohen J, 1987, STAT POWER ANAL BEHA; CRIMMINS EM, 1994, DEMOGRAPHY, V31, P159, DOI 10.2307/2061913; EBRAHIM S, 1995, SOC SCI MED, V41, P1383, DOI 10.1016/0277-9536(95)00116-O; Fisher BJ, 1995, INT J AGING HUM DEV, V41, P239, DOI 10.2190/HA9X-H48D-9GYB-85XW; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; Gatz M, 1995, EMERGING ISSUES IN MENTAL HEALTH AND AGING, pR15; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; HOPKINS HL, 1993, WILLARD SPACKMANS OC; Jackson J, 1996, OCCUPATIONAL SCI EVO; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; LARSON KO, 1996, ROTE ROLE OCCUPATION; LARUE A, 1979, J GERONTOL, V34, P687, DOI 10.1093/geronj/34.5.687; LEVINE RE, 1992, AM J OCCUP THER, V47, P147; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MURRELL SA, 1989, PSYCHOL AGING, V4, P166; ORY MG, 1994, SOC INDIC RES, V33, P89, DOI 10.1007/BF01078959; Pearlin LI, 1995, EMERGING ISSUES IN MENTAL HEALTH AND AGING, P97, DOI 10.1037/10179-004; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; Townsend E, 1996, OCCUP THER J RES, V16, P179, DOI 10.1177/153944929601600303; U. S. Bureau of the Census, 1996, STAT ABSTR US; *US BUR CENS, 1992, PUBL US BUR CENS; VERBRUGGE LM, 1993, SOC SCI MED, V38, P1; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WOOD V, 1969, J GERONTOL, V24, P465, DOI 10.1093/geronj/24.4.465; YERXA E J, 1989, Occupational Therapy in Health Care, V6, P1; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zemke R., 1996, OCCUPATIONAL SCI EVO; [No title captured]	42	395	398	0	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1321	1326		10.1001/jama.278.16.1321	http://dx.doi.org/10.1001/jama.278.16.1321			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343462				2022-12-28	WOS:A1997YA90500032
J	Wright, WB; Budakian, R; Pine, DJ; Putterman, SJ				Wright, WB; Budakian, R; Pine, DJ; Putterman, SJ			Imaging of intermittency in ripple-wave turbulence	SCIENCE			English	Article							E+E ANNIHILATION; LIGHT; JETS	The dynamics of a fluid surface filled with high-amplitude ripples were studied with a technique (diffusing light photography) that resolves the height at all locations instantaneously. Even when nonlinearities are strong enough to generate a (Kolmogorov) cascade from long wavelength (where energy is input) to shorter wavelength, the resulting turbulent state contains large coherent spatial structures. The appearance of these structures in a thermal equilibrium state (with the same average energy) would be highly improbable.	UNIV CALIF LOS ANGELES, DEPT PHYS, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles			Pine, David J/B-7740-2016	Pine, David J/0000-0002-3304-6684				ALBAJAR C, 1988, NUCL PHYS B, V309, P405, DOI 10.1016/0550-3213(88)90450-6; ARNISON G, 1983, PHYS LETT B, V123, P115, DOI 10.1016/0370-2693(83)90970-X; BARTEL W, 1986, Z PHYS C PART FIELDS, V33, P23, DOI 10.1007/BF01410449; CATANI S, 1991, PHYS LETT B, V269, P432, DOI 10.1016/0370-2693(91)90196-W; CHRISTIANSEN B, 1992, PHYS REV LETT, V68, P2157, DOI 10.1103/PhysRevLett.68.2157; DURIAN DJ, 1994, PHYS REV E, V50, P857, DOI 10.1103/PhysRevE.50.857; Faraday M., 1831, T R SOC, P299; FOIAS C, 1991, PHYS FLUIDS A-FLUID, V3, P898, DOI 10.1063/1.858212; FRISCH U, 1990, PHYS TODAY, V43, P24, DOI 10.1063/1.881235; GLUCKMAN BJ, 1993, PHYS REV LETT, V71, P2034, DOI 10.1103/PhysRevLett.71.2034; GRANT HL, 1962, J FLUID MECH, V12, P241, DOI 10.1017/S002211206200018X; HEISENBERG W, 1948, PROC R SOC LON SER-A, V195, P402, DOI 10.1098/rspa.1948.0127; KAPLAN PD, 1993, APPL OPTICS, V32, P3828, DOI 10.1364/AO.32.003828; Kolmogoroff A, 1941, CR ACAD SCI URSS, V30, P301, DOI 10.1098/rspa.1991.0075; KOLMOGOROV AN, 1962, J FLUID MECH, V13, P82, DOI 10.1017/S0022112062000518; KRAICHNAN RH, 1967, PHYS FLUIDS, V10, P2080, DOI 10.1063/1.1762412; KRAICHNAN RH, 1991, TURBULENCE STOCHASTI; KRAICHNAN RH, 1997, B AM PHYS SOC, V42, P53; LANDAU LD, 1955, FLUID MECHANICS; OBOUKHOV AM, 1962, J FLUID MECH, V13, P77, DOI 10.1017/S0022112062000506; OBOUKHOV AM, 1941, DOKL AKAD NAUK SSSR, V32, P19; Pushkarev AN, 1996, PHYS REV LETT, V76, P3320, DOI 10.1103/PhysRevLett.76.3320; Richardson L.F., 1922, WEATHER PREDICTION N, DOI DOI 10.1017/CBO9780511618291; Richardson LF, 1926, P R SOC LOND A-CONTA, V110, P709, DOI 10.1098/rspa.1926.0043; SADDOUGHI SG, 1994, J FLUID MECH, V268, P333, DOI 10.1017/S0022112094001370; SAGDEEV RZ, 1979, REV MOD PHYS, V51, P1, DOI 10.1103/RevModPhys.51.1; SEYMOUR MH, 1994, Z PHYS C PART FIELDS, V62, P127, DOI 10.1007/BF01559532; TRITTON DJ, 1977, PHYSICAL FLUID DYNAM, P13; Vera MU, 1996, PHYS REV E, V53, P3215, DOI 10.1103/PhysRevE.53.3215; Wright WB, 1996, PHYS REV LETT, V76, P4528, DOI 10.1103/PhysRevLett.76.4528; WRIGHT WB, 1996, THESIS U CALIFORNIA; ZAKHAROV VE, 1992, KOLMOGOROV SPECTRA T, P33	32	35	35	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 28	1997	278	5343					1609	1612		10.1126/science.278.5343.1609	http://dx.doi.org/10.1126/science.278.5343.1609			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374457				2022-12-28	WOS:A1997YJ87400036
J	deRoux, N; Young, J; Misrahi, M; Genet, R; Chanson, P; Schaison, G; Milgrom, E				deRoux, N; Young, J; Misrahi, M; Genet, R; Chanson, P; Schaison, G; Milgrom, E			A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GNRH RECEPTOR; THYROTROPIN-RECEPTOR; KALLMANNS SYNDROME; GENE; CLONING; EXPRESSION; DEFICIENCY; ACTIVATION; RESISTANCE; SEQUENCE		HOP BICETRE, SERV ENDOCRINOL & MALAD REPROD, INST FEDERAT RECH HORMONES & GENET 21, F-94275 LE KREMLIN BICETRE, FRANCE; HOP BICETRE, INST FEDERAT RECH HORMONES & GENET 21, INSERM, U135, F-94275 LE KREMLIN BICETRE, FRANCE; CEA SACLAY, DEPT INGN & ETUD PROT, F-91191 GIF SUR YVETTE, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay			Young, Jacques/N-5251-2019; Chanson, Philippe/F-8511-2013; Young, Jacques/T-2976-2018	Young, Jacques/0000-0001-9286-5631; Chanson, Philippe/0000-0001-5096-5722; Young, Jacques/0000-0001-9286-5631; de Roux, Nicolas/0000-0002-8545-2780				Arora KK, 1996, MOL ENDOCRINOL, V10, P979, DOI 10.1210/me.10.8.979; BICK D, 1992, NEW ENGL J MED, V326, P1752, DOI 10.1056/NEJM199206253262606; CHI L, 1993, MOL CELL ENDOCRINOL, V91, pR1, DOI 10.1016/0303-7207(93)90278-R; CliftonBligh RJ, 1997, J CLIN ENDOCR METAB, V82, P1094, DOI 10.1210/jc.82.4.1094; Collu R, 1997, J CLIN ENDOCR METAB, V82, P1561, DOI 10.1210/jc.82.5.1561; Crowley W F Jr, 1985, Recent Prog Horm Res, V41, P473; Davidson JS, 1996, J BIOL CHEM, V271, P15510, DOI 10.1074/jbc.271.26.15510; deRoux N, 1996, J CLIN ENDOCR METAB, V81, P4229, DOI 10.1210/jc.81.12.4229; FAN NC, 1995, MOL CELL ENDOCRINOL, V107, pR1, DOI 10.1016/0303-7207(94)03460-B; FAN NC, 1994, MOL CELL ENDOCRINOL, V103, pR1; HARDELIN JP, 1993, J CLIN ENDOCR METAB, V76, P827, DOI 10.1210/jc.76.4.827; HARDELIN JP, 1992, P NATL ACAD SCI USA, V89, P8190, DOI 10.1073/pnas.89.17.8190; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; KOTTLER ML, 1995, HUM GENET, V96, P477; Latronico AC, 1996, NEW ENGL J MED, V334, P507, DOI 10.1056/NEJM199602223340805; Laue LL, 1996, MOL ENDOCRINOL, V10, P987, DOI 10.1210/me.10.8.987; LAYMAN LC, 1996, 10 INT C END SAN FRA, P855; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; MEITINGER T, 1990, AM J HUM GENET, V47, P664; MEITINGER T, 1990, AM J HUM GENET, V47, P883; Misrahi M, 1997, J CLIN ENDOCR METAB, V82, P2159, DOI 10.1210/jcem.82.7.4039; MYBURGH DB, 1997, 79 ANN M END SOC MIN, P167; NAKAYAMA Y, 1990, J CLIN ENDOCR METAB, V70, P1233, DOI 10.1210/jcem-70-5-1233; REINHART J, 1992, J BIOL CHEM, V267, P21281; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUNTHORNTHEPVARAKUL T, 1995, NEW ENGL J MED, V332, P155, DOI 10.1056/NEJM199501193320305; THOMAS G, 1992, STAT MED, V11, P2133, DOI 10.1002/sim.4780111610; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; WEISS J, 1991, BIOL REPROD, V45, P743, DOI 10.1095/biolreprod45.5.743; WEISS J, 1989, J CLIN ENDOCR METAB, V69, P299, DOI 10.1210/jcem-69-2-299; WHITCOMB RW, 1990, J CLIN ENDOCR METAB, V70, P3, DOI 10.1210/jcem-70-1-3; WHITCOMB RW, 1993, ENDOCRIN METAB CLIN, V22, P125, DOI 10.1016/S0889-8529(18)30183-X	34	353	360	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1597	1602		10.1056/NEJM199711273372205	http://dx.doi.org/10.1056/NEJM199711273372205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371856				2022-12-28	WOS:A1997YH52100005
J	RayCoquard, I; Philip, T; Lehmann, M; Fervers, B; Farsi, F; Chauvin, F				RayCoquard, I; Philip, T; Lehmann, M; Fervers, B; Farsi, F; Chauvin, F			Impact of a clinical guidelines program for breast and colon cancer in a French cancer center	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CARCINOMA; RADIATION-THERAPY; RANDOMIZED TRIAL; ADJUVANT THERAPY; FOLLOW-UP; FLUOROURACIL; CHEMOTHERAPY; WOMEN; METASTASES; MEDICINE	Context.-Between 1993 and 1994, the 80 physicians in the French comprehensive cancer center, Leon Berard, developed and implemented a Clinical Practice Guidelines (CPGs) project based on an analysis of the literature and a consensus of intrainstitutional experts. Objective.-The aims of this project are to assist community-based oncologists in their decision making and to minimize inappropriate variation in practices. A study was designed to assess the impact of CPGs on management of breast and colon cancer. Design.-A ''before-after'' study, using institutional computerized records of patients with breast or colon cancer. Setting.-Records for 100 women with localized breast cancer were randomly selected from those available in 1993 and 1995, and those for all patients newly referred with colon cancer in 1993 and 1995 (77 and 81 patients, respectively). Medical decisions on these records were analyzed to assess their compliance with the CPGs. (A systematic search of the literature was performed to determine the scientific evidence for noncompliant decisions.) Results.-Of 375 available medical decisions, 350 were assessable. The compliance rate with CPGs for breast cancer was significantly higher in 1995 compared with 1993, 54% (54/99; 95% confidence interval [CI]; 44%-64%) vs 19% (18/95; 95% CI, 11%-27%) (P<.001), The compliance rate for colon cancer was also significantly higher in 1995 than in 1993, 70% (62/88; 95% CI, 60%-80%) vs 50% (34/68; 95% CI, 38%-62%) (P=.009), In 1993, 42% (40/95; 95% CI, 32%-52%) of medical decisions for breast cancer and in 1995, 68% (67/99; 95% CI, 59%-77%) conformed with the CPGs or were judged to be based on ''scientific evidence.'' In 1993, 71% (48/68; 95% CI, 60%-81%) of medical decisions for colon cancer, and in 1995 81% (71/88; 95% CI, 73%-89%) conformed with the CPGs or were judged to be based on scientific evidence. Conclusions.-Compliance rates were significantly higher in 1995 for both cancers. The development and implementation of CPGs for cancer management seem to result in significant changes in medical practice, although a causal relationship between changes and CPGs is not demonstrated in this study.	FEDERAT NATL CTR LUTTE CONTRE CANC, PARIS, FRANCE		RayCoquard, I (corresponding author), CTR LEON BERARD, 28 RUE LAENNEC, F-69008 LYON, FRANCE.		Fervers, Béatrice/AAD-1847-2022	Fervers, Béatrice/0000-0003-3498-6499				A Donabedian, 1982, CRITERIA STANDARDS Q, VII; ALLEE PE, 1989, INT J RADIAT ONCOL, V17, P1171, DOI 10.1016/0360-3016(89)90522-1; ASLER VB, 1954, ANN SURG, V139, P846; BEKRADA M, 1994, B CANC, V6, P562; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; BUDD GT, 1987, J CLIN ONCOL, V5, P272, DOI 10.1200/JCO.1987.5.2.272; CALLE R, 1980, B CANCER, V67, P313; COBURN MC, 1994, J AM COLL SURGEONS, V179, P65; Coombes RC, 1996, J CLIN ONCOL, V14, P35, DOI 10.1200/JCO.1996.14.1.35; *EARL BREAST CANC, 1992, LANCET, V339, P1; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2239, DOI 10.1001/jama.263.16.2239; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P1446, DOI 10.1001/jama.265.11.1446; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; *FED NAT CTR LUTT, 1995, STAND OPT REC PRIS C, P110; Field MJ, 1990, CLIN PRACTICE GUIDEL, P38; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAYWARD RSA, 1993, CAN MED ASSOC J, V148, P507; HUGUES K, 1991, P AN M AM SOC CLIN, V10, P145; HURTELOUP P, 1988, J CLIN ONCOL, V6, P679; JAGER W, 1991, J TUMOR MARKER ONCOL, V6, P56; JAKESZ R, 1994, CHIRURG, V65, P497; LAGIOS MD, 1982, CANCER-AM CANCER SOC, V50, P1309, DOI 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-#; LIVRAGHI T, 1991, RADIOLOGY, V179, P709, DOI 10.1148/radiology.179.3.2027979; MARGOLESE RG, 1989, ARCH SURG-CHICAGO, V124, P548; MARGOLIS CZ, 1983, JAMA-J AM MED ASSOC, V249, P627, DOI 10.1001/jama.249.5.627; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112, DOI 10.1200/JCO.1992.10.7.1112; ROUGIER P, 1992, P AM SOC CLIN ONCOL, V111, P63; RUTQVIST LE, 1993, RADIOTHER ONCOL, V26, P104, DOI 10.1016/0167-8140(93)90090-U; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SCHAAKEKONING C, 1985, INT J RADIAT ONCOL, V11, P1759, DOI 10.1016/0360-3016(85)90028-8; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; SCHOLL SM, 1994, EUR J CANCER, V30A, P645, DOI 10.1016/0959-8049(94)90537-1; SHERMAN DM, 1978, CANCER, V41, P2013, DOI 10.1002/1097-0142(197805)41:5<2013::AID-CNCR2820410549>3.0.CO;2-T; SUNSHINE JA, 1985, AM J SURG, V150, P44, DOI 10.1016/0002-9610(85)90008-X; *UN INT CONTR CANC, 1988, UICC TNM CLASS TUM M, P99; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; WAZER DE, 1994, CANCER, V74, P878, DOI 10.1002/1097-0142(19940801)74:3<878::AID-CNCR2820740314>3.0.CO;2-4; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; WOOLF SH, 1993, ARCH INTERN MED, V153, P2646, DOI 10.1001/archinte.153.23.2646; ZANIBONI A, 1993, P AN M AM SOC CLIN, V12, P191	45	91	91	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1591	1595		10.1001/jama.278.19.1591	http://dx.doi.org/10.1001/jama.278.19.1591			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF407	9370505				2022-12-28	WOS:A1997YF40700040
J	Darby, SC; Ewart, DW; Giangrande, PLF; Spooner, RJD; Rizza, CR; Dusheiko, GM; Lee, CA; Ludlam, CA; Preston, FE				Darby, SC; Ewart, DW; Giangrande, PLF; Spooner, RJD; Rizza, CR; Dusheiko, GM; Lee, CA; Ludlam, CA; Preston, FE			Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C	LANCET			English	Article							NON-B-HEPATITIS; A NON-B; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATOCELLULAR-CARCINOMA; HEMOPHILIC PATIENTS; FACTOR-VIII; MULTITRANSFUSED HEMOPHILIACS; NATURAL-HISTORY; HIV-INFECTION; RNA LEVELS	Background Most people with haemophilia who were treated with blood products before the introduction of virus-inactivation procedures were infected with the hepatitis-C virus (HCV). However, there is little quantitative information about the long-term effects on mortality of such infection. Methods We carried out a cohort study of mortality from liver cancer and liver disease in 4865 haemophilic men and boys in the UK. They were treated between 1969 and 1985 with blood products carrying a high risk of HCV infection, and were followed up from first recorded exposure to Jan 1, 1993. Findings Based on death-certificate information, mortality was 16.7 times higher than in the general population for liver disease (95% CI 12.5-22.0; 51 deaths), and 5.6 times higher (1.8-13.0; five deaths) for liver cancer. For men and boys with severe haemophilia who were not infected with HIV-1, the cumulative risks of death from chronic or unspecified liver disease or from liver cancer in the 25 years since first recorded exposure to high HCV-risk products were 1.4% (0.7-3.0) at all ages, and 0.10% (0.01-0.7), 2.2% (0.8-6.1), and 14.3% (4.5-40.9) for those with first recorded exposure at ages under 25, 25-44, and 45 or older. For those with haemophilia and HIV-1 infection, the corresponding risks were 6.5% (4.5-9.5) at all ages, and 3.8% (2.1-6.8), 17.1% (10.0-28.5), and 18.7% (6.4-47.6) in the three age-groups. In those with severe haemophilia, age-standardised all-cause mortality was stable during 1969-84 but increased during 1985-92 in both HIV-1-infected and HIV-1-uninfected groups. Among those not infected with HIV-1, the increase in all-cause mortality resulted largely from deaths attributed to chronic or unspecified liver disease or liver cancer in men aged over 45. Interpretation There is an emerging risk of mortality from liver disease and liver cancer in the UK haemophilia population in individuals both infected and uninfected with HIV-1, which probably results from infection with hepatitis C.	ROYAL INFIRM, EDINBURGH HAEMOPHILIA CTR, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND; CHURCHILL HOSP, OXFORD HAEMOPHILIA CTR, OXFORD OX3 7LJ, ENGLAND; UNIV LONDON, ROYAL FREE HOSP, DEPT MED, LONDON, ENGLAND; UNIV LONDON, ROYAL FREE HOSP, HAEMOPHILIA CTR, LONDON, ENGLAND; UNIV LONDON, ROYAL FREE HOSP, HAEMOSTASIS UNIT, LONDON, ENGLAND; ROYAL HALLAMSHIRE HOSP, SHEFFIELD HAEMOPHILIA & THROMBOSIS CTR, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND	Royal Infirmary of Edinburgh; Radcliffe Infirmary; University of Oxford; University of Oxford; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Sheffield			Dusheiko, Geoffrey M/C-7677-2010					*AIDS GROUP UK HAE, 1989, PHIL T R SOC LOND B, V325, P179; BJORO K, 1994, NEW ENGL J MED, V331, P1607, DOI 10.1056/NEJM199412153312402; Breslow N. E., 1987, STATISTICAL METHODS, VII; COLOMBO M, 1991, AM J HEMATOL, V37, P243, DOI 10.1002/ajh.2830370406; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; EYSTER ME, 1994, BLOOD, V84, P1020; FLETCHER ML, 1983, BRIT MED J, V287, P1754, DOI 10.1136/bmj.287.6407.1754; *INT AG RES CANC, 1994, IARC MON EV CARC RIS, V59; JARVIS LM, 1994, J INFECT DIS, V170, P1018, DOI 10.1093/infdis/170.4.1018; Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X; KERNOFF PBA, 1985, BRIT J HAEMATOL, V60, P469, DOI 10.1111/j.1365-2141.1985.tb07444.x; LEE CA, 1989, BRIT J HAEMATOL, V72, P235, DOI 10.1111/j.1365-2141.1989.tb07688.x; Makris M, 1996, BRIT J HAEMATOL, V94, P746, DOI 10.1046/j.1365-2141.1996.02343.x; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; MANNUCCI PM, 1994, LANCET, V343, P597, DOI 10.1016/S0140-6736(94)91548-2; MAUSERBUNSCHOTEN EP, 1995, J MED VIROL, V45, P241, DOI 10.1002/jmv.1890450302; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; PRESTON FE, 1995, BLOOD, V85, P1259, DOI 10.1182/blood.V85.5.1259.bloodjournal8551259; RIZZA CR, 1983, BRIT MED J, V286, P929, DOI 10.1136/bmj.286.6369.929; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHERLOCK S, 1993, DISEASE LIVER BILIAR, P260; TELFER P, 1994, BRIT J HAEMATOL, V87, P555, DOI 10.1111/j.1365-2141.1994.tb08312.x; TELFER PT, 1994, BRIT J HAEMATOL, V88, P397, DOI 10.1111/j.1365-2141.1994.tb05038.x; TELFER PT, 1995, THROMB HAEMOSTASIS, V74, P1259; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Tuveri R, 1997, J MED VIROL, V51, P36, DOI 10.1002/(SICI)1096-9071(199701)51:1<36::AID-JMV6>3.0.CO;2-T; WATSON HG, 1992, BRIT J HAEMATOL, V80, P514, DOI 10.1111/j.1365-2141.1992.tb04566.x; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; 1974, BRIT J HAEMATOL, V27, P391	33	416	429	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	1997	350	9089					1425	1431		10.1016/S0140-6736(97)05413-5	http://dx.doi.org/10.1016/S0140-6736(97)05413-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371165				2022-12-28	WOS:A1997YF95300008
J	Marcellin, P; Boyer, N; Gervais, A; Martinot, M; Pouteau, M; Castelnau, C; Kilani, A; Areias, J; Auperin, A; Benhamou, JP; Degott, C; Erlinger, S				Marcellin, P; Boyer, N; Gervais, A; Martinot, M; Pouteau, M; Castelnau, C; Kilani, A; Areias, J; Auperin, A; Benhamou, JP; Degott, C; Erlinger, S			Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy	ANNALS OF INTERNAL MEDICINE			English	Article						RNA, viral; hepatitis C-like viruses; hepatitis C; interferon-alpha; aminotransferases	NON-B-HEPATITIS; CHRONIC NON-A; CHRONIC ACTIVE HEPATITIS; CONTROLLED TRIAL; FOLLOW-UP; VIRUS-RNA; ALFA-2B; CIRRHOSIS; PLACEBO; SYSTEM	Background: Less than 20% of patients with chronic hepatitis C have a sustained response to interferon-alpha therapy. The long-term benefit of interferon-alpha with regard to hepatic viral clearance and histologic improvement remains unknown. Objective: To determine the long-term biochemical, virologic, and histologic outcomes in patients with chronic hepatitis C who have a sustained response to interferon-alpha therapy. Design: Prospective cohort study. Setting: University hospital. Patients: 80 patients who had chronic hepatitis C, had a sustained biochemical and virologic response to interferon-alpha therapy, and were followed for at least 12 months. Measurements: Serum hepatitis C virus (HCV) RNA detected by polymerase chain reaction (PCR); HCV genotyping determined by line probe assay; liver histologic studies; liver HCV RNA detected by PCR on frozen liver tissue samples (in 27 patients); and repeated measurements of serum alanine aminotransferase (ALT) levels. Liver biopsy was done before treatment in all 80 patients, and at least one biopsy was done in 69 patients 1 to 6 years after treatment. Results: The 80 patients had follow-up 1 to 7.6 years (mean +/- SD, 4.0 +/- 2.0 years) after interferon-alpha treatment. The follow-up period was 1, 2, 3, 4, 5, 6, and more than 6 years in 11, 13, 14, 18, 10, 12, and 2 patients, respectively, after the end of therapy. During the entire follow-up period, 93% (95% CI, 84% to 97%) of patients had persistently normal serum ALT levels. Serum HCV RNA remained undetectable in 96% (CI, 89% to 99%) of patients, A comparison of liver histologic findings before and 1 to 6.2 years after interferon-alpha treatment showed a clear improvement in 94% (CI, 83% to 99%) of patients, In 62% of patients, the last biopsy done showed normal or nearly normal histologic findings. Liver HCV RNA was detectable before treatment in all 13 patients tested and was undetectable 1 to 5 years after treatment in all 27 patients tested. Conclusions: In patients with chronic hepatitis C who have persistently normal serum ALT levels and no detectable serum HCV RNA 6 months after interferon-alpha therapy, a long-term sustained biochemical and virologic response is generally seen. This response is associated with an absence of detectable intrahepatic HCV RNA and marked histologic improvement.	HOP BEAUJON, UNITE RECH PHYSIOPATHOL HEPAT, INSERM U24, F-92118 CLICHY, FRANCE; HOP BEAUJON, SERV ANAT & CYTOL PATHOL, F-92118 CLICHY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Marcellin, P (corresponding author), HOP BEAUJON, SERV HEPATOL, 100 BLVD GEN LECLERC, F-92118 CLICHY, FRANCE.		Yang, Chen/G-1379-2010					Bacon B. R., 1995, Hepatology, V22, p152A; Benhamou J. P., 1995, Hepatology, V22, p151A; BHATTACHERJEE V, 1995, J GEN VIROL, V76, P1737, DOI 10.1099/0022-1317-76-7-1737; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; Chemello L, 1996, ANN INTERN MED, V124, P1058, DOI 10.7326/0003-4819-124-12-199606150-00005; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIMARTINO V, 1995, HEPATOLOGY, V22, P1216; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MARCELLIN P, 1995, GASTROENTEROLOGY, V109, P156, DOI 10.1016/0016-5085(95)90281-3; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1002/hep.1840130302; MARCELLIN P, 1994, LIVER, V14, P302; MARCELLIN P, 1994, HEPATOLOGY, V20, pA154; MARTINOTPEIGNOUX M, 1992, J INFECT DIS, V165, P595, DOI 10.1093/infdis/165.3.595; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1002/hep.1840180603; SHINDO M, 1995, ANN INTERN MED, V122, P586, DOI 10.7326/0003-4819-122-8-199504150-00005; SHINDO M, 1992, HEPATOLOGY, V15, P1013, DOI 10.1002/hep.1840150607; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993	28	480	490	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					875	+		10.7326/0003-4819-127-10-199711150-00003	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382365				2022-12-28	WOS:A1997YF54500003
J	Xu, XP; Rijcken, B; Schouten, JP; Weiss, ST				Xu, XP; Rijcken, B; Schouten, JP; Weiss, ST			Airways responsiveness and development and remission of chronic respiratory symptoms in adults	LANCET			English	Article							RANDOM-POPULATION SAMPLE; BRONCHIAL RESPONSIVENESS; PULMONARY-FUNCTION; ASTHMA; INFLAMMATION; EPIDEMIOLOGY; EOSINOPHILS; HISTAMINE; COMMUNITY; SMOKING	Background Many patients with chronic obstructive lung disease show increased airways responsiveness to histamine. We investigated the hypothesis that increased airways responsiveness predicts the development and remission of chronic respiratory symptoms. Methods We used data from 24-year follow-up (1965-90) of 2684 participants in a cohort study in Vlagtwedde and Vlaardingen, Netherlands. Increased airways responsiveness was defined as a PC10 value (concentration of histamine for which challenge led to a 10% fall in forced expiratory volume in 1 s) of less than 8 mg/mL. Information on respiratory symptoms was collected by means of a standard questionnaire every 3 years. Logistic regression was used to control for age, area of residence, cigarette smoking status, and sex. Findings Participants with increased airways responsiveness (1281 observations) were more likely than those without increased airways responsiveness (5801 observations) to develop the following symptoms during any 3-year follow-up interval: chronic cough (odds ratio 1.9 [95% CI 1.2-2.9]), chronic phlegm (2.0 [1.3-3.0]), dyspnoea (2.3 [1.5-3.5]), asthmatic attacks (3.7 [2.2-6.1]), and persistent wheeze (2.7 [1.7-4.4]). The estimate of the odds ratio for the development of any of the six symptoms was 1.7 (1.2-2.3). Participants with increased airways responsiveness were less likely than those without this characteristic to show remission of these respiratory symptoms. The estimate of the odds ratio for the remission of any of the six symptoms was 0.42 (0.28-0.61). Interpretation These prospective analyses show that increased airways responsiveness is positively associated with the development of chronic. respiratory symptoms and negatively associated with the remission of these symptoms in adults.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA; UNIV GRONINGEN, UNIV HOSP GRONINGEN, DEPT EPIDEMIOL, GRONINGEN, NETHERLANDS	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Groningen					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL049460] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49460] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FREW AJ, 1992, AM REV RESPIR DIS, V146, P878, DOI 10.1164/ajrccm/146.4.878; HELSING KJ, 1979, AM REV RESPIR DIS, V120, P1221; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; LEFKOPOULOU M, 1989, J AM STAT ASSOC, V84, P810, DOI 10.2307/2289671; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; ORIE NGM, 1961, BRONCHITIS INT S, P44; PHAM QT, 1984, BRIT J IND MED, V41, P267; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62; RIJCKEN B, 1989, AM REV RESPIR DIS, V140, P615, DOI 10.1164/ajrccm/140.3.615; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; VANDERLE.R, 1972, INT J EPIDEMIOL, V1, P47, DOI 10.1093/ije/1.1.47; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; VANDERLENDE R, 1981, CLIN RES PROC, V17, P775; VANDERLENDE R, 1969, EPIDEMIOLOGY CHRONIC; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; XU X, 1994, EUR RESPIR J, V7, P1056; XU X, 1991, American Review of Respiratory Disease, V143, pA90; XU XP, 1995, CHEST, V108, P656, DOI 10.1378/chest.108.3.656; XU XP, 1995, AM J EPIDEMIOL, V141, P554, DOI 10.1093/oxfordjournals.aje.a117471	27	94	99	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	1997	350	9089					1431	1434		10.1016/S0140-6736(97)10041-1	http://dx.doi.org/10.1016/S0140-6736(97)10041-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371166				2022-12-28	WOS:A1997YF95300009
J	Bennett, AM; Tonks, NK				Bennett, AM; Tonks, NK			Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; CYCLIN D1; MYOGENIC DIFFERENTIATION; MYOD FAMILY; FACTOR-BETA; EXPRESSION; INHIBITION; MYOBLASTS; CELLS; RAS	The signal transduction pathway or pathways linking extracellular signals to myogenesis are poorly defined. Upon mitogen withdrawal from C2C12 myoblasts, the mitogen-activated protein kinase (MAPK) p42Erk2 is inactivated concomitant with up-regulation of muscle-specific genes, Overexpression of MAPK phosphatase-1 (MKP-1) inhibited p42Erk2 activity and was sufficient to relieve the inhibitory effects of mitogens on muscle-specific gene expression. Later during myogenesis, endogenous expression of MKP-1 decreased. MKP-1 overexpression during differentiation prevented myotube formation despite appropriate expression of myosin heavy chain, This indicates that muscle-specific gene expression is necessary but not sufficient to commit differentiated myocytes to myotubes and suggests a function for the MAPKs during the early and late stages of skeletal muscle differentiation.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory				Bennett, Anton/0000-0001-5187-7599				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BENNETT AJ, UNPUB; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KONG YF, 1995, MOL CELL BIOL, V15, P5205; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	29	298	307	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1288	1291		10.1126/science.278.5341.1288	http://dx.doi.org/10.1126/science.278.5341.1288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360925				2022-12-28	WOS:A1997YG04300044
J	Dove, SK; Cooke, FT; Douglas, MR; Sayers, LG; Parker, PJ; Michell, RH				Dove, SK; Cooke, FT; Douglas, MR; Sayers, LG; Parker, PJ; Michell, RH			Osmotic stress activates phosphatidylinositol-3,5-bisphosphate synthesis	NATURE			English	Article							INOSITOL PHOSPHATE ISOMERS; LIQUID-CHROMATOGRAPHY; CELLS; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; POLYPHOSPHOINOSITIDE; TRISPHOSPHATE; PURIFICATION; METABOLISM; PATHWAY; YEAST	Inositol phospholipids play multiple roles in cell signalling systems. Two widespread eukaryotic phosphoinositide-based signal transduction mechanisms, phosphoinositidase C-catalysed phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P-2) hydrolysis and 3-OH kinase-catalysed PtdIns(4,5)P-2 phosphorylation, make the second messengers inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) sn-1,2-diacylglycerol and PtdIns(3,4,5)P-3 (refs 1-7). In addition, PtdIns(4,5)P-2 and PtdIns3P have been implicated in exocytosis and membrane trafficking(8). We now show that when the yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe are hyperosmotically stressed, they rapidly synthesize phosphatidylinositol-3,5-bisphosphate (PtdIns(3,5)P-2) by a process that involves activation of a PtdIns3P 5-OH kinase. This PtdIns(3,5)P-2 accumulation only occurs in yeasts that have an active vps34-encoded PtdIns 3-OH kinase, showing that this latter kinase makes the PtdIns3P needed for PtdIns(3,5)P-2 synthesis and indicating that PtdIns(3,5)P-2 may have a role in sorting vesicular proteins. PtdIns(3,5)P-2 is also present in mammalian and plant cells: in monkey Cos-7 cells, its labelling is inversely related to the external osmotic pressure. The stimulation of a PtdIns3P 5-OH kinase-catalysed synthesis of PtdIns(3,5)P-2, a molecule that might be a new type of phosphoinositide 'second messenger', thus appears to be central to a widespread and previously uncharacterized regulatory pathway.	UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT RHEUMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	University of Birmingham; University of Birmingham; Cancer Research UK	Dove, SK (corresponding author), UNIV BIRMINGHAM,CTR CLIN RES IMMUNOL & SIGNALLING,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Parker, Peter j/D-5192-2013; Michell, Robert H/AAT-4974-2020	Michell, Robert H/0000-0001-9422-9858; parker, peter/0000-0002-6218-2933				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOUGHNEY C, 1988, BIOCHEM J, V251, P927, DOI 10.1042/bj2510927; EINSPAHR KJ, 1988, J BIOL CHEM, V263, P5775; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Jenkinson S, 1995, Methods Mol Biol, V41, P151; LETCHER AJ, 1990, METHODS INOSITIDE RE, P31; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; WREGGETT KA, 1989, BIOCHEM J, V262, P997, DOI 10.1042/bj2620997; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	27	380	390	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					187	192		10.1038/36613	http://dx.doi.org/10.1038/36613			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367158				2022-12-28	WOS:A1997YF49400058
J	Mergener, L; Baillie, J				Mergener, L; Baillie, J			Chronic pancreatitis	LANCET			English	Article							MEDICAL-SURGICAL SERIES; INSUFFICIENCY; EXOCRINE; MALABSORPTION; PSEUDOCYSTS; SECRETION; ETIOLOGY; DRAINAGE; DIVISUM; SURGERY		DUKE UNIV, MED CTR, DEPT MED, DIV GASTROENTEROL, DURHAM, NC 27710 USA	Duke University								AHEARNE PM, 1992, AM J SURG, V163, P111, DOI 10.1016/0002-9610(92)90262-P; AMMANN RW, 1984, GASTROENTEROLOGY, V86, P820; ASHBY K, 1995, GASTROINTEST ENDOSC, V42, P306, DOI 10.1016/S0016-5107(95)70127-3; AXON ATR, 1984, GUT, V25, P1107, DOI 10.1136/gut.25.10.1107; BESS MA, 1980, JAMA-J AM MED ASSOC, V243, P246; Binmoeller KF, 1995, ENDOSCOPY, V27, P638, DOI 10.1055/s-2007-1005780; BOCKMAN DE, 1988, GASTROENTEROLOGY, V94, P1459; BOLONDI L, 1989, RADIOL CLIN N AM, V27, P815; BOZKURT T, 1994, GUT, V35, P1132, DOI 10.1136/gut.35.8.1132; BRAGANZA JM, 1988, FREE RADICALS CHEM P, P357; CASTLEMAN B, 1972, NEW ENGL J MED, V286, P1353; Cohn JA, 1997, GASTROENTEROLOGY, V112, pA434; COTTON PB, 1984, PANCREATITIS CONCEPT, P239; DEVIERE J, 1994, ENDOSCOPY, V26, P808, DOI 10.1055/s-2007-1009114; DIBISCEGLIE AM, 1984, J CLIN GASTROENTEROL, V6, P199; DIMAGNO EP, 1973, NEW ENGL J MED, V288, P813, DOI 10.1056/NEJM197304192881603; DURBEC JP, 1978, DIGESTION, V18, P337, DOI 10.1159/000198221; DURBEC JP, 1980, C INSERM, V95, P33; EVANS WB, 1966, AM J DIG DIS, V11, P594, DOI 10.1007/BF02233507; FORSMARK CE, 1997, GASTROINTESTINAL DIS, P823; GASTARD J, 1973, DIGESTION, V9, P416, DOI 10.1159/000197470; GRAHAM DY, 1979, DIGEST DIS SCI, V24, P906, DOI 10.1007/BF01311943; Grendell JH, 1993, GASTROINTESTINAL DIS, P1654; Hawes R H, 1995, Gastrointest Endosc Clin N Am, V5, P61; HOWELL DA, 1993, GASTROINTEST ENDOSC, V39, P693, DOI 10.1016/S0016-5107(93)70225-4; HUIBREGTSE K, 1994, AM J GASTROENTEROL, V89, pS66; HURWITZ M, 1992, AM J SURG, V164, P299, DOI 10.1016/S0002-9610(05)81092-X; IHSE I, 1977, DIGESTION, V15, P303, DOI 10.1159/000198016; IHSE I, 1990, BRIT J SURG, V77, P121, DOI 10.1002/bjs.1800770202; JURKOVICH GJ, 1990, SURG CLIN N AM, V70, P575; KOZAREK RA, 1994, AM J SURG, V168, P223, DOI 10.1016/S0002-9610(05)80190-4; LANKISCH PG, 1993, DIGESTION, V54, P148, DOI 10.1159/000201029; LAYER P, 1990, CHRONIC PANCREATITIS, P35; LEGER L, 1974, ANN SURG, V180, P185, DOI 10.1097/00000658-197408000-00010; Lehman G A, 1995, Gastrointest Endosc Clin N Am, V5, P145; LEHMAN GA, 1993, GASTROINTEST ENDOSC, V39, P1, DOI 10.1016/S0016-5107(93)70001-2; LEUNG JWC, 1982, GUT, V23, pA451; LEVY P, 1989, GASTROENTEROLOGY, V96, P1165, DOI 10.1016/0016-5085(89)91637-5; LITTENBERG G, 1979, MEDICINE, V58, P385, DOI 10.1097/00005792-197911000-00001; MALFERTHEINER P, 1989, RADIOL CLIN N AM, V27, P51; MAYUNOR CH, 1997, GASTROINTESTINAL DIS, P777; MIHAS AA, 1976, LANCET, V2, P1032; MULTIGNER L, 1985, GASTROENTEROLOGY, V89, P387, DOI 10.1016/0016-5085(85)90341-5; Mundorf JB, 1996, GASTROINTEST ENDOSC, V43, P481; NOVIS BH, 1975, LANCET, V2, P748; OKAZAKI K, 1988, AM J GASTROENTEROL, V83, P820; OWYANG C, 1991, TXB GASTROENTEROLOGY, P2091; PITCHUMONI CS, 1988, PANCREAS, V3, P220, DOI 10.1097/00006676-198804000-00018; PITCHUMONI CS, 1984, CLIN GASTROENTEROL, V13, P941; PITCHUMONI CS, 1990, CHRONIC PANCREATITIS, P15; PUESTOW CB, 1958, ARCH SURG-CHICAGO, V76, P898; RYAN ME, 1994, GASTROINTEST ENDOSC, V40, P133, DOI 10.1016/S0016-5107(94)70154-7; SALAM AA, 1973, SURGERY, V74, P961; SARLES H, 1989, ANNU REV MED, V40, P453; SARLES H, 1965, PANCR S BAS; SAWYER R, 1994, AM J SURG, V168, P6, DOI 10.1016/S0002-9610(05)80061-3; SHERMAN S, 1997, GASTROINTESTINAL DIS, P974; SLAFF J, 1984, GASTROENTEROLOGY, V87, P44; Sossenheimer MJ, 1997, AM J GASTROENTEROL, V92, P1113; STEER ML, 1995, NEW ENGL J MED, V332, P1482, DOI 10.1056/NEJM199506013322206; Tarnasky PR, 1997, AM J GASTROENTEROL, V92, P1125; TOSKES PP, 1971, NEW ENGL J MED, V284, P627, DOI 10.1056/NEJM197103252841202; WERNER S, 1974, ACTA CHIR SCAND, V140, P618; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; WILSON JS, 1985, GUT, V26, P882, DOI 10.1136/gut.26.9.882; Wyllie R, 1997, AM J GASTROENTEROL, V92, P1079	66	87	88	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	1997	350	9088					1379	1385		10.1016/S0140-6736(97)07332-7	http://dx.doi.org/10.1016/S0140-6736(97)07332-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365465				2022-12-28	WOS:A1997YE87200047
J	Parker, D				Parker, D			Health effects of child labour	LANCET			English	Editorial Material											Parker, D (corresponding author), MINNESOTA DEPT HLTH,POB 9441,MINNEAPOLIS,MN 55440, USA.							ASTHANA S, 1995, SOC SCI MED, V40, P177, DOI 10.1016/0277-9536(94)E0066-2; Harvey PJ, 1994, TRADING AWAY FUTURE; ISLAM MA, 1994, EUR J CLIN NUTR, V48, P416; PARKER DL, 1997, STOLEN DREAMS PORTRA; RAJU T N K, 1989, Indian Journal of Pediatrics, V56, P193, DOI 10.1007/BF02726606; SAIYED HN, 1995, INDIAN J MED RES, V102, P138	6	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1395	1396		10.1016/S0140-6736(05)65169-0	http://dx.doi.org/10.1016/S0140-6736(05)65169-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365469				2022-12-28	WOS:A1997YE87200051
J	Balcer, LJ; Galetta, SL				Balcer, LJ; Galetta, SL			Pancoast's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Balcer, LJ (corresponding author), UNIV PENN,MED CTR,PHILADELPHIA,PA 19104, USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1359	1359		10.1056/NEJM199711063371905	http://dx.doi.org/10.1056/NEJM199711063371905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358130				2022-12-28	WOS:A1997YE44600005
J	Costello, A				Costello, A			Integrated management of childhood illness	LANCET			English	Editorial Material											Costello, A (corresponding author), INST CHILD HLTH,CTR INT CHILD HLTH,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.							CHAMBERS R, 1977, WHOSE REALITY COUNTS; WHO UNICEF, 1997, INT MAN CHILDH ILLN; *WORLD BANK, 1993, WORLD DEV REP	3	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1266	1266		10.1016/S0140-6736(05)62471-3	http://dx.doi.org/10.1016/S0140-6736(05)62471-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357404				2022-12-28	WOS:A1997YD68900006
J	Scott, K; Sun, YM; Beckingham, K; Zuker, CS				Scott, K; Sun, YM; Beckingham, K; Zuker, CS			Calmodulin regulation of Drosophila light-activated channels and receptor function mediates termination of the light response in vivo	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; PHOTORECEPTOR CELL; INDUCED PHOSPHORYLATION; PROTEIN-KINASE; PHOSRESTIN-I; TRP; GENE; PHOTOTRANSDUCTION; ARRESTIN; CA2+	Calmodulin (CAM) participates in a variety of intracellular transduction processes by modulating signaling molecules in response to calcium changes. We report the characterization of Drosophila Cam mutants and the role of CAM in photoreceptor cell function. Contrary to current models of excitation and TRP channel function, we demonstrate that the transient phenotype of trp mutants can be explained by CAM regulation of the TRPL channel rather than by the loss of a store-operated conductance leading to depletion of the internal stores. We also analyzed light responses in a variety of mutant and transgenic backgrounds and demonstrate the importance of calmodulin in mediating calcium-dependent negative regulation of phototransduction. Our results show that CAM coordinates termination of the light response by modulating receptor and ion channel activity.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; RICE UNIV,DEPT BIOCHEM,HOUSTON,TX 77005; RICE UNIV,DEPT CELL BIOL,HOUSTON,TX 77005	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rice University; Rice University								Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; Arnon A, 1997, SCIENCE, V275, P1119, DOI 10.1126/science.275.5303.1119; Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN P, 1988, MOL ASPECTS CELLULAR; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DOYLE KE, 1990, J MOL BIOL, V213, P599, DOI 10.1016/S0022-2836(05)80245-1; Hardie RC, 1997, CELL CALCIUM, V21, P431, DOI 10.1016/S0143-4160(97)90054-3; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HARDIE RC, 1993, P ROY SOC B-BIOL SCI, V252, P223, DOI 10.1098/rspb.1993.0069; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Heiman RG, 1996, P NATL ACAD SCI USA, V93, P2420, DOI 10.1073/pnas.93.6.2420; Hofstee CA, 1996, VISUAL NEUROSCI, V13, P897, DOI 10.1017/S0952523800009147; Kahn ES, 1997, J NEUROCHEM, V68, P169; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; Maniatis T., 1982, MOL CLONING; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; Minke B, 1996, CURR OPIN NEUROBIOL, V6, P459, DOI 10.1016/S0959-4388(96)80050-X; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PETERSEN CH, 1995, BIOCHEM J, V311, P31; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PORTER JA, 1995, EMBO J, V14, P4450, DOI 10.1002/j.1460-2075.1995.tb00124.x; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; XU T, 1993, DEVELOPMENT, V117, P1223; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; YAMANAKA MK, 1987, NUCLEIC ACIDS RES, V15, P3335, DOI 10.1093/nar/15.8.3335; YEANDLE S, 1957, STUDIES SLOW POTENTI; YOSHIOKA T, 1983, BIOCHEM BIOPH RES CO, V111, P567, DOI 10.1016/0006-291X(83)90344-3; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	59	167	169	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					375	383		10.1016/S0092-8674(00)80421-3	http://dx.doi.org/10.1016/S0092-8674(00)80421-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363946	Bronze			2022-12-28	WOS:A1997YD94100011
J	Woronicz, JD; Gao, X; Cao, Z; Rothe, M; Goeddel, DV				Woronicz, JD; Gao, X; Cao, Z; Rothe, M; Goeddel, DV			I kappa B kinase-beta: NF-kappa B activation and complex formation with I kappa B kinase-alpha and NIK	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR; FAMILY	Activation of the transcription factor nuclear factor kappa B (NF-kappa B) by inflammatory cytokines requires the successive action or NF-kappa B-inducing kinase (NIK) and I kappa B kinase-alpha (IKK-alpha). A widely expressed protein kinase was identified that is 52 percent identical to IKK-alpha. I kappa B kinase-beta (IKK-beta) activated NF-kappa B when overexpressed and phosphorylated serine residues 32 and 36 of I kappa B-alpha and serines 19 and 23 of I kappa B-beta. The activity of IKK-beta was stimulated by tumor necrosis factor and interleukin-1 treatment. IKK-alpha and IKK-beta formed heterodimers that interacted with NIK. Overexpression of a catalytically inactive form of IKK-beta blocked cytokine-induced NF-kappa B activation. Thus, an active I kappa B kinase complex may require three distinct protein kinases.	TULARIK, S SAN FRANCISCO, CA 94080 USA									Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CONNELLY MA, 1995, CELL MOL BIOL RES, V41, P5437; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gao X., UNPUB; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUANG J, IN PRESS P NATL ACAD; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOCK BA, 1995, GENOMICS, V27, P348, DOI 10.1006/geno.1995.1054; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WORONICZ JD, UNPUB	22	1054	1119	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					866	869		10.1126/science.278.5339.866	http://dx.doi.org/10.1126/science.278.5339.866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346485				2022-12-28	WOS:A1997YD47900047
J	McIntire, SL; Reimer, RJ; Schuske, K; Edwards, RH; Jorgensen, EM				McIntire, SL; Reimer, RJ; Schuske, K; Edwards, RH; Jorgensen, EM			Identification and characterization of the vesicular GABA transporter	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; BRAIN SYNAPTIC VESICLES; CAENORHABDITIS-ELEGANS; C-ELEGANS; ACETYLCHOLINE TRANSPORTER; MONOAMINE TRANSPORTER; ACTIVE-TRANSPORT; GLUTAMATE UPTAKE; RAT-BRAIN; EXPRESSION	Synaptic transmission involves the regulated exocytosis of vesicles filled with neurotransmitter. Classical transmitters are synthesized in the cytoplasm, and so must be transported into synaptic vesicles. Although the vesicular transporters for monoamines and acetylcholine have been identified, the proteins responsible for packaging the primary inhibitory and excitatory transmitters, gamma-aminobutyric acid (GABA) and glutamate remain unknown(1,2) Studies in the nematode Caenorhabditis elegans have implicated the gene unc-47 in the release of GABA(3). Here we show that the sequence of unc-47 predicts a protein with ten transmembrane domains, that the gene is expressed by GABA neurons, and that the protein colocalizes,vith synaptic vesicles. Further, a rat homologue of unc-47 is expressed by central GABA neurons and confers vesicular GABA transport in transfected cells with kinetics and substrate specificity similar to those previously reported for synaptic vesicles from the brain. Comparison of this vesicular GABA transporter (VGAT) with a vesicular transporter for monoamines shows that there are differences in the bioenergetic dependence of transport, and these presumably account for the differences in structure. Thus VGAT is the first of a new family of neurotransmitter transporters.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL,GRAD PROGRAM CELL BIOL & BIOMED SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah								ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BRENNER S, 1974, GENETICS, V77, P71; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CARLSON MD, 1989, J NEUROCHEM, V53, P1889, DOI 10.1111/j.1471-4159.1989.tb09258.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHRISTENSEN H, 1991, EUR J PHARM-MOLEC PH, V207, P73, DOI 10.1016/S0922-4106(05)80040-9; CLARK SG, 1994, GENETICS, V137, P987; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FERGUSON EL, 1985, GENETICS, V110, P17; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; FYKSE EM, 1988, J NEUROCHEM, V50, P1237, DOI 10.1111/j.1471-4159.1988.tb10599.x; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; NAITO S, 1983, J BIOL CHEM, V258, P696; NONET MI, IN PRESS J NEUROSCI; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; SASSOON D, 1993, GUIDE TECHNIQUES MOU, P384; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	30	649	671	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					870	876		10.1038/39908	http://dx.doi.org/10.1038/39908			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349821				2022-12-28	WOS:A1997YC14800062
J	Sisk, JE; Moskowitz, AJ; Whang, W; Lin, JD; Fedson, DS; McBean, AM; Plouffe, JF; Cetron, MS; Butler, JC				Sisk, JE; Moskowitz, AJ; Whang, W; Lin, JD; Fedson, DS; McBean, AM; Plouffe, JF; Cetron, MS; Butler, JC			Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STREPTOCOCCUS-PNEUMONIAE; TENTATIVE GUIDELINES; ECONOMIC EVALUATIONS; RISK; EFFICACY; COUNTY; IMMUNIZATION; POPULATION; INFLUENZA; DISEASE	Context.-Clinical, epidemiologic, and policy considerations support updating the cost-effectiveness of pneumococcal vaccination for elderly people and targeting the evaluation only to prevention of pneumococcal bacteremia. Objective.-To assess the implications for medical costs and health effects of vaccination against pneumococcal bacteremia in elderly people. Design.-Cost-effectiveness analysis of pneumococcal vaccination compared with no vaccination, from a societal perspective. Setting and Participants.-The elderly population aged 65 years and older in the United States in 3 geographic areas: metropolitan Atlanta, Ga; Franklin County, Ohio; and Monroe County, New York. Main Outcome Measures.-Incremental medical costs and health effects, expressed in quality-adjusted life-years per person vaccinated. Results.-Vaccination was cost saving, ie, it both reduced medical expenses and improved health, for all age groups and geographic areas analyzed in the base case, For people aged 65 years and older, vaccination saved $8.27 and gained 1.21 quality-adjusted days of life per person vaccinated, Vaccination of the 23 million elderly people unvaccinated in 1993 would have gained about 78 000 years of healthy life and saved $194 million, In univariate sensitivity analysis, the results remained cost saving except for doubling vaccination costs, including future medical costs of survivors, and lowering vaccination effectiveness, With assumptions most unfavorable to vaccination, cost per quality-adjusted life-year ranged from $35 822 for ages 65 to 74 years to $598 487 for ages 85 years and older. In probabilistic sensitivity analysis, probability intervals were more narrow, with less than 5% probability that the ratio for ages 85 years and older would exceed $100 000. Conclusions.-Pneumococcal vaccination saves costs in the prevention of bacteremia alone and is greatly underused among the elderly population, on both health and economic grounds. These results support recent recommendations of the Advisory Committee on Immunization Practices and public and private efforts under way to improve vaccination rates.	SUNY STONY BROOK, STONY BROOK, NY 11794 USA; PASTEUR MERIEUX MSD, LYON, FRANCE; UNIV MINNESOTA, MINNEAPOLIS, MN USA; OHIO STATE UNIV, COLUMBUS, OH 43210 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Sanofi-Aventis; Sanofi France; University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Ohio State University; Centers for Disease Control & Prevention - USA	Sisk, JE (corresponding author), COLUMBIA UNIV, SCH PUBL HLTH, DIV HLTH POLICY & MANAGEMENT, 600 W 168TH ST, 6TH FLOOR, NEW YORK, NY 10032 USA.		Whang, William/AAE-3853-2019	Moskowitz, Alan/0000-0002-4412-9450				*ACP TASK FORC AD, 1994, GUID AD IMM, P107; AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013; BENNETT NM, 1992, AM J PUBLIC HEALTH, V82, P1513, DOI 10.2105/AJPH.82.11.1513; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CAMPBELL JF, 1989, HAWAII MED J, V48, P517; *CDC, 1984, MMWR-MORBID MORTAL W, V33, P273; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P506; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; CHIANG CL, 1991, ANNU REV PUBL HEALTH, V12, P281, DOI 10.1146/annurev.pu.12.050191.001433; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; ERICKSON P, 1995, STAT NOTES, V7, P1; FARR BM, 1995, ARCH INTERN MED, V155, P2336, DOI 10.1001/archinte.155.21.2336; Fedson D S, 1992, Clin Geriatr Med, V8, P183; FEDSON D S, 1990, Journal of the American Medical Association, V264, P1117, DOI 10.1001/jama.264.9.1117; Fedson D S, 1993, Semin Respir Infect, V8, P285; FEDSON DS, 1994, ARCH INTERN MED, V154, P2531, DOI 10.1001/archinte.154.22.2531; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V272, P113; Fedson DS, 1994, VACCINES, P517; FORRESTER HL, 1987, AM J MED, V83, P425, DOI 10.1016/0002-9343(87)90751-0; GAILLAT J, 1985, REV EPIDEMIOL SANTE, V33, P437; Gold MR, 1996, COST EFFECTIVENESS H; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS14; HILLIER FS, 1974, OPER RES, P620; HIRSCHMANN JV, 1994, ARCH INTERN MED, V154, P373, DOI 10.1001/archinte.154.4.373; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; ISTRE GR, 1987, J INFECT DIS, V156, P732, DOI 10.1093/infdis/156.5.732; KEELER EB, 1983, MANAGE SCI, V29, P300, DOI 10.1287/mnsc.29.3.300; LASCHOBER MA, 1996, HLTH HLTH CARE MED P, P44; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MCBEAN AM, 1991, ARCH INTERN MED, V151, P2009, DOI 10.1001/archinte.151.10.2009; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; PLOUFFE JF, 1994, J CLIN MICROBIOL, V32, P1606, DOI 10.1128/JCM.32.6.1606-1607.1994; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; RIDDIOUGH M A, 1983, Journal of the American Medical Association, V249, P3189, DOI 10.1001/jama.249.23.3189; Schoenbaum S C, 1993, HMO Pract, V7, P5; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMBERKOFF MS, 1994, SEMIN RESPIR INFECT, V8, P294; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SISK JE, 1986, ANN INTERN MED, V104, P78; *US C OFF TECHN AS, 1990, COSTS EFF COL CANC S; *US C OFF TECHN AS, 1990, COSTS EFF CERV CANC; *US COUNC EC ADV, 1997, EC REP PRES, P365; *US PHS, 1991, HLTH PEOPL 2000 NAT; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WILLEMS JS, 1980, NEW ENGL J MED, V303, P553, DOI 10.1056/NEJM198009043031004; WILLEMS JS, 1981, J INFECT DIS, V144, P486, DOI 10.1093/infdis/144.5.486; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616	52	267	276	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1333	1339		10.1001/jama.278.16.1333	http://dx.doi.org/10.1001/jama.278.16.1333			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343464				2022-12-28	WOS:A1997YA90500034
J	Ellis, SJ; Matthews, C				Ellis, SJ; Matthews, C			Keeping patients informed	LANCET			English	Letter											Ellis, SJ (corresponding author), UNIV KEELE,DEPT NEUROL,KEELE ST5 4LN,STAFFS,ENGLAND.			Ellis, Simon/0000-0002-9131-6427				Audit Commission, 1993, WHAT SEEMS BE MATT C; ELLIS DA, 1979, BRIT MED J, V1, P456, DOI 10.1136/bmj.1.6161.456; Ley P., 1976, COMMUNICATION DOCTOR, P77; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; SNAITH RP, 1994, HOSPITAL ANXIETY DEP	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1180	1181		10.1016/S0140-6736(05)63831-7	http://dx.doi.org/10.1016/S0140-6736(05)63831-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343535				2022-12-28	WOS:A1997YB19900064
J	Sergeant, P; Meyns, B				Sergeant, P; Meyns, B			Criticism is easy but art is difficult	LANCET			English	Editorial Material											Sergeant, P (corresponding author), UNIV HOSP GASTHUISBERG,DEPT SURG,B-3000 LOUVAIN,BELGIUM.							BLACKSTONE EH, 1986, J AM STAT ASSOC, V81, P615, DOI 10.2307/2288989; FERRAZZI P, 1986, J THORAC CARDIOVASC, V92, P187; Sergeant P, 1997, EUR J CARDIO-THORAC, V11, P2, DOI 10.1016/S1010-7940(96)01032-9; SERGEANT P, 1990, EUR J CARDIO-THORAC, V4, P72, DOI 10.1016/1010-7940(90)90218-O	4	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1114	1115		10.1016/S0140-6736(97)22042-8	http://dx.doi.org/10.1016/S0140-6736(97)22042-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343493				2022-12-28	WOS:A1997YB19900002
J	Hajduk, PJ; Meadows, RP; Fesik, SW				Hajduk, PJ; Meadows, RP; Fesik, SW			Drug design - Discovering high-affinity ligands for proteins	SCIENCE			English	Editorial Material											Hajduk, PJ (corresponding author), ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064, USA.							BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/bf00124387; ECKER DJ, 1995, BIO-TECHNOL, V13, P351, DOI 10.1038/nbt0495-351; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hajduk PJ, 1997, J MED CHEM, V40, P3144, DOI 10.1021/jm9703404; HAJDUK PJ, IN PRESS J AM CHEM S; HAJDUK PJ, 1997, IN PRESS J AM CHEM S, V119, P5818; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; OLEJNICZAK ET, 1997, IN PRESS J AM CHEM S, V119, P5828; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; VERLINDE CLMJ, 1992, J COMPUT AID MOL DES, V6, P131, DOI 10.1007/BF00129424	12	172	182	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					497	&		10.1126/science.278.5337.497	http://dx.doi.org/10.1126/science.278.5337.497			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381145				2022-12-28	WOS:A1997YB35500054
J	Hoyt, MA				Hoyt, MA			Eliminating all obstacles: Regulated proteolysis in the eukaryotic cell cycle	CELL			English	Review							UBIQUITIN; START; G1				Hoyt, MA (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.							Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; HENCHOZ S, 1997, IN PRESS GENES DEV; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUBBARD EJA, 1997, IN PRESS GENES DEV; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHOTT EJ, 1997, IN PRESS GENETICS; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; VERMA R, 1997, IN PRESS SCIENCE; VISINTIN R, 1997, IN PRESS SCIENCE; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	18	81	81	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					149	151		10.1016/S0092-8674(00)80396-7	http://dx.doi.org/10.1016/S0092-8674(00)80396-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346231	hybrid			2022-12-28	WOS:A1997YC35000001
J	Doull, IJM; Lampe, FC; Smith, S; Schreiber, J; Freezer, NJ; Holgate, ST				Doull, IJM; Lampe, FC; Smith, S; Schreiber, J; Freezer, NJ; Holgate, ST			Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-FUNCTION; BECLOMETHASONE DIPROPIONATE; PRESCHOOL-CHILDREN; ASTHMA; RESPONSIVENESS; ATTACKS	Objectives: To determine the effect of regular prophylactic inhaled corticosteroids on wheezing episodes associated with viral infection in school age children. Design: Randomised, double blind, placebo controlled trial. Setting: Community based study in Southampton. Subjects: 104 children aged 7 to 9 years who had had wheezing in association with symptoms of upper and lower respiratory tract infection in the preceding 12 months. Interventions: After a run in period of 2-6 weeks children were randomly allocated twice daily inhaled beclomethasone dipropionate 200 mu g or placebo through a Diskhaler for 6 months with a wash out period of 2 months. Children were assessed monthly. Main outcome measures: Forced expiratory volume in 1 second (FEV1); bronchial responsiveness to methacholine (PD20); percentage of days with symptoms of upper and lower respiratory tract infection with frequency, severity, and duration of episodes of upper and lower respiratory symptoms and of reduced peak expiratory flow rate. Results: During the treatment period there was a significant increase in mean FEV1 (1.63 v 1.53 1; adjusted difference 0.09 1 (95% confidence interval 0.04 to 0.14); P = 0.001) and methacholine PD20 (12.8 v 7.2 mu mol/l; adjusted ratio of means 1.7 (1.2 to 2.4); P = 0.007) in children receiving beclomethasone dipropionate compared with placebo. There were, however no significant differences in the percentage of days with symptoms or in the frequency severity or duration of episodes of upper or lower respiratory symptoms or of reduced peak expiratory now rate during the treatment period between the two groups. Conclusions: Although lung function is improved with regular beclomethasone dipropionate 400 mu g/day, this treatment offers no clinically significant benefit in school age children with wheezing episodes associated with viral infection.	UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, CTR BLOCK, SOUTHAMPTON, HANTS, ENGLAND	University of Southampton			Lampe, Fiona/I-5826-2019; Doull, Iolo/Y-6174-2019	Lampe, Fiona/0000-0001-6851-5471; 				BRUNETTE MG, 1988, PEDIATRICS, V81, P624; CLOUGH JB, 1994, AM J RESP CRIT CARE, V150, P48, DOI 10.1164/ajrccm.150.1.8025771; CONNETT G, 1993, ARCH DIS CHILD, V68, P85, DOI 10.1136/adc.68.1.85; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KESTEN S, 1994, CHEST, V105, P1077, DOI 10.1378/chest.105.4.1077; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; ROSENTHAL M, 1993, THORAX, V48, P794, DOI 10.1136/thx.48.8.794; SILVERMAN M, 1993, THORAX, V48, P1200, DOI 10.1136/thx.48.12.1200; SPENCE DPS, 1994, AM J RESP CRIT CARE, V149, P1142, DOI 10.1164/ajrccm.149.5.8173754; STICK SM, 1995, ARCH DIS CHILD, V73, P327, DOI 10.1136/adc.73.4.327; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; WILSON N, 1995, ARCH DIS CHILD, V72, P317, DOI 10.1136/adc.72.4.317; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	17	113	114	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	1997	315	7112					858	862		10.1136/bmj.315.7112.858	http://dx.doi.org/10.1136/bmj.315.7112.858			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353508	Green Published			2022-12-28	WOS:A1997YA00700028
J	Modell, B; Petrou, M; Layton, M; Varnavides, L; Slater, C; Ward, RHT; Rodeck, C; Nicolaides, K; Gibbons, S; Fitches, A; Old, J				Modell, B; Petrou, M; Layton, M; Varnavides, L; Slater, C; Ward, RHT; Rodeck, C; Nicolaides, K; Gibbons, S; Fitches, A; Old, J			Audit of prenatal diagnosis for haemoglobin disorders in the United Kingdom: the first 20 years	BRITISH MEDICAL JOURNAL			English	Article							ANTENATAL DIAGNOSIS; THALASSEMIA; HEMOGLOBINOPATHIES; UK	Objectives: To audit services for prenatal diagnosis for haemoglobin disorders in the United Kingdom. Design: Comparison of the annual number of cases recorded in a United Kingdom register of prenatal diagnoses for haemoglobin disorders, with the annual number of pregnancies at risk of these disorders, by ethnic group and regional health authority The number of pregnancies at risk was estimated using data on ethnic group from the 1991 census and data from the United Kingdom thalassaemia register, which records the number of babies born with thalassaemia. Setting: The three national prenatal diagnosis centres for haemoglobin disorders. Subjects: 2068 cases of prenatal diagnosis for haemoglobin disorders in the United Kingdom from 1974 to 1994. Main outcome measures: Utilisation of prenatal diagnosis by risk, ethnic group, and regional health authority. Proportion of referrals in the first trimester and before the birth of any affected child. Results: National utilisation of prenatal diagnosis for haemoglobin disorders was around 20%, During the past 10 years it has remained steady at about 50% for thalassaemias and risen from 7% to 13% for sickle cell disorders, Utilisation for sickle cell disorders varies regionally from 2% to 20%. Utilisation for thalassaemias varies by ethnic group, It is almost 90% for Cypriots and ranges regionally for British Pakistanis from 0% to over 60%. About 60% of first prenatal diagnoses are done for couples without an affected child, Less than 50% of first referrals are in the first trimester. Conclusions: National utilisation of prenatal diagnosis for haemoglobin disorders is far lower than expected, and there are wide regional variations. A high proportion of referrals are still in the second trimester and after the birth of an affected child, The findings point to serious shortcomings in present antenatal screening practice and in local screening policies and to inadequate counselling resources, especially for British Pakistanis.	ROYAL FREE SCH MED, ARCHWAY RESOURCE CTR, WHITTINGTON HOSP, LONDON N19 5HT, ENGLAND; UCL, SCH MED, DEPT OBSTET & GYNAECOL, LONDON WC1E 6HX, ENGLAND; UNIV LONDON KINGS COLL HOSP, DEPT HAEMATOL MED, LONDON SE5 9RS, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, DEPT OBSTET & GYNAECOL, LONDON SE5 8RX, ENGLAND; UCL, SCH MED, WHITTINGTON HOSP, DEPT PRIMARY CARE & POPULAT SCI, LONDON N19 5HT, ENGLAND; INST MOL MED, OXFORD OX3 9DU, ENGLAND	University of London; University College London; University of London; University College London; UCL Medical School; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London; University of London; University College London; UCL Medical School; University of Oxford			Fitches, Alison/ABF-3962-2020	Nicolaides, Kypros/0000-0003-1266-0711	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTER BP, 1976, NEW ENGL J MED, V295, P1437, DOI 10.1056/NEJM197612232952601; ANGASTINIOTIS MA, 1981, LANCET, V1, P369; ANIONWU EN, 1996, RES CULTURAL DIFFERE, P100; ANIONWU EN, 1987, J MED GENET, V25, P769; CAO A, 1993, BAILLIERE CLIN HAEM, V6, P263, DOI 10.1016/S0950-3536(05)80072-1; DARR A, 1991, THESIS U LONDON LOND; FAIRWEATHER DVI, 1978, BRIT MED J, V1, P350, DOI 10.1136/bmj.1.6109.350; Harris R, 1996, J ROY COLL PHYS LOND, V30, P316; *HLTH ED AUTH, IN PRESS SUCKL CELL; MATSAKIS M, 1980, BRIT J HAEMATOL, V45, P185; MODELL B, 1996, ETHNICITY HLTH REV L; MODELL B, 1972, BRIT MED J, V2, P737; MODELL B, 1980, BRIT MED J, V2, P737; MODELL B, 1992, WHO REGIONAL PUBLICA, V38; Neuenschwander H, 1997, BRIT MED J, V315, P784; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; OLD JM, 1990, LANCET, V336, P834, DOI 10.1016/0140-6736(90)92338-I; OLD JM, 1982, LANCET, V2, P1413; OWEN D, 1996, ETHNICITY 1991 CENSU, V1, P80; PETROU M, 1992, BRIT J OBSTET GYNAEC, V99, P985, DOI 10.1111/j.1471-0528.1992.tb13703.x; Petrou M, 1995, PRENATAL DIAG, V15, P1275, DOI 10.1002/pd.1970151308; PETROU M, 1992, J MED GENET, V29, P820, DOI 10.1136/jmg.29.11.820; PETROU M, 1990, ANN NY ACAD SCI, V612, P251; ROBERTS BE, 1988, CLIN LAB HAEMATOL, V10, P87; RODECK CH, 1989, PERINATAL HEMATOLOGY, P1; ROWLEY PT, 1987, BIRTH DEFECTS ORIG B, V5; *ROYAL COLL PHYS L, 1989, PREN DIAGN GEN SCREE; WARD RHT, 1983, BRIT MED J, V286, P1542, DOI 10.1136/bmj.286.6377.1542; *WORK PART STAND M, 1994, REPORT	29	54	54	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					779	784						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345170	Green Published			2022-12-28	WOS:A1997XY91100020
J	Muzio, M; Ni, J; Feng, P; Dixit, VM				Muzio, M; Ni, J; Feng, P; Dixit, VM			IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling	SCIENCE			English	Article							INTERLEUKIN-1 RECEPTOR; DORSOVENTRAL SIGNAL; DROSOPHILA EMBRYO; DEATH DOMAIN; KINASE; ACTIVATION; TUBE; TRANSDUCTION; EXPRESSION; PROTEINS	The interleukin-1 receptor (IL-1R) signaling pathway leads to nuclear factor kappa B (NF-kappa B) activation in mammals and is similar to the Toll pathway in Drosophila: the IL-1R-associated kinase (IRAK) is homologous to Pelle. Two additional proximal mediators were identified that are required for IL-1R-induced NF-kappa B activation: IRAK-2, a Pelle family member, and MyD88, a death domain-containing adapter molecule. Both associate with the IL-IR signaling complex. Dominant negative forms of either attenuate IL-1R-mediated NF-kappa B activation. Therefore, IRAK-2 and MyD88 may provide additional therapeutic targets for inhibiting IL-1-induced inflammation.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			Muzio, Marta/J-9360-2018; dixit, vishva m/A-4496-2012	Muzio, Marta/0000-0002-7761-759X; dixit, vishva m/0000-0001-6983-0326				Bonnert TP, 1997, FEBS LETT, V402, P81, DOI 10.1016/S0014-5793(96)01506-2; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eriksson A, 1995, CYTOKINE, V7, P649; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hardiman G, 1996, ONCOGENE, V13, P2467; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LORD KA, 1990, ONCOGENE, V5, P1095; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MEDZHITOV R, 1997, NATURE, V38, P394; Norris JL, 1996, GENE DEV, V10, P862, DOI 10.1101/gad.10.7.862; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Singh R, 1997, J CLIN INVEST, V100, P419, DOI 10.1172/JCI119549; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727	27	946	1022	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1612	1615		10.1126/science.278.5343.1612	http://dx.doi.org/10.1126/science.278.5343.1612			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374458				2022-12-28	WOS:A1997YJ87400037
J	Naylor, CD; Sermer, M; Chen, EL; Farine, D				Naylor, CD; Sermer, M; Chen, EL; Farine, D			Selective screening for gestational diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOLERANCE TEST VALUE; GLUCOSE-TOLERANCE; PERINATAL MORBIDITY; RISK-FACTORS; PREGNANCY; CRITERIA; WOMEN; DELIVERY; IMPACT; WEIGHT	Background The usual approach to detecting gestational diabetes mellitus is to screen all pregnant women by measuring their plasma glucose after a 50-g oral glucose load at 24 to 28 weeks' gestation. Women are referred for an oral glucose-tolerance test if the plasma glucose concentration one hour later is greater than or equal to 140 mg per deciliter (7.8 mmol per liter). We hypothesized that the efficiency of screening could be enhanced by considering women's risks of gestational diabetes on the basis of their clinical characteristics. Methods We studied 3131 pregnant women who underwent both the screening and the diagnostic tests. We randomly selected data on half the women and used them to derive new screening strategies. We categorized each woman's risk of gestational diabetes mellitus on the basis of her age, body-mass index before pregnancy, and race. We developed strategies that entailed no screening for low-risk women, usual care for intermediate-risk women, and universal screening with lower thresholds - plasma glucose values of 130 mg per deciliter (7.2 mmol per liter) or 128 mg per deciliter (7.1 mmol per liter) - for high-risk women. The strategies were validated with data on the other half of the women. Results The new strategies allowed a 34.6 percent reduction in the number of screening tests performed (95 percent confidence interval, 32.3 to 37.0 percent) and detected 81.2 to 82.6 percent of the women with gestational diabetes as compared with the 78.3 percent detected through usual care. The percentage of false positive screening tests was significantly reduced, from 19.9 percent with usual care to 16.0 percent (P = 0.02) or 15.4 percent (P < 0.001) with the new strategies, depending on the threshold values for high-risk women. Conclusions Consideration of women's clinical characteristics allows efficient selective screening for gestational diabetes. (C) 1997, Massachusetts Medical Society.	UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; TORONTO HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5T 2S8,CANADA; MT SINAI HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT OBSTET & GYNECOL,TORONTO,ON,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Naylor, CD (corresponding author), SUNNYBROOK HLTH SCI CTR,INST CLIN EVALUAT SCI,CLIN EPIDEMIOL UNIT,G106,2075 BAYVIEW AVE,N YORK,ON M4N 3M5,CANADA.							*AM DIAB ASS, 1987, AM J OBSTET GYNECOL, V156, P488; BERKOWITZ GS, 1992, AM J EPIDEMIOL, V135, P965, DOI 10.1093/oxfordjournals.aje.a116408; *CAN TASK FORC PER, 1992, CMAJ, V147, P435; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COUSTAN DR, 1986, AM J OBSTET GYNECOL, V154, P1031, DOI 10.1016/0002-9378(86)90744-1; COUSTAN DR, 1989, OBSTET GYNECOL, V73, P557; COUSTAN DR, 1984, AM J OBSTET GYNECOL, V150, P836, DOI 10.1016/0002-9378(84)90459-9; COUSTAN DR, 1985, CLIN OBSTET GYNECOL, V28, P507, DOI 10.1097/00003081-198528030-00006; DIETRICH ML, 1987, AM J OBSTET GYNECOL, V156, P1403, DOI 10.1016/0002-9378(87)90007-X; DORNHORST A, 1992, DIABETIC MED, V9, P820, DOI 10.1111/j.1464-5491.1992.tb01900.x; *EXP COMM DIAGN CL, 1997, DIABETES CARE S1, V20, pS1183; GABBE SG, 1986, NEW ENGL J MED, V315, P1025, DOI 10.1056/NEJM198610163151609; GABBE SG, 1977, AM J OBSTET GYNECOL, V127, P465, DOI 10.1016/0002-9378(77)90436-7; GREEN JR, 1990, AM J OBSTET GYNECOL, V163, P86, DOI 10.1016/S0002-9378(11)90675-9; KITZMILLER JL, 1978, AM J OBSTET GYNECOL, V131, P560, DOI 10.1016/0002-9378(78)90120-5; LANGER O, 1987, AM J OBSTET GYNECOL, V157, P758, DOI 10.1016/S0002-9378(87)80045-5; LINDSAY MK, 1989, OBSTET GYNECOL, V73, P103; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MARQUETTE GP, 1985, OBSTET GYNECOL, V66, P181; METZGER BE, 1991, DIABETES, V40, P197, DOI 10.2337/diab.40.2.S197; NAHUM GG, 1993, OBSTET GYNECOL, V81, P517; *NAT DIAB DAT GROU, 1979, DIABETES, V28, P1039; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P1165, DOI 10.1001/jama.275.15.1165; OSULLIVAN JB, 1973, AM J OBSTET GYNECOL, V116, P895; OSULLIVAN JB, 1980, DIABETES CARE, V3, P437, DOI 10.2337/diacare.3.3.437; OWEN J, 1995, AM J OBSTET GYNECOL, V172, P615, DOI 10.1016/0002-9378(95)90581-2; Peters RK, 1996, LANCET, V347, P227, DOI 10.1016/S0140-6736(96)90405-5; *PREV SERV TASK FO, 1996, GUID CLIN PREV SERV, P193; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; SERMER M, 1994, AM J OBSTET GYNECOL, V171, P607, DOI 10.1016/0002-9378(94)90072-8; Tu JV, 1997, J CLIN EPIDEMIOL, V50, P743, DOI 10.1016/S0895-4356(97)89028-2; WALKINSHAW SA, 1995, PREGNANCY CHILDBIRTH; WALKINSHAW SA, 1997, PREGNANCY CHILDBIRTH; WEEKS JW, 1994, AM J OBSTET GYNECOL, V171, P1003, DOI 10.1016/0002-9378(94)90023-X; Widness J A, 1985, Diabetes, V34 Suppl 2, P61; 1985, DIABETES S2, V34, P123	37	178	186	1	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1591	1596		10.1056/NEJM199711273372204	http://dx.doi.org/10.1056/NEJM199711273372204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371855	Bronze			2022-12-28	WOS:A1997YH52100004
J	Beaufort, L; Lancelot, Y; Camberlin, P; Cayre, O; Vincent, E; Bassinot, F; Labeyrie, L				Beaufort, L; Lancelot, Y; Camberlin, P; Cayre, O; Vincent, E; Bassinot, F; Labeyrie, L			Insolation cycles as a major control equatorial Indian Ocean primary production	SCIENCE			English	Article							ARABIAN SEA; MONSOON; CLIMATE; ATMOSPHERE; ATLANTIC; PACIFIC; TEMPERATURE; QUATERNARY; GLACIATION; PRECESSION	Analysis of a continuous sedimentary record taken in the Maldives indicates that strong primary production fluctuations (70 to 390 grams of carbon per square meter per year) have occurred in the equatorial Indian Ocean during the past 910,000 years. The record of primary production is coherent and in phase with the February equatorial insolation, whereas it shows diverse phase behavior with delta(18)O, depending on the orbital frequency (eccentricity, obliquity, or precession) examined. These observations imply a direct control of productivity in the equatorial oceanic system by insolation. In the equatorial Indian Ocean, productivity is driven by the wind intensity of westerlies, which is related to the Southern Oscillation; therefore, it is suggested that a precession forcing on the Southern Oscillation is responsible for the observed paleoproductivity dynamics.	UNIV BOURGOGNE,CTR RECH CLIMATOL,F-21004 DIJON,FRANCE; CEA,CNRS,CTR FAIBLES RADIOACTIVITES,F-91198 GIF SUR YVETTE,FRANCE	Universite de Bourgogne; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Beaufort, L (corresponding author), CEREGE,CNRS,GEOL QUATERNAIRE LAB,BOITE POSTALE 80,F-13545 AIX PROVENCE 4,FRANCE.		Labeyrie, Laurent Denis/AAV-8405-2021; Beaufort, Luc/ABG-2289-2021; Beaufort, Luc/AAH-5305-2021	Labeyrie, Laurent Denis/0000-0002-1554-2449; Beaufort, Luc/0000-0001-6055-9373; Camberlin, Pierre/0000-0003-4896-2332				Antoine D, 1996, GLOBAL BIOGEOCHEM CY, V10, P57, DOI 10.1029/95GB02832; BASSINOT FC, 1994, EARTH PLANET SC LETT, V126, P91, DOI 10.1016/0012-821X(94)90244-5; Beaufort L, 1996, QUATERN INT, V31, P13, DOI 10.1016/1040-6182(95)00017-D; Beaufort L., 1994, GLOBAL PRECIPITATION, P27, DOI [10.1007/978-3-642-79268-7_2, DOI 10.1007/978-3-642-79268-7_2]; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; BJERKNES J, 1969, MON WEATHER REV, V97, P163, DOI 10.1175/1520-0493(1969)097<0163:ATFTEP>2.3.CO;2; BROECKER WS, 1982, PROG OCEANOGR, V11, P151, DOI 10.1016/0079-6611(82)90007-6; Caulet J.P., 1992, Geological Society Special Publication, P379; CAYRE O, IN PRESS QUAT SCI RE; Clemens SC, 1990, PALEOCEANOGRAPHY, V5, P109, DOI 10.1029/PA005i002p00109; DUPLESSY JC, 1982, NATURE, V295, P494, DOI 10.1038/295494a0; EMEIS KC, 1995, QUATERNARY RES, V43, P355, DOI 10.1006/qres.1995.1041; Flohn H., 1971, BONNER METEOR ABHAND, V15, P180; FONTUGNE MR, 1986, PALAEOGEOGR PALAEOCL, V56, P69, DOI 10.1016/0031-0182(86)90108-2; HASTENRATH S, 1993, J GEOPHYS RES-OCEANS, V98, P20219, DOI 10.1029/93JC02330; IMBRIE J, 1980, SCIENCE, V207, P943, DOI 10.1126/science.207.4434.943; IMBRIE J, 1993, PALEOCEANOGRAPHY, V8, P699, DOI 10.1029/93PA02751; Imbrie J, 1992, PALEOCEANOGRAPHY, V7, P701, DOI 10.1029/92PA02253; KEIR RS, 1983, J GEOPHYS RES-OCEANS, V88, P6027, DOI 10.1029/JC088iC10p06027; Knox R. A., 1987, MONSOONS, P365; LAU KM, 1988, J ATMOS SCI, V45, P506, DOI 10.1175/1520-0469(1988)045<0506:IAIVOT>2.0.CO;2; LAU KM, 1994, J ATMOS SCI, V51, P1169, DOI 10.1175/1520-0469(1994)051<1169:MLFCMI>2.0.CO;2; LYLE M, 1988, NATURE, V335, P529, DOI 10.1038/335529a0; LYLE MW, 1992, NATURE, V355, P812, DOI 10.1038/355812a0; McIntyre A, 1996, SCIENCE, V274, P1867, DOI 10.1126/science.274.5294.1867; MOLFINO B, 1990, SCIENCE, V249, P766, DOI 10.1126/science.249.4970.766; OKADA H, 1973, DEEP-SEA RES, V20, P355, DOI 10.1016/0011-7471(73)90059-4; POKRAS EM, 1987, NATURE, V326, P486, DOI 10.1038/326486a0; Prell W. L., 1985, 025 TR US DEP EN; PRELL WL, 1981, OCEANOL ACTA, V4, P91; SALBY ML, 1994, J ATMOS SCI, V51, P2207, DOI 10.1175/1520-0469(1994)051<2207:IBOCTA>2.0.CO;2; SARKAR A, 1990, NATURE, V343, P549, DOI 10.1038/343549a0; SHACKLETON NJ, 1983, NATURE, V306, P319, DOI 10.1038/306319a0; SHACKLETON NJ, 1985, GEOPHYS MONOGR SER, V32, P303; SIROCKO F, 1993, NATURE, V364, P322, DOI 10.1038/364322a0; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; WOODRUFF SD, 1987, B AM METEOROL SOC, V68, P1239, DOI 10.1175/1520-0477(1987)068<1239:ACOADS>2.0.CO;2; YASUNARI T, 1991, B AM METEOROL SOC, V72, P1331, DOI 10.1175/1520-0477(1991)072<1331:TMYNCO>2.0.CO;2; [No title captured]	39	249	284	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1451	1454		10.1126/science.278.5342.1451	http://dx.doi.org/10.1126/science.278.5342.1451			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367955				2022-12-28	WOS:A1997YG85800041
J	Kigotho, AW				Kigotho, AW			HIV-1 statistics bring good news for Uganda	LANCET			English	News Item																			0	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1456	1456		10.1016/S0140-6736(05)64230-4	http://dx.doi.org/10.1016/S0140-6736(05)64230-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371180				2022-12-28	WOS:A1997YF95300037
J	Hamilton, T				Hamilton, T			Facing the future	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1471	1472						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363951				2022-12-28	WOS:A1997YE44500001
J	Welsh, J				Welsh, J			Nurses at risk	LANCET			English	Editorial Material											Welsh, J (corresponding author), AMNESTY INT BRITISH SECT,MED OFF,1 EASTON ST,LONDON WC1X 8DJ,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1396	1396		10.1016/S0140-6736(05)65170-7	http://dx.doi.org/10.1016/S0140-6736(05)65170-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365470				2022-12-28	WOS:A1997YE87200052
J	DiPrisco, GV; Pearlstein, E; Robitaille, R; Dubuc, R				DiPrisco, GV; Pearlstein, E; Robitaille, R; Dubuc, R			Role of sensory-evoked NMDA plateau potentials in the initiation of locomotion	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; RETICULOSPINAL NEURONS; BRAIN-STEM; SPINAL-CORD; MEMBRANE-PROPERTIES; FICTIVE LOCOMOTION; SEA LAMPREY; ACTIVATION; RECEPTORS; NETWORK	Reticulospinal (RS) neurons constitute the main descending motor system of lampreys. This study reports an natural conditions whereby N-methyl-D-aspartate (NMDA)-mediated plateau potentials were elicited and associated with the onset of locomotion. Reticulospinal neurons responded in a linear fashion to mild skin stimulation. With stronger stimuli, large depolarizing plateaus with spiking activity were elicited and were accompanied by swimming movements, Calcium imaging revealed sustained intracellular calcium rise upon sensory stimulation. Blocking NMDA receptors on RS neurons prevented the plateau potentials as well as the associated rise in intracellular calcium. Thus, the activation of NMDA receptors mediates a switch from sensory-reception mode to a motor command mode in RS neurons.	UNIV QUEBEC, DEPT KINANTHROPOL, MONTREAL, PQ H3C 3P8, CANADA; UNIV MONTREAL, DEPT PHYSIOL, CTR RECH SCI NEUROL, MONTREAL, PQ H3C 3J7, CANADA	University of Quebec; University of Quebec Montreal; Universite de Montreal			Pearlstein, Edouard/P-4616-2016	Pearlstein, Edouard/0000-0001-9405-5667; Robitaille, Richard/0000-0001-6628-0146				BOWERMAN RF, 1976, COMP BIOCHEM PHYS A, V54, P1, DOI 10.1016/S0300-9629(76)80061-8; BRODIN L, 1985, BRAIN RES, V360, P139, DOI 10.1016/0006-8993(85)91229-6; BRODIN L, 1988, ARCH ITAL BIOL, V126, P317; Brodin L, 1990, PREPARATIONS VERTEBR, P103; BUCHANAN JT, 1987, BRAIN RES, V408, P321, DOI 10.1016/0006-8993(87)90397-0; CAZALETS JR, 1992, J PHYSIOL-LONDON, V455, P187, DOI 10.1113/jphysiol.1992.sp019296; CURRIE SN, 1983, BRAIN RES, V279, P238, DOI 10.1016/0006-8993(83)90183-X; DAVIS WJ, 1976, IDENTIFIED NEURONS B, P293; DELIAGINA TG, 1993, EXP BRAIN RES, V95, P421; DELIAGINA TG, 1995, J EXP BIOL, V198, P2581; DIPRISCO GV, 1995, BRAIN RES, V695, P76, DOI 10.1016/0006-8993(95)00936-K; DOUGLAS JR, 1993, J NEUROSCI, V13, P990; Drew T, 1996, EXP BRAIN RES, V111, P153; DUBUC R, 1993, J COMP NEUROL, V327, P251, DOI 10.1002/cne.903270207; DUBUC R, 1993, J COMP NEUROL, V327, P260, DOI 10.1002/cne.903270208; EATON RC, 1991, BRAIN BEHAV EVOLUT, V37, P272, DOI 10.1159/000114365; Frost WN, 1996, P NATL ACAD SCI USA, V93, P422, DOI 10.1073/pnas.93.1.422; GILLETTE R, 1978, SCIENCE, V199, P798, DOI 10.1126/science.622571; Grillner S, 1988, Adv Neurol, V47, P425; GRILLNER S, 1991, ANNU REV NEUROSCI, V14, P169, DOI 10.1146/annurev.neuro.14.1.169; GRILLNER S, 1995, TRENDS NEUROSCI, V18, P270, DOI 10.1016/0166-2236(95)93914-J; HAGEVIK A, 1994, BRAIN RES, V636, P147, DOI 10.1016/0006-8993(94)90190-2; Hirschfeld H, 1997, J VESTIBUL RES-EQUIL, V7, P265, DOI 10.1016/S0957-4271(96)00180-2; KASICKI S, 1989, BRAIN RES, V484, P203, DOI 10.1016/0006-8993(89)90363-6; KOYAMA H, 1987, J COMP NEUROL, V264, P437, DOI 10.1002/cne.902640402; KUPFERMANN I, 1978, BEHAV BRAIN SCI, V1, P3, DOI 10.1017/S0140525X00059057; LETHBRIDGE RC, 1982, BIOL LAMPREYS, V3, P377; MCCLELLAN AD, 1984, BRAIN RES, V300, P357, DOI 10.1016/0006-8993(84)90846-1; MCCLELLAN AD, 1994, BRAIN RES, V663, P61, DOI 10.1016/0006-8993(94)90462-6; MILNER KL, 1988, BRAIN RES, V452, P273, DOI 10.1016/0006-8993(88)90031-5; NELSON DA, 1995, NEURON, V15, P23, DOI 10.1016/0896-6273(95)90061-6; Nelson S B, 1992, Curr Opin Neurobiol, V2, P484, DOI 10.1016/0959-4388(92)90184-M; NIEUWENHUYS R, 1972, J COMP NEUROL, V145, P165, DOI 10.1002/cne.901450204; ODONOVAN MJ, 1993, J NEUROSCI METH, V46, P91, DOI 10.1016/0165-0270(93)90145-H; OHTA Y, 1989, J NEUROPHYSIOL, V62, P1079, DOI 10.1152/jn.1989.62.5.1079; OMalley DM, 1996, NEURON, V17, P1145, DOI 10.1016/S0896-6273(00)80246-9; ORLOVSKY GN, 1992, EXP BRAIN RES, V90, P479; PETERSON BW, 1971, BRAIN RES, V27, P373, DOI 10.1016/0006-8993(71)90264-2; RONAN M, 1989, J COMP NEUROL, V281, P54, DOI 10.1002/cne.902810106; Rossignol S, 1996, HDB PHYSL SECTION 12, P173; Rossignol SLJ, 1988, NEURAL CONTROL RHYTH, P201; ROVAINEN CM, 1967, J NEUROPHYSIOL, V30, P1000, DOI 10.1152/jn.1967.30.5.1000; ROVAINEN CM, 1982, BIOL LAMPREYS, P1; SALT TE, 1986, NATURE, V322, P263, DOI 10.1038/322263a0; SHIMAMURA M, 1983, BRAIN RES, V260, P27, DOI 10.1016/0006-8993(83)90761-8; SILLAR KT, 1994, EUR J MORPHOL, V32, P185; SIROTA M, 1995, CAN J PHYSL PHARM, V73; SWAIN GP, 1993, J COMP NEUROL, V336, P194, DOI 10.1002/cne.903360204; WALLEN P, 1987, J NEUROSCI, V7, P2745; WICKELGREN WO, 1977, J PHYSIOL-LONDON, V270, P89, DOI 10.1113/jphysiol.1977.sp011940; WIERSMA CAG, 1964, COMP BIOCHEM PHYSIOL, V12, P509, DOI 10.1016/0010-406X(64)90153-7; Zompa IC, 1996, BRAIN RES, V718, P221, DOI 10.1016/0006-8993(96)00131-X	52	107	107	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1122	1125		10.1126/science.278.5340.1122	http://dx.doi.org/10.1126/science.278.5340.1122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353193				2022-12-28	WOS:A1997YE65200052
J	OScalaidhe, SP; Wilson, FAW; GoldmanRakic, PS				OScalaidhe, SP; Wilson, FAW; GoldmanRakic, PS			Areal segregation of face-processing neurons in prefrontal cortex	SCIENCE			English	Article							INFERIOR TEMPORAL NEURONS; RHESUS-MONKEY; VISUAL PATHWAYS; MACAQUE MONKEY; UNIT-ACTIVITY; FRONTAL-LOBE; PARIETAL; MEMORY; ORGANIZATION; SUBDIVISIONS	A central issue in cognitive neuroscience concerns the functional architecture of the prefrontal cortex and the degree to which it is organized by sensory domain. To examine this issue, multiple areas of the macaque monkey prefrontal cortex were mapped for selective responses to visual stimuli that are prototypical of the brain's object vision pathway-pictorial representations of faces. Prefrontal neurons not only selectively process information related to the identity of faces but, importantly, such neurons are localized to a remarkably restricted area. These findings suggest that the prefrontal cortex is functionally compartmentalized with respect to the nature of its inputs.			OScalaidhe, SP (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038546, R37MH038546, P50MH044866] Funding Source: NIH RePORTER; NIMH NIH HHS [MH44866, MH38546] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN RA, 1990, J COMP NEUROL, V296, P65, DOI 10.1002/cne.902960106; BARBAS H, 1985, NEUROSCIENCE, V15, P619, DOI 10.1016/0306-4522(85)90064-8; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; BATES JF, 1995, SOC NEUR ABSTR, V21, P1054; BAYLIS GC, 1987, J NEUROSCI, V7, P330; BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; Bullier J, 1996, BEHAV BRAIN RES, V76, P89, DOI 10.1016/0166-4328(95)00182-4; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; COURTNEY SM, 1996, CEREB CORTEX, V6, P1047; DESIMONE R, 1979, BRAIN RES, V178, P363, DOI 10.1016/0006-8993(79)90699-1; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FERRERA VP, 1994, J NEUROSCI, V14, P6171; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; GOLDMAN PS, 1970, EXP NEUROL, V27, P291, DOI 10.1016/0014-4886(70)90222-0; GROSS CG, 1962, EXP NEUROL, V5, P453, DOI 10.1016/0014-4886(62)90057-2; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; JACOBSON S, 1977, BRAIN RES, V132, P209, DOI 10.1016/0006-8993(77)90417-6; KAWAMURA K, 1984, Neuroscience Research, V1, P89, DOI 10.1016/S0168-0102(84)80007-3; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; MACPHERSON JM, 1979, BRAIN RES, V175, P183, DOI 10.1016/0006-8993(79)90530-4; McCarthy G, 1996, CEREB CORTEX, V6, P600, DOI 10.1093/cercor/6.4.600; MERZENICH MM, 1973, BRAIN RES, V50, P275, DOI 10.1016/0006-8993(73)90731-2; MISHKIN M, 1978, BRAIN RES, V143, P313, DOI 10.1016/0006-8993(78)90571-1; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; OWEN AM, 1997, TRNEDS COGN NEUROSCI, V4, P123; PASSINGHAM R, 1975, BRAIN RES, V92, P89, DOI 10.1016/0006-8993(75)90529-6; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PIGAREV IN, 1979, NEUROSCI LETT, V12, P207, DOI 10.1016/0304-3940(79)96063-4; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; ROBINSON CJ, 1980, J COMP NEUROL, V192, P69, DOI 10.1002/cne.901920105; RODMAN HR, 1993, J NEUROPHYSIOL, V70, P1115, DOI 10.1152/jn.1993.70.3.1115; RODMAN HR, 1994, CEREB CORTEX, V5, P484; ROLLS ET, 1986, EXP BRAIN RES, V65, P38; SARY G, 1993, SCIENCE, V260, P995, DOI 10.1126/science.8493538; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; Sereno A. B., 1997, Society for Neuroscience Abstracts, V23, P302; Sereno A. B., 1995, Society for Neuroscience Abstracts, V21, P282; SUZUKI H, 1983, EXP BRAIN RES, V53, P47; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; VANESSEN DC, 1980, J COMP NEUROL, V191, P255, DOI 10.1002/cne.901910208; WEBSTER MJ, 1994, CEREB CORTEX, V5, P470; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	45	256	258	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1135	1138		10.1126/science.278.5340.1135	http://dx.doi.org/10.1126/science.278.5340.1135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353197				2022-12-28	WOS:A1997YE65200056
J	Lahn, BT; Page, DC				Lahn, BT; Page, DC			Functional coherence of the human Y chromosome	SCIENCE			English	Article							ESCAPES X-INACTIVATION; SEX-DETERMINING REGION; AMINO-ACID-SEQUENCE; FAT-FACETS GENE; TURNER SYNDROME; MOLECULAR-CLONING; PROTEIN GENE; DROSOPHILA; EXPRESSION; MOUSE	A systematic search of the nonrecombining region or the human Y chromosome (NRY) identified 12 novel genes or families, 10 with full-length complementary DNA sequences. All 12 genes, and six of eight NRY genes or families previously isolated by less systematic means, fell into two classes. Genes in the first group were expressed in many organs; these housekeeping genes have X homologs that escape X inactivation. The second group, consisting of Y-chromosomal gene families expressed specifically in testes, may account for infertility among men with Y deletions. The coherence of the NRY's gene content contrasts with the apparently haphazard content of most eukaryotic chromosomes.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lahn, BT (corresponding author), MIT,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							Affara N, 1996, CYTOGENET CELL GENET, V73, P33; AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; ARNEMANN J, 1991, GENOMICS, V11, P108, DOI 10.1016/0888-7543(91)90107-P; Boynton ZL, 1996, J BACTERIOL, V178, P3015, DOI 10.1128/jb.178.11.3015-3024.1996; Bull J.J., 1983, EVOLUTION SEX DETERM; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; Delbridge ML, 1997, NAT GENET, V15, P131, DOI 10.1038/ng0297-131; DEVER TE, 1994, J BIOL CHEM, V269, P3212; FERGUSON-SMITH M A, 1965, J Med Genet, V2, P142, DOI 10.1136/jmg.2.2.142; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FORD CE, 1959, LANCET, V1, P711; FREIJE D, 1992, SCIENCE, V258, P1784, DOI 10.1126/science.1465614; GONDO H, 1987, J IMMUNOL, V139, P3840; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Jones MH, 1996, HUM MOL GENET, V5, P1695, DOI 10.1093/hmg/5.11.1695; JUST W, 1992, HUM GENET, V89, P240; KANAZAWA M, 1993, ENZYME PROTEIN, V47, P9, DOI 10.1159/000468650; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUOH SW, 1995, GENOMICS, V29, P353, DOI 10.1006/geno.1995.9994; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Madireddi MT, 1996, CELL, V87, P75, DOI 10.1016/S0092-8674(00)81324-0; MANZ E, 1993, GENOMICS, V17, P726, DOI 10.1006/geno.1993.1393; Mumm S, 1997, GENOME RES, V7, P307, DOI 10.1101/gr.7.4.307; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; Pryor JL, 1997, NEW ENGL J MED, V336, P534, DOI 10.1056/NEJM199702203360802; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; SAFER D, 1991, J BIOL CHEM, V266, P4029; SALIDO EC, 1992, AM J HUM GENET, V50, P303; SALO P, 1995, HUM GENET, V95, P283, DOI 10.1007/BF00225194; SALO P, 1995, GENE CHROMOSOME CANC, V14, P210, DOI 10.1002/gcc.2870140309; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; SCHMITZ A, 1992, APPL ENVIRON MICROB, V58, P4068, DOI 10.1128/AEM.58.12.4068-4071.1992; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SCHWARTZ A, IN PRESS HUM MOL GEN; SEBOUN E, 1986, COLS SPRING HARBOR S, V1, P237; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SIMMLER MC, 1985, NATURE, V317, P692, DOI 10.1038/317692a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STEN C, 1957, AM J HUM GENET, V9, P147; Stokes DG, 1996, P NATL ACAD SCI USA, V93, P7137, DOI 10.1073/pnas.93.14.7137; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TSUCHIYA K, 1995, AM J HUM GENET, V57, P1400; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WATANABE M, 1993, NAT GENET, V4, P268, DOI 10.1038/ng0793-268; ZINN AR, 1993, TRENDS GENET, V9, P90, DOI 10.1016/0168-9525(93)90230-F	68	666	707	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					675	680		10.1126/science.278.5338.675	http://dx.doi.org/10.1126/science.278.5338.675			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381176				2022-12-28	WOS:A1997YC32300052
J	Small, GW; Rabins, PV; Barry, PP; Buckholtz, NS; DeKosky, ST; Ferris, SH; Finkel, SI; Gwyther, LP; Khachaturian, ZS; Lebowitz, BD; McRae, TD; Morris, JC; Oakley, F; Schneider, LS; Streim, JE; Sunderland, T; Teri, LA; Tune, LE				Small, GW; Rabins, PV; Barry, PP; Buckholtz, NS; DeKosky, ST; Ferris, SH; Finkel, SI; Gwyther, LP; Khachaturian, ZS; Lebowitz, BD; McRae, TD; Morris, JC; Oakley, F; Schneider, LS; Streim, JE; Sunderland, T; Teri, LA; Tune, LE			Diagnosis and treatment of Alzheimer disease and related disorders - Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED TRIAL; NURSING-HOME PLACEMENT; BEHAVIORAL SYMPTOMS; CLINICAL-DIAGNOSIS; SENILE DEMENTIA; OLDER PATIENTS; PREVALENCE; TACRINE; CARE; GENE	Objective.-A consensus conference on the diagnosis and treatment of Alzheimer disease (AD) and related disorders was organized by the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society on January 4 and 5, 1997, The target audience was primary care physicians, and the following questions were addressed: (1) How prevalent is AD and what are its risk factors? What is its impact on society? (2) What are the different forms of dementia and how can they be recognized? (3) What constitutes safe and effective treatment for AD? What are the indications and contraindications for specific treatments? (4) What management strategies are available to the primary care practitioner? (5) What are the available medical specialty and community resources? (6) What are the important policy issues and how can policymakers improve access to care for dementia patients? (7) What are the most promising questions for future research? Participants.-Consensus panel members and expert presenters were drawn from psychiatry, neurology, geriatrics, primary care, psychology, nursing, social work, occupational therapy, epidemiology, and public health and policy. Evidence.-The expert presenters summarized data from the world scientific literature on the questions posed to the panel. Consensus Process.-The panelists listened to the experts' presentations, reviewed their background papers, and then provided responses to the questions based on these materials, The panel chairs prepared the initial drafts of the consensus statement, and these drafts were read by all panelists and edited until consensus was reached. Conclusions.-Alzheimer disease is the most common disorder causing cognitive decline in old age and exacts a substantial cost on society, Although the diagnosis of AD is often missed or delayed, it is primarily one of inclusion, not exclusion, and usually can be made using standardized clinical criteria, Most cases can be diagnosed and managed in primary care settings, yet some patients with atypical presentations, severe impairment, or complex comorbidity benefit from specialist referral, Alzheimer disease is progressive and irreversible, but pharmacologic therapies for cognitive impairment and nonpharmacologic and pharmacologic treatments for the behavioral problems associated with dementia can enhance quality of life, Psychotherapeutic intervention with family members is often indicated, as nearly half of all caregivers become depressed, Health care delivery to these patients is fragmented and inadequate, and changes in disease management models are adding stresses to the system, New approaches are needed to ensure patients' access to essential resources, and future research should aim to improve diagnostic and therapeutic effectiveness.	JOHNS HOPKINS UNIV, BALTIMORE, MD USA; BOSTON UNIV, BOSTON, MA 02215 USA; NIA, BETHESDA, MD 20892 USA; UNIV PITTSBURGH, PITTSBURGH, PA USA; NYU, NEW YORK, NY USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA; DUKE UNIV, DURHAM, NC USA; RONALD & NANCY REAGAN RES INST, BETHESDA, MD USA; NIMH, BETHESDA, MD 20892 USA; WASHINGTON UNIV, ST LOUIS, MO USA; NIH, BETHESDA, MD 20892 USA; UNIV SO CALIF, LOS ANGELES, CA USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; WESLEY WOODS GERIATR HOSP, ATLANTA, GA USA	Johns Hopkins University; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; New York University; Northwestern University; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Washington University (WUSTL); National Institutes of Health (NIH) - USA; University of Southern California; University of Pennsylvania; University of Washington; University of Washington Seattle	Small, GW (corresponding author), UNIV CALIF LOS ANGELES, NEUROPSYCHIAT INST & HOSP, 760 WESTWOOD PLAZA, ROOM 37-432, LOS ANGELES, CA 90024 USA.		Morris, John C/A-1686-2012	Ferris, Steven/0000-0001-8641-6223; DeKosky, Steven/0000-0003-3743-2758; Lebowitz, Barry/0000-0002-6467-646X				*ADV PAN ALZH DIS, 1996, NIH PUBL; ALEXOPOULOS GS, 1993, AM J PSYCHIAT, V150, P1693; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ARNOLD SE, 1993, MED CLIN N AM, V77, P215, DOI 10.1016/S0025-7125(16)30280-2; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; BAINES S, 1987, BRIT J PSYCHIAT, V151, P222, DOI 10.1192/bjp.151.2.222; Barrett JJ, 1997, ALZ DIS ASSOC DIS, V11, P99, DOI 10.1097/00002093-199706000-00006; BREITNER JCS, 1988, NEUROLOGY, V38, P307; BRUST JCM, 1983, STROKE, V14, P298, DOI 10.1161/01.STR.14.2.298; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; CHACKO RC, 1993, J NEUROPSYCH CLIN N, V5, P206; COHENMANSFIELD J, 1991, ARCH INTERN MED, V151, P289, DOI 10.1001/archinte.151.2.289; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; COSTA PT, 1996, AHCPR PUBL; DARTIGUES JF, 1991, REV NEUROL-FRANCE, V147, P225; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FARRER LA, 1995, JAMA-J AM MED ASSOC, V274, P1627, DOI 10.1001/jama.1995.03530200063039; FITTEN LJ, 1995, JAMA-J AM MED ASSOC, V273, P1360, DOI 10.1001/jama.273.17.1360; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; GERMAN PS, 1987, JAMA-J AM MED ASSOC, V257, P489, DOI 10.1001/jama.257.4.489; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRAD RM, 1995, J FAM PRACTICE, V41, P473; GWYTHER LP, 1996, PRIM PSYCHIAT, V3, P27; HEEREN TJ, 1991, J AM GERIATR SOC, V39, P755, DOI 10.1111/j.1532-5415.1991.tb02696.x; HENDRIE HC, 1995, AM J PSYCHIAT, V152, P1485; Herholz K., 1990, DEMENTIA, V1, P156; HOFFMAN RS, 1982, JAMA-J AM MED ASSOC, V248, P964, DOI 10.1001/jama.248.8.964; Jeste DV, 1996, J CLIN PSYCHIAT, V57, P39; JORM AF, 1990, EPIDEMIOLOGY ALZHEIM; Kaufer DI, 1996, J GERIATR PSYCH NEUR, V9, P1, DOI 10.1177/089198879600900101; KIPPENHAN JS, 1992, J NUCL MED, V33, P1459; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; Knopman D, 1996, NEUROLOGY, V47, P166, DOI 10.1212/WNL.47.1.166; Larson EB, 1996, J GERONTOL A-BIOL, V51, pM313, DOI 10.1093/gerona/51A.6.M313; Lerner AJ, 1997, ALZ DIS ASSOC DIS, V11, P16, DOI 10.1097/00002093-199703000-00004; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Logsdon RG, 1997, GERONTOLOGIST, V37, P40, DOI 10.1093/geront/37.1.40; MADHUSOODANAN S, 1995, J CLIN PSYCHIAT, V56, P514; MANT A, 1988, FAM PRACT, V5, P184, DOI 10.1093/fampra/5.3.184; MCCARTNEY JR, 1985, J AM GERIATR SOC, V33, P467, DOI 10.1111/j.1532-5415.1985.tb05457.x; McDaniel L D, 1993, J Geriatr Psychiatry Neurol, V6, P230; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Mega MS, 1996, NEUROLOGY, V46, P130, DOI 10.1212/WNL.46.1.130; Mellow A M, 1993, J Geriatr Psychiatry Neurol, V6, P205; MEYERS K, 1990, J GERONTOL NURS, V16, P32; MINTZER JE, 1993, GERONTOLOGIST, V33, P801, DOI 10.1093/geront/33.6.801; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MOHS RC, 1987, ARCH GEN PSYCHIAT, V44, P405; *NAT I AG, 1996, NIH PUBL; NYTH AL, 1992, ACTA PSYCHIAT SCAND, V86, P138, DOI 10.1111/j.1600-0447.1992.tb03242.x; OKAGAKI JF, 1994, NEUROLOGY, V44, P2203; OVERMAN W, 1988, AM J PSYCHIAT, V145, P1495; PATTERSON MB, 1994, ALZ DIS ASSOC DIS, V8, P4, DOI 10.1097/00002093-199424004-00002; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; *PFIZ INC, 1997, AR DON PACK INS; PINHOLT EM, 1987, ARCH INTERN MED, V147, P484, DOI 10.1001/archinte.147.3.484; RADA RT, 1976, J AM GERIATR SOC, V24, P105, DOI 10.1111/j.1532-5415.1976.tb04280.x; Rasmusson DX, 1996, ALZ DIS ASSOC DIS, V10, P180, DOI 10.1097/00002093-199601040-00002; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; RITCHIE K, 1995, LANCET, V346, P931, DOI 10.1016/S0140-6736(95)91556-7; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; Ross GW, 1997, JAMA-J AM MED ASSOC, V277, P800, DOI 10.1001/jama.277.10.800; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; RYAN DH, 1994, INT J GERIATR PSYCH, V9, P141, DOI 10.1002/gps.930090208; SAKAUYE KM, 1993, AM J GERIATR PSYCHIA, V1, P894; SALZMAN C, 1995, AM J GERIAT PSYCHIAT, V3, P26, DOI 10.1097/00019442-199524310-00004; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SCHNEIDER LS, 1993, NEUROLOGY, V43, pS64; SCHNEIDER LS, 1990, J AM GERIATR SOC, V28, P558; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P775, DOI 10.1001/jama.277.10.775; STERN Y, 1994, NEUROLOGY, V44, P2300, DOI 10.1212/WNL.44.12.2300; Sultzer DL, 1997, AM J GERIAT PSYCHIAT, V5, P60; TARIOT PN, 1994, J AM GERIATR SOC, V42, P1160, DOI 10.1111/j.1532-5415.1994.tb06982.x; TERI L, 1991, Clinical Gerontologist, V10, P49, DOI 10.1300/J018v10n04_06; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; TERI L, 1997, J GERONTOL B-PSYCHOL, V52, P159, DOI DOI 10.1093/GER0NB/52B.4.P159; *US DEP VET AFF U, 1997, DEM ID ASS GUID PRIM; *WARN CO, 1996, COGN TACR PACK INS; WATKINS PB, 1994, JAMA-J AM MED ASSOC, V271, P992, DOI 10.1001/jama.271.13.992; WOODS P, 1995, GERIATR NURS, V16, P9, DOI 10.1016/S0197-4572(05)80072-2	86	713	731	1	150	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1363	1371		10.1001/jama.278.16.1363	http://dx.doi.org/10.1001/jama.278.16.1363			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343469				2022-12-28	WOS:A1997YA90500039
J	Lim, H; Paria, BC; Das, SK; Dinchuk, JE; Langenbach, R; Trzaskos, JM; Dey, SK				Lim, H; Paria, BC; Das, SK; Dinchuk, JE; Langenbach, R; Trzaskos, JM; Dey, SK			Multiple female reproductive failures in cyclooxygenase 2-deficient mice	CELL			English	Article							DECIDUAL CELL REACTION; MOUSE UTERUS; SELECTIVE-INHIBITION; BLASTOCYST IMPLANTATION; PREOVULATORY FOLLICLES; OVARIAN-STEROIDS; GENE DISRUPTION; H SYNTHASE-1; EXPRESSION; RAT	Cyclooxygenase (COX) is the rate-limiting enzyme in the synthesis of prostaglandins (PGs) and exists in two isoforms, COX-1 and COX-2. In spite of long-standing speculation, definitive roles of PGs in various events of early pregnancy remain elusive. We demonstrate herein that the targeted disruption of COX-2, but not COX-1, in mice produces multiple failures in female reproductive processes that include ovulation, fertilization, implantation, and decidualization. Using multiple approaches, we conclude that these defects are the direct result of target organ-specific COX-2 deficiency but are not the result of deficiency of pituitary gonadotropins or ovarian steroid hormones, or reduced responsiveness of the target organs to their respective hormones.	UNIV KANSAS, MED CTR, DEPT MOL & INTEGRAT PHYSIOL, KANSAS CITY, KS 66160 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; NIEHS, LAB EXPT CARCINOGENESIS & MUTAGENESIS, RES TRIANGLE PK, NC 27709 USA	University of Kansas; University of Kansas Medical Center; DuPont; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Lim, Hyunjung J/D-5343-2011	Lim, Hyunjung J/0000-0003-2191-666X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD029968, R01HD012304, R37HD012304] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 29968, HD 33994, HD 12304] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Benson GV, 1996, DEVELOPMENT, V122, P2687; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; DAS SK, 1994, DEVELOPMENT, V120, P1071; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOURDIEU DJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P326, DOI 10.1016/0167-4889(90)90104-L; EPPIG JJ, 1991, BIOESSAYS, V13, P569, DOI 10.1002/bies.950131105; ESPEY LL, 1994, BIOL REPROD, V50, P233, DOI 10.1095/biolreprod50.2.233; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1683, DOI 10.1210/endo-125-3-1683; KENNEDY TG, 1985, BIOL REPROD, V33, P140, DOI 10.1095/biolreprod33.1.140; KENNEDY TG, 1983, BIOL REPROD, V29, P1069, DOI 10.1095/biolreprod29.5.1069; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIM H, 1997, IN PRESS ENDOCRINOLO; MCMASTER MT, 1993, J REPROD FERTIL, V99, P561, DOI 10.1530/jrf.0.0990561; MCMASTER MT, 1992, MOL ENDOCRINOL, V6, P101, DOI 10.1210/me.6.1.101; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; PETERSON JW, 1996, MOL CELL BIOL, V64, P2137; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; PINTO DJ, 1995, MED CHEM RES, V5, P394; PSYCHOYOS A, 1973, HDB PHYSL, P187; RANKIN JC, 1977, BIOL REPROD, V17, P549, DOI 10.1095/biolreprod17.4.549; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; SATOKATA I, 1995, NATURE, V374, P460, DOI 10.1038/374460a0; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TSAFRIRI A, 1996, REPROD ENDOCRINOLOGY, P235; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WHITTEN WK, 1968, J REPROD FERTIL, V17, P399, DOI 10.1530/jrf.0.0170399; WORDINGER RJ, 1986, J REPROD FERTIL, V77, P471, DOI 10.1530/jrf.0.0770471; Yang ZM, 1997, BIOL REPROD, V56, P368, DOI 10.1095/biolreprod56.2.368; YOSHINAG.K, 1966, J REPROD FERTIL, V12, P593, DOI 10.1530/jrf.0.0120593	54	1141	1188	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					197	208		10.1016/S0092-8674(00)80402-X	http://dx.doi.org/10.1016/S0092-8674(00)80402-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346237				2022-12-28	WOS:A1997YC35000007
J	Endres, MJ; Jaffer, S; Haggarty, B; Turner, JD; Doranz, BJ; OBrien, PJ; Kolson, DL; Hoxie, JA				Endres, MJ; Jaffer, S; Haggarty, B; Turner, JD; Doranz, BJ; OBrien, PJ; Kolson, DL; Hoxie, JA			Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYTOPLASMIC DOMAIN; REPLICATION; EXPRESSION	Retroviral vectors containing CD4 and an appropriate chemokine receptor were evaluated for the ability to transduce cells infected with human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV). These CD4-chemokine receptor pseudotypes were able to target HIV- and SIV-infected cell lines and monocyte-derived macrophages in a manner that corresponded to the specificity of the viral envelope glycoprotein for its CD4-chemokine receptor complex. This approach could offer a way to deliver antiviral genes directly to HIV-infected cells in vivo and could provide an additional treatment strategy in conjunction with existing antiviral therapies.	UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Endres, MJ (corresponding author), UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104, USA.		O'Brien, Peter J/B-5182-2013; Good (formerly Turner), Julie/I-8305-2018	O'Brien, Peter J/0000-0003-4127-2718; 	NHLBI NIH HHS [HL 07439] Funding Source: Medline; NIAID NIH HHS [AI33854, AI40880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033854, R01AI040880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLIET JW, IN PRESS J VIROL; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COLLMAN R, 1989, J EXP MED, V170, P1149, DOI 10.1084/jem.170.4.1149; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; ENDRES M, UNPUB; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; LABRANCHE CC, 1995, J VIROL, V69, P5217, DOI 10.1128/JVI.69.9.5217-5227.1995; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Mebatsion T, 1997, CELL, V90, P841, DOI 10.1016/S0092-8674(00)80349-9; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nolan GP, 1997, CELL, V90, P821, DOI 10.1016/S0092-8674(00)80345-1; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5	22	59	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1462	1464		10.1126/science.278.5342.1462	http://dx.doi.org/10.1126/science.278.5342.1462			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367958				2022-12-28	WOS:A1997YG85800044
J	Trimble, SW				Trimble, SW			Contribution of stream channel erosion to sediment yield from an urbanizing watershed	SCIENCE			English	Article							RIVER BASIN; URBANIZATION; DRAINAGE; STORAGE; BUDGET	Stream channel erosion has long been suspected as the major contributor to long-term sediment yield from urbanizing watersheds. For San Diego Creek in southern California, measurements from 1983 to 1993 showed that stream channel erosion furnished 10(5) megagrams per year of sediment, or about two-thirds of the total sediment yield. Thus, because channel erosion can be a major source of sediment yield from urbanizing areas, channel stabilization should be a priority in managing sediment yield.	UNIV CALIF LOS ANGELES,INST ENVIRONM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Trimble, SW (corresponding author), UNIV CALIF LOS ANGELES,DEPT GEOG,405 HILGARD AVE,LOS ANGELES,CA 90095, USA.							ARNOLD CL, 1982, J GEOL, V90, P155, DOI 10.1086/628660; ASHMORE P, 1993, PROG PHYS GEOG, V17, P190, DOI 10.1177/030913339301700206; BOOTH DB, 1990, WATER RESOUR BULL, V26, P407; *BOYL ENG CORP, 1981, HYDR AN NEWP BAY W 2; CHANG HH, 1988, J HYDROL, V99, P201, DOI 10.1016/0022-1694(88)90048-0; CHURCH M, 1989, NATURE, V337, P352; Cooke R.U., 1982, URBAN GEOMORPHOLOGY; COOKE RU, 1977, ARROYOS ENV CHANGE; Dietrich W.E., 1978, ZIETSCHRIFT GEOMORPH, V29, P191, DOI [10.1130/0091-7613(2001)029, DOI 10.1130/0091-7613(2001)029]; EBISEMIJU FS, 1989, APPL GEOGR, V9, P273, DOI 10.1016/0143-6228(89)90028-3; EMMETT WW, 1980, 801189 US GEOL SURV; FOWLER K, 1997, 954135 US GEOL SURV; Graf W. L., 1988, FLUVIAL PROCESSES DR; GRAF WL, 1975, WATER RESOUR RES, V11, P690, DOI 10.1029/WR011i005p00690; GRAF WL, 1977, WATER RESOUR RES, V13, P459, DOI 10.1029/WR013i002p00459; GREGORY KJ, 1992, APPL GEOGR, V12, P299, DOI 10.1016/0143-6228(92)90011-B; HAMMER TR, 1972, WATER RESOUR RES, V8, P1530, DOI 10.1029/WR008i006p01530; HOAG BL, 1983, THESIS U CALIFORNIA; HOLLIS GE, 1976, J HYDROL, V30, P351, DOI 10.1016/0022-1694(76)90118-9; KELSEY HM, 1980, GEOL SOC AM BULL, V91, P190, DOI 10.1130/0016-7606(1980)91<190:ASBAAA>2.0.CO;2; KNOX JC, 1989, INT ASS SCI HYDROLOG, V184, P157; LEOPOLD L, 1972, GEOL SOC AM BULL, V84, P1845; Leopold L.B., 1968, GEOL SURV CIRCULAR, VUSG, pS554; MEADE RH, 1982, J GEOL, V90, P235, DOI 10.1086/628677; NELTER R, 1989, ENVIRON GEOL WAT SCI, V14, P167; NEWSON M, 1992, LAND WATER DEV; ODERMERHO F, 1992, PROF GEOGR, V44, P332; PATTON PC, 1986, GEOL SOC AM BULL, V97, P369, DOI 10.1130/0016-7606(1986)97<369:PAROFO>2.0.CO;2; PHILLIPS JD, 1987, AM J SCI, V287, P780, DOI 10.2475/ajs.287.8.780; Roberts C.R., 1989, FLOODS HYDROLOGICAL, P57; Rose WJ, 1992, 904124 US GEOL SURV; SCHICK AP, 1993, PHYS GEOGR, V14, P225, DOI 10.1080/02723646.1993.10642477; SCHUMM SA, 1976, SCIENCE, V191, P871, DOI 10.1126/science.191.4229.871; SLAYMAKER O, 1993, PHYSICAL GEOGR, V14, P305; SWANSON F, 1982, SEDIMENT BUDGET ROUT; TRIMBLE S, 1994, SAN DIEGO CREEK SEDI; TRIMBLE S, UNPUB; TRIMBLE S, 1981, GEOMORPHIC ANAL NE 2; Trimble S.W., 1995, CHANGING RIVER CHANN, P201; TRIMBLE SW, 1975, SCIENCE, V188, P1207, DOI 10.1126/science.188.4194.1207; TRIMBLE SW, 1981, SCIENCE, V214, P181, DOI 10.1126/science.214.4517.181; TRIMBLE SW, 1976, SCIENCE, V191, P871; U.S. Geological Survey, 1997, AN RIV WAT; Wolman M. G., 1967, GEOGR ANN A, V49, P385, DOI DOI 10.2307/520904; WOLMAN MG, 1967, WATER RESOUR RES, V3, P451, DOI 10.1029/WR003i002p00451	45	251	259	4	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1442	1444		10.1126/science.278.5342.1442	http://dx.doi.org/10.1126/science.278.5342.1442			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367952				2022-12-28	WOS:A1997YG85800038
J	Kim, WR; Poterucha, JJ; Hermans, JE; Therneau, TM; Dickson, ER; Evans, RW; Gross, JB				Kim, WR; Poterucha, JJ; Hermans, JE; Therneau, TM; Dickson, ER; Evans, RW; Gross, JB			Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; hepatitis C; interferon-alpha; age factors; quality-adjusted life-years	NON-B-HEPATITIS; TERM FOLLOW-UP; CHRONIC NON-A; CONTROLLED TRIAL; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; POSTTRANSFUSION HEPATITIS; VIRUS GENOTYPES; LIVER-DISEASE; UNITED-STATES	Background: Interferon-alpha is effective in only a small number of patients with chronic hepatitis C, although prolonged treatment may increase the response rate. There is concern that the expense of interferon-alpha therapy may not be justified by the low response rates and uncertain long-term benefit. Objective: To compare clinical and economic outcomes after 6 months and 12 months of interferon-alpha therapy for chronic hepatitis C. Design: A Markov model depicting the natural progression of chronic hepatitis C. On the basis of this model, a simulated trial compared no therapy with 6 and 12 months of interferon-alpha therapy at standard doses (3 million U three times weekly). Patients: Four age-specific cohorts (30, 40, 50, and 60 years of age) with chronic hepatitis C. Measurements: Number of deaths from liver disease, total costs, and cumulative quality-adjusted life-years (QALYs). Results: Six and 12 months of interferon-alpha treatment gained 0.25 QALYs at an incremental cost of $1000 and 0.37 QALYs at an incremental cost of $1900, respectively. Thus, although 6 months of interferon-alpha therapy was less efficacious than 12 months of therapy, it was more cost-effective ($4000 per QALY gained compared with $5000 per QALY gained). Nonetheless, in patients younger than 60 years of age, both 6 and 12 months of therapy compared favorably with other established medical interventions, such as screening mammography and cholesterol reduction programs. Important variables affecting the cost-effectiveness of interferon-alpha treatment included the cost and efficacy of interferon-alpha, the cost of treatment for decompensated cirrhosis, and quality of life in patients with chronic hepatitis C. Conclusion: From the standpoint of cost-effectiveness, interferon-alpha therapy for 6 or 12 months may be justified in patients with chronic hepatitis C. The possible exception is patients older than 60 years of age.	MAYO CLIN & MAYO FDN, DIV GASTROENTEROL & HEPATOL W19, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, SECT HLTH SERV EVALUAT, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic				Kim, W. Ray/0000-0002-3030-860X	NIDDK NIH HHS [DK34238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Ampurdanes S, 1996, J HEPATOL, V25, P827, DOI 10.1016/S0168-8278(96)80285-6; AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; Belle S H, 1995, Clin Transpl, P19; BENNETT WG, 1995, HEPATOLOGY, V22, P735; BROWN DM, 1994, DIGESTIVE DIS US EPI; Cane EJ, 1996, NEW ENGL J MED, V334, P815, DOI 10.1056/NEJM199603283341302; *CDCP HEP BRANCH, 1997, 1997 HEP C FACT SHEE; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DAVIS GL, 1994, CLIN THER, V16, P334; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; Evans R W, 1995, Liver Transpl Surg, V1, P61, DOI 10.1002/lt.500010114; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Friedlander L, 1996, DIGEST DIS SCI, V41, P1678, DOI 10.1007/BF02087924; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; Hoofnagle JH, 1996, NEW ENGL J MED, V334, P1470, DOI 10.1056/NEJM199605303342210; Kim W R, 1995, Clin Transpl, P315; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KIYOSAWA K, 1994, INTERVIROLOGY, V37, P101, DOI 10.1159/000150363; KORETZ RL, 1990, HEPATOLOGY, V12, P880; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; MARCELLIN P, 1995, GASTROENTEROLOGY, V109, P156, DOI 10.1016/0016-5085(95)90281-3; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1002/hep.1840130302; *NAT CTR HLTH STAT, 1994, VIT STAT US A, V2; Petitti DB, 1994, METAANALYSIS DECISIO, P119; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; SAEZROYUELA F, 1991, HEPATOLOGY, V13, P327, DOI 10.1002/hep.1840130220; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SILINI E, 1995, HEPATOLOGY, V21, P285, DOI 10.1016/0270-9139(95)90082-9; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Torrance GW, 1987, METHODS EC EVALUATIO; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; VAQUER P, 1994, LIVER, V14, P265; WEJSTAL R, 1991, LIVER, V11, P143; Wong LL, 1997, ARCH INTERN MED, V157, P1429, DOI 10.1001/archinte.157.13.1429; YANO M, 1993, GUT, V34, pS13, DOI 10.1136/gut.34.2_Suppl.S13; YOUSUF M, 1992, SCAND J GASTROENTERO, V27, P812, DOI 10.3109/00365529209011189; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; 1995, DRUG TOPICS RED BOOK	49	151	151	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					866	+		10.7326/0003-4819-127-10-199711150-00002	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382364				2022-12-28	WOS:A1997YF54500002
J	Swanton, C; Mann, DJ; Fleckenstein, B; Neipel, F; Peters, G; Jones, N				Swanton, C; Mann, DJ; Fleckenstein, B; Neipel, F; Peters, G; Jones, N			Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins	NATURE			English	Article							DEPENDENT KINASES; KAPOSIS-SARCOMA; DNA-SEQUENCES; IDENTIFICATION; TRANSITION; CANCER; P27	The passage of mammalian cells through the restriction point into the S phase of the cell cycle is regulated by the activities of Cdk4 and Cdk6 complexed with the D-type cyclins and by cyclin E/Cdk2 (refs 1-3). The activities of these holoenzymes are constrained by CDK inhibitory proteins(4,5). The importance of the restriction point is illustrated by its deregulation in many tumour cells(6,7) and upon infection with DNA tumour viruses(8). Here we describe the properties of cyclins encoded by two herpesviruses, herpesvirus saimiri (HVS) which can transform blood lymphocytes(9) and induce malignancies of lymphoid origin in New World primates(9,10) and human herpesvirus 8 (HHV8) implicated as a causative agent of Kaposi's sarcoma and body cavity lymphomas(11,12). Both viral cyclins form active kinase complexes with Cdk6 that are resistant to inhibition by the CDK inhibitors p16(Ink4a), p21(Cip1) and p27(Kip1). Furthermore, ectopic expression of a viral cyclin prevents G1 arrest imposed by each inhibitor and stimulates cell-cycle progression in quiescent fibroblasts. These results suggest a new mechanism for deregulation of the cell cycle and indicate that the viral cyclins may contribute to the oncogenic nature of these viruses.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; UNIV ERLANGEN NURNBERG,INST KLIN & MOL VIROL,D-8520 ERLANGEN,GERMANY	Cancer Research UK; University of Erlangen Nuremberg				Swanton, Charles/0000-0002-4299-3018				BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P252; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; KATO J, 1993, GENE DEV, V7, P331; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	25	273	282	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					184	187		10.1038/36606	http://dx.doi.org/10.1038/36606			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367157				2022-12-28	WOS:A1997YF49400057
J	Sturm, R				Sturm, R			How expensive is unlimited mental health care coverage under managed care?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To study costs, access, and intensity of mental health care under managed care carve-out plans with generous coverage; compare with assumptions used in policy debates; and simulate the consequences of removing coverage limits for mental health care as required by the Mental Health Parity Act. Design.-Claims data from 1995 and 1996 for 24 managed care carve-out plans; all plans offered unlimited mental health coverage with minimal co-payments. Outcome Measures.-Probability of care, intensity of care, and total costs broken down by service type and type of enrollee. Results.-Assumptions used in last year's policy debate overstate actual managed care costs by a factor of 4 to 8. In the plans studied, costs are lower owing to reduced hospitalization rates, a relative shift to outpatient care, and reduced payments per service. However, access to menial health specialty care increased (7.0% of enrollees) compared with the preceding fee-for-service plans (6.5%) or free care in the RAND Health Insurance Experiment (5.0%). Removing an annual limit of $25 000 for mental health care, which is the average among plans currently imposing limits, will increase insurance payments only by about $1 per enrollee per year. Children are the main beneficiaries of expanded benefits. Conclusions.-Concerns about costs have stifled many health system reform proposals, However, policy decisions were often based on incorrect assumptions and outdated data that led to dramatic overestimates. For mental health care, the cost consequences of improved coverage under managed care, which by now accounts for most private insurance, are relatively minor.			Sturm, R (corresponding author), RAND CORP,1700 MAIN ST,SANTA MONICA,CA 90401, USA.				NIMH NIH HHS [MH54147, MH54623] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH054147] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Duan N., 1983, J BUS STAT, V1, P115, DOI DOI 10.2307/1391852; Frank RG, 1996, ARCH GEN PSYCHIAT, V53, P933; FRANK RG, 1995, HEALTH AFFAIR, V14, P102, DOI 10.1377/hlthaff.14.3.102; GOLDMAN W, 1997, 108 U CAL LOS ANG RE; *HAY HUGG CO INC, 1995, HLTH CAR BEN VAL COM; Jensen GA, 1997, HEALTH AFFAIR, V16, P125, DOI 10.1377/hlthaff.16.1.125; Newhouse J., 1993, FREE ALL; OGRADY MJ, 1996, 96466 EPW US LIB C; Sturm R, 1996, MED CARE, V34, P723, DOI 10.1097/00005650-199607000-00005; STURM R, 1997, 105 U CAL RES CTR MA; WELLS K, 1996, CARING DEPRESSION; WELLS KB, 1982, R2960HHS RAND CORP	12	98	98	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1533	1537		10.1001/jama.278.18.1533	http://dx.doi.org/10.1001/jama.278.18.1533			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YE445	9363977				2022-12-28	WOS:A1997YE44500041
J	Katz, J				Katz, J			Phantom limb pain	LANCET			English	Editorial Material							REGIONAL ANALGESIA; AMPUTATION; BLOCK		TORONTO GEN HOSP,DEPT ANAESTHESIA,TORONTO,ON M5G 2C4,CANADA; MT SINAI HOSP,DEPT ANAESTHESIA,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,DEPT ANAESTHESIA,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,DEPT PUBL HLTH SCI,TORONTO,ON M5G 2C4,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto	Katz, J (corresponding author), TORONTO GEN HOSP,DEPT PSYCHOL,TORONTO,ON M5G 2C4,CANADA.		Katz, Joel/HDO-1635-2022; Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X				BACH S, 1988, PAIN, V33, P297, DOI 10.1016/0304-3959(88)90288-6; ELIZAGA AM, 1994, J REHABIL RES DEV, V31, P179; FISHER A, 1991, ANESTH ANALG, V72, P300; JAHANGIRI M, 1994, ANN ROY COLL SURG, V76, P324; Katz J, 1997, LANCET, V349, P519, DOI 10.1016/S0140-6736(97)80081-5; Pinzur MS, 1996, J BONE JOINT SURG AM, V78A, P1501, DOI 10.2106/00004623-199610000-00007; SCHUG SA, 1995, REGION ANESTH, V20, P256; WARFIELD CA, 1995, ANESTHESIOLOGY, V83, P1090, DOI 10.1097/00000542-199511000-00023	8	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1338	1339		10.1016/S0140-6736(05)65130-6	http://dx.doi.org/10.1016/S0140-6736(05)65130-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365444				2022-12-28	WOS:A1997YE87200004
J	Butler, RN				Butler, RN			Population aging and health	BRITISH MEDICAL JOURNAL			English	Article											Butler, RN (corresponding author), MT SINAI MED CTR,INT LONGEV CTR US,NEW YORK,NY 10029, USA.							BRINSTOCK RH, IN PRESS LIFE OLDER; HOBBS FB, 1996, CURRENT POPULATION R, P23; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593	3	81	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1082	1084		10.1136/bmj.315.7115.1082	http://dx.doi.org/10.1136/bmj.315.7115.1082			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366742	Green Published			2022-12-28	WOS:A1997YD44500033
J	RiesgoEscovar, JR; Hafen, E				RiesgoEscovar, JR; Hafen, E			Common and distinct roles of DFos and DJun during Drosophila development	SCIENCE			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; C-FOS; GENE-EXPRESSION; NULL MUTATION; AP-1 COMPLEX; CELL FATE; HOMOLOG; TRANSCRIPTION; MORPHOGENESIS; PATHWAYS	The Drosophila homolog of c-Jun regulates epithelial cell shape changes during the process of dorsal closure in mid-embryogenesis. Here, mutations in the DFos gene are described. In dorsal closure, DFos cooperates with DJun by regulating the expression of dpp; Dpp acts as a relay signal that triggers cell shape changes and DFos expression in neighboring cells. In addition to the joint requirement of DFos and DJun during dorsal closure, DFos functions independently of DJun during early stages of embryogenesis. These findings demonstrate common and distinct roles of DFos and DJun during embryogenesis and suggest a conserved link between AP-1 (activating protein-1) and TGF-beta (transforming growth factor-beta) signaling during epithelial cell shape changes.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich								BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLENZ M, 1996, SEMIN CELL DEV BIOL, V7, P113; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; FEHON RG, 1994, DEVELOPMENT, V120, P545; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Heitzler P, 1996, GENETICS, V143, P1271; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JURGENS G, 1984, ROUX ARCH DEVEL BIOL, V193, P183; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; LINDSEY DL, 1992, GENETICS BIOL DROSOP; LIU ZG, 1997, CURR OPIN CELL BIOL, V9, P240; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; RAY RP, 1991, DEVELOPMENT, V113, P35; Riese J, 1997, DEVELOPMENT, V124, P3353; RIESGOESCOVAR J, UNPUB; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; Rusch J, 1997, DEVELOPMENT, V124, P303; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; TATEI K, 1995, MECH DEVELOP, V51, P157, DOI 10.1016/0925-4773(95)00349-5; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	35	122	125	2	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					669	672		10.1126/science.278.5338.669	http://dx.doi.org/10.1126/science.278.5338.669			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381174				2022-12-28	WOS:A1997YC32300050
J	Duhamel, JR; Bremmer, F; BenHamed, S; Graf, W				Duhamel, JR; Bremmer, F; BenHamed, S; Graf, W			Spatial invariance of visual receptive fields in parietal cortex neurons	NATURE			English	Article							RESPONSE PROPERTIES; MACAQUE MONKEY; AREA MT; SPACE; CONNECTIONS; MOVEMENT; MEMORY; GAZE	Spatial information is conveyed to the primary visual cortex in retinal coordinates, Movement trajectory programming, however, requires a transformation from this sensory frame of reference into a frame appropriate for the selected part of the body, such as the eye, head or arms(1-4). To achieve this transformation, visual information must be combined with information from other sources: for instance, the location of an object of interest can be defined with respect to the observer's head if the position of the eyes in the orbit is known and is added to the object's retinal coordinates, Here we show that in a subdivision of the monkey parietal lobe, the ventral intraparietal area (VIP), the activity of visual neurons is modulated by eye-position signals, as in many other areas of the cortical visual system(5-10). We find that individual receptive fields of a population of VIP neurons are organized along-a continuum, from eye to head coordinates, In the latter case, neurons encode the azimuth and/or elevation of a visual stimulus, independently of the direction in which the eyes are looking, thus representing spatial locations explicitly in at least a head-centred frame of reference.	RUHR UNIV BOCHUM,DEPT ZOOL & NEUROBIOL,D-44780 BOCHUM,GERMANY	Ruhr University Bochum	Duhamel, JR (corresponding author), COLL FRANCE,CNRS,LAB PHYSIOL PERCEPT & ACT,11 PL MARCELIN BERTELOT,F-75005 PARIS,FRANCE.		Duhamel, Jean-René/M-4723-2017; Ben Hamed, Suliann/O-6070-2014; Bremmer, Frank/F-3268-2012	Duhamel, Jean-René/0000-0003-0210-1027; Ben Hamed, Suliann/0000-0003-1510-7284; Bremmer, Frank/0000-0003-1597-7407				ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; ANDERSEN RA, 1990, J COMP NEUROL, V296, P65, DOI 10.1002/cne.902960106; Bernstein N, 1967, COORDINATION REGULAT; BOUSSAOUD D, 1993, EXP BRAIN RES, V91, P202; Bremmer F, 1997, J NEUROPHYSIOL, V77, P944, DOI 10.1152/jn.1997.77.2.944; BREMMER F, 1997, CONTRIBUTION PARIETA, P619; Colby CL, 1996, COGNITIVE BRAIN RES, V5, P105, DOI 10.1016/S0926-6410(96)00046-8; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; COLBY CL, 1991, NEUROPSYCHOLOGIA, V29, P487; Duhamel J.-R, 1991, BRAIN SPACE; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; DUHAMEL JR, IN PRESS J NEUROPHYS; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; GALLETTI C, 1989, J NEUROSCI, V9, P1112; Galletti C, 1995, EUR J NEUROSCI, V7, P2486, DOI 10.1111/j.1460-9568.1995.tb01047.x; GALLETTI C, 1993, EXP BRAIN RES, V96, P221; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; HYVARINEN J, 1981, BRAIN RES, V206, P287, DOI 10.1016/0006-8993(81)90533-3; LEWIS JW, 1996, SOC NEUR ABSTR, V22; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; MATELLI M, 1994, SOC NEUR ABSTR, V20; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; TANNE J, 1996, SOC NEUR ABSTR, V22; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P190, DOI 10.1002/cne.902480204; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	29	428	431	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					845	848		10.1038/39865	http://dx.doi.org/10.1038/39865			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349815				2022-12-28	WOS:A1997YC14800056
J	Regnard, C; Allport, S; Stephenson, L				Regnard, C; Allport, S; Stephenson, L			ABC of palliative care - Mouth care, skin care, and lymphoedema	BRITISH MEDICAL JOURNAL			English	Article											Regnard, C (corresponding author), ST OSWALD HOSPICE,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND.								0	13	13	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					1002	&		10.1136/bmj.315.7114.1002	http://dx.doi.org/10.1136/bmj.315.7114.1002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365302	Green Published			2022-12-28	WOS:A1997YC30700029
J	Fishman, MC; Olson, EN				Fishman, MC; Olson, EN			Parsing the heart: Genetic modules for organ assembly	CELL			English	Review							MORPHOGENESIS; DROSOPHILA; TINMAN		UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Fishman, MC (corresponding author), HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129, USA.							BODMER R, 1993, DEVELOPMENT, V118, P719; Chen JN, 1996, DEVELOPMENT, V123, P293; Cleaver OB, 1996, DEVELOPMENT, V122, P3549; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Fishman MC, 1997, DEVELOPMENT, V124, P2099; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lohr JL, 1997, DEVELOPMENT, V124, P1465; LYONS L, 1995, GENE DEV, V9, P1654; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Raff R.A., 1996, SHAPE LIFE; RANDALL DJ, 1980, HEARTS HEART LIKE OR; ROMER AS, 1967, SCIENCE, V158, P1629, DOI 10.1126/science.158.3809.1629; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Stainier DYR, 1996, DEVELOPMENT, V123, P285; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Yamamura H, 1997, DEV BIOL, V186, P58, DOI 10.1006/dbio.1997.8559	20	134	136	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					153	156		10.1016/S0092-8674(00)80397-9	http://dx.doi.org/10.1016/S0092-8674(00)80397-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346232	Bronze			2022-12-28	WOS:A1997YC35000002
J	Hubbard, WB				Hubbard, WB			Lensing by Triton's atmosphere	SCIENCE			English	Editorial Material											Hubbard, WB (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.							Elliot JL, 1997, SCIENCE, V278, P436, DOI 10.1126/science.278.5337.436; HUBBARD WB, 1993, ASTRON ASTROPHYS, V269, P541; PEALE SJ, 1997, ICARUS, V126, P269; TYLER GL, 1989, SCIENCE, V246, P1466, DOI 10.1126/science.246.4936.1466	4	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					403	404		10.1126/science.278.5337.403	http://dx.doi.org/10.1126/science.278.5337.403			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381144				2022-12-28	WOS:A1997YB35500029
J	Fuster, V; Nash, IS				Fuster, V; Nash, IS			The generalist/cardiovascular specialist: A proposal for a new training track	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEALTH-CARE SYSTEM; INTERNAL-MEDICINE; MANAGED CARE; PHYSICIAN; FUTURE; CARDIOLOGY; REFORM; SUBSPECIALISTS; GENERALISTS; INFARCTION	The economic forces that are reshaping the delivery of health care in the United States have led to intense examination of the appropriate roles for specialists and generalists. Resolving this issue has profound implications for the future of U.S. health care and for the economic health of academic training centers and individual physicians. The issues are particularly intense in cardiovascular care, a field that has had dramatic success in the application of new diagnostic and therapeutic technology and rapid growth in specialist practitioners but is now under pressure to shrink its ranks. A new generalist/cardiovascular specialist training track and a parallel reduction in the number of standard fellowship training positions in cardiovascular disease may be a partial solution. The first 2 years of the proposed 5-year program would consist of training in internal medicine, the final 2 would consist of training in cardiovascular disease, and the middle year would be a flexible combination of the two. Graduates would be Board eligible in internal medicine but would have enhanced competency in cardiovascular disease. This plan may improve the balance between generalists and specialists, improve the quality of primary and specialized cardiovascular care, and strengthen departments of medicine and academic training centers while facing new economic realities.	MT SINAI MED CTR, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai			Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; BILLI JE, 1995, NEW ENGL J MED, V333, P979, DOI 10.1056/NEJM199510123331507; BOROWSKY SJ, 1995, J AM COLL CARDIOL, V26, P1484, DOI 10.1016/0735-1097(95)00337-1; CONTI CR, 1995, CLIN CARDIOL, V18, P119, DOI 10.1002/clc.4960180303; *COUNC GRAD MED ED, 1992, IMPR ACC HLTH CAR PH; Feldman AM, 1997, CIRCULATION, V95, P740, DOI 10.1161/01.CIR.95.3.740; Freudenheim Milt, 1997, N Y Times Web, P20; Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; Gabriel SE, 1996, MAYO CLIN PROC, V71, P415, DOI 10.4065/71.4.415; GINSBURG JA, 1994, ANN INTERN MED, V121, P542, DOI 10.7326/0003-4819-121-7-199410010-00013; GOLDMAN L, 1995, JAMA-J AM MED ASSOC, V273, P1549, DOI 10.1001/jama.273.19.1549; GOLDSTEIN S, 1994, AM J CARDIOL, V74, P394, DOI 10.1016/0002-9149(94)90410-3; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HAVRANEK EP, 1996, AM J MANAG CARE, V2, P783; HOWELL JD, 1986, ANN INTERN MED, V105, P772, DOI 10.7326/0003-4819-105-5-722; *J MAC JR FDN, 1992, ANN REP; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Langdon LO, 1996, ANN INTERN MED, V124, P686, DOI 10.7326/0003-4819-124-7-199604010-00011; MANU P, 1983, SOC SCI MED, V17, P1339, DOI 10.1016/0277-9536(83)90193-4; Nash IS, 1997, J AM COLL CARDIOL, V29, P475, DOI 10.1016/S0735-1097(96)00528-1; NASSER WK, 1994, AM J CARDIOL, V73, P724, DOI 10.1016/0002-9149(94)90952-0; PARMLEY WW, 1994, J AM COLL CARDIOL, V23, P1514, DOI 10.1016/0735-1097(94)90401-4; Pew Health Professions Commission, 1994, PRIM CAR WORKF 2000; *PHYS PAYM REV COM, 1993, PHYS PAYM REV COMM A; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1083, DOI 10.1001/jama.270.9.1083; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V267, P1665, DOI 10.1001/jama.267.12.1665; SCHROEDER SA, 1994, JAMA-J AM MED ASSOC, V272, P239, DOI 10.1001/jama.272.3.239; SCHWARTZ JS, 1996, AM J MANAG CARE, V2, P925; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; VETROVEC GW, 1995, J AM COLL CARDIOL, V26, P1125, DOI 10.1016/0735-1097(95)00323-1; Weiner JP, 1996, ANN INTERN MED, V124, P681, DOI 10.7326/0003-4819-124-7-199604010-00009; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WHITCOMB ME, 1995, NEW ENGL J MED, V333, P454, DOI 10.1056/NEJM199508173330712; 1993, ACAD MED, V68, P1; 1994, J AM COLL CARDIOL, V24, P275	37	10	10	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				630	634		10.7326/0003-4819-127-8_Part_1-199710150-00008	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341062				2022-12-28	WOS:A1997YB41900008
J	Rudick, RA; Cohen, JA; WeinstockGuttman, B; Kinkel, RP; Ransohoff, RM				Rudick, RA; Cohen, JA; WeinstockGuttman, B; Kinkel, RP; Ransohoff, RM			Management of multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; PLACEBO-CONTROLLED TRIAL; ACUTE OPTIC NEURITIS; DOUBLE-BLIND; INTERFERON-BETA; ORAL METHOTREXATE; DISEASE-ACTIVITY; CLINICAL-TRIAL; FOLLOW-UP				Rudick, RA (corresponding author), CLEVELAND CLIN EDUC FDN,DEPT NEUROL,MELLEN CTR MULTIPLE SCLEROSIS TREATMENT & RES,CLEVELAND,OH 44106, USA.							*AM AC NEUR, 1994, NEUROLOGY, V44, P1537; Archer DR, 1997, NAT MED, V3, P54, DOI 10.1038/nm0197-54; BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; BECK RW, 1995, ARCH OPHTHALMOL-CHIC, V113, P136, DOI 10.1001/archopht.1995.01100020014004; BENNUN A, 1983, J IMMUNOL, V130, P1205; BO L, 1994, J NEUROIMMUNOL, V51, P135, DOI 10.1016/0165-5728(94)90075-2; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; BOURDETTE DN, 1994, J IMMUNOL, V152, P2510; BOURDETTE DN, 1994, J IMMUNOL, V153, P910; *BRIT DUTCH MULT S, 1988, LANCET, V2, P179; Brocke Stefan, 1994, Trends in Microbiology, V2, P250, DOI 10.1016/0966-842X(94)90630-0; *CAN COOP MULT SCL, 1991, LANCET, V337, P441; CHEN YH, 1995, J IMMUNOL, V155, P910; COHEN JA, 1995, NEUROLOGY, V45, pA418; Confavreux C, 1996, NEUROLOGY, V46, P1607, DOI 10.1212/WNL.46.6.1607; DURELLI L, 1994, NEUROLOGY, V44, P406, DOI 10.1212/WNL.44.3_Part_1.406; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; ELLISON GW, 1989, NEUROLOGY, V39, P1018, DOI 10.1212/WNL.39.8.1018; ELLISON GW, 1996, MULTIPLE SCLEROSIS A, P1; ELLISON GW, 1992, TREATMENT MULTIPLE S, P1; FILIPPI M, 1994, NEUROLOGY, V44, P635, DOI 10.1212/WNL.44.4.635; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Gold DP, 1997, J NEUROIMMUNOL, V76, P29, DOI 10.1016/S0165-5728(97)00029-5; GOODKIN DE, 1995, ANN NEUROL, V37, P30, DOI 10.1002/ana.410370108; GOODKIN DE, 1987, ARCH NEUROL-CHICAGO, V44, P823, DOI 10.1001/archneur.1987.00520200027013; Goodkin DE, 1996, NEUROLOGY, V47, P1153; GOODKIN DE, 1996, MULTIPLE SCLEROSIS A; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; *IFNB MULT SCLER S, 1995, NEUROLOGY, V45, P1277; Jacobs L D, 1995, Mult Scler, V1, P118; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; Kuokkanen S, 1996, NAT GENET, V13, P477, DOI 10.1038/ng0896-477; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LAROCCA NG, 1996, MULTIPLE SCLEROSIS A, P145; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Leppert D, 1996, ANN NEUROL, V40, P846, DOI 10.1002/ana.410400606; LHERMITTE F, 1984, LANCET, V1, P276; LU HT, 1995, J EXP MED, V182, P1517, DOI 10.1084/jem.182.5.1517; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; MANDLER RN, 1993, ANN NEUROL, V34, P162, DOI 10.1002/ana.410340211; MCFARLAND HF, 1992, ANN NEUROL, V32, P758, DOI 10.1002/ana.410320609; MILLAR HJ, 1967, LANCET, V2, P429; MILLER DH, 1996, ANN NEUROL, V36, P6; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; *MULT SCLER STUD G, 1990, ANN NEUROL, V27, P591; MUSHLIN AI, 1994, ARCH NEUROL-CHICAGO, V51, P67, DOI 10.1001/archneur.1994.00540130093017; NICOLLE MW, 1994, J CLIN INVEST, V93, P1361, DOI 10.1172/JCI117112; NOSEWORTHY JH, 1994, J NEUROL NEUROSUR PS, V57, P11, DOI 10.1136/jnnp.57.Suppl.11; NOSEWORTHY JH, 1984, NEUROL CLIN, V2, P759, DOI 10.1016/S0733-8619(18)31073-9; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Paty DW, 1996, NEUROLOGY, V47, P865, DOI 10.1212/WNL.47.4.865; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; Rep MHG, 1996, J NEUROIMMUNOL, V67, P111; ROSE AS, 1968, ARCH NEUROL S, V18, P1; Rudick R, 1997, ANN NEUROL, V42, P379, DOI 10.1002/ana.410420318; Rudick RA, 1997, NEUROLOGY, V49, P358, DOI 10.1212/WNL.49.2.358; Rudick RA, 1996, ANN NEUROL, V40, P618, DOI 10.1002/ana.410400412; RUDICK RA, 1992, TREATMENT MULTIPLE S; RUNMARKER B, 1994, J NEUROL, V241, P597, DOI 10.1007/BF00920623; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; SADOVNICK AD, 1995, NEUROL CLIN, V13, P99, DOI 10.1016/S0733-8619(18)30063-X; SIBLEY WA, 1985, LANCET, V1, P1313; STONE LA, 1995, ANN NEUROL, V37, P611, DOI 10.1002/ana.410370511; Stuve O, 1996, ANN NEUROL, V40, P853, DOI 10.1002/ana.410400607; The IFNB Multiple Sclerosis Study Group, 1996, NEUROLOGY, V47, P889; The IFNb Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; THOMPSON AJ, 1991, ANN NEUROL, V29, P53, DOI 10.1002/ana.410290111; THOMPSON AJ, 1989, NEUROLOGY, V39, P969, DOI 10.1212/WNL.39.7.969; TIPPETT DS, 1991, NEUROLOGY, V41, P703, DOI 10.1212/WNL.41.5.703; TRAUGOTT U, 1983, J NEUROIMMUNOL, V4, P201, DOI 10.1016/0165-5728(83)90036-X; Tuohy VK, 1997, J CLIN INVEST, V99, P1682, DOI 10.1172/JCI119331; WEINER HL, 1993, NEUROLOGY, V43, P910, DOI 10.1212/WNL.43.5.910; WEINSHENKER BG, 1994, ANN NEUROL, V36, pS6, DOI 10.1002/ana.410360704; WEINSHENKER BG, 1991, BRAIN, V114, P1045, DOI 10.1093/brain/114.2.1045; WEINSHENKER BG, 1996, MULTIPLE SCLEROSIS A, P105; WeinstockGuttman B, 1997, NEUROLOGIST, V3, P178, DOI 10.1097/00127893-199705000-00005; Williams R, 1995, J EPIDEMIOL COMMUN H, V49, P563, DOI 10.1136/jech.49.6.563; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Yao DL, 1996, LIFE SCI, V58, P1301, DOI 10.1016/0024-3205(96)00095-1; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777; YUDKIN PL, 1991, LANCET, V338, P1051, DOI 10.1016/0140-6736(91)91909-E; 1983, ARCH NEUROL-CHICAGO, V40, P663	88	155	163	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1604	1611		10.1056/NEJM199711273372207	http://dx.doi.org/10.1056/NEJM199711273372207			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371858				2022-12-28	WOS:A1997YH52100007
J	Blumberg, G; Kang, MS; Klein, MV; Kadowaki, K; Kendziora, C				Blumberg, G; Kang, MS; Klein, MV; Kadowaki, K; Kendziora, C			Evolution of magnetic and superconducting fluctuations with doping of high-T-c superconductors	SCIENCE			English	Article							ELECTRONIC RAMAN-SCATTERING; CUPRATE ANTIFERROMAGNETIC INSULATORS; MOTT-HUBBARD SYSTEMS; NORMAL-STATE; SPIN DYNAMICS; NEUTRON-SCATTERING; BOSE CONDENSATION; SINGLE-CRYSTAL; GAP; BI2SR2CACU2O8+DELTA	Electronic Raman scattering from high-and low-energy excitations was studied as a function of temperature, extent of hole doping, and energy of the incident photons in Bi2Sr2CaCu2O8+/-delta superconductors, For underdoped superconductors, short-range antiferromagnetic (AF) correlations were found to persist with hole doping, and doped single holes were found to be incoherent in the AF environment. Above the superconducting (SC) transition temperature T-c, the system exhibited a sharp Raman resonance of B-1g symmetry and energy of 75 millielectron-volts and a pseudogap for electron-hole excitations below 75 millielectron-volts, a manifestation of a partially coherent state forming from doped incoherent quasi particles, The occupancy of the coherent state increases with cooling until phase ordering at T-c produces a global SC state.	UNIV ILLINOIS, DEPT PHYS, URBANA, IL 61801 USA; INST CHEM PHYS & BIOPHYS, EE-0001 TALLINN, ESTONIA; UNIV TSUKUBA, INST MAT SCI, TSUKUBA, IBARAKI 305, JAPAN; USN, RES LAB, WASHINGTON, DC 20375 USA	University of Illinois System; University of Illinois Urbana-Champaign; National Institute of Chemical Physics & Biophysics (NICPB); University of Tsukuba; United States Department of Defense; United States Navy; Naval Research Laboratory	Blumberg, G (corresponding author), UNIV ILLINOIS, NSF SCI & TECHNOL CTR SUPERCONDUCT, URBANA, IL 61801 USA.		Kadowaki, Kazuo/L-8660-2017	Kadowaki, Kazuo/0000-0002-9899-0094; Blumberg, Girsh/0000-0003-0388-8327				ANDERSON PW, 1991, PHYS TODAY, V44, P54, DOI 10.1063/1.881261; ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; ANDERSON PW, 1994, PHYS TODAY, V47, P11, DOI 10.1063/1.2808399; Batlogg B, 1996, NATURE, V382, P20, DOI 10.1038/382020a0; BATLOGG B, 1994, PHYSICA C, V235, P130, DOI 10.1016/0921-4534(94)91330-7; Blumberg G, 1996, PHYS REV B, V53, P11930, DOI 10.1103/PhysRevB.53.R11930; Blumberg G, 1996, P SOC PHOTO-OPT INS, V2696, P205, DOI 10.1117/12.241756; BLUMBERG G, 1994, PHYS REV B, V49, P13295, DOI 10.1103/PhysRevB.49.13295; BONCA J, 1989, PHYS REV B, V39, P7074, DOI 10.1103/PhysRevB.39.7074; BONINSEGNI M, 1993, PHYS REV B, V47, P11897, DOI 10.1103/PhysRevB.47.11897; BRANCH D, 1995, PHYS REV B, V52, P603, DOI 10.1103/PhysRevB.52.603; BRENIG W, 1995, PHYS REP, V251, P154; BUCHER B, 1993, PHYS REV LETT, V70, P2012, DOI 10.1103/PhysRevLett.70.2012; CHUBUKOV AV, 1995, PHYS REV B, V52, P9760, DOI 10.1103/PhysRevB.52.9760; CHUBUKOV AV, 1995, PHYS REV LETT, V74, P3057, DOI 10.1103/PhysRevLett.74.3057; Chubukov AV, 1996, J PHYS-CONDENS MAT, V8, P10017, DOI 10.1088/0953-8984/8/48/021; CHUBUKOV AV, IN PRESS PHYS REP; DEVEREAUX TP, 1994, PHYS REV LETT, V72, P396, DOI 10.1103/PhysRevLett.72.396; DEVEREAUX TP, 1995, PHYS REV B, V51, P16336, DOI 10.1103/PhysRevB.51.16336; Devereaux TP, 1996, PHYS REV B, V54, P12523, DOI 10.1103/PhysRevB.54.12523; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; EMERY VJ, 1995, PHYS REV LETT, V74, P3253, DOI 10.1103/PhysRevLett.74.3253; Emery VJ, 1997, PHYS REV B, V56, P6120, DOI 10.1103/PhysRevB.56.6120; Emery VJ, 1997, PHYSICA C, V282, P174, DOI 10.1016/S0921-4534(97)00255-4; FONG HF, 1995, PHYS REV LETT, V75, P316, DOI 10.1103/PhysRevLett.75.316; Fradkin E, 1997, NATURE, V387, P18, DOI 10.1038/387018a0; Geshkenbein VB, 1997, PHYS REV B, V55, P3173, DOI 10.1103/PhysRevB.55.3173; GHIRON K, 1992, PHYS REV B, V46, P5837, DOI 10.1103/PhysRevB.46.5837; Hackl R, 1996, J LOW TEMP PHYS, V105, P733, DOI 10.1007/BF00768471; HIRSCH JE, 1987, PHYS REV LETT, V59, P228, DOI 10.1103/PhysRevLett.59.228; ITO T, 1993, PHYS REV LETT, V70, P3995, DOI 10.1103/PhysRevLett.70.3995; KAMPF AP, 1994, PHYS REP, V249, P220; Kang M, 1996, PHYS REV LETT, V77, P4434, DOI 10.1103/PhysRevLett.77.4434; KENDZIORA C, 1992, PHYS REV B, V45, P13025, DOI 10.1103/PhysRevB.45.13025; Kendziora C, 1996, PHYSICA C, V257, P74, DOI 10.1016/0921-4534(95)00663-X; KENDZIORA C, 1995, PHYS REV B, V52, pR9867, DOI 10.1103/PhysRevB.52.R9867; Lee PA, 1997, PHYS REV LETT, V78, P4111, DOI 10.1103/PhysRevLett.78.4111; LIU R, 1992, PHYS REV B, V45, P7392, DOI 10.1103/PhysRevB.45.7392; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; LORAM JW, 1993, PHYS REV LETT, V71, P1740, DOI 10.1103/PhysRevLett.71.1740; LYONS KB, 1988, PHYS REV LETT, V60, P732, DOI 10.1103/PhysRevLett.60.732; Marshall DS, 1996, PHYS REV LETT, V76, P4841, DOI 10.1103/PhysRevLett.76.4841; Martin RL, 1996, PHYS REV B, V54, pR9647, DOI 10.1103/PhysRevB.54.R9647; MOOK HA, 1993, PHYS REV LETT, V70, P3490, DOI 10.1103/PhysRevLett.70.3490; MORR DK, 1995, IN PRESS PHYS REV B, V52, P9760; Nagaosa N, 1997, SCIENCE, V275, P1078, DOI 10.1126/science.275.5303.1078; Nemetschek R, 1997, PHYS REV LETT, V78, P4837, DOI 10.1103/PhysRevLett.78.4837; Oda M, 1997, PHYSICA C, V281, P135, DOI 10.1016/S0921-4534(97)00505-4; Ong NP, 1996, SCIENCE, V273, P321, DOI 10.1126/science.273.5273.321; ORENSTEIN J, 1990, PHYS REV B, V42, P6342, DOI 10.1103/PhysRevB.42.6342; Pines D, 1997, Z PHYS B CON MAT, V103, P129, DOI 10.1007/s002570050346; Pressl M, 1996, J RAMAN SPECTROSC, V27, P343, DOI 10.1002/(SICI)1097-4555(199603)27:3/4<343::AID-JRS956>3.0.CO;2-S; Puchkov AV, 1996, PHYS REV LETT, V77, P1853, DOI 10.1103/PhysRevLett.77.1853; Puchkov AV, 1996, J PHYS-CONDENS MAT, V8, P10049, DOI 10.1088/0953-8984/8/48/023; RANDERIA M, 1989, PHYS REV LETT, V62, P981, DOI 10.1103/PhysRevLett.62.981; RANDERIA M, 1990, PHYS REV B, V41, P327, DOI 10.1103/PhysRevB.41.327; RENNER C, UNPUB; REZNIK D, 1992, PHYS REV B, V46, P11725, DOI 10.1103/PhysRevB.46.11725; ROSSATMIGNOD J, 1991, PHYSICA B, V169, P58, DOI 10.1016/0921-4526(91)90208-V; ROSSATMIGNOD J, 1993, PHYSICA B, V186-88, P1, DOI 10.1016/0921-4526(93)90483-M; Schmalian J, 1997, PHYS REV B, V56, pR509, DOI 10.1103/PhysRevB.56.R509; SHASTRY BS, 1991, INT J MOD PHYS B, V5, P365, DOI 10.1142/S0217979291000237; SHASTRY BS, 1990, PHYS REV LETT, V65, P1068, DOI 10.1103/PhysRevLett.65.1068; SLAKEY F, 1991, PHYS REV B, V43, P3764, DOI 10.1103/PhysRevB.43.3764; SLAKEY F, 1990, PHYS REV B, V42, P2643, DOI 10.1103/PhysRevB.42.2643; STAUFER T, 1991, SOLID STATE COMMUN, V79, P409, DOI 10.1016/0038-1098(91)90494-G; Strohm T, 1997, PHYS REV B, V55, P12725, DOI 10.1103/PhysRevB.55.12725; SUGAI S, 1989, SPRINGER SERIES MATE, V11, P207; TRUGMAN SA, 1988, PHYS REV B, V37, P1597, DOI 10.1103/PhysRevB.37.1597; UEMURA YJ, 1989, PHYS REV LETT, V62, P2317, DOI 10.1103/PhysRevLett.62.2317; UEMURA YJ, 1995, POLARONS BIPOLARONS, P453; VARMA CM, 1989, PHYS REV LETT, V63, P1996, DOI 10.1103/PhysRevLett.63.1996; WALSTEDT RE, 1990, PHYS REV B, V41, P9574, DOI 10.1103/PhysRevB.41.9574; WARREN WW, 1989, PHYS REV LETT, V62, P1193, DOI 10.1103/PhysRevLett.62.1193; ZHANG FC, 1988, PHYS REV B, V37, P3759, DOI 10.1103/PhysRevB.37.3759; Zhang SC, 1997, SCIENCE, V275, P1089, DOI 10.1126/science.275.5303.1089; ZIBOLD A, UNPUB	78	116	121	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	1997	278	5342					1427	1432		10.1126/science.278.5342.1427	http://dx.doi.org/10.1126/science.278.5342.1427			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367948	Green Submitted			2022-12-28	WOS:A1997YG85800034
J	AuBuchon, JP; Birkmeyer, JD; Busch, MP				AuBuchon, JP; Birkmeyer, JD; Busch, MP			Safety of the blood supply in the United States: Opportunities and controversies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS IMMUNE GLOBULIN; COST-EFFECTIVENESS ANALYSIS; DETERGENT-TREATED PLASMA; FRESH-FROZEN PLASMA; RISK; INFECTION; TRANSFUSION; HEALTH	The risk for viral transmission by transfusion has been reduced dramatically through improved techniques for selecting and testing blood donors. Initiatives to further improve the safety of the blood supply, including more stringent donor qualifications, additional testing for infectious disease markers, viral inactivation processes, and refinement of transfusion decisions, are possible. However, because the risk for viral transmission by allogeneic transfusion is already low, additional measures will have limited yield and poor cost-effectiveness. Furthermore, unexpected side effects of some of these ''improvements'' may reduce the safety of the blood supply by introducing new risks. Cost-effectiveness analyses of blood safety initiatives have highlighted such successes as the introduction of virus-specific assays for screening donated blood and have identified other interventions that have poor cost-effectiveness estimates. They have also quantitated the threshold level at which the risks of an intervention outweigh its benefits. These analyses have had little effect on decisions about blood safety, possibly because of overwhelming fear of AIDS and difficulties in applying cost-effectiveness estimates to a politically and emotionally charged issue. Future interventions for improving blood supply safety must be evaluated thoroughly and chosen carefully so that the intended goals are met. Communication with the public should be undertaken so that the public understands that some of the desired measures may result in inefficient allocation of health care resources.	DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT PATHOL & MED, LEBANON, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT SURG, LEBANON, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT COMMUNITY & FAMILY MED, LEBANON, NH 03756 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94118 USA	Dartmouth College; Dartmouth College; Dartmouth College; University of California System; University of California San Francisco	AuBuchon, JP (corresponding author), DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT PATHOL, 1 MED CTR DR, LEBANON, NH 03756 USA.				NHLBI NIH HHS [N01-HB-47114] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047114] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, JAMA, V274, P1374; Au Buchon J. P., 1996, Transfusion (Bethesda), V36, p43S; AUBUCHON JP, 1994, JAMA-J AM MED ASSOC, V272, P1210, DOI 10.1001/jama.272.15.1210; AuBuchon JP, 1997, TRANSFUSION, V37, P45, DOI 10.1046/j.1537-2995.1997.37197176950.x; BASKETT TF, 1990, CAN MED ASSOC J, V142, P337; BenHur E, 1996, AIDS, V10, P1183, DOI 10.1097/00002030-199609000-00002; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; Bresee JS, 1996, JAMA-J AM MED ASSOC, V276, P1563, DOI 10.1001/jama.276.19.1563; Busch M., 1996, Transfusion (Bethesda), V36, p59S; Busch MP, 1995, TRANSFUSION, V35, P903, DOI 10.1046/j.1537-2995.1995.351196110893.x; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; BUSCH MP, 1995, MOL GENETICS DIAGNOS; COHEN BJ, 1990, J VIROL METHODS, V30, P233, DOI 10.1016/0166-0934(90)90065-N; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; Elixhauser A, 1991, Int J Technol Assess Health Care, V7, P604; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; Evans RW, 1996, TRANSFUSION, V36, P671, DOI 10.1046/j.1537-2995.1996.36896374368.x; EVANS RW, 1986, SURG CLIN N AM, V66, P603; FOWLER FJ, 1995, MED DECIS MAKING, V15, P195, DOI 10.1177/0272989X9501500301; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HOROWITZ B, 1992, BLOOD, V79, P826; HUX JE, 1994, J GEN INTERN MED, V9, P195, DOI 10.1007/BF02600123; Kleinman S, 1996, CLIN PRACTICE TRANSF; Korelitz JJ, 1996, TRANSFUSION, V36, P203, DOI 10.1046/j.1537-2995.1996.36396182135.x; Korelitz JJ, 1996, TRANSFUSION, V36, P232, DOI 10.1046/j.1537-2995.1996.36396182141.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Lefrere JJ, 1996, TRANSFUSION, V36, P394, DOI 10.1046/j.1537-2995.1996.36596282581.x; Leveton Lauren B., 1995, HIV BLOOD SUPPLY ANA, P49; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; Lynch TJ, 1996, TRANSFUSION, V36, P770, DOI 10.1046/j.1537-2995.1996.36996420751.x; MINTZ PD, 1992, AM J CLIN PATHOL, V98, P150, DOI 10.1093/ajcp/98.2.150; MORGAN MG, 1993, SCI AM, V269, P32, DOI 10.1038/scientificamerican0793-32; NELSON KE, 1995, INFECT DIS TESTING B; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SCHNEIDERMAN LJ, 1992, AM J PUBLIC HEALTH, V82, P584, DOI 10.2105/AJPH.82.4.584; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Shilts R., 1987, BAND PLAYED POLITICS; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WILLIAMSON LM, 1995, VOX SANG, V69, P159, DOI 10.1111/j.1423-0410.1995.tb02590.x	49	124	128	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					904	909		10.7326/0003-4819-127-10-199711150-00009	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382369				2022-12-28	WOS:A1997YF54500007
J	Wong, JK; Hezareh, M; Gunthard, HF; Havlir, DV; Ignacio, CC; Spina, CA; Richman, DD				Wong, JK; Hezareh, M; Gunthard, HF; Havlir, DV; Ignacio, CC; Spina, CA; Richman, DD			Recovery of replication-competent HIV despite prolonged suppression of plasma viremia	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR NECROSIS FACTOR; TYPE-1; EXPRESSION; SEQUENCE; PROTEASE	In evaluating current combination drug regimens for treatment of human immunodeficiency virus (HIV) disease, it is important to determine the existence of viral reservoirs. After depletion of CD8 cells from the peripheral blood mononuclear cells (PBMCs) of both patients and normal donors, activation of patient CD4 lymphocytes with immobilized antibodies to CD3 and CD28 enabled the isolation of virus from PBMCs of six patients despite the suppression of their plasma HIV RNA to fewer than 50 copies per milliliter for up to 2 years. Partial sequencing of HIV pol revealed no new drug resistance mutations or discernible evolution, providing evidence for viral latency rather than drug failure.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,TREATMENT CTR,SAN DIEGO,CA 92103; VET AFFAIRS SAN DIEGO HEALTHCARE SYST,SAN DIEGO,CA 92063	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Wong, JK (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		gunthard, huldrych f/F-1724-2011	gunthard, huldrych f/0000-0002-1142-6723	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI038858, K11AI001361, U01AI027670] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FREUNDLICH B, 1983, J IMMUNOL METHODS, V62, P31, DOI 10.1016/0022-1759(83)90107-2; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lech WJ, 1996, J VIROL, V70, P2038, DOI 10.1128/JVI.70.3.2038-2043.1996; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MATSUYAMA T, 1989, AIDS RES HUM RETROV, V5, P139, DOI 10.1089/aid.1989.5.139; Mulder J, 1997, J CLIN MICROBIOL, V35, P1278, DOI 10.1128/JCM.35.5.1278-1280.1997; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Sanchez G, 1997, J VIROL, V71, P2233, DOI 10.1128/JVI.71.3.2233-2240.1997; Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1989, IMMUNOLOGY, V66, P628; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	25	1721	1763	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1291	1295		10.1126/science.278.5341.1291	http://dx.doi.org/10.1126/science.278.5341.1291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360926				2022-12-28	WOS:A1997YG04300045
J	Shuster, E				Shuster, E			Fifty years later: The significance of the Nuremberg Code	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-RIGHTS				Shuster, E (corresponding author), VET AFFAIRS MED CTR,UNIV & WOODLAND AVE,PHILADELPHIA,PA 19104, USA.							Advisory Committee on Human Radiation Experiments, 1995, FIN REP; ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; Alexander L., 1976, PSYCHIAT J U OTTAWA, V1, P40; AMBROSELLI C, 1988, ETHIQUE MED; Annas G., 1992, NAZI DOCTORS NUREMBE, P227; Annas George J., 1992, NAZI DOCTORS NUREMBE; ANNAS GJ, 1977, INFORMED CONSENT HUM; AZIZASHUSTER E, 1972, MED SOIMEME; BAYLE F, 1950, CROIX GAMMEE CADUCCC; CANGUILHEM G, 1988, IDEOLOGY RATIONALITY, P51; *COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; Grodin MA, 1996, JAMA-J AM MED ASSOC, V276, P1682, DOI 10.1001/jama.276.20.1682; GRODIN MA, 1993, HASTINGS CENT REP, V23, P8, DOI 10.2307/3562583; Grodin MA., 1992, NAZI DOCTORS NUREMBE, P121; IVY AC, 1949, JAMA-J AM MED ASSOC, V139, P131, DOI 10.1001/jama.1949.02900200001001; JONES WHS, 1923, HIPPOCRATIC CORPUS O, V1; Katz J., 1984, SILENT WORLD DOCTOR; Moreno J D, 1997, J Contemp Health Law Policy, V13, P347; 1946, JAMA-J AM MED ASSOC, V132, P1090; 1976, HASTINGS CENT REP S, V6, P1; 1948, JAMA-J AM MED ASSOC, V136, P457	21	226	230	2	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1436	1440		10.1056/NEJM199711133372006	http://dx.doi.org/10.1056/NEJM199711133372006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF253	9358142				2022-12-28	WOS:A1997YF25300006
J	Korth, C; Stierli, B; Streit, P; Moser, M; Schaller, O; Fischer, R; SchulzSchaeffer, W; Kretzschmar, H; Raeber, A; Braun, U; Ehrensperger, F; Hornemann, S; Glockshuber, R; Riek, R; Billeter, M; Wuthrich, K; Oesch, B				Korth, C; Stierli, B; Streit, P; Moser, M; Schaller, O; Fischer, R; SchulzSchaeffer, W; Kretzschmar, H; Raeber, A; Braun, U; Ehrensperger, F; Hornemann, S; Glockshuber, R; Riek, R; Billeter, M; Wuthrich, K; Oesch, B			Prion (PrPSc)-specific epitope defined by a monoclonal antibody	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE PRION; PROTEIN PRP; MICE; GENE; FORMS	Prions are infectious particles causing transmissible spongiform encephalopathies (TSEs). They consist, at least in part, of an isoform (PrPSc) of the ubiquitous cellular prion protein (PrPC). Conformational differences between PrPC and PrPSc are evident from increased beta-sheet content and protease resistance in PrPSc (refs 1-3). Here we describe a monoclonal antibody, 15B3, that can discriminate between the normal and disease-specific forms of PrP. Such an antibody has been long sought as it should be invaluable far characterizing the infectious particle as well as for diagnosis of TSEs such as bovine spongiform encephalopathy (BSE) or Creutzfeldt-Jakob disease (CJD) in humans. 15B3 specifically precipitates bovine, murine or human PrPSc, but not PrPC, suggesting that it recognizes an epitope common to prions from different species. Using immobilized synthetic peptides, iue mapped three polypeptide segments in PrP as the 15B3 epitope. In the NMR structure of recombinant mouse PrP, segments 2 and 3 of the 15B3 epitope are near neighbours in space, and segment 1 is located in a different part nf the molecule, We discuss models for the PrPSc-specific epitope that ensure close spatial proximity of all three 15B3 segments, either by intermolecular contacts in oligomeric forms of the prion protein or by intramolecular rearrangement.	UNIV ZURICH, BRAIN RES INST, CH-8029 ZURICH, SWITZERLAND; ETH ZURICH, INST BIOCHEM, CH-8092 ZURICH, SWITZERLAND; UNIV GOTTINGEN, INST NEUROPATHOL, D-37075 GOTTINGEN, GERMANY; UNIV ZURICH, INST NEUROPATHOL, CH-8091 ZURICH, SWITZERLAND; UNIV ZURICH, KLIN WIEDERKAUER & PFERDEMED, CH-8057 ZURICH, SWITZERLAND; UNIV ZURICH, INST VET PATHOL, CH-8057 ZURICH, SWITZERLAND; ETH ZURICH, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Gottingen; University of Zurich; University of Zurich; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Korth, C (corresponding author), UNIV ZURICH, PRION AG, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.		Korth, Carsten/F-7433-2010; Billeter, Martin/A-8293-2010	Riek, Roland/0000-0002-6333-066X				Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CHANDLER RL, 1961, LANCET, V1, P1378; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Glockshuber R, 1997, TRENDS BIOCHEM SCI, V22, P241, DOI 10.1016/S0968-0004(97)01070-0; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; Kaneko K, 1997, J MOL BIOL, V270, P574, DOI 10.1006/jmbi.1997.1135; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; KITAMOTO T, 1989, J GEN VIROL, V70, P3371, DOI 10.1099/0022-1317-70-12-3371; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OESCH B, 1994, BIOCHEMISTRY-US, V33, P5926, DOI 10.1021/bi00185a033; PADAN EA, 1985, J BIOL CHEM, V260, P8280; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Warwicker J, 1996, BIOCHEM BIOPH RES CO, V226, P777, DOI 10.1006/bbrc.1996.1428; Weiss S, 1996, BIOCHEM BIOPH RES CO, V219, P173, DOI 10.1006/bbrc.1996.0201	27	516	566	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					74	77		10.1038/36337	http://dx.doi.org/10.1038/36337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363892				2022-12-28	WOS:A1997YE47700054
J	Fredricks, DN; Relman, DA				Fredricks, DN; Relman, DA			Cultivation of Whipple bacillus: the irony and the ecstasy	LANCET			English	Editorial Material							DISEASE; IDENTIFICATION		STANFORD UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; VET AFFAIRS PALO ALTO HLTH CARE SYST,PALO ALTO,CA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Fredricks, DN (corresponding author), STANFORD UNIV,MED CTR,DEPT MED,DIV INFECT DIS & GEOG MED,STANFORD,CA 94305, USA.			Fredricks, David/0000-0003-2735-6800; Relman, David A./0000-0001-8331-1354				BEUSCHER HU, 1995, INFECT IMMUN, V63, P1270, DOI 10.1128/IAI.63.4.1270-1277.1995; DOBBINS WO, 1981, GASTROENTEROLOGY, V80, P1468; Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE, V5th edition; MARACK P, 1994, CELL, V76, P323; Ramzan NN, 1997, ANN INTERN MED, V126, P520, DOI 10.7326/0003-4819-126-7-199704010-00004; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Schoedon G, 1997, J INFECT DIS, V176, P672, DOI 10.1086/514089; SILVA MT, 1985, J GEN MICROBIOL, V131, P1001; TRIER JS, 1965, GASTROENTEROLOGY, V48, P684; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z	12	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1262	1263		10.1016/S0140-6736(97)22044-1	http://dx.doi.org/10.1016/S0140-6736(97)22044-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357400	Green Submitted			2022-12-28	WOS:A1997YD68900002
J	Grant, I				Grant, I			Lesson of the week - Delayed closure of injuries to the hand caused by blasts helps to preserve function	BRITISH MEDICAL JOURNAL			English	Review											Grant, I (corresponding author), VICTORIA HOSP,BLONDE MCINDOE CTR,E GRINSTEAD RH19 3DZ,SUSSEX,ENGLAND.							BROWN PW, 1995, J HAND SURG-AM, V20A, pS61, DOI 10.1016/S0363-5023(95)80172-3; BROWN PW, 1973, CLIN ORTHOP RELAT R, V96, P42; FRYKBERG ER, 1988, ANN SURG, V208, P569, DOI 10.1097/00000658-198811000-00005; NICOLL J, 1994, ANN R COLL SURG ENGL, V76, P161; Quirinia A, 1996, J TRAUMA, V41, P1018, DOI 10.1097/00005373-199612000-00013; Swanson A B, 1975, Clin Plast Surg, V2, P615	6	0	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1146	1147						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374892				2022-12-28	WOS:A1997YE61500032
J	MacKie, RM; Hunter, D; Hunter, JAA; Rankin, R; Evans, A; McLaren, K; Fallowfield, M; Hutcheon, A; Morris, A				MacKie, RM; Hunter, D; Hunter, JAA; Rankin, R; Evans, A; McLaren, K; Fallowfield, M; Hutcheon, A; Morris, A			Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94	BRITISH MEDICAL JOURNAL			English	Article							TRENDS	Objective: To determine the changing incidence of and mortality from cutaneous malignant melanoma in Scotland from 1979 to 1994. Design: Detailed registration of clinical and pathological features, surgical and other treatment, and follow up of all cases of cutaneous malignant melanoma diagnosed from 1979 to 1994 and registered with specialist database for Scotland. Setting: Scotland. Subjects: 6288 patients with invasive primary cutaneous malignant melanoma diagnosed between 1 January 1979 and 31 December 1994. Results: The annual age standardised incidence of cutaneous malignant melanoma rose significantly from 3.5 to 7.8 per 100 000 per year in men and from 6.8 to 12.3 per 100 000 per year in women (P < 0.001 for both). World standardised rates increased from 2.7 to 6.0 per 100 000 per year in men and 4.6 to 8.50 per 100 000 in women. The incidence of melanoma continued to increase significantly in men of all ages during the study but the rate stabilised in women after 1986. Mortality from cutaneous malignant melanoma was 1.3 per million per annum in men in 1979, rising to 2.3 per million per annum in 1994 (P < 0.01); it was 2.4 per million per annum in women in 1979, falling to 1.9 per million per annum in 1994 (P = 0.09). The underlying mortality trends showed a continuing rise for men but a downward trend for women that was not significant (P = 0.09). In men, melanoma free survival was 69% at 5 years and 61% at 10 years; in women the corresponding rates were 82% and 75%. Younger patients had higher survival rates, which were not entirely explained by thinner rumours. Over the 15 year period, survival rates improved by 12% overall, only partly owing to thinner tumours. Conclusions: In Scotland the incidence of melanoma in women has stabilised, while mortality associated with melanoma in women shows a downward trend.	RUCHILL HOSP,CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV EDINBURGH,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; RAIGMORE HOSP,INVERNESS IV8 3UJ,SCOTLAND; NINEWELLS HOSP,DUNDEE DD2 1UB,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,GLASGOW G11 6NJ,LANARK,SCOTLAND; ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZB,SCOTLAND; TAYSIDE HLTH BOARD,DUNDEE DD1 9NL,SCOTLAND	University of Edinburgh; University of Dundee; University of Glasgow; University of Aberdeen	MacKie, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,ROBERTSON BLDG,GLASGOW G12 8QQ,LANARK,SCOTLAND.							Balzi D, 1997, CANCER CAUSE CONTROL, V8, P85, DOI 10.1023/A:1018491323442; BRAHME EM, 1994, CANCER, V73, P2324; BURTON RC, 1994, MELANOMA RES, V4, P107, DOI 10.1097/00008390-199404000-00005; BURTON RC, 1993, INT J CANCER, V55, P765, DOI 10.1002/ijc.2910550512; Giles GG, 1996, BMJ-BRIT MED J, V312, P1121; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; MACKIE RM, 1985, LANCET, V2, P859; MACKIE RM, 1992, BRIT MED J, V304, P1012, DOI 10.1136/bmj.304.6833.1012; MELIA J, 1995, BRIT J CANCER, V72, P224, DOI 10.1038/bjc.1995.307; *OFF POP CENS SURV, 1995, MORT STAT CAUS E DH2; *OFF POP CENS SURV, 1994, CANC STAT REG EN MB1; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; ROUSH GC, 1992, CANCER-AM CANCER SOC, V69, P1714, DOI 10.1002/1097-0142(19920401)69:7&lt;1714::AID-CNCR2820690712&gt;3.0.CO;2-Z; SCOTTO J, 1991, INT J CANCER, V49, P490, DOI 10.1002/ijc.2910490403; STREETLY A, 1995, INT J EPIDEMIOL, V24, P897, DOI 10.1093/ije/24.5.897	15	128	128	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1117	1121						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374883	Green Published			2022-12-28	WOS:A1997YE61500019
J	Fuhlbrigge, RC; Kieffer, JD; Armerding, D; Kupper, TS				Fuhlbrigge, RC; Kieffer, JD; Armerding, D; Kupper, TS			Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells	NATURE			English	Article							P-SELECTIN; LEUKOCYTE ADHESION; FUCOSYL-TRANSFERASE; GLYCOPROTEIN LIGAND; PHYSIOLOGICAL FLOW; MYELOID CELLS; FUCT-VII; RECEPTOR; MOLECULE; BINDING	T cells play a pathogenic role in many inflammatory and certain malignant skin diseases, including psoriasis, atopic and allergic contact dermatitis, and cutaneous T-cell lymphoma(1-6). Memory T cells that infiltrate the skin express a unique skin-homing receptor called cutaneous lymphocyte-associated antigen (CLA), a carbohydrate epitope that facilitates the targeting of T cells to inflamed skin(1,7,8). CLA is defined by both its reactivity with a unique monoclonal antibody, HECA-452, and its activity as a ligand for E-selectin(2,9-11), but the structure of the protein component of CLA has not previously been defined. Here we report that CLA is an inducible carbohydrate modification of P-selectin glycoprotein ligand-1 (PSGL-1), a known surface glycoprotein that is expressed constitutively on all human peripheral-blood T cells, Cultured peripheral-blood T cells can be differentiated into CLA-bearing cells, which bind both E-selectin and P-selectin, or CLA-negative cells, which bind P-selectin but do not bind E-selectin, suggesting that there is independent regulation of selectin-binding phenotypes, We propose that differential post-translational modification of a single cell-surface receptor, PSGL-1, mediated by fucosyltransferase VII, serves as a mechanism for regulating tissue-specific homing of memory T cells.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV DERMATOL,HARVARD SKIN DIS RES CTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Kupper, Thomas/O-4962-2019					ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; ALON R, 1994, J CELL BIOL, V127, P1485, DOI 10.1083/jcb.127.5.1485; BABI LFS, 1995, J IMMUNOL, V154, P1543; BERG EL, 1991, J BIOL CHEM, V266, P14869; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Diacovo TG, 1996, J EXP MED, V183, P1193, DOI 10.1084/jem.183.3.1193; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; JONES DA, 1994, J CLIN INVEST, V94, P2443, DOI 10.1172/JCI117612; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kieffer JD, 1995, BIOCHEM BIOPH RES CO, V217, P466, DOI 10.1006/bbrc.1995.2799; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Lowe John B., 1994, P163; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1637, DOI 10.1152/ajpheart.1994.267.4.H1637; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Pitzalis C, 1996, ARTHRITIS RHEUM, V39, P137, DOI 10.1002/art.1780390118; ROOK AH, 1995, HEMATOL ONCOL CLIN N, V9, P997, DOI 10.1016/S0889-8588(18)30054-6; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Wagers AJ, 1996, BLOOD, V88, P2125, DOI 10.1182/blood.V88.6.2125.bloodjournal8862125	27	421	444	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					978	981		10.1038/40166	http://dx.doi.org/10.1038/40166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353122				2022-12-28	WOS:A1997YD29900058
J	Ikeya, M; Lee, SMK; Johnson, JE; McMahon, AP; Takada, S				Ikeya, M; Lee, SMK; Johnson, JE; McMahon, AP; Takada, S			Wnt signalling required for expansion of neural crest and CNS progenitors	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; VITAL DYE ANALYSIS; MOUSE EMBRYO; CELL-MIGRATION; INT-1 PROTOONCOGENE; EXPRESSION; TRANSFORMATION; HINDBRAIN; PATHWAYS; DOMAINS	Interactions between cells help to elaborate pattern within the vertebrate central nervous system (CNS)(1). The genes Wnt-1 and Wnt-3a, which encode members of the Wnt family of cysteine-rich secreted signals, are coexpressed at the dorsal midline of the developing neural tube, coincident with dorsal patterning(2,3). Each signal is essential for embryonic development, Wnt-1 for midbrain patterning(4,5) and Wnt-3a for formation of the paraxial mesoderm(6), but the absence of a dorsal neural-tube phenotype in each mutant suggests that Wnt signalling may be redundant. Here we demonstrate that in the absence of both Wnt-1 and Wnt-3a there is a marked deficiency in neural crest derivatives, which originate from the dorsal neural tube(7), and a pronounced reduction in dorsolateral neural precursors within the neural tube itself. These phenotypes do not seem to result from a disruption in the mechanisms responsible for establishing normal dorsoventral polarity. Rather, our results are consistent with a model in which local Wnt signalling regulates the expansion of dorsal neural precursors. Given the widespread expression of different Wnt genes in discrete areas of the mammalian neural tube(3), this may represent a general model for the action of Wnt signalling in the developing CNS.	KYOTO UNIV, FAC SCI, CTR MOL & DEV BIOL, SAKYO KU, KYOTO 60601, JAPAN; HARVARD UNIV, BIOLABS, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA	Kyoto University; Harvard University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Johnson, Jane/F-8881-2010; McMahon, Andrew P/ABE-7520-2020	Ikeya, Makoto/0000-0002-3930-8032; /0000-0002-8605-2746; Takada, Shinji/0000-0003-4125-6056				Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; Couly G, 1996, DEVELOPMENT, V122, P3393; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Kontges G, 1996, DEVELOPMENT, V122, P3229; Le Douarin N.M., 1982, NEURAL CREST; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MARK M, 1993, DEVELOPMENT, V119, P319; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; SERBEDZIJA GN, 1989, DEVELOPMENT, V106, P809; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	30	560	571	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	1997	389	6654					966	970		10.1038/40146	http://dx.doi.org/10.1038/40146			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353119				2022-12-28	WOS:A1997YD29900055
J	Khaw, KT				Khaw, KT			Healthy aging	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; LOWER BLOOD-PRESSURE; SALT REDUCTION; VITAMIN-E; MORTALITY; STROKE; MEN; FRACTURE; WOMEN; TRIAL				Khaw, KT (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN MED, CLIN GERONTOL UNIT, BOX 110, CAMBRIDGE CB2 2QQ, ENGLAND.		Khaw, Kay-Tee/AAZ-3209-2021					Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; BARKER DJP, 1994, J ROY COLL PHYS LOND, V28, P544; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BONE M, 1996, HLTH EXPECTANCY ITS; BOYCE WJ, 1985, LANCET, V1, P150; BURR ML, 1989, LANCET, V2, P757; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CUMMINGS SR, 1995, AM J MED, V98, pS24, DOI 10.1016/S0002-9343(05)80041-5; CURFMAN GD, 1993, NEW ENGL J MED, V328, P574, DOI 10.1056/NEJM199302253280810; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *DEP HLTH, 1994, NUTR ASP CARD DIS RE; *DEP HLTH, 1995, HLTH NAT VAR HLTH RE; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DUBBELMAN R, 1993, AM J CLIN NUTR, V58, P106, DOI 10.1093/ajcn/58.1.106; FARCHI G, 1995, EUR J CLIN NUTR, V49, P408; Fries JF, 1996, J ROY SOC MED, V89, P64, DOI 10.1177/014107689608900202; FRIES JF, 1980, NEW ENGL J MED, V313, P407; Gaziano J M, 1996, J Cardiovasc Risk, V3, P368; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; GRUNDY E, 1997, HLTH ADULT BRITAIN 1, P182; KANNEL WB, 1987, J AM COLL CARDIOL, V10, pA25, DOI 10.1016/S0735-1097(87)80443-6; KESTELOOT H, 1989, NEW HORIZONS PREVENT; KHAW KT, 1996, EPIDEMIOLOGY OLD AGE, P171; KIRKWOOD TBL, 1995, AGE AGEING, V24, P167, DOI 10.1093/ageing/24.2.167; KITA T, 1986, CIRCULATION S2, V74, P131; KROMHOUT D, 1984, AM J EPIDEMIOL, V119, P733, DOI 10.1093/oxfordjournals.aje.a113794; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; Magni Eugenio, 1994, Journal of Nutrition for the Elderly, V13, P25, DOI 10.1300/J052v13n04_04; MARTIN J, 1988, OPCS SURVEYS DISABIL; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; Murray CJL, 1997, LANCET, V349, P1347, DOI 10.1016/S0140-6736(96)07494-6; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; *OFF NAT STAT, 1996, NAT POP PROJ PP2, V20; PEDERSEN TR, 1994, LANCET, V344, P1383; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; Qizilbash N, 1995, LANCET, V346, P1647; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; SRIDHAR MK, 1995, BRIT MED J, V310, P75, DOI 10.1136/bmj.310.6972.75; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Tuormaa T E, 1988, Nutr Health, V6, P53; *US DEP HHS, 1988, USDHHS PHS PUBL; WHO, 1995, WORLD HLTH STAT ANN; *WHO STUD GROUP, 1990, WHO TECH REP SER, V797; WIDDOWSON EM, 1992, AM J CLIN NUTR, V55, P1246; WORTH RM, 1975, AM J EPIDEMIOL, V102, P481, DOI 10.1093/oxfordjournals.aje.a112186; YOUNG A, 1996, EPIDEMIOLOGY OLD AGE, P190	51	63	65	2	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1090	1096		10.1136/bmj.315.7115.1090	http://dx.doi.org/10.1136/bmj.315.7115.1090			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366744	Green Published			2022-12-28	WOS:A1997YD44500035
J	Dahmane, N; Lee, J; Robins, P; Heller, P; Altaba, ARI				Dahmane, N; Lee, J; Robins, P; Heller, P; Altaba, ARI			Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours	NATURE			English	Article							BASAL-CELL CARCINOMAS; HUMAN HOMOLOG; CANDIDATE GENE; EXPRESSION; MUTATIONS; IDENTIFICATION; ONCOGENE; PROTEIN	Sporadic basal cell carcinoma (BCC) is the most common type of malignant cancer in fair-skinned adults. Familial BCCs and a fraction of sporadic BCCs have lost the function of Patched (Ptc), a Sonic hedgehog (Shh) receptor(1-3) that acts negatively on this signalling pathway. Overexpression of Shh can induce BCCs in mice(4). Here we show that ectopic expression of the zinc-finger transcription factor Gli1 in the embryonic frog epidermis results in the development of tumours that express endogenous Gli1. We also show that Shh and the Gli genes are normally expressed in hair follicles, and that human sporadic BCCs consistently express Gli1 but not Shh or Gli3. Because Gli1, but not Gli3, acts as a target and mediator of Shh signalling(5), our results suggest that expression of GLi(1) in basal cells induces BCC formation. Moreover, loss of Ptc or overexpression of Shh cannot be the sole causes of Gli1 induction and sporadic BCC formation, as they do not occur consistently. Thus any mutations leading to the expression of Gli1 in basal cells are predicted to induce CC formation.	NYU,MED CTR,SKIRBALL INST,DEV GENET PROGRAM,NEW YORK,NY 10016; NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016	New York University; New York University; New York University				Ruiz i Altaba, Ariel/0000-0003-2292-3933				Ackerman A.B., 1993, NEOPLASMS FOLLICULAR; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; ALTABA ARI, 1995, DEV BIOL, V1270, P299; ALTABA ARI, 1993, ESSENTIAL DEV BIOL P; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GRIMWOOD RE, 1986, J INVEST DERMATOL, V86, P191, DOI 10.1111/1523-1747.ep12284253; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Iseki S, 1996, BIOCHEM BIOPH RES CO, V218, P688, DOI 10.1006/bbrc.1996.0123; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Lee J, 1997, DEVELOPMENT, V124, P2537; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; ROBERTS WM, 1989, CANCER RES, V49, P5407; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5048; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; XIAO HG, 1994, PEDIATR NEUROSURG, V20, P178, DOI 10.1159/000120783	29	515	539	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					876	881		10.1038/39918	http://dx.doi.org/10.1038/39918			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349822				2022-12-28	WOS:A1997YC14800063
J	Lowe, SL; Peter, F; Subramaniam, VN; Wong, SH; Hong, WJ				Lowe, SL; Peter, F; Subramaniam, VN; Wong, SH; Hong, WJ			A SNARE involved in protein transport through the Golgi apparatus	NATURE			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; VESICULAR TRANSPORT; FUSION; VESICLES; COMPLEX; ER; BOS1P; YEAST	In eukaryotic cells, the Golgi apparatus receives newly synthesized proteins from the endoplasmic reticulum (ER) and delivers them after covalent modification to their destination in the cell. These proteins move from the inside (cis) face to the plasma-membrane side (trans) of the Golgi, through a stack of cisternae, towards the trans-Golgi network (TGN), but very little is known about how proteins are moved through the Golgi compartments. In a model known as the maturation model, no special transport process was considered necessary, with protein movement along the Golgi being achieved by maturation of the cisternae. Alternatively, proteins could be transported by vesicles or membrane tubules. Although little is known about membrane-tubule-mediated transport, the molecular mechanism for vesicle-mediated transport is quite well understood, occurring through docking of SNAREs on the vesicle with those on the target membrane. We have now identified a protein of relative molecular mass 27K which is associated with the Golgi apparatus. The cytoplasmic domain of this protein or antibodies raised against it quantitatively inhibit transport in vitro from the ER to the trans-Golgi/TGN, acting at a stage between the cis/medial- and the trans-Golgi/TGN. This protein, which behaves like a SNARE and has been named GS27 (for Golgi SNARE of 27K), is identical to membrin, a protein implicated earlier in ER-to-Golgi transport. Our results suggest that protein movement from medial- to the trans-Golgi/TGN depends on SNARE-mediated vesicular transport.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 119076,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Subramaniam, V. Nathan/A-1901-2010; HONG, Wanjin/E-9927-2010	Subramaniam, V. Nathan/0000-0002-4583-7790; 				BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HONG W, 1996, PROTEIN TRAFFICKING; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; Lowe SL, 1996, J CELL SCI, V109, P209; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PLUTNER H, 1992, J CELL BIOL, V119, P1077; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	28	69	73	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					881	884		10.1038/39923	http://dx.doi.org/10.1038/39923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349823				2022-12-28	WOS:A1997YC14800064
J	Vahtera, J; Kivimaki, M; Pentti, J				Vahtera, J; Kivimaki, M; Pentti, J			Effect of organisational downsizing on health of employees	LANCET			English	Article							SICKNESS ABSENCE; JOB INSECURITY; HEART-DISEASE; WHITEHALL-II; UNEMPLOYMENT; MEN; ABSENTEEISM; MORTALITY; WOMEN; WORK	Background Reduction of personnel by businesses and other organisations (organisational downsizing) is common in Europe, but little is known about its effects on the health of employees. Methods We used employers' records to investigate the relation between downsizing and subsequent absenteeism because of ill health in 981 local-government workers who remained in employment in Raisio, south-western Finland, during a period of economic decline (1991-95). Data were separated into three time periods: 1991, before downsizing; 1993, major downsizing in some workplaces and occupations; and 1993-95, after downsizing. We obtained data on sick leave from records kept by the occupational health-care unit in Raisio. We also investigated whether the effects of downsizing were dependent on ten other predictors of sick leave. Findings There was a significant association between downsizing and medically certified sick leave. The rate of absenteeism was 2.3 times greater (95% CI 2.0-2.7) after major downsizing, classified by occupation, than after minor downsizing. The corresponding rate ratios for musculoskeletal disorders and trauma were 5.7 (4.1-8.0) and 2.7 (1.7-4.2), respectively. The effects of downsizing by workplace depended on the age distribution of the staff. When the proportion of employees who were older than 50 years was high, downsizing increased the individual risk of absence because of ill health by 3.2-14.0 times, depending on diagnostic category. When the proportion of employees over 50 years was low, downsizing had only slight effects on health. Other risk factors that increased rates of sick leave after downsizing were age over 44 years, a large workplace, poor health before downsizing, and high income. Interpretation Downsizing is a risk to the health of employees. But this risk varies according to individual factors, such as age, socioeconomic status, and health, as well as factors related to place of work, for example, size and age structure of the staff.	FINNISH INST OCCUPAT HLTH, HELSINKI, FINLAND; UNIV JYVASKYLA, DEPT PSYCHOL, JYVASKYLA, FINLAND	Finnish Institute of Occupational Health; University of Jyvaskyla	Vahtera, J (corresponding author), FINNISH INST OCCUPAT HLTH, HAMEENKATU 10, FIN-20500 TURKU, FINLAND.		Blewett, Verna L/A-5270-2012; Kivimaki, Mika/B-3607-2012; Vahtera, Jussi/J-3271-2013	Kivimaki, Mika/0000-0002-4699-5627; 				ARNETZ BB, 1987, PSYCHOSOM MED, V49, P3, DOI 10.1097/00006842-198701000-00001; BEALE N, 1988, BRIT MED J, V296, P1508, DOI 10.1136/bmj.296.6635.1508; BRENNER MH, 1987, SOC SCI MED, V25, P119; COHEN J., 1983, APPL MULTIPLE REGRES, V2; DEKKER SWA, 1995, AUST PSYCHOL, V30, P57, DOI 10.1080/00050069508259607; FERRIE JE, 1995, BRIT MED J, V311, P1264, DOI 10.1136/bmj.311.7015.1264; GREEN A, 1982, JEMF QUART, V18, P155; HALL DT, 1971, ADMIN SCI QUART, V16, P533, DOI 10.2307/2391771; Hartley J., 1991, JOBINSECURITY; IVANCEVICH JM, 1986, J OCCUP BEHAV, V7, P39, DOI 10.1002/job.4030070106; JANLERT U, 1992, J INTERN MED, V231, P241, DOI 10.1111/j.1365-2796.1992.tb00530.x; KLAUKKA T, 1982, SCAND J RHEUMATOL, P5; KRANTZ J, 1985, J APPL BEHAV SCI, V21, P1, DOI 10.1177/002188638502100102; MARMOT M, 1995, J EPIDEMIOL COMMUN H, V49, P124, DOI 10.1136/jech.49.2.124; Martikainen PT, 1996, LANCET, V348, P909, DOI 10.1016/S0140-6736(96)03291-6; MARTIN J, 1988, 1 OFF POP CENS SURV; MATTIASSON I, 1990, BRIT MED J, V301, P461, DOI 10.1136/bmj.301.6750.461; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MOSER KA, 1984, LANCET, V2, P1324; NORTH F, 1993, BRIT MED J, V306, P361, DOI 10.1136/bmj.306.6874.361; ORPEN C, 1993, PERCEPT MOTOR SKILL, V76, P885, DOI 10.2466/pms.1993.76.3.885; SIEGRIST J, 1990, SOC SCI MED, V31, P1127, DOI 10.1016/0277-9536(90)90234-J; *STAT FINL, 1995, FINN STAT YB; Statistics Finland, 1987, CLASS OCC HDB, V14; SUTTON RI, 1987, ADMIN SCI QUART, V32, P542, DOI 10.2307/2392883; SUTTON RI, 1984, HUMAN RESOURCE MANAG, V22, P391; VANVUUREN T, 1991, JOB INSECURITY COPIN, P65; VOLINN E, 1991, NEUROSURG CLIN N AM, V2, P729; WETZEL D, 1994, ORG DEV J, V12, P1; World Health Organization, 1977, INT CLASS DIS; ZACCARO SJ, 1991, ORGAN BEHAV HUM DEC, V50, P24, DOI 10.1016/0749-5978(91)90032-O	31	250	253	1	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	1997	350	9085					1124	1128		10.1016/S0140-6736(97)03216-9	http://dx.doi.org/10.1016/S0140-6736(97)03216-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB199	9343499				2022-12-28	WOS:A1997YB19900009
J	Cerritelli, ME; Cheng, NQ; Rosenberg, AH; McPherson, CE; Booy, FP; Steven, AC				Cerritelli, ME; Cheng, NQ; Rosenberg, AH; McPherson, CE; Booy, FP; Steven, AC			Encapsidated conformation of bacteriophage T7 DNA	CELL			English	Article							DOUBLE-STRANDED DNA; CRYO-ELECTRON-MICROSCOPY; HERPES-SIMPLEX VIRUS; X-RAY-DIFFRACTION; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; SIMIAN VIRUS-40; WILD-TYPE; HEADS; ORGANIZATION	The structural organization of encapsidated T7 DNA was investigated by cryo-electron microscopy and image processing. A tail-deletion mutant was found to present two preferred views of phage heads: views along the axis through the capsid vertex where the connector protein resides and via which DNA is packaged; and side views perpendicular to this axis. The resulting images reveal striking patterns of concentric rings in axial views, and punctate arrays in side views. As corroborated by computer modeling, these data establish that the T7 chromosome is spooled around this axis in approximately six coaxial shells in a quasicrystalline packing, possibly guided by the core complex on the inner surface of the connector.	NIAMSD,STRUCT BIOL LAB,NIH,BETHESDA,MD 20892; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); United States Department of Energy (DOE); Brookhaven National Laboratory								ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; AUBREY KL, 1992, BIOCHEMISTRY-US, V31, P11835, DOI 10.1021/bi00162a023; BAKER TS, 1989, BIOPHYS J, V55, P243, DOI 10.1016/S0006-3495(89)82799-7; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BLACK LW, 1985, P NATL ACAD SCI USA, V82, P7960, DOI 10.1073/pnas.82.23.7960; BOOY FP, 1985, J MOL BIOL, V184, P667, DOI 10.1016/0022-2836(85)90312-2; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; BOOY FP, 1992, P 50 ANN M EMSA, V1, P452; BOOY FP, 1992, MEMBRANE FUSION, P21; Casjens S., 1988, BACTERIOPHAGES, V1, P16; Cerritelli ME, 1996, J MOL BIOL, V258, P286, DOI 10.1006/jmbi.1996.0250; Cerritelli ME, 1996, J MOL BIOL, V258, P299, DOI 10.1006/jmbi.1996.0251; Cerritelli ME, 1996, J MOL BIOL, V260, P767, DOI 10.1006/jmbi.1996.0436; CHUNG YB, 1990, J MOL BIOL, V216, P939, DOI 10.1016/S0022-2836(99)80012-6; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DIERKSEN K, 1995, BIOPHYS J, V68, P1416, DOI 10.1016/S0006-3495(95)80314-0; DONATE LE, 1990, VIROLOGY, V179, P936, DOI 10.1016/0042-6822(90)90172-N; EARNSHAW W, 1976, J MOL BIOL, V104, P387, DOI 10.1016/0022-2836(76)90278-3; EARNSHAW WC, 1979, J MOL BIOL, V134, P575, DOI 10.1016/0022-2836(79)90368-1; EARNSHAW WC, 1978, CELL, V14, P559, DOI 10.1016/0092-8674(78)90242-8; EARNSHAW WC, 1977, NATURE, V268, P598, DOI 10.1038/268598a0; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; Garcia LR, 1996, J BACTERIOL, V178, P6921, DOI 10.1128/jb.178.23.6921-6929.1996; GELLERT M, 1964, J MOL BIOL, V8, P341, DOI 10.1016/S0022-2836(64)80197-2; HARRISON SC, 1983, J MOL BIOL, V171, P577, DOI 10.1016/0022-2836(83)90045-1; HUD NV, 1995, BIOPHYS J, V69, P1355, DOI 10.1016/S0006-3495(95)80002-0; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; KOSTURKO LD, 1979, CELL, V16, P515, DOI 10.1016/0092-8674(79)90026-6; LEPAULT J, 1987, EMBO J, V6, P1507, DOI 10.1002/j.1460-2075.1987.tb02393.x; LEPAULT J, 1985, J MOL BIOL, V182, P431, DOI 10.1016/0022-2836(85)90202-5; Livolant F, 1996, PROG POLYM SCI, V21, P1115, DOI 10.1016/S0079-6700(96)00016-0; MOFFATT BA, 1988, J BACTERIOL, V170, P2095, DOI 10.1128/jb.170.5.2095-2105.1988; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; NORTH AC, 1961, NATURE, V191, P1242, DOI 10.1038/1911242a0; RICHARDS KE, 1973, J MOL BIOL, V78, P255, DOI 10.1016/0022-2836(73)90114-9; ROEDER GS, 1977, VIROLOGY, V76, P263, DOI 10.1016/0042-6822(77)90302-6; SERWER P, 1986, J MOL BIOL, V190, P509, DOI 10.1016/0022-2836(86)90019-7; SERWER P, 1992, J MOL BIOL, V223, P999, DOI 10.1016/0022-2836(92)90258-L; Serwer P, 1997, J STRUCT BIOL, V120, P32, DOI 10.1006/jsbi.1997.3895; SERWER P, 1976, J MOL BIOL, V107, P271, DOI 10.1016/S0022-2836(76)80005-8; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; Steven A. C., 1986, ELECT MICROSCOPY PRO, P1; Steven AC, 1997, FASEB J, V11, P733, DOI 10.1096/fasebj.11.10.9271358; THOMAS GJ, 1990, J RAMAN SPECTROSC, V21, P569, DOI 10.1002/jrs.1250210908; TRUS BL, 1992, P NATL ACAD SCI USA, V89, P11508, DOI 10.1073/pnas.89.23.11508; Trus BL, 1996, J STRUCT BIOL, V116, P61, DOI 10.1006/jsbi.1996.0011; WIDOM J, 1983, J MOL BIOL, V171, P419, DOI 10.1016/0022-2836(83)90038-4	49	298	302	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					271	280		10.1016/S0092-8674(00)80409-2	http://dx.doi.org/10.1016/S0092-8674(00)80409-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346244	Bronze			2022-12-28	WOS:A1997YC35000014
J	Zandi, E; Rothwarf, DM; Delhase, M; Hayakawa, M; Karin, M				Zandi, E; Rothwarf, DM; Delhase, M; Hayakawa, M; Karin, M			The I kappa B kinase complex (IKK) contains two kinase subunits, IKK alpha and IKK beta, necessary for I kappa B phosphorylation and NF-kappa B activation	CELL			English	Article							SITE-SPECIFIC PHOSPHORYLATION; INDUCED APOPTOSIS; CELL-DEATH; PROTEINS; SIGNAL; FAMILY; UBIQUITINATION; DISSOCIATION; PROTEOLYSIS; DEGRADATION	Recently we purified a 900 kDa cytokine-responsive I kappa B kinase complex (IKK) and molecularly cloned one of its subunits, IKK alpha, a serine kinase. We now describe the molecular cloning and characterization of IKK beta, a second subunit of the IKK complex. IKK beta is 50% identical to IKK alpha and like it contains a kinase domain, a leucine zipper, and a helix-loop-helix. Although IKK alpha and IKK beta can undergo homotypic interaction, they also interact with each other and the functional IKK complex contains both subunits. The catalytic activities of both IKK alpha and IKK beta make essential contributions to I kappa B phosphorylation and NF-kappa B activation. While the interactions between IKK alpha and IKK beta may be mediated through their leucine zipper motifs, their helix-loop-helix motifs may be involved in interactions with essential regulatory subunits.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LAB GENE REGULAT & SIGNAL TRANSDUCT,LA JOLLA,CA 92093	University of California System; University of California San Diego			Delhase, Mireille/ABE-5256-2021	Delhase, Mireille/0000-0003-2312-1051	NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006376] Funding Source: NIH RePORTER; NCI NIH HHS [CA50528] Funding Source: Medline; NIEHS NIH HHS [ES06376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	28	1566	1637	1	43	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					243	252		10.1016/S0092-8674(00)80406-7	http://dx.doi.org/10.1016/S0092-8674(00)80406-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346241	Bronze			2022-12-28	WOS:A1997YC35000011
J	Rees, G; Frith, CD; Lavie, N				Rees, G; Frith, CD; Lavie, N			Modulating irrelevant motion perception by varying attentional load in an unrelated task	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; MONKEY VISUAL-CORTEX; AREA MT; SUPERIOR COLLICULUS; MACAQUE; MECHANISMS; SEGREGATION; PATHWAYS; FMRI	Lavie's theory of attention proposes that the processing load in a relevant task determines the extent to which irrelevant distracters are processed. This theory was tested by asking participants in a study to perform linguistic tasks of low or high load while ignoring irrelevant visual motion in the periphery of the display. Although task and distracter were unrelated, both functional imaging of motion-related activity in cortical area V5 and psychophysical measures of the motion aftereffect showed reduced motion processing during high load in the linguistic task. These findings fulfill the prediction that perception of irrelevant distracters depends on the relevant processing load.	UNIV LONDON UNIV COLL,DEPT PSYCHOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	Rees, G (corresponding author), INST NEUROL,WELLCOME DEPT COGNIT NEUROL,12 QUEEN SQ,LONDON WC1N 3BG,ENGLAND.		Frith, Chris D/A-2171-2009; Rees, Geraint/C-1493-2008	Frith, Chris D/0000-0002-8665-0690; Rees, Geraint/0000-0002-9623-7007	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Broadbent D.E., 1958, PERCEPTION COMMUNICA; Buchel C, 1997, CEREB CORTEX, V7, P768, DOI 10.1093/cercor/7.8.768; CHAUDHURI A, 1991, NATURE, V344, P641; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DESIMONE R, 1989, Society for Neuroscience Abstracts, V15, P162; DESIMONE R, 1990, COLD SPRING HARB SYM, V55, P963; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1995, NEUROIMAGE, V2, P157, DOI 10.1006/nimg.1995.1018; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; GIBSON JJ, 1977, SCAND J PSYCHOL, V18, P161, DOI 10.1111/j.1467-9450.1977.tb00272.x; Gibson JJ, 1950, PERCEPTION VISUAL WO; GIRARD P, 1989, J NEUROPHYSIOL, V62, P1287, DOI 10.1152/jn.1989.62.6.1287; GROSS CG, 1991, NEUROPSYCHOLOGIA, V29, P497, DOI 10.1016/0028-3932(91)90007-U; Kahneman D., 1984, VARIETIES ATTENTION, P29; LAVIE N, 1995, J EXP PSYCHOL HUMAN, V21, P451, DOI 10.1037/0096-1523.21.3.451; LAVIE N, 1994, PERCEPT PSYCHOPHYS, V56, P182; MOTTER BC, 1981, J NEUROSCI, V1, P3, DOI 10.1523/JNEUROSCI.01-01-00003.1981; Neill W. Trammell, 1995, P207, DOI 10.1016/B978-012208930-5/50008-8; OCraven KM, 1997, NEURON, V18, P591, DOI 10.1016/S0896-6273(00)80300-1; RODMAN HR, 1990, J NEUROSCI, V10, P1154; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shipp S, 1995, J ANAT, V187, P547; SHIPP S, 1985, NATURE, V315, P322, DOI 10.1038/315322a0; SHULMAN GL, 1991, J EXP PSYCHOL HUMAN, V17, P726, DOI 10.1037/0096-1523.17.3.726; Talairach J., 1988, COPLANAR STEREOTAXIC; TOOTELL RBH, 1995, NATURE, V375, P139, DOI 10.1038/375139a0; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; TRELSMAN AM, 1969, PSYCHOL REV, V76, P282; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; UNGERLEIDER LG, 1984, J COMP NEUROL, V223, P368, DOI 10.1002/cne.902230304; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; ZEKI S, 1991, J NEUROSCI, V11, P641	34	458	469	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1616	1619		10.1126/science.278.5343.1616	http://dx.doi.org/10.1126/science.278.5343.1616			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YJ874	9374459				2022-12-28	WOS:A1997YJ87400038
J	Jackson, R				Jackson, R			An ancient British medical kit from Stanway, Essex	LANCET			English	Article											Jackson, R (corresponding author), BRITISH MUSEUM, DEPT PREHIST & ROMANO BRITISH ANTIQU, LONDON WC1B 3DG, ENGLAND.							Krug A, 1993, Medizinhist J, V28, P93; Bliquez L. J., 1994, ROMAN SURG INSTRUMEN; CELSUS, MED; CRUMMY P, 1996, COLCHESTER ARCHAEOLO, V10, P1; CRUMMY P, 1997, MINERVA, V8, P5; CRUMMY P, 1997, CURR ARCHAEOL, V153, P337; Feugere M., 1985, JB ROMISCH GERMANISC, V32, P436; HIPPOCRATES, DE DECENTI HABITU; Jackson R, 1995, Clio Med, V27, P189; Jackson R., 1994, MED CELSE ASPECTS HI, V13, P167; JACKSON R, 1991, MEMOIRES, V10, P101; JACKSON R, 1992, EPIDAUROS SALERNO, V34, P167; Jackson R., 1986, BRITANNIA, V17, P119; JACKSON R, IN PRESS MED NEI SEC; Jackson R., 1990, J ROMAN ARCHAEOL, V3, P5, DOI DOI 10.1017/S1047759400010813; Jackson R.P.J., 1996, AUFSTIEG NIEDERGANG, V2.37.3, P2228; Jackson Ralph, 1993, AUFSTIEG NIEDERGANG, V37, p[1, 79]; Jackson Ralph, 1988, DOCTORS DIS ROMAN EM; KUNZL E, 1983, MED INSTRUMENTE SEPU, V115; KUNZL E, 1995, HIST ARCHEOLOGIE, V2, P221; KUNZL E, 1996, AUFSTIEG NIEDERGANG, P2433; 1997, TIMES HOME NEWS 0710; [No title captured]	23	10	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	1997	350	9089					1471	1473		10.1016/S0140-6736(97)09087-9	http://dx.doi.org/10.1016/S0140-6736(97)09087-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371183				2022-12-28	WOS:A1997YF95300047
J	Finzi, D; Hermankova, M; Pierson, T; Carruth, LM; Buck, C; Chaisson, RE; Quinn, TC; Chadwick, K; Margolick, J; Brookmeyer, R; Gallant, J; Markowitz, M; Ho, DD; Richman, DD; Siliciano, RF				Finzi, D; Hermankova, M; Pierson, T; Carruth, LM; Buck, C; Chaisson, RE; Quinn, TC; Chadwick, K; Margolick, J; Brookmeyer, R; Gallant, J; Markowitz, M; Ho, DD; Richman, DD; Siliciano, RF			Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DYNAMICS IN-VIVO; PERIPHERAL-BLOOD; LIFE-SPAN; T-CELL; INFECTION; LYMPHOCYTES; RESISTANCE; PLASMA; INHIBITOR	The hypothesis that quiescent CD4(+) T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus-type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4(+) T lymphocytes. The frequency of resting CD4(+) T cells harboring talent HIV-l was low, 0.2 to 16.4 per 10(6) cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4(+) T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Diego; University of California System; University of California San Diego			Quinn, Thomas/A-2494-2010; Buck, Christopher/G-8358-2017	Buck, Christopher/0000-0003-3165-8094	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI028108, U01AI027670, R01AI023871, R01AI028108] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28108, AI27670, AI23871] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; CHUN TW, IN PRESS P NATL ACAD; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; EBERLE J, 1995, AIDS RES HUM RETROV, V11, P671, DOI 10.1089/aid.1995.11.671; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FINZI DD, UNPUB; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P707; Mellors J. W., 1995, International Antiviral News, V3, P8; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATEL SS, 1988, J IMMUNOL, V141, P3726; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PLATAK M, 1993, SCIENCE, V259, P1749; Sanchez G, 1997, J VIROL, V71, P2233, DOI 10.1128/JVI.71.3.2233-2240.1997; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; Stellbrink HJ, 1997, AIDS, V11, P1103, DOI 10.1097/00002030-199709000-00004; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WONG JK, IN PRESS P NATL ACAD	33	2361	2425	4	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1295	1300		10.1126/science.278.5341.1295	http://dx.doi.org/10.1126/science.278.5341.1295			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360927				2022-12-28	WOS:A1997YG04300046
J	Lacronique, V; Boureux, A; DellaValle, V; Poirel, H; Quang, CT; Mauchauffe, M; Berthou, C; Lessard, M; Berger, R; Ghysdael, J; Bernard, OA				Lacronique, V; Boureux, A; DellaValle, V; Poirel, H; Quang, CT; Mauchauffe, M; Berthou, C; Lessard, M; Berger, R; Ghysdael, J; Bernard, OA			A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RECEPTOR SUPERFAMILY; HEMATOPOIETIC-CELLS; TYROSINE KINASE; GENE; TEL; T(12-21); DEFECTS	The Janus family of tyrosine kinases (JAK) plays an essential role in development and in coupling cytokine receptors to downstream intracellular signaling events. A t(9;12)(p24;p13) chromosomal translocation in a T cell childhood acute lymphoblastic leukemia patient was characterized and shown to fuse the 3' portion of JAK2 to the 5' region of TEL, a gene encoding a member of the ETS transcription factor family, The TEL-JAK2 fusion protein includes the catalytic domain of JAK2 and the TEL-specific oligomerization domain, TEL-induced oligomerization of TEL-JAK2 resulted in the constitutive activation of its tyrosine kinase activity and conferred cytokine-independent proliferation to the interleukin-3-dependent Ba/F3 hematopoietic cell line.	INST GENET MOL, INSERM, U301, F-75010 PARIS, FRANCE; INST GENET MOL, CNRS, SD 401 301, F-75010 PARIS, FRANCE; CTR UNIV ORSAY, INST CURIE, SECT RECH, CNRS, UNITE MIXTE RECH 146, F-91405 ORSAY, FRANCE; CTR HOSP REG BREST, HOP MORVAN, LAB CYTOGENET, UNITE HEMATOL, F-29609 BREST, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; CHU Brest; Universite de Bretagne Occidentale			Penard-Lacronique, Virginie/R-1938-2019; Bernard, Olivier A./E-5721-2016; Penard-Lacronique, Virginie/E-5729-2016; QUANG, christine TRAN/G-7508-2016; GHYSDAEL, Jacques/F-3377-2013	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747				Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Bernard OA, 1996, LEUKEMIA LYMPHOMA, V23, P459, DOI 10.3109/10428199609054854; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIURA O, 1994, BLOOD, V84, P1501; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429	25	646	678	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	1997	278	5341					1309	1312		10.1126/science.278.5341.1309	http://dx.doi.org/10.1126/science.278.5341.1309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360930				2022-12-28	WOS:A1997YG04300049
J	Pecherstorfer, M				Pecherstorfer, M			Cutaneous melanoma metastases	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Pecherstorfer, M (corresponding author), WILHELMINENSPITAL STADT WIEN,A-1171 VIENNA,AUSTRIA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1435	1435		10.1056/NEJM199711133372005	http://dx.doi.org/10.1056/NEJM199711133372005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF253	9358141				2022-12-28	WOS:A1997YF25300005
J	Knopp, RH; Walden, CE; Retzlaff, BM; McCann, BS; Dowdy, AA; Albers, JJ; Gey, GO; Cooper, MN				Knopp, RH; Walden, CE; Retzlaff, BM; McCann, BS; Dowdy, AA; Albers, JJ; Gey, GO; Cooper, MN			Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men - The dietary alternatives study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; APOLIPOPROTEIN-B; ARTERY DISEASE; LIPID-LEVELS; PLASMA-LIPOPROTEINS; WEIGHT-LOSS; HYPERTRIGLYCERIDEMIA; TRIGLYCERIDE; CONSUMPTION	Context.-The long-term effect of aggressively vs moderately fat-restricted diets has not been studied extensively in free-living subjects with different types of hyperlipidemia. Objective.-To compare the cholesterol-lowering effects of 4 levels of dietary fat intake restriction after 1 year, Design.-Randomized, parallel, comparison trial. Setting.-Male employees of a large industry. Participants.-A total of 444 men had low-density lipoprotein cholesterol (LDL-C) levels above the 75th age-specific percentile, Subjects with triglyceride (TG) levels less than the 75th age-specific percentile were defined as hypercholesterolemic (HC) and those with TG levels at or above the 75th age-specific percentile were defined as combined hyperlipidemic (CHL). Interventions.-Hypercholesterolemic subjects were randomized to diets 1, 2, 3, and 4 taught to contain 30%, 26%, 22%, and 18% fat, and the CHL subjects were randomized to diets 1, 2, and 3, All 4 diets were taught to subjects and spouses or partners in a weekly 2-hour classes. Main Outcome Measures.-Plasma lipoprotein levels after 1 year. Results.-Fat intake after 1 year declined from a mean of 34% to 36% of energy to 27%, 26%, 25%, and 22% in the 4 HC diet groups and 28%, 26%, and 25% in the 3 CHL diet groups. Mean+/-SD percent LDL-C reductions were 5.3%+16.2%, 13.4%+/-12.6%, 8.4%+/-11.2%, and 13.0%+/-15.7% in the HC diet groups and 7.0%+/-16.2%, 2.8%+/-15.8%, and 4.6%+/-13.5% in the CHL diet groups (P<.01 in all but 1 instance). Apoprotein B levels decreased 8.6%, 10.7%, 4.3%, and 5.3% in the HC groups and 14.6%, 11.4%, and 9.9% in the CHL groups(P<.05-.01 in each instance). Triglyceride levels increased significantly in subjects following HC diets 3 and 4, 21.7% and 38.7% (P<.05 and .01), but not in any CHL subjects. High-density lipoprotein cholesterol decreased 2.8% and 3.2% in subjects on HC diets 3 and 4, respectively (P<.05 in both cases). Conclusions.-After 1 year, moderate restriction of dietary fat intake attains meaningful and sustained LDL-C reductions in HC subjects and apoprotein B reductions in both HC and CHL subjects. More extreme restriction of fat intake offers little further advantage in HC or CHL subjects and potentially undesirable effects in HC subjects.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98104; UNIV WASHINGTON,CARDIOVASC BEHAV MED PROGRAM,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98104; BOEING MED DEPT,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Boeing	Knopp, RH (corresponding author), UNIV WASHINGTON,NW LIPID RES CLIN,BOX 359720,326 9TH AVE,SEATTLE,WA 98104, USA.		McCann, Barbara S./GPG-1789-2022	McCann, Barbara S./0000-0003-0384-8763	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047, P30DK035816] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL28891] Funding Source: Medline; NIDDK NIH HHS [DK-35816, DK-17047] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADOLPHSON JL, 1989, J LIPID RES, V30, P597; ALBERS JJ, 1975, METABOLISM, V24, P1339, DOI 10.1016/0026-0495(75)90050-5; *AM DIAB ASS AM DI, 1986, EXCH LISTS MEAL PLAN; *AM HEART ASS, 1984, COUNS PAT HYP; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BERNARD JR, 1991, ARCH INTERN MED, V151, P1389; BOVBJERG VE, 1994, ANN BEHAV MED S, V16, P49; BOYD NF, 1990, AM J CLIN NUTR, V52, P470, DOI 10.1093/ajcn/52.3.470; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN GD, 1984, J AM DIET ASSOC, V84, P546; CHAIT A, 1993, CIRCULATION, V88, P3008, DOI 10.1161/01.CIR.88.6.3008; CHILDS MT, 1990, AM J CLIN NUTR, V52, P632, DOI 10.1093/ajcn/52.4.632; CLEVIDENCE BA, 1992, AM J CLIN NUTR, V55, P689, DOI 10.1093/ajcn/55.3.689; COMINACINI L, 1988, AM J CLIN NUTR, V48, P57, DOI 10.1093/ajcn/48.1.57; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; DENNIS B, 1980, J AM DIET ASSOC, V77, P641; *EXP PAN, 1988, ARCH INTERN MED, V148, P36; *EXP PAN DET EV TR, 1993, JAMA-J AM MED ASSOC, V269, P3015; GLATZ JFC, 1989, AM J CLIN NUTR, V49, P269, DOI 10.1093/ajcn/49.2.269; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GOTTO AM, 1984, CIRCULATION, V72, pA1067; GRUNDY SM, 1990, J LIPID RES, V31, P1149; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2351, DOI 10.1001/jama.256.17.2351; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; KASIM SE, 1993, AM J CLIN NUTR, V57, P146, DOI 10.1093/ajcn/57.2.146; KATZEL LI, 1995, METABOLISM, V44, P307, DOI 10.1016/0026-0495(95)90159-0; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P244; LAVIE CJ, 1994, AM J CARDIOL, V74, P1192, DOI 10.1016/0002-9149(94)90546-0; LICHTENSTEIN AH, 1994, ARTERIOSCLER THROMB, V14, P1751, DOI 10.1161/01.ATV.14.11.1751; *LIP RES CLIN, NIH PUBL, P1; *LIP RES CLIN, 1974, DHEW PUBL NIH, V1; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MCCANN BS, 1990, J AM DIET ASSOC, V90, P1408; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; RETZLAFF BM, 1995, AM J CLIN NUTR, V62, P988, DOI 10.1093/ajcn/62.5.988; RETZLAFF BM, 1991, AM J CLIN NUTR, V53, P890, DOI 10.1093/ajcn/53.4.890; RETZLAFF BM, 1995, J AM DIET ASSOC, V95, P1274, DOI 10.1016/S0002-8223(95)00335-5; ROMANO AT, 1973, CLIN CHEM, V19, P1152; Schaefer EJ, 1996, AM J CLIN NUTR, V63, P234, DOI 10.1093/ajcn/63.2.234; SCHAEFER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1450, DOI 10.1001/jama.274.18.1450; THUESEN L, 1986, AM J CLIN NUTR, V44, P212, DOI 10.1093/ajcn/44.2.212; TOOTHAKER LE, 1991, MULTIPLE COMP RES, P50; VESSBY B, 1974, ARTERY, V1, P63; WALDEN CE, 1991, J AM COLL NUTR, V10, P429; Warnick G R, 1986, Methods Enzymol, V129, P101; WARNICK GR, 1982, CLIN CHEM, V28, P1379	49	132	135	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1509	1515		10.1001/jama.278.18.1509	http://dx.doi.org/10.1001/jama.278.18.1509			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363971				2022-12-28	WOS:A1997YE44500035
J	Wallace, MR; Chamberlin, CJ; Zerboni, L; Sawyer, MH; Oldfield, EC; Olson, PE; Arvin, AM				Wallace, MR; Chamberlin, CJ; Zerboni, L; Sawyer, MH; Oldfield, EC; Olson, PE; Arvin, AM			Reliability of a history of previous varicella infection in adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 15-18, 1996	NEW ORLEANS, LA				ZOSTER VIRUS-INFECTIONS; HUMAN-IMMUNODEFICIENCY-VIRUS; CHILDREN; SUSCEPTIBILITY; CHICKENPOX; ANTIBODY; VACCINE; REINFECTION; RESPONSES	Context.-Apparent second episodes of varicella are reported in immunocompetent hosts, but laboratory confirmation of prior immune status has rarely been possible. Objective.-To evaluate adult patients with varicella who claimed to have had previous varicella to determine whether they had true second episodes or primary cases with inaccurate clinical histories. Design.-Adult subjects with varicella who enrolled in an antiviral treatment trial were interviewed about a history of varicella. The clinical course of varicella was documented prospectively in all subjects. Serum samples that predated the acute illness were obtained from the US Navy's central serum storage facility for subjects who reported a previous episode of varicella. These stored samples were tested in parallel by enzyme-linked immunosorbent assay, latex agglutination, and Western blot for IgG antibodies to varicella-zoster virus (VZV), Participants.-Twenty military personnel with varicella and a history of the disease. Setting.-A military hospital in San Diego, Calif. Main Outcome Measure.-Presence or absence of antibodies to VZV. Results.-Twenty (10.8%) of 184 adults with serologically confirmed acute varicella reported a prior history of varicella. The clinical course of these 20 patients did not differ from those with no history of varicella. Serum samples that had been collected a mean of 12.4 months (median, 12 months; range, 3 days to 34 months) before the incident episode were available for 19 subjects. All 19 serum samples lacked IgG antibodies to VZV, Conclusion.-A history of previous varicella infection in adults with varicella may not be reliable. True second episodes of varicella are probably rare in immunocompetent adults.	NAVAL MED CTR, DIV INFECT DIS, DEPT INTERNAL MED, SAN DIEGO, CA 94305 USA; STANFORD UNIV, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT INFECT DIS, STANFORD, CA 92103 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, SAN DIEGO, CA USA	United States Department of Defense; United States Navy; Naval Medical Center San Diego; Stanford University; Stanford University; University of California System; University of California San Diego								ACHESON DWK, 1988, J INFECTION, V16, P193, DOI 10.1016/S0163-4453(88)94122-9; ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200; Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361, DOI 10.1128/CMR.9.3.361; BAXTER JD, 1994, CLIN INFECT DIS, V18, P785, DOI 10.1093/clinids/18.5.785; FELDMAN S, 1987, PEDIATRICS, V80, P465; Gallagher J, 1996, OCCUP MED-OXFORD, V46, P289, DOI 10.1093/occmed/46.4.289; GERSHON AA, 1990, J INFECT DIS, V161, P661, DOI 10.1093/infdis/161.4.661; GERSHON AA, 1981, AM J MED SCI, V282, P12, DOI 10.1097/00000441-198107000-00002; GERSHON AA, 1984, J INFECT DIS, V149, P137, DOI 10.1093/infdis/149.2.137; GERSHON AA, 1995, PEDIATR INFECT DIS J, V14, P742, DOI 10.1097/00006454-199509000-00003; GORDON JE, 1962, AM J MED SCI, V244, P132; GUERVICH I, 1990, INFECT CONT HOSP EP, V11, P510; JUNKER AK, 1994, J MED VIROL, V43, P119, DOI 10.1002/jmv.1890430204; Junker K, 1989, Curr Probl Dermatol, V18, P152; JURA E, 1989, PEDIATR INFECT DIS J, V8, P586, DOI 10.1097/00006454-198909000-00003; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; LOCKSLEY RM, 1985, J INFECT DIS, V152, P1172, DOI 10.1093/infdis/152.6.1172; MARTIN KA, 1994, J INFECT DIS, V170, P991, DOI 10.1093/infdis/170.4.991; MCKINNEY WP, 1989, AM J INFECT CONTROL, V17, P26, DOI 10.1016/S0196-6553(89)80009-4; MORENS DM, 1980, ANN INTERN MED, V93, P414, DOI 10.7326/0003-4819-93-3-414; MYERS MG, 1982, PEDIATRICS, V70, P199; PALUMBO PE, 1984, J GEN VIROL, V65, P2141, DOI 10.1099/0022-1317-65-12-2141; ROSS AH, 1962, NEW ENGL J MED, V267, P369, DOI 10.1056/NEJM196208232670801; ROTBART HA, 1993, J INFECT DIS, V167, P195, DOI 10.1093/infdis/167.1.195; STEELE RW, 1982, PEDIATRICS, V70, P604; STEINBERG SP, 1991, J CLIN MICROBIOL, V29, P1527, DOI 10.1128/JCM.29.7.1527-1529.1991; STRAUS SE, 1988, ANN INTERN MED, V108, P221, DOI 10.7326/0003-4819-108-2-221; vonSeidlein L, 1996, J PEDIATR-US, V128, P52, DOI 10.1016/S0022-3476(96)70427-4; Wallace MR, 1996, J INFECT DIS, V174, P249, DOI 10.1093/infdis/174.2.249; WALLACE MR, 1994, SOUTHERN MED J, V87, P74, DOI 10.1097/00007611-199401000-00016; WILLIAMS V, 1974, J INFECT DIS, V130, P669, DOI 10.1093/infdis/130.6.669	31	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1520	1522		10.1001/jama.278.18.1520	http://dx.doi.org/10.1001/jama.278.18.1520			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363973				2022-12-28	WOS:A1997YE44500037
J	Tjandra, N; Bax, A				Tjandra, N; Bax, A			Direct measurement of distances and angles in biomolecules by NMR in a dilute liquid crystalline medium	SCIENCE			English	Article							QUANTITATIVE J-CORRELATION; PHOSPHOLIPID MICELLES; HUMAN UBIQUITIN; PROTEINS; RELAXATION; SPECTROSCOPY; RESOLUTION	In isotropic solution, internuclear dipolar couplings average to zero as a result of rotational diffusion. By dissolving macromolecules in a dilute aqueous nematic discotic liquid-crystalline medium containing widely spaced magnetically oriented particles, a tunable degree of solute alignment with the magnetic field can be created while retaining the high resolution and sensitivity of the regular isotropic nuclear magnetic resonance (NMR) spectrum. Dipolar couplings between H-1-H-1, H-1-C-13, H-1-N-15, and C-13-C-13 pairs in such an oriented macromolecule no longer average to zero, and are readily measured. Distances and angles derived from dipolar couplings in human ubiquitin are in excellent agreement with its crystal structure. The approach promises to improve the accuracy of structures determined by NMR, and extend the size limit.	NIDDKD, CHEM PHYS LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Tjandra, N (corresponding author), NHLBI, BIOPHYS CHEM LAB, NIH, BLDG 10, BETHESDA, MD 20892 USA.							Bax A, 1997, J BIOMOL NMR, V10, P289, DOI 10.1023/A:1018308717741; BODEN N, 1987, J PHYS CHEM-US, V91, P4092, DOI 10.1021/j100299a031; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; Emsley J.W., 1975, NMR SPECTROSCOPY USI; GRIESINGER C, 1986, J CHEM PHYS, V85, P6837, DOI 10.1063/1.451421; Harrison WJ, 1996, FARADAY DISCUSS, V104, P139, DOI 10.1039/fd9960400139; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kung HC, 1995, J MAGN RESON SER B, V109, P323, DOI 10.1006/jmrb.1995.9987; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MacArthur MW, 1996, J MOL BIOL, V264, P1180, DOI 10.1006/jmbi.1996.0705; METZ G, 1995, J AM CHEM SOC, V117, P564, DOI 10.1021/ja00106a078; Ottiger M, 1997, J AM CHEM SOC, V119, P9825, DOI 10.1021/ja971639e; RAM P, 1988, BIOCHIM BIOPHYS ACTA, V940, P289, DOI 10.1016/0005-2736(88)90203-9; SANDERS CR, 1994, PROG NUCL MAG RES SP, V26, P421, DOI 10.1016/0079-6565(94)80012-X; SANDERS CR, 1992, BIOCHEMISTRY-US, V31, P8898, DOI 10.1021/bi00152a029; SAUPE A, 1963, PHYS REV LETT, V11, P462, DOI 10.1103/PhysRevLett.11.462; Tjandra N, 1996, J AM CHEM SOC, V118, P6264, DOI 10.1021/ja960106n; Tjandra N, 1997, J MAGN RESON, V124, P512, DOI 10.1006/jmre.1996.1088; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; Tolman JR, 1996, J MAGN RESON SER B, V112, P245, DOI 10.1006/jmrb.1996.0138; Tolman JR, 1997, NAT STRUCT BIOL, V4, P292, DOI 10.1038/nsb0497-292; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Vold RR, 1996, J MAGN RESON SER B, V113, P267, DOI 10.1006/jmrb.1996.0187; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wuthrich K, 1986, NMR PROTEINS NUCL AC; [No title captured]	31	1429	1446	6	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1111	1114		10.1126/science.278.5340.1111	http://dx.doi.org/10.1126/science.278.5340.1111			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353189				2022-12-28	WOS:A1997YE65200048
J	Sun, XW; Kuhn, L; Ellerbrock, TV; Chiasson, MA; Bush, TJ; Wright, TC				Sun, XW; Kuhn, L; Ellerbrock, TV; Chiasson, MA; Bush, TJ; Wright, TC			Human papillomavirus infection in women infected with the human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CERVICAL INTRAEPITHELIAL NEOPLASIA; CHAIN-REACTION AMPLIFICATION; RISK; DYSPLASIA	Background Among women infected with the human immunodeficiency virus (HIV), there is a high prevalence of human papillomavirus (HPV) infections. However, little is known about the natural history of HPV infections in HIV-seropositive women, and persistent HPV infections may explain the increased risk of cervical squamous intraepithelial lesions and invasive cervical cancer in HIV-seropositive women. Methods A total of 220 HIV-seropositive and 231 HIV-seronegative women in the New York City area were evaluated at two or more semiannual gynecologic examinations that included a Pap test, a test for HPV DNA, and colposcopy. Results HPV DNA was detected at the initial ex amination in 56 percent of the HIV-seropositive and 31 percent of the HIV-seronegative women. After four examinations, the cumulative prevalence of HPV infection was 83 percent in the seropositive women and 62 percent in the seronegative women (P<0.001). Persistent HPV infections were found in 24 percent of the seropositive women but in only 4 percent of the seronegative women (P<0.001). Twenty percent of the seropositive women and 3 percent of the seronegative women had persistent infections with HPV-16-associated viral types (16, 31, 33, 35, or 58) or HPV-18-associated types (18 or 45) (P<0.001), which are most strongly associated with cervical cancer. The detection of HPV DNA in women with previously negative tests was not associated with sexual activity during the interval since the preceding examination. Conclusions HIV-seropositive women have a high rate of persistent HPV infections with the types of HPV that are strongly associated with the development of high-grade squamous intraepithelial lesions and invasive cervical cancer. These persistent infections may explain the increased incidence of squamous intraepithelial lesions in HIV-seropositive women. (C) 1997, Massachusetts Medical Society.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY 10027; COLUMBIA UNIV,DIV EPIDEMIOL,NEW YORK,NY 10027; CTR DIS CONTROL & PREVENT,NATL CTR HIV STD & TB PREVENT,DIV HIV AIDS PREVENT,ATLANTA,GA; NEW YORK CITY DEPT HLTH,BUR DIS INTERVENT RES,NEW YORK,NY 10013	Columbia University; Columbia University; Columbia University; Centers for Disease Control & Prevention - USA; New York City Department of Health & Mental Hygiene			Manzotti, Grazia/C-5985-2008		PHS HHS [U64/CCU206822] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077; Bernard HU, 1996, J INFECT DIS, V173, P516; Chiasson MA, 1997, OBSTET GYNECOL, V89, P690, DOI 10.1016/S0029-7844(97)00069-0; Collett D, 1994, MODELLING SURVIVAL D; EVANDER M, 1995, J INFECT DIS, V171, P1026, DOI 10.1093/infdis/171.4.1026; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Hillemanns P, 1996, AIDS, V10, P1641, DOI 10.1097/00002030-199612000-00008; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; *IIARC, 1995, IARC MON EV CARC RIS, V64; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KOULOS JP, 1993, GYNECOL ONCOL, V48, P364, DOI 10.1006/gyno.1993.1064; KREISS JK, 1992, SEX TRANSM DIS, V19, P54, DOI 10.1097/00007435-199201000-00011; LAGA M, 1992, INT J CANCER, V50, P45, DOI 10.1002/ijc.2910500110; LUNGU O, 1992, MOL CELL PROBE, V6, P145, DOI 10.1016/0890-8508(92)90059-7; MANOS MM, 1989, CANCER CEL, V7, P209; SCHIFFMAN MH, 1995, J NATL CANCER I, V87, P1345, DOI 10.1093/jnci/87.18.1345; SUN XW, 1995, OBSTET GYNECOL, V85, P680, DOI 10.1016/0029-7844(95)00025-M; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; WILLIAMS AB, 1994, OBSTET GYNECOL, V83, P205; WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591	20	403	421	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1343	1349		10.1056/NEJM199711063371903	http://dx.doi.org/10.1056/NEJM199711063371903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358128				2022-12-28	WOS:A1997YE44600003
J	Burkey, Y; Black, M; Reeve, H				Burkey, Y; Black, M; Reeve, H			Patients' views on their discharge from follow up in outpatient clinics: qualitative study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To discover the views of patients about their discharge from outpatient clinics, to detect any change in these perceptions over time, and explore how the discharge process might be improved for the patient. Design: A qualitative study comprising in-depth or semistructured interviews with patients 2 weeks and 3 months after discharge from an outpatient clinic. Subjects: 45 patients who had attended outpatient clinics on three or more occasions. Setting: Five general medical outpatient clinics from a Manchester provider trust. Main outcome measures: Aspects of the discharge consultation valued by patients included confidence that the doctor knew and understood their case; clarity of the discharge process; an explanation of the reasons for discharge; information about treatment, future care, and the mechanism for re-referral; and being seen by doctors who sought their views and allowed time for questions and reflection. Conclusions: Patients' views about their discharge changed over time and varied in relation to several factors, which included patients' perceptions of the discharge process, patients' expectations, the way in which the outpatient clinics were organised, and patients' relationships with, and confidence in, their general practitioners.	UNIV MANCHESTER,NATL PRIMARY CARE RES & DEV CTR,MANCHESTER M13 9PL,LANCS,ENGLAND; UNIV SALFORD,PUBL HLTH RES & RESOURCE CTR,SALFORD M5 4QA,LANCS,ENGLAND; UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND	University of Manchester; University of Salford; University of Manchester								Burkey Y, 1997, FAM PRACT, V14, P29, DOI 10.1093/fampra/14.1.29; *DEP HLTH, 1995, OUTP WARD ATT ENGL F; FAULKNER A, 1993, EVALUATION DELIVERY; Fitzpatrick R., 1984, EXPERIENCE ILLNESS, P154; Horder J P, 1985, Health Trends, V17, P64; Lester J P, 1980, J R Coll Gen Pract, V30, P230; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; Shaw C D, 1981, Health Trends, V13, P107; Stacey M, 1994, RES PEOPLES HLTH, P85; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008	10	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1138	1141						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374889				2022-12-28	WOS:A1997YE61500028
J	Sun, FL; Dean, WL; Kelsey, G; Allen, ND; Reik, W				Sun, FL; Dean, WL; Kelsey, G; Allen, ND; Reik, W			Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome	NATURE			English	Article							GROWTH-FACTOR-II; PERINATAL LETHALITY; TRANSGENIC MICE; GENE; OVERGROWTH; METHYLATION; EXPRESSION; H19; CHROMOSOME-7; MUTATIONS	The gene IGF2, which encodes a fetal insulin-like growth factor, is imprinted, so only one of two parental copies of the gene is expressed, The altered expression of IGF2 has been implicated in Beckwith-Wiedemann syndrome, a human fetal overgrowth syndrome, which is characterized by overgrowth of several organs and an increased risk of developing childhood tumours, We have introduced Igf2 transgenes into the mouse genome by using embryonic stern cells, which leads to transactivation of the endogenous Igf2 gene, The consequent overexpression of Igf2 results in most of the symptoms of Beckwith-Wiedemann syndrome, including prenatal overgrowth, polyhydramnios, fetal and neonatal lethality, disproportionate organ overgrowth including tongue enlargement, and skeletal abnormalities. These phenotypes establish Igf2 overexpression as a key determinant of Beckwith-Wiedemann syndrome.	BABRAHAM INST,DEPT GENET & DEV,LAB DEV GENET & IMPRINTING,CAMBRIDGE CB2 4AT,ENGLAND; BABRAHAM INST,DEPT GENET & DEV,DEV NEUROBIOL LAB,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute			Reik, Wolf/I-6794-2012; allen, nick d/A-4336-2010	Reik, Wolf/0000-0003-0216-9881; Dean, Wendy/0000-0001-9441-5044; Allen, Nicholas/0000-0003-4009-186X; Kelsey, Gavin/0000-0002-9762-5634				BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Brown KW, 1996, HUM MOL GENET, V5, P2027, DOI 10.1093/hmg/5.12.2027; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ELLIOTT M, 1994, J MED GENET, V31, P560, DOI 10.1136/jmg.31.7.560; FEIL R, 1994, DEVELOPMENT, V120, P2933; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; Hatada I, 1997, J BIOL CHEM, V272, P9120, DOI 10.1074/jbc.272.14.9120; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HEDBORG F, 1994, AM J PATHOL, V145, P802; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Joyce JA, 1997, HUM MOL GENET, V6, P1543, DOI 10.1093/hmg/6.9.1543; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEE JE, 1993, MOL REPROD DEV, V35, P382, DOI 10.1002/mrd.1080350411; LEE JT, 1997, NATURE, V386, P272; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; McLaughlin KJ, 1996, DEVELOPMENT, V122, P265; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki H, 1996, DNA Res, V3, P331, DOI 10.1093/dnares/3.5.331; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; SLATTER RE, 1994, J MED GENET, V31, P749, DOI 10.1136/jmg.31.10.749; WALTER J, 1996, EPIGENETIC MECHANISM, P1195; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WARD A, 1992, INSULIN LIKE GROWTH, P45; Ward Andrew, 1997, Genes and Function, V1, P25; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	44	251	261	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					809	815		10.1038/39797	http://dx.doi.org/10.1038/39797			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349812				2022-12-28	WOS:A1997YC14800047
J	Ruskin, PE				Ruskin, PE			Aging and caring	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1384	1384		10.1001/jama.278.16.1384	http://dx.doi.org/10.1001/jama.278.16.1384			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA905	9343474				2022-12-28	WOS:A1997YA90500046
J	Diderichsen, F; Varde, E; Whitehead, M				Diderichsen, F; Varde, E; Whitehead, M			Resource allocation to health authorities: the quest for an equitable formula in Britain and Sweden	BRITISH MEDICAL JOURNAL			English	Article							SMALL-AREA ANALYSIS; INPATIENT SERVICES; ENGLAND; NHS; DETERMINANTS; CRITIQUE; RATES; CARE				Diderichsen, F (corresponding author), KAROLINSKA INST,DEPT PUBL HLTH SCI,DIV SOCIAL MED,S-17283 SUNDBYBERG,SWEDEN.			Diderichsen, Finn/0000-0002-9998-4972				BENZEVAL M, 1994, HEALTH ECON, V3, P105, DOI 10.1002/hec.4730030207; BROWN RS, 1994, HMOS ELDERLY; CarrHill RA, 1996, BRIT MED J, V312, P1008; CARRHILL RA, 1994, BRIT MED J, V309, P1046, DOI 10.1136/bmj.309.6961.1046; Department of Health and Social Security, 1976, SHAR RES HLTH ENGL R; DIDERICHSEN F, 1995, HEALTH POLICY, V32, P141, DOI 10.1016/0168-8510(95)00732-8; DIDERICHSEN F, 1995, PUBLIC HLTH REPORT 1; DIDERICHSEN F, 1987, NEED BASED PLANNING; HACKING J, 1996, HLTH SERVICE J  0118, P26; HAGLUND B, 1994, EQUITY CARE, P3; *HLTH POL TARG NEE, 1984, HLTH CAR 1990S, P40; HOLLAND WW, 1986, LANCET, V2, P1087; JUDGE K, 1994, BRIT MED J, V308, P1363, DOI 10.1136/bmj.308.6940.1363; MAYS N, 1989, COMMUNITY MED, V11, P173; MAYS N, 1995, INT J EPIDEMIOL, V24, P96; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; Newhouse J P, 1989, Health Care Financ Rev, V10, P41; NHS Management Board, 1988, REV RES ALL WORK PAR; RAFTERY J, 1993, BRIT MED J, V307, P1121, DOI 10.1136/bmj.307.6912.1121; ROYSTON GHD, 1992, SOCIO ECON PLAN SCI, V26, P169, DOI 10.1016/0038-0121(92)90008-S; SHELDON TA, 1993, BRIT MED J, V306, P835, DOI 10.1136/bmj.306.6881.835; SHELDON TA, 1992, J ROY STAT SOC A STA, V155, P403, DOI 10.2307/2982891; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050; van Vliet R C, 1993, Health Econ, V2, P177, DOI 10.1002/hec.4730020210; VANVLIET RCJA, 1992, SOC SCI MED, V34, P1035, DOI 10.1016/0277-9536(92)90134-C; WHITEHEAD M, 1994, BRIT MED J, V308, P1284, DOI 10.1136/bmj.308.6939.1284	26	38	39	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					875	878		10.1136/bmj.315.7112.875	http://dx.doi.org/10.1136/bmj.315.7112.875			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA007	9353512	Green Published			2022-12-28	WOS:A1997YA00700033
J	Kroman, N; Wohlfahrt, J; Andersen, KW; Mouridsen, HT; Westergaard, T; Melbye, M				Kroman, N; Wohlfahrt, J; Andersen, KW; Mouridsen, HT; Westergaard, T; Melbye, M			Time since childbirth and prognosis in primary breast cancer: population based study	BRITISH MEDICAL JOURNAL			English	Article							FULL TERM PREGNANCY; WOMEN; RISK; INCREASE; BIRTH; AGE	Objective: To investigate whether time since birth of last child was of prognostic importance in Women with primary breast cancer. Design: Retrospective cohort study based on a population based database of breast cancer diagnoses with detailed information on tumour characteristics, treatment regimens, reproductive factors, and vital status. Setting: Denmark. Subjects: 5652 women with primary breast cancer aged 45 years or less at the time of diagnosis. Main outcome measures: 5 and 10 year survival; relative risk of dying. Results: Women diagnosed in the first 2 years after last childbirth had a crude 5 year survival of 58.7% and 10 year survival of 46.1% compared with 78.4% and 66.0% for Women whose last childbirth was more than 2 years before their diagnosis. After adjustment for age, reproductive factors, and stage of disease (tumour size, axillary nodal status, and histological grading), a diagnosis sooner than 2 years since last childbirth was significantly associated with a poor survival (relative risk 1.58, 95% confidence interval 1.24 to 2.02) compared with women who gave birth more than 5 years previously. Further analyses showed that the effect was not modified by age at diagnosis, tumour size, and nodal status. Conclusion: A diagnosis of breast cancer less than 2 years after having given birth is associated with a particularly pool-survival irrespective of the stage of disease at debut. Therefore, a recent pregnancy should be regarded as a negative prognostic factor and should be considered in. counselling these patients and in the decisions regarding adjuvant treatment.	STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL RES,DK-2300 COPENHAGEN,DENMARK; CENT HOSP HILLEROD,DEPT SURG A,DK-3400 HILLEROD,DENMARK; RIGSHOSP,DANISH BREAST CANC COOPERAT GRP,DK-2100 COPENHAGEN,DENMARK	Aarhus University; Statens Serum Institut; Danish Breast Cancer Cooperative Group (DBCG); Rigshospitalet; University of Copenhagen				melbye, mads/0000-0001-8264-6785				ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ANDERSEN KW, 1988, ACTA ONCOL, V27, P627, DOI 10.3109/02841868809091763; BOETANI JCM, 1988, PREV MED, V17, P634; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; Clark R M, 1989, Clin Oncol (R Coll Radiol), V1, P11, DOI 10.1016/S0936-6555(89)80004-4; COX DR, 1972, J R STAT SOC B, V34, P187; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; GRUBBS CJ, 1983, J NATL CANCER I, V71, P625; GUINEE VF, 1994, LANCET, V343, P1587; HART CA, 1988, BAILLIERE CLIN IMMUN, V2, P735; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; MAX MH, 1984, AM SURGEON, V50, P23; Michels KB, 1996, LANCET, V347, P431, DOI 10.1016/S0140-6736(96)90010-0; PETREK JA, 1994, MONOGR NCI, P113; *SAS I, 1992, P229 SAS I STAT; STEWART T, 1995, LANCET, V346, P796, DOI 10.1016/S0140-6736(95)91618-0; STIRRAT GM, 1994, BRIT MED J, V308, P1385, DOI 10.1136/bmj.308.6941.1385; STORM HH, 1991, CANC REGISTRATION PR, P220; TRETLI S, 1988, BRIT J CANCER, V58, P382, DOI 10.1038/bjc.1988.224; VONSCHOULTZ E, 1995, J CLIN ONCOL, V13, P430, DOI 10.1200/JCO.1995.13.2.430; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578	21	72	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					851	855		10.1136/bmj.315.7112.851	http://dx.doi.org/10.1136/bmj.315.7112.851			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353505	Green Published			2022-12-28	WOS:A1997YA00700023
J	Neuenschwander, H; Modell, B				Neuenschwander, H; Modell, B			Audit of process of antenatal screening for sickle cell disorders at a north London hospital	BRITISH MEDICAL JOURNAL			English	Article									UCL, SCH MED, WHITTINGTON HOSP, DEPT PRIMARY CARE & POPULAT SCI, LONDON N19 5HT, ENGLAND	University of London; University College London; UCL Medical School					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Modell B, 1997, BRIT MED J, V315, P779, DOI 10.1136/bmj.315.7111.779; MODELL M, 1990, BRIT MED J, V300, P1702, DOI 10.1136/bmj.300.6741.1702; PETROU M, 1992, J MED GENET, V29, P820, DOI 10.1136/jmg.29.11.820; *STAND MED ADV COM, 1994, REPORT WORKING PARTY	4	17	17	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					784	785						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345171				2022-12-28	WOS:A1997XY91100021
J	Linderoth, NA; Simon, MN; Russel, M				Linderoth, NA; Simon, MN; Russel, M			The filamentous phage pIV multimer visualized by scanning transmission electron microscopy	SCIENCE			English	Article							GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE PROTEIN; SECRETION; EXPORT; CHANNELS; PATHWAY; PORINS; FORMS	A family of homomultimeric outer-membrane proteins termed secretins mediates the secretion of large macromolecules such as enzymes and filamentous bacteriophages across bacterial outer membranes to the extracellular milieu. The secretin encoded by done filamentous phage fl was purified. Mass determination of individual molecules by scanning transmission electron microscopy revealed two forms, a unit multimer composed of about 14 subunits and a multimer dimer. The secretin is roughly cylindrical and has an internal diameter of about 80 angstroms, which is large enough to accommodate filamentous phage (diameter of 65 angstroms).	ROCKEFELLER UNIV,NEW YORK,NY 10021; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Rockefeller University; United States Department of Energy (DOE); Brookhaven National Laboratory					PHS HHS [P41-4401777] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chen LY, 1996, J BIOL CHEM, V271, P2703, DOI 10.1074/jbc.271.5.2703; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Daefler S, 1997, J MOL BIOL, V266, P978, DOI 10.1006/jmbi.1996.0866; Drake SL, 1995, MOL MICROBIOL, V18, P975, DOI 10.1111/j.1365-2958.1995.18050975.x; ENDEMANN H, 1995, J MOL BIOL, V250, P496, DOI 10.1006/jmbi.1995.0393; GENIN S, 1994, MOL GEN GENET, V243, P112, DOI 10.1007/BF00283883; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; KAZMIERCZAK BI, 1994, J MOL BIOL, V238, P187, DOI 10.1006/jmbi.1994.1280; LAVER WG, 1969, VIROLOGY, V38, P105, DOI 10.1016/0042-6822(69)90132-9; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; Lindeberg M, 1996, MOL MICROBIOL, V20, P175, DOI 10.1111/j.1365-2958.1996.tb02499.x; LINDEROTH N, UNPUB; Linderoth NA, 1996, J BACTERIOL, V178, P1962, DOI 10.1128/jb.178.7.1962-1970.1996; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; Model P., 1988, BACTERIOPHAGES, P375; NEWHALL WJ, 1980, INFECT IMMUN, V27, P475, DOI 10.1128/IAI.27.2.475-482.1980; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; RUSSEL M, 1995, TRENDS MICROBIOL, V3, P223, DOI 10.1016/S0966-842X(00)88929-5; RUSSEL M, 1994, SCIENCE, V265, P612, DOI 10.1126/science.8036510; Russel M, 1997, GENE, V192, P23, DOI 10.1016/S0378-1119(96)00801-3; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Wall J., 1979, INTRO ANAL ELECTRON, P333; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WALL JS, 1985, P 43 ANN M EL MICR S, P716	30	123	124	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1635	1638		10.1126/science.278.5343.1635	http://dx.doi.org/10.1126/science.278.5343.1635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374466				2022-12-28	WOS:A1997YJ87400045
J	Sikes, HD; Schwartz, DK				Sikes, HD; Schwartz, DK			Two-dimensional melting of an anisotropic crystal observed at the molecular level	SCIENCE			English	Article							LANGMUIR-BLODGETT-FILMS; ATOMIC-FORCE MICROSCOPY; CADMIUM ARACHIDATE; 2 DIMENSIONS; PHASE-TRANSITIONS; ORDER; MONOLAYERS; DIFFRACTION	A distinctive two-dimensional (2D) melting transition occurring at nearly 100 degrees Celsius (degrees C) has been observed in Langmuir-Blodgett films by in situ atomic force microscopy (AFM). A 2D orthorhombic crystal phase melted to a 2D smectic phase at about 91 degrees C. The smectic phase was characterized by 1D molecular periodicity with short-range correlations (about 40 angstroms). At 95 degrees C, the smectic order melted! to form a hexatic phase. infrared spectroscopy measurements were consistent with the AFM observations. These observations support the dislocation-mediated melting scenario for an anisotropic 2D crystal predicted by Ostlund and Halperin. A longer wavelength height modulation was also observed in the smectic and hexatic phases.	TULANE UNIV,DEPT CHEM,NEW ORLEANS,LA 70118	Tulane University			Schwartz, Daniel K/H-5153-2012	Schwartz, Daniel K/0000-0001-5397-7200; /0000-0002-7096-138X				[Anonymous], 1988, STRUCTURE LIQUID CRY; BOHM C, 1989, THIN SOLID FILMS, V178, P511, DOI 10.1016/0040-6090(89)90346-5; BUHAENKO MR, 1988, THIN SOLID FILMS, V159, P253, DOI 10.1016/0040-6090(88)90637-2; CAMERON DG, 1986, SPECTROSC-BIOMED APP, P53; Chao CY, 1996, PHYS REV LETT, V77, P2750, DOI 10.1103/PhysRevLett.77.2750; GARNAES J, 1992, NATURE, V357, P54, DOI 10.1038/357054a0; GAROFF S, 1986, J PHYS-PARIS, V47, P701, DOI 10.1051/jphys:01986004704070100; HALPERIN BI, 1978, PHYS REV LETT, V41, P121, DOI 10.1103/PhysRevLett.41.121; HASEGAWA T, 1995, LANGMUIR, V11, P1236, DOI 10.1021/la00004a032; JOSEFOWICZ JY, 1993, SCIENCE, V260, P323, DOI 10.1126/science.260.5106.323; KNOBLER CM, 1992, ANNU REV PHYS CHEM, V43, P207, DOI 10.1146/annurev.pc.43.100192.001231; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; MURRAY CA, 1990, PHYS REV B, V42, P688, DOI 10.1103/PhysRevB.42.688; Musevic I, 1996, REV SCI INSTRUM, V67, P2554, DOI 10.1063/1.1147212; NELSON DR, 1978, PHYS REV B, V18, P2318, DOI 10.1103/PhysRevB.18.2318; NELSON DR, 1979, PHYS REV B, V19, P2457, DOI 10.1103/PhysRevB.19.2457; OSTLUND S, 1981, PHYS REV B, V23, P335, DOI 10.1103/PhysRevB.23.335; RABE JP, 1987, J CHEM PHYS, V86, P1601, DOI 10.1063/1.452199; ROTHBERG L, 1987, CHEM PHYS LETT, V133, P67, DOI 10.1016/0009-2614(87)80055-6; SASANUMA Y, 1991, THIN SOLID FILMS, V199, P359, DOI 10.1016/0040-6090(91)90018-S; SCHWARTZ DK, 1993, PHYS REV E, V47, P452, DOI 10.1103/PhysRevE.47.452; SCHWARTZ DK, 1992, SCIENCE, V257, P508, DOI 10.1126/science.257.5069.508; SHIMOMURA M, 1992, LANGMUIR, V8, P887, DOI 10.1021/la00039a024; TIPPMANNKRAYER P, 1992, THIN SOLID FILMS, V210, P577, DOI 10.1016/0040-6090(92)90346-D; TONER J, 1981, PHYS REV B, V23, P316, DOI 10.1103/PhysRevB.23.316; VISWANATHAN R, 1995, SCIENCE, V269, P51, DOI 10.1126/science.7604278; YOUNG AP, 1979, PHYS REV B, V19, P1855, DOI 10.1103/PhysRevB.19.1855	27	53	53	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1604	1607		10.1126/science.278.5343.1604	http://dx.doi.org/10.1126/science.278.5343.1604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374455				2022-12-28	WOS:A1997YJ87400034
J	Bouma, MJ; Kovats, RS; Goubet, SA; Cox, JSH; Haines, A				Bouma, MJ; Kovats, RS; Goubet, SA; Cox, JSH; Haines, A			Global assessment of El Nino's disaster burden	LANCET			English	Article							SOUTHERN-OSCILLATION; MALARIA; EVENTS; ENSO	Background Natural disasters have profound effects on health and require medical intervention as part of relief operations. The world's populations are becoming increasingly Vulnerable to extreme weather events, which are responsible for most natural disasters. The El Nino Southern Oscillation (ENSO) is the most prominent global climate system associated with year-to-year weather variability and extreme events. We have estimated the burden on human health of natural disasters associated with ENSO. Methods We used time-series regression analysis of the relation between El Nino years and the annual rates of persons affected by natural disasters per 1000 population during 1964-93, globally and also by region and disaster type. Correlations between sea-surface temperature (SST) anomalies (index of ENSO) and the rates of persons affected by natural disasters per 1000 population were determined globally, by region and by disaster type. Findings The rate of persons affected by natural disasters worldwide is strongly associated with ENSO; rates are greater during the first El Nino year (p=0.05) and the following year (p=0.01) than in the pre-Nino year. The correlation between rates of persons affected by natural disasters and SST anomalies in the Eastern Pacific (a key ENSO indicator) is highest in the last quarter of the previous year (r=0.53, p<0.01). These associations are strongest in South Asia, the region where more than 50% of all disaster Victims live. Worldwide, rates of persons affected by drought/famine (half of all disaster victims) and by Volcanic eruptions show significant associations with the ENSO cycle, being highest in the post-Nino year and El Nino year, respectively, and being significantly associated with SST anomalies. Interpretation The strong relation between ENSO and populations affected by natural disasters can be described as a ''natural disaster cycle''. Determining the phase in this cycle, using SST from the Eastern Equatorial Pacific, could benefit disaster preparedness on a global scale, for South Asia in particular, and for all populations affected by drought/famine and volcanic disasters.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT INFECT & TROP DIS, LONDON WC1E 7HT, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 7HT, ENGLAND; ROYAL FREE HOSP, SCH MED, JOINT DEPT PRIMARY CARE & POPULAT SCI, LONDON, ENGLAND; UCL, SCH MED, JOINT DEPT PRIMARY CARE & POPULAT SCI, LONDON W1N 8AA, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School				Kovats, Sari/0000-0002-4823-8099; Haines, Andy/0000-0002-8053-4605				[Anonymous], 1997, PUBLIC HLTH CONSEQUE; Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; BUCHANONSMITH M, 1996, FAMINE EARLY WARNING; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CHATFIELD C, 1992, ANAL TIME SERIES INT, P136; CHEN D, 1995, SCIENCE, V269, P1699, DOI 10.1126/science.269.5231.1699; DILLEY M, 1995, DISASTERS, V19, P181, DOI 10.1111/j.1467-7717.1995.tb00338.x; Glantz M. H., 1994, P WORKSH ENSO FEWS B; GLANTZ MH, 1982, OCEANUS, V27, P14; *INT FED RED CROSS, 1996, WORLD DIS REP 1996; International Decade for Natural Disaster Reduction, 1994, YOK STRAT PLAN ACT S; McCarthy M, 1997, LANCET, V350, P344; MICMICHAEL AJ, 1996, CLIMATE CHANGE HUMAN; NICHOLLS N, 1988, J CLIMATOL, V8, P91, DOI 10.1002/joc.3370080109; PARKER DE, 1994, J GEOPHYS RES, V99, P373; Quinn W. H., 1987, J GEOPHYS RES, V92, P449; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; SAPIR DG, 1992, DISASTERS, V16, P74, DOI 10.1111/j.1467-7717.1992.tb00378.x; SPENNEMANN DHR, 1995, DISASTERS, V19, P194, DOI 10.1111/j.1467-7717.1995.tb00339.x; *UN, 1995, DEM YB 1993; *WORLD MET ORG, 1998, 819 WMO; WU GX, 1992, MON WEATHER REV, V120, P958, DOI 10.1175/1520-0493(1992)120<0958:AGSOTR>2.0.CO;2	23	61	64	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1435	1438		10.1016/S0140-6736(97)04509-1	http://dx.doi.org/10.1016/S0140-6736(97)04509-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371167				2022-12-28	WOS:A1997YF95300010
J	Golledge, J				Golledge, J			Lower-limb arterial disease	LANCET			English	Article							PERIPHERAL VASCULAR-DISEASE; SUPERFICIAL FEMORAL-ARTERY; NITRIC-OXIDE SYNTHASE; INTERMITTENT CLAUDICATION; BALLOON ANGIOPLASTY; RANDOMIZED TRIAL; LEG ISCHEMIA; GENE-THERAPY; THROMBOLYSIS; PREVALENCE		BEDFORD HOSP, BEDFORD, ENGLAND				golledge, jonathan/I-2371-2013					ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BAUM RA, 1995, JAMA-J AM MED ASSOC, V75, P361; Beard JD, 1996, EUR J VASC ENDOVASC, V12, P131; Bosch JL, 1997, RADIOLOGY, V204, P87, DOI 10.1148/radiology.204.1.9205227; CAMERON HA, 1988, BRIT J CLIN PHARMACO, V26, P569, DOI 10.1111/j.1365-2125.1988.tb05297.x; Channon KM, 1996, CARDIOVASC RES, V32, P962; CLOWES AW, 1991, J VASC SURG, V13, P885; DORMANDY J, 1996, BRIT J SURG, V83, P557; Dormandy J A, 1991, Eur J Vasc Surg, V5, P131, DOI 10.1016/S0950-821X(05)80676-0; DUPREZ D, 1992, EUR HEART J, V13, P149, DOI 10.1093/oxfordjournals.eurheartj.a060138; Fisher CM, 1996, EUR J VASC ENDOVASC, V11, P349, DOI 10.1016/S1078-5884(96)80084-0; Fowkes F G, 1988, Eur J Vasc Surg, V2, P283, DOI 10.1016/S0950-821X(88)80002-1; GARDNER AW, 1995, JAMA-J AM MED ASSOC, V274, P975, DOI 10.1001/jama.274.12.975; GOLLEDGE J, 1995, POSTGRAD MED J, V71, P146, DOI 10.1136/pgmj.71.833.146; HARRIS PL, 1995, EUR J VASC ENDOVASC, V10, P108; HERTZER NR, 1981, ANN SURG, V193, P492; HESS H, 1982, NEW ENGL J MED, V307, P1627, DOI 10.1056/NEJM198212233072606; HUGHSON WG, 1978, BRIT MED J, V1, P1379, DOI 10.1136/bmj.1.6124.1379; HUNINK MGM, 1995, JAMA-J AM MED ASSOC, V274, P165, DOI 10.1001/jama.274.2.165; JIVEGARD L, 1995, EUR J VASC ENDOVASC, V9, P448, DOI 10.1016/S1078-5884(05)80014-0; KANNEL WB, 1973, GERIATRICS, V28, P61; KAUFMAN SL, 1984, RADIOLOGY, V151, P323, DOI 10.1148/radiology.151.2.6369390; KRETSCHMER G, 1992, ARCH SURG-CHICAGO, V127, P1112; LENG GC, 1993, J VASC SURG, V17, P510, DOI 10.1016/0741-5214(93)90151-B; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; Lepantalo M, 1996, EUR J VASC ENDOVASC, V11, P153, DOI 10.1016/S1078-5884(96)80044-X; LOWE GDO, 1994, CLIN PROBLEMS VASCUL; LUDWIG S, 1995, NAT MED, V1, P513, DOI 10.1038/nm0695-513; NAJI A, 1978, Annals of Surgery, V188, P79, DOI 10.1097/00000658-197807000-00013; Ouriel K, 1996, J VASC SURG, V23, P64, DOI 10.1016/S0741-5214(05)80036-9; Ouriel K, 1996, J VASC SURG, V23, P46, DOI 10.1016/S0741-5214(05)80034-5; Pell JP, 1997, EUR J VASC ENDOVASC, V13, P315, DOI 10.1016/S1078-5884(97)80104-9; Pemberton M, 1996, EUR J VASC ENDOVASC, V12, P452, DOI 10.1016/S1078-5884(96)80013-X; Perkins JMT, 1996, EUR J VASC ENDOVASC, V11, P409, DOI 10.1016/S1078-5884(96)80171-7; RAPTIS S, 1995, EUR J VASC ENDOVASC, V9, P97, DOI 10.1016/S1078-5884(05)80232-1; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; RUTHERFORD RB, 1984, J VASC SURG, V1, P765, DOI 10.1067/mva.1984.avs0010765; Stanley B, 1996, J VASC SURG, V23, P679, DOI 10.1016/S0741-5214(96)80049-8; Tielbeek AV, 1996, EUR J VASC ENDOVASC, V12, P145, DOI 10.1016/S1078-5884(96)80099-2; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; TYRRELL MR, 1993, BRIT J SURG, V80, P177, DOI 10.1002/bjs.1800800214; VARTY K, 1997, BR J SURG S1, V84, P1; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Weaver FA, 1996, J VASC SURG, V24, P513, DOI 10.1016/S0741-5214(96)70067-8; Whyman MR, 1996, EUR J VASC ENDOVASC, V12, P167, DOI 10.1016/S1078-5884(96)80102-X; WHYMAN MR, 1997, BRIT J SURG, V84, P571; Wolfe JHN, 1997, EUR J VASC ENDOVASC, V13, P578, DOI 10.1016/S1078-5884(97)80067-6; 1996, TRIALS TRIBULATIONS, P353	48	55	56	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	1997	350	9089					1459	1465		10.1016/S0140-6736(97)07421-7	http://dx.doi.org/10.1016/S0140-6736(97)07421-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371181				2022-12-28	WOS:A1997YF95300045
J	Hueber, AO; Zornig, M; Lyon, D; Suda, T; Nagata, S; Evan, GI				Hueber, AO; Zornig, M; Lyon, D; Suda, T; Nagata, S; Evan, GI			Requirement for the CD95 receptor-ligand pathway in c-myc-induced apoptosis	SCIENCE			English	Article							T-CELL HYBRIDOMAS; FAS-LIGAND; IMMUNE EVASION; TUMOR-CELLS; DEATH; BCL-2; FAS/APO-1; PROTEIN; MICE; FIBROBLASTS	Induction of apoptosis by oncogenes like c-myc may be important in restraining the emergence of neoplasia, However, the mechanism by which c-myc induces apoptosis is unknown. CD95 (also termed Fas or APO-I) is a cell surface transmembrane receptor of the tumor necrosis factor receptor family that activates an intrinsic apoptotic suicide program in cells upon binding either its ligand CD95L or antibody, c-myc-induced apoptosis was shown to require interaction on the cell surface between CD95 and its ligand. c-Myc acts downstream of the CD95 receptor by sensitizing cells to the CD95 death signal. Moreover, IGF-I signaling and Bcl-2 suppress c-myc-induced apoptosis by also acting downstream of CD95, These findings link two apoptotic pathways previously thought to be independent and establish the dependency of Myc on CD95 signaling for its killing activity.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; OSAKA UNIV, SCH MED, DEPT GENET, SUITA, OSAKA 565, JAPAN	Cancer Research UK; Osaka University			Nagata, Shigekazu/AAG-3203-2019; Anne-Odile, Hueber/G-4352-2013; Anne-Odile, Hueber/P-9860-2019	Nagata, Shigekazu/0000-0001-9758-8426; Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HUEBER AO, UNPUB; ITOH N, 1993, J IMMUNOL, V151, P621; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, UNPUB; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; ZORNIG M, 1995, ONCOGENE, V10, P2397	35	318	324	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	1997	278	5341					1305	1309		10.1126/science.278.5341.1305	http://dx.doi.org/10.1126/science.278.5341.1305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360929				2022-12-28	WOS:A1997YG04300048
J	Hu, YM; Wang, YQ; Luo, ZX; Li, CK				Hu, YM; Wang, YQ; Luo, ZX; Li, CK			A new symmetrodont mammal from China and its implications for mammalian evolution	NATURE			English	Article							FUNCTIONAL-ANATOMY; SHOULDER GIRDLE; EAR	A new symmetrodont mammal has been discovered in the Mesozoic era (Late Jurassic or Early Cretaceous period) of Liaoning Province, China, Archaic therian mammals, including symmetrodonts, are extinct relatives of the living marsupial and placental therians. However, these archaic therians have been mostly documented by fragmentary fossils. This new fossil taxon, represented by a nearly complete postcranial skeleton and a partial skull with dentition, is the best-preserved symmetrodont mammal yet discovered. It provides a new insight into the relationships of the major lineages of mammals and the evolution of the mammalian skeleton. Our analysis suggests that this new taxon represents a part of the early therian radiation before the divergence of living marsupials and placentals; that therians and multituberculates are more closely related to each other than either group is to other mammalian lineages; that archaic therians lacked the more parasagittal posture of the forelimb of most living therian mammals; and that archaic therians, such as symmetrodonts, retained the primitive feature of a finger-like promontorium (possibly with a straight cochlea) of the non-therian mammals. The fully coiled cochlea evolved later in more derived therian mammals, and is therefore convergent to the partially coiled cochlea of monotremes.	CARNEGIE MUSEUM NAT HIST, SECT VERTEBRATE PALEONTOL, PITTSBURGH, PA 15213 USA; CHINESE ACAD SCI, INST VERTEBRATE PALEONTOL & PALEOANTHROPOL, BEIJING 100044, PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS			Luo, Zhe-XI/AAU-2263-2021					Cassiliano M.L., 1979, P150; Chen P., 1980, B NANJING I GEOL PAL, V1, P22; CHEN PJ, 1994, CRETACEOUS RES, V15, P245, DOI 10.1006/cres.1994.1015; Cifelli R.L., 1990, Journal of Vertebrate Paleontology, V10, P332; Clemens W. A., 1963, Palaeontology, V6, P373; Crompton A., 1971, EARLY MAMMALS, P65; Crompton A.W., 1979, P59; CROMPTON AW, 1993, MAMMAL PHYLOGENY, P30; FOX RC, 1985, J PALEONTOL, V59, P21; Gambaryan PP, 1997, ACTA PALAEONTOL POL, V42, P13; GRAYBEAL A, 1989, ZOOL J LINN SOC-LOND, V96, P107, DOI 10.1111/j.1096-3642.1989.tb01823.x; HOPSON JA, 1994, MAJOR FEATURES VERTE, P190; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; HOU LH, 1995, NATURE, V377, P616, DOI 10.1038/377616a0; JENKINS FA, 1973, AM J ANAT, V137, P281, DOI 10.1002/aja.1001370304; JENKINS FA, 1976, PHILOS T ROY SOC B, V273, P387, DOI 10.1098/rstb.1976.0022; JENKINS FA, 1974, J MORPHOL, V144, P71, DOI 10.1002/jmor.1051440105; JENKINS FA, 1979, J ZOOL, V188, P379; JENKINS FA, 1988, J VERTEBR PALEONTOL, V6, P1; Ji Q., 1996, CHINESE GEOL, V233, P30; Ji Q., 1997, CHINESE GEOL, V238, P38; Jin F, 1996, VERTEBRATA PALASIATI, V34, P102; KEMP TS, 1983, ZOOL J LINN SOC-LOND, V77, P353, DOI 10.1111/j.1096-3642.1983.tb00859.x; KERMACK KA, 1981, ZOOL J LINN SOC-LOND, V71, P1, DOI 10.1111/j.1096-3642.1981.tb01127.x; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; KIELANJAWOROWSKA Z, 1987, NATURE, V326, P871, DOI 10.1038/326871a0; KIELANJAWOROWSKA Z, 1986, PHILOS T R SOC B, V313, P525, DOI 10.1098/rstb.1986.0055; KLIMA M, 1987, ADV ANAT EMBRYOL CEL, V109, P1; Klima M., 1973, Advances Anat Embryol Cell Biol, V47, P1; KRAUSE D W, 1983, Bulletin of the Museum of Comparative Zoology, V150, P199; Krebs B., 1991, Berliner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V133, P1; Lillegraven J.A., 1991, Contributions to Geology University of Wyoming, V28, P39; Luo Z., 1991, Journal of Vertebrate Paleontology, V11, P220; LUO ZX, 1994, J VERTEBR PALEONTOL, V14, P341, DOI 10.1080/02724634.1994.10011564; LUO ZX, 1995, J VERTEBR PALEONTOL, V15, P113, DOI 10.1080/02724634.1995.10011211; Marshall Larry G., 1995, Memoires du Museum National d'Histoire Naturelle, V165, P21; MENG J, 1995, NATURE, V377, P141, DOI 10.1038/377141a0; MENG J, 1995, J VERTEBR PALEONTOL, V15, P122, DOI 10.1080/02724634.1995.10011212; Rougier G.W., 1992, Journal of Vertebrate Paleontology, V12, P188; Rougier G.W., 1993, THESIS U NACL BUENOS; Rougier Guillermo W., 1996, American Museum Novitates, V3183, P1; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; SERENO PC, 1995, NATURE, V377, P144, DOI 10.1038/377144a0; SMIPSON GG, 1928, CATALOGUE MESOZOIC M; SMITH PE, 1995, CAN J EARTH SCI, V32, P1426, DOI 10.1139/e95-115; Wang Yuanqing, 1995, P221; Wible J.R., 1991, Journal of Vertebrate Paleontology, V11, P1; WIBLE JR, 1993, MAMMAL PHYLOGENY, V1, P45; Zeller U., 1989, ABHANDLUNGEN SENCKEN, V545, P1; [No title captured]	50	181	213	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					137	142		10.1038/36505	http://dx.doi.org/10.1038/36505			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367151				2022-12-28	WOS:A1997YF49400043
J	Yamasaki, K; Morimoto, N; Gion, T; Yanaga, K				Yamasaki, K; Morimoto, N; Gion, T; Yanaga, K			Delirium and a subclavian abscess	LANCET			English	Article									KYUSHU UNIV,FAC MED,DEPT NEUROPSYCHIAT,FUKUOKA 81282,JAPAN; KYUSHU UNIV,FAC MED,DEPT SURG 2,FUKUOKA 81282,JAPAN	Kyushu University; Kyushu University			Yanaga, Katsuhiko/Y-6290-2019	Yanaga, Katsuhiko/0000-0001-8918-4720				Muir AH, 1903, LANCET, V1, P960; OCONNOR AFF, 1977, J LARYNGOL OTOL, V91, P903, DOI 10.1017/S002221510008453X; SHORT AR, 1910, MED PRESS CIRCULAR, V2, P309	3	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1294	1294		10.1016/S0140-6736(97)08026-4	http://dx.doi.org/10.1016/S0140-6736(97)08026-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357410				2022-12-28	WOS:A1997YD68900012
J	Tinetti, ME; Williams, CS				Tinetti, ME; Williams, CS			Falls, injuries due to falls, and the risk of admission to a nursing home	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; ELDERLY PEOPLE; OLDER PERSONS; FUNCTIONAL STATUS; COMMUNITY; POPULATION; ADULTS; EFFICACY; CARE; FEAR	Background Falls warrant investigation as a risk factor for nursing home admission because falls are common and are associated with functional disability and because they may be preventable. Methods We conducted a prospective study of a probability sample of 1103 people over 71 years of age who were living in the community. Data on demographic and medical characteristics, use of health care, and cognitive, functional, psychological, and social functioning were obtained at base line and one year later during assessments in the participants' homes. The primary outcome studied was the number of days from the initial assessment to a first longterm admission to a skilled-nursing facility during three years of follow-up, Patients were assigned to four categories during follow-up: those who had no falls, those who had one fall without serious injury, those who had two or more falls without serious injury, and those who had at least one fall causing serious injury. Results A total of 133 participants (12.1 percent) had long-term admissions to nursing homes. In an unadjusted model, the risk of admission increased progressively, as compared with that for the patients with no falls, for those with a single noninjurious fall (relative risk, 4.9; 95 percent confidence interval, 3.2 to 7.5), those with multiple noninjurious falls (relative risk, 8.5; 95 percent confidence interval, 3.4 to 21.2), and those with at least one fall causing serious injury (relative risk, 19.9; 95 percent confidence interval, 12.2 to 32.6). Adjustment for other risk factors lowered these ratios to 3.1 (95 percent confidence interval, 1.9 to 4.9) for one noninjurious fall, 5.5 (95 percent confidence interval, 2.1 to 14.2) for two or more noninjurious falls, and 10.2 (95 percent confidence interval, 5.8 to 17.9) for at least one fall causing serious injury, but the association between falls and admission to a nursing home remained strong and significant. The population attributable risk of long-term admission to a nursing home for these three groups (the proportion of admissions directly attributable to the three categories of falls) was 13 percent, 3 percent, and 10 percent, respectively. Conclusions Among older people living in the community falls are a strong predictor of placement in a skilled-nursing facility; interventions that prevent falls and their sequelae may therefore delay or reduce the frequency of nursing home admissions. (C) 1997, Massachusetts Medical Society.			Tinetti, ME (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, 333 CEDAR ST, POB 208025, NEW HAVEN, CT 06520 USA.				NIA NIH HHS [P60AG10487, R01 AG07447] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Dunn J E, 1993, J Aging Health, V5, P194, DOI 10.1177/089826439300500203; Foley D J, 1992, J Aging Health, V4, P155, DOI 10.1177/089826439200400201; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GREENE VL, 1990, J GERONTOL, V45, pS250, DOI 10.1093/geronj/45.6.S250; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; JETTE AM, 1992, GERONTOLOGIST, V32, P634, DOI 10.1093/geront/32.5.634; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KIEL DP, 1991, MED CARE, V29, P221; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LIU K, 1991, MED CARE, V29, P125, DOI 10.1097/00005650-199102000-00005; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; MURTAUGH CM, 1990, MED CARE, V28, P952, DOI 10.1097/00005650-199010000-00009; NEVITT MC, 1991, J GERONTOL, V46, pM164, DOI 10.1093/geronj/46.5.M164; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REINSCH S, 1992, GERONTOLOGIST, V32, P450, DOI 10.1093/geront/32.4.450; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; Seeman T. E., 1993, J AGING HEALTH, V5, P455, DOI DOI 10.1177/089826439300500403; Spielberger C., 1983, STAI MANUAL; TINETTI ME, 1990, J GERONTOL, V45, pP239, DOI 10.1093/geronj/45.6.P239; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; WOLINSKY FD, 1993, J GERONTOL, V48, pS93; WOLINSKY FD, 1992, MED CARE, V30, P587, DOI 10.1097/00005650-199207000-00002	37	921	943	2	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1279	1284		10.1056/NEJM199710303371806	http://dx.doi.org/10.1056/NEJM199710303371806			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC920	9345078				2022-12-28	WOS:A1997YC92000006
J	Egleston, CV; Browning, C; Hamdi, I; CampbellHewson, G; Robinson, SM				Egleston, CV; Browning, C; Hamdi, I; CampbellHewson, G; Robinson, SM			Comparison of two assays for measuring plasma concentrations of paracetamol	BRITISH MEDICAL JOURNAL			English	Article									ADDENBROOKES NHS TRUST,DEPT ACCID & EMERGENCY MED,CAMBRIDGE CB2 2QQ,ENGLAND; NORFOLK & NORWICH HOSP,DEPT ACCID & EMERGENCY MED,NORWICH NR1 3SR,NORFOLK,ENGLAND; ADDENBROOKES NHS TRUST,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Addenbrooke's Hospital								BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097	2	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					991	992		10.1136/bmj.315.7114.991	http://dx.doi.org/10.1136/bmj.315.7114.991			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365297	Green Published			2022-12-28	WOS:A1997YC30700022
J	Hackshaw, AK; Law, MR; Wald, NJ				Hackshaw, AK; Law, MR; Wald, NJ			The accumulated evidence on lung cancer and environmental tobacco smoke	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PASSIVE SMOKING; NONSMOKING WOMEN; RISK-FACTORS; URINARY COTININE; DIETARY-INTAKE; CHINESE-WOMEN; CIGARETTE-SMOKING; CLINICAL-TRIALS; AIR-POLLUTION; UNITED-STATES	Objective: To estimate the risk of lung cancer in lifelong non-smokers exposed to environmental tobacco smoke. Design: Analysis of 37 published epidemiological studies of the risk of lung cancer (4626 cases) in non-smokers who did and did not live with a smoker. The risk estimate was compared with that from linear extrapolation of the risk in smokers using seven studies of biochemical markers of tobacco smoke intake. Main outcome measure: Relative risk of lung cancer in lifelong non-smokers according to whether the spouse currently smoked or had never smoked. Results: The excess risk of lung cancer was 24% (95% confidence interval 13% to 36%) in non-smokers who lived with a smoker (P < 0.001). Adjustment for the effects of bias (positive and negative) and dietary confounding had little overall effect; the adjusted excess risk was 26% (7% to 47%). The dose-response relation of the risk of lung cancer with both the number of cigarettes smoked by the spouse and the duration of exposure was significant. The excess risk derived by linear extrapolation from that in smokers was 19%, similar to the direct estimate of 26%. Conclusion: The epidemiological and biochemical evidence on exposure to environmental tobacco smoke, with the supporting evidence of tobacco specific carcinogens in the blood and urine of non-smokers exposed to environmental tobacco smoke, provides compelling confirmation that breathing other people's tobacco smoke is a cause of lung cancer.	UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND; ROYAL LONDON SCH MED & DENT, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London			Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021	Pirich, Christian/0000-0002-4502-0609				AKIBA S, 1986, CANCER RES, V46, P4804; ALAVANJA MCR, 1993, J NATL CANCER I, V85, P1906, DOI 10.1093/jnci/85.23.1906; *AUSTR NAT HLTH ME, 1987, EFF PASS SMOK HLTH R; AXELSON O, 1988, SCAND J WORK ENV HEA, V14, P286, DOI 10.5271/sjweh.1918; BARTSCH H, 1990, JNCI-J NATL CANCER I, V82, P1826, DOI 10.1093/jnci/82.23.1826; BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005; BRITTEN N, 1988, INT J EPIDEMIOL, V17, P525, DOI 10.1093/ije/17.3.525; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; BROWNSON RC, 1987, AM J EPIDEMIOL, V125, P25, DOI 10.1093/oxfordjournals.aje.a114509; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P1525, DOI 10.2105/AJPH.82.11.1525; BUFFLER PA, 1984, LUNG CANCER CAUSES P, P83; BURCHFIEL CM, 1986, AM REV RESPIR DIS, V133, P966; BUTLER TL, 1988, THESIS U CALIFORNIA; CANDELORA EC, 1992, NUTR CANCER, V17, P263, DOI 10.1080/01635589209514195; Cardenas VM, 1997, CANCER CAUSE CONTROL, V8, P57, DOI 10.1023/A:1018483121625; CHAN WC, 1982, CANCER CAMPAIGN, V6, P199; CORREA P, 1983, LANCET, V2, P595; CRAWFORD FG, 1994, J NATL CANCER I, V86, P1398, DOI 10.1093/jnci/86.18.1398; CUMMINGS KM, 1990, ARCH ENVIRON HEALTH, V45, P74, DOI 10.1080/00039896.1990.9935929; Dai XD, 1996, LUNG CANCER-J IASLC, V14, pS85, DOI 10.1016/S0169-5002(96)90213-5; DALAGER NA, 1986, CANCER RES, V46, P4808; DEMOUZON J, 1988, INT J EPIDEMIOL, V17, P378, DOI 10.1093/ije/17.2.378; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DU YX, 1993, P IND AIR 93, V1, P511; FERRIS BG, 1985, ENVIRON HEALTH PERSP, V62, P289, DOI 10.2307/3430127; FEYERABEND C, 1982, BRIT MED J, V284, P1002, DOI 10.1136/bmj.284.6321.1002; FONTHAM ETH, 1991, CANCER EPIDEM BIOMAR, V1, P35; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; FORASTIERE F, 1993, ARCH ENVIRON HEALTH, V48, P230, DOI 10.1080/00039896.1993.9940364; GAO YT, 1987, INT J CANCER, V40, P604, DOI 10.1002/ijc.2910400505; GARFINKEL L, 1981, JNCI-J NATL CANCER I, V66, P1061, DOI 10.1093/jnci/66.6.1061; GARFINKEL L, 1985, J NATL CANCER I, V75, P463; GENG GY, 1988, SMOKING HLTH 1987, P483; GER LP, 1993, ANTICANCER RES, V13, P1491; GILLIS CR, 1984, EUR J RESPIR DIS, V65, P121; GOODMAN MT, 1992, EUR J CANCER, V28A, P495, DOI 10.1016/S0959-8049(05)80086-3; HADDOW JE, 1986, BRIT MED J, V293, P1306, DOI 10.1136/bmj.293.6557.1306-b; HAMMOND SK, 1993, J NATL CANCER I, V85, P474, DOI 10.1093/jnci/85.6.474; HEBERT JR, 1990, EUR J CLIN NUTR, V44, P185; HEBERT L, UNPUB REPORT FURTHER; HECHT SS, 1993, NEW ENGL J MED, V329, P1543, DOI 10.1056/NEJM199311183292105; HIRAYAMA T, 1984, PREV MED, V13, P680, DOI 10.1016/S0091-7435(84)80017-1; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; HIRAYAMA T, 1984, LUNG CANCER CAUSES P, P175; HIRAYAMA T, 1989, PRESENT FUTURE INDOO; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; HOLOWATY EJ, 1991, CAN J PUBLIC HEALTH, V82, P304; HUMBLE CG, 1987, AM J PUBLIC HEALTH, V77, P598, DOI 10.2105/AJPH.77.5.598; INOUE R, 1988, SMOKING HLTH 1987, P283; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335; JARVIS MJ, 1991, INT J EPIDEMIOL, V20, P126, DOI 10.1093/ije/20.1.126; JOCKEL KH, 1991, VDI REPORTS, V888; KABAT GC, 1984, CANCER, V53, P1214, DOI 10.1002/1097-0142(19840301)53:5<1214::AID-CNCR2820530532>3.0.CO;2-8; KABAT GC, 1995, AM J EPIDEMIOL, V142, P141, DOI 10.1093/oxfordjournals.aje.a117612; KABAT GC, 1990, 1990 ANN WINT TOX FO, P187; KALANDIDI A, 1990, CANCER CAUSE CONTROL, V1, P15, DOI 10.1007/BF00053179; Katada H, 1988, Gan No Rinsho, V34, P21; KNOTH A, 1983, MED KLIN PRAX, V78, P54; KOO LC, 1988, NUTR CANCER, V11, P155, DOI 10.1080/01635588809513983; KOO LC, 1987, INT J CANCER, V39, P162, DOI 10.1002/ijc.2910390207; LAM Q, 1993, BIOMED ENVIRON SCI, V6, P112; LAM TH, 1987, BRIT J CANCER, V56, P673, DOI 10.1038/bjc.1987.264; LAM TH, 1988, SMOKING HLTH 1987; LAM WK, 1985, THESIS U HONG KONG H; Law MR, 1997, BRIT J CANCER, V75, P1690, DOI 10.1038/bjc.1997.287; LAYARD M, 1994, FED REG, V5; LEE PN, 1987, HUM TOXICOL, V6, P517, DOI 10.1177/096032718700600612; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; LEE PN, 1992, ENV TOBACCO SMOKE MO; LEMARCHAND L, 1991, CANCER CAUSE CONTROL, V2, P11, DOI 10.1007/BF00052356; LI WX, 1989, CHIN J PREV MED, V23, P93; LIU ZY, 1991, INT J EPIDEMIOL, V20, P26, DOI 10.1093/ije/20.1.26; LLOYD OL, 1986, J SOC OCCUP MED, V36, P2; Luo RX, 1996, LUNG CANCER-J IASLC, V14, pS113, DOI 10.1016/S0169-5002(96)90217-2; MACLURE M, 1989, AM J PUBLIC HEALTH, V79, P1381, DOI 10.2105/AJPH.79.10.1381; MARGETTS BM, 1993, BMJ-BRIT MED J, V307, P1381, DOI 10.1136/bmj.307.6916.1381; MATANOSKI G, 1995, AM J EPIDEMIOL, V142, P149, DOI 10.1093/oxfordjournals.aje.a117613; MAYNE ST, 1994, J NATL CANCER I, V86, P33, DOI 10.1093/jnci/86.1.33; MCPHILLIPS JB, 1994, J AM DIET ASSOC, V94, P287, DOI 10.1016/0002-8223(94)90370-0; MILLER GH, 1994, CANCER DETECT PREV, V18, P421; National Research Council Committee on Passive Smoking, 1986, ENV TOB SMOK MEAS EX; *OFF POP CENS SURV, 1996, LIV BRIT RES 1994 GE; OGSTON SA, 1987, J EPIDEMIOL COMMUN H, V41, P21, DOI 10.1136/jech.41.1.21; PERSHAGEN G, 1987, AM J EPIDEMIOL, V125, P17, DOI 10.1093/oxfordjournals.aje.a114504; POJER R, 1984, CLIN CHEM, V30, P1377; PUNTONI R, 1995, CARCINOGENESIS, V16, P1465, DOI 10.1093/carcin/16.7.1465; QING L, 1993, AM J EPIDEMIOL, V137, P145, DOI 10.1093/oxfordjournals.aje.a116654; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; RONA RJ, 1985, INT J EPIDEMIOL, V14, P402, DOI 10.1093/ije/14.3.402; SANDLER DP, 1985, AM J EPIDEMIOL, V121, P37, DOI 10.1093/oxfordjournals.aje.a113980; Shen XB, 1996, LUNG CANCER-J IASLC, V14, pS107, DOI 10.1016/S0169-5002(96)90216-0; SHIMIZU H, 1988, TOHOKU J EXP MED, V154, P389, DOI 10.1620/tjem.154.389; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; SIDNEY S, 1989, AM J EPIDEMIOL, V129, P1305, DOI 10.1093/oxfordjournals.aje.a115250; SOBUE T, 1990, INT J EPIDEMIOL, V19, pS62, DOI 10.1093/ije/19.Supplement_1.S62; STEINMETZ KA, 1993, CANCER RES, V53, P536; STOCKWELL HG, 1992, J NATL CANCER I, V84, P1417, DOI 10.1093/jnci/84.18.1417; SUTTON GC, 1980, ANN HUM BIOL, V7, P449, DOI 10.1080/03014468000004561; SVENSSON C, 1989, ACTA ONCOL, V28, P623, DOI 10.3109/02841868909092282; THOMPSON SG, 1990, THORAX, V45, P356, DOI 10.1136/thx.45.5.356; THORNTON A, 1994, J CLIN EPIDEMIOL, V47, P1143, DOI 10.1016/0895-4356(94)90101-5; TRIBBLE DL, 1993, AM J CLIN NUTR, V58, P886, DOI 10.1093/ajcn/58.6.886; TRICHOPOULOS D, 1981, INT J CANCER, V27, P1, DOI 10.1002/ijc.2910270102; TRICHOPOULOS D, 1983, LANCET, V2, P677; *UK DEP HLTH SOC S, 1988, 4 UK DEP HLTH SOC SE; *US DEP HHS, 1986, PUBL; WALD N, 1984, LANCET, V1, P1067; WALD NJ, 1984, LANCET, V1, P230; WALD NJ, 1986, BMJ-BRIT MED J, V293, P1217, DOI 10.1136/bmj.293.6556.1217; WANG FL, 1994, INT J EPIDEMIOL, V23, P223, DOI 10.1093/ije/23.2.223; Wang SY, 1996, LUNG CANCER-J IASLC, V14, pS99, DOI 10.1016/S0169-5002(96)90215-9; Wang TJ, 1996, LUNG CANCER-J IASLC, V14, pS93, DOI 10.1016/S0169-5002(96)90214-7; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; WILLERS S, 1992, ARCH ENVIRON HEALTH, V47, P357, DOI 10.1080/00039896.1992.9938375; WU AH, 1985, JNCI-J NATL CANCER I, V74, P747; WUWILLIAMS AH, 1990, BRIT J CANCER, V62, P982, DOI 10.1038/bjc.1990.421; YE SZ, 1994, LUNG CANCER S1, V14, pS161; YE Z, 1990, CHIN J CLIN ONCOL, V17, P195; ZARIDZE DG, 1995, VESTN ROS AKAD MED, V4, P6	121	484	499	0	57	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	1997	315	7114					980	988		10.1136/bmj.315.7114.980	http://dx.doi.org/10.1136/bmj.315.7114.980			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365295	Green Published			2022-12-28	WOS:A1997YC30700019
J	Sykes, J; Johnson, R; Hanks, GW				Sykes, J; Johnson, R; Hanks, GW			ABC of palliative care - Difficult pain problems	BRITISH MEDICAL JOURNAL			English	Article									BRISTOL ROYAL INFIRM & GEN HOSP,PAIN CLIN,BRISTOL,AVON,ENGLAND	Bristol Royal Infirmary	Sykes, J (corresponding author), CTY HOSP,HEREFORD HR1 2ER,ENGLAND.							GYBELS JM, 1989, NEUROSURGICAL TREATM; HANKS GW, 1997, OXFORD TXB PALLIATIV	2	16	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					867	869		10.1136/bmj.315.7112.867	http://dx.doi.org/10.1136/bmj.315.7112.867			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353510	Green Published			2022-12-28	WOS:A1997YA00700031
J	Bridges, BA				Bridges, BA			RNA synthesis - MutT prevents leakiness	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; DNA-SYNTHESIS; MUTAGENESIS; OXIDATION; MUTATORS; BACTERIA				Bridges, BA (corresponding author), UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND.							Bridges BA, 1996, J BACTERIOL, V178, P2709, DOI 10.1128/jb.178.9.2709-2711.1996; Bridges BA, 1996, CANCER SURV, V28, P155; BRIDGES BA, UNPUB; FOWLER RG, 1994, J BACTERIOL, V176, P7727, DOI 10.1128/JB.176.24.7727-7729.1994; HAYAKAWA H, UNPUB; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; NINIO J, 1991, GENETICS, V129, P957; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	12	10	10	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					78	79		10.1126/science.278.5335.78	http://dx.doi.org/10.1126/science.278.5335.78			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9340758				2022-12-28	WOS:A1997XZ12400038
J	Pruchnicki, A				Pruchnicki, A			First, do no harm (pending prior approval)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Pruchnicki, A (corresponding author), MT SINAI MED CTR,NEW YORK,NY 10029, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1627	1628		10.1056/NEJM199711273372212	http://dx.doi.org/10.1056/NEJM199711273372212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371863				2022-12-28	WOS:A1997YH52100012
J	Ermler, U; Grabarse, W; Shima, S; Goubeaud, M; Thauer, RK				Ermler, U; Grabarse, W; Shima, S; Goubeaud, M; Thauer, RK			Crystal structure of methyl coenzyme M reductase: The key enzyme of biological methane formation	SCIENCE			English	Article							METHYLCOENZYME-M METHYLREDUCTASE; F430 PENTAMETHYL ESTER; METHANOBACTERIUM-THERMOAUTOTROPHICUM; METHANOGENIC BACTERIA; COMPONENT-C; INVITRO METHANOGENESIS; STRAIN MARBURG; SYSTEM; NICKEL; SPECTROSCOPY	Methyl-coenzyme M reductase (MCR), the enzyme responsible for the microbial formation of methane, is a 300-kilodalton protein organized as a hexamer in an alpha(2) beta(2) gamma(2) arrangement. The crystal structure of the enzyme from Methanobacterium thermoautotrophicum, determined at 1.45 angstrom resolution for the inactive enzyme state MCRox1-silent, reveals that two molecules of the nickel porphinoid coenzyme F-430 are embedded between the subunits alpha,alpha',beta, and gamma and alpha',alpha,beta', and gamma', forming two identical active sites. Each site is accessible for the substrate methyl-coenzyme M through a narrow channel locked after binding of the second substrate coenzyme B. Together with a second structurally characterized enzyme state (MCRsilent) containing the heterodisulfide of coenzymes M and B, a reaction mechanism is proposed that uses a radical intermediate and a nickel organic compound.	UNIV MARBURG, MIKROBIOL LAB, D-35043 MARBURG, GERMANY; MAX PLANCK INST TERR MIKROBIOL, D-35043 MARBURG, GERMANY	Philipps University Marburg; Max Planck Society	Ermler, U (corresponding author), MAX PLANCK INST BIOPHYS, HEINRICH HOFFMAN STR 7, D-60528 FRANKFURT, GERMANY.							AHN YH, 1991, J AM CHEM SOC, V113, P4700, DOI 10.1021/ja00012a059; ALBRACHT SPJ, 1988, BIOCHIM BIOPHYS ACTA, V955, P86, DOI 10.1016/0167-4838(88)90182-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERKESSEL A, 1991, BIOORG CHEM, V19, P101, DOI 10.1016/0045-2068(91)90047-S; BOKRANZ M, 1988, J BACTERIOL, V170, P568, DOI 10.1128/jb.170.2.568-577.1988; BONACKER LG, 1993, EUR J BIOCHEM, V217, P587, DOI 10.1111/j.1432-1033.1993.tb18281.x; BRNGER AT, 1992, XPLOR MANUAL VERSION; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COWTAN KD, 1994, PROTEIN CRYSTALLOGR, V31, P83; ELLEFSON WL, 1981, J BIOL CHEM, V256, P4259; ELLERMANN J, 1988, EUR J BIOCHEM, V172, P669, DOI 10.1111/j.1432-1033.1988.tb13941.x; Ermler U, 1997, STRUCTURE, V5, P635, DOI 10.1016/S0969-2126(97)00219-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FARBER G, 1991, HELV CHIM ACTA, V74, P697, DOI 10.1002/hlca.19910740404; Goubeaud M, 1997, EUR J BIOCHEM, V243, P110, DOI 10.1111/j.1432-1033.1997.00110.x; HARTZELL PL, 1986, P NATL ACAD SCI USA, V83, P6726, DOI 10.1073/pnas.83.18.6726; HARTZELL PL, 1987, J BIOL CHEM, V262, P5581; HOGAN KB, 1991, NATURE, V354, P181, DOI 10.1038/354181a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JAUN B, 1990, HELV CHIM ACTA, V73, P2209, DOI 10.1002/hlca.19900730818; JAUN B, 1993, MET IONS BIOL SYST, V29, P287; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, PROTEIN CRYSTALLOGR, V26, P83; LIN SK, 1992, HELV CHIM ACTA, V75, P1478, DOI 10.1002/hlca.19920750504; LIN SK, 1991, HELV CHIM ACTA, V74, P1725, DOI 10.1002/hlca.19910740814; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NOLL KM, 1986, BIOCHEM BIOPH RES CO, V139, P889, DOI 10.1016/S0006-291X(86)80261-3; Nolling J, 1996, INT J SYST BACTERIOL, V46, P1170, DOI 10.1099/00207713-46-4-1170; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PFALTZ A, 1982, HELV CHIM ACTA, V65, P828, DOI 10.1002/hlca.19820650320; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROSPERT S, 1991, FEBS LETT, V291, P371, DOI 10.1016/0014-5793(91)81323-Z; ROUVIERE PE, 1989, J BACTERIOL, V171, P4556, DOI 10.1128/jb.171.9.4556-4562.1989; SCOTT RA, 1986, FRONTIERS BIOINORGAN, P20; Sheldon Garrett Ward, 1991, P CCP4 STUD WEEK, P3; Shima S, 1997, J BIOCHEM, V121, P829, DOI 10.1093/oxfordjournals.jbchem.a021660; Thauer R, 1997, ANTON LEEUW INT J G, V71, P21, DOI 10.1023/A:1000149705588; WOLFE RS, 1991, ANNU REV MICROBIOL, V45, P1, DOI 10.1146/annurev.mi.45.100191.000245	46	418	445	3	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	1997	278	5342					1457	1462		10.1126/science.278.5342.1457	http://dx.doi.org/10.1126/science.278.5342.1457			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367957				2022-12-28	WOS:A1997YG85800043
J	Nikolajsen, L; Ilkjaer, S; Christensen, JH; Kroner, K; Jensen, TS				Nikolajsen, L; Ilkjaer, S; Christensen, JH; Kroner, K; Jensen, TS			Randomised trial of epidural bupivacaine and morphine in prevention of stump and phantom pain in lower-limb amputation	LANCET			English	Article							MAJOR ABDOMINAL-SURGERY; POSTOPERATIVE PAIN; NEUROPATHIC PAIN; ANESTHESIA; ANALGESIA; AMPUTEES; RATS; REQUIREMENTS; CONSUMPTION; INDUCTION	Background Epidural analgesia before limb amputation is commonly used to reduce postamputation pain. But there have been no controlled studies with large numbers of patients to prove such a preemptive effect. We investigated whether postamputation stump and phantom pain in the first year is reduced by preoperative epidural blockade with bupivacaine and morphine. Methods In a randomised, double-blind trial, 60 patients scheduled for lower-limb amputation were randomly assigned epidural bupivacaine (0.25% 4-7 mL/h) and morphine (0.16-0.28 mg/h) for 18 h before and during the operation (29 patients; blockade group) or epidural saline (4-7 mL/h) and oral or intramuscular morphine (31 patients; control group). All patients had general anaesthesia for the amputation and were asked about stump and phantom pain after 1 week and then after 3, 6, and 12 months by two independent examiners. Study endpoints were rate of stump and phantom pain, intensity of stump and phantom pain, and consumption of opioids. Findings Two patients in each group were withdrawn before amputation. The groups were well matched in baseline characteristics. Median duration of preoperative saline treatment was 18.5 h (IQR 17-20). Median duration of preoperative epidural blockade in the blockade group was 18 h (15-20.3). The combined median duration of postoperative epidural pain treatment in both groups was 166 h (89.3-308.3). After 1 week, 14 (52%) patients in the blockade group and 15 (56%) in the control group had phantom pain (95% CI -30.6 to 22.7, p=0.9). The figures for blockade versus control group were: 14 (82%) vs ten (50%; 4.0 to 60.8, p=0.09) at 3 months; 13 (81%) vs 11 (55%; -2.7 to 55.3, p=0.2) at 6 months; and nine (75%) vs 11 (69%; -27.0 to 39.6, p=1.0) at 12 months. Intensity of stump and phantom pain and consumption of opioids were similar in both groups at all four postoperative interviews. Interpretation Perioperative epidural blockade started a median of 18 h (15-20.3) before the amputation and continued into the postoperative period does not prevent phantom or stump pain.	AARHUS UNIV HOSP,DEPT NEUROL,DK-8000 AARHUS C,DENMARK; AARHUS UNIV HOSP,DEPT ANAESTHESIOL,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DANISH PAIN RES CTR,DK-8000 AARHUS C,DENMARK	Aarhus University; Aarhus University; Aarhus University			Jensen, Troels Staehelin/A-3418-2009	Jensen, Troels Staehelin/0000-0002-3487-6380; Nikolajsen, Lone/0000-0002-2705-7088; Nikolajsen, Lone/0000-0002-5261-806X				AQUILAR JL, 1996, BRIT J ANAESTH, V76, P72; BACH S, 1988, PAIN, V33, P297, DOI 10.1016/0304-3959(88)90288-6; CARLEN PL, 1978, NEUROLOGY, V28, P211, DOI 10.1212/WNL.28.3.211; Choe H, 1997, ANESTH ANALG, V84, P560, DOI 10.1097/00000539-199703000-00017; DAHL JB, 1992, BRIT J ANAESTH, V69, P4, DOI 10.1093/bja/69.1.4; EJLERSEN E, 1992, ANESTH ANALG, V74, P495; ELIZAGA AM, 1994, J REHABIL RES DEV, V31, P179; FISCHER A, 1991, ANESTH ANALG, V72, P300; GONZALEZDARDER JM, 1986, PAIN, V24, P87, DOI 10.1016/0304-3959(86)90029-1; JAHANGIRI M, 1994, ANN ROY COLL SURG, V76, P324; JENSEN TS, 1983, PAIN, V17, P243, DOI 10.1016/0304-3959(83)90097-0; JENSEN TS, 1985, PAIN, V21, P267, DOI 10.1016/0304-3959(85)90090-9; Jensen TS., 1994, TXB PAIN, P651; KATSULYLIAPIS I, 1996, BRIT J ANAESTH, V76, P125; Katz J, 1997, LANCET, V349, P519, DOI 10.1016/S0140-6736(97)80081-5; KATZ J, 1994, PAIN, V59, P395, DOI 10.1016/0304-3959(94)90026-4; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; Magnusson JE, 1996, BRAIN RES, V723, P214, DOI 10.1016/0006-8993(96)00255-7; Nikolajsen L, 1997, PAIN, V72, P393, DOI 10.1016/S0304-3959(97)00061-4; Pinzur MS, 1996, J BONE JOINT SURG AM, V78A, P1501, DOI 10.2106/00004623-199610000-00007; PRYLE BJ, 1993, ANAESTHESIA, V48, P120; PUKE MJC, 1993, ANESTH ANALG, V77, P104; Rockemann MG, 1996, ANESTHESIOLOGY, V84, P1027, DOI 10.1097/00000542-199605000-00003; SELTZER Z, 1991, PAIN, V46, P327, DOI 10.1016/0304-3959(91)90115-E; SHERMAN RA, 1983, AM J PHYS MED REHAB, V62, P227; SHIR Y, 1994, ANESTHESIOLOGY, V80, P49, DOI 10.1097/00000542-199401000-00011; SHUG SA, 1995, REGION ANESTH PAIN M, V20, P256; SOTGIU ML, 1995, PAIN, V61, P3, DOI 10.1016/0304-3959(94)00120-4; TWYCROSS RG, 1994, TXB PAIN, P943; WALL PD, 1988, PAIN, V33, P289, DOI 10.1016/0304-3959(88)90286-2; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C	31	201	205	2	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1353	1357		10.1016/S0140-6736(97)06315-0	http://dx.doi.org/10.1016/S0140-6736(97)06315-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365449				2022-12-28	WOS:A1997YE87200009
J	Schmidt, WA; Kraft, HE; Vorpahl, K; Volker, L; GromnicaIhle, EJ				Schmidt, WA; Kraft, HE; Vorpahl, K; Volker, L; GromnicaIhle, EJ			Color duplex ultrasonography in the diagnosis of temporal arteritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GIANT-CELL ARTERITIS; DOPPLER ULTRASOUND FLOW; POLYMYALGIA-RHEUMATICA; CRANIAL ARTERITIS; BIOPSY; SONOGRAPHY; CRITERIA	Background The diagnosis of temporal arteritis usually requires a biopsy of the temporal artery. We examined the usefulness of color duplex ultrasonography in patients suspected of having temporal arteritis. Methods In this prospective study, all patients seen in the departments of rheumatology and ophthalmology from January 1994 to October 1996 who had clinically suspected active temporal arteritis or polymyalgia rheumatica were examined by duplex ultrasonography. The final diagnoses, made according to standard criteria, were temporal arteritis in 30 patients, 21 with biopsy-confirmed disease; polymyalgia rheumatica in 37; and negative histologic findings and a diagnosis other than temporal arteritis or polymyalgia rheumatica in 15. We also studied 30 control patients matched for age and sex to the patients with arteritis. Two ultrasound studies were performed and read before the biopsies; one ultrasonographer was unaware of the clinical information. Results In 22 (73 percent) of the 30 patients with temporal arteritis, ultrasonography showed a dark halo around the lumen of the temporal arteries. The halos disappeared after a mean of 16 days (range, 7 to 56) of treatment with corticosteroids. Twenty four patients (80 percent) had stenoses or occlusions of temporal-artery segments, and 28 patients (93 per cent) had stenoses, occlusions, or a halo. No halos were identified in the 82 patients without temporal arteritis; 6 (7 percent) had stenoses or occlusions. For each of the three types of abnormalities identified by ultrasonography, the interrater agreement was greater than or equal to 95 percent. Conclusions There are characteristic signs of temporal arteritis that can be visualized by color duplex ultrasonography. The most specific sign is a dark halo, which may be due to edema of the artery wall. In patients with typical clinical signs and a halo on ultrasonography, it may be possible to make a diagnosis of temporal arteritis and begin treatment without performing a temporal-artery biopsy. (C) 1997, Massachusetts Medical Society.	KLINIKUM BUCH, DEPT OPHTHALMOL, BERLIN, GERMANY; KLINIKUM BUCH, DEPT PATHOL, BERLIN, GERMANY; KLINIKUM BUCH, DEPT ANGIOL, BERLIN, GERMANY		Schmidt, WA (corresponding author), CLIN RHEUMATOL, ZEPERNICKER STR 1, D-13125 BERLIN, GERMANY.		Schmidt, Wolfgang/W-5599-2019	Schmidt, Wolfgang/0000-0001-7831-8738				ABURN NS, 1993, EYE, V7, P639, DOI 10.1038/eye.1993.147; ASHTONKEY M, 1991, BAILLIERE CLIN RHEUM, V5, P387, DOI 10.1016/S0950-3579(05)80061-5; BARRIER J, 1982, JAMA-J AM MED ASSOC, V248, P2158, DOI 10.1001/jama.248.17.2158; BECKMAN RL, 1990, J CLIN NEURO-OPHTHAL, V10, P304; BIENFANG DC, 1984, AM J OPHTHALMOL, V97, P526, DOI 10.1016/S0002-9394(14)76141-0; BIRD HA, 1979, ANN RHEUM DIS, V38, P434, DOI 10.1136/ard.38.5.434; BUNHOLZL C, 1988, ULTRASCHALL MED, V9, P232; Dany F, 1981, J Mal Vasc, V6, P273; DANY F, 1989, J MAL VASCUL, V14, P104; DAUMANN C, 1989, KLIN MONATSBL AUGENH, V194, P37, DOI 10.1055/s-2008-1046333; DORNBERGER V, 1987, MED WELT, V38, P1302; ELLIOTT PD, 1972, RADIOLOGY, V102, P635; FRIEDMAN G, 1988, ISRAEL J MED SCI, V24, P686; Ghanchi FD, 1996, EYE, V10, P459, DOI 10.1038/eye.1996.101; GILLANDERS LA, 1969, ANN RHEUM DIS, V28, P267, DOI 10.1136/ard.28.3.267; HO AC, 1994, ARCH OPHTHALMOL-CHIC, V112, P938, DOI 10.1001/archopht.1994.01090190086026; HORWITZ HM, 1977, J RHEUMATOL, V4, P76; HUNDER GG, 1972, ARTHRITIS RHEUM, V15, P561, DOI 10.1002/art.1780150602; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; KELLEY JS, 1978, ARCH OPHTHALMOL-CHIC, V96, P845; LIE JT, 1994, J RHEUMATOL, V21, P366; LIE JT, 1994, J RHEUMATOL, V21, P186; LIEB WE, 1992, ACTA OPHTHALMOL, V70, P50; LIOZON F, 1983, PRESSE MED, V12, P2113; LIOZON F, 1986, ANN MED INTERNE, V137, P307; MARANO SR, 1985, NEUROSURGERY, V16, P786, DOI 10.1227/00006123-198506000-00008; MENKES CJ, 1981, NOUV PRESSE MED, V10, P2371; MORGAN GJ, 1978, ARTHRITIS RHEUM, V21, P362, DOI 10.1002/art.1780210312; PUECHAL, 1995, LANCET, V346, P62; PUECHAL X, 1995, LANCET, V345, P1437, DOI 10.1016/S0140-6736(95)92626-7; SALVARANI C, 1994, ARTHRITIS RHEUM, V37, P1621, DOI 10.1002/art.1780371111; SCHMIDT WA, 1995, LANCET, V345, P866, DOI 10.1016/S0140-6736(95)93005-1; SCOTT KR, 1991, OPHTHALMIC SURG LAS, V22, P519; SIEMSSEN SJ, 1987, BRIT J PLAST SURG, V40, P73, DOI 10.1016/0007-1226(87)90015-4; SLAVIN ML, 1986, ARCH OPHTHALMOL-CHIC, V104, P1127; SMALL P, 1991, ARTHRITIS RHEUM, V34, P220, DOI 10.1002/art.1780340215; STEIGERWALT RD, 1994, INT ANGIOL, V13, P286; STOCK AL, 1980, HEAD NECK SURG, V2, P466, DOI 10.1002/hed.2890020604; VINCKIER L, 1989, J MAL VASCUL, V14, P116; VOLLRATHJUNGER C, 1989, KLIN MONATSBL AUGENH, V195, P169, DOI 10.1055/s-2008-1046431; WILLIAMSON TH, 1992, BRIT J OPHTHALMOL, V76, P690, DOI 10.1136/bjo.76.11.690	41	508	515	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1336	1342		10.1056/NEJM199711063371902	http://dx.doi.org/10.1056/NEJM199711063371902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358127				2022-12-28	WOS:A1997YE44600002
J	Shieh, SY; Ikeda, M; Taya, Y; Prives, C				Shieh, SY; Ikeda, M; Taya, Y; Prives, C			DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2	CELL			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA GENE; STRAND-BREAK-REPAIR; WILD-TYPE P53; V(D)J RECOMBINATION; BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE	DNA-damaging agents signal to p53 through as yet unidentified posttranscriptional mechanisms. Here we show that phosphorylation of human p53 at serine 15 occurs after DNA damage and that this leads to reduced interaction of p53 with its negative regulator, the oncoprotein MDM2 in vivo and in vitro. Furthermore, using purified DNA-dependent protein kinase (DNA-PK), we demonstrate that phosphorylation of p53 at serines 15 and 37 impairs the ability of MDM2 to inhibit p53-dependent transactivation. We present evidence that these effects are most likely due to a conformational change induced upon phosphorylation of p53. Our studies provide a plausible mechanism by which the induction of p53 can be modulated by DNA-PK (or other protein kinases with similar specificity) in response to DNA damage.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA; MBL CO LTD, INA LABS, INA, NAGANO 396, JAPAN; NATL CANC CTR, RES INST, CHUO KU, TOKYO 104, JAPAN	Columbia University; National Cancer Center - Japan			qiao, zhixin/I-3408-2012; Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	NATIONAL CANCER INSTITUTE [R37CA058316, R01CA058316] Funding Source: NIH RePORTER; NCI NIH HHS [CA58316] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bottger V, 1996, ONCOGENE, V13, P2141; CANMAN CE, 1994, CANCER RES, V54, P5054; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Danska JS, 1996, MOL CELL BIOL, V16, P5507; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, COLD SPRING HARB SYM, V65, P521, DOI 10.1101/sqb.2000.65.521; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1995, ONCOGENE, V11, P609; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Rathmell WK, 1997, CANCER RES, V57, P68; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	63	1687	1721	0	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					325	334		10.1016/S0092-8674(00)80416-X	http://dx.doi.org/10.1016/S0092-8674(00)80416-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363941	hybrid			2022-12-28	WOS:A1997YD94100006
J	Levy, BD; Petasis, NA; Serhan, CN				Levy, BD; Petasis, NA; Serhan, CN			Polyisoprenyl phosphates in intracellular signalling	NATURE			English	Article							CELL-FREE SYSTEM; PRESQUALENE PYROPHOSPHATE; RESPIRATORY BURST; HUMAN-NEUTROPHILS; ACTIVATION; SQUALENE; NADPH; BIOSYNTHESIS; LEUKOCYTES; MECHANISM	In response to environmental stimuli, leukocyte membrane remodelling generates biologically active lipids that can serve as both intra-and extracellular mediators(1). There are several classes of lipids that can mediate inflammatory reactions.(1) We report here on a new intracellular lipid signal that regulates oxygen-radical formation in neutrophils, a key response in microbial killing, inflammation and tissue injury. Screening of neutrophil-derived extracts rich in phosphorylated, non-saponifiable lipids revealed a potent inhibitor of superoxide anion (O-2(-)) production. Structural analysis of biologically active fractions gave four major phosphorylated lipids: most abundant was presqualene diphosphate (PSDP). Upon activation of neutrophil receptors, PSDP and its monophosphate form, presqualene monophosphate (PSMP), undergo rapid remodelling. At submicromolar concentrations, PSDP but not PSMP inhibit O-2(-) production by human neutrophil cell-free oxidase preparations. We prepared PSDP and PSMP by total organic synthesis and matched both the physical properties and biological activity of the neutrophil-derived compounds. Our results indicate that PSDP, a recognized intermediate of cholesterol biosynthesis(2), is present in immune effector cells and is a potent regulator of the cellular response in host defence.	BRIGHAM & WOMENS HOSP, DEPT ANESTHESIA, CTR EXPT THERAPEUT & REPERFUS INJURY, BOSTON, MA 02115 USA; UNIV SO CALIF, DEPT CHEM, LOS ANGELES, CA 90089 USA	Harvard University; Brigham & Women's Hospital; University of Southern California			Petasis, Nicos/B-3162-2009	Petasis, Nicos/0000-0002-8864-4446				ADAIR WL, 1985, METHOD ENZYMOL, V111, P201; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; Bokoch G M, 1994, Curr Opin Hematol, V1, P53; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CHEN PS, 1956, ANAL CHEM, V28, P175; COREY EJ, 1976, J AM CHEM SOC, V98, P1291, DOI 10.1021/ja00421a056; EPSTEIN WW, 1970, J BIOL CHEM, V245, P4597; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOMEZCAMBRONERO J, 1991, ADV EXP MED BIOL, V314, P35; Jarstfer MB, 1996, J AM CHEM SOC, V118, P13089, DOI 10.1021/ja963308s; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MOOKHTIAR KA, 1994, J BIOL CHEM, V269, P11201; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; POPJAK G, 1969, J BIOL CHEM, V244, P1897; QUINN MT, 1995, J LEUKOCYTE BIOL, V58, P263, DOI 10.1002/jlb.58.3.263; ROGERS DH, 1995, J ORG CHEM, V60, P941, DOI 10.1021/jo00109a026; SCHEER A, 1995, BIOCHEMISTRY-US, V34, P4952, DOI 10.1021/bi00015a006; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHECHTER I, 1980, J LIPID RES, V21, P277; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TOU J, 1995, LIPIDS, V30, P373, DOI 10.1007/BF02536294; VANDESSEL GAF, 1993, CRC HDB CHROMATOGRAP, P321; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27	26	54	57	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					985	990		10.1038/40180	http://dx.doi.org/10.1038/40180			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353124				2022-12-28	WOS:A1997YD29900060
J	Mannesse, CK; Derkx, FHM; deRidder, MAJ; MainintVeld, AJ; vanderCammen, TJM				Mannesse, CK; Derkx, FHM; deRidder, MAJ; MainintVeld, AJ; vanderCammen, TJM			Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							OPERATIONAL ASSESSMENT; ALGORITHM		ERASMUS UNIV ROTTERDAM,INST EPIDEMIOL & BIOSTAT,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	Mannesse, CK (corresponding author), UNIV HOSP ROTTERDAM DIJKZIGT,DEPT INTERNAL MED 1,DIV GERIATR MED,ROOM D442,DR MOLEWATERPLEIN 40,NL-3015 GD ROTTERDAM,NETHERLANDS.							*BRIT MED ASS ROYA, 1994, BRIT NAT FORM; Egberts TCG, 1996, BRIT MED J, V313, P530; HUTCHINSON TA, 1979, JAMA-J AM MED ASSOC, V242, P633, DOI 10.1001/jama.242.7.633; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; VANKRAAIJ DJW, 1994, NETH J MED, V44, P166	5	67	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1057	1058		10.1136/bmj.315.7115.1057	http://dx.doi.org/10.1136/bmj.315.7115.1057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366733	Green Published			2022-12-28	WOS:A1997YD44500023
J	Nicholson, KG; Kent, J; Hammersley, V; Cancio, E				Nicholson, KG; Kent, J; Hammersley, V; Cancio, E			Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden	BRITISH MEDICAL JOURNAL			English	Article							INFLUENZA-A INFECTION; SYNCYTIAL VIRUS; RHINOVIRUS INFECTIONS; ILLNESS; TECUMSEH; CHILDREN; RIMANTADINE; MORTALITY; FREQUENCY; ENGLAND	Objective: To evaluate the disease burden of upper respiratory infections in elderly people living at home. Design: Prospective surveillance of elderly people. Intervention: None. Setting: Leicestershire, England Subjects: 533 subjects 60 to 90 years of age. Main outcome measures: Pathogens, symptoms, restriction of activity, duration of illness, medical consultations, interval between onset of illness and medical consultation, antibiotic use, admission to hospital, and death. Results: 231 pathogens were identified for 211 (43%) of 497 episodes for which diagnostic specimens were available: 121 (52%) were rhinoviruses, 59 (26%) were coronaviruses, 22 (9.5%) were influenza A or B, 17 (7%) were respiratory syncytial virus, 7 (3%) were parainfluenza viruses, and 3 (1%) were Chlamydia species; an adenovirus and Mycoplasma pneumoniae caused one infection each. Infections occurred at a rate of 1.2 episodes per person per annum (95% confidence interval 1.0 to 1.7; range 0-10) and were clinically indistinguishable. Lower respiratory tract symptoms complicated 65% of upper respiratory infections and increased the medical consultation rate 2.4-fold (chi(2) test P < 0.001). The median interval between onset of illness and medical consultation was 3 days for influenza and 5 days for other infections. Rhinoviruses caused the greatest disease burden overall followed by episodes of unknown aetiology, coronaviruses, influenza A and B, and respiratory syncytial virus. Conclusions: Respiratory viruses cause substantial morbidity in elderly people. Although respiratory syncytial virus and influenza cause considerable individual morbidity, the burden of disease from rhinovirus infections and infections of unknown aetiology seems greater overall. The interval between onset of illness and consultation together with diagnostic difficulties raises concern regarding the role of antiviral drugs in treating influenza.			Nicholson, KG (corresponding author), UNIV LEICESTER,SCH MED,DEPT MICROBIOL & IMMUNOL,LEICESTER LE1 9HN,LEICS,ENGLAND.							[Anonymous], IMM INF DIS; *COMM ISS PRIOR NE, 1985, NEW VACC DEV EST PRI, V1, P51; FALSEY AR, 1995, J AM GERIATR SOC, V43, P30, DOI 10.1111/j.1532-5415.1995.tb06238.x; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; FALSEY AR, 1992, J AM GERIATR SOC, V40, P115, DOI 10.1111/j.1532-5415.1992.tb01929.x; FLEMING DM, 1993, EUR J EPIDEMIOL, V9, P571, DOI 10.1007/BF00211429; GALBRAIT.AW, 1969, B WORLD HEALTH ORGAN, V41, P677; HALL CB, 1987, PEDIATRICS, V80, P275; HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; KELLNER G, 1989, ACTA PAEDIATR SCAND, V78, P390, DOI 10.1111/j.1651-2227.1989.tb11098.x; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164; MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957; NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251; TANNOCK GA, 1993, FAM PRACT, V10, P378, DOI 10.1093/fampra/10.4.378; THOMPSON J, 1987, J MED VIROL, V21, P249, DOI 10.1002/jmv.1890210308; TYRRELL DAJ, 1993, EPIDEMIOL INFECT, V111, P143, DOI 10.1017/S0950268800056764; WINGFIELD WL, 1969, NEW ENGL J MED, V281, P579, DOI 10.1056/NEJM196909112811102	23	252	267	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1060	1064		10.1136/bmj.315.7115.1060	http://dx.doi.org/10.1136/bmj.315.7115.1060			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366736	Green Published			2022-12-28	WOS:A1997YD44500026
J	Cresswell, JL; Barker, DJP; Osmond, C; Egger, P; Phillips, DIW; Fraser, RB				Cresswell, JL; Barker, DJP; Osmond, C; Egger, P; Phillips, DIW; Fraser, RB			Fetal growth, length of gestation, and polycystic ovaries in adult life	LANCET			English	Article							DISEASE; WOMEN; HYPERANDROGENISM; DYSREGULATION; SECRETION; ENDOCRINE; FEATURES; HORMONE	Background Polycystic ovaries are a common disorder associated with menstrual irregularities, subfertility, hirsutism, acne, and a range of endocrine abnormalities, including high concentrations of plasma luteinising hormone (LH) and excessive androgen production. The pathophysiology is not understood. We investigated whether the disorder originates during intrauterine life. Methods We examined 235 women aged 40-42 years who were born in Sheffield, UK. We related the prevalence of polycystic ovaries and the plasma concentrations of gonadotropin hormones and androgens to the women's body size at birth, and the length of gestation. Findings 49 (21%) of the women had polycystic ovaries. We defined two groups of women with the disorder, which correspond to the two groups that commonly present clinically. The first group comprised obese women who were androgenised, with higher than normal concentrations of plasma LH and testosterone. These women had above-average birthweight and were born to overweight mothers. The second group comprised women of normal weight who had high plasma LH, but normal testosterone concentrations. These women were born after term (40 weeks' gestation). Interpretation The two common forms of polycystic ovary syndrome have different origins in intrauterine life. Obese, hirsute women with polycystic ovaries have higher than normal ovarian secretion of androgens that are associated with high birthweight and maternal obesity. Thin women with polycystic ovaries have altered hypothalamic control of LH release resulting from prolonged gestation.	UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND; UNIV SHEFFIELD, NO GEN HOSP, DEPT OBSTET & GYNAECOL, CTR CLIN SCI, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND	University of Southampton; Northern General Hospital; University of Sheffield			fraser, robert b/B-9856-2009	Osmond, Clive/0000-0002-9054-4655				ADAMS J, 1985, LANCET, V2, P1375; BARKER DJP, 1995, LANCET, V345, P1087, DOI 10.1016/S0140-6736(95)90821-8; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P62, DOI 10.1210/endo-68-1-62; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P68, DOI 10.1210/endo-68-1-68; BURGHEN GA, 1980, J CLIN ENDOCR METAB, V50, P113, DOI 10.1210/jcem-50-1-113; CONWAY GS, 1989, CLIN ENDOCRINOL, V30, P459, DOI 10.1111/j.1365-2265.1989.tb00446.x; CONWAY GS, 1992, CLIN ENDOCRINOL, V37, P119, DOI 10.1111/j.1365-2265.1992.tb02295.x; Dunaif Andrea, 1993, P301; EHRMANN DA, 1995, ENDOCR REV, V16, P322, DOI 10.1210/er.16.3.322; ERICKSON GF, 1979, J CLIN ENDOCR METAB, V49, P514, DOI 10.1210/jcem-49-4-514; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; FIORE M, 1988, CLIN CHEM, V34, P1726; FRANKS S, 1985, CLIN OBSTET GYNAECOL, V12, P605; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; Gruenwald P, 1974, CIBA F S, V27, P3; HAGUE WM, 1988, CLIN ENDOCRINOL, V29, P593, DOI 10.1111/j.1365-2265.1988.tb03707.x; PASQUALI R, 1993, CLIN ENDOCRINOL, V39, P1, DOI 10.1111/j.1365-2265.1993.tb01744.x; Pfeiffer CA, 1936, AM J ANAT, V58, P195, DOI 10.1002/aja.1000580112; Phillips DIW, 1996, DIABETOLOGIA, V39, P1119; POLSON DW, 1988, LANCET, V1, P870; ROSENFIELD RL, 1990, FERTIL STERIL, V53, P785; SAAL FSV, 1980, SCIENCE, V208, P597, DOI 10.1126/science.7367881; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; YEN SSC, 1970, J CLIN ENDOCR METAB, V30, P435, DOI 10.1210/jcem-30-4-435; YEN SSC, 1980, CLIN ENDOCRINOL, V12, P177, DOI 10.1111/j.1365-2265.1980.tb02132.x	25	163	169	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	1997	350	9085					1131	1135		10.1016/S0140-6736(97)06062-5	http://dx.doi.org/10.1016/S0140-6736(97)06062-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343501				2022-12-28	WOS:A1997YB19900011
J	Feldman, RMR; Correll, CC; Kaplan, KB; Deshaies, RJ				Feldman, RMR; Correll, CC; Kaplan, KB; Deshaies, RJ			A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; ACTIVATING ENZYME; CRYSTAL-STRUCTURE; PROTEIN LIGASE; YEAST; DEGRADATION; PATHWAY	In S. cerevisiae, the G1/S transition requires Cdc4p, Cdc34p, Cdc53p, Skp1p, and the Cln/Cdc28p cyclin-dependent kinase (Cdk). These proteins are thought to promote the proteolytic inactivation of the S-phase Cdk inhibitor Sic1p. We show here that Cdc4p, Cdc53p, and Skp1p assemble into a ubiquitin ligase complex named SCFCdc4p. When mixed together, SCFCdc4p sub- units, E1 enzyme, the E2 enzyme Cdc34p, and ubiquitin are sufficient to reconstitute ubiquitination of Cdk-phosphorylated Sic1p. Phosphorylated Sic1p substrate is specifically targeted for ubiquitination by binding to a Cdc4p/Skp1p subcomplex. Taken together, these data illuminate the molecular basis for the G1/S transition in budding yeast and suggest a general mechanism for phosphorylation-targeted ubiquitination in eukaryotes.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	California Institute of Technology; Massachusetts Institute of Technology (MIT)			Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052466] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52466-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harlow E., 1988, ANTIBODIES LAB MANUA; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HULBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KIPREOS E, 1995, 10 INT C EL M SUMM, P83; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, METHOD ENZYMOL, V283, P366; VERMA R, 1997, IN PRESS SCIENCE; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	700	725	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	1997	91	2					221	230		10.1016/S0092-8674(00)80404-3	http://dx.doi.org/10.1016/S0092-8674(00)80404-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346239	Bronze			2022-12-28	WOS:A1997YC35000009
J	Neville, BGR				Neville, BGR			Fortnightly review - Epilepsy in childhood	BRITISH MEDICAL JOURNAL			English	Review							CONVULSIVE DISORDERS; MAGNETIC-RESONANCE; INFANTILE SPASMS; 1ST YEAR; CHILDREN; SEIZURES; LIFE		UCL, SCH MED, GREAT ORMOND ST HOSP CHILDREN NHS TRUST, LONDON WC1N 2AP, ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; UCL Medical School	Neville, BGR (corresponding author), UCL, SCH MED, NEUROSCI UNIT, WOLFSON CTR, INST CHILD HLTH, LONDON WC1N 2AP, ENGLAND.							AICARDI J, 1994, EPILEPSY CHILDREN; BEAUMANOIR A, 1993, EPILEPTIC SYNDROMES, P231; BEAUSSART M, 1972, EPILEPSIA, V13, P795, DOI 10.1111/j.1528-1157.1972.tb05164.x; CAVAZZUTI GB, 1984, DEV MED CHILD NEUROL, V26, P425; CHEVRIE JJ, 1978, EPILEPSIA, V19, P67; Chiron C, 1991, J CHILD NEUROL S2, P52; CHUGANI HT, 1990, ANN NEUROL, V27, P406, DOI 10.1002/ana.410270408; CROSS JH, 1995, DEV MED CHILD NEUROL, V37, P673; CROSS JH, 1993, ARCH DIS CHILD, V69, P104, DOI 10.1136/adc.69.1.104; deSilva M, 1996, LANCET, V347, P709, DOI 10.1016/S0140-6736(96)90074-4; DUCHOWNY M, 1995, CURR OPIN NEUROL, V8, P112, DOI 10.1097/00019052-199504000-00004; ELMSLIE F, 1996, EMERY RIMOINS PRINCI, P2177; Engel J., 1993, WHO SHOULD BE SURG C; FALCONER MA, 1968, ARCH NEUROL-CHICAGO, V19, P353, DOI 10.1001/archneur.1968.00480040019001; GADIAN DC, 1994, ACTA NEUROL SCAND, V89, P116, DOI 10.1111/j.1600-0404.1994.tb05202.x; Gastaut Henri, 1992, P201; Gomez MR, 1988, TUBEROUS SCLEROSIS; HRACHOVY RA, 1989, PEDIATR CLIN N AM, V36, P311; JACKSON GD, 1993, NEUROLOGY, V43, P1973; KROLL JS, 1985, DEV MED CHILD NEUROL, V27, P377; LIU Z, 1995, PEDIATR NEUROL, V12, P5, DOI 10.1016/0887-8994(94)00122-I; Maquet P, 1995, BRAIN, V118, P1497, DOI 10.1093/brain/118.6.1497; MELDRUM BS, 1974, BRAIN, V97, P407, DOI 10.1093/brain/97.1.407; Morrell F, 1995, BRAIN, V118, P1529, DOI 10.1093/brain/118.6.1529; NELSON KB, 1990, ANN NEUROL, V27, P127, DOI 10.1002/ana.410270206; NELSON KB, 1981, FEBRILE SEIZURES; Neville BGR, 1997, PEDIATR NEUROL, V16, P137, DOI 10.1016/S0887-8994(96)00297-4; NEVILLE BGR, 1995, J NEUROL NEUROSUR PS, V58, P371, DOI 10.1136/jnnp.58.3.371; Ounsted C, 1987, TEMPORAL LOBE EPILEP; Pellock JM, 1996, EPILEPSIA, V37, pS66, DOI 10.1111/j.1528-1157.1996.tb06024.x; Prasad AN, 1996, EPILEPSIA, V37, pS81, DOI 10.1111/j.1528-1157.1996.tb06026.x; PRYOR DS, 1981, ARCH DIS CHILD, V56, P753, DOI 10.1136/adc.56.10.753; Sadzot B, 1997, BMJ-BRIT MED J, V314, P391, DOI 10.1136/bmj.314.7078.391; STEPHENSON JBP, 1990, CLIN DEV MED, V9; TAYLOR DC, 1972, EPILEPSIA, V13, P727, DOI 10.1111/j.1528-1157.1972.tb05160.x; TAYLOR DC, 1996, EPILEPSIA S4, V37, P51; VERITY CM, 1993, BMJ-BRIT MED J, V307, P225, DOI 10.1136/bmj.307.6898.225	37	23	23	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					924	930						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361544				2022-12-28	WOS:A1997YB07300030
J	Kumar, A; Commane, M; Flickinger, TW; Horvath, CM; Stark, GR				Kumar, A; Commane, M; Flickinger, TW; Horvath, CM; Stark, GR			Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; INTERFERON-ALPHA; ACTIVATION; TRANSCRIPTION; INHIBITION; PATHWAY; GAMMA; GENE; PROTEINS	Signal transducers and activators of transcription (STATs) enhance transcription of specific genes in response to cytokines and growth factors. STAT1 is also required for efficient constitutive expression of the caspases Ice, Cpp32, and Ich-l in human fibroblasts. As a consequence, STAT1-null cells are resistant to apoptosis by tumor necrosis factor alpha (TNF-alpha). Reintroduction of STAT1 alpha restored both TNF-alpha-induced apoptosis and the expression of Ice, Cpp32, and Ich-1. Variant STAT1 proteins carrying point mutations that inactivate domains required for STAT dimer formation nevertheless restored protease expression and sensitivity to apoptosis, indicating that the functions of STAT1 required for these activities are different from those that mediate induced gene expression.	CLEVELAND CLIN FDN,LERNER RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195; ROCKEFELLER UNIV,MOL CELL BIOL LAB,NEW YORK,NY 10021	Cleveland Clinic Foundation; Rockefeller University				Horvath, Curt/0000-0003-2449-225X	NCI NIH HHS [P01 CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHATTERJEEKISHO.M, UNPUB; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FRAER A, 1996, CELL, V85, P781; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HOVANESIAN AG, 1993, SEMIN VIROL, V4, P23; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEUNG SY, UNPUB; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUBEN BY, 1988, CANCER RES, V48, P6006; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Wilson Z. E., UNPUB	27	430	438	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1630	1632		10.1126/science.278.5343.1630	http://dx.doi.org/10.1126/science.278.5343.1630			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374464				2022-12-28	WOS:A1997YJ87400043
J	Ranta, E; Kaitala, V; Lundberg, P				Ranta, E; Kaitala, V; Lundberg, P			The spatial dimension in population fluctuations	SCIENCE			English	Article							DYNAMICS; CYCLES; MODELS	Theoretical research into the dynamics of coupled populations has suggested a rich ensemble of spatial structures that are created and maintained either by external disturbances or self-reinforcing interactions among the populations, Long-term data of the Canadian lynx from eight Canadian provinces display large-scale spatial synchrony in population fluctuations. The synchronous dynamics are not time-invariant, however, as pairs of populations that are initially in step may drift out of phase and back into phase. These observations are in agreement with predictions of a spatially-linked population model and support contemporary population ecology theory.	UNIV JYVASKYLA,DEPT BIOL & ENVIRONM SCI,FIN-40351 JYVASKYLA,FINLAND; LUND UNIV,DEPT THEORET ECOL,S-22362 LUND,SWEDEN	University of Jyvaskyla; Lund University	Ranta, E (corresponding author), UNIV HELSINKI,INTEGRAT ECOL UNIT,DIV POPULAT BIOL,DEPT ECOL & SYSTEMAT,POB 17 ARKADIANKATU 7,FIN-00014 HELSINKI,FINLAND.		Lundberg, Per/A-2479-2010	Lundberg, Per/0000-0002-9609-726X				BASCOMPTE J, 1995, TRENDS ECOL EVOL, V10, P361, DOI 10.1016/S0169-5347(00)89134-X; Chatfield C., 2016, ANAL TIME SERIES INT; COMINS HN, 1992, J ANIM ECOL, V61, P735, DOI 10.2307/5627; Elton C, 1942, J ANIM ECOL, V11, P215, DOI 10.2307/1358; Elton C., 1927, ANIMAL ECOLOGY; FRYXELL JM, 1993, EVOL ECOL, V7, P379, DOI 10.1007/BF01237869; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; HASSELL MP, 1995, J ANIM ECOL, V64, P662, DOI 10.2307/5808; HENTTONEN H, 1987, OIKOS, V50, P353, DOI 10.2307/3565496; Kaitala V, 1996, J ANIM ECOL, V65, P249, DOI 10.2307/5728; Keith L.B., 1990, Current Mammalogy, V2, P119; Keith L.B., 1963, WILDLIFES 10 YEAR CY; Koenig WD, 1996, TRENDS ECOL EVOL, V11, P514, DOI 10.1016/S0169-5347(96)20074-6; Korpimaki E, 1996, BIOSCIENCE, V46, P754, DOI 10.2307/1312851; LINDSTROM J, 1997, OIKOS, V77, P565; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MAY RM, 1973, AM NAT, V107, P46, DOI 10.1086/282816; MORAN PAP, 1953, AUST J ZOOL, V1, P291, DOI 10.1071/ZO9530291; RANTA E, 1995, P ROY SOC B-BIOL SCI, V262, P113, DOI 10.1098/rspb.1995.0184; Ranta E, 1997, OIKOS, V78, P136, DOI 10.2307/3545809; Ranta E, 1997, AM NAT, V149, P765, DOI 10.1086/286019; Ranta E, 1997, ECOGRAPHY, V20, P454, DOI 10.1111/j.1600-0587.1997.tb00412.x; RANTA E, IN PRESS NATURE; Royama T., 1992, ANAL POPULATION ECOL; TURCHIN P, 1990, NATURE, V344, P660, DOI 10.1038/344660a0	25	150	157	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1621	1623		10.1126/science.278.5343.1621	http://dx.doi.org/10.1126/science.278.5343.1621			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374461				2022-12-28	WOS:A1997YJ87400040
J	Sijbesma, RP; Beijer, FH; Brunsveld, L; Folmer, BJB; Hirschberg, JHKK; Lange, RFM; Lowe, JKL; Meijer, EW				Sijbesma, RP; Beijer, FH; Brunsveld, L; Folmer, BJB; Hirschberg, JHKK; Lange, RFM; Lowe, JKL; Meijer, EW			Reversible polymers formed from self-complementary monomers using quadruple hydrogen bonding	SCIENCE			English	Article							ASSOCIATION CHAIN POLYMERS; COPOLYMERS	Units of 2-ureido-4-pyrimidone that dimerize strongly in a self-complementary array of four cooperative hydrogen bonds were used as the associating end group in reversible self-assembling polymer systems. The unidirectional design of the binding sites prevents uncontrolled multidirectional association or gelation. Linear polymers and reversible networks were formed from monomers with two and three binding sites, respectively. The thermal and environmental control over lifetime and bond strength makes many properties, such as viscosity, chain length, and composition, tunable in a way not accessible to traditional polymers. Hence, polymer networks with thermodynamically controlled architectures can be formed, for use in, for example, coatings and hot melts, where a reversible, strongly temperature-dependent rheology is highly advantageous.	EINDHOVEN UNIV TECHNOL,ORGAN CHEM LAB,NL-5600 MB EINDHOVEN,NETHERLANDS; DSM RES BV,NL-6160 MD GELEEN,NETHERLANDS	Eindhoven University of Technology; DSM NV			Meijer, E.W./K-7632-2013; Lewis, Christopher L/I-8254-2015; Sijbesma, Rintje Pieter P/D-3551-2012	Meijer, E.W./0000-0003-4126-7492; Sijbesma, Rintje Pieter P/0000-0002-8975-636X; Brunsveld, Luc/0000-0001-5675-511X				Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0; ALEXANDER C, 1994, MACROMOL SYMP, V77, P283, DOI 10.1002/masy.19940770130; BEIJER FH, UNPUB; BLADON P, 1993, MACROMOLECULES, V26, P6604, DOI 10.1021/ma00076a045; CATES ME, 1987, MACROMOLECULES, V20, P2289, DOI 10.1021/ma00175a038; DUCHARME Y, 1988, J ORG CHEM, V53, P5787, DOI 10.1021/jo00259a037; EISENBACH CD, 1995, MACROMOL CHEM PHYSIC, V196, P1077, DOI 10.1002/macp.1995.021960410; Flory PJ., 1953, PRINCIPLES POLYM CHE, V672; Fouquey C., 1990, ADV MATER, V2, P254; HILGER C, 1992, MACROMOLECULES, V25, P2498, DOI 10.1021/ma00035a031; KOTERA M, 1994, J CHEM SOC CHEM COMM, P197, DOI 10.1039/c39940000197; LEE CM, 1994, POLYMER, V35, P4550, DOI 10.1016/0032-3861(94)90801-X; LEHN JM, 1993, MAKROMOL CHEM-M SYMP, V69, P1, DOI 10.1002/masy.19930690103; LILLYA CP, 1992, MACROMOLECULES, V25, P2076, DOI 10.1021/ma00034a003; MOLLER M, 1987, ACS S SER, V350, pCH7; MURRAY TJ, 1992, J AM CHEM SOC, V114, P4010, DOI 10.1021/ja00036a079; STPOURCAIN CB, 1995, MACROMOLECULES, V28, P4116, DOI 10.1021/ma00116a010	17	1851	1923	30	835	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1601	1604		10.1126/science.278.5343.1601	http://dx.doi.org/10.1126/science.278.5343.1601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374454				2022-12-28	WOS:A1997YJ87400033
J	Iezzoni, LI				Iezzoni, LI			The risks of risk adjustment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IN-HOSPITAL MORTALITY; NEW-YORK-STATE; SEVERITY-MEASUREMENT METHODS; PROSPECTIVE PAYMENT SYSTEM; DIAGNOSIS-RELATED GROUPS; BYPASS GRAFT-SURGERY; DEATH RATES; MYOCARDIAL-INFARCTION; PERFORMANCE REPORTS; CLINICAL OUTCOMES	Context.-Risk adjustment is essential before comparing patient outcomes across hospitals. Hospital report cards around the country use different risk adjustment methods. Objectives.-To examine the history and current practices of risk adjusting hospital death rates and consider the implications for using risk-adjusted mortality comparisons to assess quality. Data Sources and Study Selection.-This article examines severity measures used in states and regions to produce comparisons of risk-adjusted hospital death rates. Detailed results are presented from a study comparing current commercial severity measures using a single database. It included adults admitted for acute myocardial infarction (n=11 880), coronary artery bypass graft surgery (n=7765), pneumonia (n=18 016), and stroke (n=9407). Logistic regressions within each condition predicted in-hospital death using severity scores. Odds ratios for in-hospital death were compared across pairs of severity measures. For each hospital, z scores compared actual and expected death rates. Results.-The severity measure called Disease Staging had the highest c statistic (which measures how well a severity measure discriminates between patients who lived and those who died) for acute myocardial infarction, 0.86; the measure called All Patient Refined Diagnosis Related Groups had the highest for coronary artery bypass graft surgery, 0.83; and the measure, MedisGroups, had the highest for pneumonia, 0.85 and stroke, 0.87. Different severity measures predicted different probabilities of death for many patients. Severity measures frequently disagreed about which hospitals had particularly low or high z scores. Agreement in identifying low-and high-mortality hospitals between severity-adjusted and unadjusted death rates was often better than agreement between severity measures. Conclusions.-Severity does not explain differences in death rates across hospitals. Different severity measures frequently produce different impressions about relative hospital performance. Severity-adjusted mortality rates alone are unlikely to isolate quality differences across hospitals.	HARVARD UNIV, SCH MED, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA USA; HARVARD UNIV, SCH MED, CHARLES A DANA RES INST, BOSTON, MA USA; HARVARD UNIV, SCH MED, HARVARD THORNDIKE LAB, BOSTON, MA USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Iezzoni, LI (corresponding author), BETH ISRAEL MED CTR, DEPT MED, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, E CAMPUS LY-326, BOSTON, MA 02215 USA.				AHRQ HHS [R01 HS06742] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALEMI F, 1990, MED CARE, V28, P762, DOI 10.1097/00005650-199009000-00006; BEST WR, 1994, MED CARE, V32, P390, DOI 10.1097/00005650-199404000-00007; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; BRINKLEY J, 1986, NY TIMES        0312, P1; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; DUBOIS RW, 1995, PROVIDING QUALITY CA; EDWARDS N, 1994, HEALTH CARE FINANC R, V16, P45; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; FARR W, 1864, MED TIMES GAZET 0213, P187; Fetter RB, 1980, MED CARE S, V18, P1; FREEMAN JL, 1995, MED CARE, V33, P806, DOI 10.1097/00005650-199508000-00006; GOLDFIELD N, 1996, PHYSICIAN PROFILING; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; GONNELLA JS, 1976, MED CARE, V14, P13, DOI 10.1097/00005650-197601000-00002; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; Hannan EL, 1997, HEALTH SERV RES, V31, P659; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARTZ AJ, 1993, HEALTH SERV RES, V27, P765; HORN SD, 1981, MED CARE, V19, P354, DOI 10.1097/00005650-198103000-00010; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Hughes JS, 1996, J GEN INTERN MED, V11, P303, DOI 10.1007/BF02598273; Iezzoni L I, 1992, QRB Qual Rev Bull, V18, P44; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; IEZZONI LI, 1992, MED CARE, V30, P347, DOI 10.1097/00005650-199204000-00005; Iezzoni LI, 1997, MED CARE, V35, P158, DOI 10.1097/00005650-199702000-00006; Iezzoni LI, 1996, MED DECIS MAKING, V16, P348, DOI 10.1177/0272989X9601600405; IEZZONI LI, 1993, MED CARE, V31, P277, DOI 10.1097/00005650-199303000-00009; Iezzoni LI, 1996, MED CARE, V34, P11, DOI 10.1097/00005650-199601000-00002; IEZZONI LI, 1995, INT J QUAL HEALTH C, V7, P81, DOI 10.1093/intqhc/7.2.81; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; IEZZONI LI, 1990, JAMA-J AM MED ASSOC, V264, P1426, DOI 10.1001/jama.264.11.1426; Iezzoni LI, 1996, ANN INTERN MED, V124, P1079, DOI 10.7326/0003-4819-124-12-199606150-00009; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; Iezzoni LI, 1996, J GEN INTERN MED, V11, P23, DOI 10.1007/BF02603481; IEZZONI LI, 1991, INQUIRY-J HEALTH CAR, V28, P117; IEZZONI LI, 1994, JOINT COMM J QUAL IM, V20, P305, DOI 10.1016/S1070-3241(16)30075-X; IEZZONI LI, IN PRESS MED CARE; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; IEZZONI LL, 1995, PROVIDING QUALITY CA, P59; IGLEHART JK, 1988, HEALTH AFFAIR, V7, P79, DOI 10.1377/hlthaff.7.1.79; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KHURI SF, 1995, J AM COLL SURGEONS, V180, P519; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Landon B, 1996, INQUIRY-J HEALTH CAR, V33, P155; MACKENZIE TA, 1991, PATIENT CLASSIFICATI, P1; MACKIERNAN YD, 1996, AM J PUBLIC HEALTH, V86, P1379; MARKSON LE, 1991, EVAL HEALTH PROF, V14, P201, DOI 10.1177/016327879101400205; MCMAHON LF, 1986, ANN INTERN MED, V104, P562, DOI 10.7326/0003-4819-104-4-562; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; Omoigui NA, 1996, CIRCULATION, V93, P27, DOI 10.1161/01.CIR.93.1.27; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; *PENNS HLTH CAR CO, 1996, FOC HEART ATT W PENN; Pennsylvania Health Care Cost Containment Council, 1995, CONS GUID COR ART BY, V4; Romano PS, 1995, JOINT COMM J QUAL IM, V21, P668, DOI 10.1016/S1070-3241(16)30195-X; ROSENTHAL GE, 1994, JOINT COMM J QUAL IM, V20, P425, DOI 10.1016/S1070-3241(16)30088-8; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; STEEN PM, 1994, ANN THORAC SURG, V58, P1836, DOI 10.1016/0003-4975(94)91723-X; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; SULLIVAN LW, 1991, MED HOSP MORTALITY I; THOMAS JW, 1989, INQUIRY-J HEALTH CAR, V26, P483; THOMAS JW, 1993, INQUIRY-J HEALTH CAR, V30, P6; THOMAS JW, 1991, INQUIRY-J HEALTH CAR, V28, P39; *US GEN ACC OFF, 1995, GAOHEHS95201; *US GEN ACC OFF, 1994, GAOHEHS951; *US GEN ACC OFF, 1994, GAOHEHS94219; VERNA G, 1996, CINCINNATI BUSINESS, V13, pC8; VLADECK BC, 1984, ANN INTERN MED, V100, P576, DOI 10.7326/0003-4819-100-4-576; Vogel RA, 1996, CLEV CLIN J MED, V63, P124; WILSON P, 1993, ANN REPORT CALIFORNI; WILSON P, 1996, 2 OFF STAT HLTH PLAN, V1; YOUNG WW, 1994, HEALTH SERV RES, V29, P367; YOUNG WW, 1982, MED CARE, V20, P501, DOI 10.1097/00005650-198205000-00006; 1995, STATE HLTH WATCH, V2, P10	92	371	374	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1600	1607		10.1001/jama.278.19.1600	http://dx.doi.org/10.1001/jama.278.19.1600			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YF407	9370507				2022-12-28	WOS:A1997YF40700042
J	Bennett, WG; Inoue, Y; Beck, JR; Wong, JB; Pauker, SG; Davis, GL				Bennett, WG; Inoue, Y; Beck, JR; Wong, JB; Pauker, SG; Davis, GL			Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; hepatitis C; interferon-alpha 2b; life expectancy; models, statistical	NON-B-HEPATITIS; CHRONIC ACTIVE HEPATITIS; CHRONIC NON-A; TERM FOLLOW-UP; PROGNOSTIC FACTORS; ALPHA-INTERFERON; CONTROLLED TRIAL; VIRUS-RNA; ALFA-2B; TRANSFUSION	Background: Chronic hepatitis C is a major cause of illness and death in the United States. Interferon-alpha 2b can induce clinical, biochemical, and virologic remission in some patients with chronic hepatitis C, but the long-term cost-effectiveness of this treatment, particularly in patients with histologically mild disease, is unknown. Objective: To estimate the cost-effectiveness of interferon-alpha 2b in mild chronic hepatitis C. Design: Meta-analysis of five prospective trials and cost-effectiveness analysis. Projection of the clinical and economic outcomes expected from loss of hepatitis C virus was done by using a Markov simulation. The potential effect of uncertainty in the model assumptions was tested by using sensitivity analyses. Data Sources: Search of the MEDLINE database, opinions of expert panels, hospital cost data, and adjusted physician charges. Patients: Hypothetical cohorts with histologically mild chronic hepatitis C. Intervention: The model assumed a single 6-month course of recombinant interferon-alpha 2b. Measurements: Life expectancy, quality-adjusted life expectancy, costs, and marginal cost-effectiveness ratios from a managed care perspective. Results: In 27% of patients with mild chronic hepatitis C treated with interferon-alpha 2b for 6 months, serum alanine aminotransferase levels permanently returned to normal and viral status remained negative. The model estimated that interferon-alpha 2b treatment in this population should increase life expectancy by 3.1 years if given at 20 years of age, by 1.5 years at 35 years of age, and by 22 days at 70 years of age; discounted marginal cost-effectiveness ratios are $500, $1900, and $62 000 per year of life gained, respectively. Varying the long-term response rates and progression rates for mild and moderate chronic hepatitis to near zero in sensitivity analyses substantially affected the results: Ratios ranged from $31 000 for a 20-year-old patient to $640 000 for a 70-year-old patient. Conclusions: On the basis of estimations in this mathematical model of the natural history of chronic hepatitis C, treating mild chronic hepatitis with interferon-alpha 2b should prolong life expectancy at a reasonable marginal cost per year of life gained, particularly in younger patients.	UNIV FLORIDA, COLL MED, GAINESVILLE, FL 32610 USA; YAMAGUCHI UNIV, SCH MED, UBE, YAMAGUCHI 755, JAPAN; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; BAYLOR COLL MED, INFORMAT TECHNOL PROGRAM, HOUSTON, TX 77030 USA	State University System of Florida; University of Florida; Yamaguchi University; Tufts University; Tufts Medical Center; Baylor College of Medicine				Wong, John/0000-0003-4203-9010				ALTER M, 1997, IN PRESS CLIN LIVER; [Anonymous], 1997, HEPATOLOGY, V26, pS2; ASCHER NL, 1994, HEPATOLOGY, V20, pS24; Boyer N., 1995, Hepatology, V22, p291A, DOI 10.1016/0270-9139(95)94887-2; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHRISTENSEN E, 1989, SCAND J GASTROENTERO, V24, P999, DOI 10.3109/00365528909089247; COLCHER MD, 1994, HEPATOLOGY, V20, P618; DAVIS GL, 1994, CLIN THER, V16, P334; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DAVIS GL, 1994, GASTROENTEROL CLIN N, V23, P603; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DETRE KM, 1996, VIRAL HEPATITIS REV, V2, P219; Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EISENSTAEDT RS, 1988, AM J PUBLIC HEALTH, V78, P450, DOI 10.2105/AJPH.78.4.450; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; Gold MR, 1996, COST EFFECTIVENESS H; GRAFFEO M, 1994, AM J GASTROENTEROL, V89, P1815; JOHANNESSON M, 1994, MED DECIS MAKING, V14, P236, DOI 10.1177/0272989X9401400305; JOUET P, 1994, GASTROENTEROLOGY, V106, P686, DOI 10.1016/0016-5085(94)90703-X; KILPE VE, 1993, TRANSPLANTATION, V56, P554, DOI 10.1097/00007890-199309000-00012; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lindsay KL, 1996, HEPATOLOGY, V24, P1034; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1002/hep.1840130302; MARCELLIN P, 1994, LIVER, V14, P302; MATTSSON L, 1989, THESIS KAROLINSKA I; METREAU JM, 1993, GUT, V34, pS112, DOI 10.1136/gut.34.2_Suppl.S112; MIHOLLAND AV, 1973, NEW ENGL J MED, V288, P1272; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; SALERNO F, 1993, AM J GASTROENTEROL, V88, P514; SARACCO G, 1990, J HEPATOL, V11, pS43, DOI 10.1016/0168-8278(90)90162-K; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHIELL A, 1994, MED J AUSTRALIA, V160, P268, DOI 10.5694/j.1326-5377.1994.tb125830.x; SHINDO M, 1995, ANN INTERN MED, V122, P586, DOI 10.7326/0003-4819-122-8-199504150-00005; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; SONNENBERG FA, 1986, MEDINFO 86, P1152; TINE F, 1991, J HEPATOL, V13, P192, DOI 10.1016/0168-8278(91)90814-R; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; *UNOS DIV ORG TRAN, 1995, UNOS UPDATE, V11, P15; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; WASSERMAN Y, 1995, PHYSICIANS FEE REFER; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WONG JB, 1995, ANN INTERN MED, V122, P664, DOI 10.7326/0003-4819-122-9-199505010-00004; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; YOUSUF M, 1992, SCAND J GASTROENTERO, V27, P812, DOI 10.3109/00365529209011189; 1995, ANTHONYS DRG GUIDEBO; 1995, RED BOOK; 1993, UNOS UPDATE, V9, P27	55	290	293	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					855	+		10.7326/0003-4819-127-10-199711150-00001	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382363				2022-12-28	WOS:A1997YF54500001
J	Connolly, SJ; Cairns, J; Gent, M; Roberts, R; Yusuf, S; Julian, DG; Camm, AJ; Frangin, G; Janse, MJ; Munoz, A; Schwartz, PJ; Simon, P; Rosenbaum, MB; Elizari, MV; Cagide, A; Girotti, LA; Martinez, JM; Carbajales, J; Scapin, O; Garguichevich, J; Hauad, S; Belziti, C; Sinisi, A; Ceremuzynski, L; Budaj, A; Kleczar, E; Nartowicz, E; SmielakKorombel, J; Dyduszynski, A; Maciejewicz, J; Kokowicz, P; NavarroLopez, F; Cosin, J; Marrugat, J; Guindo, J; deLuna, AB; Pfisterer, M; Osswald, S; Burckhardt, D; Burkart, F; Hockings, B; George, T; Mahrous, F; Taylor, R; Hajar, H; Singh, S; Fletcher, R; Fisher, S; Singh, B; Doval, H; Nul, D; Grancelli, H; Perrone, S; Bortman, G; Curiel, R; Ramos, J; Gambarte, A; Gentile, A; Sirena, J; Tibaldi, M; Toplikar, J; Nicklas, J; McKenna, W; Stewart, R; Mickelson, J; Das, S; Schork, A; Krickler, S; Quain, L; Morady, F; Pitt, B; Hamer, A; Arkles, L; Johns, J; Morrison, L; Roberts, J				Connolly, SJ; Cairns, J; Gent, M; Roberts, R; Yusuf, S; Julian, DG; Camm, AJ; Frangin, G; Janse, MJ; Munoz, A; Schwartz, PJ; Simon, P; Rosenbaum, MB; Elizari, MV; Cagide, A; Girotti, LA; Martinez, JM; Carbajales, J; Scapin, O; Garguichevich, J; Hauad, S; Belziti, C; Sinisi, A; Ceremuzynski, L; Budaj, A; Kleczar, E; Nartowicz, E; SmielakKorombel, J; Dyduszynski, A; Maciejewicz, J; Kokowicz, P; NavarroLopez, F; Cosin, J; Marrugat, J; Guindo, J; deLuna, AB; Pfisterer, M; Osswald, S; Burckhardt, D; Burkart, F; Hockings, B; George, T; Mahrous, F; Taylor, R; Hajar, H; Singh, S; Fletcher, R; Fisher, S; Singh, B; Doval, H; Nul, D; Grancelli, H; Perrone, S; Bortman, G; Curiel, R; Ramos, J; Gambarte, A; Gentile, A; Sirena, J; Tibaldi, M; Toplikar, J; Nicklas, J; McKenna, W; Stewart, R; Mickelson, J; Das, S; Schork, A; Krickler, S; Quain, L; Morady, F; Pitt, B; Hamer, A; Arkles, L; Johns, J; Morrison, L; Roberts, J			Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials	LANCET			English	Article							LOW-DOSE AMIODARONE; COMPLEX VENTRICULAR ARRHYTHMIAS; PLACEBO-CONTROLLED TRIAL; CLINICAL-TRIALS; DOUBLE-BLIND; THERAPY; METAANALYSIS; DYSFUNCTION; DRUG	Background There have been 13 randomised controlled trials of prophylactic amiodarone in patients with recent myocardial infarction (MI) or congestive heart failure (CHF). None of these was powered to detect a mortality reduction of about 20%. We undertook a meta-analysis, based on data from individual patients, to provide a more sensitive and accurate assessment of the benefits and risks of prophylactic amiodarone. Methods Individual data from the studies were abstracted according to a predefined protocol. The summary odds ratios were calculated according to standard methods. Findings There were eight post-MI and five CHF trials; nine trials were double-blind and placebo-controlled, and four compared amiodarone with usual care. 6553 patients were randomly assigned treatment, of which 78% were in post-MI trials and 22% in CHF trials. 89% had had previous MI. The mean left-ventricular ejection fraction was 31%, and median frequency of ventricular premature depolarisation 18 per h. Total mortality was reduced by 13% (odds ratio 0.87 [95% CI 0.78-0.99], p=0.030) based on classic fixed-effects meta-analysis and by 15% (0.85 [0.71-1.02], p=0.081) with the more conservative random-effects approach. Arrhythmic/sudden death was reduced by 29% (0.71 [0.59-0.85], p=0.0003). There was no effect on nonarrhythmic deaths (1.02 [0.87-1.19], p=0.84). There was no difference in treatment effect between post-Mi and CHF studies. The risk of arrhythmic/sudden death in control-group patients was higher in CHF than in post-MI studies (10.7 vs 4.1%), and the best single predictor of risk of arrhythmic/sudden death among all patients was symptomatic CHF. The excess (amiodarone minus control) risk of pulmonary toxicity was 1% per year. Interpretation Prophylactic amiodarone reduces the rate of arrhythmic/sudden death in high-risk patients with recent MI or CHF and this effect results in an overall reduction of 13% in total mortality.	ATMA COORDINATING & METHODS CTR, HAMILTON, ON, CANADA				Osswald, Stefan/A-6904-2018; McKenna, William J/C-3243-2008; Cairns, John/AAI-8744-2021; Schwartz, Peter J/J-4267-2016	Osswald, Stefan/0000-0002-9240-6731; McKenna, William J/0000-0001-7994-2460; Schwartz, Peter J/0000-0003-0367-1048				[Anonymous], 1989, NEW ENGL J MED, V321, P406; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; COLDITZ GA, 1995, AM J EPIDEMIOL, V142, P371, DOI 10.1093/oxfordjournals.aje.a117644; DELORIER J, 1997, NEW ENGL J MED, V337, P536; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1, P12; ELIZARI M, 1996, CIRCULATION S1, V94, P90; GARGUICHEVICH JJ, 1995, AM HEART J, V130, P494, DOI 10.1016/0002-8703(95)90357-7; Gottlieb SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HOCKINGS BEF, 1987, AM J CARDIOL, V60, P967, DOI 10.1016/0002-9149(87)90334-1; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; LeFeuvre CA, 1996, AM J CARDIOL, V78, P1345, DOI 10.1016/S0002-9149(96)00652-2; MANTEL N, 1959, J NATL CANCER I, V22, P719; NAVARROLOPEZ F, 1993, AM J CARDIOL, V72, P1243, DOI 10.1016/0002-9149(93)90291-J; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; PODRID PJ, 1995, ANN INTERN MED, V122, P689, DOI 10.7326/0003-4819-122-9-199505010-00008; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105	27	446	462	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	1997	350	9089					1417	1424						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371164				2022-12-28	WOS:A1997YF95300007
J	Toh, BH; vanDriel, IR; Gleeson, PA				Toh, BH; vanDriel, IR; Gleeson, PA			Mechanisms of disease: Pernicious anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GASTRIC PARIETAL-CELLS; AUTOIMMUNE GASTRITIS; H+,K+-ADENOSINE TRIPHOSPHATASE; INTRINSIC-FACTOR; BETA-SUBUNIT; PROTON PUMP; NEONATAL THYMECTOMY; ATROPHIC GASTRITIS; MOLECULAR TARGETS; ALPHA-SUBUNIT				Toh, BH (corresponding author), MONASH UNIV,SCH MED,DEPT PATHOL & IMMUNOL,PRAHRAN,VIC 3181,AUSTRALIA.			van Driel, Ian/0000-0001-5371-120X; Gleeson, Paul/0000-0002-5336-6503				AHMED SA, 1981, EXPERIENTIA, V37, P1341; Alderuccio F, 1997, AUTOIMMUNITY, V25, P167, DOI 10.3109/08916939709008023; ALDERUCCIO F, 1993, J EXP MED, V178, P419, DOI 10.1084/jem.178.2.419; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; BARDHAN KD, 1968, LANCET, V1, P62; Barrett SP, 1996, EUR J IMMUNOL, V26, P1652, DOI 10.1002/eji.1830260737; BARRETT SP, 1995, EUR J IMMUNOL, V25, P2686, DOI 10.1002/eji.1830250943; BARRETT SP, 1995, EUR J IMMUNOL, V25, P238, DOI 10.1002/eji.1830250139; BAUR S, 1968, LANCET, V2, P887; BONOMO A, 1995, IMMUNOL TODAY, V16, P61, DOI 10.1016/0167-5699(95)80089-1; BURMAN P, 1989, GASTROENTEROLOGY, V96, P1434, DOI 10.1016/0016-5085(89)90509-X; CALLAGHAN JM, 1993, AUTOIMMUNITY, V16, P289, DOI 10.3109/08916939309014648; CALLAGHAN JM, 1990, J CELL SCI, V95, P563; Carmel R, 1996, ARCH INTERN MED, V156, P1097, DOI 10.1001/archinte.156.10.1097; CARMEL R, 1978, NEW ENGL J MED, V298, P647, DOI 10.1056/NEJM197803232981203; CASTLE WB, 1953, NEW ENGL J MED, V249, P603, DOI 10.1056/NEJM195310082491505; CHANARIN I, 1979, MEGALOBLASTIC ANAEMI, P457; COWLING DC, 1974, MED J AUSTRALIA, V1, P15, DOI 10.5694/j.1326-5377.1974.tb93091.x; de Aizpurua H J, 1983, Clin Exp Immunol, V52, P341; DEAIZPURUA HJ, 1985, NEW ENGL J MED, V313, P479, DOI 10.1056/NEJM198508223130805; DEAIZPURUA HJ, 1983, NEW ENGL J MED, V309, P625, DOI 10.1056/NEJM198309153091102; DELVA PL, 1965, CAN MED ASSOC J, V92, P1129; FONG TL, 1991, GASTROENTEROLOGY, V100, P328, DOI 10.1016/0016-5085(91)90199-U; GLEESON PA, 1991, IMMUNOL TODAY, V12, P233, DOI 10.1016/0167-5699(91)90036-S; Gleeson PA, 1996, IMMUNOL REV, V149, P97, DOI 10.1111/j.1600-065X.1996.tb00901.x; GOLDKORN I, 1989, J BIOL CHEM, V264, P18768; Herbert V., 1996, PRESENT KNOWLEDGE NU, V7th ed, pp. 191; HOEDEMAEKER PJ, 1970, LAB INVEST, V22, P184; HSING AW, 1993, CANCER, V71, P745, DOI 10.1002/1097-0142(19930201)71:3<745::AID-CNCR2820710316>3.0.CO;2-1; IRVINE WJ, 1965, NEW ENGL J MED, V273, P432, DOI 10.1056/NEJM196508192730807; Irvine WJ, 1962, BMJ-BRIT MED J, V2, P454; JONES CM, 1991, GASTROENTEROLOGY, V101, P287, DOI 10.1016/0016-5085(91)90002-3; JONES CM, 1992, GASTROENTEROLOGY, V102, P1829; JORGE AD, 1973, GUT, V14, P104, DOI 10.1136/gut.14.2.104; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KATZ M, 1972, NEW ENGL J MED, V287, P425, DOI 10.1056/NEJM197208312870902; KAYE MD, 1983, CLIN IMMUNOL IMMUNOP, V28, P431, DOI 10.1016/0090-1229(83)90110-1; KOJIMA A, 1981, IMMUNOGENETICS, V14, P15, DOI 10.1007/BF00344296; Martinelli TM, 1996, GASTROENTEROLOGY, V110, P1791, DOI 10.1053/gast.1996.v110.pm8964405; MASALA C, 1980, CLIN EXP IMMUNOL, V41, P271; MCINTYRE OR, 1965, NEW ENGL J MED, V272, P981, DOI 10.1056/NEJM196505132721901; MULLER HK, 1971, J CLIN PATHOL, V24, P13, DOI 10.1136/jcp.24.1.13; NISHIO A, 1994, GASTROENTEROLOGY, V107, P1408, DOI 10.1016/0016-5085(94)90543-6; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Pettitt JM, 1996, TRENDS CELL BIOL, V6, P49, DOI 10.1016/0962-8924(96)81010-5; SAKAGUCHI S, 1989, J IMMUNOL, V142, P471; Scarff KJ, 1997, IMMUNOLOGY, V92, P91, DOI 10.1046/j.1365-2567.1997.00302.x; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; SJOBLOM SM, 1993, GUT, V34, P28, DOI 10.1136/gut.34.1.28; SMITH H, 1992, J IMMUNOL, V149, P2212; STRICKLAND RG, 1973, AM J DIG DIS, V18, P426, DOI 10.1007/BF01071995; STRICKLAND RG, 1972, PATHOLOGY, V4, P259, DOI 10.3109/00313027209068951; SuriPayer E, 1996, J IMMUNOL, V157, P1799; Taguchi O, 1996, EUR J IMMUNOL, V26, P1608, DOI 10.1002/eji.1830260730; TANAKA N, 1970, GASTROENTEROLOGY, V58, P482; TAYLOR KB, 1959, LANCET, V2, P106; TAYLOR KB, 1962, BRIT MED J, V2, P1347; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; WALL A. J., 1968, CLIN EXP IMMUNOL, V3, P359; WATERS HM, 1993, J CLIN PATHOL, V46, P45, DOI 10.1136/jcp.46.1.45; Whittingham S, 1985, AUTOIMMUN DIS, P243; Whittingham S., 1991, IMMUNOGENETICS AUTOI, P215	62	378	391	0	36	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1441	1448		10.1056/NEJM199711133372007	http://dx.doi.org/10.1056/NEJM199711133372007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF253	9358143				2022-12-28	WOS:A1997YF25300007
J	Chen, ZM; Xu, Z; Collins, R; Li, WX; Peto, R				Chen, ZM; Xu, Z; Collins, R; Li, WX; Peto, R			Early health effects of the emerging tobacco epidemic in China - A 16-year prospective study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MALE BRITISH DOCTORS; REPUBLIC-OF-CHINA; HEPATITIS-B VIRUS; CIGARETTE-SMOKING; RISK-FACTORS; HEPATOCELLULAR-CARCINOMA; LUNG-CANCER; ESOPHAGEAL CANCER; UNITED-STATES	Context.-In recent decades, there has been a rapid and substantial increase in tobacco consumption in China, particularly by men, but little is known from local epidemiologic studies about the pattern of smoking-related deaths. Objective.-To assess the current health effects of cigarette smoking in Shanghai, China. Design.-Prospective observational study of mortality in relation to cigarette smoking. Setting.-Eleven factories in urban Shanghai. Subjects.-A total of 9351 adults (6494 men and 2857 women) aged 35 to 64 years at baseline survey during the 1970s. Outcome Measures.-All-cause and cause-specific mortality. Results.-During an average follow-up of 16 years, 881 men and 207 women died. Among men, 61% had described themselves as current cigarette smokers at baseline, and their overall mortality was significantly greater than that of nonsmokers (relative risk [RR], 1.4, 95% confidence interval [CI], 1.2-1.7; P<.001). The excess was almost twice as great (RR, 1.8, 95% CI, 1.5-22; P<.001) among the men who had begun smoking before the age of 25 years and was significantly associated with the number of cigarettes smoked (P<.001 for trend) after adjustment for other major risk factors. The chief sources of the excess were lung cancer (RR, 3.8; 95% CI, 2.1-6.8; P<.001), esophageal cancer (RR, 3.6; 95% CI, 1.2-10.5; P=.02), liver cancer (RR, 2.0; 95% CI, 1.1-3.7; P=.03), coronary heart disease (RR, 1.8, 95% CI, 1.0-3.2; P=.04), and chronic obstructive pulmonary disease (RR, 2.5; 95% CI, 1.4-4.4; P<.01). Among the men in this Chinese population, about 20% (95% CI, 12%-29%) of all deaths during the study period could be attributed to cigarette smoking. Of these deaths, one third involved lung cancer, one third involved other cancers, and one third involved other diseases. Only 7% of women described themselves as current cigarette smokers at baseline, but among them there was also a statistically significant excess of overall mortality (RR, 1.7, 95% CI, 1.2-2.5; P<.01), Conclusions.-Cigarette smoking is already a major cause of death in China, and among middle-aged Shanghai men, about 20% of all deaths during the 1980s were due to smoking. The excess was greatest among men who began smoking before the age of 25 years, about 47% of whom would, at 1987 mortality rates, die between the ages of 35 and 69 years (compared with only 29% of nonsmokers). These estimates reflect the consequences of past smoking patterns. The future health effects of current smoking patterns are likely to be greater because of the recent large increase in cigarette consumption, particularly at younger ages, in China.	UNIV OXFORD,CLIN TRIAL SERV UNIT,OXFORD,ENGLAND; UNIV OXFORD,EPIDEMIOL STUDIES UNIT,OXFORD,ENGLAND; SHANGHAI MED UNIV,DEPT EPIDEMIOL,SHANGHAI 200032,PEOPLES R CHINA	University of Oxford; University of Oxford; Fudan University								ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; CARSTENSEN JM, 1987, J EPIDEMIOL COMMUN H, V41, P166, DOI 10.1136/jech.41.2.166; CHEN DY, 1987, CHIN MED J, V7, P382; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CHENG KK, 1992, LANCET, V339, P1314, DOI 10.1016/0140-6736(92)91960-G; *COLL GROUP INV PR, 1987, CHIN MED J, V67, P229; COX DR, 1972, J R STAT SOC B, V34, P187; DENG J, 1985, CHIN J PREV MED, V5, P271; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; GAO YT, 1988, INT J EPIDEMIOL, V17, P277, DOI 10.1093/ije/17.2.277; GAO YT, 1994, INT J CANCER, V58, P192, DOI 10.1002/ijc.2910580208; GONG YL, 1995, JAMA-J AM MED ASSOC, V274, P1232, DOI 10.1001/jama.274.15.1232; HAHEIM LL, 1993, STROKE, V24, P1484, DOI 10.1161/01.STR.24.10.1484; HAMMOND E C, 1958, J Am Med Assoc, V166, P1159; HU JF, 1994, INT J CANCER, V57, P38, DOI 10.1002/ijc.2910570108; KULLER LH, 1989, AM REV RESPIR DIS, V140, pS76, DOI 10.1164/ajrccm/140.3_Pt_2.S76; KULLER LH, 1991, PREV MED, V20, P638, DOI 10.1016/0091-7435(91)90060-H; LAM KC, 1982, CANCER RES, V42, P5246; Lan Qing, 1993, Biomedical and Environmental Sciences, V6, P112; LAVECCHIA C, 1988, INT J CANCER, V42, P872, DOI 10.1002/ijc.2910420614; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; LI SC, 1985, NEUROLOGY, V35, P1708, DOI 10.1212/WNL.35.12.1708; LI WX, 1979, ACTA ACAD MED PRIMAE, V6, P65; LIU BQ, IN PRESS BMJ; LIU ZY, 1992, INT J EPIDEMIOL, V21, P197, DOI 10.1093/ije/21.2.197; LU SN, 1988, CANCER-AM CANCER SOC, V62, P2051, DOI 10.1002/1097-0142(19881101)62:9<2051::AID-CNCR2820620930>3.0.CO;2-1; MENOTTI A, 1990, PREV MED, V19, P270, DOI 10.1016/0091-7435(90)90027-H; Muir C S, 1992, Eur J Cancer Prev, V1, P259, DOI 10.1097/00008469-199204000-00007; MUMFORD JL, 1987, SCIENCE, V235, P217, DOI 10.1126/science.3798109; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; PETO R, 1986, LANCET, V2, P1038; PETO R, 1987, LANCET, V2, P211; PETO R, 1994, MORTALITY TOBACCO DE; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; *SHANGH COLL GROUP, 1981, CHIN J PREV MED, V15, P75; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Surgeon General, 1989, RED HLTH CONS SMOK 2; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; WANG YP, 1992, CANCER CAUSE CONTROL, V3, P107, DOI 10.1007/BF00051650; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; WOO J, 1991, STROKE, V22, P203, DOI 10.1161/01.STR.22.2.203; XU ZY, 1989, J NATL CANCER I, V81, P1800, DOI 10.1093/jnci/81.23.1800; YAO LC, 1984, CHIN J EPIDEMIOL, V5, P88; YU JJ, 1990, JAMA-J AM MED ASSOC, V264, P1575, DOI 10.1001/jama.264.12.1575; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; YU MC, 1987, CANCER RES, V47, P654; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646; ZARIDZE D, 1986, IARC SCI PUBLICATION, V74	56	124	131	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1500	1504		10.1001/jama.278.18.1500	http://dx.doi.org/10.1001/jama.278.18.1500			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363969				2022-12-28	WOS:A1997YE44500033
J	Heyning, JE; Mead, JG				Heyning, JE; Mead, JG			Thermoregulation in the mouths of feeding gray whales	SCIENCE			English	Article							RETE	Vascular structures for heat conservation in the tongue of the gray whale (Eschrichtius robustus) are reported here. Numerous individual countercurrent heat exchangers are found throughout the massive tongue, These converge at the base of the tongue to form a bilateral pair of retia. Temperature measurements from the oral cavity of a live gray whale indicate that more heat may be lost through the blubber layer over the body than through the tongue, despite the fact that the tongue is far more vascularized and has much less insulation, These heal exchangers substantially reduce heat loss when these whales feed in cold waters.	NATL MUSEUM NAT HIST,DIV MAMMALS,WASHINGTON,DC 20560	Smithsonian Institution; Smithsonian National Museum of Natural History	Heyning, JE (corresponding author), NAT HIST MUSEUM LOS ANGELES,SECT VERTEBRATES,900 EXPOSIT BLVD,LOS ANGELES,CA 90007, USA.							BRODIE P, 1985, CAN J ZOOL, V63, P2267, DOI 10.1139/z85-336; CARTE A, 1869, PHILOS T R SOC LONDO, V158, P201; Elsner R., 1974, FUNCTIONAL ANATOMY M, P143; FORD TJ, 1992, NATURE, V359, P680, DOI 10.1038/359680a0; HEYNING JE, 1993, NATURE, V361, P24, DOI 10.1038/361024b0; HOKKANEN JEI, 1990, J THEOR BIOL, V145, P465, DOI 10.1016/S0022-5193(05)80482-5; IRVING L, 1955, J APPL PHYSIOL, V7, P355, DOI 10.1152/jappl.1955.7.4.355; PFEIFFER CJ, 1990, ACTA ANAT, V139, P141; ROMMEL SA, 1992, ANAT RECORD, V232, P150, DOI 10.1002/ar.1092320117; ROMMEL SA, 1993, ANAT REC, V237, P537; RYG M, 1993, J ZOOL, V230, P193, DOI 10.1111/j.1469-7998.1993.tb02682.x; Schmidt-Nielsen K, 1997, ANIMAL PHYSL ADAPTAT; SCHOLANDER P. F., 1958, HVALRADETS SKRIFTER SCI RESULTS MARINE BIOL RES, V44, P1; SCHOLANDER PF, 1955, J APPL PHYSIOL, V8, P279, DOI 10.1152/jappl.1955.8.3.279; SLIJPER EJ, 1936, CAPITA ZOOLOGICA, V617, P1; van Utrecht WL, 1958, ZOOL ANZ, V161, P77	16	21	21	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1138	1139		10.1126/science.278.5340.1138	http://dx.doi.org/10.1126/science.278.5340.1138			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353198				2022-12-28	WOS:A1997YE65200057
J	Hong, WK; Sporn, MB				Hong, WK; Sporn, MB			Recent advances in chemoprevention of cancer	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; 2ND PRIMARY TUMORS; CARDIOVASCULAR-DISEASE; MAMMARY-CARCINOMA; RETINOIC ACID; BETA-CAROTENE; LUNG-CANCER; VITAMIN-A; PREVENTION; RAT	Chemoprevention is the use of pharmacologic or natural agents that inhibit the development of invasive cancer either by blocking the DNA damage that initiates carcinogenesis or by arresting or reversing the progression of premalignant cells in which such damage has already occurred. Recent advances in our understanding of the mechanisms of carcinogenesis have led to the synthesis of new drugs that can inhibit tumor development in experimental animals by selective action on specific molecular targets, such as the estrogen, androgen, and retinoid receptors or inducible cyclooxygenase. Several of these agents (including tamoxifen, 13-cis-retinoic acid, retinyl palmitate, and an acyclic retinoid) are clinically effective in preventing the development of cancer, particularly in patients who are at high risk for developing second primary tumors after surgical removal of the initial tumor.	DARTMOUTH COLL,SCH MED,DEPT PHARMACOL,HANOVER,NH 03755; DARTMOUTH COLL,SCH MED,NORRIS COTTON CANC CTR,HANOVER,NH 03755	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Hong, WK (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC HEAD & NECK MED ONCOL,1515 HOLCOMBE BLVD,BOX 80,HOUSTON,TX 77030, USA.							*ALPH TOC BET CAR, 1994, OMEN, V330, P1029; Anzano MA, 1996, J NATL CANCER I, V88, P123, DOI 10.1093/jnci/88.2.123; Aquilina JW, 1997, JNCI-J NATL CANCER I, V89, P689, DOI 10.1093/jnci/89.10.689; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; Boolbol SK, 1996, CANCER RES, V56, P2556; CLARK WH, 1995, ACTA ONCOL, V34, P3, DOI 10.3109/02841869509093632; Cunha GR, 1996, ACTA ANAT, V155, P63; DELMAS PD, 1997, 79 ANN M END SOC MIN; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Gottardis MM, 1996, CANCER RES, V56, P5566; GOTTARDIS MM, 1987, CANCER RES, V47, P4020; GOUVEIA J, 1983, LANCET, V1, P710; GREENWALD P, 1995, CA-CANCER J CLIN, V45, P31, DOI 10.3322/canjclin.45.1.31; GREENWALD P, 1996, SCI AM, V275, P64; Gudas Lorraine J., 1994, P443; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; Jordan VC, 1997, JNCI-J NATL CANCER I, V89, P747, DOI 10.1093/jnci/89.11.747; JORDAN VC, 1994, LONG TERM TAMOXIFEN, P257; Katzenellenbogen BS, 1997, ENDOCRINOLOGY, V138, P861, DOI 10.1210/en.138.3.861; KELLOFF GJ, 1994, CANCER RES, V54, pS2015; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOSARY CL, 1995, NIH PUBL; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LEE JS, 1994, J CLIN ONCOL, V12, P937, DOI 10.1200/JCO.1994.12.5.937; LIPPMAN SM, 1994, J CLIN ONCOL, V12, P851, DOI 10.1200/JCO.1994.12.4.851; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LUCIA MS, 1995, CANCER RES, V55, P5621; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAO L, 1997, J NATL CANCER I, V89, P887; MEYSKENS FL, 1994, J NATL CANCER I, V86, P539, DOI 10.1093/jnci/86.7.539; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PAPADIMITRAKOPO.V, 1997, 33 ANN M AM SOC CLIN; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; POLLARD M, 1991, CANCER RES, V51, P3610; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; SHIN DM, 1957, 33 ANN M AM SOC CLIN; SPORN M, 1997, 88 ANN M AM ASS CANC; SPORN MB, 1991, CANCER RES, V51, P6215; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WATTENBERG LW, 1993, CANCER RES, V53, P5890; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	52	749	765	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1073	1077		10.1126/science.278.5340.1073	http://dx.doi.org/10.1126/science.278.5340.1073			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353183				2022-12-28	WOS:A1997YE65200035
J	English, RM; Badcock, JC; Giay, T; Ngu, T; Waters, AM; Bennett, SA				English, RM; Badcock, JC; Giay, T; Ngu, T; Waters, AM; Bennett, SA			Effect of nutrition improvement project on morbidity from infectious diseases in preschool children in Vietnam: comparison with control commune	BRITISH MEDICAL JOURNAL			English	Article								Objective: To evaluate the effect of a nutrition improvement project based on home garden production and nutrition education on morbidity from acute respiratory infection and diarrhoeal disease in preschool children. Design: The morbidity survey comprised five data collections undertaken by trained interviewers to ascertain the incidence and severity of respiratory infections and the incidence of diarrhoeal disease in children in two communes, Setting: A project commune and a control commune in Vietnam. Subjects: Preschool children to 6 years of age living in the project commune Khai Xuan (average 469 children) and the control commune Ching Gong (average 251 children). Main outcome measures: Differences between the two communes over time in the incidence and severity of respiratory infections and the incidence of diarrhoeal disease. Results: In Khai Xuan there was a significant reduction (P < 0.0001) in the incidence of respiratory infections (from 49.5% to 11.2%) and diarrhoeal infections (18.3% to 5.1%); the incidence of pneumonia and severe pneumonia was also significantly reduced (P < 0.0001). In Ching Gong there was no significant change in the incidence and severity of respiratory disease nor in the incidence of diarrhoeal disease. Conclusions: These findings emphasise the successful health outcome of a nutrition project based on household food production and nutrition education and the value of evaluating nutrition projects by reference to measurable health outcomes.	UNICEF,SUVA,FIJI; NATL INST NUTR,HANOI,VIETNAM; AUSTRALIAN INST HLTH & WELF,BRUCE,ACT 2617,AUSTRALIA		English, RM (corresponding author), UNIV QUEENSLAND,DEPT SOCIAL & PREVENT MED,SCH MED,HERSTON,QLD 4006,AUSTRALIA.							Beaton G., 1993, 13 ACCSCN; BEATON GH, 1982, AM J CLIN NUTR, V35, P864, DOI 10.1093/ajcn/35.4.864; *FAO, 1990, GCPVIE013AUL FAO; Ghassemi H, 1992, Asia Pac J Clin Nutr, V1, P195; Gillespie S., 1991, 10 ACCSCN; *MIN HLTH, 1993, HLTH STAT VIETN 1990; RIVERA J, 1993, NUTR ISSUES FOOD AID, P55; *SOC REP VIETN, 1995, NAT PLAN ACT NUTR 19; TILDEN R, 1993, IMPACT FAO VITAMIN A; TOMKINS A, 1989, MALNUTRITION INFEC 5; *WHO, 1986, CDDSER862 WHO	11	44	45	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1122	1125						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374884	Green Published			2022-12-28	WOS:A1997YE61500021
J	Nyangulu, DS; Harries, AD; Kangombe, C; Yadidi, AE; Chokani, K; Cullinan, T; Maher, D; Nunn, P; Salaniponi, FM				Nyangulu, DS; Harries, AD; Kangombe, C; Yadidi, AE; Chokani, K; Cullinan, T; Maher, D; Nunn, P; Salaniponi, FM			Tuberculosis in a prison population in Malawi	LANCET			English	Article							NEW-YORK-CITY; ASSOCIATION; INFECTION; SYSTEM	Background Much concern has been expressed about the high prevalence of tuberculosis in prisons in industrialised countries, Since there is almost no information from developing countries, we investigated the rate of pulmonary tuberculosis in a large prison in Malawi. Methods Between May and July, 1996, we carried out an active case-finding survey in Zomba Central Prison, Malawi, through the National Tuberculosis Control Programme. We interviewed prisoners, and those with a cough of at least 1 week's duration were screened by sputum-smear microscopy. If microscopy was negative, prisoners underwent chest radiography. We offered HIV testing, with voluntary consent and counselling before and after tests, to all prisoners, whether positive or negative for pulmonary tuberculosis. Findings 914 (70%) of 1315 prisoners were screened (905 men, nine women; mean age 30 years [SD 11]), 47 (5%) screened prisoners (all men) had pulmonary tuberculosis: 14 were taking antituberculosis treatment and 33 were undiagnosed at the start of the study; 18 were sputum-smear positive and 15 were sputum-smear negative. 16 (73%) of 22 prisoners with previously undiagnosed pulmonary tuberculosis and 30 (75%) of 40 prisoners with cough but no evidence of pulmonary tuberculosis were HIV seropositive, In all prisoners, except one, symptoms of pulmonary tuberculosis had developed after they had entered prison. Interpretation We found a high rate of pulmonary tuberculosis in Zomba Central Prison, which suggests active transmission of tuberculosis. As a result of this study, the National Tuberculosis Control Programme has implemented interventions in eight prisons in Malawi to improve tuberculosis control, including collection of health data, education of prisoners and clinical staff about tuberculosis, active screening of prisoners for pulmonary tuberculosis by sputum-smear microscopy, and active case-finding in the prisons.	MINIST HLTH,NATL TB CONTROL PROGRAMME,LILONGWE,MALAWI; UNIV MALAWI,COLL MED,LILONGWE,MALAWI; ZOMBA CENT PRISON,ZOMBA,MALAWI; WHO,GLOBAL TB PROGRAMME,CH-1211 GENEVA,SWITZERLAND	University of Malawi; World Health Organization				Maher, Dermot/0000-0003-0466-1976				ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; *CDCP, 1989, MMWR-MORBID MORTAL W, V38, P313; CHAVES F, 1993, MED CLIN-BARCELONA, V101, P525; DROBNIEWSKI F, 1995, LANCET, V346, P948, DOI 10.1016/S0140-6736(95)91562-1; Harries A. D., 1994, P241; Harries AD, 1997, T ROY SOC TROP MED H, V91, P416, DOI 10.1016/S0035-9203(97)90262-5; MARTIN V, 1994, TUBERCLE LUNG DIS, V74, P49; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151	11	68	72	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1284	1287		10.1016/S0140-6736(97)05023-X	http://dx.doi.org/10.1016/S0140-6736(97)05023-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357408				2022-12-28	WOS:A1997YD68900010
J	Regidor, E; Navarro, P; Dominguez, V; Rodriguez, C				Regidor, E; Navarro, P; Dominguez, V; Rodriguez, C			Inequalities in income and long term disability in Spain: analysis of recent hypotheses using cross sectional study based on individual data	BRITISH MEDICAL JOURNAL			English	Article							INDUSTRIALIZED COUNTRIES; LIFE EXPECTANCY; UNITED-STATES; SOCIAL-CLASS; MORTALITY; HEALTH; BRITAIN; FINLAND; SWEDEN	Objective: To compare the relation between inequalities in long term disability and income in the 17 regions of Spain. Design: Data were taken from the survey on impairments, disabilities, and handicaps that was carried out in Spain in 1986. For each region the inequality in long term disability associated with income was calculated as the odds ratio associated with reducing monthly household income by 10 000 pesetas (about pound 50) (estimate of effect of inequality of income) and the odds ratio for the inequality in long term disability between those at the bottom and those at die top of the income hierarchy (relative index of inequality). Main outcome measure: Prevalence of long term disability. Results: Five of the eight regions where lowering income had a greater effect on long term disability were among those with the lowest income per head, while six of the remaining nine regions where the effect was smaller were among those with the highest income per head. Three regions with the highest estimate of relative index of inequality had the highest estimate of effect, and another three regions with the lowest estimate of relative index of inequality had the lowest estimate of effect. In contrast the relative position of the remaining 11 regions varied from one measure to another. Conclusions: These results support the theory that additional increments in material wellbeing have a negligible effect on health in countries with high socioeconomic development. However, inequality in income distribution did not determine inequality in health between those at the bottom and those at the top of the income hierarchy in many Spanish regions.	MINIST HLTH,DEPT EPIDEMIOL,MADRID 28071,SPAIN		Regidor, E (corresponding author), UNIV COMPLUTENSE MADRID,FAC MED,DEPT PREVENT MED & PUBL HLTH,CIUDAD UNIV,E-28040 MADRID,SPAIN.			Regidor, Enrique/0000-0002-2374-9861				ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; AIACH P, 1990, SOC SCI MED, V31, P267, DOI 10.1016/0277-9536(90)90273-U; Duncan GJ, 1996, INT J HEALTH SERV, V26, P419, DOI 10.2190/1KU0-4Y3K-ACFL-BYU7; EDWARDS WS, 1994, VITAL HLTH STATIST 2, V120; FEINSTEIN JS, 1993, MILBANK Q, V71, P279, DOI 10.2307/3350401; Gomez Rodriguez P, 1989, World Health Stat Q, V42, P161; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; HELIOVAARA M, 1993, J CLIN EPIDEMIOL, V46, P181, DOI 10.1016/0895-4356(93)90056-7; *I NAC EST, 1987, ENC DESC DEF MIN; *I NAC EST, 1995, CENS POBL 1991 BAS D; JUDGE K, 1995, BRIT MED J, V311, P1282, DOI 10.1136/bmj.311.7015.1282; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; Kunst AE, 1994, MEASURING SOCIOECONO; KUNST AE, 1996, SOCIOECONOMIC INEQUA; KUNST AK, 1995, J EPIDEMIOL COMMUNIT, V84, P932; LAHELMA E, 1990, SOC SCI MED, V31, P257, DOI 10.1016/0277-9536(90)90272-T; LAHELMA E, 1994, SOC SCI MED, V38, P517, DOI 10.1016/0277-9536(94)90248-8; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; LUNDBERG O, 1986, SOC SCI MED, V23, P11; Mackenbach JP, 1997, LANCET, V349, P1655, DOI 10.1016/S0140-6736(96)07226-1; Norusis M J, 1993, SPSS WINDOWS ADV STA; PAMUK ER, 1985, POP STUD-J DEMOG, V39, P17, DOI 10.1080/0032472031000141256; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3; vanDoorslaer E, 1997, J HEALTH ECON, V16, P93, DOI 10.1016/S0167-6296(96)00532-2; WENNEMO I, 1993, SOCIOL HEALTH ILL, V15, P429, DOI 10.1111/1467-9566.ep11372773; WILKINSON RG, 1990, SOCIOL HEALTH ILL, V12, P391, DOI 10.1111/1467-9566.ep11340405; WILKINSON RG, 1992, AM J PUBLIC HEALTH, V82, P1082, DOI 10.2105/AJPH.82.8.1082; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilkinson RG, 1997, BRIT MED J, V314, P591, DOI 10.1136/bmj.314.7080.591; WILKINSON RG, 1994, BRIT MED J, V308, P1113, DOI 10.1136/bmj.308.6937.1113; WILKINSON RG, 1986, CLASS HLTH RES LONGI, P88	35	19	19	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1130	1135						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YE615	9374886				2022-12-28	WOS:A1997YE61500025
J	Soderlund, N; Csaba, I; Gray, A; Milne, R; Raftery, J				Soderlund, N; Csaba, I; Gray, A; Milne, R; Raftery, J			Impact of the NHS reforms on English hospital productivity: an analysis of the first three years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PAYMENT	Objectives: To evaluate the effect of purchaser mix, market competition, and trust status on hospital productivity within the NHS internal market. Methods: Hospital cost and activity data were taken from routinely collected data for acute NHS hospitals in England for 1991-2 to 1993-4. Cross sectional and longitudinal regression methods were used to estimate the effect of trust status, competition, and purchaser mix on average hospital costs per inpatient, after adjusting for outpatient activity levels, casemix, teaching activity, regional salary variation, hospital size, scale of activity and scope of cases treated. Results: Real productivity gains were apparent across the study period for NHS hospitals on average. Casemix adjustment drastically improved cross sectional comparisons between hospitals. Gaining trust status and increasing host district purchaser share were associated with productivity increases after adjustment for casemix, regional salar differences, and hospital size and scope. Hospitals that became trusts during the study period were on average less productive at the beginning of the period than those that did not, and there were no significant productivity differences between trust waves at the end of the period in 1993-4. Market concentration was not associated with productivity differences. Conclusion: Further analysis is needed to deter-mine whether overall and trust associated productivity gains are transient effects, one off shifts, or self perpetuating reorientations of organisational behaviour. Hospitals may have chosen to become trusts because they anticipated being able to increase productivity. Increases in the proportions of small purchasers were associated with increasing costs. Importantly, this study could not adjust for changes in the quality of care.	UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, ENGLAND; UNIV OXFORD, CTR SOCIOLEGAL STUDIES, OXFORD OX2 6UD, ENGLAND; NATL CASEMIX OFF, WINCHESTER SO22 5DH, HANTS, ENGLAND	University of Oxford; University of Oxford				Milne, Ruairidh/0000-0002-5117-4380				[Anonymous], 1995, BRIT MED J, V310, P1045; BARTLETT W, 1992, IMPACT NHS REFORMS H; Belsey DA, 1980, REGRESSION DIAGNOSTI; Culyer AJ., 1990, COMPETITION HLTH CAR; DRANOVE D, 1988, J HEALTH ECON, V7, P47, DOI 10.1016/0167-6296(88)90004-5; EVANS RG, 1971, CAN J ECONOMICS, V4, P198, DOI 10.2307/133526; FOSTER RW, 1985, J HEALTH ECON, V4, P261, DOI 10.1016/0167-6296(85)90032-3; GLENNERSTER H, 1993, HEALTH POLICY, V23, P179, DOI 10.1016/0168-8510(93)90056-U; MILLER P, 1994, NEAREST DEAREST ARE; PROPPER C, 1994, MARKET STRUCTURE PRI; *SAS I, 1994, SAS STAT AN SYST; SLOAN FA, 1984, J HEALTH POLIT POLIC, V8, P660, DOI 10.1215/03616878-8-4-660; Smee CH, 1995, STATE HLTH SER, P177; SODERLUND N, 1995, J PUBLIC HEALTH MED, V17, P25; STATEN M, 1987, J HEALTH ECON, V6, P43, DOI 10.1016/0167-6296(87)90030-0; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; ZWANZIGER J, 1988, J HEALTH ECON, V7, P301, DOI 10.1016/0167-6296(88)90018-5; [No title captured]	18	22	22	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 1	1997	315	7116					1126	1129						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YE615	9374885				2022-12-28	WOS:A1997YE61500023
J	Ikegami, N				Ikegami, N			Public long-term care insurance in Japan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								A public long-term care (LTC) insurance program is likely to be introduced to Japan in the year 2000. A consensus on the need for more LTC resources in the rapidly aging society and dissatisfaction with the current system are some of the factors that have contributed to its introduction. Half the costs will be paid by premiums that will be levied on all those older than 40 years, and half will be covered by general taxation. The insurer will be the municipalities with a pooling mechanism at the national level to balance the differences in their demographic structure. The benefits will include institutional care, respite care, day care, home help, visiting nurses, and loan of devices. Eligibility status will be classified into 6 levels that will be determined by assessment of functional and cognitive status. However, there are few mechanisms to limit benefits and contain costs. Problems also exist in the design of the eligibility classification and in the assessment instrument. The proposed LTC insurance system highlights the need for defining what should be included in a ''basic package'' of LTC as an entitlement for every citizen, for an organizational mechanism and an assessment instrument to deliver services efficiently and equitably, and for physicians to work outside the traditional medical model. To what degree the Japanese public in general, and physicians in particular, is willing to deal with these issues is a challenge for the 21st century.			Ikegami, N (corresponding author), KEIO UNIV,SCH MED,DEPT HLTH POLICY & MANAGEMENT,SHINJUKU KU,SHINANOMACHI 35,TOKYO 160,JAPAN.							ALBER J, 1996, SOCIAL POLICY STUDIE, V9, P261; Block SD, 1996, JAMA-J AM MED ASSOC, V276, P677, DOI 10.1001/jama.276.9.677; Campbell JC, 1992, POLICIES CHANGE JAPA, P245; CAMPBELL JC, IN PRESS ART BALANCI; Campbell John Creighton., 1989, DEMOCRACY JAPAN; CHALLIS D, 1994, NEW AGENDAS CHALLENG, P303; CLARK DW, 1973, DHEW PUBLICATION; IKEGAMI N, 1995, NEW ENGL J MED, V332, P598, DOI 10.1056/NEJM199503023320910; IKEGAMI N, 1995, NEW ENGL J MED, V333, P1295, DOI 10.1056/NEJM199511093331922; IKEGAMI N, 1994, GERONTOLOGIST, V34, P628, DOI 10.1093/geront/34.5.628; Ikegami N, 1989, Int J Health Plann Manage, V4, P181, DOI 10.1002/hpm.4740040305; IKEGAMI N, 1996, BYOIN KANRI, V33, P343; IKEGAMI N, IN PRESS AGE AGEING; ISHIKAWA A, 1996, ILLUSTRATED WHITE PA, P32; *JAP MED ASS, 1997, REF HLTH INS SYST 21; *JAP MIN HLTH WELF, 1965, 1963 PAT SURV; *JAP MIN HLTH WELF, 1996, 36 M HLTH SOC SERV C; *JAP MIN HLTH WELF, 1995, 1995 WHIT PAP HLTH W, P19; *JAP MIN HLTH WELF, 1996, POINTS LTC INS; *JAP MIN HLTH WELF, 1995, 1993 PAT SURV; *JAP MIN HLTH WELF, 1997, 1995 REP STAT HLTH F; *JAP MIN HLTH WELF, 1996, TRENDS NAT WELF, P198; KAIHARA N, 1992, ESTIMATION NEW DEMAN; KERKSTRA A, 1996, HOME CARE EUROPE, P219; Morris JN, 1997, J AM GERIATR SOC, V45, P1017, DOI 10.1111/j.1532-5415.1997.tb02975.x; OHKUMA K, 1988, GERIATRIC HOSP; OKUYAMA M, 1996, ILLUSTRATED WHITE PA, P48; *ORG EC COOP DEV, 1996, SOC POL STUD OECD, V9, P13; *PRIM MIN OFF, 1995, OP SURV PEOPL ATT LT; *TOKYO METR GOV WE, 1991, SURV LIV ELD FY 1990, P115; TSUBOI, 1997, NICHI JMA NEWS  0120, P1	31	82	85	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1310	1314		10.1001/jama.278.16.1310	http://dx.doi.org/10.1001/jama.278.16.1310			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA905	9343449				2022-12-28	WOS:A1997YA90500013
J	Gordon, M				Gordon, M			Is the best yet to be?	LANCET			English	Article							LIMITS; CARE				Gordon, M (corresponding author), BAYCREST CTR GERIATR CARE,3560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.							CALLAHAN D, 1994, GERONTOLOGIST, V34, P393, DOI 10.1093/geront/34.3.393; CAMPION EW, 1994, NEW ENGL J MED, V330, P1819, DOI 10.1056/NEJM199406233302509; CASSEL CK, 1992, HEALTH AFFAIR, V11, P87, DOI 10.1377/hlthaff.11.2.87; COHEN GD, 1997, 7 DEADLY MYTHS UNCOV; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; GORDON M, 1993, CAN MED ASSOC J, V148, P393; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; ROOS NP, 1991, AM J PUBLIC HEALTH, V81, P63, DOI 10.2105/AJPH.81.1.63; ROSENTHAL J, 1997, NY TIMES        0309, P39; Rowe JW, 1997, GERONTOLOGIST, V37, P433, DOI 10.1093/geront/37.4.433; Scharf S, 1996, DRUG AGING, V9, P399, DOI 10.2165/00002512-199609060-00002; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2354; Shaw AB, 1996, DRUG AGING, V9, P403, DOI 10.2165/00002512-199609060-00003; WEINBERGER M, 1993, AM J PUBLIC HEALTH, V83, P338, DOI 10.2105/AJPH.83.3.338; Williams TF, 1997, J AM GERIATR SOC, V45, P244, DOI 10.1111/j.1532-5415.1997.tb04516.x; 1997, NY TIMES        0309	16	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1166	1167		10.1016/S0140-6736(97)05069-1	http://dx.doi.org/10.1016/S0140-6736(97)05069-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB199	9343520				2022-12-28	WOS:A1997YB19900048
J	Webb, AK; Hanley, SP				Webb, AK; Hanley, SP			Personal paper: The conflict in transferring a cystic fibrosis specialist service between two hospitals in Manchester	BRITISH MEDICAL JOURNAL			English	Article									N MANCHESTER HLTH AUTHOR,MANCHESTER M8 5RB,LANCS,ENGLAND		Webb, AK (corresponding author), WYTHENSHAWE HOSP,NW LUNG CTR,BRADBURY CYST FIBROSIS UNIT,MANCHESTER M23 9LT,LANCS,ENGLAND.							FORSYTHE M, 1994, BRIT MED J, V308, P151, DOI 10.1136/bmj.308.6922.151; Hughes D, 1995, Health Serv J, V105, P18; ROBSON M, 1992, THORAX, V47, P684, DOI 10.1136/thx.47.9.684; SMITH R, 1992, BRIT MED J, V305, P1308, DOI 10.1136/bmj.305.6865.1308; SMITH R, 1994, BRIT MED J, V309, P1644, DOI 10.1136/bmj.309.6969.1644; WEBB AK, 1994, THORAX, V49, P291, DOI 10.1136/thx.49.4.291	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					1009	1011		10.1136/bmj.315.7114.1009	http://dx.doi.org/10.1136/bmj.315.7114.1009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365304	Green Published			2022-12-28	WOS:A1997YC30700031
J	Datta, SR; Dudek, H; Tao, X; Masters, S; Fu, HA; Gotoh, Y; Greenberg, ME				Datta, SR; Dudek, H; Tao, X; Masters, S; Fu, HA; Gotoh, Y; Greenberg, ME			Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery	CELL			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; GROWTH-FACTOR; APOPTOSIS; TRANSDUCTION; INHIBITION; ACTIVATION; MECHANISMS	Growth factors can promote cell survival by activating the phosphatidylinositide-3'-OH kinase and its downstream target, the serine-threonine kinase Akt. However, the mechanism by which Akt functions to promote survival is not understood. We show that growth factor activation of the PI3'K/Akt signaling pathway culminates in the phosphorylation of the BCL-2 family member BAD, thereby suppressing apoptosis and promoting cell survival. Akt phosphorylates BAD in vitro and in vivo, and blocks the BAD-induced death of primary neurons in a site-specific manner. These findings define a mechanism by which growth factors directly inactivate a critical component of the cell-intrinsic death machinery.	CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,GRAD PROGRAM MOL THERAPEUT & TOXICOL,ATLANTA,GA 30322	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Emory University; Emory University			Roszak, Joanna/F-4003-2010	Datta, Sandeep/0000-0002-8068-3862	NICHD NIH HHS [P30-HD 18655] Funding Source: Medline; NIGMS NIH HHS [GM53165] Funding Source: Medline; NINDS NIH HHS [NS28829] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; BARRES BA, 1993, DEVELOPMENT, V118, P283; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COFFER PJ, 1992, EUR J BIOCHEM, V205, P1217; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GALLI C, 1995, J NEUROSCI, V15, P1172; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Miller TM, 1996, J NEUROSCI, V16, P7487; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Vemuri GS, 1996, DEVELOPMENT, V122, P2529; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	57	4772	4951	2	189	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					231	241		10.1016/S0092-8674(00)80405-5	http://dx.doi.org/10.1016/S0092-8674(00)80405-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346240	Bronze			2022-12-28	WOS:A1997YC35000010
J	Smith, MA; Atherly, AJ; Kane, RL; Pacala, JT				Smith, MA; Atherly, AJ; Kane, RL; Pacala, JT			Peer review of the quality of care - Reliability and sources of variability for outcome and process assessments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Peer assessments have traditionally been used to judge the quality of care, but a major drawback has been poor interrater reliability. Objectives.-To compare the interrater reliability for outcome and process assessments in a population of frail older adults and to identify systematic sources of variability that contribute to poor reliability. Setting.-Eight sites participating in a managed care program that integrates acute and long-term care for frail older adults. Patients. A total of 313 frail older adults. Design.-Retrospective review of the medical record with 180 charts randomly assigned to 2 geriatricians, 2 geriatric nurse practitioners, or 1 geriatrician and 1 geriatric nurse practitioner and 133 charts randomly assigned to either a geriatrician or a geriatric nurse practitioner. Main Outcome Measures.-Interrater reliabilities for structured implicit judgments about process and outcomes for overall care and care for each of 8 tracer conditions (eg, arthritis). Results.-Outcome measures had higher interrater reliability than process measures. Five outcome measures achieved fair to good reliability (more than 0.40), while none of the process measures achieved reliabilities more than 0.40. Three factors contributed to poorer reliabilities for process measures: (1) an inability of reviewers to differentiate among cases with respect to the quality of management, (2) systematic bias from individual reviewers, and (3) systematic bias related to the professional training of the reviewer (ie, physician or nurse practitioner). Conclusions.-Peer assessments can play an important role in characterizing the quality of care for complex patients with multiple interrelated chronic conditions, but reliability can be poor. Strategies to achieve adequate reliability for these assessments should be applied. These strategies include emphasizing outcomes measurement, providing more structured assessments to identify true differences in patient management, adjusting systematic bias resulting from the individual reviewer and their professional background, and averaging scores from multiple reviewers. Future research on the reliability of peer assessments should focus on improving the ability of process measures to differentiate among cases with respect to the quality of management and on identifying additional sources of systematic bias for both process and outcome measures, Explicit recognition of factors influencing reliability will strengthen efforts to develop sound measures for quality assurance.	UNIV MINNESOTA, SCH PUBL HLTH, DIV HLTH SERV RES, MINNEAPOLIS, MN 55454 USA; UNIV MINNESOTA, DEPT FAMILY PRACTICE & COMMUNITY HLTH, MINNEAPOLIS, MN 55454 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Smith, MA (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.							BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; BROOK RH, 1973, PUBL US DHEW PHS; Callahan D, 1996, NEW ENGL J MED, V335, P744, DOI 10.1056/NEJM199609053351013; CRONBACH LJ, 1972, DEPENDABILITY BEHAVI; DANS PE, 1985, NEW ENGL J MED, V313, P1131, DOI 10.1056/NEJM198510313131806; Dunn G., 1989, DESIGN ANAL RELIABIL; Ellwood PM, 1996, JAMA-J AM MED ASSOC, V276, P1083, DOI 10.1001/jama.276.13.1083; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Fleiss JL, 1981, STAT METHODS RATES P; GOLDMAN RL, 1994, EVAL HEALTH PROF, V17, P3, DOI 10.1177/016327879401700101; GOLDMAN RL, 1992, JAMA-J AM MED ASSOC, V267, P958, DOI 10.1001/jama.267.7.958; HAYWARD RA, 1993, ANN INTERN MED, V118, P550, DOI 10.7326/0003-4819-118-7-199304010-00010; Iglehart JK, 1996, NEW ENGL J MED, V335, P995, DOI 10.1056/NEJM199609263351322; Kane R L, 1993, Health Care Financ Rev, V14, P89; Localio AR, 1996, ANN INTERN MED, V125, P457, DOI 10.7326/0003-4819-125-6-199609150-00005; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; RUBIN HR, 1990, GUIDELINES STRUCTURE; *SAS I INC, 1995, SAS VERS 6 11; Shavelson R.J., 1991, GENERALIZABILITY THE; SHAVELSON RJ, 1981, BRIT J MATH STAT PSY, V34, P133, DOI 10.1111/j.2044-8317.1981.tb00625.x	20	63	63	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1573	1578		10.1001/jama.278.19.1573	http://dx.doi.org/10.1001/jama.278.19.1573			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YF407	9370502				2022-12-28	WOS:A1997YF40700037
J	Mason, S; Brown, J; Levene, M				Mason, S; Brown, J; Levene, M			What is this thing called ''randomise''?	LANCET			English	Editorial Material									UNIV LEEDS,SCH MED,CTR REPROD GROWTH & DEV,LEEDS LS2 9NS,W YORKSHIRE,ENGLAND	University of Leeds	Mason, S (corresponding author), UNIV LEEDS,SCH MED,NO & YORKSHIRE CLIN TRIALS UNIT,LEEDS LS2 9NS,W YORKSHIRE,ENGLAND.			brown, julia/0000-0002-2719-7064				INGELFINGER FJ, 1972, NEW ENGL J MED, V287, P465, DOI 10.1056/NEJM197208312870912; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; 1995, LANCET, V345, P805	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1416	1416		10.1016/S0140-6736(05)64205-5	http://dx.doi.org/10.1016/S0140-6736(05)64205-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371163				2022-12-28	WOS:A1997YF95300006
J	Kassirer, JP; Angell, M				Kassirer, JP; Angell, M			Controversial Journal editorials	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; Campion EW, 1997, NEW ENGL J MED, V337, P44, DOI 10.1056/NEJM199707033370109; Curfman GD, 1997, NEW ENGL J MED, V337, P629, DOI 10.1056/NEJM199708283370909; Kassirer JP, 1997, NEW ENGL J MED, V336, P366, DOI 10.1056/NEJM199701303360509; KASSIRER JP, 1991, NEW ENGL J MED, V325, P1510, DOI 10.1056/NEJM199111213252112; KASSIRER JP, 1993, NEW ENGL J MED, V329, P570, DOI 10.1056/NEJM199308193290810; ROSENFELD RN, 1997, AM AURORA, pR13; STEINBROOK R, 1997, NEW ENGL J MED, V337, P779	9	7	7	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1460	1461		10.1056/NEJM199711133372009	http://dx.doi.org/10.1056/NEJM199711133372009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF253	9358145				2022-12-28	WOS:A1997YF25300009
J	OhkiHamazaki, H; Watase, K; Yamamoto, K; Ogura, H; Yamano, M; Yamada, K; Maeno, H; Imaki, J; Kikuyama, S; Wada, E; Wada, K				OhkiHamazaki, H; Watase, K; Yamamoto, K; Ogura, H; Yamano, M; Yamada, K; Maeno, H; Imaki, J; Kikuyama, S; Wada, E; Wada, K			Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity	NATURE			English	Article							LUNG-CARCINOMA CELLS; LEPTIN LEVELS; MOLECULAR-CLONING; PEPTIDE RECEPTOR; PLASMA	Mammalian bombesin-like peptides are widely distributed in the central nervous system as well as in the gastrointestinal tract, where they modulate smooth-muscle contraction, exocrine and endocrine processes, metabolism and behaviour(1). They bind to G-protein-coupled receptors on the cell surface to elicit their effects, Bombesin-like peptide receptors cloned so far include, gastrin-releasing peptide receptor (GRP-R)(2,3), neuromedin B receptor (NMB-R)(4,5), and bombesin receptor subtype-3 (BRS-3)(6,7). However, despite the molecular characterization of BRS-3, determination of its function has been difficult as a result of its low affinity for bombesin and its lack of an identified natural ligand, We have generated BRS-3-deficient mice in an attempt to determine the in vivo function of the receptor, Mice lacking functional BRS-3 developed a mild obesity, associated with hypertension and impairment of glucose metabolism, They also exhibited reduced metabolic rate, increased feeding efficiency and subsequent hyperphagia, Our data suggest that BRS-3 is required for the regulation of endocrine processes and metabolism responsible for energy balance and adiposity, BRS-3-deficient mice provide a useful new model for the investigation of human obesity and associated diseases.	TOKYO INST PSYCHIAT,DEPT NEUROCHEM,SETAGAYA KU,TOKYO 156,JAPAN; WASEDA UNIV,SCH EDUC,DEPT BIOL,SHINJUKU KU,TOKYO 16950,JAPAN; EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN; OSAKA PREFECTURAL COLL HLTH SCI,HABIKINO,OSAKA 583,JAPAN; NIPPON MED COLL,DEPT ANAT,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Institute of Psychiatry; Waseda University; Eisai Co Ltd; Nippon Medical School	OhkiHamazaki, H (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT DEGENERAT NEUROL DIS,KODAIRA,TOKYO 187,JAPAN.		Ohki-Hamazaki, Hiroko/R-5489-2019	Ohki-Hamazaki, Hiroko/0000-0003-4658-5385; Yamamoto, Kazutoshi/0000-0002-7935-7015				BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; FATHI Z, 1993, J BIOL CHEM, V268, P5979; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OhkiHamazaki H, 1997, BRAIN RES, V762, P165, DOI 10.1016/S0006-8993(97)00380-6; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; Wu JM, 1996, MOL PHARMACOL, V50, P1355; YAMAMOTO K, 1982, ENDOCRINOL JAPON, V29, P159; YANOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435	19	239	250	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					165	169		10.1038/36568	http://dx.doi.org/10.1038/36568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367152				2022-12-28	WOS:A1997YF49400052
J	Goodwin, JS				Goodwin, JS			Chaos, and the limits of modern medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1399	1400		10.1001/jama.278.17.1399	http://dx.doi.org/10.1001/jama.278.17.1399			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355988				2022-12-28	WOS:A1997YC91700011
J	Howard, G; Chambless, LE; Kronmal, RA				Howard, G; Chambless, LE; Kronmal, RA			Assessing differences in clinical trials comparing surgical vs nonsurgical therapy - Using common (statistical) sense	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The statement of hypotheses and choice of statistical tests in clinical trials that compare surgical with nonsurgical treatment are complicated by the likelihood of excess risk in the surgical group during the perioperative period but lower risk after that compared with the more uniform risk in the nonsurgical group. Commonly used statistical survival analyses implicitly assume a constant ratio of risks in the 2 groups during the follow-up period. However, the changing pattern of risk for one treatment but not the other implies that the assessment of the relative efficacy of the treatments varies with the length of the follow-up. As such, determining whether survival curves for the 2 groups are different may not translate easily into selecting the best treatment. Alternative statements of the hypothesis based on consideration of the time horizon of patients and on clinical judgment may be more consistent with the goals of the study. Regardless of the choice of a statistical test, the choice of treatment is a decision specific to the individual patient and should be influenced by the patient's life expectancy, attitude toward taking risks, quality of life, and cost considerations. When the survival curves cross, there is a trade-off between the risk of surgery and the increase in life expectancy among the survivors of surgery, Accordingly, assessment of differences in outcomes in clinical trials comparing surgical vs nonsurgical therapy should provide both a conclusion about whether 1 treatment can reasonably be considered best for most patients and should provide information to the individual patient and physician on the expected outcome to aid in the decision-making process.	UNIV N CAROLINA, DEPT BIOSTAT, CHAPEL HILL, NC USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle	Howard, G (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA.			Howard, George/0000-0002-3068-5720				BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542; Elandt-Johnson R C, 1980, SURVIVAL MODELS DATA; FISHER CJ, 1994, CRIT CARE MED, V22, P12, DOI 10.1097/00003246-199401000-00008; FISHER L, 1984, NEW ENGL J MED, V310, P750; FLEMMING T, 1991, COUNTING PROCESSES S; FRIEDMAN LM, 1996, FUNDAMENTALS CLIN TR; GILL R, 1987, BIOMETRIKA, V74, P289, DOI 10.2307/2336143; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEE ET, 1975, BIOMETRIKA, V62, P425, DOI 10.1093/biomet/62.2.425; Miller R.G., 1981, SIMULTANEOUS STAT IN, Ved 2nd, DOI DOI 10.1007/s11263-015-0816-y; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; The PI of CASS and Their Associates, 1981, CIRCULATION S1, V63, pII; TOOLE JF, 1989, STROKE, V20, P844; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	16	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1432	1436						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9356002				2022-12-28	WOS:A1997YC91700030
J	Nightingale, SL				Nightingale, SL			New requirements for labeling of dietary supplements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-28	WOS:A1997YC91700005
J	Grobbee, DE; Hoes, AW				Grobbee, DE; Hoes, AW			Confounding and indication for treatment in evaluation of drug treatment for hypertension	BRITISH MEDICAL JOURNAL			English	Article							DIASTOLIC BLOOD-PRESSURE; CALCIUM-CHANNEL BLOCKERS; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; CARDIOVASCULAR RISK; ELDERLY MEN; FOLLOW-UP; MORTALITY; ATHEROSCLEROSIS				Grobbee, DE (corresponding author), UNIV UTRECHT,SCH MED,ACAD HOSP,JULIUS CTR PATIENT ORIENTED RES,POB 80035,NL-3508 TA UTRECHT,NETHERLANDS.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ARNETT DK, 1994, AM J EPIDEMIOL, V140, P669, DOI 10.1093/oxfordjournals.aje.a117315; Bots ML, 1996, ARCH INTERN MED, V156, P843, DOI 10.1001/archinte.156.8.843; BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; COOPE J, 1988, J HUM HYPERTENS, V2, P79; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FLECHTER AK, 1992, NEW ENGL J MED, V326, P251; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; Grobbee DE, 1995, J HYPERTENS, V13, P1539; Hansson L., 1995, Blood Pressure, V4, P313, DOI 10.3109/08037059509077613; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; HOES AW, 1991, CIRCULATION, V84, P78; HOES AW, 1993, EUR J EPIDEMIOL, V9, P285, DOI 10.1007/BF00146265; LANGER RD, 1989, BRIT MED J, V298, P1356, DOI 10.1136/bmj.298.6684.1356; LINDBLAD U, 1994, BRIT MED J, V308, P681, DOI 10.1136/bmj.308.6930.681; Marwick C, 1996, JAMA-J AM MED ASSOC, V275, P423, DOI 10.1001/jama.275.6.423; MCCRUISHANK JM, 1987, LANCET, V1, P581; Merlo J, 1996, BRIT MED J, V313, P457; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; RAJALA S, 1983, LANCET, V2, P520; SAMUELSSON OG, 1990, J HYPERTENS, V8, P547, DOI 10.1097/00004872-199006000-00008; Simon JA, 1996, BRIT MED J, V313, P437; SLEIGHT P, 1988, LANCET, V1, P235; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; STEWART IMG, 1979, LANCET, V1, P861; TAYLOR JO, 1991, AM J EPIDEMIOL, V134, P489, DOI 10.1093/oxfordjournals.aje.a116121; Walker AM, 1996, LANCET, V348, P489, DOI 10.1016/S0140-6736(05)64664-8; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1; ZANCHETTI A, 1989, J HYPERTENS, V7, pS338, DOI 10.1097/00004872-198900076-00165	33	113	113	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1151	1154						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374894				2022-12-28	WOS:A1997YE61500035
J	Gussekloo, J; Westendorp, RGJ; Remarque, EJ; Lagaay, AM; Heeren, TJ; Knook, DL				Gussekloo, J; Westendorp, RGJ; Remarque, EJ; Lagaay, AM; Heeren, TJ; Knook, DL			Impact of mild cognitive impairment on survival in very elderly people: cohort study	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-STATE-EXAMINATION; COMMUNITY RESIDENTS; MORTALITY		UNIV UTRECHT,DEPT PSYCHIAT,UTRECHT,NETHERLANDS	Utrecht University	Gussekloo, J (corresponding author), LEIDEN UNIV HOSP,DEPT GEN INTERNAL MED,SECT GERONTOL & GERIATR,P 3 Q,POB 9600,NL-2300 RC LEIDEN,NETHERLANDS.		Gussekloo, Jacobijn/ABE-3879-2021; Remarque, Ed/AAE-8643-2020; Remarque, Edmond J/B-2217-2010	Gussekloo, Jacobijn/0000-0001-7186-8278; 	NIA NIH HHS [5 RO 1 AG 06354] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006354] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		HEEREN TJ, 1990, J AM GERIATR SOC, V38, P1093, DOI 10.1111/j.1532-5415.1990.tb01371.x; IZAKS GJ, 1995, PSYCHOL MED, V25, P841, DOI 10.1017/S0033291700035091; KELMAN HR, 1994, AM J PUBLIC HEALTH, V84, P1255, DOI 10.2105/AJPH.84.8.1255; LIU IY, 1990, AM J EPIDEMIOL, V132, P136, DOI 10.1093/oxfordjournals.aje.a115625; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x	5	87	93	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1053	1054		10.1136/bmj.315.7115.1053	http://dx.doi.org/10.1136/bmj.315.7115.1053			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YD445	9366730	Green Published			2022-12-28	WOS:A1997YD44500019
J	Rochon, PA; Gurwitz, JH				Rochon, PA; Gurwitz, JH			Optimising drug treatment for elderly people: the prescribing cascade	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; THERAPY; OSTEOARTHRITIS; TRIAL; KNEE; HYPERTENSION; MORBIDITY; MORTALITY		UNIV TORONTO, DEPT PREVENT MED & BIOSTAT, BAYCREST CTR GERIATR CARE, N YORK, ON M6A 2E1, CANADA; MEYERS PRIMARY CARE INST, WORCESTER, MA 01608 USA	University of Toronto; University Toronto Affiliates; Baycrest	Rochon, PA (corresponding author), UNIV TORONTO, DEPT MED, DIV GERIATR MED, BAYCREST CTR GERIATR CARE, 3560 BATHURST ST, N YORK, ON M6A 2E1, CANADA.		Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151				AMERY A, 1985, LANCET, V1, P1349; ANDREN L, 1983, J HYPERTENS S2, V1, P384; [Anonymous], 1991, JAMA, V265, P3255; AVORN J, 1995, JAMA-J AM MED ASSOC, V274, P1780, DOI 10.1001/jama.274.22.1780; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FELSON DT, 1992, ANN INTERN MED, V116, P535, DOI 10.7326/0003-4819-116-7-535; FLETCHER AE, 1991, AM J MED, V90, pS42, DOI 10.1016/0002-9343(91)90435-Z; FRISHMAN WH, 1994, ARCH INTERN MED, V154, P1461, DOI 10.1001/archinte.154.13.1461; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Gurwitz JH, 1997, J CLIN EPIDEMIOL, V50, P953, DOI 10.1016/S0895-4356(97)00101-7; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781, DOI 10.1001/jama.272.10.781; HALL AP, 1967, AM J MED, V42, P27, DOI 10.1016/0002-9343(67)90004-6; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; KELLEY WN, 1993, TXB RHEUMATOLOGY, P1291; Koller W, 1987, Adv Neurol, V45, P317; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; LANGFORD HG, 1987, ARCH INTERN MED, V147, P645, DOI 10.1001/archinte.147.4.645; MARTTILA RJ, 1976, ACTA NEUROL SCAND, V53, P81; MECONI M, 1987, J AM GERIATR SOC, V35, P239; POPE JE, 1993, ARCH INTERN MED, V153, P477, DOI 10.1001/archinte.153.4.477; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; ROCHON PA, 1995, LANCET, V346, P32, DOI 10.1016/S0140-6736(95)92656-9; Solomon DH, 1997, AM J MED, V102, P208; ZIEGLER MG, 1988, CLIN EXP HYPERTENS A, V10, P791, DOI 10.1080/07300077.1988.11878785	27	327	340	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1096	1099		10.1136/bmj.315.7115.1096	http://dx.doi.org/10.1136/bmj.315.7115.1096			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366745	Green Published			2022-12-28	WOS:A1997YD44500036
J	delPeso, L; GonzalezGarcia, M; Page, C; Herrera, R; Nunez, G				delPeso, L; GonzalezGarcia, M; Page, C; Herrera, R; Nunez, G			Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt	SCIENCE			English	Article							CELL-DEATH; ONCOGENE; APOPTOSIS; SURVIVAL; BCL-2	BAD is a distant member of the Bcl-2 family that promotes cell death. Phosphorylation of BAD prevents this. BAD phosphorylation induced by interleukin-3 (IL-3) was inhibited by specific inhibitors of phosphoinositide 3-kinase (PI 3-kinase), Akt, a survival-promoting serine-threonine protein kinase, was activated by IL-3 in a PI 3-kinase-dependent manner. Active, but not inactive, forms of AM were found to phosphorylate BAD in vivo and in vitro at the same residues that are phosphorylated in response to IL-3, Thus, the proapoptotic function of BAD is regulated by the PI 3-kinase-Akt pathway.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Pfizer			del Peso, Luis/K-9391-2014; Nuñez, Gabriel/A-7160-2014	del Peso, Luis/0000-0003-4014-5688; 	NCI NIH HHS [CA-64556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DELPESO L, UNPUB; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRANKE TF, 1997, CELL, V88, P355; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	24	1034	1066	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					687	689						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381178				2022-12-28	WOS:A1997YC32300054
J	Lumsden, A; Gulisano, M				Lumsden, A; Gulisano, M			Neocortical neurons: Where do they come from?	SCIENCE			English	Editorial Material							GANGLIONIC EMINENCE; FOREBRAIN; MIGRATION; DISPERSION; RAT				Lumsden, A (corresponding author), GUYS HOSP,DEPT DEV NEUROBIOL,MRC,BRAIN DEV PROGRAMME,LONDON SE1 9RT,ENGLAND.		Gulisano, Massimo/F-6609-2012; Lumsden, Andrew/C-5146-2009	Gulisano, Massimo/0000-0001-8654-1745; 				Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; DeCarlos JA, 1996, J NEUROSCI, V16, P6146; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; GOETZ M, 1996, NEURON, V16, P551; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Metin C, 1996, J NEUROSCI, V16, P3219; ORourke NA, 1996, NEURON, V16, P1061, DOI 10.1016/S0896-6273(00)80130-0; PORTEUS MH, 1994, J NEUROSCI, V14, P6370; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; VANEDEN CG, 1989, J COMP NEUROL, V289, P213, DOI 10.1002/cne.902890204; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Wingate RJT, 1996, DEVELOPMENT, V122, P2143	15	12	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					402	403		10.1126/science.278.5337.402	http://dx.doi.org/10.1126/science.278.5337.402			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381143				2022-12-28	WOS:A1997YB35500028
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Worlds collide	SCIENCE			English	Editorial Material																		Feng MZ, 1997, NAT BIOTECHNOL, V15, P866, DOI 10.1038/nbt0997-866	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					501	501						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381146				2022-12-28	WOS:A1997YB35500055
J	Series, F; Marc, I				Series, F; Marc, I			Efficacy of automatic continuous positive airway pressure therapy that uses an estimated required pressure in the treatment of the obstructive sleep apnea syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						sleep apnea syndromes; positive-pressure respiration; hypersomnia; sleep disorders; respiration disorders	DAYTIME SLEEPINESS; CLOSING PRESSURES; CPAP; NIGHT; COLLAPSIBILITY; REVERSAL	Background: Continuous positive airway pressure (CPAP) is effective therapy for the obstructive sleep apnea syndrome (OSAS). Automatic CPAP devices continuously adjust the positive pressure to the required levels. Objective: To determine the efficacy of an automatic CPAP machine used with an estimated reference pressure value. Design: A before-and-after, single-blind trial in which patients were randomly allocated to one of three modes of CPAP administration. Setting: Referral-based sleep center in a public health care institution. Patients: 36 outpatients with OSAS. Intervention: Continuous positive airway pressure was given at a conventional fixed pressure (group 1), automatic CPAP was given at a measured reference pressure (group 2), and automatic CRAP was given at an estimated reference pressure (group 3). In group 1, the effective pressure was determined during a titration sleep study. In groups 2 and 3, the pressure interval was allowed to vary from 4 cm H2O below reference pressure to 3 cm H2O above reference pressure. In group 3, the estimated value of the reference pressure was determined according to individual anthropometric characteristics. Measurements: Sleep studies were performed and measurements of diurnal sleepiness were obtained at each visit. Results: Sleep and breathing disorders and hypersomnolence were alleviated similarly in the three groups. The apnea + hypopnea index remained abnormal in one patient in group 3 for whom the reference pressure had been underestimated. A strong negative correlation was found between the percentage of time spent below reference pressure during CPAP and the difference between the effective and estimated pressures. Conclusion: Automatic CPAP can be used with an estimated reference pressure without doing a titration sleep study. The positive pressure trend can be used to determine whether treatment failure is caused by an inadequate pressure setting and to determine the amount of pressure to apply.			Series, F (corresponding author), HOP LAVAL, CTR PNEUMOL, 2725 CHEMIN ST FOY, Ste Foy, PQ G1V 4G5, CANADA.			Marc, Isabelle/0000-0001-6060-8550				[Anonymous], 1992, SLEEP, V15, P174; BERTHONJONES M, 1993, SLEEP, V16, pS120, DOI 10.1093/sleep/16.suppl_8.S120; DERDERIAN SS, 1988, CHEST, V94, P1023, DOI 10.1378/chest.94.5.1023; FUJITA S, 1985, LARYNGOSCOPE, V95, P70; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; ISSA FG, 1984, J APPL PHYSIOL, V57, P520, DOI 10.1152/jappl.1984.57.2.520; ISSA FG, 1984, J APPL PHYSIOL, V57, P528, DOI 10.1152/jappl.1984.57.2.528; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; KALES A, 1985, J CHRON DIS, V38, P427, DOI 10.1016/0021-9681(85)90138-9; Kales A, 1968, NIH PUBLICATION, V204; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; MARRONE O, 1991, EUR RESPIR J, V4, P660; Meurice JC, 1996, AM J RESP CRIT CARE, V153, P794, DOI 10.1164/ajrccm.153.2.8564134; Meurice JC, 1996, AM J RESP CRIT CARE, V153, P255, DOI 10.1164/ajrccm.153.1.8542125; MILJETEIG H, 1993, AM REV RESPIR DIS, V147, P1526, DOI 10.1164/ajrccm/147.6_Pt_1.1526; MILLMAN RP, 1989, J CLIN PSYCHIAT, V50, P348; OSULLIVAN RA, 1995, AM J RESP CRIT CARE, V151, P194, DOI 10.1164/ajrccm.151.1.7812552; PARTINEN M, 1990, CHEST, V97, P27, DOI 10.1378/chest.97.1.27; POCETA JS, 1992, CHEST, V101, P893, DOI 10.1378/chest.101.4.893; SANDERS MH, 1993, AM REV RESPIR DIS, V147, P1169, DOI 10.1164/ajrccm/147.5.1169; SFORZA E, 1990, AM REV RESPIR DIS, V141, P866, DOI 10.1164/ajrccm/141.4_Pt_1.866; SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850; SULLIVAN CE, 1981, LANCET, V1, P862; THUT DC, 1993, J APPL PHYSIOL, V75, P2084, DOI 10.1152/jappl.1993.75.5.2084; WASICKO MJ, 1990, AM REV RESPIR DIS, V141, P1569, DOI 10.1164/ajrccm/141.6.1569; YAMASHIRO Y, 1995, CHEST, V107, P62, DOI 10.1378/chest.107.1.62; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	28	64	64	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				588	+		10.7326/0003-4819-127-8_Part_1-199710150-00002	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341056				2022-12-28	WOS:A1997YB41900002
J	Izurieta, HS; Strebel, PM; Blake, PA				Izurieta, HS; Strebel, PM; Blake, PA			Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTHY-CHILDREN; FOLLOW-UP; CHICKENPOX; CORTICOSTEROIDS; INFECTIONS; EFFICACY; TRIALS	Context.-Because lyophilized varicella vaccine must be stored frozen at -15 degrees C or less (less than or equal to 5 degrees F) and administered within 30 minutes after reconstitution, the potential exists for decreased vaccine effectiveness when the vaccine is used under field conditions. Objectives.-To describe an outbreak of varicella in a child care center and to determine postlicensure effectiveness of varicella vaccine. Design.-Retrospective cohort study. Setting.-A child care center in DeKalb County, Georgia, in 1996. Participants.-Of the 184 children registered in the child care center, 148 were eligible for the study based on absence of history of varicella before January 1, 1996. Main Outcome Measures.-Data on disease status, severity and impact of disease, and risk factors for varicella and for vaccine failure were obtained from parents and their children's pediatricians, Varicella vaccine effectiveness was calculated among children aged 12 months or older (eligible for vaccination) using the cohort method. Results.-The outbreak started on January 17, 1996, and lasted 15 weeks. Of the 148 eligible children, 81 (55%) developed varicella, Cases among children younger than 12 months (n=7) were more severe than cases among older children, Varicella occurred in 9 (14%) of 66 vaccinated children and 72 (88%) of 82 unvaccinated children. Varicella was less severe and resulted in fewer days of absence from the child care center among vaccinated compared with unvaccinated cases. Varicella vaccine effectiveness against all forms of disease was 86% (95% confidence interval [CI], 73%-92%), and against moderate-to-severe varicella disease it was 100% (95% CI, 96%-100%). Vaccinated children with asthma or other reactive airway diseases were 7.1 times more likely to have varicella than were vaccinated children without reactive airway diseases (95% CI, 2.4-21.3). Conclusions.-Varicella vaccine administered under routine conditions in physicians' offices was highly effective in preventing varicella in an outbreak characterized by intense exposure. The role of asthma and other reactive airway diseases as risk factors for varicella disease and vaccine failure deserves to be investigated further.	GEORGIA DEPT HUMAN RESOURCES,DIV PUBL HLTH,ATLANTA,GA									[Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], 1994, WORD PROCESSING DATA; ARBETER AM, 1984, AM J DIS CHILD, V138, P434, DOI 10.1001/archpedi.1984.02140430012004; ASANO Y, 1994, PEDIATRICS, V94, P524; ASANO Y, 1982, BIKEN J, V25, P43; AZBUG MJ, 1993, J PEDIATR, V123, P577; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; BRADDING P, 1995, CLIN EXP ALLERGY, V25, P912, DOI 10.1111/j.1365-2222.1995.tb00391.x; BRUNELL PA, 1988, PEDIATRICS, V81, P779; CHOONG K, 1995, PEDIATR INFECT DIS J, V14, P809; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; DELCLAUX B, 1992, PRESSE MED, V21, P1432; FINGER R, 1994, PUBLIC HEALTH REP, V109, P750; Fleiss JL, 1981, STAT METHODS RATES P; GERSHON A, 1991, REV INFECT DIS S11, V13, P5957; IPSEN J, 1984, SCAND J SOC MED, V12, P121, DOI 10.1177/140349488401200305; JONES SEE, 1995, PEDIATR INFECT DIS J, V14, P404; JUST M, 1985, POSTGRAD MED J, V61, P129; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; KUTTER B, 1991, VACCINE, V9, P643; Lee E.T., 1992, STATISTICAL METHODS; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; PREBLUD SR, 1981, PEDIATRICS, V68, P14; REMINGTON RD, 1985, STATISTICS APPLICATI, P187; TAKAHASH.M, 1974, LANCET, V2, P1288, DOI 10.1016/S0140-6736(74)90144-5; TINKELMAN DG, 1992, PEDIATRICS, V90, P479; WELCH MJ, 1994, J ASTHMA, V31, P43, DOI 10.3109/02770909409056768; Wharton M, 1996, INFECT DIS CLIN N AM, V10, P571, DOI 10.1016/S0891-5520(05)70313-5; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006; WHITE CJ, 1991, PEDIATRICS, V87, P604	31	117	122	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1495	1499						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363968				2022-12-28	WOS:A1997YE44500032
J	Kirschner, RH				Kirschner, RH			Police brutality in the USA	LANCET			English	Editorial Material											Kirschner, RH (corresponding author), DEPAUL UNIV,COLL LAW,INT FORENS PROGRAM,25 E JACKSON BLVD,CHICAGO,IL 60604, USA.								0	3	3	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1395	1395		10.1016/S0140-6736(97)10182-9	http://dx.doi.org/10.1016/S0140-6736(97)10182-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365468				2022-12-28	WOS:A1997YE87200050
J	Nguyen, MT; Camenisch, T; Snouwaert, JN; Hicks, E; Coffman, TM; Anderson, PAW; Malouf, MN; Koller, BH				Nguyen, MT; Camenisch, T; Snouwaert, JN; Hicks, E; Coffman, TM; Anderson, PAW; Malouf, MN; Koller, BH			The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth	NATURE			English	Article							PATENT DUCTUS-ARTERIOSUS; PROSTANOID RECEPTORS; CLOSURE; INDOMETHACIN; CLONING; SUBTYPE; RATS	Survival of newborn placental mammals depends on closure of the ductus arteriosus (DA), an arterial connection in the fetus which directs blood away from the pulmonary circulation and towards the placenta where oxygenation occurs(1). Here we show that morphological changes resulting in closure of the DA in mice are virtually identical to those observed in larger mammals, including humans(2), and that maintenance of the DA in the open, or patent, stare in fetal mice is dependent on prostaglandin synthesis, This requirement is absent in mice lacking the prostaglandin E-2 EP4 receptor (EP4(-/-) mice). In EP4(-/-) mice of the 129 strain, remodelling of the DA fails to occur after birth, resulting in a left-to-right shunt of blood and subseqently in death. This suggests that the neonatal drop in prostaglandin E-2 (refs 3-7) that triggers ductal closure is sensed through the EP4 receptor, In contrast, 5% of EP4(-/-) mice of mixed genetic background survive, and selective breeding of these mice leads to a 21% survival rate, suggesting that alleles at other loci can provide an alternative mechanism for ductal closure.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; DUKE UNIV,DEPT MED,DURHAM,NC 27710; DURHAM VET AFFAIRS MED CTR,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV PEDIAT CARDIOL,DURHAM,NC 27710; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; University of North Carolina; University of North Carolina Chapel Hill				Camenisch, Todd/0000-0002-7797-9822				CHALLIS JRG, 1976, PROSTAGLANDINS, V11, P1041, DOI 10.1016/0090-6980(76)90011-3; CHRISTIANSEN NC, 1975, LANCET, V2, P24; CLYMAN RI, 1987, SEMIN PERINATOL, V11, P64; CLYMAN RI, 1980, J PEDIATR-US, V97, P455, DOI 10.1016/S0022-3476(80)80205-8; CLYMAN RI, 1980, PROSTAGLANDINS, V15, P325; COCEANI F, 1980, SEMIN PERINATOL, V4, P109; COCEANI F, 1994, BIOCHEM PHARMACOL, V48, P1315, DOI 10.1016/0006-2952(94)90552-5; COCEANI F, 1973, CAN J PHYSIOL PHARM, V51, P220, DOI 10.1139/y73-031; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; ELLIOTT RB, 1975, LANCET, V1, P140; ENGELHARDT JF, 1992, J CLIN INVEST, V90, P2598, DOI 10.1172/JCI116155; FRIEDMAN WF, 1976, NEW ENGL J MED, V295, P526, DOI 10.1056/NEJM197609022951003; GERSONY WM, 1986, PEDIATR CLIN N AM, V33, P545; GITTENBERGERDEGROOT AC, 1985, J AM COLL CARDIOL, V6, P394, DOI 10.1016/S0735-1097(85)80178-9; HEYMANN MA, 1976, NEW ENGL J MED, V295, P530, DOI 10.1056/NEJM197609022951004; HEYMANN MA, 1975, PHYSIOL REV, V55, P62, DOI 10.1152/physrev.1975.55.1.62; HONDA A, 1993, J BIOL CHEM, V268, P7759; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Jager BV, 1942, AM J PATHOL, V18, P595; JARKOVSKA D, 1992, PHYSIOL RES, V41, P323; MITCHELL MD, 1980, J REPROD FERTIL, V58, P283, DOI 10.1530/jrf.0.0580283; MOHN A, 1995, DNA CLONING, V4, P143; MOISE KJ, 1988, NEW ENGL J MED, V319, P327, DOI 10.1056/NEJM198808113190602; MOMMA K, 1987, PEDIATR RES, V22, P567, DOI 10.1203/00006450-198711000-00018; OLLEY PM, 1976, CIRCULATION, V53, P728, DOI 10.1161/01.CIR.53.4.728; PATTERSON DF, 1979, PEDIATR CARDIOL, V2, P45; PIPER PJ, 1970, NATURE, V225, P600, DOI 10.1038/225600a0; REGAN JW, 1994, MOL PHARMACOL, V46, P213; SHARPE GL, 1975, PROSTAGLANDINS, V9, P585, DOI 10.1016/0090-6980(75)90064-7; SMITH GCS, 1994, J PHARMACOL EXP THER, V271, P390	30	272	279	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					78	81		10.1038/36342	http://dx.doi.org/10.1038/36342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363893				2022-12-28	WOS:A1997YE47700055
J	Huang, ZP; Hankinson, SE; Colditz, GA; Stampfer, MJ; Hunter, DJ; Manson, JE; Hennekens, CH; Rosner, B; Speizer, FE; Willett, WC				Huang, ZP; Hankinson, SE; Colditz, GA; Stampfer, MJ; Hunter, DJ; Manson, JE; Hennekens, CH; Rosner, B; Speizer, FE; Willett, WC			Dual effects of weight and weight gain on breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; POSTMENOPAUSAL WOMEN; RELATIVE WEIGHT; HORMONE LEVELS; HEIGHT; SIZE; ASSOCIATION; ESTROGENS; SURVIVAL; LIFE	Context.-Breast cancer is a major cause of mortality among women. It is important to identify modifiable risk factors for this disease. Objective.-To examine body mass index (BMI) at the age of 18 years and at midlife and adult weight change in relation to breast cancer incidence and mortality. Design.-Cohort study. Setting.-A cohort of 95 256 US female nurses aged 30 to 55 years who were followed up for 16 years. Main Outcome Measure.-Incident and fatal breast cancer. Results.-During 1 203 498 person-years, 2517 incident breast cancers (60% postmenopausal) were documented. Higher current BMI was associated with lower breast cancer incidence before menopause and was minimally associated with incidence after menopause. However, a stronger positive relationship was seen among postmenopausal women who never used hormone replacement (relative risk=1.59 for BMI >31 kg/m(2) vs less than or equal to 20 kg/m(2); 95% confidence interval, 1.09-2.32; P for trend <.001). Higher BMI at the age of 18 years was associated with lower breast cancer incidence both before and after menopause. Weight gain after the age of 18 years was unrelated to breast cancer incidence before menopause, but was positively associated with incidence after menopause. This increased risk with weight gain was limited to women who never used postmenopausal hormones; among these women, the relative risk was 1.99 (95% confidence interval, 1.43-2.76) for weight gain of more than 20 kg vs unchanged weight (P for trend <.001). Current BMI and weight gain were even more strongly associated with fatal postmenopausal breast cancer. In this population, the percentage of postmenopausal breast cancer accounted for by weight gain alone was approximately 16% and by hormone replacement therapy alone was 5%, but when the interaction between these variables was considered, together they accounted for about one third of postmenopausal breast cancers. Conclusions.-Avoiding adult weight gain may contribute importantly to the prevention of breast cancer after menopause, particularly among women who do not use postmenopausal hormones.	HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, CAMBRIDGE, MA 02138 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356, R25CA057711] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356, 5-R25-CA57711-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARDBARBASH R, 1990, CANCER RES, V50, P2152; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; BARNESJOSIAH D, 1995, CANCER CAUSE CONTROL, V6, P112, DOI 10.1007/BF00052771; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; DANIELL HW, 1993, BREAST CANCER RES TR, V25, P193, DOI 10.1007/BF00689833; HANKINSON SE, 1995, J NATL CANCER I, V87, P1297, DOI 10.1093/jnci/87.17.1297; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KUMAR NB, 1995, CANCER-AM CANCER SOC, V76, P243, DOI 10.1002/1097-0142(19950715)76:2<243::AID-CNCR2820760214>3.0.CO;2-R; LEMARCHAND L, 1988, AM J EPIDEMIOL, V128, P137; Lipworth L, 1996, EPIDEMIOLOGY, V7, P96, DOI 10.1097/00001648-199601000-00017; LONDON SJ, 1989, JAMA-J AM MED ASSOC, V262, P2853; NEGRI E, 1988, AM J EPIDEMIOL, V128, P1207, DOI 10.1093/oxfordjournals.aje.a115075; NEWCOMB PA, 1995, EPIDEMIOLOGY, V6, P318, DOI 10.1097/00001648-199505000-00022; PATHAK DR, 1992, AM J EPIDEMIOL, V135, P153, DOI 10.1093/oxfordjournals.aje.a116268; Potischman N, 1996, JNCI-J NATL CANCER I, V88, P756, DOI 10.1093/jnci/88.11.756; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SENIE RT, 1992, ANN INTERN MED, V116, P26, DOI 10.7326/0003-4819-116-1-26; TORNBERG SA, 1994, BRIT J CANCER, V69, P358, DOI 10.1038/bjc.1994.65; TRETLI S, 1990, BRIT J CANCER, V62, P299, DOI 10.1038/bjc.1990.282; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; URSIN G, 1995, EPIDEMIOLOGY, V6, P137, DOI 10.1097/00001648-199503000-00009; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P731, DOI 10.1093/oxfordjournals.aje.a114156; Ziegler RG, 1996, J NATL CANCER I, V88, P650, DOI 10.1093/jnci/88.10.650	27	592	598	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1407	1411		10.1001/jama.278.17.1407	http://dx.doi.org/10.1001/jama.278.17.1407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355998				2022-12-28	WOS:A1997YC91700026
J	Valentine, JS; Gralla, EB				Valentine, JS; Gralla, EB			Biochemistry - Delivering copper inside yeast and human cells	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; OXIDASE				Valentine, JS (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,405 HILGARD AVE,LOS ANGELES,CA 90095, USA.		Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X				AMARAVADI R, 1997, HUM GENET, V9, P329; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	12	197	203	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					817	818		10.1126/science.278.5339.817	http://dx.doi.org/10.1126/science.278.5339.817			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9381192				2022-12-28	WOS:A1997YD47900030
J	McDonnell, WM; Jung, F				McDonnell, WM; Jung, F			Barium impaction in the sigmoid colon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									VET AFFAIRS MED CTR,ANN ARBOR,MI 48105	US Department of Veterans Affairs; Veterans Health Administration (VHA)	McDonnell, WM (corresponding author), WESTERN WASHINGTON MED GRP,EVERETT,WA 98201, USA.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1278	1278		10.1056/NEJM199710303371805	http://dx.doi.org/10.1056/NEJM199710303371805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345077				2022-12-28	WOS:A1997YC92000005
J	Mann, DMA				Mann, DMA			Molecular biology's impact on our understanding of aging	BRITISH MEDICAL JOURNAL			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; E EPSILON-2 ALLELE; SENILE PLAQUES; IN-VIVO; GENE; PRESENILIN-1; LONGEVITY; MUTATION; BRAINS				Mann, DMA (corresponding author), UNIV MANCHESTER,DEPT PATHOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND.							Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COHEN G, 1983, HDB NEUROCHEMISTRY; COHEN G, 1994, NEURODEGENERATIVE DI; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GIBB WRG, 1986, NEUROPATH APPL NEURO, V12, P223, DOI 10.1111/j.1365-2990.1986.tb00136.x; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HEINCKE JW, 1995, MOL ASPECTS AGING; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Lowenstein PR, 1996, PROTOCOLS GENE TRANS; MANN DMA, 1988, MECH AGEING DEV, V43, P99, DOI 10.1016/0047-6374(88)90041-3; MANN DMA, 1990, NEUROPATH APPL NEURO, V16, P17, DOI 10.1111/j.1365-2990.1990.tb00928.x; MILLER RA, 1995, MOL ASPECTS AGING; MORRIS JC, 1991, NEUROLOGY, V41, P469, DOI 10.1212/WNL.41.4.469; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OSIEWACZ HD, 1995, MOL ASPECTS AGING; PICKERINGBROWN SM, 1994, LANCET, V343, P1155, DOI 10.1016/S0140-6736(94)90257-7; PRICE JL, 1991, NEUROBIOL AGING, V12, P295, DOI 10.1016/0197-4580(91)90006-6; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; ROYSTON MC, 1994, NEUROREPORT, V5, P2583, DOI 10.1097/00001756-199412000-00044; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; WALLACE DC, 1995, MOL ASPECTS AGING; WEST HL, 1994, NEUROSCI LETT, V175, P46, DOI 10.1016/0304-3940(94)91074-X	31	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1078	1081		10.1136/bmj.315.7115.1078	http://dx.doi.org/10.1136/bmj.315.7115.1078			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366741	Green Published			2022-12-28	WOS:A1997YD44500032
J	Pahor, M; Applegate, WB				Pahor, M; Applegate, WB			Recent advances - Geriatric medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARDIOVASCULAR-DISEASE; ANTIHYPERTENSIVE TREATMENT; BREAST-CANCER; BETA-CAROTENE; OLDER ADULTS; RISK; INTERVENTION; SUPPLEMENTATION				Pahor, M (corresponding author), UNIV TENNESSEE, DEPT PREVENT MED, MEMPHIS, TN 38105 USA.							AMIONE GT, 1996, J AM COLL CARDIOL, V27, P1201; Banerjee S, 1996, BRIT MED J, V313, P1058; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Egan KM, 1996, J NATL CANCER I, V88, P988, DOI 10.1093/jnci/88.14.988; Forster A, 1996, BRIT MED J, V312, P1642, DOI 10.1136/bmj.312.7047.1642; Gong LS, 1996, J HYPERTENS, V14, P1237, DOI 10.1097/00004872-199610000-00013; Guo ZC, 1996, BRIT MED J, V312, P805, DOI 10.1136/bmj.312.7034.805; Gutthann SP, 1996, ARCH INTERN MED, V156, P2433, DOI 10.1001/archinte.1996.00440200041005; Harris RE, 1996, EPIDEMIOLOGY, V7, P203, DOI 10.1097/00001648-199603000-00017; Helzlsouer KJ, 1996, JNCI-J NATL CANCER I, V88, P32, DOI 10.1093/jnci/88.1.32; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Hirota C, 1996, CANCER-AM CANCER SOC, V78, P1660; Kelly JP, 1996, LANCET, V348, P1413, DOI 10.1016/S0140-6736(96)01254-8; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Lanas A, 1997, GASTROENTEROLOGY, V112, P683, DOI 10.1053/gast.1997.v112.pm9041228; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; Matsuhashi N, 1997, GUT, V40, P344, DOI 10.1136/gut.40.3.344; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; Nyyssonen K, 1997, BRIT MED J, V314, P634, DOI 10.1136/bmj.314.7081.634; OBRIEN J, 1995, BRIT MED J, V311, P1208, DOI 10.1136/bmj.311.7014.1208; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Peleg II, 1996, DIGEST DIS SCI, V41, P1319, DOI 10.1007/BF02088554; Prince MJ, 1996, BMJ-BRIT MED J, V312, P801; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rozzini R, 1996, J AM GERIATR SOC, V44, P1025, DOI 10.1111/j.1532-5415.1996.tb02932.x; Sandercock P, 1997, LANCET, V349, P1569; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Taha AS, 1996, NEW ENGL J MED, V334, P1435, DOI 10.1056/NEJM199605303342204; TSUTAMOTO T, 1996, CIRCULATION S1, V94, P495; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x; YEH M, 1996, CIRCULATION S1, V94, P496	42	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1071	1074		10.1136/bmj.315.7115.1071	http://dx.doi.org/10.1136/bmj.315.7115.1071			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366739	Green Published			2022-12-28	WOS:A1997YD44500030
J	Horton, R				Horton, R			The omnipresent still syndrome	LANCET			English	Article																		GALBRAITH JK, 1994, NEW ENGL J MED, V331, P484; Glasgow-McDowell M A, 1996, N C Med J, V57, P401; SINGER PN, 1997, SELECTED WORKS, P235; Walker A., 1997, AGEING EUROPE; WILLIAMS A, 1997, BMJ-BRIT MED J, V314, P8	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1156	1156		10.1016/S0140-6736(05)63816-0	http://dx.doi.org/10.1016/S0140-6736(05)63816-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343514				2022-12-28	WOS:A1997YB19900042
J	Lye, M				Lye, M			Access to advances in cardiology	LANCET			English	Article							MYOCARDIAL-INFARCTION; DRUG-THERAPY				Lye, M (corresponding author), UNIV LIVERPOOL,UNIV CLIN DEPT,DUNCAN BLDG,LIVERPOOL L69 3GA,MERSEYSIDE,ENGLAND.							Abrahamsson P, 1996, CARDIOL ELDER, V4, P89; ADAMS JN, 1995, BRIT HEART J, V73, P87; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; *DIG INV GROUP, 1997, NEW ENGL J MED, V336, P525; *EUR SEC PREV STUD, 1996, LANCET, V347, P1203; Evans JG, 1997, BRIT MED J, V314, P822, DOI 10.1136/bmj.314.7083.822; Fishkind D, 1997, J AM GERIATR SOC, V45, P809, DOI 10.1111/j.1532-5415.1997.tb01506.x; Gottlieb S, 1997, CIRCULATION, V95, P342; Hall AS, 1997, LANCET, V349, P1493, DOI 10.1016/S0140-6736(97)04442-5; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Krumholz HM, 1997, AM J CARDIOL, V79, P581, DOI 10.1016/S0002-9149(96)00819-3; LYE M, IN PRESS TXB GERIATR; Newman J, 1997, ARCH INTERN MED, V157, P1103; *NHS EX, 1997, EL9741 DEP HLTH NHS; OKEEFFE ST, 1996, HEART FAILURE CLIN P, P47; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Playford DA, 1997, DRUG AGING, V10, P444, DOI 10.2165/00002512-199710060-00005; Ramanathan K, 1996, DRUG AGING, V8, P237, DOI 10.2165/00002512-199608040-00002; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; *TASK FORC WORK GR, 1997, EUR HEART J, V18, P736	20	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1162	1163		10.1016/S0140-6736(97)08414-6	http://dx.doi.org/10.1016/S0140-6736(97)08414-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343518				2022-12-28	WOS:A1997YB19900046
J	Kawano, T; Cui, JQ; Koezuka, Y; Toura, I; Kaneko, Y; Motoki, K; Ueno, H; Nakagawa, R; Sato, H; Kondo, E; Koseki, H; Taniguchi, M				Kawano, T; Cui, JQ; Koezuka, Y; Toura, I; Kaneko, Y; Motoki, K; Ueno, H; Nakagawa, R; Sato, H; Kondo, E; Koseki, H; Taniguchi, M			CD1d-restricted and TCR-mediated activation of V(alpha)14 NKT cells by glycosylceramides	SCIENCE			English	Article							RECEPTOR-ALPHA-CHAIN; T-CELLS; ANTITUMOR ACTIVITIES; POSITIVE SELECTION; BONE-MARROW; EXPRESSION; THYMOCYTES; ANTIGEN; GALACTOSYLCERAMIDES; MOLECULES	Natural killer T (NKT) lymphocytes express an invariant T cell antigen receptor (TCR) encoded by the V(alpha)14 and J(alpha)281 gene segments. A glycosylceramide-containing alpha-anomeric sugar with a longer fatty acyl chain (C-26) and sphingosine base (C-18) was identified as a ligand for this TCR. Glycosylceramide-mediated proliferative responses of V(alpha)14 NKT cells were abrogated by treatment with chloroquine-concanamycin A or by monoclonal antibodies against CD1dN(beta)8, CD40/CD40L, or B7/CTLA-4/CD28, but not by interference with the function of a transporter-associated protein. Thus, this lymphocyte shares distinct recognition systems with either T or NK cells.	CHIBA UNIV,SCH MED,DIV MOL IMMUNOL,CTR BIOMED SCI,CHUO KU,CHIBA 260,JAPAN; PHARMACEUT RES LAB,KIRIN BREWERY,TAKASAKI,GUMMA 37012,JAPAN; JAPAN SCI & TECHNOL CORP,CORE RES EVOL SCI & TECHNOL PROJECT,TOKYO,JAPAN	Chiba University; Kirin Brewery Company Limited; Japan Science & Technology Agency (JST)			Taniguchi, Masaru/N-7932-2015; Koseki, Haruhiko/I-3825-2014	Taniguchi, Masaru/0000-0001-7821-7179; Koseki, Haruhiko/0000-0001-8424-5854				ADACHI Y, 1995, P NATL ACAD SCI USA, V92, P1200, DOI 10.1073/pnas.92.4.1200; ALI S, 1993, BIOCHEMISTRY-US, V32, P11696, DOI 10.1021/bi00094a028; BALLAS ZK, 1990, J IMMUNOL, V145, P1039; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BREIMER ME, 1975, J LIPID RES, V16, P189; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; CORVER J, 1995, J VIROL, V69, P3220, DOI 10.1128/JVI.69.5.3220-3223.1995; COSTANTINO V, 1995, LIEBIGS ANN, P1471; CROSSMAN MW, 1984, BIOCHIM BIOPHYS ACTA, V795, P411, DOI 10.1016/0005-2760(84)90092-4; CROWLEY M, 1989, CELL IMMUNOL, V118, P108, DOI 10.1016/0008-8749(89)90361-4; CUI J, 1997, SCIENCE, V278, P263; DAHIYA R, 1986, LIPIDS, V21, P107, DOI 10.1007/BF02534429; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; IMAI K, 1986, P NATL ACAD SCI USA, V83, P8708, DOI 10.1073/pnas.83.22.8708; JENSEN PE, 1988, J IMMUNOL, V141, P2545; KARLSSON KA, 1973, BIOCHIM BIOPHYS ACTA, V316, P317, DOI 10.1016/0005-2760(73)90072-6; KAWAHARA K, 1994, BIOSCI BIOTECH BIOCH, V58, P600, DOI 10.1271/bbb.58.600; KAWASAKI S, 1994, J BACTERIOL, V176, P284, DOI 10.1128/JB.176.2.284-290.1994; Kobayashi E, 1995, ONCOL RES, V7, P529; Koseki H, 1989, Int Immunol, V1, P557, DOI 10.1093/intimm/1.6.557; LAINE RA, 1987, METHOD ENZYMOL, V138, P186; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LAVIE Y, 1994, BBA-MOL CELL RES, V1220, P323, DOI 10.1016/0167-4889(94)90156-2; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; MAKINO Y, 1995, INT IMMUNOL, V7, P1157, DOI 10.1093/intimm/7.7.1157; Makino Y, 1996, P NATL ACAD SCI USA, V93, P6516, DOI 10.1073/pnas.93.13.6516; MASUDA K, 1997, J IMMUNOL, V158, P276; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Mieza MA, 1996, J IMMUNOL, V156, P4035; MORETTA L, 1994, ADV IMMUNOL, V55, P341; MORITA M, 1995, J MED CHEM, V38, P2176, DOI 10.1021/jm00012a018; MOTOKI K, 1995, BIOL PHARM BULL, V18, P1487; NATORI T, 1993, TETRAHEDRON LETT, V34, P5591, DOI 10.1016/S0040-4039(00)73889-5; NISHIMURA K, 1985, J BIOCHEM-TOKYO, V98, P1247, DOI 10.1093/oxfordjournals.jbchem.a135391; NISHIMURA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P269; OKABE K, 1968, BIOCHEM BIOPH RES CO, V31, P137, DOI 10.1016/0006-291X(68)90043-0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; SVENNERHOLM L, 1972, BIOCHIM BIOPHYS ACTA, V280, P626, DOI 10.1016/0005-2760(72)90142-7; SYKES M, 1990, J IMMUNOL, V145, P3209; Taniguchi M, 1996, P NATL ACAD SCI USA, V93, P11025, DOI 10.1073/pnas.93.20.11025; WATANABE K, 1976, J BIOL CHEM, V251, P2385; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; WOO JT, 1992, EUR J BIOCHEM, V207, P383, DOI 10.1111/j.1432-1033.1992.tb17061.x; YOKOYAMA WM, 1995, P NATL ACAD SCI USA, V92, P3081, DOI 10.1073/pnas.92.8.3081; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	53	2051	2158	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1626	1629		10.1126/science.278.5343.1626	http://dx.doi.org/10.1126/science.278.5343.1626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374463				2022-12-28	WOS:A1997YJ87400042
J	Lidor, C; Nunley, JA				Lidor, C; Nunley, JA			Mucormycosis of the hand and forearm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Lidor, C (corresponding author), DUKE UNIV,MED CTR,DURHAM,NC 27710, USA.								0	7	8	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1511	1511		10.1056/NEJM199711203372105	http://dx.doi.org/10.1056/NEJM199711203372105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366583				2022-12-28	WOS:A1997YG24900005
J	Anderson, RM; Donnelly, CA; Gupta, S				Anderson, RM; Donnelly, CA; Gupta, S			Vaccine design, evaluation, and community-based use for antigenically variable infectious agents	LANCET			English	Article							OUTER-MEMBRANE PROTEIN; HEPATITIS-B; TRANSMISSION DYNAMICS; PLASMODIUM-FALCIPARUM; THEORETICAL FRAMEWORK; MEASLES VACCINATION; EFFICACY; POPULATIONS; DIVERSITY; MALARIA	A major challenge for vaccine design and development, and for trials of new vaccines, is to tackle antigenically variable infectious agents. Here we outline a few general conceptual issues and then discuss new frameworks that are being developed to help understand how vaccination might change the distribution, abundance, and type of strains in a population. Herd immunity is a key concept in population-based immunisation programmes and has to be considered in vaccine design and use even though it may cause a conflict between the needs of the individual versus those of the community. This issue is of increasing importance since once common infections are becoming rare due to effective vaccination. Concomitantly, adverse effects arising from immunisation are becoming more apparent as infection-induced morbidity declines to very low levels. Efficacy is widely regarded as a key criterion in vaccine design but duration of protection is of equal importance. Whether it Is possible to produce effective vaccines to antigenically diverse pathogens remains uncertain but progress towards this goal will be enhanced by a better understanding of the population genetics of the target infectious agent facilitated by molecular epidemiological studies to assess the genetic constitution of pathogen populations and changes therein over time.			Anderson, RM (corresponding author), UNIV OXFORD, DEPT ZOOL, WELLCOME TRUST CTR EPIDEMIOL INFECT DIS, S PARKS RD, OXFORD OX1 4XD, ENGLAND.			Donnelly, Christl/0000-0002-0195-2463; Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AABY P, 1988, LANCET, V2, P809; AGUR Z, 1993, P NATL ACAD SCI USA, V90, P11698, DOI 10.1073/pnas.90.24.11698; ANDERSON R M, 1991; ANDERSON RM, 1994, PHILOS T R SOC B, V346, P457, DOI 10.1098/rstb.1994.0162; ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; Anderson RM, 1996, LANCET, V348, P1010, DOI 10.1016/S0140-6736(96)07100-0; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; Anderson RM, 1996, LANCET, V347, P1778, DOI 10.1016/S0140-6736(96)91609-8; ANDERSON RM, 1995, P ROY SOC B-BIOL SCI, V261, P147, DOI 10.1098/rspb.1995.0129; Antia R, 1996, P NATL ACAD SCI USA, V93, P985, DOI 10.1073/pnas.93.3.985; BABAD HR, 1995, EPIDEMIOL INFECT, V114, P319, DOI 10.1017/S0950268800057976; BELL TA, 1989, SEX TRANSM DIS, V16, P118, DOI 10.1097/00007435-198904000-00015; BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289; BOLKER B, 1993, IMA J MATH APPL MED, V10, P83; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; Farrington CP, 1996, AM J EPIDEMIOL, V143, P961; Feavers IM, 1996, CLIN DIAGN LAB IMMUN, V3, P444, DOI 10.1128/CDLI.3.4.444-450.1996; FEAVERS IM, 1992, MOL MICROBIOL, V6, P489, DOI 10.1111/j.1365-2958.1992.tb01493.x; Ferguson NM, 1996, P NATL ACAD SCI USA, V93, P7231, DOI 10.1073/pnas.93.14.7231; Ferguson NM, 1996, MATH BIOSCI, V138, P101, DOI 10.1016/S0025-5564(96)00127-7; GORMAN OT, 1992, CURR TOP MICROBIOL, V176, P75; GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859; GUPTA S, 1994, P ROY SOC B-BIOL SCI, V256, P231, DOI 10.1098/rspb.1994.0075; GUPTA S, 1994, PARASITE IMMUNOL, V16, P361, DOI 10.1111/j.1365-3024.1994.tb00361.x; Gupta S, 1997, P ROY SOC B-BIOL SCI, V264, P1435, DOI 10.1098/rspb.1997.0200; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437; Halloran ME, 1996, AM J EPIDEMIOL, V144, P83, DOI 10.1093/oxfordjournals.aje.a008858; HALLORAN ME, 1991, EPIDEMIOLOGY, V2, P331, DOI 10.1097/00001648-199109000-00004; Keeling MJ, 1997, SCIENCE, V275, P65, DOI 10.1126/science.275.5296.65; KOOPMAN JS, 1995, AM J EPIDEMIOL, V142, P1113, DOI 10.1093/oxfordjournals.aje.a117564; KOSKINIEMI M, 1989, LANCET, V1, P31; LAU JYN, 1993, LANCET, V342, P1335; Lipsitch M, 1997, P NATL ACAD SCI USA, V94, P6571, DOI 10.1073/pnas.94.12.6571; Longini IM, 1996, J R STAT SOC C-APPL, V45, P165; MCLEAN AR, 1995, P ROY SOC B-BIOL SCI, V261, P389, DOI 10.1098/rspb.1995.0164; NOKES DJ, 1992, LANCET, V339, P1052, DOI 10.1016/0140-6736(92)90572-K; NORDER H, 1993, J GEN VIROL, V74, P1341, DOI 10.1099/0022-1317-74-7-1341; Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; SHORTRIDGE KF, 1995, LANCET, V346, P1210, DOI 10.1016/S0140-6736(95)92906-1; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; Snow RW, 1996, AM J TROP MED HYG, V55, P144, DOI 10.4269/ajtmh.1996.55.2.TM0550020144; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; VANDERLEY P, 1992, INFECT IMMUN, V60, P3156, DOI 10.1128/IAI.60.8.3156-3161.1992; WATSON DA, 1995, EUR J CLIN MICROBIOL, V14, P479, DOI 10.1007/BF02113425; WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6; WILLIAMS JR, 1996, J R COLL PHYSICIANS, V8, P67	49	26	26	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	1997	350	9089					1466	1470		10.1016/S0140-6736(97)03255-8	http://dx.doi.org/10.1016/S0140-6736(97)03255-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371182				2022-12-28	WOS:A1997YF95300046
J	Fisher, GJ; Wang, ZQ; Datta, SC; Varani, J; Kang, S; Voorhees, JJ				Fisher, GJ; Wang, ZQ; Datta, SC; Varani, J; Kang, S; Voorhees, JJ			Pathophysiology of premature skin aging induced by ultraviolet light	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	57th Annual Meeting of the Society-for-Investigative-Dermatology	MAY 01-08, 1996	WASHINGTON, D.C.	Soc Invest Dermatol, Yonsei Univ, Coll Med, Seoul, Korea			TRETINOIN RETINOIC ACID; COLLAGENASE GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TISSUE INHIBITOR; PHOTOAGED SKIN; CROSS-LINKING; I COLLAGEN; METALLOPROTEINASES; DEGRADATION; PROMOTER	Background Long-term exposure to ultraviolet irradiation from sunlight causes premature skin aging (photoaging), characterized in part by wrinkles, altered pigmentation, and loss of skin tone. Photoaged skin displays prominent alterations in the collagenous extracellular matrix of connective tissue. We investigated the role of matrix-degrading metalloproteinases, a family of proteolytic enzymes, as mediators of collagen damage in photoaging. Methods We studied 59 whites (33 men and 26 women, ranging in age from 21 to 58 years) with light-to-moderate skin pigmentation, none of whom had current or prior skin disease. Only some of the participants were included in each of the studies. We irradiated their buttock skin with fluorescent ultraviolet lights under standard conditions and obtained skin samples from irradiated and nonirradiated areas by keratome or punch biopsy. in some studies, tretinoin and its vehicle were applied to skin under occlusion 48 hours before ultraviolet irradiation. The expression of matrix metalloproteinases was determined by in situ hybridization, immunohistology, and in situ zymography. Irradiation-induced degradation of skin collagen was measured by radioimmunoassay of soluble cross-linked telopeptides. The protein lever of tissue inhibitor of matrix metalloproteinases type 1 was determined by Western blot analysis. Results A single exposure to ultraviolet irradiation increased the expression of three matrix metalloproteinases - collagenase, a 92-kd gelatinase, and stromelysin - in skin connective tissue and outer skin layers, as compared with nonirradiated skin. The degradation of endogenous type I collagen fibrils was increased by 58 percent in irradiated skin, as compared with nonirradiated skin. Collagenase and gelatinase activity remained maximally elevated (4.4 and 2.3 times, respectively) for seven days with four exposures to ultraviolet irradiation, delivered at two-day intervals, as compared with base-line levels, Pretreatment of skin with tretinoin (all-trans-retinoic acid) inhibited the induction of matrix metalloproteinase proteins and activity (by 70 to 80 percent) in both connective tissue and outer layers of irradiated skin. Ultraviolet irradiation also induced tissue inhibitor of matrix metalloproteinases-1, which regulates the enzyme. Induction of the inhibitor was not affected by tretinoin. Conclusions Multiple exposures to ultraviolet irradiation lead to sustained elevations of matrix metalloproteinases that degrade skin collagen and may contribute to photoaging. Treatment with topical tretinoin inhibits irradiation-induced matrix metalloproteinases but not their endogenous inhibitor. (C) 1997, Massachusetts Medical Society.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), UNIV MICHIGAN, SCH MED,DEPT DERMATOL,MED SCI 1,RM 6447, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA.		DATTA, SUBHAS CHANDRA/GRY-6638-2022	Scharffetter-Kochanek, Karin/0000-0002-9655-685X				AUTIO P, 1993, ARCH DERMATOL RES, V285, P322, DOI 10.1007/BF00371831; Bernstein EF, 1996, J AM ACAD DERMATOL, V34, P209, DOI 10.1016/S0190-9622(96)80114-9; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; CALDERONE DC, 1995, J AM ACAD DERMATOL, V32, P1016, DOI 10.1016/0190-9622(95)91342-4; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; ELLIS CN, 1990, J AM ACAD DERMATOL, V23, P629, DOI 10.1016/0190-9622(90)70265-J; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; FISHER GJ, 1991, J INVEST DERMATOL, V96, P814; GACK S, 1994, J BIOL CHEM, V269, P10363; GALIS ZS, 1995, FASEB J, V9, P974, DOI 10.1096/fasebj.9.10.7615167; GILCHREST BA, 1992, BRIT J DERMATOL, V127, P25, DOI 10.1111/j.1365-2133.1992.tb16984.x; GRIFFITHS CEM, 1993, NEW ENGL J MED, V329, P530, DOI 10.1056/NEJM199308193290803; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; Kaminer Michael S., 1995, P1; KANG SW, 1995, J INVEST DERMATOL, V105, P549, DOI 10.1111/1523-1747.ep12323445; KAZAMA T, 1988, J INVEST DERMATOL, V91, P560, DOI 10.1111/1523-1747.ep12476939; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; Lavker Robert M., 1995, P123; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; OHKUBO T, 1973, ACTA DERM-VENEREOL, V53, P121; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; RISTELI J, 1993, CLIN CHEM, V39, P635; SATO H, 1993, ONCOGENE, V8, P395; SCHWARTZ E, 1993, PHOTOCHEM PHOTOBIOL, V58, P841, DOI 10.1111/j.1751-1097.1993.tb04981.x; SMITH JG, 1962, J INVEST DERMATOL, V39, P347, DOI 10.1038/jid.1962.122; TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; UITTO J, 1993, DERMATOLOGY GEN MED, V1, P299; WARREN R, 1992, J AM ACAD DERMATOL, V26, P558; WARREN R, 1991, J AM ACAD DERMATOL, V25, P751, DOI 10.1016/S0190-9622(08)80964-4; WEINSTOCK MA, 1994, J INVEST DERMATOL, V102, pS4, DOI 10.1111/1523-1747.ep12385720; WOODLEY DT, 1991, J INVEST DERMATOL, V97, P580, DOI 10.1111/1523-1747.ep12481920; WOOLSON RF, 1987, STATISTICAL METHODS, P314; YAMAUCHI M, 1991, J INVEST DERMATOL, V97, P938	43	979	1048	7	98	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1419	1428		10.1056/NEJM199711133372003	http://dx.doi.org/10.1056/NEJM199711133372003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YF253	9358139				2022-12-28	WOS:A1997YF25300003
J	Lacroix, A; Tremblay, J; Rousseau, G; Bouvier, M; Hamet, P				Lacroix, A; Tremblay, J; Rousseau, G; Bouvier, M; Hamet, P			Propranolol therapy for ectopic beta-adrenergic receptors adrenal Cushing's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; HAMSTER BETA-2-ADRENERGIC RECEPTOR; MESSENGER-RNA LEVELS; BETA-3-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; FIBROBLASTS; EXPRESSION; ADENOMA		CHUM,RES CTR,DEPT MED,MONTREAL,PQ H2W 1T8,CANADA; UNIV MONTREAL,RES GRP AUTON NERVOUS SYST,DEPT BIOCHEM,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal; Universite de Montreal	Lacroix, A (corresponding author), CHUM,RES CTR,DIV ENDOCRINOL,PAVILLON HOTEL DIEU,3850 ST URBAIN,MONTREAL,PQ H2W 1T8,CANADA.		Rousseau, Guy/E-1106-2012; Lacroix, Andre/AAI-5645-2020; Bouvier, Michel/H-2758-2014; Cossette, Suzanne/I-8008-2016	Bouvier, Michel/0000-0003-1128-0100; 				ARCHAMBEAUDMOUV.F, 1996, P 78 ANN M INT END S, P899; BLIN N, 1993, MOL PHARMACOL, V44, P1094; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; deHerder WW, 1996, J CLIN ENDOCR METAB, V81, P3168, DOI 10.1210/jc.81.9.3168; FEVE B, 1990, J BIOL CHEM, V265, P16343; HAMET P, 1987, CLIN INVEST MED, V10, P530; Hieble JP, 1995, PHARM COMMUN, V6, P183; HINSHAW HT, 1974, HORMONES CANCER, P309; HIRATA Y, 1981, J CLIN ENDOCR METAB, V53, P953, DOI 10.1210/jcem-53-5-953; HORIBA N, 1995, J CLIN ENDOCR METAB, V80, P2336, DOI 10.1210/jc.80.8.2336; KATZ MS, 1985, J CLIN ENDOCR METAB, V60, P900, DOI 10.1210/jcem-60-5-900; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; Lacroix A, 1997, J CLIN ENDOCR METAB, V82, P2414, DOI 10.1210/jc.82.8.2414; LEINONEN P, 1991, CLIN ENDOCRINOL, V34, P31, DOI 10.1111/j.1365-2265.1991.tb01732.x; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; MALBON CC, 1988, BIOCHEM BIOPH RES CO, V154, P676, DOI 10.1016/0006-291X(88)90192-1; MATSUKURA S, 1980, CANCER RES, V40, P3768; MILLINGTON DS, 1977, ACTA ENDOCRINOL-COP, V59, P319; NANTEL F, 1993, MOL PHARMACOL, V43, P548; NDIAYE N, 1997, 79 ANN M END SOC MIN, P304; Nieman LK, 1995, ENDOCRINOLOGY, P1741; PERRAUDIN V, 1995, J CLIN ENDOCR METAB, V80, P2661, DOI 10.1210/jc.80.9.2661; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; WILLIAMS LT, 1977, J CLIN INVEST, V59, P319, DOI 10.1172/JCI108643	28	147	154	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1429	1434		10.1056/NEJM199711133372004	http://dx.doi.org/10.1056/NEJM199711133372004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF253	9358140				2022-12-28	WOS:A1997YF25300004
J	Jacobson, SJ; Kopecky, EA; Joshi, P; Babul, N				Jacobson, SJ; Kopecky, EA; Joshi, P; Babul, N			Randomised trial of oral morphine for painful episodes of sickle-cell disease in children	LANCET			English	Article							MANAGEMENT; CRISIS; SCALE; ANALGESIA; TABLETS; IMPACT	Background Oral controlled-release morphine can provide effective analgesia through a non-invasive route and may facilitate outpatient management of severe episodes of sickle-cell pain. We compared the clinical efficacy and safety of oral morphine with continuous intravenous morphine in children with severe episodes of sickle-cell pain, by a double-blind, randomised, parallel-group design. Methods 56 children aged 5-17 years received loading doses of intravenous morphine of up to 0.15 mg/kg, followed by randomly assigned oral morphine 1.9 mg/kg every 12 h plus intravenous placebo (saline), or intravenous morphine 0.04 mg kg(-1) h(-1), plus placebo tablet. Breakthrough pain was treated with oral, immediate-release morphine 0.4 mg/kg every 2-3 h as required. Pain was assessed daily at 0900 h, 1300 h, 1700 h, and 2100 h with a picture face scale, a pictorial scale (Oucher), a behavioural-observational scale (CHEOPS), and by an investigator. Findings 50 children completed the study (28 boys, 22 girls; mean age 11.2 years [SD 3.5]; mean oral morphine dose 2.99 mg/kg daily [0.75]; mean intravenous morphine dose, 0.81 mg/kg daily [0.30]). Mean overall pain scores were similar for oral and intravenous morphine (CHEOPS, 6.3 [1.5] vs 6.4 [1.4], p=0.8; Oucher, 31.5 [25.4] vs 39.2 [21.7], p=0.3; Faces, 2.2 [1.4] vs 2.4 [1.3], p=0.6; clinical rating, 1.7 [0.7] vs 1.9 [0.5], p=0.3). Opioid analgesia was required for a mean of 4.2 days (1.7) and 5.4 days (2.6), respectively (p=0.0591). Pain scores from all scales correlated significantly (r=0.5865-0.8980, p=0.0001). Frequency of rescue analgesia did not differ significantly between the oral and intravenous morphine groups (0.7 [0.8] vs 0.9 [0.7] doses daily, p=0.2). Frequency and severity of adverse events did not differ significantly. Interpretation Oral, controlled-release morphine isa reliable, non-invasive alternative to continuous intravenous morphine for the management of painful episodes of sickle-cell disease in children.	UNIV TORONTO, HOSP SICK CHILDREN, DEPT PEDIAT, DIV CLIN PHARMACOL, TORONTO, ON M5G 1X8, CANADA; PURDUE FREDERICK, PICKERING, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Jacobson, SJ (corresponding author), UNIV TORONTO, HOSP SICK CHILDREN, DEPT PEDIAT, DIV GEN PEDIAT, 555 UNIV AVE, TORONTO, ON M5G 1X8, CANADA.							Babul N, 1993, J Palliat Care, V9, P19; BENJAMIN LJ, 1991, ADV PAIN RES THER, V18, P317; Beyer JE, 1984, OUCHER USERS MANUAL; BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9; BROOKOFF D, 1992, ANN INTERN MED, V116, P364, DOI 10.7326/0003-4819-116-5-364; BROZOVIC M, 1986, LANCET, V2, P624; COLE TB, 1986, AM J DIS CHILD, V140, P1255, DOI 10.1001/archpedi.1986.02140260057025; Conti C, 1996, Md Med J, V45, P33; FRIEDMAN EW, 1986, ANN EMERG MED, V15, P787, DOI 10.1016/S0196-0644(86)80373-0; KAIKO RF, 1989, ROYAL SOC MED SERVIC, V149, P147; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; Portenoy R K, 1990, J Pain Symptom Manage, V5, P307, DOI 10.1016/0885-3924(90)90047-N; PORTER J, 1980, NEW ENGL J MED, V302, P123; POWERS RD, 1986, AM J EMERG MED, V4, P267, DOI 10.1016/0735-6757(86)90083-5; ROBIEUX IC, 1992, PEDIATR HEMAT ONCOL, V9, P317, DOI 10.3109/08880019209016603; SHAPIRO BS, 1995, PAIN, V61, P139, DOI 10.1016/0304-3959(94)00164-A; SHAPIRO BS, 1989, PEDIATR CLIN N AM, V36, P1029; SPRINKLE RH, 1986, AM J PEDIAT HEMATOL, V8, P105; STEINGART R, 1992, MED CLIN N AM, V76, P669, DOI 10.1016/S0025-7125(16)30346-7; TEASDALE G, 1974, LANCET, V2, P81; TERESI ME, 1994, AM J PAIN MANAG, V4, P62; THIRLWELL MP, 1989, CANCER, V63, P2275, DOI 10.1002/1097-0142(19890601)63:11<2275::AID-CNCR2820631136>3.0.CO;2-4; VICHINSKY EP, 1982, AM J PEDIAT HEMATOL, V4, P328; WARFIELD CA, 1993, SEMIN ONCOL, V20, P36	26	68	69	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	1997	350	9088					1358	1361		10.1016/S0140-6736(97)08462-6	http://dx.doi.org/10.1016/S0140-6736(97)08462-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365450				2022-12-28	WOS:A1997YE87200010
J	Look, AT				Look, AT			Oncogenic transcription factors in the human acute leukemias	SCIENCE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANS-RETINOIC ACID; COOPERATIVE DNA-BINDING; PROGRAMMED CELL-DEATH; LONG-TERM REMISSION; HOMEOBOX GENE; DIFFERENTIATION THERAPY; CAENORHABDITIS-ELEGANS	Chromosomal translocations in the human acute leukemias rearrange the regulatory and coding regions of a variety of transcription factor genes. The resultant protein products can interfere with regulatory cascades that control the growth, differentiation, and survival of normal blood cell precursors. Support for this interpretation comes from the results of gene manipulation studies in mice, as well as the sequence homology of oncogenic transcription factors with proteins known to regulate embryonic development in primitive organisms, including the nematode Caenorhabditis elegans and the fruit fly Drosophila melanogaster. Many of these genetic alterations have important prognostic implications that can guide the selection of therapy. The insights gained from studies of translocation-generated oncogenes and their protein products should hasten the development of highly specific, and hence less toxic, forms of leukemia therapy.	UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Look, AT (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.				NCI NIH HHS [CA-20180, CA-59571, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180, R01CA059571, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Askari FK, 1996, NEW ENGL J MED, V334, P316, DOI 10.1056/NEJM199602013340508; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CRIST WM, 1989, BLOOD, V74, P1970; DEAR TN, 1995, DEVELOPMENT, V121, P2909; DIVERIO D, 1993, BLOOD, V82, P3556; FENAUX P, 1995, LEUKEMIA LYMPHOMA, V16, P431, DOI 10.3109/10428199509054430; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Jurlander J, 1996, BLOOD, V88, P2183, DOI 10.1182/blood.V88.6.2183.bloodjournal8862183; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; Look A. Thomas, 1995, P1047; Look AT, 1995, ADV CANCER RES, V67, P25, DOI 10.1016/S0065-230X(08)60709-5; LOOK AT, 1997, METABOLIC BASIS INHE; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Maconochie M, 1996, ANNU REV GENET, V30, P529, DOI 10.1146/annurev.genet.30.1.529; MARTINEZCLIMENT JA, 1995, LEUKEMIA, V9, P95; McLean TW, 1996, BLOOD, V88, P4252; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MILLER WH, 1993, BLOOD, V82, P1689; Mrozek K, 1997, SEMIN ONCOL, V24, P17; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NUCIFORA G, 1993, BLOOD, V82, P712; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PACE U, 1994, CANCER RES, V54, P6365; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1993, BLOOD, V81, P2237; RAIMONDI SC, 1990, J CLIN ONCOL, V8, P1380, DOI 10.1200/JCO.1990.8.8.1380; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROWLEY JD, 1990, SEMIN HEMATOL, V27, P122; Rubnitz JE, 1997, J CLIN ONCOL, V15, P1150, DOI 10.1200/JCO.1997.15.3.1150; Rubnitz JE, 1997, BLOOD, V89, P1143, DOI 10.1182/blood.V89.4.1143; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; STRASSER A, 1995, CURR OPIN IMMUNOL, V7, P228, DOI 10.1016/0952-7915(95)80007-7; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; TOBAL K, 1995, BRIT J HAEMATOL, V91, P104, DOI 10.1111/j.1365-2141.1995.tb05253.x; VANDIJK MA, 1995, MECH DEVELOP, V52, P99, DOI 10.1016/0925-4773(95)00394-G; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	78	938	965	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1059	1064		10.1126/science.278.5340.1059	http://dx.doi.org/10.1126/science.278.5340.1059			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353180				2022-12-28	WOS:A1997YE65200032
J	Cook, JG; Bardwell, L; Thorner, J				Cook, JG; Bardwell, L; Thorner, J			Inhibitory and activating functions for MAPK Kss1 in the S-cerevisiae filamentous-growth signalling pathway	NATURE			English	Article							PHEROMONE RESPONSE PATHWAY; YEAST SACCHAROMYCES-CEREVISIAE; INVASIVE GROWTH; KINASE CASCADE; CELL; GENE; PHOSPHORYLATION; ELEMENTS; FUS3; STE7	Mitogen-activated protein kinase (MAPK) cascades are conserved signalling modules that regulate responses to diverse extracellular stimuli, developmental cues and environmental stresses (reviewed in refs 1-3). A MAPK is phosphorylated and activated by a MAPK kinase (MAPKK), which is activated by an upstream protein kinase, such as Raf, Mos or a MAPKK kinase. Ste7, a MAPKK in the yeast Saccharomyces cerevisiae, is required for two developmental pathways: mating(4) and invasive (filamentous) growth(5,6). Kss1 and Fus3, the MAPK targets of Ste7, are required for mating(7,8), but their role in invasive growth has been unclear.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019; Bardwell, Lee/I-8284-2019	THORNER, Jeremy/0000-0002-2583-500X; Bardwell, Lee/0000-0002-2393-8363; Cook, Jeanette/0000-0003-0849-7405				BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Sherman F., 1986, METHODS YEAST GENETI; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; ZHOU Z, 1995, MOL CELL BIOL, V13, P2069	24	218	220	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	1997	390	6655					85	88		10.1038/36355	http://dx.doi.org/10.1038/36355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363895				2022-12-28	WOS:A1997YE47700057
J	Frisch, M; Glimelius, B; vandenBrule, AJC; Wohlfahrt, J; Meijer, CJLM; Walboomers, JMM; Goldman, S; Svensson, C; Adami, HO; Melbye, M				Frisch, M; Glimelius, B; vandenBrule, AJC; Wohlfahrt, J; Meijer, CJLM; Walboomers, JMM; Goldman, S; Svensson, C; Adami, HO; Melbye, M			Sexually transmitted infection as a cause of anal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN PAPILLOMAVIRUS DNA; HOMOSEXUAL MEN; INTRAEPITHELIAL NEOPLASIA; CARCINOMA; PREVALENCE; DISEASES; PARALLEL; DENMARK; SMOKING; RISK	Background The incidence of anal cancer has increased in recent decades, particularly among women. To identify underlying risk factors, we conducted a population-based case-control study in Denmark and Sweden. Methods We conducted telephone interviews with 324 women and 93 men in whom invasive or in situ anal cancer was diagnosed between 1991 and 1994, 534 controls with adenocarcinoma of the rectum, and 554 population controls. The interviews covered a wide spectrum of possible risk factors for anal cancer. Odds ratios were calculated by logistic regression. Specimens of anal-cancer tissue and samples of rectal adenocarcinomas were tested for human papillomavirus (HPV) DNA with the polymerase chain reaction. Results Multivariate analysis revealed consistent and statistically significant associations between measures of sexual promiscuity and the risk of anal cancer in both men and women. There was a significant trend toward an association between higher numbers of partners of the opposite sex in women (P<0.001) and men (P<0.05) and strong associations with a variety of venereal diseases. In women, receptive anal intercourse, particularly before the age of 30 years, and venereal infections in the partner were also associated with an increased risk (odds ratios, 3.4 and 2.4, respectively). Fifteen percent of the men with anal cancer reported having had homosexual contact, as compared with none of the controls (P<0.001). Highrisk types of HPV, notably HPV-16, were detected in 84 percent of the anal-cancer specimens examined, whereas all rectal-adenocarcinoma specimens tested were negative for HPV. Conclusions Our study provides strong evidence that a sexually transmitted infection causes anal cancer. The presence of high-risk types of HPV, notably HPV-16 (which is known to cause cancer of the cervix), in the majority of anal-cancer tissue specimens suggests that most anal cancers are potentially preventable. (C) 1997, Massachusetts Medical Society.	UNIV UPPSALA HOSP, DEPT ONCOL, S-75185 UPPSALA, SWEDEN; VRIJE UNIV AMSTERDAM, UNIV HOSP, DEPT PATHOL, SECT MOL PATHOL, AMSTERDAM, NETHERLANDS; ERSTA HOSP, DEPT SURG, STOCKHOLM, SWEDEN; HUDDINGE UNIV HOSP, ONCOL DEPT SO STOCKHOLM, STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MED EPIDEMIOL, STOCKHOLM, SWEDEN; HARVARD UNIV, DEPT EPIDEMIOL, BOSTON, MA USA; HARVARD UNIV, HARVARD CTR CANC PREVENT, BOSTON, MA USA	Uppsala University; Uppsala University Hospital; Vrije Universiteit Amsterdam; Ersta Sjukhus; Karolinska Institutet; Karolinska Institutet; Harvard University; Harvard University	Frisch, M (corresponding author), STATENS SERUM INST, DEPT EPIDEMIOL RES, DANISH EPIDEMIOL SCI CTR, DK-2300 COPENHAGEN, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785				Austin D F, 1982, Natl Cancer Inst Monogr, V62, P89; BERAL V, 1974, LANCET, V1, P1037; Binkley George E., 1945, AMER JOUR DIGEST DIS, V12, P46; COOPER HS, 1979, DIS COLON RECTUM, V22, P557, DOI 10.1007/BF02587005; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; DALING JR, 1982, JAMA-J AM MED ASSOC, V247, P1988; DALING JR, 1992, AM J EPIDEMIOL, V135, P180, DOI 10.1093/oxfordjournals.aje.a116270; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; HIGGINS GD, 1991, CANCER-AM CANCER SOC, V68, P561, DOI 10.1002/1097-0142(19910801)68:3<561::AID-CNCR2820680320>3.0.CO;2-R; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HOLM R, 1994, MODERN PATHOL, V7, P449; HOLMES F, 1988, GASTROENTEROLOGY, V95, P107, DOI 10.1016/0016-5085(88)90297-1; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; *IARC, 1995, IARC MON EV CARC RIS, V64; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; JUDSON FN, 1980, AM J EPIDEMIOL, V112, P836, DOI 10.1093/oxfordjournals.aje.a113056; LI FP, 1982, LANCET, V2, P391; MELBYE M, 1992, AM J EPIDEMIOL, V135, P593, DOI 10.1093/oxfordjournals.aje.a116338; MELBYE M, 1994, AM J EPIDEMIOL, V139, P772, DOI 10.1093/oxfordjournals.aje.a117073; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MUNOZ N, 1989, IARC SCI PUBL, V94, P9; NOFFSINGER AE, 1995, CANCER, V75, P958, DOI 10.1002/1097-0142(19950215)75:4<958::AID-CNCR2820750410>3.0.CO;2-1; PALEFSKY JM, 1991, CANCER RES, V51, P1014; PALMER JG, 1989, DIS COLON RECTUM, V32, P1016, DOI 10.1007/BF02553872; SAS INSTITUTE INC., 1996, SAS STAT SOFTW CHANG, p[231, 531]; SCHOLEFIELD JH, 1989, LANCET, V2, P765; SCHOLEFIELD JH, 1990, J CLIN PATHOL, V43, P133, DOI 10.1136/jcp.43.2.133; SCHOLEFIELD JH, 1991, GUT, V32, P674, DOI 10.1136/gut.32.6.674; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; Schottenfeld D, 1996, CANC EPIDEMIOLOGY PR, P813; World Health Organization, 1976, INT CLASS DIS	34	460	474	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1350	1358		10.1056/NEJM199711063371904	http://dx.doi.org/10.1056/NEJM199711063371904			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358129				2022-12-28	WOS:A1997YE44600004
J	Jalan, R; Hayes, PC				Jalan, R; Hayes, PC			Hepatic encephalopathy and ascites	LANCET			English	Article							ATRIAL NATRIURETIC FACTOR; ACUTE LIVER-FAILURE; REFRACTORY ASCITES; CIRRHOTIC-PATIENTS; SYSTEMIC HEMODYNAMICS; HEPATORENAL-SYNDROME; RANDOMIZED TRIAL; INTRAVENOUS ALBUMIN; WATER-RETENTION; DOUBLE-BLIND		ROYAL INFIRM,CTR LIVER & DIGEST DISORDERS,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh	Jalan, R (corresponding author), ROYAL INFIRM,DEPT MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1983, HEPATIC COMA SYNDROM; Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164; BARALDI M, 1983, LIFE SCI, V32, P1417, DOI 10.1016/0024-3205(83)90906-2; Basile AS, 1997, HEPATOLOGY, V25, P1303, DOI 10.1002/hep.510250636; BASILE AS, 1991, PHARMACOL REV, V43, P27; BOSCH J, 1980, GASTROENTEROLOGY, V78, P92; Brensing KA, 1997, LANCET, V349, P697, DOI 10.1016/S0140-6736(97)24010-9; BUTTERWORTH RF, 1994, ADV EXP MED BIOL, V368, P79; DETROYER A, 1976, ANN INTERN MED, V85, P336, DOI 10.7326/0003-4819-85-3-336; EPSTEIN M, 1985, GASTROENTEROLOGY, V89, P1415, DOI 10.1016/0016-5085(85)90664-X; EPSTEIN M, 1985, MINER ELECTROL METAB, V11, P25; Ferenci P, 1996, SEMIN LIVER DIS, V16, P329, DOI 10.1055/s-2007-1007245; FISCHER JE, 1971, LANCET, V2, P75, DOI 10.1016/s0140-6736(71)92048-4; FISCHER JE, 1990, JPEN-PARENTER ENTER, V14, pS249, DOI 10.1177/014860719001400518; Forrest EH, 1996, ALIMENT PHARM THERAP, V10, P219, DOI 10.1111/j.0953-0673.1996.00219.x; GERBES AL, 1995, HEPATOLOGY, V21, P735, DOI 10.1002/hep.1840210321; GINES A, 1993, GASTROENTEROLOGY, V105, P229, DOI 10.1016/0016-5085(93)90031-7; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1988, HEPATOLOGY, V8, P636, DOI 10.1002/hep.1840080333; GINES P, 1991, NEW ENGL J MED, V325, P829, DOI 10.1056/NEJM199109193251201; GINES P, 1986, J HEPATOL, V3, P111; HAYES PC, 1992, AM J GASTROENTEROL, V87, P1433; HENRIKSEN JH, 1994, SEMIN LIVER DIS, V14, P35, DOI 10.1055/s-2007-1007296; HENRIKSEN JH, 1984, J HEPATOL, V1, P55; HINDFELT B, 1977, J CLIN INVEST, V59, P386, DOI 10.1172/JCI108651; Itzhak Y, 1995, BRAIN RES, V705, P345, DOI 10.1016/0006-8993(95)01244-3; Jalan R, 1997, GUT, V40, P664, DOI 10.1136/gut.40.5.664; Jalan R, 1996, HEPATOLOGY, V24, P1298; JONES EA, 1988, Q J MED, V69, P851; Kircheis G, 1997, HEPATOLOGY, V25, P1351, DOI 10.1002/hep.510250609; KREIS R, 1991, NMR BIOMED, V4, P109, DOI 10.1002/nbm.1940040214; LANG F, 1991, HEPATOLOGY, V14, P590, DOI 10.1016/0270-9139(91)90043-U; LAUBENBERGER J, 1996, GASTROENTEROLOGY, V112, P1610; Lebrec D, 1996, J HEPATOL, V25, P135, DOI 10.1016/S0168-8278(96)80065-1; LOCKWOOD AH, 1991, J CEREBR BLOOD F MET, V11, P337, DOI 10.1038/jcbfm.1991.67; MACGILCHRIST A, 1994, CLIN SCI, V87, P329, DOI 10.1042/cs0870329; MANS AM, 1982, J NEUROCHEM, V38, P705, DOI 10.1111/j.1471-4159.1982.tb08689.x; MCCORMICK PA, 1990, GUT, V31, P204, DOI 10.1136/gut.31.2.204; Michalak A, 1996, HEPATOLOGY, V24, P908, DOI 10.1002/hep.510240425; Moore K, 1997, CLIN SCI, V92, P433, DOI 10.1042/cs0920433; MOORE K, 1991, GASTROENTEROLOGY, V100, P1069, DOI 10.1016/0016-5085(91)90284-R; MOORE KP, 1990, J HEPATOL, V11, P262; Moreau R, 1996, J GASTROEN HEPATOL, V11, P857, DOI 10.1111/j.1440-1746.1996.tb00093.x; MORGAN MY, 1987, HEPATOLOGY, V7, P1278, DOI 10.1002/hep.1840070617; Mullen KD, 1996, SEMIN LIVER DIS, V16, P255, DOI 10.1055/s-2007-1007238; OCARROLL RE, 1991, LANCET, V337, P1250, DOI 10.1016/0140-6736(91)92920-W; OCHS A, 1995, NEW ENGL J MED, V332, P1192, DOI 10.1056/NEJM199505043321803; PERSSON PB, 1990, AM J PHYSIOL, V258, pF364, DOI 10.1152/ajprenal.1990.258.2.F364; PLANAS R, 1990, GASTROENTEROLOGY, V99, P1736, DOI 10.1016/0016-5085(90)90481-F; POMIERLAYRARGUE.G, 1995, METAB BRAIN DIS, V10, P351; QUERO JC, 1996, SEMIN LIVER DIS, V16, P343; RINGLARSEN H, 1982, HEPATOLOGY, V2, P304; Rocky D, 1997, HEPATOLOGY, V25, P2, DOI 10.1002/hep.510250102; SCHEDL HP, 1960, J CLIN INVEST, V39, P248, DOI 10.1172/JCI104035; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SIMMONS F, 1970, GASTROENTEROLOGY, V59, P827; SOETERS PB, 1977, J SURG RES, V23, P183, DOI 10.1016/0022-4804(77)90019-1; Spahr L, 1996, HEPATOLOGY, V24, P1116; STAHL J, 1963, ANN INTERN MED, V58, P1, DOI 10.7326/0003-4819-58-1-1; SUSHMA S, 1992, HEPATOLOGY, V16, P138, DOI 10.1002/hep.1840160123; TOBE SW, 1993, AM J KIDNEY DIS, V21, P472, DOI 10.1016/S0272-6386(12)80392-1; Wong F, 1997, J GASTROEN HEPATOL, V12, P437, DOI 10.1111/j.1440-1746.1997.tb00463.x	62	49	52	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1309	1315		10.1016/S0140-6736(97)07503-X	http://dx.doi.org/10.1016/S0140-6736(97)07503-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357420				2022-12-28	WOS:A1997YD68900043
J	Nossal, GJV				Nossal, GJV			Host immunobiology and vaccine development	LANCET			English	Article							T-CELLS; IMMUNE-RESPONSES; INVIVO; SUBSETS	As the rules of immunoregulation become clearer, the design of vaccines and adjuvants is becoming more scientific. To understand these rules, the interactions between three kinds of cells need to be grasped. Antigen-presenting cells (APCs) initiate the immunoglobulin cascade. The most important of these are dendritic cells, which must first capture antigen, a process aided by particulate matter, the presence of natural or acquired antibodies, or the capacity to activate complement. Then T cells become activated through conjoint action of processed antigenic peptides and APC surface and secreted molecules. T cells mediate inflammation, develop cytotoxic capacity, and help in antibody formation. Whether cells of type 1 or type 2 predominate influences the direction of both cellular and humoral responses. B cells are then activated, leading to antibody formation and often to better antigen presentation. Both T and B cell memory, embedded in long-lived lymphocyte populations, aid heightened immune reactivity when the antigen is re-encountered. The best vaccines stimulate strong memory.			Nossal, GJV (corresponding author), UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA.							BERCK C, 1991, CELL, V67, P1121; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; CHILLER JM, 1970, P NATL ACAD SCI USA, V65, P551, DOI 10.1073/pnas.65.3.551; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DONNELLY JJ, 1994, J IMMUNOL METHODS, V176, P145, DOI 10.1016/0022-1759(94)90308-5; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GROSS A, 1993, J IMMUNOL, V150, P2112; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; KELSO A, 1991, IMMUNOL REV, V123, P85, DOI 10.1111/j.1600-065X.1991.tb00607.x; KELSOE G, 1995, IMMUNOL TODAY, V16, P324, DOI 10.1016/0167-5699(95)80146-4; MCKENZIE SJ, 1984, J IMMUNOL, V133, P1818; MILLER JFAP, 1972, INT REV CYTOL, V33, P77, DOI 10.1016/S0074-7696(08)61449-7; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; Nossal G. J. V., 1971, Antigens, lymphoid cells and the immune response.; NOSSAL GJV, 1968, J EXP MED, V128, P839, DOI 10.1084/jem.128.4.839; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SZAKAL AK, 1989, ANNU REV IMMUNOL, V7, P91, DOI 10.1146/annurev.immunol.7.1.91; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	27	28	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1316	1319		10.1016/S0140-6736(97)03257-1	http://dx.doi.org/10.1016/S0140-6736(97)03257-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357421				2022-12-28	WOS:A1997YD68900044
J	Pak, DTS; Pflumm, M; Chesnokov, I; Huang, DW; Kellum, R; Marr, J; Romanowski, P; Botchan, MR				Pak, DTS; Pflumm, M; Chesnokov, I; Huang, DW; Kellum, R; Marr, J; Romanowski, P; Botchan, MR			Association of the origin recognition complex with heterochromatin and HP1 in higher eukaryotes	CELL			English	Article							POSITION-EFFECT VARIEGATION; NONHISTONE CHROMOSOMAL PROTEIN; DNA-REPLICATION; DROSOPHILA-MELANOGASTER; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL STATES; CHROMATIN STRUCTURE; CELL-CYCLE; YEAST; GENE	The origin recognition complex (ORC) is required to initiate eukaryotic DNA replication and also engages in transcriptional silencing in S. cerevisiae. We observed a striking preferential but not exclusive association of Drosophila ORC2 with heterochromatin on interphase and mitotic chromosomes. HP1, a heterochromatin-localized protein required for position effect variegation (PEV), colocalized with DmORC2 at these sites. Consistent with this localization, intact DmORC and HP1 were found in physical complex. The association was shown biochemically to require the chromodomain and shadow domains of HP1. The amino terminus of DmORC1 contained a strong HP1-binding site, mirroring an interaction found independently in Xenopus by a yeast two-hybrid screen. Finally, heterozygous DmORC2 recessive lethal mutations resulted in a suppression of PEV. These results indicate that ORC may play a widespread role in packaging chromosomal domains through interactions with heterochromatin-organizing factors.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA; MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; WELLCOME TRUST & CANC RES CAMPAIGN INST, CAMBRIDGE CB2 1QR, ENGLAND	University of California System; University of California Berkeley; McGill University				Chesnokov, Igor/0000-0002-6659-2913	NCI NIH HHS [CA30490, CA09041] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030490, R37CA030490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3163; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Botchan M, 1996, P NATL ACAD SCI USA, V93, P9997, DOI 10.1073/pnas.93.19.9997; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; EHRENHOFERMURRAY AE, 1995, SCIENCE, V270, P1671, DOI 10.1126/science.270.5242.1671; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Elgin S.C.R., 1978, P112; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; FOE VE, 1989, DEVELOPMENT, V107, P1; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; GATTI M, 1992, ANNU REV GENET, V26, P239, DOI 10.1146/annurev.ge.26.120192.001323; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GATTI M, 1976, CHROMOSOMA, V57, P351, DOI 10.1007/BF00332160; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Harlow E., 1988, ANTIBODIES LAB MANUA; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HENIKOFF S, 1995, CURR TOP MICROBIOL, V197, P193; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELLUM R, 1995, J CELL SCI, V108, P1407; KELLUM R, 1995, J CELL SCI, V108, P1419; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOHE AR, 1993, GENETICS, V134, P1149; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; PAK DTS, 1996, THESIS U CALIFORNIA; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; PIMPINELLI S, 1976, CHROMOSOMA, V57, P377, DOI 10.1007/BF00332161; PIMPINELLI S, 1985, GENETICS, V109, P721; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNELL R, 1986, MOL CELL BIOL, V6, P494, DOI 10.1128/MCB.6.2.494; Silver L M, 1978, Methods Cell Biol, V18, P151; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Spofford J., 1976, GENET BIOL DROSOPHIL, VVolume 1, P955; SZABAD J, 1982, DEV BIOL, V93, P240, DOI 10.1016/0012-1606(82)90256-1; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	66	346	348	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					311	323		10.1016/S0092-8674(00)80415-8	http://dx.doi.org/10.1016/S0092-8674(00)80415-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363940	Bronze			2022-12-28	WOS:A1997YD94100005
J	Musey, L; Hughes, J; Schacker, T; Shea, T; Corey, L; McElrath, MJ				Musey, L; Hughes, J; Schacker, T; Shea, T; Corey, L; McElrath, MJ			Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; HIV-1 INFECTION; LYMPHOCYTE ACTIVITY; LIMITING DILUTION; IMMUNE-RESPONSES; VACCINIA VIRUS; GAG; VIREMIA; GENE; INDIVIDUALS	Background Early in human immunodeficiency virus type 1 (HIV-1) infection there is a decline in viral replication that has been attributed to host immunity, but the components of this response, particularly the ability of cytotoxic T lymphocytes to control viral burden and influence the outcome of disease, are poorly understood. Methods We prospectively studied 33 patients with primary HIV-1 infection for HIV-specific activated cytotoxic T lymphocytes and memory cytotoxic T lymphocytes and compared these lymphocyte responses with changes in viral load and clinical status over the subsequent 18 to 24 months. Results Soon after infection, activated HIV-specific cytotoxic T lymphocytes, mediated primarily by CD8+ cells, were detected in 17 of 23 patients (74 percent). Memory cytotoxic T lymphocytes were found in 6 of 6 patients tested (100 percent) during the first three months of infection and in 17 of 21 patients (81 percent) tested during the first six months. The frequencies of memory cytotoxic T lymphocytes varied markedly over time, but overall they declined over the first 6 to 8 months and then stabilized over the next 12 to 18 months. The patients with higher frequencies of Env-specific memory cytotoxic T lymphocytes had a median level of plasma HIV-1 RNA about one third that of the patients with lower frequencies (median number of RNA copies per milliliter, 22,000 vs. 62,000; P=0.006). Patients with low frequencies of Env-specific memory cytotoxic T lymphocytes (or none) in early infection had a more rapid decline to less than 300 CD4+ cells per cubic millimeter (P=0.05). Conclusions In early HIV-1 infection, the induction of memory cytotoxic T lymphocytes, particularly those specific for Env, helps control viral replication and is associated with slower declines in CD4+ cell counts. Host cytolytic effector responses appear to delay the progression of HIV-1 disease. (C) 1997, Massachusetts Medical Society.	FRED HUTCHINSON CANC RES CTR,PROGRAM INFECT DIS,DIV CLIN RES,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,DEPT BIOSTAT,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757, R01AI035605, R37AI035605] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35605, AI 05065, AI 27757] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Cleveland W.S., 1993, STAT METHODS S, P309; CLOUSE KA, 1989, J CLIN MICROBIOL, V27, P2316, DOI 10.1128/JCM.27.10.2316-2323.1989; Dalod M, 1996, AIDS RES HUM RETROV, V12, P497, DOI 10.1089/aid.1996.12.497; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; Efron B., 1994, MONOGRAPHS STAT APPL; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FLEXNER C, 1988, VIROLOGY, V166, P339, DOI 10.1016/0042-6822(88)90504-1; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; Kagi D, 1995, EUR J IMMUNOL, V25, P3256, DOI 10.1002/eji.1830251209; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LAMHAMEDICHERRADI S, 1995, AIDS, V9, P421, DOI 10.1097/00002030-199509050-00002; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MCFARLAND EJ, 1993, J INFECT DIS, V167, P719, DOI 10.1093/infdis/167.3.719; MCFARLAND EJ, 1994, J INFECT DIS, V170, P766, DOI 10.1093/infdis/170.4.766; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Musey L, 1997, J EXP MED, V185, P293, DOI 10.1084/jem.185.2.293; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RIVIERE Y, 1995, AIDS RES HUM RETROV, V11, P903, DOI 10.1089/aid.1995.11.903; Schacker T, 1997, ANN INTERN MED, V126, P174, DOI 10.7326/0003-4819-126-2-199701150-00024; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SHPAER EG, 1994, AIDS RES HUM RETROV, V10, P1679, DOI 10.1089/aid.1994.10.1679; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; SWAIN SL, 1979, J IMMUNOL, V123, P1062; TASWELL C, 1981, J IMMUNOL, V126, P1614; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537	42	464	492	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1267	1274		10.1056/NEJM199710303371803	http://dx.doi.org/10.1056/NEJM199710303371803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345075				2022-12-28	WOS:A1997YC92000003
J	Uehata, M; Ishizaki, T; Satoh, H; Ono, T; Kawahara, T; Morishita, T; Tamakawa, H; Yamagami, K; Inui, J; Maekawa, M; Narumiya, S				Uehata, M; Ishizaki, T; Satoh, H; Ono, T; Kawahara, T; Morishita, T; Tamakawa, H; Yamagami, K; Inui, J; Maekawa, M; Narumiya, S			Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension	NATURE			English	Article							SERINE/THREONINE KINASE; SIGNAL-TRANSDUCTION; BINDING; PHOSPHATASE; CONTRACTION; INHIBITION; FAMILY; GTPASE; CA-2+; BRAIN	Abnormal smooth-muscle contractility may be a major cause of disease states such as hypertension, and a smooth-muscle relaxant that modulates this process would be useful therapeutically. Smooth-muscle contraction is regulated by the cytosolic Ca2+ concentration and by the Ca2+ sensitivity of myofilaments(1): the former activates myosin light-chain kinase and the latter is achieved partly by inhibition of myosin phosphatase(1-3). The small GTPase Rho and its target, Rho-associated kinase, participate in this latter mechanism in vitro(4-6), but their participation has not been demonstrated in intact muscles. Here we show that a pyridine derivative, Y-27632, selectively inhibits smooth-muscle contraction by inhibiting Ca2+ sensitization. We identified the Y-27632 target as a Rho-associated protein kinase, p160ROCK(7). Y-27632 consistently suppresses Rho-induced, p160ROCK-mediated formation of stress fibres in cultured cells and dramatically corrects hypertension in several hypertensive rat models. Our findings indicate that p160ROCK-mediated Ca2+ sensitization is involved in the pathophysiology of hypertension and suggest that compounds that inhibit this process might be useful therapeutically.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 60601,JAPAN	Kyoto University	Uehata, M (corresponding author), YOSHITOMI PHARMACEUT IND LTD,DISCOVERY RES TOKYO,IRUMA,SAITAMA 358,JAPAN.		Yamagami, Keiji/E-9500-2012					ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BUBIN CS, 1974, METHOD ENZYMOL, V38, P308; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SATOH H, 1984, EUR J PHARMACOL, V97, P321, DOI 10.1016/0014-2999(84)90468-0; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; TAKAYASU M, 1986, J NEUROSURG, V65, P80, DOI 10.3171/jns.1986.65.1.0080; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1	29	2434	2583	1	117	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					990	994		10.1038/40187	http://dx.doi.org/10.1038/40187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353125				2022-12-28	WOS:A1997YD29900061
J	Harvey, I; Frankel, S; Marks, R; Shalom, D; Morgan, M				Harvey, I; Frankel, S; Marks, R; Shalom, D; Morgan, M			Foot morbidity and exposure to chiropody: population based study	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL CARDIFF,COLL MED,DEPT DERMATOL,CARDIFF CF4 4XN,S GLAM,WALES; TEMPLE PEACE & HLTH,CTR APPL PUBL HLTH,CARDIFF CF1 3NW,S GLAM,WALES	Cardiff University	Harvey, I (corresponding author), DEPT SOCIAL MED,CANYNGE HALL,BRISTOL BS8 2PR,AVON,ENGLAND.		Morgan, Maria/D-3379-2009	Morgan, Maria/0000-0002-5182-7222				BENNETT N, 1996, RESULTS 1994 GEN HOU; BRYAN S, 1991, HEALTH POLICY, V18, P169, DOI 10.1016/0168-8510(91)90098-I; CARTWRIGHT A, 1986, MORE TROUBLE FEET; *CHIR TASK FORC, 1994, FEET 1; Harvey I, 1996, BRIT J CANCER, V74, P1302, DOI 10.1038/bjc.1996.534	5	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1054	1055		10.1136/bmj.315.7115.1054	http://dx.doi.org/10.1136/bmj.315.7115.1054			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366731	Green Published			2022-12-28	WOS:A1997YD44500020
J	Greene, EA; Pietrokovski, S; Henikoff, S; Bork, P; Attwood, TK; Hood, L; Bairoch, A				Greene, EA; Pietrokovski, S; Henikoff, S; Bork, P; Attwood, TK; Hood, L; Bairoch, A			Building gene families	SCIENCE			English	Article									EUROPEAN MOL BIOL LAB, HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOL MED, BERLIN, GERMANY; UCL, LONDON WC1E 6BT, ENGLAND; UNIV WASHINGTON, SEATTLE, WA 98195 USA; UNIV GENEVA, CH-1211 GENEVA 4, SWITZERLAND	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of London; University College London; University of Washington; University of Washington Seattle; University of Geneva	Greene, EA (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Bairoch, Amos/X-7411-2019; Bork, Peer/F-1813-2013	Bairoch, Amos/0000-0003-2826-6444; Bork, Peer/0000-0002-2627-833X; Henikoff, Steven/0000-0002-7621-8685; Pietrokovski, Shmuel/0000-0001-8573-5863					0	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					615	626						12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381172				2022-12-28	WOS:A1997YC32300040
J	Holtzman, NA; Murphy, PD; Watson, MS; Barr, PA				Holtzman, NA; Murphy, PD; Watson, MS; Barr, PA			Predictive genetic testing: From basic research to clinical practice	SCIENCE			English	Editorial Material							BREAST-CANCER; DISEASE; MUTATIONS; CHILDREN; COMPLEX; CARRIER		ALBANY MED CTR,DEPT OBSTET & GYNECOL,ALBANY,NY 12208; WASHINGTON UNIV,ST LOUIS CHILDRENS HOSP,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,ST LOUIS CHILDRENS HOSP,SCH MED,DEPT GENET,ST LOUIS,MO 63110; BARR STERNBERG & MOSS PC,BENNINGTON,VT 05201	Albany Medical College; St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Holtzman, NA (corresponding author), JOHNS HOPKINS MED INST,550 N BROADWAY,SUITE 511,BALTIMORE,MD 21205, USA.							*AM SOC CLIN ONC, 1996, J CLIN ONCOL, V14, P1730; *AM SOC HUM GEN, 1994, AM J HUM GENET, V55, P1; *AM SOC HUM GEN, 1990, AM J HUM GENET, V46, P393; [Anonymous], 1995, JAMA, V274, P1627; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Croyle R T, 1995, Womens Health, V1, P329; DESOMVIELE C, 1990, J MED GENET, V27, P34; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; EASTON DF, 1995, AM J HUM GENET, V56, P265; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GUSELLA JF, 1986, NATURE, V323, P118, DOI 10.1038/323118a0; GUSELLA JF, 1986, NATURE, V320, P329; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; Holtzman NA, 1997, EPIDEMIOL REV, V19, P163, DOI 10.1093/oxfordjournals.epirev.a017939; HOLTZMAN NA, 1986, NEW ENGL J MED, V314, P593, DOI 10.1056/NEJM198603063141001; HOLTZMAN NA, 1997, ADV ONCOL, V13, P9; Holtzman NA, 1997, PROMOTING SAFE EFFEC; HOLTZMAN NA, 1996, ACCOUNTABILITY RES, V5, P95; HOWELL RR, IN PRESS NIH CONSENS; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; *NAT I AG ALZH ASS, 1996, LANCET, V347, P1091; *NIH, 1990, NEW ENGL J MED, V323, P70; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; SCHATZKIN A, 1995, J NATL CANCER I, V87, P1126, DOI 10.1093/jnci/87.15.1126; SESHADRI S, 1995, ARCH NEUROL-CHICAGO, V52, P1074, DOI 10.1001/archneur.1995.00540350068018; Smith O, 1996, NAT MED, V2, P613, DOI 10.1038/nm0696-613; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TAMBOR ES, 1994, AM J HUM GENET, V55, P626; TORIBARA NW, 1995, NEW ENGL J MED, V332, P861, DOI 10.1056/NEJM199503303321306; TREACY E, 1995, AM J HUM GENET, V56, P359; VICHINSKY E, 1988, PEDIATRICS, V81, P749; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047; 1993, BALTIMORE SUN   0506, P1; 1995, BALTIMORE SUN   0506, pA3	40	55	55	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					602	605		10.1126/science.278.5338.602	http://dx.doi.org/10.1126/science.278.5338.602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381169				2022-12-28	WOS:A1997YC32300037
J	Kelner, KL				Kelner, KL			The importance of telomerase	SCIENCE			English	Editorial Material																		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822	5	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					600	600		10.1126/science.278.5338.600	http://dx.doi.org/10.1126/science.278.5338.600			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381167				2022-12-28	WOS:A1997YC32300035
J	Patterson, C; Rosenthal, C				Patterson, C; Rosenthal, C			Living a little more dangerously	LANCET			English	Article							HEALTH; RISK; DISCOURSE		MCMASTER UNIV,OFF GERONTOL STUDIES,HAMILTON,ON,CANADA	McMaster University	Patterson, C (corresponding author), MCMASTER UNIV,DIV GERIATR MED,HAMILTON,ON L8N 3Z5,CANADA.							*ASS RES SCI ENJ, 1997, WORKSH VAL PLEAS QUE; CONNIDIS I, 1987, AGING CANADA SOCIAL, P451; KAUFMAN SR, 1994, MED ANTHROPOL Q, V8, P430, DOI 10.1525/maq.1994.8.4.02a00060; LAVE LB, 1987, SCIENCE, V236, P291, DOI 10.1126/science.3563509; LUPTON D, 1993, INT J HEALTH SERV, V23, P425, DOI 10.2190/16AY-E2GC-DFLD-51X2; MACMILLAN MS, 1994, J ADV NURS, V29, P249; RODIN J, 1986, SCIENCE, V233, P1271, DOI 10.1126/science.3749877; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Tierney MC, 1997, CAN J AGING, V16, P177, DOI 10.1017/S0714980800014288	9	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1164	1165		10.1016/S0140-6736(97)08231-7	http://dx.doi.org/10.1016/S0140-6736(97)08231-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB199	9343519				2022-12-28	WOS:A1997YB19900047
J	Longo, DR; Land, G; Schramm, W; Fraas, J; Hoskins, B; Howell, V				Longo, DR; Land, G; Schramm, W; Fraas, J; Hoskins, B; Howell, V			Consumer reports in health care - Do they make a difference in patient care?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; QUALITY; OUTCOMES; ILLNESS; SURGERY	Context.-Consumer reports in health care are a relatively recent phenomenon. Primarily designed to assist consumers in making more informed decisions about their personal health care, they appear to have an important by-product-they led to positive changes in the behavior of clinicians and health care delivery organizations. While there has been much speculation on their impact on health care consumer behavior, consumer reports offer an effective strategy in improving the quality of patient care, Objective.-To examine the impact of an obstetrics consumer report developed and issued by the Missouri Department of Health on hospital behavior. Design and Setting.-A retrospective study of hospital behavior using both primary survey and secondary clinical data. Participants.-Consumer reports were issued in 1993 to all Missouri hospitals providing obstetrical services (n=90). A survey was conducted a year later, and the results were analyzed with other available data to determine the effect of the report, Two hospitals discontinued obstetrical services by the time of the survey; of the remaining 88 hospitals, 82 (93%) responded to the survey. Main Outcome Measures.-The following outcomes were examined: (1) number and percentage of hospitals that previously did not have services at the time report was issued, but had, or planned to have, services after a guide was published; (2) the percentage of obstetrical policies that were changed, planned to change, or are under discussion for change (car seal program, obstetrical follow-up services, formal transfer agreement, nurse educator for breast-feeding, and availability of tubal ligations); and (3) clinical outcomes, including satisfaction, appropriateness of charges, and the rates of cesarean delivery, high-risk infant transfer, ultrasound, vaginal birth after cesarean, very low birth weight, and newborn death. Results.-Within 1 year of the report, approximately 50% of hospitals that did not have car seat programs, formal transfer agreements, or nurse educators for breast-feeding prior to the report either instituted or planned to institute these services. Hospitals in competitive markets that did not offer one of these services at the time of the report were more likely to institute a service and/or were about twice as likely to consider improving several indicators. Clinical outcome indicators all improved in the expected direction. Conclusion.-Public release of consumer reports may be useful not only in assisting consumers to make informed health care choices, but also in facilitating improvement in the quality of hospital services offered and care provided, Changes occur especially in competitive markets.	MISSOURI DEPT HLTH,DEPT HLTH RESOURCES,JEFFERSON CITY,MO		Longo, DR (corresponding author), UNIV MISSOURI,SCH MED,DEPT FAMILY & COMMUNITY MED,MA306 MED SCI BLDG,COLUMBIA,MO 65212, USA.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				*AG HLTH CAR POL R, 1995, EFF DISS HLTH CLIN I; ANDERSON OW, 1982, HEALTH SERV RES, V17, P125; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; *CLEV HLTH QUAL CH, 1993, SUMM REP APR 28 1993; Donabedian A, 1992, QRB Qual Rev Bull, V18, P356; DONABEDIAN A, 1980, DEFINITION QUALITY A; Donabedian A, 1980, EXPLORATIONS QUALITY, V1; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; *FAULKN GRAYS HLTH, 1994, MED QUAL MAN SOURC; GEERTSMA RH, 1982, J MED EDUC, V57, P752; Green J, 1997, JAMA-J AM MED ASSOC, V277, P1152, DOI 10.1001/jama.277.14.1152; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HANNAN EL, 1992, HEALTH SERV RES, V27, P517; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HIBBARD J, 1995, PUBLICATION US DEP C; Hibbard JH, 1996, MED CARE RES REV, V53, P28, DOI 10.1177/107755879605300102; Jensen C K, 1992, QRB Qual Rev Bull, V18, P164; KAPLAN SH, 1989, PROVIDING QUALITY CA, P25; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; Land G, 1995, J Public Health Manag Pract, V1, P35; Longo D R, 1994, Am J Med Qual, V9, P104, DOI 10.1177/0885713X9400900302; Longo D R, 1994, Int J Qual Health Care, V6, P133; LONGO DR, 1994, ARCH FAM MED, V3, P37; LUKACIK G, 1992, JAMA-J AM MED ASSOC, V268, P3092; Malcolm J A Jr, 1992, Pa Med, V95, P12; Malcolm J A Jr, 1992, Pa Med, V95, P18; McGee J, 1994, J Ambul Care Manage, V17, P1; *MISS DEP HLTH, 1994, SHOWM BUY GUID OUTP; *MISS DEP HLTH, 1994, SHOWM BUY GUID OBST; *MISS DEP HLTH, 1995, SHOWM BUY GUID OUTP; NASH DB, 1989, PROVIDING QUALITY CA, P5; Nightingale F., 1969, NOTES NURSING WHAT I; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; Pauly M V, 1996, Am J Med Qual, V11, P112, DOI 10.1177/0885713X9601100302; REISER SJ, 1993, JAMA-J AM MED ASSOC, V269, P1012, DOI 10.1001/jama.269.8.1012; *RES TRIANGL I, 1995, 282920045 RES TRIANG; RICHARDS T, 1994, STATEWIDE METROPOLIT; Rogers EM., 1983, DIFFUSION INNOVATION; SHEILS JF, MANAGED CARE MISSOUR; Sirio C A, 1996, Am J Med Qual, V11, pS82; Sirio C A, 1996, Am J Med Qual, V11, pS78; Tilley S, 1996, Am J Med Qual, V11, pS22; *US C, 1988, QUAL MED CAR INF CON; *US GEN ACC OFF, 1994, HLTH CAR REF REP CAR; Ziegenfuss J T Jr, 1996, Am J Med Qual, V11, P55, DOI 10.1177/0885713X9601100201; 1993, QI TQM, V3, P178	48	91	91	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1579	1584		10.1001/jama.278.19.1579	http://dx.doi.org/10.1001/jama.278.19.1579			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YF407	9370503				2022-12-28	WOS:A1997YF40700038
J	Husman, AMD; Koot, M; Cornelissen, M; Keet, IPM; Brouwer, M; Broersen, SM; Bakker, M; Roos, MTL; Prins, M; deWolf, F; Coutinho, RA; Miedema, F; Goudsmit, J; Schuitemaker, H				Husman, AMD; Koot, M; Cornelissen, M; Keet, IPM; Brouwer, M; Broersen, SM; Bakker, M; Roos, MTL; Prins, M; deWolf, F; Coutinho, RA; Miedema, F; Goudsmit, J; Schuitemaker, H			Association between CCR5 genotype and the clinical course of HIV-1 infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; CCR5 genotype; biological markers; viral load; CD4 lymphocyte count	HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; TYPE-1 INFECTION; HOMOSEXUAL-MEN; BIOLOGICAL PHENOTYPE; PROGRESSION; AIDS; INDIVIDUALS; RECEPTOR; PATHOGENESIS	Background: Heterozygosity for a 32-nucleotide deletion in the C-C chemokine receptor 5 gene (CCR5 Delta 32) is associated with delayed disease progression in persons infected with HIV-1. Objective: To compare the predictive value of CCR5 genotype with that of established markers in the clinical course of HIV-1 infection. Design: Retrospective longitudinal study and nested case-control study. The latter included only long-term survivors, who were individually matched with progressors. Setting: Amsterdam, the Netherlands. Participants: 364 homosexual men with HIV-1 infection. Measurements: Polymerase chain reaction was used for CCR5 genotyping. Univariate and multivariate Cox proportional hazard analyses were done for disease progression with CCR5 genotype, CD4(+) T-lymphocyte counts, T-lymphocyte function, HIV-1 biological phenotype (syncytium-inducing or non-syncytium-inducing HIV-1), and viral RNA load in serum as covariates. Results: In the case-control study, 48% of long-term survivors were heterozygous for CCR5 Delta 32 compared with 9% of progressors (odds ratio, 6.9 [95% CI, 1.9 to 24.8]). in the total study sample, CCR5 Delta 32 heterozygotes had significantly delayed disease progression (P < 0.001; relative hazard, 0.4 [CI, 0.3 to 0.6]), a 1.5-fold slower decrease in CD4(+) T-lymphocyte count (P = 0.01), and a 2.6-fold lower viral RNA load (P = 0.01) at approximately 2.3 years after seroconversion compared with CCR5 wild-type homozygotes. At the end of the study, both groups showed the same prevalence of syncytium-inducing HIV-1, but CCR5 Delta 32 heterozygotes had a delayed conversion rate. The protective effect of CCR5 Delta 32 heterozygosity was stronger in the presence of only non-syncytium-inducing HIV-1. The CCR5 genotype predicted disease progression independent of viral RNA load, CD4(+) T-lymphocyte counts, T-lymphocyte function, and HIV-1 biological phenotype. Conclusions: The addition of CCR5 genotype to currently available laboratory markers may allow better estimation of the clinical course of HIV-1 infection.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT CLIN VIROIMMUNOL, NL-1066 CX AMSTERDAM, NETHERLANDS; DEPT CLIN VIROIMMUNOL, LAB EXPT & CLIN IMMUNOL, NL-1066 CX AMSTERDAM, NETHERLANDS									Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DEGRUTTOLA V, 1994, BIOMETRICS, V50, P1003, DOI 10.2307/2533439; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615; DEWOLF F, IN PRESS AIDS; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Faucett CL, 1996, STAT MED, V15, P1663, DOI 10.1002/(SICI)1097-0258(19960815)15:15<1663::AID-SIM294>3.0.CO;2-1; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; Fouchier RAM, 1995, AIDS RES HUM RETROV, V11, P1473, DOI 10.1089/aid.1995.11.1473; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; Koot M, 1996, J INFECT DIS, V173, P349, DOI 10.1093/infdis/173.2.349; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; PHILLIPS AN, 1992, AIDS, V6, P1391, DOI 10.1097/00002030-199211000-00025; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; VANGEMEN B, 1994, J VIROL METHODS, V49, P157, DOI 10.1016/0166-0934(94)90040-X; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665; 1987, MMWR-MORBID MORTAL W, V36, P15	41	228	231	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					882	+		10.7326/0003-4819-127-10-199711150-00004	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382366				2022-12-28	WOS:A1997YF54500004
J	Sachs, F				Sachs, F			In defence of small science	NATURE			English	Editorial Material							NIH				Sachs, F (corresponding author), SUNY BUFFALO, DEPT BIOPHYS SCI, BUFFALO, NY 14124 USA.							Bray GA, 1999, DIABETES CARE, V22, P623; CHANDRA S, 1989, P NATL ACAD SCI USA, V86, P1870, DOI 10.1073/pnas.86.6.1870; GARRISON HH, 1995, FASEB J, V9, P703, DOI 10.1096/fasebj.9.9.7601333; Jones S., 1993, LANGUAGE GENES BIOL; MANDEL HG, 1995, SCIENCE, V269, P13, DOI 10.1126/science.7604271; RUZEK DL, 1996, TRENES US FUNDING BI; Sachs F, 1997, NATURE, V388, P222, DOI 10.1038/40736; SACHS F, 1993, NATURE, V363, P578, DOI 10.1038/363578b0; Wenneras C, 1997, NATURE, V387, P341, DOI 10.1038/387341a0	9	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	1997	390	6656					203	203		10.1038/36643	http://dx.doi.org/10.1038/36643			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367161				2022-12-28	WOS:A1997YF49400065
J	Hartwell, LH; Szankasi, P; Roberts, CJ; Murray, AW; Friend, SH				Hartwell, LH; Szankasi, P; Roberts, CJ; Murray, AW; Friend, SH			Integrating genetic approaches into the discovery of anticancer drugs	SCIENCE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; ATAXIA-TELANGIECTASIA; FUNCTIONAL HOMOLOG; DROSOPHILA; AMPLIFICATION; RESISTANCE; PATHWAYS; PROTEIN	The discovery of anticancer drugs is now driven by the numerous molecular alterations identified in tumor cells over the past decade. To exploit these alterations, it is necessary to understand how they define a molecular context that allows increased sensitivity to particular compounds. Traditional genetic approaches together with the new wealth of genomic information for both human and model organisms open up strategies by which drugs can be profiled for their ability to selectively kill cells in a molecular context that matches those found in tumors. Similarly, it may be possible to identify and validate new targets for drugs that would selectively kill tumor cells with a particular molecular context. This article outlines some of the ways that yeast genetics can be used to streamline anticancer drug discovery.	FRED HUTCHINSON CANC RES CTR, DEPT MOL PHARMACOL, SEATTLE PROJECT, SEATTLE, WA 98109 USA; ROSETTA INPHARMAT INC, KIRKLAND, WA 98034 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94142 USA	Fred Hutchinson Cancer Center; University of California System; University of California San Francisco					NCI NIH HHS [N01-BC65017] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Broach JR, 1991, CURR OPIN GENET DEV, V1, P370, DOI 10.1016/S0959-437X(05)80302-8; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHEN JM, 1992, CARCINOGENESIS, V13, P1503; COMIS RL, 1994, SEMIN ONCOL, V21, P109; Couture LA, 1996, TRENDS GENET, V12, P510, DOI 10.1016/S0168-9525(97)81398-4; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DOYE V, 1995, TRENDS GENET, V11, P235, DOI 10.1016/S0168-9525(00)89057-5; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Dunn CJ, 1996, DRUG AGING, V9, P122, DOI 10.2165/00002512-199609020-00007; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; FRIEDBERG EC, 1995, DNA REPAIR; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Hoffmann FM, 1992, CURR OPIN GENET DEV, V2, P45, DOI 10.1016/S0959-437X(05)80320-X; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JEGGO PA, 1989, CANCER RES, V49, P7057; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KAYNE PS, 1995, CURR OPIN GENET DEV, V5, P38, DOI 10.1016/S0959-437X(95)90051-9; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kornberg A., 1991, DNA REPLICATION; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Lydall D, 1996, CURR OPIN GENET DEV, V6, P4, DOI 10.1016/S0959-437X(96)90003-9; MEYN MS, 1995, CANCER RES, V55, P5991; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; NIWA O, 1995, CANCER RES, V55, P5670; Perlmutter RM, 1996, CURR OPIN IMMUNOL, V8, P285, DOI 10.1016/S0952-7915(96)80069-0; Perry M.C., 1996, CHEMOTHERAPY SOURCE, Vsecond; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Silber JR, 1996, P NATL ACAD SCI USA, V93, P6941, DOI 10.1073/pnas.93.14.6941; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smith G, 1995, CANCER SURV, V25, P27; STERNBERG PW, 1994, COLD SPRING HARB SYM, V59, P155, DOI 10.1101/SQB.1994.059.01.019; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; THORNTON BR, UNPUB; TISTY TD, 1993, COLD SPRING HARB SYM, V58, P645; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WANI MA, 1994, CANCER RES, V54, P2504; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Williams BO, 1996, CURR OPIN GENET DEV, V6, P65; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Zhou P, 1996, CANCER RES, V56, P36	73	559	673	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1064	1068		10.1126/science.278.5340.1064	http://dx.doi.org/10.1126/science.278.5340.1064			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353181				2022-12-28	WOS:A1997YE65200033
J	Tu, YP; Wang, J; Ross, EM				Tu, YP; Wang, J; Ross, EM			Inhibition of brain G(z) GAP and other RGS proteins by palmitoylation of G protein alpha subunits	SCIENCE			English	Article							BINDING REGULATORY PROTEIN; GTPASE-ACTIVATING PROTEINS; LIPID MODIFICATIONS; MEMBRANE ATTACHMENT; PERTUSSIS TOXIN; AMINO-TERMINUS; BETA-GAMMA; MYRISTOYLATION; RECEPTOR; G(S-ALPHA)	Palmitoylation of the alpha subunit of the guanine nucleotide-binding protein G(z) inhibited by more than 90 percent its response to the guanosine triphosphatase (GTPase)-accelerating activity of G(z) GAP, a G(z)-selective member of the regulators of G-protein signaling (RGS) protein family of GTPase-activating proteins (GAPs). Palmitoylation both decreased the affinity of G(z) GAP for the GTP-bound form of G alpha(z) by at least 90 percent and decreased the maximum rate of GTP hydrolysis. Inhibition was reversed by removal of the palmitoyl group by dithiothreitol. Palmitoylation of G alpha(z) also inhibited its response to the GAP activity of G alpha-interacting protein (GAIP), another RGS protein, and palmitoylation of G alpha(l1) inhibited ils response to RGS4. The extent of inhibition of G(z) GAP, GAIP, RGS4, and RGS10 correlated roughly with their intrinsic GAP activities for the G alpha target used in the assay. Reversible palmitoylation is thus a major determinant of G(z) deactivation after its stimulation by receptors, and may be a general mechanism for prolonging or potentiating G-protein signaling.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM30355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BRANDT DR, 1985, J BIOL CHEM, V260, P266; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FERGUSON KM, 1991, METHOD ENZYMOL, V195, P188; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Galbiati F, 1996, BIOCHEM J, V313, P717, DOI 10.1042/bj3130717; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; Hepler J.R., 1997, P NATL ACAD SCI USA, V94, p428; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MILLIGAN G, 1995, BIOCHEM SOC T, V23, P583, DOI 10.1042/bst0230583; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TU Y, UNPUB; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	39	119	123	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1132	1135		10.1126/science.278.5340.1132	http://dx.doi.org/10.1126/science.278.5340.1132			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353196				2022-12-28	WOS:A1997YE65200055
J	Braunwald, E				Braunwald, E			Shattuck lecture - Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Massachusetts-Medical-Society	MAY 17, 1997	BOSTON, MA	Massachusetts Med Soc			MYOCARDIAL-INFARCTION; RISK FACTOR; DISEASE; HEART; ATHEROSCLEROSIS; HYPERTENSION; PRAVASTATIN; RECEPTOR; MEN		HARVARD UNIV, SCH MED, PARTNERS HLTH CARE SYST, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Partners Healthcare System; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital								ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; *AM HEART DIS, 1997, 1997 HEART STROK STA; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, NEW ENGL J MED, V318, P262; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1997, FACT BOOK FISC YEAR; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; ANTMAN EM, 1997, HEART DIS TXB CARDIO, P1184; BING OHL, 1994, J MOL CELL CARDIOL, V26, P943, DOI 10.1006/jmcc.1994.1115; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Burt VL, 1996, HYPERTENSION, V27, P1192; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Cusi D, 1997, LANCET, V349, P1353, DOI 10.1016/S0140-6736(97)01029-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; Graves EJ, 1997, VITAL HLTH STAT, V13; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; HERMANN HC, 1997, HEART WATCH 1997 ANN; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; ISNER JM, 1995, CIRCULATION, V91, P2687, DOI 10.1161/01.CIR.91.11.2687; Kajstura J, 1996, AM J PHYSIOL-HEART C, V271, pH1215, DOI 10.1152/ajpheart.1996.271.3.H1215; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; KOUWENHOVEN WB, 1957, SURGERY, V42, P550; LAWRENCE L, 1986, VITAL HLTH STAT, V13; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIEBERMAN EH, 1994, ANN INTERN MED, V121, P936, DOI 10.7326/0003-4819-121-12-199412150-00005; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P672, DOI 10.1161/01.ATV.10.5.672; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Murray CJL, 1996, GLOBAL BURDEN DIS IN, V1; *NAT HEART LUNG BL, 1996, MORB MORT 1996 CHART; National Center for Health Statistics, 1990, VIT STAT US 1990 1 A, V2; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; OLIVETTI G, 1995, J AM COLL CARDIOL, V26, P1068, DOI 10.1016/0735-1097(95)00282-8; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; PEDERSEN TR, 1994, LANCET, V344, P1383; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Saketkhou BB, 1997, ANN INTERN MED, V127, P126, DOI 10.7326/0003-4819-127-2-199707150-00005; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SINGH GK, 1994, MON VITAL STAT REP, V43; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Yang NN, 1997, SCIENCE, V275, P1249; 1948, NY TIMES        0711, P3	56	1047	1091	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1360	1369		10.1056/NEJM199711063371906	http://dx.doi.org/10.1056/NEJM199711063371906			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YE446	9358131	Bronze			2022-12-28	WOS:A1997YE44600006
J	Graham, JD; Thompson, KM; Goldie, SJ; SeguiGomez, M; Weinstein, MC				Graham, JD; Thompson, KM; Goldie, SJ; SeguiGomez, M; Weinstein, MC			The cost-effectiveness of air bags by seating position	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRIVER FATALITIES; BELT USE; HEALTH; QUESTION	Context.-Motor vehicle crashes continue to cause significant mortality and morbidity in the United States. Installation of air bags in new passenger vehicles is a major initiative in the field of injury prevention. Objective.-To assess the net health consequences and cost-effectiveness of driver's side and front passenger air bags from a societal perspective, taking into account the increased risk to children who occupy the front passenger seat and the diminished effectiveness for older adults. Design.-A deterministic state transition model tracked a hypothetical cohort of new vehicles over a 20-year period for 3 strategies: (1) installation of safety belts, (2) installation of driver's side air bags in addition to safety belts, and (3) installation of front passenger air bags in addition to safety belts and driver's side air bags. Changes in health outcomes, valued in terms of quality-adjusted life-years (QALYs) and costs (in 1993 dollars), were projected following the recommendations of the Panel on Cost-effectiveness in Health and Medicine. Participants.-US population-based and convenience sample data were used. Main Outcome Measure.-Incremental cost-effectiveness ratios. Results.-Safety belts are cost saving, even at 50% use. The addition of driver's side air bags to safety belts results in net health benefits at an incremental cost of $24 000 per QALY saved. The further addition of front passenger air bags results in an incremental net benefit at a higher incremental cost of $61 000 per QALY saved. Results were sensitive to the unit cost of air bag systems, their effectiveness, baseline fatality rates, the ratio of injuries to fatalities, and the real discount rate. Conclusions.-Both air bag systems save life-years at costs that are comparable to many medical and public health practices. Immediate steps can be taken to enhance the cost-effectiveness of front passenger air bags, such as moving children to the rear seat.			Graham, JD (corresponding author), HARVARD UNIV,SCH PUBL HLTH,CTR RISK ANAL,718 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Thompson, Kimberly/0000-0002-0849-9147				*AM AUT MAN ASS, 1996, MOT VEH FACTS FIG; *AM HOND MOT CO, 1996, ODYSS 1996 OWN MAN, V16, P140; ARNOULD RJ, 1981, BELL J ECON, V12, P27, DOI 10.2307/3003507; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BLINCOE LJ, 1996, EC COST MOTOR VEHICL; BREED DS, 1992, CHRONIC DIS CANAD S4, V14, pS70; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P87; DALMOTAS DJ, 1995, J TRAUMA, V38, P476, DOI 10.1097/00005373-199504000-00002; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; ERICKSON P, 1995, US DEP HLTH HUM SERV; EVANS L, 1986, ACCIDENT ANAL PREV, V18, P229, DOI 10.1016/0001-4575(86)90007-2; FERGUSON SA, 1996, UPDATE AIRBAG PERFOR; FERGUSON SA, 1996, INITIAL ESTIMATES RE; FERGUSON SA, 1995, DRIVER FATALITIES 19; FILDES B, 1996, 96S5O17 MON U; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GARTHE EA, 1996, 40 ANN M ASS ADV AUT; Gold MR, 1996, COST EFFECTIVENESS H; GRAHAM JD, 1984, RISK ANAL, V4, P25, DOI 10.1111/j.1539-6924.1984.tb00129.x; Graham John D., 1989, AUTO SAFETY ASSESSIN; HUELKE DF, 1992, J TRAUMA, V33, P894, DOI 10.1097/00005373-199212000-00017; Institute of Medicine, 1985, INJ AM CONT PUBL HLT; KAHANE C, 1996, FATAILITY REDUCTION; Lee TT, 1997, ANN INTERN MED, V126, P337, DOI 10.7326/0003-4819-126-5-199703010-00001; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LUND AK, 1995, J TRAUMA, V38, P469, DOI 10.1097/00005373-199504000-00001; MacKenzie EJ, 1996, J TRAUMA, V41, P799, DOI 10.1097/00005373-199611000-00006; Manche EE, 1997, OPHTHALMIC SURG LAS, V28, P246; MANDELBLATT JS, 1988, JAMA-J AM MED ASSOC, V259, P2409, DOI 10.1001/jama.259.16.2409; *MICR CORP, 1993, MICR EXC US GUID VER; *NAT HIGHW TRAFF S, 1995, TRAFF SAF FACTS 1994; *NAT HIGHW TRAFF S, 1996, EFF OCC PROT SYST TH; *NAT HIGHW TRAFF S, 1997, FIN REG EV ACT RED A; *NAT HIGHW TRAFF S, 1984, 208 US DEP TRANSP NA; *NAT HIGHW TRAFF S, 1993, FMVSS 208 MAND AIRB, P5; *NAT HIGHW TRAFF S, 1992, COOST EST MAN AUT CR; *NAT TRANSP SAF BO, 1996, NTSBSS9601; RICE DP, 1989, COST INJURY US REP C; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; SEGUIGOMEZ M, 1996, APPL FUNCTIONAL CAPA; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; *TREEAG SOFTW INC, 1996, TREEAG DAT 3 0 US MA; WEBER K, 1993, 933094 SOC AUT ENG I; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WERNER JV, 1994, 940802 SOC AUT ENG I; Williams AF, 1996, J SAFETY RES, V27, P33, DOI 10.1016/0022-4375(95)00027-5; WILLIAMS AF, 1987, ACCIDENT ANAL PREV, V19, P243, DOI 10.1016/0001-4575(87)90059-5; ZADOR PL, 1993, AM J PUBLIC HEALTH, V83, P661, DOI 10.2105/AJPH.83.5.661; 1997, FED REG         0319, V62, P12960	50	72	72	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1418	1425		10.1001/jama.278.17.1418	http://dx.doi.org/10.1001/jama.278.17.1418			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC917	9356000				2022-12-28	WOS:A1997YC91700028
J	OFlynn, N; Spencer, J; Jones, R				OFlynn, N; Spencer, J; Jones, R			Consent and confidentiality in teaching in general practice: survey of patients' views on presence of students	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,SCH HLTH SCI,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV LONDON,UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	Newcastle University - UK; University of London; King's College London	OFlynn, N (corresponding author), LAMBETH WALK GRP PRACTICE,LONDON SE11 6SP,ENGLAND.							Cooke F, 1996, BRIT J GEN PRACT, V46, P361; *GEN MED COUNC, 1993, TOM DOCT REC UND MED; ROBINSON LA, 1994, BRIT J GEN PRACT, V44, P489; SEABROOK M, 1994, WIDENING HORIZONS ME; WRIGHT HJ, 1974, BRIT MED J, V1, P372, DOI 10.1136/bmj.1.5904.372	5	59	61	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1142	1142						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374890				2022-12-28	WOS:A1997YE61500030
J	Ricciardolo, FLM; DiMaria, GU; Mistretta, A; Sapienza, MA; Geppetti, P				Ricciardolo, FLM; DiMaria, GU; Mistretta, A; Sapienza, MA; Geppetti, P			Impairment of bronchoprotection by nitric oxide in severe asthma	LANCET			English	Article							BRADYKININ		UNIV CATANIA, INST RESP DIS, I-95125 CATANIA, ITALY; UNIV FERRARA, DEPT CLIN & EXPT MED, PHARMACOL UNIT, I-44100 FERRARA, ITALY	University of Catania; University of Ferrara			Ricciardolo, F. L. M./K-5330-2018; Geppetti, Pierangelo/AHA-7897-2022	Ricciardolo, F. L. M./0000-0003-1826-5018; 				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Figini M, 1996, AM J RESP CRIT CARE, V153, P918, DOI 10.1164/ajrccm.153.3.8630573; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9	5	54	54	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1297	1298		10.1016/S0140-6736(05)62474-9	http://dx.doi.org/10.1016/S0140-6736(05)62474-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357414				2022-12-28	WOS:A1997YD68900016
J	Guenther, B; Onrust, R; Sali, A; ODonnell, M; Kuriyan, J				Guenther, B; Onrust, R; Sali, A; ODonnell, M; Kuriyan, J			Crystal structure of the delta' subunit of the cramp-loader complex of E-coli DNA polymerase III	CELL			English	Article							ESCHERICHIA-COLI; ADENYLATE KINASE; PROTEIN COMPLEX; GAMMA-SUBUNIT; ATP SYNTHASE; REPLICATION; HOLOENZYME; RESOLUTION; MECHANISM; TRIPHOSPHATE	The crystal structure of the delta' subunit of the clamp-loader complex of E. coli DNA polymerase III has been determined. Three consecutive domains in the structure are arranged in a C-shaped architecture. The N-terminal domain contains a nonfunctional nucleotide binding site. The catalytic component of the clamp-loader complex is the gamma subunit, which is homologous to delta'. A sequence-structure alignment suggests that nucleotides bind to gamma at an interdomain interface within the inner surface of the ''C.'' Th, alignment is extended to other clamp-loader complexes and to the RuvB family of DNA helicases, and suggests that each of these is assembled from C-shaped components that can open and close the jaws of the ''C'' in response to ATP binding and hydrolysis.	HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University				O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM54762, GM 38839, GM 45547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054762, R37GM038839, R01GM054762, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CRONET P, 1995, J MOL BIOL, V249, P654, DOI 10.1006/jmbi.1995.0326; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GUENTHER BD, 1996, THESIS ROCKEFELLER U; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOONIN EV, 1991, P NATL ACAD SCI USA, V88, P10647, DOI 10.1073/pnas.88.23.10647; Kornberg A., 1991, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1991, J BIOL CHEM, V266, P594; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOSSAL NG, 1984, BACTERIOPHAGE T, V4, P71; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1997, CURR OPIN STRUC BIOL, V7, P206, DOI 10.1016/S0959-440X(97)80027-9; SANCHEZ R, 1997, IN PRESS PROT STRUCT; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YIN KC, 1986, NUCLEIC ACIDS RES, V14, P6541, DOI 10.1093/nar/14.16.6541; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	54	213	217	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					335	345		10.1016/S0092-8674(00)80417-1	http://dx.doi.org/10.1016/S0092-8674(00)80417-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363942	hybrid			2022-12-28	WOS:A1997YD94100007
J	Weissman, D; Rabin, RL; Arthos, J; Rubbert, A; Dybul, M; Swofford, R; Venkatesan, S; Farber, JM; Fauci, AS				Weissman, D; Rabin, RL; Arthos, J; Rubbert, A; Dybul, M; Swofford, R; Venkatesan, S; Farber, JM; Fauci, AS			Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor	NATURE			English	Article							INFECTION; DISEASE; VACCINE; ENTRY	Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) enter target cells by forming a complex between the viral envelope protein and two cell-surface membrane receptors: CD4 and a 7-span transmembrane chemokine receptor (reviewed in refs 1-3). Isolates of HIV that differ in cellular tropism use different subsets of chemokine receptors as entry cofactors: macrophage-tropic HIVs primarily use CCR5, whereas T-cell-tropic and dual-tropic isolates use CXCR4 (refs 1-3) receptors. HIV-mediated signal transduction through CCR5 is not required for efficient fusion and entry of HIV in vitro(4,5). Here we show that recombinant envelope proteins from macrophage-tropic HIV and SIV induce a signal through CCR5 on CD4(+) T cells and that envelope-mediated signal transduction through CCR5 induces chemotaxis of T cells. This chemotactic response may contribute to the pathogenesis of HIV in vivo by chemo-attracting activated CD4(+) cells to sites of viral replication(1,2). HIV-mediated signalling through CCR5 may also enhance viral replication in vivo by increasing the activation state of target cells. Alternatively, envelope-mediated CCR5 signal transduction may influence viral-associated cytopathicity or apoptosis.	NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892; NIAID,CLIN INVEST LAB,FLO CYTOMETRY UNIT,NIH,BETHESDA,MD 20892; NIAID,MOL MICROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Rabin, Ronald/0000-0003-3496-0504				Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Kozak SL, 1997, J VIROL, V71, P873, DOI 10.1128/JVI.71.2.873-882.1997; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; McElrath MJ, 1996, P NATL ACAD SCI USA, V93, P3972, DOI 10.1073/pnas.93.9.3972; MORI K, 1993, J VIROL, V67, P2807, DOI 10.1128/JVI.67.5.2807-2814.1993; Mossman SP, 1996, J VIROL, V70, P1953, DOI 10.1128/JVI.70.3.1953-1960.1996; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; OH SK, 1992, J ACQ IMMUN DEF SYND, V5, P251; Oravecz T, 1996, J IMMUNOL, V157, P1329; Taub DD, 1996, J IMMUNOL, V156, P2095; TRIKOLA A, 1996, NATURE, V384, P184; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	18	298	304	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					981	985		10.1038/40173	http://dx.doi.org/10.1038/40173			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353123				2022-12-28	WOS:A1997YD29900059
J	Banks, DA; Fossel, M				Banks, DA; Fossel, M			Telomeres, cancer, and aging - Altering the human life span	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL-CYCLE CONTROL; HUMAN-FIBROBLASTS; CAENORHABDITIS-ELEGANS; REPLICATIVE SENESCENCE; HEALTH-CARE; IN-VIVO; LONGEVITY; GENES; POLICY; IMPACT	Population projections of the aging global society and its fiscal and social impact have depended on assumptions regarding the human life span. Until now, the assumption that the maximum human life span is fixed has been justified. Recent advances in cell biology, genetics, and our understanding of the cellular processes that underlie aging, however, have shown that this assumption is invalid in a number of animal models and suggest that this assumption may become invalid for humans as well. In vitro alteration of telomeres affects cellular senescence, and in vivo manipulation of genes and diet can increase maximum life span in animal models if these discoveries are extended to humans. We may soon be able to extend the maximum human life span and postpone or prevent the onset of diseases associated with aging. Such a possibility requires that we recognize a growing uncertainty in any attempt to project international health care costs into the next few decades. The costs may be significantly lower than projections, if life span increases and age-related disabilities are postponed or less severe, or perhaps higher, if life span increases without altering the onset and severity of disability. An appropriate uncertainty regarding the human life span undermines any attempt to accurately predict health costs in the next century.	UNIV CALIF BERKELEY,RICHARD & RHODA GOLDMAN SCH PUBL POLICY,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CTR ECON & DEMOG AGING,BERKELEY,CA 94720; MICHIGAN STATE UNIV,COLL HUMAN MED,E LANSING,MI 48824	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Michigan State University; Michigan State University College of Human Medicine					NATIONAL INSTITUTE ON AGING [P20AG012839] Funding Source: NIH RePORTER; NIA NIH HHS [P20-AG-12839] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*ALL AG RES, 1997, 7 DEADL MYTHS UNC FA; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Finch CE, 1990, LONGEVITY SENESCENCE; Fossel M, 1996, REVERSING HUMAN AGIN; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1980, P NATL ACAD SCI-BIOL, V77, P1885, DOI 10.1073/pnas.77.4.1885; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAYFLICK L, 1994, WHY WE AGE, P313; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; JAZWINSKI SM, 1997, NAT MAN HLTH CAR C B; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lane MA, 1997, AGE, V20, P45, DOI 10.1007/s11357-997-0004-2; LARSEN PL, 1995, GENETICS, V139, P1567; LE R, 1997, DEMOGRAPHY, V34, P67; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; Lundblad V, 1996, CELL, V87, P369, DOI 10.1016/S0092-8674(00)81358-6; MANTON KG, 1993, J GERONTOL, V48, P11, DOI 10.1093/geronj/48.Special_Issue.11; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Marcand S, 1996, CURR BIOL, V6, P1222, DOI 10.1016/S0960-9822(96)00701-4; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P1319, DOI 10.1001/jama.273.17.1319; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; *NIH, 1997, SEARCH SECR AG; OKAMOTO Y, 1992, BRIT MED J, V305, P403, DOI 10.1136/bmj.305.6850.403; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Oshima J, 1996, LANCET, V348, P1106, DOI 10.1016/S0140-6736(05)64456-X; Rao R. Nagaraja, 1996, Current Opinion in Oncology, V8, P516; Sallar AM, 1996, NEW ENGL J MED, V334, P537; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; Shay JW, 1997, J CLIN PATHOL, V50, P106, DOI 10.1136/jcp.50.2.106; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH DWE, 1993, HUMAN LONGEVITY AGIN; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stewart C, 1997, NATURE, V385, P769, DOI 10.1038/385769a0; SULLIVAN DF, 1971, HSMHA HEALTH REP, V86, P347, DOI 10.2307/4594169; U. S. Bureau of the Census, 1996, STAT ABSTR US; US Bureau of the Census, 1995, STAT ABSTR US; VANDEWALLE E, 1990, MILBANK Q, V68, P10, DOI 10.2307/3350174; WEINDRUCH R, 1988, RETARDATION AGING DI; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Winker MA, 1996, JAMA-J AM MED ASSOC, V276, P1758, DOI 10.1001/jama.1996.03540210066037; Wise DA, 1997, DEMOGRAPHY, V34, P83, DOI 10.2307/2061661; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; 1997, BALTIMORE SUN   0805, pB5; 1996, SCIENCE, V274, P1989	59	29	30	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1345	1348		10.1001/jama.278.16.1345	http://dx.doi.org/10.1001/jama.278.16.1345			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343466				2022-12-28	WOS:A1997YA90500036
J	Farrer, LA; Cupples, LA; Haines, JL; Hyman, B; Kukull, WA; Mayeux, R; Myers, RH; PericakVance, MA; Risch, N; vanDuijn, CM				Farrer, LA; Cupples, LA; Haines, JL; Hyman, B; Kukull, WA; Mayeux, R; Myers, RH; PericakVance, MA; Risch, N; vanDuijn, CM			Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							E ALLELE EPSILON-4; EARLY-ONSET ALZHEIMERS; LEWY BODY DISEASE; VASCULAR DEMENTIA; E POLYMORPHISM; RISK FACTOR; JAPANESE PATIENTS; PREDICTIVE VALUE; SENILE DEMENTIA; TYPE-4 ALLELE	Objective.-To examine more closely the association between apolipoprotein E (APOE) genotype and Alzheimer disease (AD) by age and sex in populations of various ethnic and racial denominations. Data Sources.-Forty research teams contributed data on APOE genotype, sex, age at disease onset, and ethnic background for 5930 patients who met criteria for probable or definite AD and 8607 controls without dementia who were recruited from clinical, community, and brain bank sources. Main Outcome Measures.-Odds ratios (ORs) and 95% confidence intervals (CIs) for AD, adjusted for age and study and stratified by major ethnic group (Caucasian, African American, Hispanic, and Japanese) and source, were computed for APOE genotypes epsilon 2/epsilon 2, epsilon 2/epsilon 3, epsilon 2/epsilon 4, epsilon 3/epsilon 4, and epsilon 4/epsilon 4 relative to the epsilon 3/epsilon 3 group. The influence of age and sex on the OR for each genotype was assessed using logistic regression procedures. Results.-Among Caucasian subjects from clinic-or autopsy-based studies, the risk of AD was significantly increased for people with genotypes epsilon 2/epsilon 4 (OR=2.6, 95% CI=1.6-4.0), epsilon 3/epsilon 4 (OR=3.2, 95% Cl=2.8-3.8), and epsilon 4/epsilon 4 (OR=14.9, 95% CI=10.8-20.6); whereas, the ORs were decreased for people with genotypes epsilon 2/epsilon 2 (OR=0.6, 95% CI=0.2-2.0) and epsilon 2/epsilon 3 (OR=0.6, 95% CI=0.5-0.8). The APOE epsilon 4-AD association was weaker among African Americans and Hispanics, but there was significant heterogeneity in ORs among studies of African Americans (P<.03), The APOE epsilon 4-AD association in Japanese subjects was stronger than in Caucasian subjects (epsilon 3/epsilon 4: OR=5.6, 95% CI=3.9-8.0; epsilon 4/epsilon 4, OR=33.1, 95% CI=13.6-80.5). The epsilon 2/epsilon 3 genotype appears equally protective across ethnic groups. We also found that among Caucasians, APOE genotype distributions are similar in groups of patients with AD whose diagnoses were determined clinically or by autopsy. In addition, we found that the APOE epsilon 4 effect is evident at all ages between 40 and 90 years but diminishes after age 70 years and that the risk of AD associated with a given genotype varies with sex. Conclusions.-The APOE epsilon 4 allele represents a major risk factor for AD in all ethnic groups studied, across all ages between 40 and 90 years, and in both men and women, The association between APOE epsilon 4 and AD in African Americans requires clarification, and the attenuated effect of APOE epsilon 4 in Hispanics should be investigated further.	BOSTON UNIV, SCH MED, DEPT BIOSTAT & EPIDEMIOL, BOSTON, MA 02118 USA; MASSACHUSETTS GEN HOSP, MOL NEUROGENET UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; COLUMBIA UNIV, GERTRUDE H SERGIEVSKY CTR, NEW YORK, NY 10027 USA; COLUMBIA UNIV, DEPT NEUROL, NEW YORK, NY USA; DUKE UNIV, MED CTR, DIV NEUROL, DURHAM, NC 27710 USA; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; ERASMUS UNIV ROTTERDAM, DEPT EPIDEMIOL, ROTTERDAM, NETHERLANDS	Boston University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Washington; University of Washington Seattle; Columbia University; Columbia University; Duke University; Stanford University; Erasmus University Rotterdam	Farrer, LA (corresponding author), BOSTON UNIV, SCH MED, DEPT NEUROL, 80 E CONCORD ST, BOSTON, MA 02118 USA.		Farrer, Lindsay/AAS-1035-2020; Haines, Jonathan/C-3374-2012; Kennedy, Kristen M/B-4699-2008	Haines, Jonathan/0000-0002-4351-4728; Kennedy, Kristen M/0000-0001-5373-9026; Myers, Richard/0000-0002-8365-2674; Farrer, Lindsay/0000-0001-5533-4225; Kukull, Walter/0000-0001-8761-9014; Cupples, L. Adrienne/0000-0003-0273-7965	NATIONAL INSTITUTE ON AGING [R01AG009029, U24AG021886] Funding Source: NIH RePORTER; NIA NIH HHS [AG-09029, U24 AG021886] Funding Source: Medline; Telethon [E.0482] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon)		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Benjamin R, 1996, NEURODEGENERATION, V5, P43; Benjamin R, 1995, NEURODEGENERATION, V4, P443, DOI 10.1006/neur.1995.0053; BETARD C, 1994, NEUROREPORT, V5, P1893, DOI 10.1097/00001756-199410000-00013; Bickeboller H, 1997, AM J HUM GENET, V60, P439; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; BORGAONKAR DS, 1993, LANCET, V342, P625, DOI 10.1016/0140-6736(93)91458-X; BRESLOW NE, 1978, AM J EPIDEMIOL, V108, P299, DOI 10.1093/oxfordjournals.aje.a112623; BRESLOW NE, 1980, PUBLICATION INT AGEN, V32; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; Corder EH, 1996, LANCET, V347, P542, DOI 10.1016/S0140-6736(96)91173-3; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORDER EH, 1995, JAMA-J AM MED ASSOC, V273, P373, DOI 10.1001/jama.273.5.373; DAI XY, 1994, NEUROSCI LETT, V175, P74, DOI 10.1016/0304-3940(94)91081-2; Duara R, 1996, NEUROLOGY, V46, P1575, DOI 10.1212/WNL.46.6.1575; Fallin D, 1997, GENET EPIDEMIOL, V14, P299, DOI 10.1002/(SICI)1098-2272(1997)14:3<299::AID-GEPI7>3.0.CO;2-0; FARRER LA, 1995, ANN NEUROL, V38, P797, DOI 10.1002/ana.410380515; Farrer LA, 1997, NEUROLOGIST, V3, P13, DOI 10.1097/00127893-199701000-00003; FRISONI GB, 1994, DEMENTIA, V5, P240, DOI 10.1159/000106730; GALASKO D, 1994, NEUROLOGY, V44, P1950, DOI 10.1212/WNL.44.10.1950; GEARING M, 1995, NEUROLOGY, V45, P1985, DOI 10.1212/WNL.45.11.1985; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARRINGTON CR, 1994, AM J PATHOL, V145, P1472; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; HIXSON JE, 1990, J LIPID RES, V31, P545; HOULDEN H, 1994, NEUROSCI LETT, V174, P222, DOI 10.1016/0304-3940(94)90026-4; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Kakulas BA, 1996, LANCET, V348, P483, DOI 10.1016/S0140-6736(05)64588-6; KAWAMATA J, 1994, J NEUROL NEUROSUR PS, V57, P1414, DOI 10.1136/jnnp.57.11.1414; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Kukull WA, 1996, J CLIN EPIDEMIOL, V49, P1143, DOI 10.1016/0895-4356(96)00195-3; KURZ A, 1994, NERVENARZT, V65, P774; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LANNFELT L, 1994, NEUROSCI LETT, V169, P175, DOI 10.1016/0304-3940(94)90384-0; Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641; LEHTIMAKI T, 1995, HUM GENET, V95, P39; LEHTOVIRTA M, 1995, NEUROSCI LETT, V185, P13, DOI 10.1016/0304-3940(94)11213-3; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LIPPA CF, 1995, NEUROLOGY, V45, P97, DOI 10.1212/WNL.45.1.97; LUCOTTE G, 1994, AM J MED GENET, V54, P286, DOI 10.1002/ajmg.1320540319; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAHIEUX F, 1995, REV NEUROL-FRANCE, V151, P231; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARTINS RN, 1995, NEUROREPORT, V6, P1513, DOI 10.1097/00001756-199507310-00012; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; NALBANTOGLU J, 1994, ANN NEUROL, V36, P889, DOI 10.1002/ana.410360614; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; ORDOVAS JM, 1987, J LIPID RES, V28, P371; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; PAYAMI H, 1994, JAMA-J AM MED ASSOC, V271, P1316, DOI 10.1001/jama.271.17.1316; PICKERINGBROWN SM, 1994, LANCET, V343, P1155, DOI 10.1016/S0140-6736(94)90257-7; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Rao VS, 1996, AM J HUM GENET, V59, P664; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; REBECK GW, 1993, NEURON, V11, P575; Roses A. D., 1995, American Journal of Human Genetics, V57, pA202; *SAS I, 1990, SAS US GUID; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMITH AD, 1994, LANCET, V344, P473; Smith AD, 1996, LANCET, V348, P483, DOI 10.1016/S0140-6736(05)64589-8; SOBEL E, 1995, NEUROLOGY, V45, P903, DOI 10.1212/WNL.45.5.903; SORBI S, 1994, NEUROSCI LETT, V177, P100, DOI 10.1016/0304-3940(94)90054-X; STCLAIR D, 1995, J MED GENET, V32, P57, DOI 10.1136/jmg.32.1.57; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TSAI MS, 1994, AM J HUM GENET, V54, P643; UEKI A, 1993, NEUROSCI LETT, V163, P166, DOI 10.1016/0304-3940(93)90373-S; Van Duijn C. M., 1996, Neurobiology of Aging, V17, pS79, DOI 10.1016/S0197-4580(96)80317-4; VANDUIJN CM, 1995, BMJ-BRIT MED J, V310, P627, DOI 10.1136/bmj.310.6980.627; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; YOSHIZAWA T, 1994, ANN NEUROL, V36, P656, DOI 10.1002/ana.410360416; ZANNIS VI, 1993, ADV HUM GENET, V21, P145; Zhou ZM, 1996, MOL MED, V2, P175, DOI 10.1007/BF03401614; ZUBENKO GS, 1994, AM J MED GENET, V54, P199, DOI 10.1002/ajmg.1320540306	85	3001	3084	5	256	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1349	1356		10.1001/jama.1997.03550160069041	http://dx.doi.org/10.1001/jama.1997.03550160069041			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA905	9343467				2022-12-28	WOS:A1997YA90500037
J	Sonke, GS; Stewart, AW; Beaglehole, R; Jackson, R; White, HD				Sonke, GS; Stewart, AW; Beaglehole, R; Jackson, R; White, HD			Comparison of case fatality in smokers and non-smokers after acute cardiac event	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION		UNIV AUCKLAND,FAC MED & HLTH SCI,DEPT COMMUNITY HLTH,AUCKLAND 1,NEW ZEALAND; GREEN LANE HOSP,DEPT CARDIOL,AUCKLAND 3,NEW ZEALAND	University of Auckland				Jackson, Rod/0000-0001-5914-6934; Sonke, Gabe/0000-0001-8088-9628				BARBASH GI, 1995, J AM COLL CARDIOL, V26, P1222, DOI 10.1016/0735-1097(95)00299-5; Sonke GS, 1996, BRIT MED J, V313, P853; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; WHITE HD, 1995, AM J CARDIOL, V75, P278, DOI 10.1016/0002-9149(95)80036-R	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					992	993		10.1136/bmj.315.7114.992	http://dx.doi.org/10.1136/bmj.315.7114.992			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365298	Green Published			2022-12-28	WOS:A1997YC30700023
J	Sheldon, T				Sheldon, T			Dutch and Swiss support heroin on prescription	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					835	835						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353501				2022-12-28	WOS:A1997YA00700015
J	Hwang, HY; Cheong, SW				Hwang, HY; Cheong, SW			Enhanced intergrain tunneling magnetoresistance in half-metallic CrO2 films	SCIENCE			English	Article							FERROMAGNET	Low-field tunneling magnetoresistance was observed in films of half-metallic CrO2 that were grown by high-pressure thermal decomposition of CrO3. High-temperature annealing treatments modified the intergrain barriers of the as-grown films through surface decomposition of CrO2 into insulating Cr2O3, which led to a threefold enhancement of the low-field magnetoresistance. This enhancement indicates the potential of this simple method to directly control the interface barrier characteristics that determine the magnetotransport properties.	RUTGERS STATE UNIV,DEPT PHYS & ASTRON,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick	Hwang, HY (corresponding author), AT&T BELL LABS,LUCENT TECHNOL,MURRAY HILL,NJ 07974, USA.		Hwang, Harold Y/I-6943-2012					CHAMBERLAND BL, 1977, CRC CR REV SOL STATE, V7, P1, DOI 10.1080/10408437708243431; CHAPIN DS, 1965, J PHYS CHEM-US, V69, P1402, DOI 10.1021/j100888a051; DEGROOT RA, 1983, PHYS REV LETT, V50, P2024, DOI 10.1103/PhysRevLett.50.2024; Gubkin M. K., 1993, Physics of the Solid State, V35, P728; HWANG H, UNPUB; Hwang HY, 1996, PHYS REV LETT, V77, P2041, DOI 10.1103/PhysRevLett.77.2041; KAMPER KP, 1987, PHYS REV LETT, V59, P2788, DOI 10.1103/PhysRevLett.59.2788; Kimura T, 1996, SCIENCE, V274, P1698, DOI 10.1126/science.274.5293.1698; KUBOTA B, 1960, J PHYS SOC JPN, V16, P345; LEVY PM, 1992, SCIENCE, V256, P972, DOI 10.1126/science.256.5059.972; RODBELL DS, 1966, J PHYS SOC JPN, V21, P2430, DOI 10.1143/JPSJ.21.2430; SCHWARZ K, 1986, J PHYS F MET PHYS, V16, pL211, DOI 10.1088/0305-4608/16/9/002; Sun JZ, 1996, APPL PHYS LETT, V69, P3266, DOI 10.1063/1.118031; Vasko VA, 1997, PHYS REV LETT, V78, P1134, DOI 10.1103/PhysRevLett.78.1134; WIESENDANGER R, 1990, PHYS REV LETT, V65, P247, DOI 10.1103/PhysRevLett.65.247	15	211	216	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1607	1609		10.1126/science.278.5343.1607	http://dx.doi.org/10.1126/science.278.5343.1607			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374456				2022-12-28	WOS:A1997YJ87400035
J	Martin, KA; Wyatt, R; Farzan, M; Choe, H; Marcon, L; Desjardins, E; Robinson, J; Sodroski, J; Gerard, C; Gerard, NP				Martin, KA; Wyatt, R; Farzan, M; Choe, H; Marcon, L; Desjardins, E; Robinson, J; Sodroski, J; Gerard, C; Gerard, NP			CD4-independent binding of SIV gp120 to rhesus CCR5	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; OLIGOMERIC STRUCTURE; HTLV-III; AIDS PATIENTS; T-CELLS; RECEPTOR; HIV-1; CD4; IDENTIFICATION	CCR5 and CD4 are coreceptors for immunodeficiency virus entry into target cells, The gp120 envelope glycoprotein from human immunodeficiency virus strain HIV-1(YU2) bound human CCR5 (CCR5(hu)) or rhesus macaque CCR5 (CCR5(rh)) only in the presence of CD4. The gp120 from simian immunodeficiency virus strain SIVmac239 bound CCR5(rh) without CD4, but CCR5(hu) remained CD4-dependent. The CD4-independent binding of SIVmac239 gp120 depended on a single amino acid, Asp(13), in the CCR5(rh) amino-terminus. Thus, CCR5-binding moieties on the immunodeficiency virus envelope glycoprotein can be generated by interaction with CD4 or by direct interaction with the CCR5 amino-terminus. These results may have implications for the evolution of receptor use among lentiviruses as well as utility in the development of effective intervention.	DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,PERLMUTTER LAB,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV PADUA,SCH MED,INST MICROBIOL,I-35121 PADUA,ITALY; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; TULANE UNIV,MED CTR,DEPT PEDIAT,NEW ORLEANS,LA 70112; BETH ISRAEL DEACONESS HOSP,DEPT MED,CHILDRENS HOSP,PERLMUTTER LAB,BOSTON,MA 02115; BETH ISRAEL DEACONESS HOSP,DEPT PEDIAT,CHILDRENS HOSP,PERLMUTTER LAB,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; University of Padua; Harvard University; Harvard T.H. Chan School of Public Health; Tulane University; Harvard University; Beth Israel Deaconess Medical Center; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Boston Children's Hospital				Martin, Kathleen/0000-0002-1748-0034; Farzan, Michael/0000-0002-2990-5319	NHLBI NIH HHS [HL51366, HL36162] Funding Source: Medline; NIAID NIH HHS [AI41581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051366, R37HL036162, R01HL036162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; ENDRESMJ, 1996, CELL, V87, P745; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; FARZAN M, IN PRESS J VIROL; GERARD NP, UNPUB; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; KANG CY, 1993, J IMMUNOL, V151, P449; KENT KA, 1995, J MED PRIMATOL, V24, P145, DOI 10.1111/j.1600-0684.1995.tb00160.x; Kent KA, 1993, P 8 C CENT GARD I PA, P167; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Marcon L, 1997, J VIROL, V71, P2522, DOI 10.1128/JVI.71.3.2522-2527.1997; MARTIN KH, UNPUB; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; RHODES AD, 1994, J GEN VIROL, V75, P207, DOI 10.1099/0022-1317-75-1-207; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; Robinson J, UNPUB; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Willett BJ, 1997, NATURE, V385, P587, DOI 10.1038/385587a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT RE, UNPUB	35	106	107	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1470	1473		10.1126/science.278.5342.1470	http://dx.doi.org/10.1126/science.278.5342.1470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367961				2022-12-28	WOS:A1997YG85800047
J	Hu, FB; Stampfer, MJ; Manson, JE; Rimm, E; Colditz, GA; Rosner, BA; Hennekens, CH; Willett, WC				Hu, FB; Stampfer, MJ; Manson, JE; Rimm, E; Colditz, GA; Rosner, BA; Hennekens, CH; Willett, WC			Dietary fat intake and the risk of coronary heart disease in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADIPOSE-TISSUE; FOLLOW-UP; PLASMA-LIPOPROTEINS; SERUM-CHOLESTEROL; ACID COMPOSITION; UNITED-STATES; MORTALITY; LIPIDS; DEATH; MEN	Background The relation between dietary intake of specific types of fat, particularly trans unsaturated fat, and the risk of coronary disease remains unclear. We therefore studied this relation in women enrolled in the Nurses' Health Study. Methods We prospectively studied 80,082 women who were 34 to 59 years of age and had no known coronary disease, stroke, cancer, hypercholesterolemia, or diabetes in 1980. Information on diet was obtained at base line and updated during follow-up by means of validated questionnaires. During 14 years of follow-up, we documented 939 cases of nonfatal myocardial infarction or death from coronary heart disease. Multivariate analyses included age, smoking status, total energy intake, dietary cholesterol intake, percentages of energy obtained from protein and specific types of fat, and other risk factors. Results Each increase of 5 percent of energy intake from saturated fat, as compared with equivalent energy intake from carbohydrates, was associated with a 17 percent increase in the risk of coronary disease (relative risk, 1.17; 95 percent confidence interval, 0.97 to 1.41; P=0.10). As compared with equivalent energy from carbohydrates, the relative risk for a 2 percent increment in energy intake from trans unsaturated fat was 1.93 (95 percent confidence interval, 1.43 to 2.61; P<0.001); that for a 5 percent increment in energy from monounsaturated fat was 0.81 (95 percent confidence interval, 0.65 to 1.00; P=0.05); and that for a 5 percent increment in energy from polyunsaturated fat was 0.62 (95 percent confidence interval, 0.46 to 0.85; P=0.003). Total fat intake was not significantly related to the risk of coronary disease (for a 5 percent increase in energy from fat, the relative risk was 1.02; 95 percent confidence interval, 0.97 to 1.07; P=0.55). We estimated that the replacement of 5 percent of energy from saturated fat with energy from unsaturated fats would reduce risk by 42 percent (95 percent confidence interval, 23 to 56; P<0.001) and that the replacement of 2 percent of energy from trans fat with energy from unhydrogenated, unsaturated fats would re; duce risk by 53 percent (95 percent confidence interval, 34 to 67; P<0.001). Conclusions Our findings suggest that replacing saturated and trans unsaturated fats with unhydrogenated monounsaturated and polyunsaturated fats is more effective in preventing coronary heart disease in women than reducing overall fat intake. (C) 1997, Massachusetts Medical Society.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hu, FB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009; Robles-Sardin, Alma E/M-7714-2015; Cole, Tim J/B-7883-2008; Hu, Frank/C-1919-2013	Colditz, Graham/0000-0002-7307-0291; Robles-Sardin, Alma E/0000-0003-2044-7793; Cole, Tim J/0000-0001-5711-8200; 	NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL24074, HL34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; *DEP AGR, 1992, AGR HDB SERIES; ENIG MG, 1983, J AM OIL CHEM SOC, V60, P1788, DOI 10.1007/BF02680357; Esrey KL, 1996, J CLIN EPIDEMIOL, V49, P211, DOI 10.1016/0895-4356(95)00066-6; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; GARG A, 1992, DIABETES CARE, V15, P1572, DOI 10.2337/diacare.15.11.1572; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; GRUNDY S M, 1982, Circulation, V65, p839A; GRUNDY SM, 1988, ARTERIOSCLEROSIS, V8, P95, DOI 10.1161/01.ATV.8.1.95; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Katan MB, 1997, NEW ENGL J MED, V337, P563; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI [10.1146/annurev.nu.15.070195.002353, 10.1146/annurev.nutr.15.1.473]; KEYS A, 1966, AM J CLIN NUTR, V19, P175; KINSELLA JE, 1981, AM J CLIN NUTR, V34, P2307, DOI 10.1093/ajcn/34.10.2307; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KROMHOUT D, 1984, AM J EPIDEMIOL, V119, P733, DOI 10.1093/oxfordjournals.aje.a113794; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; MCKEIGUE P, 1995, LANCET, V345, P269, DOI 10.1016/S0140-6736(95)90269-4; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; Norris J, 1997, AM J PUBLIC HEALTH, V87, P740, DOI 10.2105/AJPH.87.5.740; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P3894, DOI 10.1073/pnas.87.10.3894; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; ROBERTS TL, 1995, LANCET, V345, P278, DOI 10.1016/S0140-6736(95)90274-0; Rose G, 1982, CARDIOVASCULAR SURVE; Sacks F, 1994, J Cardiovasc Risk, V1, P3, DOI 10.1097/00043798-199406000-00002; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SLOVER HT, 1985, J AM OIL CHEM SOC, V62, P775, DOI 10.1007/BF03028753; STAMLER J, 1988, ARCH PATHOL LAB MED, V112, P1032; TRICHOPOULOS D, 1995, LANCET, V345, P1108; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722	40	1167	1231	2	126	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1491	1499		10.1056/NEJM199711203372102	http://dx.doi.org/10.1056/NEJM199711203372102			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366580				2022-12-28	WOS:A1997YG24900002
J	Hoffman, DJ				Hoffman, DJ			Farewell to his craft	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1554	1554		10.1001/jama.278.19.1554	http://dx.doi.org/10.1001/jama.278.19.1554			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF407	9370478				2022-12-28	WOS:A1997YF40700001
J	Rackoff, PJ				Rackoff, PJ			A woman on the toilet	LANCET			English	Article											Rackoff, PJ (corresponding author), BETH ISRAEL MED CTR,PHILLIPS AMBULATORY CARE CTR,10 UNION SQ,NEW YORK,NY 10003, USA.			Rackoff, Paula/0000-0002-4669-2116					0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1444	1444		10.1016/S0140-6736(97)08433-X	http://dx.doi.org/10.1016/S0140-6736(97)08433-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371169				2022-12-28	WOS:A1997YF95300012
J	Prodeus, AP; Zhou, XN; Maurer, M; Galli, SJ; Carroll, MC				Prodeus, AP; Zhou, XN; Maurer, M; Galli, SJ; Carroll, MC			Impaired mast cell-dependent natural immunity in complement C3-deficient mice	NATURE			English	Article							NECROSIS-FACTOR-ALPHA; ARTHUS REACTION; TNF-ALPHA; INFECTION; RELEASE; MOUSE; C5A; HISTAMINE; RECEPTOR	The complement system is widely regarded as essential for normal inflammation, not least because of its ability to activate mast cells(1-5). However, recent studies have called into question the importance of complement in several examples of mast cell-dependent inflammatory responses(6-9). To investigate the role of complement in mast cell-dependent natural immunity, we examined the responses of complement-deficient mice(10,11) to caecal ligation and puncture(12), model of acute septic peritonitis(12,13) that is dependent on mast cells and tumour necrosis factor-alpha (TNF-alpha). We found that C4- or C3-deficient mice(10,11) '' were much more sensitive to caecal ligation and puncture than wild-type (WT) controls (100% versus 20% in 24-h mortality, respectively). C3-deficient mice also exhibited reductions in peritoneal mast cell degranulation, production of TNF-alpha, neutrophil infiltration and clearance of bacteria. Treating the C3-deficient mice with purified C3 protein enhanced activation of peritoneal mast cells, TNF-alpha production, neutrophil recruitment, opsonophagocytosis of bacteria and resistance to caecal ligation and puncture, confirming that the defects were complement-dependent. These results provide formal evidence that complement activation is essential for the full expression of innate immunity in this mast cell-dependent model of bacterial infection.	BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center	Prodeus, AP (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115, USA.		Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; DASILVA WD, 1967, J EXP MED, V125, P921, DOI 10.1084/jem.125.5.921; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Fischer MB, 1996, J IMMUNOL, V157, P549; Fischer MB, 1997, J IMMUNOL, V159, P976; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; LEPOW IH, 1970, AM J PATHOL, V61, P13; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NILSSON UR, 1967, J EXP MED, V125, P1, DOI 10.1084/jem.125.1.1; RAMOS BF, 1994, J IMMUNOL, V152, P1380; REID KBM, 1981, ANNU REV BIOCHEM, V50, P433, DOI 10.1146/annurev.bi.50.070181.002245; Reid RR, 1997, J IMMUNOL, V159, P970; Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VRANIAN G, 1981, J IMMUNOL, V126, P2302; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385	30	224	228	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					172	175		10.1038/36586	http://dx.doi.org/10.1038/36586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367154				2022-12-28	WOS:A1997YF49400054
J	Nightingale, SL				Nightingale, SL			Workshop on minimizing medical product errors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-28	WOS:A1997YC91700008
J	Reinhardt, UE				Reinhardt, UE			Wanted: A clearly articulated social ethic for American health care - Commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PUBLIC HOSPITAL EMERGENCY; CONSEQUENCES				Reinhardt, UE (corresponding author), PRINCETON UNIV,WOODROW WILSON SCH PUBL & INT AFFAIRS,ROBERTSON HALL,PRINCETON,NJ 08544, USA.							BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; BUTLER SM, 1992, HERITAGE TALKING POI, P5; *C BUDG OFF, 1993, BEH ASS EST EFF HLTH, pR8; Epstein R., 1997, MORTAL PERIL OUR INA; EPSTEIN RA, 1997, NY TIMES        0810, P14; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; FRIEDMAN M, 1991, WALL STREET J   1112, pA19; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; KELLERMAN AL, 1991, JAMA-J AM MED ASSOC, V266, P1123, DOI 10.1001/jama.266.8.1123; LONG SH, 1994, UNIVERSAL HLTH INSUR, P4; Rawls J., 1971, THEORY JUSTICE; REINHARDT UE, 1993, HEALTH AFFAIR, V12, P172, DOI 10.1377/hlthaff.12.suppl_1.172; Reinhardt UE, 1996, JAMA-J AM MED ASSOC, V275, P1802, DOI 10.1001/jama.275.23.1802; REINHARDT UE, 1997, HLTH HLTH CARE HLTH, P1; Taylor H, 1991, Health Manage Q, V13, P2; THORPE KE, 1997, RISING NUMBER UNINSU; 1994, ISSUE SAN Q REP HLTH, V4, P5	18	39	39	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1446	1447		10.1001/jama.278.17.1446	http://dx.doi.org/10.1001/jama.278.17.1446			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9356005				2022-12-28	WOS:A1997YC91700033
J	Matilla, A; Koshy, BT; Cummings, C; Isobe, T; Orr, HT; Zoghbi, HY				Matilla, A; Koshy, BT; Cummings, C; Isobe, T; Orr, HT; Zoghbi, HY			The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1	NATURE			English	Article							EXPRESSION ANALYSIS; TYPE-1; GENE; REPEAT; CONSTRUCTION; CLONING; MATRIX; YEAST; SCA1	Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder characterized by ataxia, progressive motor deterioration, and loss of cerebellar Purkinje cells(1). SCA1 belongs to a growing group of neurodegenerative disorders caused by expansion of CAG repeats, which encode glutamine(2). Although the proteins containing these repeats are widely expressed, the neurodegeneration in SCA1 and other polyglutamine diseases selectively involves a few neuronal subtypes. The mechanism(s) underlying this neuronal specificity is unknown. Here we show that the cerebellar leucine-rich acidic nuclear protein (LANP)(3) interacts with ataxin-1, the SCA1 gene product. LANP is expressed predominantly in Purkinje cells, the primary site of pathology in SCAT. The interaction between LANP and ataxin-1 is significantly stronger when the number of glutamines is increased. Immunofluorescence studies demonstrate that both LANP and ataxin-1 colocalize in nuclear matrix-associated subnuclear structures. The features of the interaction between ataxin-1 and LANP, their spatial and temporal patterns of expression, and the colocalization studies indicate that cerebellar LANP is involved in the pathogenesis of SCA1.	BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CELL & MOL BIOL PROGRAM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; TOKYO METROPOLITAN UNIV,FAC SCI,DEPT CHEM,TOKYO 158,JAPAN; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Tokyo Metropolitan University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			MATILLA-DUEÑAS, ANTONI/C-7980-2011; Isobe, Toshiaki/Q-9279-2017	MATILLA-DUEÑAS, ANTONI/0000-0002-3514-4181; Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X				Banfi S, 1996, HUM MOL GENET, V5, P33, DOI 10.1093/hmg/5.1.33; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARPER JW, 1993, CELL, V75, P805; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; MATILLA A, UNPUB P NATL ACAD SC; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SMITH KE, 1995, FEBS LETT, V357, P86, DOI 10.1016/0014-5793(94)01328-X; WONG YHH, 1987, J NEUROCHEM, V48, P1434, DOI 10.1111/j.1471-4159.1987.tb05682.x; ZOGHBI H, 1985, SEMIN CELL BIOL, V6, P29	22	215	223	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					974	978		10.1038/40159	http://dx.doi.org/10.1038/40159			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353121				2022-12-28	WOS:A1997YD29900057
J	Bonita, R				Bonita, R			Added years, onus or bonus?	LANCET			English	Article											Bonita, R (corresponding author), UNIV AUCKLAND,N SHORE HOSP,FAC MED & HLTH SCI,PRIVATE BAG 93-503,AUCKLAND 1,NEW ZEALAND.							ALVAREZ J, 1995, WORLD HEALTH FORUM, V16, P361; Beaglehole R, 1997, PUBLIC HLTH CROSSROA; Bonita Ruth, 1996, World Health Statistics Quarterly, V49, P134; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; MCCALLUM J, 1997, AGEING SOCIAL POLICY; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1; ROBINE JM, 1997, REV CLIN GERONTOLOGY, V7, P73; SEN K, 1994, AGEING DEBATES DEMOG; van den Bos GAM, 1995, EUR J PUBLIC HEALTH, V5, P29, DOI DOI 10.1093/EURPUB/5.1.29; [WHO] World Health Organization, 1997, HLTH ENV SUST DEV 5; *WORLD BANK, 1996, HUM DEV REP 1995	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1167	1168		10.1016/S0140-6736(97)08459-6	http://dx.doi.org/10.1016/S0140-6736(97)08459-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343521				2022-12-28	WOS:A1997YB19900049
J	Vernon, SJ; Coulthard, MG; Lambert, HJ; Keir, MJ; Matthews, JNS				Vernon, SJ; Coulthard, MG; Lambert, HJ; Keir, MJ; Matthews, JNS			New renal scarring in children who at age 3 and 4 years had had normal scans with dimercaptosuccinic acid: follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTION; REFLUX; SCARS; UROGRAPHY	Objective: To determine up to what age children remain at risk of developing a new renal scar from a urinary tract infection. Design: Follow up study. Families of children who had normal ultrasound scans and scanning with dimercaptosuccinic acid (DMSA) after referral with a urinary tract infection when aged 3 (209) or 4 (220) were invited to bring the children for repeat scans 2-11 years later. A history of infections since the original scan was obtained for children not having a repeat scan. Setting: Teaching hospital. Subjects: Children from three health districts in whom a normal scan had been obtained at age 3-4 years in 1985-1992 because of a urinary tract infection. Main outcome measure: Frequency of new renal scars in each age group. Results:In each group, about 97% of children either had repeat scanning (over 80%) or were confidently believed by their general practitioner or parent not to have had another urinary infection. The rate of further infections since the original scan was similar in the 3 and 4 year old groups (48/176 (27%) and 55/179 (31%)). Few children in either group known to have had further urinary infections did not have repeat scanning (3/209 (1.4%) and 4/220 (1.8%)). In the 3 year old group, 2.4% (5/209) had one or more new kidney scars at repeat scanning,(one sided 95% confidence interval up to 5.0%), whereas none of the 4 year olds did (one sided 95% confidence interval up to 1.4%). The children who developed scars were all aged under 3.4 years when scanned originally. Conclusions: Children with a urinary tract infection but unscarred kidneys after the third birthday have about a 1 in 40 risk of developing a scar subsequently but after the fourth birthday the risk is either very low or zero. Thus the need for urinary surveillance is much reduced in a large number of children.	ROYAL VICTORIA INFIRM, DEPT CHILD HLTH, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; ROYAL VICTORIA INFIRM, DEPT MED PHYS, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT STAT, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X; Lambert, Heather/0000-0003-4389-4078				AGGARWAL VK, 1991, ARCH DIS CHILD, V66, P1284, DOI 10.1136/adc.66.11.1284; [Anonymous], 1991, J R Coll Physicians Lond, V25, P36; *BIRM REFL STUD GR, 1987, BRIT MED J, V293, P237; BLYTH CR, 1986, J AM STAT ASSOC, V81, P843, DOI 10.2307/2289018; Brooks D, 1977, J R Coll Gen Pract, V27, P678; Coulthard MG, 1997, BMJ-BRIT MED J, V315, P918; GOLDRAICH NP, 1989, PEDIATR NEPHROL, V3, P1, DOI 10.1007/BF00859614; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; HODSON CJ, 1965, BRIT MED J, V2, P191, DOI 10.1136/bmj.2.5455.191; JAKOBSSON B, 1994, ARCH DIS CHILD, V70, P111, DOI 10.1136/adc.70.2.111; MERRICK MV, 1980, BRIT J RADIOL, V53, P544, DOI 10.1259/0007-1285-53-630-544; OLBING H, 1992, J UROLOGY, V148, P1653, DOI 10.1016/S0022-5347(17)36995-1; RANSLEY PG, 1978, BR J RADIOL S, V14; ROLLESTON GL, 1974, ARCH DIS CHILD, V49, P531, DOI 10.1136/adc.49.7.531; SHAH KJ, 1978, ARCH DIS CHILD, V53, P210, DOI 10.1136/adc.53.3.210; SHIMADA K, 1989, International Urology and Nephrology, V21, P153, DOI 10.1007/BF02550803; SMELLIE JM, 1985, BRIT MED J, V290, P1957, DOI 10.1136/bmj.290.6486.1957; VERBER IG, 1989, ARCH DIS CHILD, V64, P1533, DOI 10.1136/adc.64.11.1533; VICKERS D, 1991, LANCET, V338, P767, DOI 10.1016/0140-6736(91)90662-9; WHITEAR P, 1990, BRIT J RADIOL, V63, P438, DOI 10.1259/0007-1285-63-750-438; WINTER AL, 1983, J UROLOGY, V129, P1190, DOI 10.1016/S0022-5347(17)52634-8	21	79	82	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	1997	315	7113					905	908						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361538				2022-12-28	WOS:A1997YB07300020
J	Aeppli, G; Mason, TE; Hayden, SM; Mook, HA; Kulda, J				Aeppli, G; Mason, TE; Hayden, SM; Mook, HA; Kulda, J			Nearly singular magnetic fluctuations in the normal state of a high-T-c cuprate superconductor	SCIENCE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTORS; BEHAVIOR; DYNAMICS; LA1.86SR0.14CUO4; LA1.85SR0.15CUO4; ANTIFERROMAGNETS; SUSCEPTIBILITY; LA2-XSRXCUO4; EXCITATIONS; SCATTERING	Polarized and unpolarized neutron scattering was used to measure the wave vector-and frequency-dependent magnetic fluctuations in the normal state (from the superconducting transition temperature, T-c = 35 kelvin, up to 350 kelvin) of single crystals of La1.86Sr0.14CuO4. The peaks that dominate the fluctuations have amplitudes that decrease as T-2 and widths that increase in proportion to the thermal energy, k(B)T (where k(B) is Boltzmann's constant), and energy transfer added in quadrature. The nearly singular fluctuations are consistent with a nearby quantum critical point.	UNIV TORONTO, DEPT PHYS, TORONTO, ON M5S 1A7, CANADA; NEC RES INST, PRINCETON, NJ 08540 USA; RISO NATL LAB, DK-4000 ROSKILDE, DENMARK; UNIV BRISTOL, DEPT PHYS, BRISTOL BS8 1TL, AVON, ENGLAND; OAK RIDGE NATL LAB, OAK RIDGE, TN 37831 USA; INST MAX VON LAUE PAUL LANGEVIN, F-38042 GRENOBLE, FRANCE	University of Toronto; NEC Corporation; Technical University of Denmark; University of Bristol; United States Department of Energy (DOE); Oak Ridge National Laboratory; Institut Laue-Langevin (ILL)			Hayden, Stephen M/F-4162-2011; Kulda, Jiri/G-8667-2016; Mason, Thomas/M-5809-2014	Hayden, Stephen M/0000-0002-3209-027X; Kulda, Jiri/0000-0002-0570-0570; Mason, Thomas/0000-0003-1880-3971				ARONSON MC, 1995, PHYS REV LETT, V75, P725, DOI 10.1103/PhysRevLett.75.725; BATLOGG B, 1993, ELECTRONIC PROPERTIE, P5; Bitko D, 1996, PHYS REV LETT, V77, P940, DOI 10.1103/PhysRevLett.77.940; BUCHNER B, 1994, PHYS REV LETT, V73, P1841, DOI 10.1103/PhysRevLett.73.1841; CHAKRAVARTY S, 1989, PHYS REV B, V39, P2344, DOI 10.1103/PhysRevB.39.2344; CHEONG SW, 1991, PHYS REV LETT, V67, P1791, DOI 10.1103/PhysRevLett.67.1791; CHIEN TR, 1991, PHYS REV LETT, V67, P2088, DOI 10.1103/PhysRevLett.67.2088; CHUBUKOV AV, 1994, PHYS REV B, V49, P11919, DOI 10.1103/PhysRevB.49.11919; CONTINENTINO MA, 1994, PHYS REP, V239, P179, DOI 10.1016/0370-1573(94)90112-0; HAYDEN SM, 1991, PHYS REV LETT, V66, P821, DOI 10.1103/PhysRevLett.66.821; HAYDEN SM, 1991, PHYS REV LETT, V67, P3622, DOI 10.1103/PhysRevLett.67.3622; Husmann S, 1996, SCIENCE, V274, P1874, DOI 10.1126/science.274.5294.1874; JOHNSTON DC, 1991, J MAGN MAGN MATER, V100, P218, DOI 10.1016/0304-8853(91)90822-R; KEIMER B, 1991, PHYS REV LETT, V67, P1930, DOI 10.1103/PhysRevLett.67.1930; MASON TE, 1992, PHYS REV LETT, V68, P1414, DOI 10.1103/PhysRevLett.68.1414; MASON TE, 1993, PHYS REV LETT, V71, P919, DOI 10.1103/PhysRevLett.71.919; MATSUDA M, 1994, PHYS REV B, V49, P6958, DOI 10.1103/PhysRevB.49.6958; MILLIS AJ, 1993, PHYS REV B, V48, P7183, DOI 10.1103/PhysRevB.48.7183; MOON RM, 1969, PHYS REV, V181, P883, DOI 10.1103/PhysRev.181.883; NOAKES DR, 1990, PHYS REV LETT, V65, P369, DOI 10.1103/PhysRevLett.65.369; RASOLT M, 1984, PHYS REV LETT, V53, P798, DOI 10.1103/PhysRevLett.53.798; ROSSATMIGNOD J, 1991, PHYSICA B, V169, P58, DOI 10.1016/0921-4526(91)90208-V; SACHDEV S, 1992, PHYS REV LETT, V69, P2411, DOI 10.1103/PhysRevLett.69.2411; SATO H, 1974, INT J MAGN, V6, P183; SCHLESINGER Z, 1990, PHYS REV LETT, V65, P801, DOI 10.1103/PhysRevLett.65.801; SLAKEY F, 1991, PHYS REV B, V43, P3764, DOI 10.1103/PhysRevB.43.3764; STERNLIEB BJ, 1993, PHYS REV B, V47, P5320, DOI 10.1103/PhysRevB.47.5320; THURSTON TR, 1992, PHYS REV B, V46, P9128, DOI 10.1103/PhysRevB.46.9128; Tranquada JM, 1997, PHYS REV LETT, V78, P338, DOI 10.1103/PhysRevLett.78.338; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; VAKNIN D, 1987, PHYS REV LETT, V58, P2802, DOI 10.1103/PhysRevLett.58.2802; VARMA CM, 1989, PHYS REV LETT, V63, P1996, DOI 10.1103/PhysRevLett.63.1996; VONLOHNEYSEN H, 1994, PHYS REV LETT, V72, P3262, DOI 10.1103/PhysRevLett.72.3262; Yamada K., UNPUB; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391	36	259	259	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	1997	278	5342					1432	1435		10.1126/science.278.5342.1432	http://dx.doi.org/10.1126/science.278.5342.1432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367949	Green Submitted			2022-12-28	WOS:A1997YG85800035
J	Babior, BM; Matzner, Y				Babior, BM; Matzner, Y			The familial Mediterranean fever gene - Cloned at last	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FLUIDS		HADASSAH UNIV HOSP, IL-91240 JERUSALEM, ISRAEL	Hebrew University of Jerusalem	Babior, BM (corresponding author), SCRIPPS RES INST, LA JOLLA, CA 92037 USA.				NIAID NIH HHS [AI-24227] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024227, R01AI024227] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; GOLDFINGER SE, 1972, NEW ENGL J MED, V287, P1302; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; MATZNER Y, 1984, BLOOD, V63, P629; MATZNER Y, 1995, CRIT REV ONCOL HEMAT, V18, P197, DOI 10.1016/1040-8428(94)00130-L	6	53	54	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1548	1549		10.1056/NEJM199711203372112	http://dx.doi.org/10.1056/NEJM199711203372112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366590				2022-12-28	WOS:A1997YG24900012
J	Lynch, ED; Lee, MK; Morrow, JE; Welcsh, PL; Leon, PE; King, MC				Lynch, ED; Lee, MK; Morrow, JE; Welcsh, PL; Leon, PE; King, MC			Nonsyndromic deafness DFNA1 associated with mutation of a human homolog of the Drosophila gene diaphanous	SCIENCE			English	Article							LIMB DEFORMITY LOCUS; ACTIN-FILAMENTS; FORMINS; TRANSCRIPTS	The gene responsible for autosomal dominant, fully penetrant, nonsyndromic sensorineural progressive hearing loss in a large Costa Rican kindred was previously localized to chromosome 5q31 and named DFNA1. Deafness in the family is associated with a protein-truncating mutation in a human homolog of the Drosophila gene diaphanous. The truncation is caused by a single nucleotide substitution in a splice donor, leading to a four-base pair insertion in messenger RNA and a frameshift, The diaphanous protein is a profilin ligand and target of Rho that regulates polymerization of actin, the major component of the cytoskeleton of hair cells of the inner ear.	UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA; UNIV COSTA RICA, SCH MED, SAN JOSE, COSTA RICA; UNIV COSTA RICA, CTR RES CELLULAR & MOL BIOL, SAN JOSE, COSTA RICA	University of Washington; University of Washington Seattle; Universidad Costa Rica; Universidad Costa Rica	Lynch, ED (corresponding author), UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA.			King, Mary-Claire/0000-0001-9426-1743	NIDCD NIH HHS [R01-DC01076] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001076] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Banfi S, 1997, HUM MOL GENET, V6, P1745, DOI 10.1093/hmg/6.10.1745; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chan DC, 1996, J BIOL CHEM, V271, P23472, DOI 10.1074/jbc.271.38.23472; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FLOCK A, 1977, J CELL BIOL, V75, P339, DOI 10.1083/jcb.75.2.339; Frazier JA, 1997, CURR BIOL, V7, pR414, DOI 10.1016/S0960-9822(06)00205-3; GORLIN RJ, 1995, OXFORD MONOGRAPHS ME, V28, P1; ITOH M, 1982, HEARING RES, V6, P277, DOI 10.1016/0378-5955(82)90060-0; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Lee M., UNPUB; LEON PE, 1981, AM J HUM GENET, V33, P209; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; LIU XZ, IN PRESS NATURE GENE; LYNCH ED, UNPUB; MAAS RL, 1991, AM J HUM GENET, V48, P687; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; Sambrook J, 1989, MOL CLONING; Steel KP, 1996, CURR OPIN NEUROBIOL, V6, P520, DOI 10.1016/S0959-4388(96)80059-6; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; TILNEY LG, 1982, HEARING RES, V7, P181, DOI 10.1016/0378-5955(82)90013-2; Tyson J, 1996, HUM MOL GENET, V5, P2055, DOI 10.1093/hmg/5.12.2055; VOGT TF, 1993, P NATL ACAD SCI USA, V90, P5554, DOI 10.1073/pnas.90.12.5554; Wang CC, 1997, GENOMICS, V39, P303, DOI 10.1006/geno.1996.4519; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; WynshawBoris A, 1997, MOL MED, V3, P372, DOI 10.1007/BF03401684; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	39	305	332	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	1997	278	5341					1315	1318		10.1126/science.278.5341.1315	http://dx.doi.org/10.1126/science.278.5341.1315			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360932				2022-12-28	WOS:A1997YG04300051
J	Lockwood, CJ				Lockwood, CJ			Calcium-channel blockers in the management of preterm labour	LANCET			English	Editorial Material							NIFEDIPINE; RITODRINE				Lockwood, CJ (corresponding author), NYU,SCH MED,DEPT OBSTET & GYNAECOL,NEW YORK,NY 10016, USA.							BRACERO LA, 1991, AM J PERINAT, V8, P365, DOI 10.1055/s-2007-999417; DANIELSSON BRG, 1990, TERATOLOGY, V41, P185, DOI 10.1002/tera.1420410210; Goodwin TM, 1996, AM J PERINAT, V13, P143, DOI 10.1055/s-2007-994312; KUPFERMINC M, 1993, BRIT J OBSTET GYNAEC, V100, P1090, DOI 10.1111/j.1471-0528.1993.tb15171.x; MEYER WR, 1990, J REPROD MED, V35, P649; Papatsonis DNM, 1997, OBSTET GYNECOL, V90, P230, DOI 10.1016/S0029-7844(97)00182-8; VANDIJK KGJ, 1995, J PERINAT MED, V23, P409	7	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1339	1340		10.1016/S0140-6736(05)65131-8	http://dx.doi.org/10.1016/S0140-6736(05)65131-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365445				2022-12-28	WOS:A1997YE87200005
J	Lurie, JD; Sox, HC				Lurie, JD; Sox, HC			High on the differential	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; VENTRICULAR DIASTOLIC DYSFUNCTION; SYSTOLIC FUNCTION; CARDIAC-FAILURE; DIAGNOSIS		DARTMOUTH HITCHCOCK MED CTR, DEPT MED, LEBANON, NH 03766 USA	Dartmouth College	Lurie, JD (corresponding author), VET AFFAIRS MED CTR, OUTCOMES GRP, WHITE RIVER JCT, VT 05009 USA.							ANDERSON CB, 1976, ARCH INTERN MED, V136, P292, DOI 10.1001/archinte.136.3.292; Badgett RG, 1997, JAMA-J AM MED ASSOC, V277, P1712, DOI 10.1001/jama.277.21.1712; BONOW RO, 1992, ANN INTERN MED, V117, P502, DOI 10.7326/0003-4819-117-6-502; BRAUNWALD E, 1992, HEART DIS TXB CARDIO, V1, P444; BROGAN WC, 1992, AM J MED, V92, P627, DOI 10.1016/0002-9343(92)90781-6; COHN JN, 1990, CIRCULATION, V81, P48; DODEK A, 1973, AM HEART J, V85, P281, DOI 10.1016/0002-8703(73)90473-0; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; ECHEVERRIA HH, 1983, AM J MED, V75, P750, DOI 10.1016/0002-9343(83)90403-5; Gaasch William H., 1994, JAMA (Journal of the American Medical Association), V271, P1276, DOI 10.1001/jama.271.16.1276; GHALI JK, 1991, AM J CARDIOL, V67, P1002, DOI 10.1016/0002-9149(91)90174-J; GOLDSMITH SR, 1993, AM J MED, V95, P645, DOI 10.1016/0002-9343(93)90361-R; GROSSMAN W, 1991, NEW ENGL J MED, V325, P1557; HARLAN WR, 1977, ANN INTERN MED, V86, P133, DOI 10.7326/0003-4819-86-2-133; IRIARTE M, 1993, AM J CARDIOL, V71, P308, DOI 10.1016/0002-9149(93)90796-F; Kassirer JP., 2009, LEARNING CLIN REASON; KESSLER KM, 1988, ARCH INTERN MED, V148, P2109, DOI 10.1001/archinte.148.10.2109; MCBRIDE W, 1988, NEW ENGL J MED, V319, P1651, DOI 10.1056/NEJM198812223192506; MCDERMOTT MM, 1995, AM J MED, V99, P629, DOI 10.1016/S0002-9343(99)80250-2; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; PooleWilson PA, 1997, NEW ENGL J MED, V336, P1381, DOI 10.1056/NEJM199705083361908; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1065, DOI 10.1056/NEJM198810203191606; SCHRIER RW, 1989, NEW ENGL J MED, V320, P676; SOLOMON NA, 1995, TEC ASSESS, V10, P11; SOX HC, 1997, COST EFFECTIVE DIAGN, P39; Sox HC, 1988, MED DECISION MAKING; Vasan RS, 1996, ARCH INTERN MED, V156, P146, DOI 10.1001/archinte.156.2.146; WILLIAMS JF, 1995, CIRCULATION, V92, P2764	28	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1377	1381		10.1056/NEJM199711063371908	http://dx.doi.org/10.1056/NEJM199711063371908			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358133				2022-12-28	WOS:A1997YE44600008
J	Taira, DA; Safran, DG; Seto, TB; Rogers, WH; Tarlov, AR				Taira, DA; Safran, DG; Seto, TB; Rogers, WH; Tarlov, AR			The relationship between patient income and physician discussion of health risk behaviors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE PHYSICIANS; SOCIOECONOMIC-STATUS; CONTROLLED TRIAL; UNITED-STATES; CARDIOVASCULAR-DISEASE; COUNSELING PRACTICES; US ADOLESCENTS; QUIT SMOKING; MEDICAL-CARE; PRACTITIONERS	Context.-The US Preventive Services Task Force recommends that physicians assess patients' health risk behaviors, addressing those needing modification. Objective.-To examine the relationship between patient income, health risk behaviors, the prevalence of physician discussion of these behaviors, and the receptiveness of patients to their physicians' advice. Design.-Employee survey. Participants.-A random sample of 6549 Massachusetts state employees in 12 health plans. Main Outcome Measures.-Data were obtained using a patient-completed mail survey. Trend tests were used to discern differences in the prevalence of health risk behaviors, physician discussion of these behaviors, and patient receptiveness to discussions by patient income. Results.-Although unhealthy behaviors were common among all income groups, physician discussion of health risk behaviors fell far short of the universal risk assessment recommended by the US Preventive Services Task Force. Low-income patients were more likely to be obese and smoke than high-income patients and were less likely to wear seat belts and exercise. In contrast, stress and alcohol consumption increased with income, while the proportion of heavy drinkers did not vary significantly. Physicians were more likely to discuss diet and exercise with high-income patients in need of these discussions than with low-income patients, but were more likely to discuss smoking with low-income patients who smoked than with high-income patients who smoked. Among patients with whom discussions occurred, low-income patients were much more likely to report attempting to change their behavior based on physician advice. Conclusions.-Physician counseling of patients regarding health risk behaviors should be greatly improved if the US Preventive Services Task Force recommendations are to be fulfilled. Improvement is especially needed in regard to alcohol consumption, safe sex, and seat belt use. Physicians also need to be more vigilant in properly identifying and counseling low-income patients at risk in regard to diet and exercise and high-income patients who smoke.	BETH ISRAEL DEACONESS MED CTR,DIV CARDIOVASC,BOSTON,MA; TUFTS UNIV,DEPT MED,BOSTON,MA 02111; HARVARD UNIV,SCH PUBL HLTH,DEPT MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Tufts University; Harvard University; Harvard T.H. Chan School of Public Health	Taira, DA (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,HLTH INST,750 WASHINGTON ST,BOX 345,BOSTON,MA 02111, USA.				AHRQ HHS [R01HS08841] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Altman D.G., 1991, PRACTICAL STAT MED R; *AM MED ASS, 1994, AMA GUID AD PREV SER; ANDA RF, 1987, JAMA-J AM MED ASSOC, V257, P1916; BLAIR SN, 1985, PUBLIC HEALTH REP, V100, P172; BOWMAN MA, 1992, ARCH INTERN MED, V152, P1823, DOI 10.1001/archinte.152.9.1823; BROWN JB, 1992, MED CARE, V30, P400, DOI 10.1097/00005650-199205000-00003; BRUNNER EJ, 1993, ATHEROSCLEROSIS, V102, P195, DOI 10.1016/0021-9150(93)90162-N; CAMPBELL MJ, 1985, BRIT MED J, V290, P1044, DOI 10.1136/bmj.290.6474.1044; *CDCP, 1995, JAMA-J AM MED ASSOC, V273, P102; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; DIETRICH AJ, 1984, AM J PUBLIC HEALTH, V74, P223, DOI 10.2105/AJPH.74.3.223; FARQUHAR JW, 1993, CIRCULATION, V88, P1376, DOI 10.1161/01.CIR.88.3.1376; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; Feldman M K, 1993, Minn Med, V76, P14; FLYNN BS, 1992, AM J PUBLIC HEALTH, V82, P827, DOI 10.2105/AJPH.82.6.827; FRIEDMAN C, 1994, AM J PREV MED, V10, P367, DOI 10.1016/S0749-3797(18)30567-1; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GERBERT B, 1986, MED CARE, V24, P838, DOI 10.1097/00005650-198609000-00005; GLYNN TJ, 1991, NIH PUBLICATION; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; HARRIS S S, 1989, Journal of the American Medical Association, V261, P3590; Harwood H. J., 1984, EC COSTS SOC ALCOHOL; Heaney CA, 1996, HEALTH EDUC QUART, V23, P133, DOI 10.1177/109019819602300201; INUI TS, 1976, ANN INTERN MED, V84, P646, DOI 10.7326/0003-4819-84-6-646; Jeffery RW, 1996, AM J PUBLIC HEALTH, V86, P1005, DOI 10.2105/AJPH.86.7.1005; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; LEWIS CE, 1991, ANN INTERN MED, V114, P54, DOI 10.7326/0003-4819-114-1-54; LEWIS CE, 1986, J GEN INTERN MED, V1, P14, DOI 10.1007/BF02596319; LOGSDON DN, 1989, AM J PREV MED, V5, P249, DOI 10.1016/S0749-3797(18)31065-1; Lowry R, 1996, JAMA-J AM MED ASSOC, V276, P792, DOI 10.1001/jama.276.10.792; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MONTANO DE, 1995, AM J PUBLIC HEALTH, V85, P795, DOI 10.2105/AJPH.85.6.795; MULDER JA, 1981, J FAM PRACTICE, V13, P345; *NAT CTR HLTH STAT, 1993, CURR EST NATL HLTH I; OCKENE JK, 1991, J GEN INTERN MED, V6, P1, DOI 10.1007/BF02599381; ORLEANS CT, 1985, ANNU REV MED, V36, P51; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; PAPPAS G, 1994, AM J PUBLIC HEALTH, V84, P892, DOI 10.2105/AJPH.84.6.892; Passaro KT, 1997, INT J EPIDEMIOL, V26, P315, DOI 10.1093/ije/26.2.315; Pate RR, 1996, AM J PUBLIC HEALTH, V86, P1577, DOI 10.2105/AJPH.86.11.1577; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PEDERSON LL, 1982, PREV MED, V11, P536, DOI 10.1016/0091-7435(82)90067-6; PEDERSON LL, 1982, PREV MED, V11, P71, DOI 10.1016/0091-7435(82)90006-8; PEKKANEN J, 1995, BRIT MED J, V311, P589, DOI 10.1136/bmj.311.7005.589; PEREZSTABLE EJ, 1994, AM J PUBLIC HEALTH, V84, P971, DOI 10.2105/AJPH.84.6.971; PILL RM, 1989, J ROY COLL GEN PRACT, V39, P196; PINCUS T, 1994, J CLIN EPIDEMIOL, V47, P355, DOI 10.1016/0895-4356(94)90156-2; RICE DP, 1986, MILBANK Q, V64, P489, DOI 10.2307/3349924; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; SHERMAN SE, 1993, J GEN INTERN MED, V8, P243, DOI 10.1007/BF02600089; SILAGY C, 1992, BRIT MED J, V305, P871, DOI 10.1136/bmj.305.6858.871; SOBAL J, 1985, AM J PUBLIC HEALTH, V75, P1427, DOI 10.2105/AJPH.75.12.1427; STANGE KC, 1992, J FAM PRACTICE, V34, P409; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wechsler H, 1996, NEW ENGL J MED, V334, P996, DOI 10.1056/NEJM199604113341519; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; Zapka J G, 1995, J Ambul Care Manage, V18, P73	62	105	105	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1412	1417		10.1001/jama.278.17.1412	http://dx.doi.org/10.1001/jama.278.17.1412			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC917	9355999				2022-12-28	WOS:A1997YC91700027
J	Maniatis, T				Maniatis, T			Signal transduction - Catalysis by a multiprotein I kappa B kinase complex	SCIENCE			English	Editorial Material							ACTIVATION; PROTEINS; FAMILY; DEATH; ALPHA				Maniatis, T (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	20	227	235	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					818	819		10.1126/science.278.5339.818	http://dx.doi.org/10.1126/science.278.5339.818			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9381193				2022-12-28	WOS:A1997YD47900031
J	Oliver, D; Britton, M; Seed, P; Martin, FC; Hopper, AH				Oliver, D; Britton, M; Seed, P; Martin, FC; Hopper, AH			Development and evaluation of evidence based risk assessment tool (STRATIFY) to predict which elderly inpatients will fall: case-control and cohort studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NURSING-HOME; PATIENT	Objectives: To identify clinical characteristics of elderly inpatients that predict their chance of falling (phase 1) and to use these characteristics to derive a risk assessment tool and to evaluate its power in predicting falls (phases 2 and 3). Design: Phase 1: a prospective case-control study. Phases 2 and 3: prospective evaluations of the derived risk assessment tool in predicting falls in two cohorts. Setting: Elderly care units of St Thomas's Hospital (phase 1 and 2) and Kent and Canterbury Hospital (phase 3). Subjects: Elderly hospital inpatients (aged greater than or equal to 65 years): 116 cases and 116 controls in phase 1, 217 patients in phase 2, and 331 in phase 3. Main outcome measures: 21 separate clinical characteristics were assessed in phase 1, including the abbreviated mental test score, modified Barthel index, a transfer and mobility score obtained by combining the transfer and mobility sections of the Barthel index, and several nursing judgments. Results:In phase 1 five factors were independently associated with a higher risk of falls: fall as a presenting complaint (odds ratio 4.64 (95% confidence interval 2.59 to 8.33); a transfer and mobility score of 3 or 4 (2.10 (1.22 to 3.61)); and primary nurses' judgment that a patient was agitated (20.9 (9.62 to 45.62)), needed frequent toileting (2.48 (1.08 to 5.70)), and was visually impaired (3.56 (1.26 to 10.05)). A risk assessment score (range 0-5) was derived by scoring one point for each of these five factors. In phases 2 and 3 a risk assessment score >2 was used to define high risk: the sensitivity and specificity of the score to predict falls during the following week was 93% and 88% respectively in phase 2 and 92% and 68% respectively in phase 3. Conclusion: This simple risk assessment tool predicted with clinically useful sensitivity and specificity a high percentage of falls among elderly hospital inpatients.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, DEPT STAT, DIV PUBL HLTH SCI, ST THOMAS HOSP, LONDON SE1 7EH, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Oliver, D (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, DEPT CARE ELDERLY, DIV MED, ST THOMAS HOSP, LONDON SE1 7EH, ENGLAND.		Seed, Paul T/C-4435-2008	Seed, Paul T/0000-0001-7904-7933				Baker S P, 1985, Clin Geriatr Med, V1, P501; BATES DW, 1995, AM J MED, V99, P137, DOI 10.1016/S0002-9343(99)80133-8; Brady R, 1993, J Gerontol Nurs, V19, P26; Cannard G, 1996, Nurs Times, V92, P36; Collin C, 1988, Int Disabil Stud, V10, P61; DeVincenzo D K, 1987, Rehabil Nurs, V12, P248; Gilleard C., 1984, AGE AGEING S4, V23, P17; Gluck T, 1996, GERONTOLOGY, V42, P104, DOI 10.1159/000213779; Hendrich A L, 1988, J Nurs Qual Assur, V3, P28; HINDMARSH JJ, 1989, ARCH INTERN MED, V149, P2217, DOI 10.1001/archinte.149.10.2217; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; KAPOOR WN, 1991, AM J MED, V90, P91; MORSE JM, 1987, GERONTOLOGIST, V27, P516, DOI 10.1093/geront/27.4.516; MORSE K, 1996, PREVENTING INPATIENT; MORTON D, 1989, AM J NURS, V89, P204, DOI 10.2307/3471090; MURPHY J, 1982, GERONTOLOGY, V28, P265, DOI 10.1159/000212543; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; SCHMID NA, 1990, MIL MED, V155, P202, DOI 10.1093/milmed/155.5.202; Streiner DL, 1989, PDQ EPIDEMIOLOGY, P33; VETTER NJ, 1989, INT J GERIATR PSYCH, V4, P159, DOI 10.1002/gps.930040307; Waterlow J, 1985, Nurs Times, V81, P49; WATERLOW J, 1985, NURS TIMES, V81, P48; WERNER P, 1994, J AM GERIATR SOC, V42, P321, DOI 10.1111/j.1532-5415.1994.tb01759.x; 1996, EFFECTIVE HLTH CARE, V2, P1	25	416	454	1	57	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1049	1053		10.1136/bmj.315.7115.1049	http://dx.doi.org/10.1136/bmj.315.7115.1049			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366729	Green Published			2022-12-28	WOS:A1997YD44500018
J	Rowen, L; Mahairas, G; Hood, L				Rowen, L; Mahairas, G; Hood, L			Sequencing the human genome	SCIENCE			English	Editorial Material							MAP; DNA				Rowen, L (corresponding author), UNIV WASHINGTON, DEPT MOL BIOTECHNOL, POB 357730, SEATTLE, WA 98195 USA.							Adams M. D., 1994, AUTOMATED DNA SEQUEN; ADAMS MD, 1995, NATURE, V377, P3; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Kaneko T, 1996, DNA Res, V3, P109; ROWEN L, UNPUB; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Venter JC, 1996, NATURE, V381, P364, DOI 10.1038/381364a0; Wilson R. A., COMMUNICATION	17	89	91	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					605	607		10.1126/science.278.5338.605	http://dx.doi.org/10.1126/science.278.5338.605			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381170				2022-12-28	WOS:A1997YC32300038
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			BLAST off!	SCIENCE			English	Editorial Material																		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999	2	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					501	502						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381147				2022-12-28	WOS:A1997YB35500056
J	Rehkamper, M; Halliday, AN; Barfod, D; Fitton, JG				Rehkamper, M; Halliday, AN; Barfod, D; Fitton, JG			Platinum-group element abundance patterns in different mantle environments	SCIENCE			English	Article							SIDEROPHILE ELEMENTS; GROUP MINERALS; OPHIOLITIC COMPLEXES; OUTOKUMPU OPHIOLITE; IRIDIUM; PALLADIUM; CHROMITE; GOLD; GEOCHEMISTRY; PERIDOTITES	Mantle-derived xenoliths from the Cameroon Line and northern Tanzania display differences in their platinum-group element (PGE) abundance patterns. The Cameroon Line Iherzolites have uniform PGE patterns indicating a homogeneous upper mantle over several hundreds of kilometers, with approximately chondritic PGE ratios. The PGE patterns of the Tanzanian peridotites are similar to the PGE systematics of ultramafic rocks from ophiolites. The differences can be explained if the northern Tanzanian lithosphere developed in a fluid-rich suprasubduction zone environment, whereas the Cameroon Line lithosphere only experienced melt extraction from anhydrous peridotites.	UNIV EDINBURGH,DEPT GEOL & GEOPHYS,EDINBURGH EH9 3JW,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Rehkamper, M (corresponding author), UNIV MICHIGAN,DEPT GEOL SCI,1006 CC LITTLE BLDG,ANN ARBOR,MI 48109, USA.		Barfod, Dan/E-9775-2011; Barfod, Dan/P-1527-2019	Barfod, Dan/0000-0001-8934-4034				AGIORGITIS G, 1978, CHEM GEOL, V23, P267, DOI 10.1016/0009-2541(78)90082-7; BALLHAUS CG, 1986, CONTRIB MINERAL PETR, V94, P193, DOI 10.1007/BF00592936; Brandon AD, 1996, SCIENCE, V272, P861, DOI 10.1126/science.272.5263.861; Cahen L., 1984, GEOCHRONOLOGY EVOLUT; Chou CL, 1978, P LUNAR PLANET SCI, V9, P219; COCHERIE A, 1989, CHEM GEOL, V77, P27, DOI 10.1016/0009-2541(89)90012-0; COHEN RS, 1984, EARTH PLANET SC LETT, V68, P209, DOI 10.1016/0012-821X(84)90153-5; COPOBIANCO CJ, 1994, CHEM GEOL, V113, P23; DAWSON JB, 1970, J PETROL, V11, P519, DOI 10.1093/petrology/11.3.519; DAWSON JB, 1987, MANTLE METASOMATISM, P125; DICK HJB, 1984, CONTRIB MINERAL PETR, V86, P54, DOI 10.1007/BF00373711; ELTHON D, 1991, NATURE, V354, P140, DOI 10.1038/354140a0; FLEET ME, 1993, GEOCHIM COSMOCHIM AC, V57, P3519, DOI 10.1016/0016-7037(93)90136-K; Gueddari K, 1996, CHEM GEOL, V134, P181, DOI 10.1016/S0009-2541(96)00085-X; HALLIDAY AN, 1995, INT J MASS SPECTROM, V146, P21, DOI 10.1016/0168-1176(95)04200-5; Hart S.R., 1996, EARTH PROCESSES READ, P123; HUTCHISON R, 1970, EARTH PLANET SC LETT, V9, P87, DOI 10.1016/0012-821X(70)90030-0; Jagoutz E., 1979, P LUNAR PLANET SCI, V2, P2031; Jochum KP, 1996, GEOCHIM COSMOCHIM AC, V60, P3353, DOI 10.1016/0016-7037(96)00186-X; JOHAN Z, 1983, FORTSCHR MINERAL, V61, P105; KALLEMEYN GW, 1986, GEOCHIM COSMOCHIM AC, V50, P2153, DOI 10.1016/0016-7037(86)90070-0; KEAYS RR, 1982, ECON GEOL, V77, P1535, DOI 10.2113/gsecongeo.77.6.1535; KESSON SE, 1989, CHEM GEOL, V78, P97, DOI 10.1016/0009-2541(89)90110-1; KUSHIRO I, 1969, AM J SCI, V267, P269; Leblanc M, 1995, ECON GEOL BULL SOC, V90, P2028, DOI 10.2113/gsecongeo.90.7.2028; Lee DC, 1996, J PETROL, V37, P415, DOI 10.1093/petrology/37.2.415; Li J, 1996, NATURE, V381, P686, DOI 10.1038/381686a0; LORAND JP, 1996, J C ABSTR, V1, P369; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; MCELDUFF B, 1990, MINER PETROL, V42, P211, DOI 10.1007/BF01162692; MCLAREN CH, 1982, ECON GEOL, V77, P1348, DOI 10.2113/gsecongeo.77.6.1348; MITCHELL RH, 1981, GEOCHIM COSMOCHIM AC, V45, P2425, DOI 10.1016/0016-7037(81)90096-X; MORGAN JW, 1981, TECTONOPHYSICS, V75, P47, DOI 10.1016/0040-1951(81)90209-2; MORGAN JW, 1986, J GEOPHYS RES-SOLID, V91, P2375, DOI 10.1029/JB091iB12p12375; MURTHY VR, 1991, SCIENCE, V253, P303, DOI 10.1126/science.253.5017.303; NIXON PH, 1987, MANTLE XENOLITHS, P215; OSHIN IO, 1982, ECON GEOL, V77, P1556, DOI 10.2113/gsecongeo.77.6.1556; PAGE NJ, 1984, ECON GEOL, V79, P177, DOI 10.2113/gsecongeo.79.1.177; PAGE NJ, 1984, CAN MINERAL, V22, P137; PAGE NJ, 1982, CAN MINERAL, V20, P537; Pattou L, 1996, NATURE, V379, P712, DOI 10.1038/379712a0; Pearce J.A., 1984, GEOL SOC LOND SPEC P, V16, P77, DOI [10.1144/GSL.SP.1984.016.01.06, DOI 10.1144/GSL.SP.1984.016.01.06]; PERRY SJ, 1984, CHEM GEOL, V43, P115; Rehkamper M, 1997, TALANTA, V44, P663, DOI 10.1016/S0039-9140(96)02100-5; REHKAMPER M, IN PRESS FRES J ANAL; Ridley W. I., 1975, PHYS CHEM EARTH, V9, P559; Righter K, 1997, EARTH PLANET SC LETT, V146, P541, DOI 10.1016/S0012-821X(96)00243-9; RUDNICK RL, 1993, EARTH PLANET SC LETT, V114, P463, DOI 10.1016/0012-821X(93)90076-L; RUDNICK RL, 1991, P 5 INT KIMB C AR BR, V1, P336; Schiano P, 1997, EARTH PLANET SC LETT, V146, P489, DOI 10.1016/S0012-821X(96)00254-3; SCHMIDT G, 1996, J C ABSTR, V1, P544; SCHMIDT G, 1997, LPI CONTRIBUTION, V921, P186; SHIREY SB, 1995, ANAL CHEM, V67, P2136, DOI 10.1021/ac00109a036; STOCKMAN HW, 1984, ECON GEOL, V79, P491, DOI 10.2113/gsecongeo.79.3.491; TALKINGTON RW, 1984, TSCHER MINER PETROG, V32, P285; TOTEU SF, 1987, PRECAMBRIAN RES, V37, P71, DOI 10.1016/0301-9268(87)90040-4; VUOLLO J, 1995, ECON GEOL BULL SOC, V90, P445, DOI 10.2113/gsecongeo.90.2.445; WALKER D, 1993, SCIENCE, V262, P1858, DOI 10.1126/science.262.5141.1858; Walker RJ, 1996, EARTH PLANET SC LETT, V141, P161, DOI 10.1016/0012-821X(96)00076-3; WASSON JT, 1988, PHILOS T R SOC A, V325, P535, DOI 10.1098/rsta.1988.0066; WOOD SA, 1987, GEOCHIM COSMOCHIM AC, V51, P3041, DOI 10.1016/0016-7037(87)90377-2	62	110	121	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1595	1598		10.1126/science.278.5343.1595	http://dx.doi.org/10.1126/science.278.5343.1595			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374452				2022-12-28	WOS:A1997YJ87400031
J	Alexander, FE				Alexander, FE			Blood transfusion and risk of non-Hodgkin lymphoma	LANCET			English	Editorial Material							TIME TRENDS				Alexander, FE (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							Adami J, 1997, ANN INTERN MED, V127, P365, DOI 10.7326/0003-4819-127-5-199709010-00004; BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; Brandt L, 1996, BRIT J CANCER, V73, P1148, DOI 10.1038/bjc.1996.220; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; Cerhan JR, 1997, J NATL CANCER I, V89, P314, DOI 10.1093/jnci/89.4.314; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; DEVESA SS, 1992, CANCER RES, V52, pS5432; GELB AB, 1994, HUM PATHOL, V25, P953, DOI 10.1016/0046-8177(94)90018-3; HARTGE P, 1992, CANCER RES, V52, pS5566; MANN R, 1994, J TRAUMA, V37, P220, DOI 10.1097/00005373-199408000-00012; Mckinney P A, 1990, Leuk Lymphoma, V2, P67, DOI 10.3109/10428199009042516; MEMON A, 1994, INT J CANCER, V58, P366, DOI 10.1002/ijc.2910580310; RollandPortal I, 1997, INT J EPIDEMIOL, V26, P945, DOI 10.1093/ije/26.5.945; Schreiber GB, 1997, J ACQ IMMUN DEF SYND, V14, P263, DOI 10.1097/00042560-199703010-00011	15	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1414	1415		10.1016/S0140-6736(05)64203-1	http://dx.doi.org/10.1016/S0140-6736(05)64203-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371161				2022-12-28	WOS:A1997YF95300004
J	Evans, DJ; Taylor, DA; Zetterstrom, O; Chung, F; OConnor, BJ; Barnes, PJ				Evans, DJ; Taylor, DA; Zetterstrom, O; Chung, F; OConnor, BJ; Barnes, PJ			A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRUG-THERAPY; GLUCOCORTICOIDS; SALMETEROL; HISTAMINE; STEROIDS	Background Inhaled glucocorticoids and oral theophylline are widely used to treat asthma. We compared the benefits of adding theophylline to inhaled glucocorticoid with those of doubling the dose of inhaled glucocorticoid in patients with persistent symptoms despite the use of inhaled glucocorticoid. Methods In a double-blind, placebo-controlled trial, we randomly assigned 62 patients to receive either 400 mu g of inhaled budesonide (low-dose budesonide) with 250 or 375 mg of theophylline (depending on body weight) or 800 mu g of inhaled budesonide (high-dose budesonide). All doses were given twice daily for three months. Lung function was measured serially, and patients kept records of peak expiratory flow, symptoms, and albuterol use. The effects of treatment on endogenous cortisol levels were also assessed. Results Both treatments resulted in improvements in lung function that were sustained throughout the study. As compared with treatment with high-dose budesonide, treatment with low-dose budesonide plus theophylline resulted in greater improvements in forced vital capacity (P = 0.03) and forced expiratory volume in one second (P = 0.03). There were significant and similar reductions in beta(2)-agonist use and the variability of peak expiratory flow, a correlate of bronchial hyperresponsiveness and the severity of asthma. Serum cortisol concentrations were significantly reduced in the group given high-dose budesonide (from a mean [+/-SE] of 18.4 +/- 2.4 mu g per deciliter to 15.9 +/- 2.1 mu g per deciliter, P = 0.02) but were unchanged in the other group. The median serum theophylline concentration was 8.7 mu g per milliliter (therapeutic range, 10 to 20) among those who received theophylline. Both treatments were well tolerated. Conclusions For patients with moderate asthma and persistent symptoms, low-dose inhaled budesonide with theophylline and high-dose inhaled budesonide produced similar benefits. Effects were achieved at theophylline concentrations below the recommended therapeutic range. The addition of low-dose theophylline to inhaled glucocorticoid may be preferable to and cheaper than increasing the dose of inhaled glucocorticoid. (C) 1997, Massachusetts Medical Society.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, DEPT THORAC MED, LONDON SW3 6LY, ENGLAND; KAROLINSKA INST, THORAC CLIN, DIV RESP MED, STOCKHOLM, SWEDEN	Imperial College London; Karolinska Institutet			Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1993, THORAX, V48, pS1; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Crowder M.J., 1990, ANAL REPEATED MEASUR; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; DENT G, 1994, AM J RESP CELL MOL, V10, P565, DOI 10.1165/ajrcmb.10.5.8179921; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HATZELMANN A, 1995, BRIT J PHARMACOL, V114, P821, DOI 10.1111/j.1476-5381.1995.tb13278.x; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; MAGNUSSEN H, 1987, AM REV RESPIR DIS, V136, P1163, DOI 10.1164/ajrccm/136.5.1163; MARY D, 1987, J IMMUNOL, V139, P1179; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PROWSE K, 1979, J INT MED RES, V7, P101; RIVINGTON RN, 1995, AM J RESP CRIT CARE, V151, P325, DOI 10.1164/ajrccm.151.2.7842186; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; STEINIJANS VW, 1988, ARZNEIMITTEL-FORSCH, V38-2, P1241; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; SULLIVAN P, 1994, LANCET, V343, P1512; WALLS AF, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb00106.x; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518; Weinberger M, 1996, NEW ENGL J MED, V334, P1380, DOI 10.1056/NEJM199605233342107; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; 1994, THORAX, V49, P96	27	263	276	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1412	1418		10.1056/NEJM199711133372002	http://dx.doi.org/10.1056/NEJM199711133372002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF253	9358138				2022-12-28	WOS:A1997YF25300002
J	Collins, MM; Ransohoff, DF; Barry, MJ				Collins, MM; Ransohoff, DF; Barry, MJ			Early detection of prostate cancer - Serendipity strikes again	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med			DIGITAL RECTAL EXAMINATION; FECAL OCCULT BLOOD; COLORECTAL-CANCER; ANTIGEN; ADENOCARCINOMA; DIAGNOSIS; STAGE-T1C; BIOPSIES; VOLUME; TRIAL	An underappreciated characteristic of prostate cancer screening is that it may detect some prostate cancers solely by serendipity or chance, Serendipity, previously described in the detection of colonic neoplasms, could affect prostate cancer detection when a screening test result is abnormal for reasons other than the presence of prostate cancer, but prostate cancer is coincidentally detected during the subsequent evaluation of the abnormal screening result. We reviewed published articles about prostate cancer screening, searching for evidence of serendipity. We defined serendipity in digital rectal examination (DRE) screening as the discovery of a prostate cancer by the random biopsy of an area of the prostate gland other than the palpable suspicious area that prompted the biopsy. We defined serendipity in prostate-specific antigen (PSA) screening as the discovery of a prostate cancer by the random biopsy of a nonpalpable (stage T1c) prostate cancer less than 1.0 cm(3) in volume, since tumors less than 1.0 cm(3) are generally too small to cause elevated PSA levels. We found that serendipity may be responsible for the detection of more than one quarter of apparently DRE-detected prostate cancers and up to one quarter of apparently PSA-detected cancers. Additionally, serendipity played a larger role in the detection of smaller tumors that are common but of uncertain clinical significance. We conclude that serendipity-detected prostate cancers contribute to an overestimation of the true information value of DRE and PSA screening. Whether serendipity is advantageous in prostate cancer screening depends on the as yet uncertain outcomes for men with smaller prostate cancers. However, given our estimates of the potential magnitude of the impact of serendipity, the currently popular DRE- and PSA-based screening strategy may not be optimal. If smaller prostate cancers are important, then we are not finding enough; if they are unimportant, then we are finding too many that we may feel compelled to treat aggressively.	MASSACHUSETTS GEN HOSP, MED SERV, DIV GEN MED, MED PRACTICES EVALUAT CTR, BOSTON, MA 02114 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC USA; UNIV N CAROLINA, DEPT EPIDEMIOL, CHAPEL HILL, NC USA	Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					AHRQ HHS [HS 08397] Funding Source: Medline; BHP HRSA HHS [5T32PE11001-08] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		BARRY MJ, 1995, UROLOGY, V46, P2, DOI 10.1016/S0090-4295(99)80151-4; BARRY MJ, 1995, ACP J CLUB, V123, P19; BILLEBAUD T, 1992, EUR UROL, V21, P6; BRAWN PN, 1991, CANCER, V68, P1592, DOI 10.1002/1097-0142(19911001)68:7<1592::AID-CNCR2820680721>3.0.CO;2-M; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; COLEY CM, 1995, UROLOGY, V46, P125, DOI 10.1016/S0090-4295(99)80181-2; Dugan JA, 1996, JAMA-J AM MED ASSOC, V275, P288, DOI 10.1001/jama.275.4.288; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; Eskew LA, 1997, J UROLOGY, V157, P199, DOI 10.1016/S0022-5347(01)65322-9; FLANIGAN RC, 1994, J UROLOGY, V152, P1506, DOI 10.1016/S0022-5347(17)32457-6; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Geary ES, 1996, J UROLOGY, V156, P1056, DOI 10.1016/S0022-5347(01)65701-X; GOHAGAN JK, 1994, J UROLOGY, V152, P1905, DOI 10.1016/S0022-5347(17)32412-6; Harmon Taz, 1997, Journal of Urology, V157, P365; Humphrey PA, 1996, J UROLOGY, V155, P816, DOI 10.1016/S0022-5347(01)66316-X; Karakiewicz PI, 1996, UROLOGY, V48, P747, DOI 10.1016/S0090-4295(96)00230-0; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; Levine Michael A., 1997, Journal of Urology, V157, P64; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; OESTERLING JE, 1993, UROL CLIN N AM, V20, P687; OHORI M, 1994, CANCER-AM CANCER SOC, V74, P104, DOI 10.1002/1097-0142(19940701)74:1<104::AID-CNCR2820740119>3.0.CO;2-5; PROROK P, 1994, CAN J ONCOL S, V4, P102; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RICHIE JP, 1993, UROLOGY, V42, P365, DOI 10.1016/0090-4295(93)90359-I; SCALETSCKY R, 1994, J UROLOGY, V152, P129, DOI 10.1016/S0022-5347(17)32834-3; SCARDINO PT, 1992, HUM PATHOL, V23, P211, DOI 10.1016/0046-8177(92)90102-9; Schroder F H, 1994, Can J Oncol, V4 Suppl 1, P102; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119; Vashi Apoorva E., 1997, Journal of Urology, V157, P365; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107	34	44	44	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1516	1519		10.1001/jama.1997.03550180066039	http://dx.doi.org/10.1001/jama.1997.03550180066039			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YE445	9363972				2022-12-28	WOS:A1997YE44500036
J	Lam, TH; He, Y; Li, LS; Li, LS; He, SF; Liang, BQ				Lam, TH; He, Y; Li, LS; Li, LS; He, SF; Liang, BQ			Mortality attributable to cigarette smoking in China	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-The few published prospective studies of smoking and mortality in China have reported low relative risks, but the durations of follow-up were short. Objective.-To assess the mortality of ever-and never-smokers in a cohort after 20 years of follow-up. Design, Setting, and Subjects.-A cohort analytic study in a machinery factory in Xi'an, China, involving 1696 people aged 35 years or older (1124 men and 572 METHODS women) examined in May 1976. Main Outcome Measures.-All-cause and tobacco-associated mortality. Results.-A total of 56% of the men and 12% of the women were ever-smokers at baseline. Through August 31, 1996, 218 persons (173 men and 45 women) had died. The relative risks (95% confidence intervals [CIs]) for ever smoking (after adjusting for age, marital status, occupation, education, diastolic blood pressure, and triglyceride and cholesterol levels) for deaths resulting from all causes, all cancer, and coronary heart disease were, respectively, 2.42 (95% CI, 1.72-3.42), 2.50 (95% CI, 1.41-4.43), and 3.61 (95% CI, 1.35-9.67) in men and 2.32 (95% CI, 1.18-4.56), 1.98 (95% CI, 0.50-7.92), and 4.67 (95% CI, 0.78-27.8) in women. Conclusions.-Previous prospective studies of smoking-related mortality in China tended to underestimate the risks, probably because of short durations of follow-up. We have demonstrated that smoking is a major cause of death in China, and the risks are similar to those seen in the United States and the United Kingdom. Thus, about half of the 300 million smokers in China will eventually die of smoking-related diseases if urgent tobacco-control measures are not instituted to prevent this growing epidemic.	FOURTH MIL MED UNIV,DEPT EPIDEMIOL,XIAN 710032,PEOPLES R CHINA; FOURTH MIL MED UNIV,DEPT CARDIOL,XIAN 710032,PEOPLES R CHINA; KUN LUN MACHINERY FACTORY HOSP,XIAN,PEOPLES R CHINA	Air Force Military Medical University; Air Force Military Medical University	Lam, TH (corresponding author), UNIV HONG KONG,DEPT COMMUNITY MED,PATRICK MANSON BLDG S WING,7 SASSOON RD,HONG KONG,HONG KONG.		; Lam, Tai Hing/C-4317-2009	He, Yao/0000-0001-6205-7895; Lam, Tai Hing/0000-0002-2033-9971				DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; GAO YT, 1996, P 1996 C SMOK HLTH H, P109; *GEN HOSP PEOPL LI, 1974, MED LAB TECHNOL, P452; HE Y, 1994, BRIT MED J, V308, P380, DOI 10.1136/bmj.308.6925.380; LI WX, 1984, CHUNG HUA LIU HSING, V2, P91; [Office of Research and Development Office of Health Environmental Assessment United States Environmental Protection Agency], 1992, RESP HLTH EFF PASS S; Peto R, 1996, JAMA-J AM MED ASSOC, V275, P1683, DOI 10.1001/jama.275.21.1683; PETO R, 1994, MORTALITY SMOKING; *SPSS INC, 1994, SPSS ADV STAT 6 1, P275; WANG J, 1987, Chinese Journal of Epidemiology, V8, P350; WU XG, 1979, CHUNG HUA HSIN HSUEH, V7, P164; WU XG, 1991, CHINESE CIRCULATION, V6, P127; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646; Zhang Y., 1996, P 1996 C SMOK HLTH H, p[17, 35, 154]	14	95	104	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1505	1508		10.1001/jama.278.18.1505	http://dx.doi.org/10.1001/jama.278.18.1505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363970				2022-12-28	WOS:A1997YE44500034
J	Cowie, MR; Struthers, AD; Wood, DA; Coats, AJS; Thompson, SG; PooleWilson, PA; Sutton, GC				Cowie, MR; Struthers, AD; Wood, DA; Coats, AJS; Thompson, SG; PooleWilson, PA; Sutton, GC			Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care	LANCET			English	Article							LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; PLASMA-CONCENTRATIONS; GENERAL-PRACTICE; ECHOCARDIOGRAPHY; RECOMMENDATIONS; MANAGEMENT; IMPAIRMENT; PREVALENCE; DIAGNOSIS	Background The reliability of a clinical diagnosis of heart failure in primary care is poor. Concentrations of natriuretic peptides are high in heart failure. This population-based study examined the predictive value of natriuretic peptides in patients with a new primary-care diagnosis of heart failure. Methods Concentrations of plasma atrial (ANP and N-terminal ANP) and B-type (BNP) natriuretic peptides were measured by radioimmunoassay in 122 consecutive patients referred to a rapid-access heart-failure clinic with a new primary-care diagnosis of heart failure. On the basis of clinical assessment, chest radiography, and transthoracic echocardiography, a panel of three cardiologists decided that 35 (29%) patients met the case definition for new heart failure. ANP and NT-ANP results were available for 117 patients (34 with heart failure) and BNP results for 106 (29 with heart failure). Findings Geometric mean concentrations of natriuretic peptides were much higher in patients with heart failure than in those with other diagnoses (29.2 vs 12.4 pmol/L for ANP; 63.9 vs 13.9 pmol/L for BNP; 1187 vs 410.6 pmol/L for NT-ANP; all p<0.001). At cut-off values chosen to give negative predictive values for heart failure of 98% (ANP greater than or equal to 18.1 pmol/L, NT-ANP greater than or equal to 537.6 pmol/L, BNP greater than or equal to 22.2 pmol/L), the sensitivity, specificity, and positive predictive value for ANP were 97%, 72%, and 55%; for NT-ANP 97%, 66%, and 54%; and for BNP 97%, 84%, and 70%. Addition of ANP or NT-ANP concentration or both did not improve the predictive power of a logistic regression model containing BNP concentration alone. Interpretation In patients with symptoms suspected by a general practitioner to be due to heart failure, plasma BNP concentration seems to be a useful indicator of which patients are likely to have heart failure and require further clinical assessment.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CLIN PHARMACOL & THERAPEUT, DUNDEE DD1 9SY, SCOTLAND; ROYAL POSTGRAD MED SCH, DEPT MED STAT & EVALUAT, LONDON, ENGLAND; HILLINGDON HOSP, UXBRIDGE, MIDDX, ENGLAND	University of Dundee; Imperial College London	Cowie, MR (corresponding author), NATL HEART & LUNG INST, IMPERIAL COLL SCH MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.		Cowie, Martin R/AAQ-2818-2020; Coats, Andrew J Stewart/E-4451-2012	Cowie, Martin R/0000-0001-7457-2552; Coats, Andrew J Stewart/0000-0002-2771-4260; Struthers, Allan/0000-0002-2926-2528	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; CHOY AMJ, 1994, BRIT HEART J, V72, P16; CLARKE KW, 1994, BRIT HEART J, V71, P584; CLARKSON PBM, 1995, INT M WORK GROUP HEA; CLELAND JG, 1995, EUR HEART J, V16, P741; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; COLQUHOUN MC, 1995, BRIT J GEN PRACT, V45, P517; Cowie M. R., 1996, European Heart Journal, V17, P131; Davidson NC, 1996, AM J CARDIOL, V77, P828, DOI 10.1016/S0002-9149(97)89176-X; DAVIS KM, 1992, JAMA-J AM MED ASSOC, V267, P2625, DOI 10.1001/jama.267.19.2625; DAVIS M, 1994, LANCET, V343, P440, DOI 10.1016/S0140-6736(94)92690-5; DEVEREUX RB, 1987, HYPERTENSION, V9, P97; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; HALL C, 1995, CIRCULATION, V91, P911; HENRY WL, 1980, CIRCULATION, V62, P212, DOI 10.1161/01.CIR.62.2.212; HLATKY MA, 1986, J AM COLL CARDIOL, V8, P966, DOI 10.1016/S0735-1097(86)80442-9; KETTUNEN RVJ, 1994, AM HEART J, V127, P1449, DOI 10.1016/0002-8703(94)90369-7; LERMAN A, 1993, LANCET, V341, P1105, DOI 10.1016/0140-6736(93)93125-K; Mair FS, 1996, BRIT J GEN PRACT, V46, P77; MOTWANI JG, 1993, LANCET, V341, P1109, DOI 10.1016/0140-6736(93)93126-L; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232; PARAMESHWAR J, 1992, BRIT J GEN PRACT, V42, P287; REMES J, 1991, BRIT HEART J, V65, P249; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; RICHARDS AM, 1986, BMJ-BRIT MED J, V293, P409, DOI 10.1136/bmj.293.6544.409; RICHARDS AM, 1993, BRIT HEART J, V69, P414; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; STRUTHERS AD, 1993, BRIT HEART J, V70, P397; STRUTHERS AD, 1994, BMJ-BRIT MED J, V308, P1615, DOI 10.1136/bmj.308.6944.1615; STRUTHERS AD, 1995, QJM-MON J ASSOC PHYS, V88, P303; WHEELDON NM, 1993, Q J MED, V86, P17	32	624	668	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	1997	350	9088					1349	1353		10.1016/S0140-6736(97)06031-5	http://dx.doi.org/10.1016/S0140-6736(97)06031-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365448				2022-12-28	WOS:A1997YE87200008
J	Arcasoy, SM; Jett, JR				Arcasoy, SM; Jett, JR			Superior pulmonary sulcus tumors and Panoast's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PREOPERATIVE RADIATION-THERAPY; CELL LUNG-CANCER; PANCOAST SYNDROME; RADICAL RESECTION; BRONCHOGENIC-CARCINOMA; IRRADIATION; SURGERY; MANAGEMENT; INFECTION; METASTASIS		MAYO CLIN, DIV THORAC DIS, ROCHESTER, MN USA	Mayo Clinic	Arcasoy, SM (corresponding author), UNIV PITTSBURGH, DIV PULM ALLERGY & CRIT CARE MED, 440 SCAIFE HALL, 3550 TERRACE ST, PITTSBURGH, PA 15261 USA.		Arcasoy, Selim M/AAR-6637-2020					AHMAD K, 1984, CANCER, V54, P913, DOI 10.1002/1097-0142(19840901)54:5<913::AID-CNCR2820540527>3.0.CO;2-6; AMIN R, 1986, GYNECOL ONCOL, V24, P126, DOI 10.1016/0090-8258(86)90016-8; ANDERSON TM, 1986, J CLIN ONCOL, V4, P1598, DOI 10.1200/JCO.1986.4.11.1598; ATTAR S, 1979, ANN THORAC SURG, V28, P578, DOI 10.1016/S0003-4975(10)63180-3; BEYER DC, 1986, AM J CLIN ONCOL-CANC, V9, P156, DOI 10.1097/00000421-198604000-00011; CHARDACK WM, 1953, J THORAC SURG, V25, P402; CHEN KTK, 1983, J SURG ONCOL, V24, P117, DOI 10.1002/jso.2930240210; CHONG KM, 1993, ANN THORAC SURG, V55, P518, DOI 10.1016/0003-4975(93)91033-J; DARTEVELLE PG, 1993, J THORAC CARDIOV SUR, V105, P1025, DOI 10.1016/S0022-5223(19)33774-2; DERBEKYAN V, 1993, J NUCL MED, V34, P1992; DEVINE JW, 1986, CANCER, V57, P941, DOI 10.1002/1097-0142(19860301)57:5<941::AID-CNCR2820570511>3.0.CO;2-E; DILLEMANS B, 1994, EUR J CARDIO-THORAC, V8, P37, DOI 10.1016/1010-7940(94)90131-7; DOLAN G, 1991, POSTGRAD MED J, V67, P914, DOI 10.1136/pgmj.67.792.914; FULLER DB, 1994, ANN THORAC SURG, V57, P1133, DOI 10.1016/0003-4975(94)91343-9; GALLAGHER KJ, 1992, ANN THORAC SURG, V53, P903, DOI 10.1016/0003-4975(92)91467-N; GEFTER WB, 1990, SEMIN ROENTGENOL, V25, P73, DOI 10.1016/0037-198X(90)90037-5; GIBNEY RTN, 1984, J CAN ASSOC RADIOL, V35, P90; Ginsberg R J, 1995, Chest Surg Clin N Am, V5, P315; GINSBERG RJ, 1994, ANN THORAC SURG, V57, P1440, DOI 10.1016/0003-4975(94)90098-1; GOLDMAN SM, 1979, AM J ROENTGENOL, V132, P419, DOI 10.2214/ajr.132.3.419; GOTTERER N, 1990, RESP MED, V84, P169, DOI 10.1016/S0954-6111(08)80024-8; Grover Frederick L., 1995, P225; Hare ES, 1838, LONDON MED GAZ, V1, P16; HATTON MQF, 1993, EUR RESPIR J, V6, P271; HEPPER NGG, 1966, ANN INTERN MED, V64, P979, DOI 10.7326/0003-4819-64-5-979; HERBERT SH, 1992, CANCER, V69, P363, DOI 10.1002/1097-0142(19920115)69:2<363::AID-CNCR2820690215>3.0.CO;2-C; HERBUT PA, 1946, ARCH PATHOL, V42, P88; HILARIS BS, 1971, CANCER, V27, P1369, DOI 10.1002/1097-0142(197106)27:6<1369::AID-CNCR2820270615>3.0.CO;2-B; HILARIS BS, 1974, SURG CLIN N AM, V54, P831; HILARIS BS, 1987, SURG CLIN N AM, V67, P965; JOHNSON DH, 1982, CHEST, V82, P602, DOI 10.1378/chest.82.5.602; KANNER RM, 1982, ADV PAIN RES THER, V4, P27; KOMAKI R, 1990, INT J RADIAT ONCOL, V19, P31, DOI 10.1016/0360-3016(90)90130-C; KOMAKI R, 1981, CANCER, V48, P1563, DOI 10.1002/1097-0142(19811001)48:7<1563::AID-CNCR2820480716>3.0.CO;2-H; KOMAKI R, 1987, CANCER, V59, P1649, DOI 10.1002/1097-0142(19870501)59:9<1649::AID-CNCR2820590921>3.0.CO;2-1; Komaki R., 1991, CHEST SURG CLIN N AM, V1, P13; MAGGI G, 1994, ANN THORAC SURG, V57, P198, DOI 10.1016/0003-4975(94)90396-4; MARANGONI C, 1993, J NEUROL NEUROSUR PS, V56, P1033, DOI 10.1136/jnnp.56.9.1033; MARTINEZMONGE R, 1994, AM J CLIN ONCOL-CANC, V17, P317, DOI 10.1097/00000421-199408000-00007; MAXFIELD RA, 1987, NEW YORK STATE J MED, V87, P326; MCLOUD TC, 1992, RADIOLOGY, V182, P319, DOI 10.1148/radiology.182.2.1732943; MILLER JI, 1979, ANN THORAC SURG, V28, P44, DOI 10.1016/S0003-4975(10)63390-5; MILLS PR, 1994, THORAX, V49, P92, DOI 10.1136/thx.49.1.92; MITCHELL DH, 1992, CLIN INFECT DIS, V14, P1142, DOI 10.1093/clinids/14.5.1142; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NEAL CR, 1991, INT J RADIAT ONCOL, V21, P651, DOI 10.1016/0360-3016(91)90683-U; Pancoast HK, 1924, J AMER MED ASSOC, V83, P1407, DOI 10.1001/jama.1924.02660180025007; Pancoast HK, 1932, J AMER MED ASSOC, V99, P1391, DOI 10.1001/jama.1932.02740690001001; PAULSON D, 1985, INT TRENDS GENERAL T, V1, P121; PAULSON DL, 1985, ANN THORAC SURG, V39, P586, DOI 10.1016/S0003-4975(10)62009-7; RABANO A, 1991, THORAX, V46, P270, DOI 10.1136/thx.46.4.270; SARTORI F, 1992, J THORAC CARDIOV SUR, V104, P679; SHAHIAN DM, 1987, ANN THORAC SURG, V43, P32, DOI 10.1016/S0003-4975(10)60163-4; SHAW RR, 1961, ANN SURG, V154, P29, DOI 10.1097/00000658-196107000-00003; SIMPSON FG, 1986, THORAX, V41, P156, DOI 10.1136/thx.41.2.156; STANFORD W, 1980, ANN THORAC SURG, V29, P406, DOI 10.1016/S0003-4975(10)61668-2; STANLEY SL, 1985, THORAX, V40, P74, DOI 10.1136/thx.40.1.74; SUNDARESAN N, 1987, J CLIN ONCOL, V5, P1739, DOI 10.1200/JCO.1987.5.11.1739; TAKASUGI JE, 1989, J THORAC IMAG, V4, P41, DOI 10.1097/00005382-198901000-00010; Tobias JW, 1932, REV MED LAT AM, V17, P1522; Umeki S, 1990, Rinsho Shinkeigaku, V30, P94; URSCHEL JD, 1994, POSTGRAD MED J, V70, P785, DOI 10.1136/pgmj.70.829.785; VAMOS G, 1960, Schweiz Z Tuberc Pneumonol, V17, P423; VANDENPLAS O, 1991, THORAX, V46, P683, DOI 10.1136/thx.46.9.683; VANHOUTTE P, 1984, CANCER, V54, P223, DOI 10.1002/1097-0142(19840715)54:2<223::AID-CNCR2820540208>3.0.CO;2-1; WALLS WJ, 1974, RADIOLOGY, V111, P99, DOI 10.1148/111.1.99; WEBB WR, 1991, RADIOLOGY, V178, P705, DOI 10.1148/radiology.178.3.1847239; WEBB WR, 1992, RADIOLOGY, V182, P621, DOI 10.1148/radiology.182.3.1311115; WINSTON DJ, 1977, AM J MED, V63, P830, DOI 10.1016/0002-9343(77)90170-X; WRIGHT CD, 1987, J THORAC CARDIOV SUR, V94, P69; YANG PC, 1988, CHEST, V94, P124, DOI 10.1378/chest.94.1.124	71	104	107	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1370	1376		10.1056/NEJM199711063371907	http://dx.doi.org/10.1056/NEJM199711063371907			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358132				2022-12-28	WOS:A1997YE44600007
J	Steyn, DW; Odendaal, HJ				Steyn, DW; Odendaal, HJ			Randomised controlled trial of ketanserin and aspirin in prevention of preeclampsia	LANCET			English	Article							HYPERTENSIVE DISORDERS; PREGNANCY; SEROTONIN	Background Pre-eclampsia is associated with extensive endothelial-cell damage and platelet activation, resulting in lower production of vasodilator prostaglandins and increased release of the vasoconstrictors thromboxane A(2) and serotonin. Damage to endothelial-cell serotonin-1 receptors leaves vasoconstriction and; platelet aggregation mediated by serotonin-2 receptors unopposed. We investigated the role of ketanserin, a selective serotonin-2-receptor antagonist, in lowering the rate of pre-eclampsia among pregnant women with mild to moderate hypertension. Methods We recruited 138 pregnant women into a double blind, randomised, placebo-controlled trial. They had diastolic blood pressure persistently more than 80 mm Hg before 20 weeks' gestation. 69 women received ketanserin and 69 received placebo. Both groups also received aspirin. Patients were initially given two tablets daily, increased to four tablets daily in diastolic blood pressure was more than 90 mm Hg. Primary outcomes were the development of pre-eclampsia and severe hypertension, and perinatal mortality. Findings There were significantly fewer cases of preeclampsia (two vs 13; relative risk 0.15 [95% CI 0.04-0.66], p=0.006) and severe hypertension (six vs 17; p=0.02) in the ketanserin than in the placebo group. There was also a trend towards less perinatal mortality (one vs six deaths) but this was not significant (p=0.28). Rates of abruptio placentae and pre-eclampsia before 34 weeks' gestation were lower in the ketanserin group, and mean birthweight was significantly higher. Interpretation We found an association between the addition of ketanserin to aspirin and a decrease in the number of cases of preeclampsia and severe hypertension, as well as improved pregnancy outcome among patients with mild to moderate midtrimester hypertension.	UNIV STELLENBOSCH,ZA-7505 TYGERBERG,SOUTH AFRICA; MRC,UNIT PERINATAL MORTAL,ZA-7505 TYGERBERG,SOUTH AFRICA	Stellenbosch University	Steyn, DW (corresponding author), TYGERBERG HOSP,DEPT OBSTET & GYNAECOL,POB 19081,ZA-7505 TYGERBERG,SOUTH AFRICA.							CHARI RS, 1995, FET MAT MED REV, V7, P61; *CLASP COLL GROUP, 1994, LANCET, V343, P619; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; DECLERCK F, 1985, J CARDIOVASC PHARM, V7, pS23; Dekker GA, 1996, J PERINAT MED, V24, P119, DOI 10.1515/jpme.1996.24.2.119; DEKKER GA, 1995, BAILLIERE CLIN OB GY, V9, P509, DOI 10.1016/S0950-3552(05)80378-5; *DHSS, 1985, REP CONF INQ MAT DEA, P17; DULEY L, 1992, BRIT J OBSTET GYNAEC, V99, P547, DOI 10.1111/j.1471-0528.1992.tb13818.x; DULEY L, 1995, COCHRANE LIB CDROM O; DZURIK R, 1985, J CARDIOVASC PHARM, V7, pS29; FRANX A, 1994, BRIT J OBSTET GYNAEC, V101, P66, DOI 10.1111/j.1471-0528.1994.tb13013.x; FRISHMAN WH, 1995, J CLIN PHARMACOL, V35, P541, DOI 10.1002/j.1552-4604.1995.tb05013.x; HULME VA, 1986, AM J OBSTET GYNECOL, V155, P260, DOI 10.1016/0002-9378(86)90802-1; MACGILLIVRAY I, 1969, CLIN SCI, V37, P395; MIDDELKOOP CM, 1993, CLIN CHEM, V39, P1675; MOORE MP, 1983, BRIT MED J, V287, P580, DOI 10.1136/bmj.287.6392.580; Odendaal H, 1991, OXFORD DATABASE PERI; Odendaal HJ, 1995, S AFR MED J, V85, P1071; PATTINSON RC, 1988, S AFR MED J, V73, P516; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; ROBERTS JM, 1994, MATERNAL FETAL MED P, P804; SIBAI BM, 1985, AM J OBSTET GYNECOL, V152, P32; TANAKA T, 1993, CARDIOVASC RES, V23, P1374; VIINIKKA L, 1993, BRIT J OBSTET GYNAEC, V100, P809, DOI 10.1111/j.1471-0528.1993.tb14304.x; WEINER CP, 1984, AM J OBSTET GYNECOL, V149, P496, DOI 10.1016/0002-9378(84)90023-1; 1990, AM J OBSTET GYNECOL, V163, P1689	26	46	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1267	1271						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357405				2022-12-28	WOS:A1997YD68900007
J	Bootman, MD; Berridge, MJ; Lipp, P				Bootman, MD; Berridge, MJ; Lipp, P			Cooking with calcium: The recipes for composing global signals from elementary events	CELL			English	Article							1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE; INOSITOL TRISPHOSPHATE; HELA-CELLS; XENOPUS OOCYTES; GATED CHANNELS; CYTOSOLIC CA2+; MODULATION; RECEPTORS; PATTERNS	Recent studies have suggested that global intracellular Ca2+ signals arise from the summation and coordination of subcellular elementary release events (e.g., ''Ca2+ puffs''), although the modes of recruitment of such signals are unknown. In order to understand how cells utilize elementary Ca2+ release events, we imaged Ca2+ transients evoked through the phosphoinositide pathway in HeLa cells using confocal microscopy. During the pacemaker phase leading to the global Ca2+ signal, elementary Ca2+ release events were recruited in (1) frequency, (2) amplitude, and (3) spatial domains. Since each digital elementary event contributes to a small change of the analog cytosolic Ca2+ concentration, the net effect of the advancement in the three domains is to drive the ambient Ca2+ concentration toward a threshold where the signal becomes regenerative, resulting in a global Ca2+ wave.	BABRAHAM INST, MOL SIGNALLING LAB, CAMBRIDGE CB2 4AT, ENGLAND; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge			Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; Bootman MD, 1996, CELL CALCIUM, V20, P97, DOI 10.1016/S0143-4160(96)90099-8; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; Lipp P, 1997, J PHYSIOL-LONDON, V502, P1, DOI 10.1111/j.1469-7793.1997.001bl.x; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Reber BFX, 1996, PFLUG ARCH EUR J PHY, V432, P893, DOI 10.1007/s004240050213; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; WOJCIKIEWICZ RJH, 1993, J EXP BIOL, V184, P145; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	28	316	320	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					367	373		10.1016/S0092-8674(00)80420-1	http://dx.doi.org/10.1016/S0092-8674(00)80420-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363945	Bronze			2022-12-28	WOS:A1997YD94100010
J	Hunter, DJ; Hankinson, SE; Laden, F; Colditz, GA; Manson, JE; Willett, WC; Speizer, FE; Wolff, MS				Hunter, DJ; Hankinson, SE; Laden, F; Colditz, GA; Manson, JE; Willett, WC; Speizer, FE; Wolff, MS			Plasma organochlorine levels and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DICHLORODIPHENYL DICHLOROETHENE DDE; POLYCHLORINATED-BIPHENYLS PCBS; BLOOD-LEVELS; HUMAN-MILK; SERUM; WOMEN; PESTICIDES; ESTROGENS; RESIDUES; LACTATION	Background Exposure to ''environmental estrogens'' such as organochlorines in pesticides and industrial chemicals has been proposed as a cause of increasing rates of breast cancer. Several studies have reported higher blood levels of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) and polychlorinated biphenyls (PCBs) in patients with breast cancer than in controls. Methods We measured plasma levels of DDE and PCBs prospectively among 240 women who gave a blood sample in 1989 or 1990 and who were subsequently given a diagnosis of breast cancer before June 1, 1992. We compared these levels with those measured in matched control women in whom breast cancer did not develop. Data on DDE were available for 236 pairs, and data on PCBs were available for 230 pairs. Results The median level of DDE was lower among case patients than among controls (4.71 vs, 5.35 parts per billion, P = 0.14), as was the median level of PCBs (4.49 vs. 4.68 parts per billion, P = 0.72), The multivariate relative risk of breast cancer for women in the highest quintile of exposure as compared with women in the lowest quintile was 0.72 for DDE (95 percent confidence interval, 0.37 to 1.40) and 0.66 for PCBs (95 percent confidence interval, 0.32 to 1.37). Exposure to high levels of both DDE and PCBs was associated with a nonsignificantly lower risk of breast cancer (relative risk for women in the highest quintiles of both DDE and PCBs as compared with women in the lowest, 0.43; 95 percent confidence interval, 0.13 to 1.44). Conclusions Our data do not support the hypothesis that exposure to 2,2-bis(p-chlorophenyl)-1,1,1-trichloroethane (DDT) and PCBs increases the risk of breast cancer. (C) 1997, Massachusetts Medical Society.	HARVARD UNIV, SCH MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD CTR CANC PREVENT, BOSTON, MA USA; MT SINAI HOSP, DIV ENVIRONM & OCCUPAT MED, NEW YORK, NY 10029 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Icahn School of Medicine at Mount Sinai	Hunter, DJ (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [U01CA062984, R01CA049449, U01CA049449, R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356, CA49449, U01 CA/ES62984] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON LF, 1994, J NATL CANCER I, V86, P576, DOI 10.1093/jnci/86.8.576; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BERGERON JM, 1994, ENVIRON HEALTH PERSP, V102, P780, DOI 10.2307/3432139; BRESLOW NE, 1980, IARC SCI PUBL, V32, P249; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; DEWAILLY E, 1994, J NATL CANCER I, V86, P232, DOI 10.1093/jnci/86.3.232; FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143; Gammon MD, 1996, CANCER EPIDEM BIOMAR, V5, P467; Gammon MD, 1997, CANCER EPIDEM BIOMAR, V6, P327; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; KUTZ FW, 1991, REV ENVIRON CONTAM T, V120, P1; Laden F, 1997, CANCER EPIDEM BIOMAR, V6, P333; LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001; PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015; ROBISON AK, 1985, TOXICOL LETT, V27, P109, DOI 10.1016/0378-4274(85)90127-4; ROGAN WJ, 1987, AM J PUBLIC HEALTH, V77, P1294, DOI 10.2105/AJPH.77.10.1294; ROGAN WJ, 1986, AM J PUBLIC HEALTH, V76, P172, DOI 10.2105/AJPH.76.2.172; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P551; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; SAVAGE EP, 1981, AM J EPIDEMIOL, V113, P413, DOI 10.1093/oxfordjournals.aje.a113109; SCRIBNER JD, 1981, CARCINOGENESIS, V2, P1235, DOI 10.1093/carcin/2.12.1235; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.1289/ehp.95103s7113; vantVeer P, 1997, BMJ-BRIT MED J, V315, P81, DOI 10.1136/bmj.315.7100.81; WASSERMANN M, 1976, B ENVIRON CONTAM TOX, V15, P478, DOI 10.1007/BF01685076; WIEMEYER SN, 1984, ARCH ENVIRON CON TOX, V13, P529, DOI 10.1007/BF01056332; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; WOLFF MS, 1995, ENVIRON HEALTH PERSP, V103, P141, DOI 10.2307/3432524; WOLFF MS, 1992, ENVIRON RES, V59, P202, DOI 10.1016/S0013-9351(05)80240-3; WOLFF MS, 1991, B ENVIRON CONTAM TOX, V47, P499, DOI 10.1007/BF01700936	33	278	284	2	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1253	1258		10.1056/NEJM199710303371801	http://dx.doi.org/10.1056/NEJM199710303371801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345073	Bronze			2022-12-28	WOS:A1997YC92000001
J	Henikoff, S; Greene, EA; Pietrokovski, S; Bork, P; Attwood, TK; Hood, L				Henikoff, S; Greene, EA; Pietrokovski, S; Bork, P; Attwood, TK; Hood, L			Gene families: The taxonomy of protein paralogs and chimeras	SCIENCE			English	Article							TRANSFER-RNA SYNTHETASES; HAEMOPHILUS-INFLUENZAE; EVOLUTIONARY HISTORY; ESCHERICHIA-COLI; DNA-SEQUENCE; HUMAN GENOME; REGIONS; KINESIN; DOMAIN; RETROTRANSPOSONS	Ancient duplications and rearrangements of protein-coding segments have resulted in complex gene family relationships. Duplications can be tandem or dispersed and can involve entire coding regions or modules that correspond to folded protein domains. As a result, gene products may acquire new specificities, altered recognition properties, or modified functions. Extreme proliferation of some families within an organism, perhaps at the expense of other families, may correspond to functional innovations during evolution. The underlying processes are still at work, and the large fraction of human and other genomes consisting of transposable elements may be a manifestation of the evolutionary benefits of genomic flexibility.	HOWARD HUGHES MED INST, SEATTLE, WA 98109 USA; EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY; UCL, DEPT BIOCHEM & MOL BIOL, LONDON WC1E 6BT, ENGLAND; UNIV WASHINGTON, DEPT MOL BIOTECHNOL, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of London; University College London; University of Washington; University of Washington Seattle	Henikoff, S (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98109 USA.		Wood, David W/B-2992-2012; Bork, Peer/F-1813-2013	Bork, Peer/0000-0002-2627-833X; Pietrokovski, Shmuel/0000-0001-8573-5863; Henikoff, Steven/0000-0002-7621-8685	NIGMS NIH HHS [GM29009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ANGERER A, 1990, J BACTERIOL, V172, P572, DOI 10.1128/jb.172.2.572-578.1990; Bailey TL, 1997, J COMPUT BIOL, V4, P45, DOI 10.1089/cmb.1997.4.45; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Bernardi G, 1995, ANNU REV GENET, V29, P445, DOI 10.1146/annurev.ge.29.120195.002305; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Bork P, 1996, METHOD ENZYMOL, V266, P162; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; BRENNER SE, 1995, NATURE, V378, P140, DOI 10.1038/378140a0; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; CHOO Y, 1995, CURR OPIN BIOTECH, V6, P431, DOI 10.1016/0958-1669(95)80073-5; Davidson JN, 1997, TRENDS GENET, V13, P281, DOI 10.1016/S0168-9525(97)01127-X; DAVIDSON JN, 1993, BIOESSAYS, V15, P157, DOI 10.1002/bies.950150303; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; deSouza SJ, 1996, P NATL ACAD SCI USA, V93, P14632, DOI 10.1073/pnas.93.25.14632; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DOOLITTLE RF, 1987, URFS ORFS PRIMER ANA; DOOLITTLE RF, 1996, METHODS ENZYMOL, V266; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; Glusman G, 1996, GENOMICS, V37, P147, DOI 10.1006/geno.1996.0536; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; Henikoff JG, 1996, COMPUT APPL BIOSCI, V12, P135; Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5; HENIKOFF S, 1990, METHOD ENZYMOL, V183, P111; Henikoff S, 1996, TRENDS BIOCHEM SCI, V21, P444, DOI 10.1016/S0968-0004(96)30039-X; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; Ingram V. M., 1963, HEMOGLOBINS GENETICS; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LABEDAN B, 1995, MOL BIOL EVOL, V12, P980; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LI Y, 1993, J BIOL CHEM, V268, P5790; Lindqvist Y, 1997, CURR OPIN STRUC BIOL, V7, P422, DOI 10.1016/S0959-440X(97)80061-9; MASLAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; NATHANS J, 1992, ANNU REV GENET, V26, P403, DOI 10.1146/annurev.ge.26.120192.002155; ORENGO C, 1994, CURR OPIN STRUC BIOL, V4, P429, DOI 10.1016/S0959-440X(94)90113-9; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; REED RR, 1992, COLD SPRING HARB SYM, V57, P501, DOI 10.1101/SQB.1992.057.01.055; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; Robertson HM, 1996, NAT GENET, V12, P360, DOI 10.1038/ng0496-360; Robertson HM, 1997, J HERED, V88, P195, DOI 10.1093/oxfordjournals.jhered.a023088; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; RUDDLE FH, 1994, ANNU REV GENET, V28, P423, DOI 10.1146/annurev.ge.28.120194.002231; Rzhetsky A, 1997, P NATL ACAD SCI USA, V94, P6820, DOI 10.1073/pnas.94.13.6820; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; SCHIMMEL P, 1991, TRENDS BIOCHEM SCI, V16, P1, DOI 10.1016/0968-0004(91)90002-D; Schneider R, 1997, NUCLEIC ACIDS RES, V25, P226, DOI 10.1093/nar/25.1.226; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; WETZEL R, 1995, J MOL EVOL, V40, P545; WHITE SE, 1994, P NATL ACAD SCI USA, V91, P11792, DOI 10.1073/pnas.91.25.11792; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	67	282	314	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					609	614		10.1126/science.278.5338.609	http://dx.doi.org/10.1126/science.278.5338.609			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381171				2022-12-28	WOS:A1997YC32300039
J	Condic, ML; Letourneau, PC				Condic, ML; Letourneau, PC			Ligand-induced changes in integrin expression regulate neuronal adhesion and neurite outgrowth	NATURE			English	Article							EXTRACELLULAR-MATRIX; LAMININ RECEPTORS; SENSORY NEURONS; GROWTH CONES; IN-VITRO; FIBRONECTIN; SUBUNIT; CHICK; LOCOMOTION; MIGRATION	Receptors of the integrin family are expressed by every cell type and are the primary means by which cells interact with the extracellular matrix. The control of integrin expression affects a wide range of developmental and cellular processes, including the regulation of gene expression, cell adhesion, cell morphogenesis and cell migration(1-3). Here we show that the concentration of substratum-bound ligand (laminin) post-translationally regulates the amount of receptor (alpha(6) beta(1) integrin) expressed on the surface of sensory neurons. When ligand availability is low, surface amounts of receptor increase, whereas integrin RNA and total integrin protein decrease. Ligand concentration determines surface levels of integrin by altering the rate at which receptor is removed from the cell surface. Furthermore, increased expression of integrin at the cell surface is associated with increased neuronal cell adhesion and neurite outgrowth, These results indicate that integrin regulation maintains neuronal growth-cone motility over a broad range of ligand concentrations, allowing axons to invade different tissues during development and regeneration.	UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Condic, ML (corresponding author), UNIV UTAH, SCH MED, DEPT ANAT & NEUROBIOL, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.		Letourneau, Paul C/A-6764-2009					ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BUETTNER HM, 1991, DEV BIOL, V145, P266, DOI 10.1016/0012-1606(91)90125-M; CAI J, 1995, CELL, V83, P693; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAIG AM, 1995, NATURE, V375, P592, DOI 10.1038/375592a0; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; DUBAND JL, 1991, J CELL SCI, V98, P517; GAIETTA G, 1994, J CELL SCI, V107, P3339; GOMEZ TM, 1994, J NEUROSCI, V14, P5959; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; MCCARTHY JB, 1984, J CELL BIOL, V98, P1474, DOI 10.1083/jcb.98.4.1474; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROGERS SL, 1986, DEV BIOL, V113, P429, DOI 10.1016/0012-1606(86)90177-6; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; TOMASELLI KJ, 1993, J NEUROSCI, V13, P4880; VEKEMAN S, 1993, FEBS LETT, V327, P207, DOI 10.1016/0014-5793(93)80171-P; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; WEAVER CD, 1995, J NEUROSCI, V15, P5275	29	156	159	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	1997	389	6653					852	856		10.1038/39878	http://dx.doi.org/10.1038/39878			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349817				2022-12-28	WOS:A1997YC14800058
J	Butler, RN				Butler, RN			Living longer, contributing longer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									MT SINAI MED CTR,INT LONGEV CTR US,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai								BASS SA, 1996, GENERATIONS      SPR, P29; FAIRLIE H, 1988, NEW REPUBLIC, V198, P19; HARTOOTYAN RA, 1996, ENCY GERONTOLOGY, V2, P613; *IND SECT, 1996, GIV VOL US; *LINK HOUS, 1997, AGING TODAY, V18, P11; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593	6	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1372	1373		10.1001/jama.278.16.1372	http://dx.doi.org/10.1001/jama.278.16.1372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343470				2022-12-28	WOS:A1997YA90500040
J	Phillips, CD; Sloane, PD; Hawes, C; Koch, G; Han, J; Spry, K; Dunteman, G; Williams, RL				Phillips, CD; Sloane, PD; Hawes, C; Koch, G; Han, J; Spry, K; Dunteman, G; Williams, RL			Effects of residence in Alzheimer disease special care units on functional outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMUM DATA SET; NURSING-HOME; DEMENTIA; IMPACT; PREDICTORS; STATE; MDS	Context.-Alzheimer disease special care units (SCUs) in nursing homes are increasingly prevalent, but little is known about their effects on residents' outcomes. Objective.-To analyze the effect of SCU residence on the rates at which residents decline in functional status. Design.-A cohort of nursing home residents assessed at multiple points during about 1 year. Facility staff completed all assessments using the Minimum Data Set for Nursing Home Resident Assessment and Care Screening (MDS). Setting.-Medicare-or Medicaid-certified nursing facilities. Patients or Other Participants.-All nursing home residents in 1993 and early 1994 in Kansas, Maine, Mississippi, and South Dakota. Serial MDS assessments of 77 337 residents in more than 800 facilities, including 1228 residents in 48 facilities with SCUs. Main Outcome Measures.-Decline in locomotion, transferring, toileting, eating, dressing, and a summary activities of daily living index; decline in urinary and bowel continence; and significant weight loss. Results.-No statistically significant difference was observed in the speed of decline for residents in SCUs and traditional units in any of the 9 outcomes. Residents were matched on a variety of characteristics, and subgroup analyses were performed. In none did we observe a pattern of better outcomes among SCU residents. Conclusions.-Although SCUs may have provided unmeasured benefits to families and residents, it does not appear that those benefits included any slowing in the rates of functional decline experienced by individuals with dementia.	UNIV N CAROLINA,DEPT FAMILY MED,CHAPEL HILL,NC 27514; UNIV N CAROLINA,DEPT BIOSTAT,CHAPEL HILL,NC; RES TRIANGLE INST,DIV STAT RES,RES TRIANGLE PK,NC 27709; RES TRIANGLE INST,PROGRAM AGING & LONG TERM CARE,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Research Triangle Institute; Research Triangle Institute	Phillips, CD (corresponding author), MENORAH PK CTR AGING,MYERS RES INST,BEACHWOOD,OH 44122, USA.				NIA NIH HHS [5-U01-AG10313-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG010313] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON WE, 1994, GERONTOLOGIST, V34, P775, DOI 10.1093/geront/34.6.775; *ADV PAN ALZH DIS, 1991, DHHS PUBL; Allison PaulD., 1982, SOCIOL METHODOL, V13, P61, DOI [10.2307/270718, DOI 10.2307/270718]; *ALZH DIS REL DIS, 1992, GUID DIGN GOALS SPEC; BanaszakHoll J, 1996, HEALTH SERV RES, V31, P97; BENSON DM, 1987, J AM GERIATR SOC, V35, P319, DOI 10.1111/j.1532-5415.1987.tb04638.x; BOLING K, 1991, DEMENTIA UNITS LONG, P3; BRAUN BI, 1991, J AM GERIATR SOC, V39, P329, DOI 10.1111/j.1532-5415.1991.tb02896.x; CHAFETZ P K, 1991, Clinical Gerontologist, V11, P19, DOI 10.1300/J018v11n01_03; CLEARY TA, 1988, GERONTOLOGIST, V28, P511, DOI 10.1093/geront/28.4.511; GOLD DT, 1991, GERONTOLOGIST, V31, P467, DOI 10.1093/geront/31.4.467; GRANT LA, 1995, J AM GERIATR SOC, V43, P569, DOI 10.1111/j.1532-5415.1995.tb06108.x; GREEN CR, 1993, J AM GERIATR SOC, V41, P654, DOI 10.1111/j.1532-5415.1993.tb06740.x; Greene J A, 1985, J Tenn Med Assoc, V78, P559; HARDWICK S, 1994, STATES 1994 PROFILES; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; HAWES C, 1997, FAMILY MEMBERS VIEWS; HEINEMANN GD, 1985, RES AGING, V7, P363, DOI 10.1177/0164027585007003003; HOLFORD TR, 1980, BIOMETRICS, V36, P299, DOI 10.2307/2529982; HOLMES D, 1990, GERONTOLOGIST, V30, P178, DOI 10.1093/geront/30.2.178; HURLEY AC, 1992, RES NURS HEALTH, V15, P369, DOI 10.1002/nur.4770150506; *I MED COMM NURS H, 1986, IMPR QUAL NURS HOM; *JOINT COMM ACCR H, 1993, STAND SURV PROT DEM; MATHEW L, 1988, AM J ALZHEIMERS CARE, V3, P16; MEHR DR, 1995, GERONTOLOGIST, V35, P179, DOI 10.1093/geront/35.2.179; MOR V, 1996, GENERATIONS, V19, P24; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS JN, 1991, RESIDENT ASSESSMENT; NORRISBAKER C, IN PRESS MEASURING E; *OFF TECHN ASS, 1992, PUBL OFF TECHN ASS; *OFF TECHN ASS, 1987, OTABA323; OHTA RJ, 1988, GERONTOLOGIST, V28, P803, DOI 10.1093/geront/28.6.803; PHILLIPS CD, IN PRESS ALZHEIMERS; RITER RN, 1992, GERONTOLOGIST, V32, P184, DOI 10.1093/geront/32.2.184; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rovner BW, 1996, J AM GERIATR SOC, V44, P7, DOI 10.1111/j.1532-5415.1996.tb05631.x; Shah BV, 1996, SUDAAN USERS MANUAL; SLOANE PD, 1991, JAMA-J AM MED ASSOC, V265, P1278, DOI 10.1001/jama.265.10.1278; SLOANE PD, 1995, GERONTOLOGIST, V35, P103, DOI 10.1093/geront/35.1.103; STARK AJ, 1995, GERONTOLOGIST, V35, P648, DOI 10.1093/geront/35.5.648; SWANSON EA, 1993, ARCH PSYCHIATR NURS, V5, P292; WELLS Y, 1987, AUST NZ J PSYCHIAT, V21, P524, DOI 10.3109/00048678709158920; ZINN JS, 1994, GERONTOLOGIST, V34, P371, DOI 10.1093/geront/34.3.371	44	58	58	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1340	1344		10.1001/jama.278.16.1340	http://dx.doi.org/10.1001/jama.278.16.1340			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343465				2022-12-28	WOS:A1997YA90500035
J	Giwercman, A; Thomsen, JK; Hertz, J; Berthelsen, JG; Jensen, V; Meinecke, B; Thormann, L; Storm, HH; Skakkebaek, NE				Giwercman, A; Thomsen, JK; Hertz, J; Berthelsen, JG; Jensen, V; Meinecke, B; Thormann, L; Storm, HH; Skakkebaek, NE			Prevalence of carcinoma in situ of the testis in 207 oligozoospermic men from infertile couples: prospective study of testicular biopsies	BRITISH MEDICAL JOURNAL			English	Article							GERM-CELL TUMORS; INSITU; MANAGEMENT; NEOPLASIA	Objective: To investigate the prevalence of carcinoma in situ of the testis in a group of oligozoospermic men from infertile couples. Design: A consecutive group of oligozoospermic men from infertile couples were offered bilateral testicular biopsy. The observed prevalence of carcinoma in situ was compared with the expected prevalence of testicular cancer in a corresponding age matched population of Danish men, assuming all untreated cases of carcinoma in situ progress to tumour stage, This calculation was based on data from the Danish Cancer Registry. Subjects: 207 men aged 18-50 years who had sperm density below 10 million/ml in two samples within the previous 2 years or sperm density below 20 million/ml in two samples within the previous 2 years and a history of cryptorchidism or one or two atrophic testicles (orchidometer volume less than 15 cm(3)), or both. Interventions: Bilateral testicular biopsies. Main outcome measures: Carcinoma in situ in the biopsy specimen. Results: No case of carcinoma in situ was found among the 207 men, The expected number in a normal age matched population of corresponding size was 0.8. Conclusion: There is no increase in risk of carcinoma in situ of the testis in moderately oligozoospermic men of couples referred because of infertility.	UNIV COPENHAGEN,HERLEV HOSP,DEPT OBSTET & GYNAECOL,COPENHAGEN,DENMARK; UNIV COPENHAGEN,GENTOFTE HOSP,DEPT OBSTET & GYNAECOL,COPENHAGEN,DENMARK; CENT HOSP HILLEROD,DEPT OBSTET & GYNAECOL,DK-3400 HILLEROD,DENMARK; UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT OBSTET & GYNAECOL,COPENHAGEN,DENMARK; DANISH CANC SOC,DIV CANC EPIDEMIOL,DANISH CANC REGISTRY,COPENHAGEN,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Danish Cancer Society	Giwercman, A (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT GROWTH & REPROD,SECT 5064,DK-2100 COPENHAGEN,DENMARK.			Storm, Hans/0000-0001-7223-8198				BERTHELSEN JG, 1982, BRIT MED J, V285, P1683, DOI 10.1136/bmj.285.6356.1683; BERTHELSEN JG, 1981, SCAND J UROL NEPHROL, V15, P165, DOI 10.3109/00365598109179596; BETTOCCHI C, 1994, J ANDROL, V15, pS14; BRUUN E, 1987, INT J ANDROL, V10, P199, DOI 10.1111/j.1365-2605.1987.tb00184.x; CHEMES HE, 1995, J ANDROL S, pP24; Dieckmann KP, 1996, J CLIN ONCOL, V14, P3126, DOI 10.1200/JCO.1996.14.12.3126; DIECKMANN KP, 1993, J CANC RES CLIN ONCO, V119, P1; GIWERCMAN A, 1987, INT J ANDROL, V10, P173, DOI 10.1111/j.1365-2605.1987.tb00180.x; GIWERCMAN A, 1993, EUR UROL, V23, P104; MULLER J, 1987, INT J ANDROL, V10, P147, DOI 10.1111/j.1365-2605.1987.tb00176.x; MUMPEROW E, 1992, UROL INT, V48, P162, DOI 10.1159/000282322; NUESCHBACHMANN IH, 1977, SCHWEIZ MED WSCHR, V107, P795; PRYOR JP, 1983, BRIT J UROL, V55, P780, DOI 10.1111/j.1464-410X.1983.tb03425.x; ROWLEY MJ, 1966, FERTIL STERIL, V17, P177; SCHUTTE B, 1988, C SCHIRREN S ADV AND, P188; SKAKKEBAEK NE, 1978, HISTOPATHOLOGY, V2, P157, DOI 10.1111/j.1365-2559.1978.tb01706.x; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; WEST AB, 1985, J UROLOGY, V133, P107, DOI 10.1016/S0022-5347(17)48810-0	19	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					989	991		10.1136/bmj.315.7114.989	http://dx.doi.org/10.1136/bmj.315.7114.989			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365296	Green Published			2022-12-28	WOS:A1997YC30700021
J	McKenna, G; Schousboe, M; Paltridge, G				McKenna, G; Schousboe, M; Paltridge, G			Lesson of the week - Subjective change in ejaculate as symptom of infection with Schistosoma haematobium in travellers	BRITISH MEDICAL JOURNAL			English	Article									CANTERBURY HLTH,SEX HLTH CTR,CHRISTCHURCH,NEW ZEALAND; CANTERBURY HLTH,CANTERBURY HLTH LABS,CHRISTCHURCH,NEW ZEALAND	Canterbury Health Laboratories								CORACHAN M, 1994, AM J TROP MED HYG, V50, P580, DOI 10.4269/ajtmh.1994.50.580; GELFAND M, 1970, AM J TROP MED HYG, V19, P779, DOI 10.4269/ajtmh.1970.19.779; McKenna G, 1996, AUST NZ J MED, V26, P226, DOI 10.1111/j.1445-5994.1996.tb00888.x; NAIDOO P, 1992, VENEREOLOGY, V5, P97; 1993, MMWR-MORBID MORTAL W, V42, P565	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					1000	1001		10.1136/bmj.315.7114.1000	http://dx.doi.org/10.1136/bmj.315.7114.1000			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC307	9365301	Green Published			2022-12-28	WOS:A1997YC30700028
J	Bergfeldt, L				Bergfeldt, L			HLA-B27-associated cardiac disease	ANNALS OF INTERNAL MEDICINE			English	Review							COMPLETE HEART-BLOCK; JUVENILE ANKYLOSING-SPONDYLITIS; HLA-B27 ASSOCIATED DISEASE; AORTIC ROOT ABNORMALITIES; HL-A 27; REITERS-SYNDROME; RHEUMATIC DISORDERS; YERSINIA ARTHRITIS; CONDUCTION SYSTEM; CLINICAL-FEATURES	Purpose: To review the available information about cardiac disease in relation to the immunogenetic marker HLA-B27 and the inflammatory disorders associated with it (seronegative spondyloarthropathies). Data Sources: English-language clinical studies, case reports, and reviews published in 1995 or earlier were identified from a search of the MEDLINE database. These papers, textbooks, and other bibliographic sources were used to identify other relevant publications, enabling collection of references from 1936 through 1995 in a stepwise manner. Study Selection: Clinical studies, case reports, and topical reviews on the HLA-B27 histocompatibility locus, seronegative spondyloarthropathies, and cardiac disease were selected. Data Extraction: information from systematic or hypothesis-driven studies, including those showing clinically and statistically meaningful associations between disorders, and additional relevant information from case reports and reviews is presented. Data Synthesis: Immunogenetic, histopathologic, clinical and electrophysiologic evidence was examined to explore the concept of HLA-B27-associated cardiac disease. Results: Relative to the general population (in which the frequency is 6% to 8%), men (but not women) with pacemakers have a significantly increased frequency of HLA-B27. Furthermore, a cardiac syndrome that consists of severe conduction system abnormalities plus aortic regurgitation is associated with HLA-B27, which was present in 67% to 88% of the patients with both of these clinical findings. This proportion of HLA-B27 is similar to that found in patients with ankylosing spondylitis and Reiter disease. Cardiac and aortic tissue both show intimal proliferation of small arteries (obliterative endarteritis) and fibrosis, as seen in tissues adjacent to afflicted joints. Both cardiac conduction abnormalities and aortic regurgitation occur in patients with Various HLA-B27-related extracardiac disorders, regardless of the severity of the latter; in about 50% of patients with these cardiac findings, a diagnosis of an HLA-B27-related rheumatic disease has not previously been made. Third-degree (complete) atrioventricular block related to HLA-B27 is located within the atrioventricular node in 95% rather than the expected 20% of cases. Conclusions: The heart and the joints are both of major importance as targets for the HLA-B27-associated disease process. HLA-B27-related cardiac lesions may be found in the absence of other rheumatologic manifestations. Furthermore, a genetically linked cardiac syndrome has been defined: the combination of conduction system abnormalities and aortic regurgitation.	KAROLINSKA HOSP & INST, STOCKHOLM, SWEDEN; STANFORD UNIV, SCH MED, STANFORD, CA 94305 USA	Karolinska Institutet; Karolinska University Hospital; Stanford University								AHO K, 1974, ARTHRITIS RHEUM-US, V17, P521, DOI 10.1002/art.1780170505; Ahvonen P, 1969, Acta Rheumatol Scand, V15, P232; Bachmann F, 1976, Med Welt, V27, P2149; BAUR MP, 1984, HISTOCOMPATIBILITY T, P333; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BERGFELDT L, 1983, AM J MED, V75, P210, DOI 10.1016/0002-9343(83)91193-2; BERGFELDT L, 1988, AM J MED, V85, P12, DOI 10.1016/0002-9343(88)90497-4; BERGFELDT L, 1984, BRIT HEART J, V51, P184; BERGFELDT L, 1983, TISSUE ANTIGENS, V21, P385; BERGFELDT L, 1991, BRIT HEART J, V65, P184; BERGFELDT L, 1984, AM J MED, V77, P961, DOI 10.1016/0002-9343(84)90552-7; BERGFELDT L, 1988, ACTA MED SCAND, V224, P627; BERGFELDT L, 1987, ACTA MED SCAND, V222, P293; BERGFELDT L, 1982, AM J MED, V73, P187, DOI 10.1016/0002-9343(82)90177-2; BERGFELDT L, 1982, ACTA MED SCAND, V212, P212; BERGFELDT L, 1986, J RHEUMATOL, V13, P941; BERGFELDT L, 1982, THESIS STOCKHOLM; BERNSTEIN L, 1949, ACTA MED SCAND, V135, P185; BERNSTEIN L, 1951, Rheumatism, V7, P18; BLOCK SR, 1972, ARTHRITIS RHEUM, V15, P218, DOI 10.1002/art.1780150214; BREWERTON DA, 1973, LANCET, V1, P904; BREWERTON DA, 1987, LANCET, V1, P995; BRIEM H, 1978, LANCET, V2, P112; BULKLEY BH, 1973, CIRCULATION, V48, P1014, DOI 10.1161/01.CIR.48.5.1014; Cabot RC, 1936, NEW ENGL J MED, V214, P690, DOI 10.1056/NEJM193604022141409; CALIN A, 1976, ANN INTERN MED, V84, P564, DOI 10.7326/0003-4819-84-5-564; CALIN A, 1976, NEW ENGL J MED, V294, P397; CASS RM, 1991, HOSP PRACT, V26, P51; CROWLEY JJ, 1993, AM J CARDIOL, V71, P1337, DOI 10.1016/0002-9149(93)90551-M; CRUICKSHANK B, 1960, Bull Rheum Dis, V10, P211; CRUICKSHANK B, 1971, CLIN ORTHOP RELAT R, V74, P43; DAVIDSON P, 1963, MAYO CLIN PROC, V38, P427; DEMOULIN JC, 1983, AM HEART J, V105, P859, DOI 10.1016/0002-8703(83)90254-5; EBRINGER A, 1990, SCAND J RHEUMATOL S, V87, P15; Ebringer A., 1976, HLA DIS PARIS INSERM, V58, P27; ENGFELDT B, 1954, ANN RHEUM DIS, V13, P219, DOI 10.1136/ard.13.3.219; EVERSMEYER WH, 1978, JAMA-J AM MED ASSOC, V240, P2652, DOI 10.1001/jama.240.24.2652; GODEAU P, 1976, ANN MED INTERNE, V127, P203; GOOD AE, 1974, SEMIN ARTHRITIS RHEU, V3, P263; GOODACRE JA, 1991, BRIT J RHEUMATOL, V30, P336; GORE JE, 1981, PEDIATRICS, V68, P423; GOULD BA, 1992, ANN RHEUM DIS, V51, P227, DOI 10.1136/ard.51.2.227; GRAHAM D C, 1958, Bull Rheum Dis, V9, P171; GREGERSEN PK, 1982, B HOSP JT DIS ORTHOP, V43, P103; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Haruta S, 1981, Nihon Naika Gakkai Zasshi, V70, P888; HARVEY DB, 1976, ARCH INTERN MED, V136, P1046, DOI 10.1001/archinte.136.9.1046; HASSEL D, 1984, AM J CARDIOL, V53, P967; HAVERMAN JF, 1988, ANN RHEUM DIS, V47, P1017, DOI 10.1136/ard.47.12.1017; HOLLINGWORTH P, 1979, BRIT HEART J, V42, P229; HUBSCHER O, 1984, J RHEUMATOL, V11, P94; KARPAWICH PP, 1981, AM J CARDIOL, V48, P1098, DOI 10.1016/0002-9149(81)90326-X; KAWASUJI M, 1982, THORAC CARDIOV SURG, V30, P310, DOI 10.1055/s-2007-1022414; KEAN WF, 1980, ANN RHEUM DIS, V39, P294, DOI 10.1136/ard.39.3.294; KINSELLA TD, 1974, CAN MED ASSOC J, V111, P1309; LABRESH KA, 1985, AM J MED, V78, P908, DOI 10.1016/0002-9343(85)90211-6; LAITINEN O, 1977, ARTHRITIS RHEUM, V20, P1121, DOI 10.1002/art.1780200512; LAKOMEK HJ, 1991, ANN RHEUM DIS, V50, P776, DOI 10.1136/ard.50.11.776; MAZIERES B, 1979, REV RHUM, V46, P137; MCMICHAEL A, 1991, RES IMMUNOL, V142, P475, DOI 10.1016/0923-2494(91)90050-S; MICHELS VV, 1987, CARDIOLOGY FUNDAMENT, P1895; MOLL JMH, 1974, MEDICINE, V53, P343, DOI 10.1097/00005792-197409000-00002; NAGYHEGYI G, 1988, CLIN EXP RHEUMATOL, V6, P17; NIELSEN H, 1986, ACTA CARDIOL, V41, P451; NITTERHAUGE S, 1981, ACTA MED SCAND, V210, P197; NOER HR, 1966, J AMER MED ASSOC, V198, P693, DOI 10.1001/jama.198.7.693; ONEILL TW, 1992, ANN RHEUM DIS, V51, P705, DOI 10.1136/ard.51.6.705; PAULUS HE, 1972, AM J MED, V53, P464, DOI 10.1016/0002-9343(72)90142-8; PEETERS AJ, 1991, ANN RHEUM DIS, V50, P348, DOI 10.1136/ard.50.6.348; PELKONEN P, 1984, ARTHRITIS RHEUM-US, V27, P698, DOI 10.1002/art.1780270615; Porciello P I, 1978, G Ital Cardiol, V8, P564; PRZYBYLA AC, 1974, AM J CARDIOL, V33, P344, DOI 10.1016/0002-9149(74)90314-2; PUECH P, 1975, CARDIAC ARRHYTHMIAS, P81; QAIYUMI S, 1985, ARCH INTERN MED, V145, P822, DOI 10.1001/archinte.145.5.822; RAJS J, 1994, P ISNUD WORKSH SUDD, P146; REID GD, 1979, J PEDIATR-US, V95, P78, DOI 10.1016/S0022-3476(79)80091-8; RIBEIRO P, 1984, EUR HEART J, V5, P419, DOI 10.1093/oxfordjournals.eurheartj.a061676; ROBERTS WC, 1974, AM J MED, V56, P237, DOI 10.1016/0002-9343(74)90602-0; ROSEN KM, 1970, CIRCULATION, V42, P925, DOI 10.1161/01.CIR.42.5.925; ROSSEN RM, 1975, AM J MED, V58, P280, DOI 10.1016/0002-9343(75)90578-1; RUPPERT GB, 1982, AM J MED, V73, P335, DOI 10.1016/0002-9343(82)90719-7; SAHI SP, 1990, BRIT J CLIN PRACT, V44, P794; SAIRANEN E, 1969, ACTA MED SCAND, V185, P57; SCHILDER DP, 1956, NEW ENGL J MED, V255, P11, DOI 10.1056/NEJM195607052550102; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; SHAH A, 1987, AM J MED, V82, P353, DOI 10.1016/0002-9343(87)90086-6; SIMPSON J, 1995, J RHEUMATOL, V22, P332; SOBIN LH, 1962, JAMA-J AM MED ASSOC, V180, P1; STAMATO T, 1995, AM J CARDIOL, V75, P744, DOI 10.1016/S0002-9149(99)80672-9; STEWART SR, 1978, NEW ENGL J MED, V299, P1448, DOI 10.1056/NEJM197812282992607; STROMINGER JL, 1986, J CLIN INVEST, V77, P1411, DOI 10.1172/JCI112451; SUKENIK S, 1987, CLIN RHEUMATOL, V6, P588, DOI 10.1007/BF02330598; SUN JP, 1992, INT J CARDIOL, V37, P65, DOI 10.1016/0167-5273(92)90133-N; SVEJGAARD A, 1977, HLA DISEASE, P46; TAKKUNEN J, 1970, Annals of Clinical Research, V2, P106; TAN PLJ, 1980, J RHEUMATOL, V7, P757; THOMAS D, 1982, AUST NZ J MED, V12, P10, DOI 10.1111/j.1445-5994.1982.tb02416.x; THOMSEN NH, 1985, DAN MED BULL, V32, P272; TSUJIMOTO M, 1978, Medical Journal of Osaka University, V28, P363; TUCKER CR, 1982, AM J CARDIOL, V49, P680, DOI 10.1016/0002-9149(82)91946-4; VARTIAINEN J, 1964, ACTA MED SCAND, V175, P771; VONLEITNER ER, 1981, DEUT MED WOCHENSCHR, V106, P939, DOI 10.1055/s-2008-1070430; WEED CL, 1966, ARCH INTERN MED, V117, P800, DOI 10.1001/archinte.117.6.800; WILKINSON M, 1958, ANN RHEUM DIS, V17, P209, DOI 10.1136/ard.17.2.209; WOODROW J C, 1991, Current Opinion in Rheumatology, V3, P586, DOI 10.1097/00002281-199108000-00005; WRIGHT V, 1980, ANKYLOSING SPONDYLIT, P42; 1990, SCAND J RHEUMATOL S, V87, P1	107	106	118	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				621	629		10.7326/0003-4819-127-8_Part_1-199710150-00007	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341061				2022-12-28	WOS:A1997YB41900007
J	Calman, KC; Royston, GHD				Calman, KC; Royston, GHD			Personal paper - Risk language and dialects	BMJ-BRITISH MEDICAL JOURNAL			English	Article									NHS, LEEDS LS2 7UE, W YORKSHIRE, ENGLAND; DEPT HLTH, LONDON SW1A 2NS, ENGLAND				Calman, Kenneth C/C-9855-2010	Royston, Geoff/0000-0001-7180-3124				BEYTHMAROM R, 1982, J FORECASTING, V1, P257, DOI 10.1002/for.3980010305; Calman KC, 1996, BRIT MED J, V313, P799; COVELLO VT, 1991, COMMUNICATING RISKS; GANN B, 1990, BMA GUIDE LIVING RIS; Marris C, 1996, NEW SCI, V151, P36; O'Brien B., 1986, WHAT ARE MY CHANCES; PALING J, 1993, YOUR ARMPITS ALLIGAT; PAULOS JA, 1990, INNUMERACY; Pidgeon N.F., 1992, RISK PERCEPTION, P89; PRESCOTTCLARKE P, 1982, PUBLIC ATTITUDES IND; ROTH E, 1990, RISK ANAL, V10, P375, DOI 10.1111/j.1539-6924.1990.tb00520.x; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; SLOVIC P, 1986, RISK ANAL, V6, P403, DOI 10.1111/j.1539-6924.1986.tb00953.x; URQUHART J, 1984, RISK WATCH; Uttal W.R., 1973, PSYCHOBIOLOGY SENSOR	15	92	94	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	1997	315	7113					939	942						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB073	9361547				2022-12-28	WOS:A1997YB07300034
J	Liu, YJ				Liu, YJ			Immunology - Reuse of B lymphocytes in germinal centers	SCIENCE			English	Editorial Material							V(D)J RECOMBINATION; CELLS				Liu, YJ (corresponding author), DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,901 CALIF AVE,PALO ALTO,CA 94304, USA.							Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; Hikida M, 1997, J IMMUNOL, V158, P2509; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; Papavasiliou F, 1997, CURR OPIN IMMUNOL, V9, P233, DOI 10.1016/S0952-7915(97)80141-0; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Schwarz K, 1996, ADV IMMUNOL, V61, P285, DOI 10.1016/S0065-2776(08)60869-X; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	14	11	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					238	239		10.1126/science.278.5336.238	http://dx.doi.org/10.1126/science.278.5336.238			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9340771				2022-12-28	WOS:A1997YA56400029
J	McMichael, AJ; Haines, A				McMichael, AJ; Haines, A			Global climate change: the potential effects on health	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NINO SOUTHERN OSCILLATION; MALARIA; EPIDEMICS; DISEASES; ENGLAND; WALES; RISK		UCL, SCH MED, LONDON NW3 2PF, ENGLAND; ROYAL FREE HOSP, SCH MED, JOINT DEPT PRIMARY CARE & POPULAT SCI, LONDON NW3 2PF, ENGLAND	University of London; University College London; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	McMichael, AJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT HLTH, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.			Haines, Andy/0000-0002-8053-4605				Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Baarse G., 1995, CZM CTR PUBLICATION; BANEA M, 1997, LANCET, V3, P349; BENTHAM G, 1995, INT J BIOMETEOROL, V39, P81, DOI 10.1007/BF01212585; Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; Burgos Juan J., 1994, Entomologia y Vectores, V1, P69; *CLIM CHANG IMP RE, 1996, POT EFF CLIM CHANG U; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; EPSTEIN P, IN PRESS NEW RESURGE; *EXP PAN INT AG CO, 1996, UK NAT STRAT GLOB EN; HAINES A, IN PRESS BMJ; Hales S, 1996, LANCET, V348, P1664, DOI 10.1016/S0140-6736(05)65737-6; KALKSTEIN LS, 1993, LANCET, V342, P1397, DOI 10.1016/0140-6736(93)92757-K; KERR RA, 1995, SCIENCE, V268, P1567, DOI 10.1126/science.268.5217.1567; KILBOURNE EM, 1992, MAXCY ROSENAU LAST P, P491; LANGFORD IH, 1995, INT J BIOMETEOROL, V38, P141, DOI 10.1007/BF01208491; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; Martens WJ, 1997, HLTH IMPACTS CLIMATE; MARTENS WJM, 1995, ENVIRON HEALTH PERSP, V103, P458, DOI 10.2307/3432584; Martens WJM, 1997, CLIMATIC CHANGE, V35, P145, DOI 10.1023/A:1005365413932; MARTIN PH, 1995, AMBIO, V24, P200; McMichael A. J, 1996, WHOEHG967; McMichael AJ, 1996, CLIMATE CHANGE 1995, P559; MCMICHAEL AJ, 1995, PLANETARY OVERLOAD G; MCMICHAEL AJ, 1995, ECSYST HLTH, V1, P15; Myers N., 1995, ENV EXODUS EMERGENT; Nicholls R. J., 1995, J COAST RES, V14, P303, DOI DOI 10.2112/07A-0003.1; PARRY ML, 1993, LANCET, V342, P1345, DOI 10.1016/0140-6736(93)92251-N; Patz JA, 1996, JAMA-J AM MED ASSOC, V275, P217, DOI 10.1001/jama.275.3.217; POSTEL S, 1992, LAST OASIS JACING WA; Reilly J, 1996, CLIMATE CHANGE 1995, P429; ROGERS DJ, 1993, LANCET, V342, P1282, DOI 10.1016/0140-6736(93)92367-3; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; SUTHERST RW, 1983, ENV CHANGE HUMAN HLT, P124; TULU A, 1996, THESIS LONDON SCH HY; WIGLEY TML, 1995, NATURE, V376, P463, DOI 10.1038/376463a0; WOODWARD A, IN PRESS CLIMATE RES; ZULUETA JD, 1975, B WORLD HEALTH ORGAN, V52, P109	39	98	103	3	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	1997	315	7111					805	809						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345177	Green Published			2022-12-28	WOS:A1997XY91100029
J	Wylie, PAL; Stevens, D; Drake, W; Stuart, J; Cartwright, K				Wylie, PAL; Stevens, D; Drake, W; Stuart, J; Cartwright, K			Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS; OUTBREAK; MENINGITIS; PENICILLIN	Objective: To study changes in the epidemiology and management of meningococcal disease in one health district during a period of high local incidence of disease. Design: Prospective case ascertainment and data collection over 14 years, with retrospective analysis of cases. Setting: West Gloucestershire (population 320 000). Subjects: Residents developing meningococcal disease between 1 January 1982 and 31 December 1995. Results: 252 cases of invasive meningococcal disease were identified, of which 102 (40%) were officially notified and 191 (76%) were confirmed by culture from a deep site. The observed disease incidence of 5.6/100 000/year was about 2.7 times the national incidence (as measured by either statutory notifications or reference laboratory reports). The period 1983-90 was characterised by a prolonged localised outbreak due to serogroup B serotype 15 sulphonamide resistant (B15R) strains. General practitioners gave benzylpenicillin before hospital admission to 18% of patients who presented with meningococcal disease in the first half of the study period and to 40% who presented in the second half. The overall case fatality rate was 6.7% (17/252). Four deaths were directly or indirectly related to lumbar puncture. Of 120 patients whose lumbar puncture yielded meningococci, nine (8%) showed no abnormality on initial examination. Conclusions: Neither laboratory records nor formal notifications alone can give an accurate estimate of the incidence of meningococcal disease. Because of the dangers of lumbar puncture, the frequency of misleading negative initial findings, and the advent of new diagnostic techniques, the need for samples of cerebrospinal fluid should be critically questioned in each case of suspected meningococcal disease.	GLOUCESTERSHIRE ROYAL HOSP,DEPT PAEDIAT,GLOUCESTER GL1 3NN,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,PUBL HLTH LAB,GLOUCESTER GL1 3NN,ENGLAND	Gloucestershire Royal Hospital; Gloucestershire Royal Hospital								*ADV LIF SUPP GROU, 1993, ADV PAED LIF SUPP PR; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CARTWRIGHT KAV, 1991, EPIDEMIOL INFECT, V106, P133, DOI 10.1017/S0950268800056491; CARTWRIGHT KAV, 1986, LANCET, V2, P558; CARTWRIGHT KAV, 1989, J CLIN PATHOL, V42, P634, DOI 10.1136/jcp.42.6.634; DAVIES LA, 1989, COMMUNITY MED, V11, P239; *DEP HLTH SOC SEC, 1988, PLCMO882 DHHS; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; Jones D M, 1995, Commun Dis Rep CDR Rev, V5, pR125; Jones D M, 1993, Commun Dis Rep CDR Rev, V3, pR129; JONES DM, 1993, J INFECTION, V27, P83, DOI 10.1016/0163-4453(93)93978-D; Laxton C E, 1994, Commun Dis Rep CDR Rev, V4, pR85; NADEL S, 1995, MENINGOCOCCAL DIS, P207; Newcombe J, 1996, J CLIN MICROBIOL, V34, P1637, DOI 10.1128/JCM.34.7.1637-1640.1996; NI HL, 1992, LANCET, V340, P1432, DOI 10.1016/0140-6736(92)92622-M; PELTOLA H, 1993, LANCET, V342, P509, DOI 10.1016/0140-6736(93)91642-Y; PELTOLA H, 1982, LANCET, V2, P595; POOLMAN JT, 1986, LANCET, V2, P555; *RES COMM BSSI, 1995, J INFECTION, V30, P89; Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255; SAMUELSSON S, 1992, EPIDEMIOL INFECT, V108, P19, DOI 10.1017/S0950268800049463; SLACK J, 1982, J ROY COLL PHYS LOND, V16, P40; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; WEIHE P, 1988, SCAND J INFECT DIS, V20, P291, DOI 10.3109/00365548809032454; Woodward C M, 1995, Commun Dis Rep CDR Rev, V5, pR135	25	58	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					774	779						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345169	Green Published			2022-12-28	WOS:A1997XY91100019
J	Broecker, WS				Broecker, WS			Thermohaline circulation, the Achilles heel of our climate system: Will man-made CO2 upset the current balance?	SCIENCE			English	Review							SEA-SURFACE TEMPERATURE; LAST GLACIAL MAXIMUM; DEEP-WATER FORMATION; GREENLAND ICE CORES; WEDDELL SEA; NORTH-ATLANTIC; BOTTOM WATER; LEVEL CURVE; RECORDS; OCEAN	During the last glacial period, Earth's climate underwent frequent large and abrupt global changes, This behavior appears to reflect the ability of the ocean's thermohaline circulation to assume more than one made of operation. The record in ancient sedimentary rocks suggests that similar abrupt changes plagued the Earth at other times. The trigger mechanism for these reorganizations may have been the antiphasing of polar insolation associated with orbital cycles, Were the ongoing increase in atmospheric CO2 levels to trigger another such reorganization, it would be bad news for a world striving to feed 11 to 16 billion people.			Broecker, WS (corresponding author), COLUMBIA UNIV, LAMONT DOHERTY EARTH OBSERV, PALISADES, NY 10964 USA.							Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; ALLEY RB, 1993, NATURE, V362, P527, DOI 10.1038/362527a0; ANDERSON LA, 1994, GLOBAL BIOGEOCHEM CY, V8, P65, DOI 10.1029/93GB03318; ANDERSON RY, 1982, J GEOPHYS RES-OCEANS, V87, P7285, DOI 10.1029/JC087iC09p07285; Baumgartner A., 1975, WORLD WATER BALANCE; BAYER R, 1991, MAR CHEM, V35, P123, DOI 10.1016/S0304-4203(09)90012-3; Behl RJ, 1996, NATURE, V379, P243, DOI 10.1038/379243a0; BISCAYE PE, IN PRESS J GEOPHYS R; BOARDMAN DR, 1989, GEOLOGY, V17, P802, DOI 10.1130/0091-7613(1989)017<0802:GESLCF>2.3.CO;2; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; Bonisch G, 1997, J GEOPHYS RES-OCEANS, V102, P18553, DOI 10.1029/97JC00740; BRIAT M, 1982, ANN GLACIOL, V3, P27, DOI DOI 10.3189/S0260305500002470; BROECKER W, IN PRESS GEOPHYS RES; Broecker W.S., 1991, OCEANOGRAPHY, V4, P79, DOI DOI 10.5670/0CEAN0G.1991.07; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; Broecker WS, 1996, GSA TODAY, V6, P1; BROECKER WS, IN PRESS J GEOPHYS R; BROECKER WS, IN PRESS GLOBAL BIOG; Carmack E. C., 1986, NATO ASI SER B-PHYS, P641; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; CHINZEI K, 1987, MAR MICROPALEONTOL, V11, P273, DOI 10.1016/0377-8398(87)90002-8; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; DANSGAARD W, 1982, SCIENCE, V218, P1273, DOI 10.1126/science.218.4579.1273; DANSGAARD W, 1989, NATURE, V339, P532, DOI 10.1038/339532a0; DEANGELIS M, 1987, NATURE, V325, P318, DOI 10.1038/325318a0; delaMare WK, 1997, NATURE, V389, P57, DOI 10.1038/37956; DENTON GH, 1994, SCIENCE, V264, P1434, DOI 10.1126/science.264.5164.1434; FAHRBACH E, 1995, J MAR RES, V53, P515, DOI 10.1357/0022240953213089; FOLDVIK A, 1988, PALAEOGEOGR PALAEOCL, V67, P3, DOI 10.1016/0031-0182(88)90119-8; FOSTER TD, 1980, DEEP-SEA RES, V27, P367, DOI 10.1016/0198-0149(80)90032-1; FOSTER TD, 1987, DEEP-SEA RES, V34, P1771, DOI 10.1016/0198-0149(87)90053-7; GAUDICHET A, 1986, Tellus Series B Chemical and Physical Meteorology, V38, P250, DOI 10.1111/j.1600-0889.1986.tb00191.x; GOLDHAMMER RK, 1987, AM J SCI, V287, P853, DOI 10.2475/ajs.287.9.853; GORDON AL, 1993, SCIENCE, V262, P95, DOI 10.1126/science.262.5130.95; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; HARDIE LA, 1986, COLO SCHOOL MINES Q, V81, P1; HECKEL PH, 1986, GEOLOGY, V14, P330, DOI 10.1130/0091-7613(1986)14<330:SCFPEM>2.0.CO;2; HERBERT TD, 1986, NATURE, V321, P739, DOI 10.1038/321739a0; HERZOG HJ, 1997, ENERGY CONVERSI S689, V38; HILEMAN B, 1997, CHEM ENG NEWS, V34; HILGEN FJ, 1997, EOS T AM GEOPHYS UN, V78, P285, DOI DOI 10.1029/97EO00186; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; HUGHEN KA, IN PRESS NATURE; JACOBS DK, 1993, NATURE, V361, P710, DOI 10.1038/361710a0; KALLEL N, 1988, OCEANOL ACTA, V11, P369; Keigwin LD, 1990, PALEOCEANOGRAPHY, V5, P1009, DOI 10.1029/PA005i006p01009; KENNETT JP, 1997, ODP GREATEST HITS BR, P13; KENT DV, 1995, J GEOPHYS RES-SOL EA, V100, P14965, DOI 10.1029/95JB01054; KUDRASS HR, 1991, NATURE, V349, P406, DOI 10.1038/349406a0; LANGEREIS CG, 1991, EARTH PLANET SC LETT, V104, P211, DOI 10.1016/0012-821X(91)90205-V; LEHMAN SJ, 1992, NATURE, V356, P757, DOI 10.1038/356757a0; Linsley BK, 1990, PALEOCEANOGRAPHY, V5, P1025, DOI 10.1029/PA005i006p01025; LOWELL TV, 1995, SCIENCE, V269, P1541, DOI 10.1126/science.269.5230.1541; Macdonald AM, 1996, NATURE, V382, P436, DOI 10.1038/382436a0; MAIERREIMER E, 1989, P JOINT OC ASS, V87; Manabe S, 1988, J CLIMATE, V1, P841, DOI 10.1175/1520-0442(1988)001<0841:TSEOAC>2.0.CO;2; Manabe S, 1997, PALEOCEANOGRAPHY, V12, P321, DOI 10.1029/96PA03932; MANABE S, 1993, NATURE, V364, P215, DOI 10.1038/364215a0; MAROTZKE J, 1991, J PHYS OCEANOGR, V21, P1372, DOI 10.1175/1520-0485(1991)021<1372:MEOTGT>2.0.CO;2; MCMANUS JF, 1994, NATURE, V371, P326, DOI 10.1038/371326a0; MEESE DA, 1994, SCIENCE, V266, P1680, DOI 10.1126/science.266.5191.1680; MEESE DA, IN PRESS J GEOPHYS R; MICHEL RL, 1978, J GEOPHYS RES-OCEANS, V83, P6192, DOI 10.1029/JC083iC12p06192; Miller JR, 1990, PALEOCEANOGRAPHY, V5, P397, DOI 10.1029/PA005i003p00397; Olsen PE, 1997, ANNU REV EARTH PL SC, V25, P337, DOI 10.1146/annurev.earth.25.1.337; Olsen PE, 1996, PALAEOGEOGR PALAEOCL, V122, P1, DOI 10.1016/0031-0182(95)00171-9; Oort AH., 1983, 14 NOAA; PETIT JR, 1990, NATURE, V343, P56, DOI 10.1038/343056a0; RAHMSTORF S, 1994, NATURE, V372, P82, DOI 10.1038/372082a0; RAHMSTORF S, 1995, NATURE, V378, P145, DOI 10.1038/378145a0; RAM M, 1994, GEOPHYS RES LETT, V21, P437, DOI 10.1029/94GL00302; Raymo ME, 1989, PALEOCEANOGRAPHY, V4, P413, DOI 10.1029/PA004i004p00413; REDDY A, 1997, ENERGY RIO; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; ROACH AT, 1995, J GEOPHYS RES-OCEANS, V100, P18443, DOI 10.1029/95JC01673; ROSTEK F, 1993, NATURE, V364, P319, DOI 10.1038/364319a0; SCHLOSSER P, 1991, MAR CHEM, V35, P97, DOI 10.1016/S0304-4203(09)90011-1; SCHLOSSER P, 1991, SCIENCE, V251, P1054, DOI 10.1126/science.251.4997.1054; SEVERINGHAUS JP, 1993, IN PRESS NATURE, V366; SOWERS T, 1995, SCIENCE, V269, P210, DOI 10.1126/science.269.5221.210; STOCKER TF, 1991, NATURE, V351, P729, DOI 10.1038/351729a0; Stocker TF, 1997, NATURE, V388, P862, DOI 10.1038/42224; STOMMEL H, 1958, DEEP-SEA RES, V5, P80, DOI 10.1016/S0146-6291(58)80014-4; STOMMEL H, 1961, TELLUS, V13, P224, DOI 10.1111/j.2153-3490.1961.tb00079.x; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; TAKAHASHI T, 1985, J GEOPHYS RES-OCEANS, V90, P6907, DOI 10.1029/JC090iC04p06907; TAYLOR KC, 1993, NATURE, V366, P549, DOI 10.1038/366549a0; TAYLOR KC, 1993, NATURE, V361, P432, DOI 10.1038/361432a0; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; Torresen T., 1985, OCEANOLOGY ANTARCTIC, P5, DOI [10.1029/AR043p0005, DOI 10.1029/AR043P0005]; TZIPEMAN E, 1997, NATURE, V386, P593; WEAVER AJ, 1993, J PHYS OCEANOGR, V23, P1470; WEISS RF, 1979, DEEP-SEA RES, V26, P1093, DOI 10.1016/0198-0149(79)90059-1; Wilkinson BH, 1996, J SEDIMENT RES, V66, P1065; WILLIAMS R, 1996, 295 PRINC U CTR EN E; WILLIAMS RH, IN PRESS ECO RESTRUC; WILSON JL, 1967, GEOL SOC AM BULL, V78, P805, DOI 10.1130/0016-7606(1967)78[805:CARSIV]2.0.CO;2; WOILLARD GM, 1978, QUATERNARY RES, V9, P1, DOI 10.1016/0033-5894(78)90079-0; ZAUCKER F, 1992, J GEOPHYS RES-ATMOS, V97, P2765, DOI 10.1029/91JD01699	100	631	658	4	218	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1582	1588		10.1126/science.278.5343.1582	http://dx.doi.org/10.1126/science.278.5343.1582			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374450				2022-12-28	WOS:A1997YJ87400029
J	Qin, XR; Lagally, MG				Qin, XR; Lagally, MG			Adatom pairing structures for Ge on Si(100): The initial stage of island formation	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; AB-INITIO; SI; SURFACE; DIFFUSION; NUCLEATION; SI(001); GROWTH; BINDING	With the use of scanning tunneling microscopy, it is shown that germanium atoms adsorbed on the (100) surface of silicon near room temperature form chainlike structures that are tilted from the substrate dimer bond direction and that consist of two-atom units arranged in adjoining substrate troughs, These units are distinctly different from surface dimers. They may provide the link missing in our understanding of the elementary processes in epitaxial film growth: the step between monomer adsorption and the initial formation of two-dimensional growth islands.	UNIV WISCONSIN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								APPELBAUM JA, 1976, PHYS REV B, V14, P588, DOI 10.1103/PhysRevB.14.588; BEDROSSIAN PJ, 1995, PHYS REV LETT, V74, P3648, DOI 10.1103/PhysRevLett.74.3648; Brocks G, 1996, PHYS REV LETT, V76, P2362, DOI 10.1103/PhysRevLett.76.2362; HAMERS RJ, 1989, ULTRAMICROSCOPY, V31, P10, DOI 10.1016/0304-3991(89)90029-6; MILMAN V, 1994, PHYS REV B, V50, P2663, DOI 10.1103/PhysRevB.50.2663; MO YW, 1991, SURF SCI, V248, P313, DOI 10.1016/0039-6028(91)91177-Y; MO YW, 1992, SURF SCI, V268, P275, DOI 10.1016/0039-6028(92)90968-C; MO YW, 1991, PHYS REV LETT, V66, P1998, DOI 10.1103/PhysRevLett.66.1998; MO YW, 1989, SURF SCI, V219, pL551, DOI 10.1016/0039-6028(89)90499-8; MO YW, 1990, J VAC SCI TECHNOL A, V8, P201, DOI 10.1116/1.577066; Qin X., UNPUB; Swartzentruber BS, 1997, PHYS REV B, V55, P1322, DOI 10.1103/PhysRevB.55.1322; TSAO JY, 1989, PHYS REV B, V40, P11951, DOI 10.1103/PhysRevB.40.11951; vanWingerden J, 1997, PHYS REV B, V55, P4723, DOI 10.1103/PhysRevB.55.4723; VENABLES JA, 1973, PHILOS MAG, V27, P697, DOI 10.1080/14786437308219242; Wulfhekel W, 1997, PHYS REV LETT, V79, P2494, DOI 10.1103/PhysRevLett.79.2494; ZHANG QM, 1995, PHYS REV LETT, V75, P101, DOI 10.1103/PhysRevLett.75.101; Zhang ZY, 1997, SCIENCE, V276, P377, DOI 10.1126/science.276.5311.377	18	51	52	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1444	1447		10.1126/science.278.5342.1444	http://dx.doi.org/10.1126/science.278.5342.1444			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367953				2022-12-28	WOS:A1997YG85800039
J	Cleary, PD; EdgmanLevitan, S				Cleary, PD; EdgmanLevitan, S			Health care quality - Incorporating consumer perspectives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Meeting on Quality Challenge Areas Across Perspectives and the Role of AHCPR	FEB 10, 1997	WASHINGTON, D.C.				MOS SHORT-FORM; OF-LIFE; SURVEY SF-36; PRACTICE GUIDELINES; NATIONAL SURVEY; PATIENT REPORTS; FEEDBACK; INFORMATION; EDUCATION; OUTCOMES	The goal of this article is to address, from the perspective of users of the health care system (consumers), the following questions: What are the most important health care quality gaps and/or challenges; what major changes should we anticipate in this area in the near future; and what should be the role of federal and state agencies, accreditation organizations, and philanthropic foundations in addressing these challenges? We discuss the needs, challenges, and potential action steps for increasing the prominence of the user's perspective in 3 areas: (1) the conceptualization and definition of quality; (2) the measurement of quality; and (3) routine quality assessment and improvement. The article concludes by making recommendations about the role that different agencies and organizations can and should play in meeting these challenges.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; PICKER INST, BOSTON, MA USA	Harvard University; Harvard Medical School	Cleary, PD (corresponding author), HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Cleary, Paul/AAF-7048-2019	Cleary, Paul/0000-0001-7527-4354	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS009205] Funding Source: NIH RePORTER; AHRQ HHS [HS09205] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Acs G, 1996, HEALTH AFFAIR, V15, P266, DOI 10.1377/hlthaff.15.2.266; APPELBAUM PS, 1993, MILBANK Q, V71, P669, DOI 10.2307/3350424; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Cleary P D, 1992, QRB Qual Rev Bull, V18, P53; Cleary P D, 1993, Qual Manag Health Care, V2, P31; CLEARY PD, 1992, AIDS CARE, V4, P325, DOI 10.1080/09540129208253102; CLEARY PD, 1993, QUAL LIFE RES, V2, P3, DOI 10.1007/BF00642884; CLEARY PD, 1993, MED CARE, V31, P569, DOI 10.1097/00005650-199307000-00001; CLEARY PD, 1994, QUAL LIFE RES, V3, P307, DOI 10.1007/BF00451722; CLEARY PD, 1986, HEALTH EDUC QUART, V13, P317, DOI 10.1177/109019818601300404; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; CLEARY PD, 1991, JAMA-J AM MED ASSOC, V266, P73, DOI 10.1001/jama.266.1.73; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; CLEARY PD, 1991, MED CARE, V29, P939, DOI 10.1097/00005650-199110000-00001; CLEARY PD, 1991, CONTROL CLIN TRIALS, V12, pS189, DOI 10.1016/S0197-2456(05)80023-6; CLEARY PD, 1995, QUAL LIFE RES, V4, P207, DOI 10.1007/BF02260860; CLEARY PD, 1988, MILBANK Q, V66, P137, DOI 10.2307/3349988; CLEARY PD, 1987, TAKING CARE UNDERSTA, P119, DOI DOI 10.1017/CBO9780511527760.009; CLEARY PD, 1986, NEW DIRECTIONS ILLNE, P119; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DAVIES AR, 1988, HEALTH AFFAIR, V7, P33, DOI 10.1377/hlthaff.7.1.33; DONABEDIAN A, 1988, INQUIRY-J HEALTH CAR, V25, P173; EAGLE KA, 1990, JAMA-J AM MED ASSOC, V264, P992, DOI 10.1001/jama.264.8.992; EdgmanLevitan S, 1996, HEALTH AFFAIR, V15, P42, DOI 10.1377/hlthaff.15.4.42; EISENHARDT KM, 1985, MANAGE SCI, V31, P134, DOI 10.1287/mnsc.31.2.134; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; GERTEIS M, 1993, HLTH MANAGEMENT Q, P2; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GOSS MEW, 1961, AM SOCIOL REV, V26, P39, DOI 10.2307/2090511; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; GUSTAFSON DH, 1987, ANNU REV PUBL HEALTH, V8, P387, DOI 10.1146/annurev.pu.08.050187.002131; GUUSAFSON D, 1993, J PSYCHOSOC ONCOL, V11, P69; Hibbard JH, 1997, HEALTH AFFAIR, V16, P218, DOI 10.1377/hlthaff.16.3.218; Hibbard JH, 1996, MED CARE RES REV, V53, P28, DOI 10.1177/107755879605300102; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LEVINSON DF, 1987, NEW ENGL J MED, V317, P1729, DOI 10.1056/NEJM198712313172708; Lincoln J.R., 1990, CULTURE CONTROL COMM; McDowell I., 1996, MEASURING HLTH GUIDE; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; NELSON E, 1987, J CHRON DIS, V40, pS55, DOI 10.1016/S0021-9681(87)80033-4; PARKERSON GR, 1990, MED CARE, V28, P1056, DOI 10.1097/00005650-199011000-00007; PUGH JA, 1989, ARCH INTERN MED, V149, P426, DOI 10.1001/archinte.149.2.426; Robinson S, 1997, JOINT COMM J QUAL IM, V23, P239, DOI 10.1016/S1070-3241(16)30313-3; SCHECTMAN JM, 1991, ARCH INTERN MED, V151, P2163, DOI 10.1001/archinte.151.11.2163; SCHECTMAN JM, 1995, MED CARE, V33, P139; SCOTT WR, 1982, HEALTH SERV RES, V17, P213; SIU AL, 1991, HEALTH AFFAIR, V10, P62, DOI 10.1377/hlthaff.10.1.62; SPIEGEL JS, 1989, ARCH INTERN MED, V149, P549, DOI 10.1001/archinte.149.3.549; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; YORDY KD, 1988, HEALTH AFFAIR, V7, P5, DOI 10.1377/hlthaff.7.1.5; ZISKIND AA, 1994, AM J CARDIOL, V73, P1219, DOI 10.1016/0002-9149(94)90187-2	61	289	294	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1608	1612		10.1001/jama.278.19.1608	http://dx.doi.org/10.1001/jama.278.19.1608			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YF407	9370508				2022-12-28	WOS:A1997YF40700043
J	Epstein, AM				Epstein, AM			Medicaid managed care and high quality - Can we have both?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RISK ADJUSTMENT; HEALTH REFORM; LESSONS; CALIFORNIA; SYSTEM		BRIGHAM & WOMENS HOSP, DIV GEN MED, SECT HLTH SERV & POLICY RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Epstein, AM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.							EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; FELTLISK S, 1997, QUALITY ASSURANCE RE; FOSSETT JW, 1989, MED CARE, V27, P386, DOI 10.1097/00005650-198904000-00006; FREUND DA, 1995, ANNU REV PUBL HEALTH, V16, P473; *GEN ACC OFF, 1994, REP CARDS US CONC SI; *GEN ACC OFF, 1996, HEHS96184 GEN ACC OF; Gold M, 1995, Health Care Financ Rev, V16, P85; Gold M, 1996, HEALTH AFFAIR, V15, P153, DOI 10.1377/hlthaff.15.3.153; Henderson T, 1996, HEALTH CARE FINANC R, V17, P135; HORVATH J, 1997, MED MANAGED CARE GUI, V1; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; JOST TS, 1994, JAMA-J AM MED ASSOC, V271, P1508, DOI 10.1001/jama.271.19.1508; *KAIS FAM FDN AG H, 1996, AM HLTH CAR CONS ROL; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; KRONICK R, 1995, INQUIRY-J HEALTH CAR, V32, P41; Kronick R, 1996, HEALTH CARE FINANC R, V17, P7; LANDON BE, IN PRESS J AMA; LISKA D, 1997, MED OVERVIEW COMPL A, P1; *MATH POL RES INC, 1995, EXP COLL SEL HEDIS 2; MCNEIL BJ, 1993, INQUIRY, V329, P1263; *NAT AC STAT HLTH, 1995, REP HLTH CAR FIN ADM; PEAR R, 1995, NY TIMES        0424, pA12; Perloff JD, 1997, MED CARE, V35, P142, DOI 10.1097/00005650-199702000-00005; Rosenbaum S., 1997, NEGOTIATING NEW HLTH; ROWLAND D, 1994, AM J PUBLIC HEALTH, V84, P550, DOI 10.2105/AJPH.84.4.550; Rowland D, 1996, B NEW YORK ACAD MED, V73, P496; RROWLAND D, 1996, HLTH AFF MILLWOOD, V15, P150; SHORT PF, 1998, INQUIRY, V25, P504; SLOAN FA, 1978, PRIVATE PHYSICIANS P; Sparer MS, 1996, J HEALTH POLIT POLIC, V21, P433, DOI 10.1215/03616878-21-3-433; *US DEP HHS, 1996, 1996 MED MAN CAR ENR; Yokoi B, 1996, HEALTH AFFAIR, V15, P178, DOI 10.1377/hlthaff.15.3.178	33	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1617	1621		10.1001/jama.278.19.1617	http://dx.doi.org/10.1001/jama.278.19.1617			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YF407	9370510				2022-12-28	WOS:A1997YF40700047
J	Schriger, DL; Baraff, LJ; Rogers, WH; Cretin, S				Schriger, DL; Baraff, LJ; Rogers, WH; Cretin, S			Implementation of clinical guidelines using a computer charting system - Effect on the initial care of health care workers exposed to body fluids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY; PERFORMANCE; EMERGENCY; POLICIES; DELIVERY; AUDIT	Context.-While clinical guidelines are considered an important mechanism to improve the quality of medical care, problems with implementation may limit their effectiveness, Few empirical data exist about the effect of computer-based systems for application of clinical guidelines on quality of care. Objective.-To determine whether real-time presentation of clinical guidelines using an electronic medical record can increase compliance with guidelines. Design.-Prospective off-on-off, interrupted time series with intent-to-treat analysis. Setting.-University hospital emergency department. Subjects.-Patients were 280 health care workers (50 in the baseline control phase, 156 in the intervention phase, and 74 in the postintervention control phase) who presented for initial treatment of occupational body fluid exposures, including 89% (248/280) who sustained punctures and 81% (208/257) who were exposed to blood. Physicians included resident physicians and attending physicians working in the emergency department during the study. Interventions.-Implementation of a computer charting system that provides real-time information regarding history and recommendations for laboratory testing, treatment, and disposition based on rules derived from clinical guidelines. Main Outcome Measures.-Quality of care as determined by essential items documented in the medical record and in aftercare instructions, compliance with testing and treatment guidelines, and total charges and percentage of charges attributable to guideline-endorsed activities. Results.-Mean percent documentation of 7 essential items regarding patient history in the medical record increased from 57% during the baseline period to 98% in the intervention phase (42% increase; 95% confidence interval [CI], 34%-49%) and 11 items in aftercare instruction increased from 31% at baseline to 93% during the intervention phase (62% increase; 95% CI, 51%-74%), but both decreased to baseline when the computer system was removed. Percent compliance with 4 laboratory testing guidelines increased from 63% at baseline to 83% during the intervention phase (20% increase; 95% CI, 9%-31%) but decreased to 52% when the computer system was removed, Compliance with 5 treatment guidelines increased from 83% at baseline to 96% during the intervention phase (13% increase; 95% CI, 9%-17%) and decreased to 84% following the intervention. Percentage of charges incurred for indicated laboratory tests and treatment increased from 44% at baseline to 81% during the intervention phase (37% increase; 95% CI, 22%-52%) and decreased to 36% following the intervention. Average total per-patient charges were $460, $384, and $373 in each phase, respectively. Conclusions.-Use of a computer-based system for clinical guidelines for management of patients with occupational exposure to body fluids improved documentation, compliance with guidelines, and percentage of charges spent on indicated activities, while decreasing overall charges. The parameters returned to baseline when the computer system was removed.	TUFTS UNIV NEW ENGLAND MED CTR, HLTH INST, BOSTON, MA 02111 USA; SHAN CRETIN & ASSOCIATES, SANTA MONICA, CA USA	Tufts Medical Center	Schriger, DL (corresponding author), UNIV CALIF LOS ANGELES, MED CTR, CTR EMERGENCY MED, 924 WESTWOOD BLVD, SUITE 300, LOS ANGELES, CA 90024 USA.			Schriger, David/0000-0003-0242-1127	AHRQ HHS [R18HS06284] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AG HLTH CAR POL R, 1997, GUID MED OUTC; Balas EA, 1996, J AM MED INFORM ASSN, V3, P56, DOI 10.1136/jamia.1996.96342649; BARAFF LJ, 1990, ANN EMERG MED, V19, P45; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P877; EDDY DM, 1994, METHODOLOGY PERSPECT, P5; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; GLASZIOU PP, 1994, MED DECIS MAKING, V14, P207; GO GW, 1991, ANN EMERG MED, V20, P1341, DOI 10.1016/S0196-0644(05)81078-9; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HOLBROOK J, 1990, ANN EMERG MED, V19, P139, DOI 10.1016/S0196-0644(05)81798-6; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1993, ANN NY ACAD SCI, V703, P226, DOI 10.1111/j.1749-6632.1993.tb26351.x; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; RICEJ A, 1995, MATH STAT DATA ANAL, P153; Schriger D. L., 1989, Proceedings: The Thirteenth Annual Symposium on Computer Applications in Medical Care (Cat. No.89TH0286-5), P611; Schriger DL, 1996, ANN EMERG MED, V27, P655; SHIFFMAN RN, 1994, MED DECIS MAKING, V14, P245, DOI 10.1177/0272989X9401400306; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; *STAT, 1997, STAT REF MAN REL 5, pU235; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TOEPP MC, 1996, DIRECTORY PRACTICE P; *US C, 1994, H608 OTA US C, V198; *US C, 1994, OTAH608 US C, P177; WEARS RL, 1994, ACAD EMERG MED, V1, pA35; Woolf SH, 1994, METHODOLOGY PERSPECT, P105; 1996, MMWR-MORBID MORTAL W, V45, P468	31	106	105	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1585	1590		10.1001/jama.278.19.1585	http://dx.doi.org/10.1001/jama.278.19.1585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF407	9370504				2022-12-28	WOS:A1997YF40700039
J	Han, PKJ				Han, PKJ			Historical changes in the objectives of the periodic health examination	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL-EXAMINATION; MEDICAL-CARE; MAINTENANCE; PREVENTION; DISEASES; TESTS	Important historical changes have occurred both in the content of the periodic health examination and in the legitimacy with which this examination has been viewed. These changes reflect fundamental shifts in the objectives of the examination and in the concerns of its advocates, the most prominent of whom have been physicians; leaders in the life insurance, private corporate, and prepaid health care industries; and medical expert panels. The shifting dominance of concerns has driven the development of the periodic health examination, and continual reassessment of the value and limitations of the examination is warranted.			Han, PKJ (corresponding author), UNIV PITTSBURGH, MONTEFIORE HOSP,MED CTR,DIV GEN INTERNAL MED, SUITE W933, 200 LOTHROP ST, PITTSBURGH, PA 15213 USA.			Han, Paul/0000-0003-0165-1940				ANDERSON OW, 1960, HLTH INFORMATION FDN, V12, P17; [Anonymous], 1986, CAN MED ASSOC J, V134, P724; [Anonymous], 1981, Ann Intern Med, V95, P729; [Anonymous], 1977, Int J Epidemiol, V6, P357; BATTISTA RN, 1984, CAN MED ASSOC J, V130, P1288; Boland BJ, 1996, AM J MED, V101, P142, DOI 10.1016/S0002-9343(96)80068-4; BOLAND BJ, 1995, AM J MED SCI, V309, P194, DOI 10.1097/00000441-199504000-00002; BRESLOW L, 1973, Preventive Medicine, V2, P177, DOI 10.1016/0091-7435(73)90063-7; BRESLOW L, 1977, NEW ENGL J MED, V296, P601, DOI 10.1056/NEJM197703172961104; BRUHN JG, 1978, SOUTHERN MED J, V71, P1469, DOI 10.1097/00007611-197812000-00008; *CAN TASK FORC PER, 1984, CAN MED ASSOC J, V130, P1278; CARNEY PA, 1993, ANN INTERN MED, V119, P129, DOI 10.7326/0003-4819-119-2-199307150-00007; CARRYER HM, 1957, AMA ARCH IND HLTH, V16, P276; CHARAP MH, 1981, ANN INTERN MED, V95, P733, DOI 10.7326/0003-4819-95-6-733; CLARK TW, 1961, ANN INTERN MED, V54, P1209, DOI 10.7326/0003-4819-54-6-1209; Collen M F, 1976, Prim Care, V3, P197; Collen M F, 1973, Prev Med, V2, P175, DOI 10.1016/0091-7435(73)90062-5; Collen M F, 1967, Hospitals, V41, P119; COLLEN MF, 1974, CONTROVERSY INTERNAL, V2, P85; *COUNC IND HLTH AM, 1956, JAMA-J AM MED ASSOC, V161, P975; Croft BP, 1916, BOSTON MED SURG J, V175, P251; CRONIN HJ, 1916, JAMA-J AM MED ASSOC, P1374; CUTLER J L, 1973, Preventive Medicine, V2, P197, DOI 10.1016/0091-7435(73)90064-9; DALES L G, 1973, Preventive Medicine, V2, P221, DOI 10.1016/0091-7435(73)90066-2; DAVID WD, 1961, ARCH ENVIRON HEALTH, V2, P339; DAVIS AB, 1981, B HIST MED, V55, P392; DELBANCO TL, 1980, ANN INTERN MED, V92, P251, DOI 10.7326/0003-4819-92-2-251; DELBANCO TL, 1975, ANN INTERN MED, V83, P271, DOI 10.7326/0003-4819-83-2-271; DOBELL H, 1861, LECT GERMS VESTIGES, P142; Dodson JM, 1925, AM J PUBLIC HEALTH, V15, P599, DOI 10.2105/AJPH.15.7.599; DUFFY J, 1992, SANITARIANS HIST PUB; Edie EB, 1925, AM J PUBLIC HEALTH, V15, P602, DOI 10.2105/AJPH.15.7.602; ELSOM KA, 1960, JAMA-J AM MED ASSOC, V172, P5, DOI 10.1001/jama.1960.03020010062003; Emerson H, 1923, J AMER MED ASSOC, V80, P1376, DOI 10.1001/jama.1923.26430460003011; Fisk EC, 1927, MAKE PERIODIC HLTH E; Fisk EL, 1926, BOSTON MED SURG J, V195, P740, DOI 10.1056/NEJM192610141951602; FISK EL, 1921, NATIONS HLTH, V3, P286; FISK EL, 1925, LONG ISLAND MED J, V19, P353; FISK EL, 1918, JAMA-J AM MED ASSOC, P300; FISK EL, 1918, JAMA-J AM MED ASSOC, P558; FITZGERALD FT, 1990, WESTERN J MED, V152, P377; FLETCHER SW, 1980, ANN INTERN MED, V92, P253, DOI 10.7326/0003-4819-92-2-253; Frame P S, 1975, J Fam Pract, V2, P189; Frame P S, 1975, J Fam Pract, V2, P123; Frame P S, 1975, J Fam Pract, V2, P29; FRAME PS, 1986, J FAM PRACTICE, V22, P341; FRAME PS, 1986, J FAM PRACTICE, V22, P511; FRAME PS, 1986, J FAM PRACTICE, V22, P417; FRAME PS, 1986, J FAM PRACTICE, V23, P29; FREMONTSMITH M, 1953, NEW ENGL J MED, V248, P170, DOI 10.1056/NEJM195301292480502; FRIEDMAN GD, 1986, J CHRON DIS, V39, P453, DOI 10.1016/0021-9681(86)90112-8; GARFIELD SR, 1970, NEW ENGL J MED, V283, P1087, DOI 10.1056/NEJM197011122832006; GARFIELD SR, 1976, NEW ENGL J MED, V294, P426, DOI 10.1056/NEJM197602192940806; GETTING VA, 1952, NEW ENGL J MED, V247, P460, DOI 10.1056/NEJM195209252471302; GOULD GM, 1900, JAMA-J AM MED ASSOC, P134; GRANTHAM P, 1983, CAN MED ASSOC J, V128, P271; JONES RJ, 1983, JAMA-J AM MED ASSOC, V249, P1626; Knight A, 1921, P ASS LIFE INSURANCE, V8, P25; KNOX EG, 1974, LANCET, V2, P1434; KRAVITZ RL, 1994, J GEN INTERN MED, V9, P75, DOI 10.1007/BF02600205; KUH C, 1945, PERMANENTE FDN MED B, V3, P12; LAWRENCE RS, 1987, JAMA-J AM MED ASSOC, V257, P2205, DOI 10.1001/jama.257.16.2205; LEE RI, 1923, BOSTON MED SURG J, V188, P929; LEVIN ML, 1952, NEW YORK STATE J MED, V52, P2600; MCGINNIS J M, 1990, Journal of General Internal Medicine, V5, pS11, DOI 10.1007/BF02600832; MORHOUS EJ, 1957, ANN INTERN MED, V46, P744, DOI 10.7326/0003-4819-46-4-744; Murray HG, 1928, J AMER MED ASSOC, V91, P627, DOI 10.1001/jama.1928.02700090021005; OBOLER SK, 1989, ANN INTERN MED, V110, P214, DOI 10.7326/0003-4819-110-3-214; OLSEN DM, 1976, NEW ENGL J MED, V294, P925, DOI 10.1056/NEJM197604222941705; REISER SJ, 1978, MILBANK FUND Q, V56, P403, DOI 10.2307/3349571; REN AG, 1994, J EPIDEMIOL COMMUN H, V48, P476, DOI 10.1136/jech.48.5.476; ROBERTS N J, 1964, Ann Intern Med, V61, P997; Rosen G, 1975, PREVENTIVE MED US 19; Rowntree LG, 1944, J AMER MED ASSOC, V125, P821, DOI 10.1001/jama.1944.02850300001001; SANAZARO PJ, 1971, DEFINITION CONCEPT H, V45, P41; SCHOR SS, 1964, ANN INTERN MED, V61, P999, DOI 10.7326/0003-4819-61-6-999; SHILLITO FH, 1953, ANN INTERN MED, V39, P7, DOI 10.7326/0003-4819-39-1-7; SIEGEL GS, 1966, ARCH ENVIRON HEALTH, V13, P292, DOI 10.1080/00039896.1966.10664561; SIEGEL GS, 1963, PUBLIC HLTH SERVICE, V1010; SMILLIE WG, 1951, JAMA-J AM MED ASSOC, V145, P1254, DOI 10.1001/jama.1951.02920340032010; SPARK R, 1996, NEW YORK TIMES  0725, P38; SPITZER WO, 1984, CAN MED ASSOC J, V130, P1276; THORNER RM, 1969, NEW ENGL J MED, V280, P1037, DOI 10.1056/NEJM196905082801904; TOBEY JA, 1923, NATIONS HLTH, V5, P648; TOBEY JA, 1923, NATIONS HLTH, V5, P610; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; 1979, CAN MED ASS J, V121, P1193; 1906, BRIT MED J, V1, P878; 1921, STAT B METROPOLITAN, V3, P1	90	56	58	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					910	917		10.7326/0003-4819-127-10-199711150-00010	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382370				2022-12-28	WOS:A1997YF54500008
J	Rameh, LE; Tolias, KF; Duckworth, BC; Cantley, LC				Rameh, LE; Tolias, KF; Duckworth, BC; Cantley, LC			A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate	NATURE			English	Article							PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE; POLYPHOSPHOINOSITIDES; 3,4-BISPHOSPHATE; PHOSPHORYLATION; 3-MONOPHOSPHATE; PURIFICATION; SEQUENCE; 4-KINASE; KINASES; CLONING	Phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P-2), a key molecule in the phosphoinositide signalling-pathway, was thought to be synthesized exclusively by phosphorylation of PtdIns-4-P at the D-5 position of the inositol ring. The enzymes that produce PtdIns-4,5-P-2 in vitro fall into two related subfamilies (type I and type II PtdInsP-5-OH kinases, or PIP(5)Ks) based on their enzymatic properties and sequence similarities(1). Here we have reinvestigated the substrate specificities of these enzymes. As expected, the type I enzyme phosphorylates PtdIns-4-P at the D- 5 position of the inositol ring. Surprisingly, the type II enzyme, which is abundant in some tissues, phosphorylates PtdIns-5-P at the D-4 position, and thus should be considered as a 4-OH kinase, or PIP(4)K. The earlier error in characterizing the activity of the type II enzyme is due to the presence of contaminating PtdIns-5-P in commercial preparations of PtdIns-4-P. Although PtdIns-5-P was previously thought not to exist in vivo, we find evidence for the presence of this lipid in mammalian fibroblasts, establishing a new pathway for PtdIns-4,5-P-2 synthesis.	BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center	Rameh, LE (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Tolias, Kimberley/0000-0002-2092-920X				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; LING LE, 1989, J BIOL CHEM, V264, P5080; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; MEYERS R, 1997, J BIOL CHEM, V272, P4385; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; YAMAMOTO K, 1990, BIOCHEM BIOPH RES CO, V168, P466, DOI 10.1016/0006-291X(90)92344-Y; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	18	343	357	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	1997	390	6656					192	196		10.1038/36621	http://dx.doi.org/10.1038/36621			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367159				2022-12-28	WOS:A1997YF49400059
J	Ibba, M; Morgan, S; Curnow, AW; Pridmore, DR; Vothknecht, UC; Gardner, W; Lin, W; Woese, CR; Soll, D				Ibba, M; Morgan, S; Curnow, AW; Pridmore, DR; Vothknecht, UC; Gardner, W; Lin, W; Woese, CR; Soll, D			A euryarchaeal Lysyl-tRNA synthetase: Resemblance to class I synthetases	SCIENCE			English	Article							TRANSFER-RNA SYNTHETASE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; SEQUENCE; RECOGNITION; GENE; ARCHAEA; GENOME	The sequencing of euryarchaeal genomes has suggested that the essential protein lysyl-transfer RNA (tRNA) synthetase (LysRS) is absent from such organisms. However, a single 62-kilodalton protein with canonical LysRS activity was purified from Methanococcus maripaludis, and the gene that encodes this protein was cloned, The predicted amino acid sequence of M. maripaludis LysRS is similar to open reading frames of unassigned function in both Methanobacterium thermoautotrophicum and Methanococcus jannaschii but is unrelated to canonical LysRS proteins reported in eubacteria, eukaryotes, and the crenarchaeote Sulfolobus solfataricus. The presence of amino acid motifs characteristic of the Rossmann dinucleotide-binding domain identifies M. maripaludis LysRS as a class I aminoacyl-tRNA synthetase, in contrast to the known examples of this enzyme, which are class II synthetases, These data question the concept that the classification of aminoacyl-tRNA synthetases does not vary throughout living systems.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT MOL CELLULAR & DEV BIOL,NEW HAVEN,CT 06511; HAMILTON COLL,DEPT BIOL,CLINTON,NY 13323; NESTLE RES CTR,CH-1000 LAUSANNE,SWITZERLAND; UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602	Yale University; Yale University; Hamilton College; Nestle SA; University System of Georgia; University of Georgia			Vothknecht, Ute C/F-4678-2014	Vothknecht, Ute C/0000-0002-8930-0127				Agou F, 1996, BIOCHEMISTRY-US, V35, P15322, DOI 10.1021/bi9617926; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bjork Glenn R., 1995, P165; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN JS, 1994, J BACTERIOL, V176, P2699, DOI 10.1128/JB.176.9.2699-2705.1994; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FREIST W, 1995, BIOL CHEM H-S, V376, P451; Grayling RA, 1996, FEMS MICROBIOL REV, V18, P203; Hong KW, 1996, EMBO J, V15, P1983, DOI 10.1002/j.1460-2075.1996.tb00549.x; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; NAGEL GM, 1995, J MOL EVOL, V40, P487; Neher R., 1963, J CHROMATOGR, V12, P329; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; Ouzounis CA, 1996, J MOL EVOL, V42, P234, DOI 10.1007/BF02198849; Sensen CW, 1996, MOL MICROBIOL, V22, P175, DOI 10.1111/j.1365-2958.1996.tb02666.x; SMITH D, IN PRESS J BACTERIOL; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWANSON R, COMMUNICATION; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WATANABE K, 1994, NUCLEIC ACIDS RES, V22, P79, DOI 10.1093/nar/22.1.79; Watanabe Kimitsuna, 1995, P225	27	178	184	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1119	1122		10.1126/science.278.5340.1119	http://dx.doi.org/10.1126/science.278.5340.1119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353192				2022-12-28	WOS:A1997YE65200051
J	Eriksson, BI; WilleJorgensen, P; Kalebo, P; Mouret, P; Rosencher, N; Bosch, P; Baur, M; Ekman, S; Bach, D; Lindbratt, S; Close, P				Eriksson, BI; WilleJorgensen, P; Kalebo, P; Mouret, P; Rosencher, N; Bosch, P; Baur, M; Ekman, S; Bach, D; Lindbratt, S; Close, P			A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; VENOUS THROMBOSIS; PULMONARY-EMBOLISM; PROPHYLAXIS; INHIBITION; SURGERY	Background Patients who undergo total hip replacement have a high risk of thromboembolic complications. Recombinant hirudin (desirudin), a specific inhibitor of thrombin, represents a new development in antithrombotic therapy. We compared the efficacy and safety of desirudin with those of a low-molecular-weight heparin (enoxaparin) for the prevention of thromboembolic complications in patients undergoing primary total hip replacement. Methods Both treatments, which were assigned in a randomized, double-blind manner, were started preoperatively: enoxaparin on the evening before surgery, and desirudin within 30 minutes before the start of surgery. The dose of desirudin was 15 mg subcutaneously twice daily, and the dose of enoxaparin was 40 mg subcutaneously once daily. The duration of treatment was 8 to 12 days. Deep-vein thrombosis was verified by bilateral venography performed at the end of the treatment period or earlier, if there were clinical signs of deep-vein thrombosis. Results At 31 centers in 10 European countries, 2079 eligible patients were randomly assigned to receive desirudin or enoxaparin. A total of 1587 patients were included in the primary analysis of efficacy. In the desirudin group, as compared with the enoxaparin group, there was a significantly lower rate of proximal deep-vein thrombosis (4.5 vs. 7.5 percent, P = 0.01; relative reduction in risk, 40.3 percent) and a lower overall rate of deep-vein thrombosis (18.4 vs. 25.5 percent, P = 0.001; relative reduction in risk, 28.0 percent). The safety profiles were similar in the two treatment groups. Conclusions When administered 30 minutes before total hip replacement, desirudin is more effective than enoxaparin in preventing deep-vein thrombosis. (C) 1997, Massachusetts Medical Society.	SAHLGRENSKA OSTRA UNIV HOSP,DEPT RADIOL,S-41685 GOTHENBURG,SWEDEN; BISPEBJERG HOSP,CTR CLIN THROMBOSIS RES,DK-2400 COPENHAGEN,DENMARK; UNIV FRANKFURT,STADT KLIN,ORTHOPAD KLIN,D-6000 FRANKFURT,GERMANY; HOP COCHIN,DEPT ANESTHESIE REANIMAT,F-75674 PARIS,FRANCE; KRANKENHAUS,DEPT ORTHOPED SURG,WIENER NEUSTADT,AUSTRIA; NOVARTIS,BASEL,SWITZERLAND; NOVARTIS,STOCKHOLM,SWEDEN	Sahlgrenska University Hospital; University of Copenhagen; Bispebjerg Hospital; Goethe University Frankfurt; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Novartis	Eriksson, BI (corresponding author), SAHLGRENSKA OSTRA UNIV HOSP,DEPT ORTHOPED,S-41685 GOTHENBURG,SWEDEN.		Rosencher, Nadia/AAS-3888-2020	Eriksson, Bengt/0000-0001-6894-7434				BIELLO DR, 1979, AM J ROENTGENOL, V133, P1033, DOI 10.2214/ajr.133.6.1033; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COLWELL CW, 1995, CLIN ORTHOPAEDICS, V319, P215; Eriksson BI, 1997, J BONE JOINT SURG AM, V79A, P326, DOI 10.2106/00004623-199703000-00002; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; Eriksson BI, 1996, LANCET, V347, P635, DOI 10.1016/S0140-6736(96)91200-3; Havig O, 1977, Acta Chir Scand Suppl, V478, P1; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; JORGENSEN LN, 1993, BRIT J SURG, V80, P689, DOI 10.1002/bjs.1800800607; KAISER B, 1986, THROMB RES, V43, P613, DOI 10.1016/0049-3848(86)90098-8; Kalebo P, 1997, ACTA RADIOL, V38, P320, DOI 10.3109/02841859709172072; Kalebo P, 1996, THROMB HAEMOSTASIS, V76, P893; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; NICOLAIDES AN, 1992, INT ANGIOL, V11, P151; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; TALBOT MD, 1990, INT S APP C, V1, P131; *THROMB RISK FACT, 1992, BRIT MED J, V305, P567; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; 1994, GOOD CLIN PRACT J S, V1	23	324	331	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1329	1335		10.1056/NEJM199711063371901	http://dx.doi.org/10.1056/NEJM199711063371901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358126				2022-12-28	WOS:A1997YE44600001
J	Stopfer, M; Bhagavan, S; Smith, BH; Laurent, G				Stopfer, M; Bhagavan, S; Smith, BH; Laurent, G			Impaired odour discrimination on desynchronization of odour-encoding neural assemblies	NATURE			English	Article							APIS-MELLIFERA; OLFACTORY NETWORK; OSCILLATIONS; HONEYBEE; CORTEX; ODORS; BULB	Stimulus-evoked oscillatory synchronization of neural assemblies has been described in the olfactory(1-5) and visual(6-8) systems of several vertebrates and invertebrates. In locusts, information about odour identity is contained in the timing of action potentials in an oscillatory population response(9-11), suggesting that oscillations may reflect a common reference far messages encoded in time, Although the stimulus-evoked oscillatory phenomenon is reliable, its roles in sensation, perception, memory formation and pattern recognition remain to be demonstrated-a task requiring a behavioural paradigm, Using honeybees, we now demonstrate that odour encoding involves, as it does in locusts, the oscillatory synchronization of assemblies of projection neurons and that this synchronization is also selectively abolished by picrotoxin, an antagonist of the GABA(A) (gamma-aminobutyric acid) receptor. By using a behavioural leaning paradigm, we show that picrotoxin-induced desynchronization impairs the discrimination of molecularly similar odorants, but not that of dissimilar odorants, It appears, therefore, that oscillatory synchronization of neuronal assemblies is functionally relevant, and essential for fine sensory discrimination This suggests that oscillatory synchronization and the kind of temporal encoding it affords provide an additional dimension by which the brain could segment spatially overlapping stimulus representations.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; OHIO STATE UNIV, DEPT ENTOMOL, COLUMBUS, OH 43210 USA	California Institute of Technology; University System of Ohio; Ohio State University			Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Stopfer, Mark/0000-0001-9200-1884				Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; Bhagavan S, 1997, PHYSIOL BEHAV, V61, P107, DOI 10.1016/S0031-9384(96)00357-5; BITTERMAN ME, 1983, J COMP PSYCHOL, V97, P107, DOI 10.1037/0735-7036.97.2.107; DELANEY KR, 1994, P NATL ACAD SCI USA, V91, P669, DOI 10.1073/pnas.91.2.669; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1988, EXP BRAIN RES, V69, P378; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; Joerges J, 1997, NATURE, V387, P285, DOI 10.1038/387285a0; Kuwabara M., 1957, Journal of the Faculty of Science Hokkaido University Zoology, V13, P458; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; Laurent G, 1996, TRENDS NEUROSCI, V19, P489, DOI 10.1016/S0166-2236(96)10054-0; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MACMILLAN CS, 1987, J COMP PHYSIOL A, V160, P359, DOI 10.1007/BF00613025; MAUELSHAGEN J, 1993, J NEUROPHYSIOL, V69, P609, DOI 10.1152/jn.1993.69.2.609; Menzel R., 1983, P206; MENZEL R, 1988, NATO ASI SERIES H, V19, P335; Menzel R., 1990, NEUROBIOLOGY COMP CO, P237; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NEUENSCHWANDER S, 1993, EUR J NEUROSCI, V5, P870, DOI 10.1111/j.1460-9568.1993.tb00939.x; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Smith BH, 1997, BEHAV NEUROSCI, V111, P57; SMITH BH, 1989, J INSECT PHYSIOL, V35, P369, DOI 10.1016/0022-1910(89)90110-8; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; YOKOI M, 1995, P NATL ACAD SCI USA, V92, P3371, DOI 10.1073/pnas.92.8.3371	26	692	703	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					70	74		10.1038/36335	http://dx.doi.org/10.1038/36335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363891				2022-12-28	WOS:A1997YE47700053
J	Angst, J				Angst, J			Fortnightly review - A regular review of the long term follow up of depression	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RECURRENT DEPRESSION; MAJOR DEPRESSION; ELECTROCONVULSIVE-THERAPY; MAINTENANCE THERAPIES; MEDICAL OUTCOMES; GENERAL HEALTH; DISORDERS; CARE; COMORBIDITY; DYSTHYMIA				Angst, J (corresponding author), UNIV ZURICH, HOSP PSYCHIAT, POSTFACH 68, CH-8029 ZURICH 8, SWITZERLAND.							Angst J, 1995, Schweiz Arch Neurol Psychiatr (1985), V146, P5; ANGST J, 1988, DEPRESSIVE ILLNESS P, P1; [Anonymous], 1989, J AFFECT DISORDERS, V17, P197; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; CASSANO GB, 1988, PHARMACOPSYCHIATRY, V21, P19, DOI 10.1055/s-2007-1014640; CORYELL W, 1990, AM J PSYCHIAT, V147, P1627; EZION T, 1990, ISR J PSYCHIATR REL, V27, P168; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; Haghighat R, 1996, J AFFECT DISORDERS, V41, P141, DOI 10.1016/S0165-0327(96)00082-1; HOWLAND RH, 1993, INT J PSYCHIAT MED, V23, P211, DOI 10.2190/AXCU-P704-23XQ-CQTR; KELLER MB, 1982, JAMA-J AM MED ASSOC, V248, P1848, DOI 10.1001/jama.248.15.1848; KELLER MB, 1986, ARCH GEN PSYCHIAT, V43, P458; KELLER MB, 1982, AM J PSYCHIAT, V139, P438; KELLER MB, 1983, AM J PSYCHIAT, V140, P689; KELLER MB, 1988, PSYCHOPHARMACOL BULL, V24, P75; KELLER MB, 1992, ARCH GEN PSYCHIAT, V49, P809; Kivela S L, 1995, Int Psychogeriatr, V7 Suppl, P69; Kocsis JH, 1996, ARCH GEN PSYCHIAT, V53, P769; KRAMER BA, 1987, CONVULSIVE THER, V3, P260; KUPFER DJ, 1992, ARCH GEN PSYCHIAT, V49, P769; KUPFER DJ, 1993, J CLIN PSYCHIAT, V54, P29; Leader JB, 1996, J AFFECT DISORDERS, V37, P91, DOI 10.1016/0165-0327(95)00076-3; LECRUBIER Y, 1993, EUR PSYCHIAT, V8, P13; LEPINE JP, 1997, PRIMARY CARE PSYC S1, V3, pS3; Marneros A., 1991, AFFEKTIVE SCHIZOAFFE; Montgomery S A, 1989, J Psychopharmacol, V3, P47, DOI 10.1177/026988118900300201; MONTGOMERY SA, 1988, BRIT J PSYCHIAT, V153, P69; MONTGOMERY SA, 1992, LONG TERM TREATMENT, V3, P53; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; PICCINELLI M, 1994, BRIT J PSYCHIAT, V164, P297, DOI 10.1192/bjp.164.3.297; PRIEN RF, 1990, J CLIN PSYCHOPHAR S3, V10, P865; Reynolds C F 3rd, 1995, Int Psychogeriatr, V7 Suppl, P27, DOI 10.1017/S104161029500233X; SCOTT AIF, 1992, BRIT MED J, V304, P883, DOI 10.1136/bmj.304.6831.883; SCOTT J, 1988, BRIT J PSYCHIAT, V153, P287, DOI 10.1192/bjp.153.3.287; SOLOMON DA, 1993, PSYCHIAT CLIN N AM, V16, P515; STIEBEL VG, 1995, PSYCHIATR SERV, V46, P265; THASE M E, 1990, Journal of Clinical Psychiatry, V51, P51; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WELLS KB, 1992, ARCH GEN PSYCHIAT, V49, P788	40	35	35	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 1	1997	315	7116					1143	1146						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YE615	9374891				2022-12-28	WOS:A1997YE61500031
J	Dickerson, RR; Kondragunta, S; Stenchikov, G; Civerolo, KL; Doddridge, BG; Holben, BN				Dickerson, RR; Kondragunta, S; Stenchikov, G; Civerolo, KL; Doddridge, BG; Holben, BN			The impact of aerosols on solar ultraviolet radiation and photochemical smog	SCIENCE			English	Article							NITROGEN-DIOXIDE PHOTOLYSIS; SKY BRIGHTNESS MEASUREMENTS; EASTERN-UNITED-STATES; AIR-POLLUTION; ACTINIC FLUX; ATMOSPHERE; OZONE; TROPOSPHERE; SCATTERING; CLOUDS	Photochemical smog, or ground-level ozone, has been the most recalcitrant of air pollution problems, but reductions in emissions of sulfur and hydrocarbons may yield unanticipated benefits in air quality. While sulfate and some organic aerosol particles scatter solar radiation back into space and can cool Earth's surface, they also change the actinic flux of ultraviolet (UV) radiation. Observations and numerical models show that UV-scattering particles in the boundary layer accelerate photochemical reactions and smog production, but UV-absorbing aerosols such as mineral dust and soot inhibit smog production. Results could have major implications for the control of air pollution.	NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20742	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Dickerson, RR (corresponding author), UNIV MARYLAND,DEPT METEOROL,COLLEGE PK,MD 20742, USA.		Dickerson, Russell R/F-2857-2010; Kondragunta, Shobha/F-5601-2010; Dickerson, Russell/ABB-1512-2020; Georgiy, Stenchikov/J-8569-2013; Stenchikov, Georgiy/AAA-4371-2022	Dickerson, Russell R/0000-0003-0206-3083; Kondragunta, Shobha/0000-0001-8593-8046; Dickerson, Russell/0000-0003-0206-3083; Stenchikov, Georgiy Lvovich/0000-0001-9033-4925				Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; BLACKBURN TE, 1992, J GEOPHYS RES-ATMOS, V97, P10109, DOI 10.1029/92JD00504; Blindauer C, 1996, J ATMOS CHEM, V24, P1, DOI 10.1007/BF00053820; BRUEHL C, 1989, GEOPHYS RES LETT, V16, P703; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; CIVEROLO KL, 1996, THESIS U MARYLAND CO; DENTENER FJ, 1993, J GEOPHYS RES-ATMOS, V98, P7149, DOI 10.1029/92JD02979; DICKERSON RR, 1982, J GEOPHYS RES-OCEANS, V87, P4933, DOI 10.1029/JC087iC07p04933; FinlaysonPitts BJ, 1997, SCIENCE, V276, P1045, DOI 10.1126/science.276.5315.1045; Flowers EC, 1969, J APPL METEOROL, V8, P955, DOI [10.1175/1520-0450(1969)0082.0.CO;2, DOI 10.1175/1520-0450(1969)0082.0.CO;2]; FRASER RS, 1985, IEEE J GEOSCI REM GE, V23, P525; Hauglustaine DA, 1996, GEOPHYS RES LETT, V23, P2609, DOI 10.1029/96GL02474; Herman JR, 1997, J GEOPHYS RES-ATMOS, V102, P16911, DOI 10.1029/96JD03680; HOLBEN BN, 1997, 6 INT S PHYS MEAS SI, P75; HUSAR RB, 1981, ATMOS ENVIRON, V15, P1919, DOI 10.1016/0004-6981(81)90226-2; HUSAR RB, 1993, ENVIRON SCI TECHNOL, V27, P12, DOI 10.1021/es00038a001; KAUFMAN YJ, 1986, J ATMOS SCI, V43, P1135, DOI 10.1175/1520-0469(1986)043<1135:FEFMOT>2.0.CO;2; KAUFMAN YJ, 1983, J CLIM APPL METEOROL, V22, P1694, DOI 10.1175/1520-0450(1983)022<1694:LEBADS>2.0.CO;2; KAUFMAN YJ, 1994, J GEOPHYS RES-ATMOS, V99, P10341, DOI 10.1029/94JD00229; KELLEY P, 1995, GEOPHYS RES LETT, V22, P2621, DOI 10.1029/95GL02563; KIEHL JT, 1993, SCIENCE, V260, P311, DOI 10.1126/science.260.5106.311; KONDRAGUNTA S, 1997, THESIS U MARYLAND CO; Lary DJ, 1997, J GEOPHYS RES-ATMOS, V102, P3671, DOI 10.1029/96JD02969; LELIEVELD J, 1990, NATURE, V343, P277; Liang JY, 1997, J GEOPHYS RES-ATMOS, V102, P5993, DOI 10.1029/96JD02957; LIU S, 1901, GEOPHYS RES LETT, V18, P2265; Lu Y, 1996, CHEMOSPHERE, V32, P739, DOI 10.1016/0045-6535(96)00028-8; MADRONICH S, 1987, J GEOPHYS RES-ATMOS, V92, P9740, DOI 10.1029/JD092iD08p09740; Meng Z, 1997, SCIENCE, V277, P116, DOI 10.1126/science.277.5322.116; Naja M, 1996, GEOPHYS RES LETT, V23, P81, DOI 10.1029/95GL03589; Nakajima T, 1996, APPL OPTICS, V35, P2672, DOI 10.1364/AO.35.002672; *NASA, 1994, CHEM KIN PHOT DAT US; National Academy of Sciences, 1991, RETH OZ PROBL URB RE; Odum JR, 1997, SCIENCE, V276, P96, DOI 10.1126/science.276.5309.96; PETERSON JT, 1976, ATMOS ENVIRON, V10, P459, DOI 10.1016/0004-6981(76)90026-3; PETERSON JT, 1981, J APPL METEOROL, V20, P229, DOI 10.1175/1520-0450(1981)020<0229:ATOCNC>2.0.CO;2; PETERSON JT, 1977, ATMOS ENVIRON, V11, P689, DOI 10.1016/0004-6981(77)90177-9; PIELKE RA, 1992, METEOROL ATMOS PHYS, V49, P69, DOI 10.1007/BF01025401; Ravishankara AR, 1997, SCIENCE, V276, P1058, DOI 10.1126/science.276.5315.1058; Remer LA, 1997, J GEOPHYS RES-ATMOS, V102, P16849, DOI 10.1029/96JD01932; Rhoads KP, 1997, J GEOPHYS RES-ATMOS, V102, P18981, DOI 10.1029/97JD01078; RUGGABER A, 1994, J ATMOS CHEM, V18, P171, DOI 10.1007/BF00696813; RYAN W, IN PRESS J AIR WASTE; SEINFELD JH, 1989, SCIENCE, V243, P745, DOI 10.1126/science.243.4892.745; Shetter RE, 1996, J GEOPHYS RES-ATMOS, V101, P14631, DOI 10.1029/96JD00211; STAMNES K, 1988, APPL OPTICS, V27, P2502, DOI 10.1364/AO.27.002502; Systems Applications International (SAI), 1995, US GUID VAR GRID URB; *US EPA, 1996, EPA454R96005; US-EPA, 1991, EPA450491013; VARSHNEY CK, 1992, ATMOS ENVIRON B-URB, V26, P291, DOI 10.1016/0957-1272(92)90004-C; Walcek CJ, 1997, ATMOS ENVIRON, V31, P1221, DOI 10.1016/S1352-2310(96)00257-9; WISCOMBE WJ, 1980, APPL OPTICS, V19, P1505, DOI 10.1364/AO.19.001505; ZAFONTE L, 1977, ENVIRON SCI TECHNOL, V11, P483, DOI 10.1021/es60128a006	54	417	460	16	199	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					827	830		10.1126/science.278.5339.827	http://dx.doi.org/10.1126/science.278.5339.827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346474				2022-12-28	WOS:A1997YD47900036
J	Gamble, TR; Yoo, SH; Vajdos, FF; vonSchwedler, UK; Worthylake, DK; Wang, H; McCutcheon, JP; Sundquist, WI; Hill, CP				Gamble, TR; Yoo, SH; Vajdos, FF; vonSchwedler, UK; Worthylake, DK; Wang, H; McCutcheon, JP; Sundquist, WI; Hill, CP			Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MAJOR HOMOLOGY REGION; RETROVIRAL GAG PROTEINS; CYCLOPHILIN-A; VIRION MORPHOGENESIS; PARTICLE FORMATION; ASSOCIATION; STEPS	The carboxyl-terminal domain, residues 146 to 231, of the human immunodeficiency virus-1 (HIV-1) capsid protein [CA(146-231)] is required for capsid dimerization and viral assembly. This domain contains a stretch of 20 residues, called the major homology region (MHR), which is conserved across retroviruses and is essential for viral assembly, maturation, and infectivity. The crystal structures of CA(146-231) and CA(151-231) reveal that the globular domain is composed of four helices and an extended aminoterminal strand. CA(146-231) dimerizes through parallel packing of helix 2 across a dyad. The MHR is distinct from the dimer interface and instead forms an intricate hydrogen-bonding network that interconnects strand 1 and helices 1 and 2. Alignment of the CA(146-231) dimer with the crystal structure of the capsid amino-terminal domain provides a model for the intact protein and extends models for assembly of the central conical core of HIV-1.	UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah				McCutcheon, John/0000-0002-5489-6039	NIAID NIH HHS [R01 AI40333, R01 AI43036] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040333, R01AI043036] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNER AT, 1996, X PLOR VERSION 3 843; Clish CB, 1996, FEBS LETT, V378, P43, DOI 10.1016/0014-5793(95)01419-5; CRAVEN RC, 1995, J VIROL, V69, P4213, DOI 10.1128/JVI.69.7.4213-4227.1995; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; GELDERBLOM HR, 1992, MEMBRANE INTERACTION, P33; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; GOFF S, 1981, J VIROL, V38, P238; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOWETT JBM, 1992, J GEN VIROL, V73, P3079, DOI 10.1099/0022-1317-73-12-3079; KRAUSSLICH HG, 1996, CURRENT TOPICS IMMUN, V214; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Orlinsky KJ, 1996, J VIROL, V70, P3440, DOI 10.1128/JVI.70.6.3440-3448.1996; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PATARCA R, 1985, NATURE, V318, P390, DOI 10.1038/318390a0; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Reicin AS, 1996, J VIROL, V70, P8645, DOI 10.1128/JVI.70.12.8645-8652.1996; ROSE S, 1992, PROTEINS, V13, P112, DOI 10.1002/prot.340130204; ROY O, 1996, VIROLOGY, V220, P530; STRAMBIODECASTILLIA C, 1992, J VIROL, V66, P7021, DOI 10.1128/JVI.66.12.7021-7032.1992; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Swingler S, 1997, J VIROL, V71, P4372, DOI 10.1128/JVI.71.6.4372-4377.1997; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; VONPOBLOTZKI A, 1993, VIROLOGY, V193, P981, DOI 10.1006/viro.1993.1210; VONSCHWEDLER U, UNPUB; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Zhang WH, 1996, J GEN VIROL, V77, P743, DOI 10.1099/0022-1317-77-4-743	36	507	518	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					849	853		10.1126/science.278.5339.849	http://dx.doi.org/10.1126/science.278.5339.849			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346481				2022-12-28	WOS:A1997YD47900043
J	Miyakawa, T; Yagi, T; Kitazawa, H; Yasuda, M; Kawai, N; Tsuboi, K; Niki, H				Miyakawa, T; Yagi, T; Kitazawa, H; Yasuda, M; Kawai, N; Tsuboi, K; Niki, H			Fyn-kinase as a determinant of ethanol sensitivity: Relation to NMDA-receptor function	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; POSTSYNAPTIC DENSITY FRACTION; LONG-TERM POTENTIATION; MUTANT MICE LACKING; TYROSINE PHOSPHORYLATION; GABA(A) RECEPTORS; A RECEPTORS; SUBUNIT 2B; RAT; ALCOHOL	Animals vary in their sensitivity to ethanol, a trait at least partly determined by genetic factors. In order to identify possible responsible genes, mice lacking Fyn, a non-receptor type tyrosine kinase, were investigated. These mice were hypersensitive to the hypnotic effect of ethanol. The administration of ethanol enhanced tyrosine phosphorylation of the N-methyl-D-aspartate receptor (NMDAR) in the hippocampus of control mice but not in Fyn-deficient mice. An acute tolerance to ethanol inhibition of NMDAR-mediated excitatory postsynaptic potentials in hippocampal slices developed in control mice but not in Fyn-deficient mice. These results indicate that Fyn affects behavioral, biochemical, and physiological responses to ethanol.	RIKEN,BRAIN SCI INST,NEUROBIOL EMOT LAB,WAKO,SAITAMA 35101,JAPAN; NATL INST PHYSIOL SCI,LAB NEUROBIOL & BEHAV GENET,OKAZAKI,AICHI 444,JAPAN; JICHI MED SCH,DEPT PHYSIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV TOKYO,FAC LETTERS,DEPT PSYCHOL,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Jichi Medical University; University of Tokyo			Miyakawa, Tsuyoshi/A-7741-2008	Miyakawa, Tsuyoshi/0000-0003-0137-8200				Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; GROVER CA, 1994, BRAIN RES, V642, P70, DOI 10.1016/0006-8993(94)90906-7; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; HARRIS RA, 1991, ANN NY ACAD SCI, V625, P508, DOI 10.1111/j.1749-6632.1991.tb33881.x; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1990, J NEUROSCI, V10, P1372; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; MIYAKAWA T, 1994, MOL BRAIN RES, V27, P179, DOI 10.1016/0169-328X(94)90201-1; Miyakawa T, 1996, NEUROREPORT, V7, P2723, DOI 10.1097/00001756-199611040-00063; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Tabakoff B, 1996, NEURON, V16, P909, DOI 10.1016/S0896-6273(00)80113-0; THURSTON AW, 1992, BIOCHEM BIOPH RES CO, V185, P1062, DOI 10.1016/0006-291X(92)91734-8; TSUBOKAWA H, 1994, NEUROSCIENCE, V59, P291, DOI 10.1016/0306-4522(94)90597-5; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; WAFFORD KA, 1990, SCIENCE, V249, P291, DOI 10.1126/science.1695761; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	27	252	252	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					698	701		10.1126/science.278.5338.698	http://dx.doi.org/10.1126/science.278.5338.698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381182				2022-12-28	WOS:A1997YC32300058
J	Pal, R; GarzinoDemo, A; Markham, PD; Burns, J; Brown, M; Gallo, RC; DeVico, AL				Pal, R; GarzinoDemo, A; Markham, PD; Burns, J; Brown, M; Gallo, RC; DeVico, AL			Inhibition of HIV-1 infection by the beta-chemokine MDC	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TERMINAL SEQUENCE; DENDRITIC CELLS; CLINICAL STATE; FLOW-CYTOMETRY; T-CELLS; REPLICATION; INDIVIDUALS; INTERLEUKIN-8; RECEPTOR	CD8(+) T lymphocytes from individuals infected with human immunodeficiency virus-type 1 (HIV-1) secrete a soluble activity that suppresses infection by HIV-1. A protein associated with this activity was purified from the culture supernatant of an immortalized CD8(+) T cell clone and identified as the beta-chemokine macrophage-derived chemokine (MDC). MDC suppressed infection of CD8(+) cell-depleted peripheral blood mononuclear cells by primary non-syncytium-inducing and syncytium-inducing isolates of HIV-1 and the T cell line-adapted isolate HIV-1(IIIB). MDC was expressed in activated, but not resting, peripheral blood mononuclear cells and binds a receptor on activated primary T cells. These observations indicate that beta-chemokines are responsible for a major proportion of HIV-1-specific suppressor activity produced by primary T cells.	UNIV MARYLAND, INST HUMAN VIROL, BALTIMORE, MD 21201 USA; ADV BIOSCI LABS, KENSINGTON, NSW 20895, AUSTRALIA; UNIV MARYLAND, SCH MED, INST HUMAN DEV, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT IMMUNOL & MICROBIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore				Garzino-Demo, Alfredo/0000-0002-4095-6950	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI055279] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-55279] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BADOLATO R, 1995, J IMMUNOL, V155, P4004; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Barker TD, 1996, J IMMUNOL, V156, P4476; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; Blackbourn DJ, 1996, P NATL ACAD SCI USA, V93, P13125, DOI 10.1073/pnas.93.23.13125; BLUEL CC, 1996, NATURE, V382, P829; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; BURNS J, IN PRESS BIOTECHNIQU; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEVICO AL, UNPUB; Dittmar MT, 1997, NATURE, V385, P495, DOI 10.1038/385495a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GARZINODEMO A, 1995, HUM GENE THER, V6, P177, DOI 10.1089/hum.1995.6.2-177; GARZINODEMO A, UNPUB; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Greimers R, 1996, CYTOMETRY, V23, P205, DOI 10.1002/(SICI)1097-0320(19960301)23:3<205::AID-CYTO4>3.0.CO;2-H; HE J, 1997, NATURE, V385, P6445; HEBERT CA, 1990, J IMMUNOL, V145, P3033; Jansson M, 1996, P NATL ACAD SCI USA, V93, P15382, DOI 10.1073/pnas.93.26.15382; Kinter AL, 1996, P NATL ACAD SCI USA, V93, P14076, DOI 10.1073/pnas.93.24.14076; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; MARKHAM PD, 1984, INT J CANCER, V33, P13, DOI 10.1002/ijc.2910330104; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Paliard X, 1996, AIDS, V10, P1317, DOI 10.1097/00002030-199610000-00002; PATTERSON S, 1987, J GEN VIROL, V68, P1177, DOI 10.1099/0022-1317-68-4-1177; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; Proost Paul, 1996, Methods (Orlando), V10, P82, DOI 10.1006/meth.1996.0082; Rubbert A, 1997, AIDS RES HUM RETROV, V13, P63, DOI 10.1089/aid.1997.13.63; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; VANDAMME J, 1990, EUR J IMMUNOL, V20, P2113, DOI 10.1002/eji.1830200933; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; WALKER CM, 1989, CELL IMMUNOL, V119, P470, DOI 10.1016/0008-8749(89)90259-1; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0	53	183	194	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					695	698		10.1126/science.278.5338.695	http://dx.doi.org/10.1126/science.278.5338.695			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381181				2022-12-28	WOS:A1997YC32300057
J	Muller, CW; Herrmann, BG				Muller, CW; Herrmann, BG			Crystallographic structure of the T domain DNA complex of the Brachyury transcription factor	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING PROTEIN; GENE; DROSOPHILA; ALIGNMENT	The mouse Brachyury (T) gene is the prototype of a growing family of so-called T-box genes which encode transcriptional regulators and have been identified in a variety of invertebrates and vertebrates, including humans(1-6). Mutations in Brachyury and other T-box genes result in drastic embryonic phenotypes, indicating that T-box gene products are essential in tissue specification, morphogenesis and organogenesis(7-11). The T-box encodes a DNA-binding domain of about 180 amino-acid residues, the T domain(12). Here we report the X-ray structure of ther domain from Xenopus laevis in complex with a 24-nucleotide palindromic DNA duplex. We show that the protein is bound as a dimer, interacting with the major and the minor grooves of the DNA. A new type of specific DNA contact is seen, in which a carboxy-terminal helix is deeply embedded into an enlarged minor groove without bending the DNA. Hydrophobic interactions and an unusual main-chain carbonyl contact to a guanine account for sequence-specific recognition in the minor groove by this helix. Thus the structure of this T domain complex with DNA reveals a new way in which a protein can recognize DNA.	MAX PLANCK INST IMMUNBIOL, D-79108 FREIBURG, GERMANY	Max Planck Society	Muller, CW (corresponding author), EUROPEAN MOL BIOL LAB, GRENOBLE OUTSTN, ILL BP 156, F-38042 GRENOBLE 9, FRANCE.		Pillay, Nischalan/F-9536-2012; Müller, Christoph W/I-7420-2012	Müller, Christoph W/0000-0003-2176-8337				Agulnik SI, 1996, GENETICS, V144, P249; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Herrmann Bernhard G., 1995, Seminars in Developmental Biology, V6, P385, DOI 10.1016/S1044-5781(06)80002-2; Holland PWH, 1995, DEVELOPMENT, V121, P4283; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; KISPERT A, 1994, GENE DEV, V8, P2137, DOI 10.1101/gad.8.18.2137; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Knezevic V, 1997, DEVELOPMENT, V124, P411; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Li QY, 1997, NAT GENET, V15, P21; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Schulte-Merker S., 1995, Seminars in Developmental Biology, V6, P411, DOI 10.1016/S1044-5781(06)80005-8; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	30	257	260	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	1997	389	6653					884	888		10.1038/39929	http://dx.doi.org/10.1038/39929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349824				2022-12-28	WOS:A1997YC14800065
J	Rankin, AC				Rankin, AC			Non-sedating antihistamines and cardiac arrhythmia	LANCET			English	Editorial Material							DE-POINTES; TERFENADINE; INTERVAL				Rankin, AC (corresponding author), ROYAL INFIRM,DEPT CARDIOL,GLASGOW G31 2ER,LANARK,SCOTLAND.							HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; LINDQUIST EIR, 1997, LANCET, V39, P1322; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; Pratt CM, 1996, AM HEART J, V131, P472, DOI 10.1016/S0002-8703(96)90525-6; PRATT CM, 1994, AM J CARDIOL, V73, P346, DOI 10.1016/0002-9149(94)90006-X; RAMPE D, 1993, MOL PHARMACOL, V44, P1240; SALATA JJ, 1995, CIRC RES, V76, P110, DOI 10.1161/01.RES.76.1.110; TAN HL, 1995, ANN INTERN MED, V122, P701, DOI 10.7326/0003-4819-122-9-199505010-00009; Thompson D, 1996, JAMA-J AM MED ASSOC, V275, P1339, DOI 10.1001/jama.275.17.1339; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; Woosley RL, 1996, ANNU REV PHARMACOL, V36, P233, DOI 10.1146/annurev.pa.36.040196.001313	11	23	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1115	1116		10.1016/S0140-6736(05)63783-X	http://dx.doi.org/10.1016/S0140-6736(05)63783-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343494				2022-12-28	WOS:A1997YB19900003
J	Forsen, T; Eriksson, JG; Tuomilehto, J; Teramo, K; Osmond, C; Barker, DJP				Forsen, T; Eriksson, JG; Tuomilehto, J; Teramo, K; Osmond, C; Barker, DJP			Mother's weight in pregnancy and coronary heart disease in a cohort of Finnish men: Follow up study	BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; FETAL; BIRTH; INSULIN; NUTRITION; THINNESS; GROWTH	Objective: To determine whether restricted growth in utero is associated with an increased risk of coronary heart disease among men in Finland, where rates of the disease are among the highest in the world. Design: Follow up study. Setting: Helsinki, Finland. Subjects: 3302 men born in Helsinki University Central Hospital during 1924-33 who went to school in the city of Helsinki and were resident in Finland in 1971. Main outcome measures: Standardised mortality ratios for coronary heart disease. Results: Men who were thin at birth, with low placental weight, had high death rates from coronary heart disease. Men whose mothers had a high body mass index in pregnancy also had high death rates. In a multivariate analysis the hazard ratio for coronary heart disease was 1.37 (95% confidence interval 1.20 to 1.57) (P < 0.0001) for every standard deviation decrease in ponderal index at birth and 1.24 (1.10 to 1.39) (P = 0.0004) for every standard deviation increase in mother's body mass index. The effect of mother's body mass index was restricted to mothers of below average stature. Conclusion: These findings suggest a new explanation for the epidemics of coronary heart disease that accompany Westernisation. Chronically malnourished women are short and light and their babies tend to be thin. The immediate effect of improved nutrition is that women become fat, which seems to increase the risk of coronary heart disease in the next generation. With continued improvements in nutrition, women become taller and heavier; their babies are adequately nourished; and maternal fatness no longer increases the risk of coronary heart disease, which therefore declines.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,DIABET & GENET EPIDEMIOL UNIT,FIN-00300 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,FIN-00290 HELSINKI,FINLAND	University of Southampton; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital				Osmond, Clive/0000-0002-9054-4655				Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; GODFREY KM, IN PRESS BR J OBSTET; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Keys A, 1966, Acta Med Scand Suppl, V460, P1; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; Law CM, 1996, J HYPERTENS, V14, P935; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; SALOMAA V, 1992, AM J EPIDEMIOL, V136, P1303, DOI 10.1093/oxfordjournals.aje.a116442; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; YLIAHO T, 1991, TEHTAALAINEN HELSING	17	285	294	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					837	840		10.1136/bmj.315.7112.837	http://dx.doi.org/10.1136/bmj.315.7112.837			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353502	Green Published			2022-12-28	WOS:A1997YA00700019
J	Walton, RT; Gierl, C; Yudkin, P; Mistry, H; Vessey, MP; Fox, J				Walton, RT; Gierl, C; Yudkin, P; Mistry, H; Vessey, MP; Fox, J			Evaluation of computer support for prescribing (CAPSULE) using simulated cases	BRITISH MEDICAL JOURNAL			English	Article							EXPERT SYSTEMS; REMINDERS; CARE; QUALITY; THERAPY	Objective: To evaluate the potential effect of computer support on general practitioners prescribing, and to compare the effectiveness of three different support levels. Design: Crossover experiment with balanced block design. Subjects: Random sample of 50 general practitioners (42 agreed to participate) from 165 in a geographically defined area of Oxfordshire. Interventions: Doctors prescribed for 36 simulated cases constructed from real consultations. Levels of computer support were control (alphabetical list of drugs), limited support (list of preferred drugs), and full support (the same list with explanations available for suggestions). Main outcome measures: Percentage of cases where doctors ignored a cheaper, equally effective drug; prescribing score (a measure of how closely prescriptions matched expert recommendations); interview to elicit doctors' views of support system. Results: Computer support significantly improved the quality of prescribing. Doctors ignored a cheaper, equally effective drug in a median 50% (range 25%-75%) of control cases, compared with 36% (8%-67%) with limited support and 35% (0-67%) with full support (P<0.001). The median prescribing score rose from 6.0 units (4.2-7.0) with control support to 6.8 (5.8 to 7.7) and 6.7 (5.6 to 7.8) with limited and full support (P<0.001). Of 41 doctors, 36 (88%) found the system easy to use and 24 (59%) said they would be likely to use it in practice. Conclusions: Computer support improved compliance with prescribing guidelines, reducing the occasions when doctors ignored a cheaper, equally effective drug. The system was easy to operate, and most participating doctors would be likely to use it in practice.	RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,GEN PRACTICE RES GRP,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 GHE,ENGLAND; IMPERIAL CANC RES FUND,ADV COMPUTAT LAB,LONDON WC2A 3PX,ENGLAND	Radcliffe Infirmary; Cancer Research UK								ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BROOK RH, 1976, ANN INTERN MED, V85, P509, DOI 10.7326/0003-4819-85-4-509; Fox J., 1990, Artificial Intelligence in Medicine, V2, P323, DOI 10.1016/0933-3657(90)90007-E; GONZALEZ ER, 1989, AM J EMERG MED, V7, P395, DOI 10.1016/0735-6757(89)90046-6; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; JONES I, 1994, PRESCRIPTION IMPROVE; McDonald C J, 1991, Proc Annu Symp Comput Appl Med Care, P925; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDONALD CJ, 1989, ANN INTERN MED, V110, P333, DOI 10.7326/0003-4819-110-5-333; NORTON PG, 1985, J FAM PRACTICE, V21, P289; SOTOS JG, 1990, AVIAT SPACE ENVIR MD, V61, P950; Walton R., 1996, J INF PRIMARY CA MAR, V2006, P2; WHITE KS, 1984, J AM COLL CARDIOL, V4, P571, DOI 10.1016/S0735-1097(84)80104-7; WHITE RH, 1987, J GEN INTERN MED, V2, P141, DOI 10.1007/BF02596140; Wise J, 1996, BRIT MED J, V313, P250, DOI 10.1136/bmj.313.7052.250a; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268	20	66	67	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					791	795						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345174				2022-12-28	WOS:A1997XY91100024
J	Jones, AH				Jones, AH			Literature and medicine: narratives of mental illness	LANCET			English	Editorial Material											Jones, AH (corresponding author), UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,ASHBEL SMITH BLDG SUITE 2210,301 UNIV BLVD,GALVESTON,TX 77555, USA.							ALVAREZ W, 1961, MINDS CAME BACK; Bateson Gregory, 1974, PERCEVALS NARRATIVE; BEERS CW, 1981, MIND FOUND ITSELF; BRINK AW, 1974, LIFE G TROSSE WRITTE; BURKE R, 1995, MUSICS OVER MY JOURN; COWPER W, 1835, MEMOIR EARLY LIFE W; Cruden Alexander, 1739, LONDON CITIZEN EXCEE; DUKE P, 1992, MY BRILLANT MADNESS; Duke Patty, 1988, CALL ME ANNA AUTOBIO; Frame J., 1982, FACES WATER; FRAME J, 1991, ANGEL MY TABLE AUTOB, V2; Freud S., 1925, COLLECT PAPERS, V4, P436; GILMAN CP, 1973, YELLOW WALLPAPER; Goodwin F, 1990, MANIC DEPRESSIVE ILL; Greenberg J., 1964, I NEVER PROMISED YOU; Ingram Allan, 1997, VOICES MADNESS; Jamison KR., 2015, UNQUIET MIND MEMOIR, V4; JONES AH, 1995, MED HUM REV, V9, P9; KEMPE M, 1936, BOOK M KEMPE MODERN; Landis Carney, 1964, VARIETIES PSYCHOPATH; Macalpine I, 1956, SCHIZOPHRENIA 1677 P; Manning M., 1994, UNDERCURRENTS THERAP; Millett Kate, 1990, LOONY BIN TRIP; NEUGEBOREN J, 1997, IMAGINGING ROBERT MY; OBER WB, 1985, LIT MED, V4, P24, DOI 10.1353/lm.2011.0013; Perceval J, 1840, NARRATIVE TREATMENT; PETERSON D, 1982, MADS PEOPLES HIST MA; Plath Sylvia, 1971, BELL JAR; Porter Roy, 1987, SOCIAL HIST MADNESS; Schiller, 1994, QUIET ROOM JOURNEY O; Seabrook W., 1935, ASYLUM; Sechehaye M, 1970, AUTOBIOGRAPHY SCHIZO; STEIR C, 1977, BLUE JOLTS TRUE STOR; Styron W., 1990, DARKNESS VISIBLE MEM; TROSSE G, 1714, LIFE G TROSSE LATE M; WARD MJ, 1973, SNAKE PIT; WOOLF V, V WOOLFS PSYCHIAT HI; YALOM ID, 1990, EVERY DAY GETS LITTL	38	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					359	361		10.1016/S0140-6736(97)07123-7	http://dx.doi.org/10.1016/S0140-6736(97)07123-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XP242	9379815				2022-12-28	WOS:A1997XP24200044
J	Cardo, DM; Culver, DH; Ciesielski, CA; Srivastava, PU; Marcus, R; Abiteboul, D; Heptonstall, J; Ippolito, G; Lot, F; McKibben, P; Bell, DM				Cardo, DM; Culver, DH; Ciesielski, CA; Srivastava, PU; Marcus, R; Abiteboul, D; Heptonstall, J; Ippolito, G; Lot, F; McKibben, P; Bell, DM			A case-control study of HIV seroconversion in health care workers after percutaneous exposure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE TREATMENT; HEPATITIS-B; RISK; TRANSMISSION; INFECTION; TYPE-1; BLOOD; INFANT	Background The average risk of human immunodeficiency virus (HIV) infection after percutaneous exposure to HIV-infected blood is 0.3 percent, but the factors that influence this risk are not well understood. Methods We conducted a case-control study Of health care workers with occupational, percutaneous exposure to HIV-infected blood. The case patients were those who became seropositive after exposure to HIV, as reported by national surveillance systems in France, Italy, the United Kingdom, and the United States. The controls were health care workers in a prospective surveillance project who were exposed to HIV but did not seroconvert. Results Logistic-regression analysis based on 33 case patients and 665 controls showed that significant risk factors for seroconversion were deep injury (odds ratio=15; 95 percent confidence interval, 6.0 to 41), injury with a device that was visibly contaminated with the source patient's blood (odds ratio=6.2; 95 percent confidence interval, 2.2 to 21), a procedure involving a needle placed in the source patient's artery or vein (odds ratio=4.3; 95 percent confidence interval, 1.7 to 12), and exposure to a source patient who died of the acquired immunodeficiency syndrome within two months afterward (odds ratio=5.6; 95 percent confidence interval, 2.0 to 16). The case patients were significantly less likely than the controls to have taken zidovudine after the exposure (odds ratio=0.19; 95 percent confidence interval, 0.06 to 0.52). Conclusions The risk of HIV infection after percutaneous exposure increases with a larger volume of blood and, probably, a higher titer of HIV in the source patient's blood. Postexposure prophylaxis with zidovudine appears to be protective. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL,NATL CTR HIV STD & TB PREVENT,DIV HIV AIDS,ATLANTA,GA 30333; INST NATL RECH & SECUR,PARIS,FRANCE; GRP ETUD RISQUE EXPOSIT SANG,PARIS,FRANCE; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND; CTR RIFERIMENTO AIDS COORDINAMENTO STUDIO ITALIAN,ROME,ITALY; RESEAU NATL SANTE PUBL,ST MAURICE,FRANCE	Centers for Disease Control & Prevention - USA; Public Health England	Cardo, DM (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,1600 CLIFTON RD,MAIL STOP E-68,ATLANTA,GA 30333, USA.		Ippolito, Giuseppe/J-7207-2017	Marcus, Ruthanne/0000-0002-9094-0674; Ippolito, Giuseppe/0000-0002-1076-2979				BELL DM, 1992, INFECT AGENT DIS, V1, P263; BELL DM, 1997, AM J MED 5B, V102; BLACK R, 1997, AM J MED, V102; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHAMBERLAND ME, IN PRESS HOSP INFECT; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; GERBERDING JL, 1997, AM J MED 5B, V102; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; JOCHIMSEN EM, 1997, AM J MED 5B, V102; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; LAFON SW, 1993, 30 INT C ANT AG CHEM; LOES SK, 1995, NEW ENGL J MED, V333, P1367; LOES SK, 1995, NEW ENGL J MED, V333, P408; LOT F, 1995, B EPIDEMIOL HEBD, V44, P193; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; *PHS, 1990, MMWR-MORBID MORTAL W, V39, P1; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Weisburd Guillermo, 1996, P460; 1995, MMWR-MORBID MORTAL W, V44, P929; 1996, MMWR-MORBID MORTAL W, V45, P468; 1991, MMWR-MORBID MORTAL W, V40, P1	27	781	818	0	31	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1485	1490		10.1056/NEJM199711203372101	http://dx.doi.org/10.1056/NEJM199711203372101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366579				2022-12-28	WOS:A1997YG24900001
J	Brook, RH				Brook, RH			Managed care is not the problem, quality is	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONTROLLED TRIAL; HEALTH		UNIV CALIF LOS ANGELES,CTR HLTH SCI,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	Brook, RH (corresponding author), RAND CORP,HLTH PROGRAM,1700 MAIN ST,POB 2138,SANTA MONICA,CA 90407, USA.							Brook RH, 1996, JAMA-J AM MED ASSOC, V276, P476, DOI 10.1001/jama.276.6.476; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; KAHN KL, 1990, RAND PUBLICATION; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Laouri M, 1997, J AM COLL CARDIOL, V29, P891, DOI 10.1016/S0735-1097(96)00434-2; Lohr K N, 1986, Med Care, V24, pS1; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; *PENNS HLTH CAR CO, 1991, CONS GUID COR ART BY; VALDEZ RB, 1989, PEDIATRICS, V83, P168	12	47	51	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1612	1614		10.1001/jama.278.19.1612	http://dx.doi.org/10.1001/jama.278.19.1612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF407	9370509				2022-12-28	WOS:A1997YF40700044
J	Yamauchi, T; Ueki, K; Tobe, K; Tamemoto, H; Sekine, N; Wada, M; Honjo, M; Takahashi, M; Takahashi, T; Hirai, H; Tushima, T; Akanuma, Y; Fujita, T; Komuro, I; Yazaki, Y; Kadowaki, T				Yamauchi, T; Ueki, K; Tobe, K; Tamemoto, H; Sekine, N; Wada, M; Honjo, M; Takahashi, M; Takahashi, T; Hirai, H; Tushima, T; Akanuma, Y; Fujita, T; Komuro, I; Yazaki, Y; Kadowaki, T			Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone	NATURE			English	Article							C-FOS PROMOTER; INTERFERON-GAMMA; BINDING-SITES; INTACT-CELLS; ACTIVATION; SUBSTRATE-1; MICE; SHC; TRANSCRIPTION; ASSOCIATION	When growth hormone binds to its receptor, which belongs to the cytokine receptor superfamily(1), it activates the Janus kinase Jak2(2) which has tyrosine-kinase activity and initiates an activation of several key intracellular proteins (for example, mitogen-activated protein (MAP) kinases(3-6)) that eventually execute the biological actions induced by growth hormone, including the expression of particular genes. In contrast to receptors that themselves have tyrosine kinase activity, the signalling pathways leading to MAP kinase activation(7,8) that are triggered by growth hormone are poorly understood, but appear to be mediated by the proteins GrB2 and Shc(9). We now show that growth hormone stimulates tyrosine phosphorylation of the receptor for epidermal growth factor (EGFR) and its association with Grb2 and at the same time stimulates MAP kinase activity in liver, an important target tissue of growth hormone, Expression of EGFR and its mutants revealed that growth-hormone-induced activation of MAP kinase and expression of the transcription factor c-fos requires phosphorylation of tyrosines on EGFR, but not its own intrinsic tyrosine-kinase activity, Moreover, tyrosine at residue 1,068 of the EGFR is proposed to be one of the principal phosphorylation sires and Grb2-binding sites stimulated by growth hormone via Jak2. Our results indicate that the role of EGFR in signalling by growth hormone is to be phosphorylated by Jak2, thereby providing docking sites for Grb2 and activating MAP kinases and gene expression, independently of the intrinsic tyrosine kinase activity of EGFR. This may represent a novel cross-talk pathway between the cytokine receptor superfamily and growth factor receptor.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 4,TOKYO 112,JAPAN; MITSUI TOATSU CHEM CO LTD,LIFE SCI LABS,MOBARA 297,JAPAN; UNIV TOKYO,DEPT VET PHYSIOL,TOKYO 113,JAPAN; TOKYO WOMENS MED COLL,DEPT INTERNAL MED 2,TOKYO 162,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,TOKYO 100,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo Women's Medical University; Asahi Life Foundation				Takahashi, Tokiharu/0000-0002-5785-8660				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; FRANK SJ, 1995, J BIOL CHEM, V270, P14765; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MeunierDurimort C, 1996, EUR J BIOCHEM, V237, P660, DOI 10.1111/j.1432-1033.1996.0660p.x; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sekine N, 1996, ENDOCRINOLOGY, V137, P1841, DOI 10.1210/en.137.5.1841; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANAKA T, 1994, J BIOL CHEM, V269, P24020; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	30	244	252	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					91	96		10.1038/36369	http://dx.doi.org/10.1038/36369			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363897				2022-12-28	WOS:A1997YE47700059
J	Nightingale, SL				Nightingale, SL			Education program for reducing risks with unpasteurized juices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-28	WOS:A1997YC91700007
J	Link, MP; Shuster, JJ; Donaldson, SS; Berard, CW; Murphy, SB				Link, MP; Shuster, JJ; Donaldson, SS; Berard, CW; Murphy, SB			Treatment of children and young adults with early-stage non-Hodgkin's lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CANCER STUDY-GROUP; LYMPHOBLASTIC LYMPHOMA; RANDOMIZED TRIAL; THERAPY; CHILDHOOD; HISTOLOGY; LSA2-L2; COMP	Background Children and young adults with early-stage non-Hodgkin's lymphoma have an excellent prognosis, but treatment is prolonged and is associated with many side effects. We performed two studies to determine whether therapy could be simplified. Methods Between 1983 and 1991, we conducted two consecutive trials in children and young adults (age, <21 years) with early-stage non-Hodgkin's lymphoma. In the first trial, patients were treated for 9 weeks with induction chemotherapy consisting of vincristine, doxorubicin, cyclophosphamide, and prednisone, followed by 24 weeks of continuation chemotherapy with mercaptopurine and methotrexate. Half the patients were randomly assigned to receive involved-field irradiation. In the second trial, after the 9 weeks of induction chemotherapy, the patients were randomly assigned to receive 24 weeks of continuation chemotherapy or no further therapy. Results A total of 340 patients were enrolled in the two trials, 12 of whom did not have complete remissions. One hundred thirteen patients received nine weeks of chemotherapy without radiotherapy, 131 received eight months of chemotherapy without radiotherapy, and 67 received eight months of chemotherapy with radiotherapy. At five years, the projected rates of continuous complete remission were 89, 86, and 88 percent for the three groups, respectively. At five years, event-free survival among the patients with early-stage lymphoblastic lymphoma was inferior to that among the patients with other subtypes of lymphoma (63 percent vs. 88 percent, P<0.001). Continuation therapy was effective only in patients with lymphoblastic lymphoma. Conclusions A nine-week chemotherapy regimen without irradiation of the primary sites of involvement is adequate therapy for most children and young adults with early-stage, nonlymphoblastic non-Hodgkin's lymphoma. (C) 1997, Massachusetts Medical Society.	STANFORD UNIV, SCH MED, DEPT RADIAT ONCOL, STANFORD, CA 94305 USA; LUCILE SALTER PACKARD CHILDRENS HOSP, STANFORD, CA USA; UNIV FLORIDA, DEPT STAT, GAINESVILLE, FL 32611 USA; PEDIAT ONCOL GRP, STAT OFF, GAINESVILLE, FL USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, MEMPHIS, TN USA; CHILDRENS MEM HOSP, CHICAGO, IL 60614 USA; NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA	Stanford University; Lucile Packard Children's Hospital (LPCH); State University System of Florida; University of Florida; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	Link, MP (corresponding author), STANFORD UNIV, SCH MED, DEPT PEDIAT, 300 PASTEUR DR, STANFORD, CA 94305 USA.		Shuster, Jonathan/ABB-5773-2021	Shuster, Jonathan/0000-0001-9499-5616	NATIONAL CANCER INSTITUTE [U10CA033603, U10CA029139, U10CA031566] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33603, CA-31566, CA-29139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON JR, 1993, J CLIN ONCOL, V11, P1024, DOI 10.1200/JCO.1993.11.6.1024; HVIZDALA EV, 1991, J CLIN ONCOL, V9, P1189, DOI 10.1200/JCO.1991.9.7.1189; HVIZDALA EV, 1988, J CLIN ONCOL, V6, P26, DOI 10.1200/JCO.1988.6.1.26; JENKIN RDT, 1984, J CLIN ONCOL, V2, P88, DOI 10.1200/JCO.1984.2.2.88; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LINK MP, 1990, NEW ENGL J MED, V322, P1169, DOI 10.1056/NEJM199004263221701; MAGRATH IT, 1984, BLOOD, V63, P1102; MEADOWS AT, 1989, J CLIN ONCOL, V7, P92, DOI 10.1200/JCO.1989.7.1.92; MURPHY SB, 1980, CANCER, V45, P630, DOI 10.1002/1097-0142(19800215)45:4<630::AID-CNCR2820450403>3.0.CO;2-5; MURPHY SB, 1989, J CLIN ONCOL, V7, P186, DOI 10.1200/JCO.1989.7.2.186; MURPHY SB, 1983, J CLIN ONCOL, V1, P326, DOI 10.1200/JCO.1983.1.5.326; MURPHY SB, 1980, SEMIN ONCOL, V7, P332; PATTE C, 1992, MED PEDIATR ONCOL, V20, P105, DOI 10.1002/mpo.2950200204; PATTE C, 1993, MED PEDIATR ONCOL, V21, P531; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; ROSENBERG SA, 1982, CANCER, V49, P2112; SULLIVAN MP, 1985, CANCER-AM CANCER SOC, V55, P323, DOI 10.1002/1097-0142(19850115)55:2<323::AID-CNCR2820550204>3.0.CO;2-9; TUBERGEN DG, 1995, J CLIN ONCOL, V13, P1368, DOI 10.1200/JCO.1995.13.6.1368; WEINSTEIN HJ, 1984, BLOOD, V64, P422	20	112	119	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1259	1266		10.1056/NEJM199710303371802	http://dx.doi.org/10.1056/NEJM199710303371802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345074				2022-12-28	WOS:A1997YC92000002
J	McMahon, LEC; Mark, EJ; Shepard, JAO				McMahon, LEC; Mark, EJ; Shepard, JAO			A 22-year-old man with a sickle cell crisis and sudden death - Sickle cell anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE CHEST SYNDROME; FAT-EMBOLISM; DISEASE; CHOLELITHIASIS		BOSTON UNIV,SCH MED,BOSTON,MA 02118	Boston University	McMahon, LEC (corresponding author), BOSTON MED CTR,BOSTON COMPREHENS SICKLE CELL CTR,BOSTON,MA 02118, USA.							ADEKILE AD, 1988, ANN TROP PAEDIATR, V8, P103, DOI 10.1080/02724936.1988.11748549; ALLISON AC, 1954, BRIT MED J, V1, P290, DOI 10.1136/bmj.1.4857.290; BARRERAS L, 1968, J AMER MED ASSOC, V203, P569, DOI 10.1001/jama.203.8.569; CASTELLA X, 1992, CHEST, V101, P1710, DOI 10.1378/chest.101.6.1710; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1989, NIH PUBLICATION; FRANCIS RB, 1991, BLOOD, V77, P1405; GERRY JL, 1978, AM J CARDIOL, V42, P211, DOI 10.1016/0002-9149(78)90902-5; Godeau B, 1996, AM J RESP CRIT CARE, V153, P1691, DOI 10.1164/ajrccm.153.5.8630622; HAUPT HM, 1982, CHEST, V81, P332, DOI 10.1378/chest.81.3.332; HUTCHINSON RM, 1973, J CLIN PATHOL, V26, P620, DOI 10.1136/jcp.26.8.620; LEE MG, 1989, GUT, V30, P569, DOI 10.1136/gut.30.5.569; NAGEL RL, 1985, NEW ENGL J MED, V312, P880, DOI 10.1056/NEJM198504043121403; NEEL JV, 1961, P C GENETIC POLYMORP, P102; OHENEFREMPONG K, 1991, SEMIN HEMATOL, V28, P213; POWARS D, 1990, SEMIN HEMATOL, V27, P360; POWARS DR, 1975, SEMIN HEMATOL, V12, P267; RENNELS MB, 1984, AM J DIS CHILD, V138, P66, DOI 10.1001/archpedi.1984.02140390054016; RUCKNAGEL DL, 1991, LANCET, V337, P831, DOI 10.1016/0140-6736(91)92525-7; SARNAIK S, 1980, J PEDIATR-US, V96, P1005, DOI 10.1016/S0022-3476(80)80626-3; SHARPSTEEN JR, 1993, AM J MED, V94, P289, DOI 10.1016/0002-9343(93)90061-S; SHELLEY WM, 1958, B JOHNS HOPKINS HOSP, V103, P8; SINGER K, 1953, BLOOD, V8, P1008, DOI 10.1182/blood.V8.11.1008.1008; SKLAR AH, 1990, INT J ARTIF ORGANS, V13, P231, DOI 10.1177/039139889001300408; VICHINSKY E, 1994, BLOOD, V83, P3107; Vichinsky EP, 1997, BLOOD, V89, P1787, DOI 10.1182/blood.V89.5.1787.1787_1787_1792; WONG WY, 1992, CLIN INFECT DIS, V14, P1124, DOI 10.1093/clinids/14.5.1124; Yater WM, 1936, AM J MED SCI, V191, P474, DOI 10.1097/00000441-193619140-00004; 1983, NEW ENGL J MED, V309, P1627	29	11	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1293	1301		10.1056/NEJM199710303371808	http://dx.doi.org/10.1056/NEJM199710303371808			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345080				2022-12-28	WOS:A1997YC92000008
J	Campbell, AJ; Robertson, MC; Gardner, MM; Norton, RN; Tilyard, MW; Buchner, DM				Campbell, AJ; Robertson, MC; Gardner, MM; Norton, RN; Tilyard, MW; Buchner, DM			Randomised controlled trial of a general practice programme of home based exercise to prevent falls in elderly women	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FICSIT TRIALS; OLDER ADULTS; RISK-FACTORS; TAI-CHI; COMMUNITY; BALANCE; INTERVENTION; STRENGTH	Objective: To assess the effectiveness of a home exercise programme of strength and balance retraining exercises in reducing falls and injuries in elderly women. Design: Randomised controlled trial of an individually tailored programme of physical therapy in the home (exercise group, n=116) compared with the usual care and an equal number of social visits (control group, n=117). Setting 17 general practices in Dunedin, New Zealand. Subjects: Women aged 80 years and older living in the community and registered with a general practice in Dunedin. Main outcome measures: Number of falls and injuries related to falls and time between falls during one year of follow up; changes in muscle strength and balance measures after six months. Results: After one year there were 152 falls in the control group and 88 falls in the exercise group. The mean (SD) rate of falls was lower in the exercise than the control group (0.87 (1.29) v 1.34 (1.93) falls per year respectively; difference 0.47; 95% confidence interval 0.04 to 0.90). The relative hazard for the first four falls in the exercise group compared with the control group was 0.68 (0.52 to 0.90). The relative hazard for a first fall with injury in the exercise group compared with the control group was 0.61 (0.39 to 0.97). After six months, balance had improved in the exercise group (difference between groups in change in balance score 0.43 (0.21 to 0.65). Conclusions: An individual programme of strength and balance retraining exercises improved physical function and was effective in reducing falls and injuries in women 80 years and older.	UNIV AUCKLAND, SCH MED, INJURY PREVENT RES CTR, AUCKLAND, NEW ZEALAND; UNIV OTAGO SCH MED, DUNEDIN SCH MED, DEPT GEN PRACTICE, DUNEDIN, NEW ZEALAND; VA PUGET SOUND HLTH CARE SYST, SEATTLE, WA 98108 USA	University of Auckland; University of Otago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Campbell, AJ (corresponding author), UNIV OTAGO SCH MED, DUNEDIN SCH MED, DEPT MED, POB 913, DUNEDIN, NEW ZEALAND.		Robertson, Mary Clare/A-3964-2009					BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HU MH, 1994, J GERONTOL, V49, pM52, DOI 10.1093/geronj/49.2.M52; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; Myers AH, 1996, BONE, V18, pS87, DOI 10.1016/8756-3282(95)00384-3; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; SPEECHLEY M, 1991, J AM GERIATR SOC, V39, P46, DOI 10.1111/j.1532-5415.1991.tb05905.x; Tinetti ME, 1996, AM J EPIDEMIOL, V144, P389; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x	24	730	755	2	99	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1065	1069		10.1136/bmj.315.7115.1065	http://dx.doi.org/10.1136/bmj.315.7115.1065			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YD445	9366737	Green Published			2022-12-28	WOS:A1997YD44500027
J	Evans, JG				Evans, JG			Geriatric medicine: a brief history	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Evans, JG (corresponding author), RADCLIFFE INFIRM, NUFFIELD DEPT CLIN MED, DIV CLIN GERATOL, OXFORD OX2 6HE, ENGLAND.							Achenbaum WA, 1995, CROSSING FRONTIERS G; BACON E, 1996, WORKS F BACON; Butler R. N., 1975, WHY SURVIVE BEING OL; Charcot J.M., 1881, CLIN LECT DIS OLD AG; Cheyne George, 1724, ESSAY HLTH LONG LIFE; COSIN L, 1954, Practitioner, V172, P552; CROSS VH, 1977, BRIT MED J, V2, P816, DOI 10.1136/bmj.2.6090.816; DAY GE, 1849, PRACTICAL TREATISE D; EVANS JG, 1983, LANCET, V1, P1430; Nascher IL., 1909, NY MED J, V90, P358; OBRIEN TD, 1973, BRIT MED J, V4, P277, DOI 10.1136/bmj.4.5887.277; *ROYAL COLL PHYS, 1994, ENS EQ QUAL CAR ELD; RUBENSTEIN LZ, 1990, IMPROVING HLTH OLDER, P417; RUSH B, 1815, MED INQUIRIES OBSERV; STAHELIN HB, 1994, AGE AGEING, V23, P179, DOI 10.1093/ageing/23.3.179; WARREN MW, 1946, LANCET, V250, P841; Warren MW, 1943, BRIT MED J, V1943, P822	17	40	44	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1075	1077		10.1136/bmj.315.7115.1075	http://dx.doi.org/10.1136/bmj.315.7115.1075			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366740	Green Published			2022-12-28	WOS:A1997YD44500031
J	DeGrendele, HC; Estess, P; Siegelman, MH				DeGrendele, HC; Estess, P; Siegelman, MH			Requirement for CD44 in activated T cell extravasation into an inflammatory site	SCIENCE			English	Article							ADHESION MOLECULE; ENDOTHELIAL-CELLS; HYALURONATE; LYMPHOCYTES; RECOGNITION; MIGRATION; ARTHRITIS; ANTIGEN; INVIVO; SUPERANTIGENS	Leukocytes extravasate from the blood into inflammatory sites through complementary ligand interactions between leukocytes and endothelial cells, Activation of T cells increases their binding to hyaluronate (HA) and enables CD44-mediated primary adhesion (rolling). This rolling could be induced in vivo in murine V(beta)8(+) T cells in response to specific superantigen stimulation; it was initially found in lymph nodes, then in peripheral blood, and finally within the peritoneum, the original inflamed site. The migration of V(beta)8(+) cells into the peritoneal cavity was dependent on CD44 and HA, as shown by inhibition studies. Thus, CD44-HA interactions can target lymphocytes to specific extralymphoid effector sites.	UNIV TEXAS, SW MED CTR, DEPT PATHOL, MOL PATHOL LAB, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [R01 CA57471] Funding Source: Medline; NHLBI NIH HHS [HL56746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057471] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CAHILL RNP, 1976, J EXP MED, V143, P870, DOI 10.1084/jem.143.4.870; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; DEGRENDELE HC, UNPUB; GUY GD, 1978, J EXP MED, V148, P1661; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HERRMANN T, 1992, EUR J IMMUNOL, V22, P1935, DOI 10.1002/eji.1830220739; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JONES DA, 1993, BIOPHYS J, V65, P1560, DOI 10.1016/S0006-3495(93)81195-0; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KENNETT RH, 1980, MONOCLONAL ANTIBODIE; KOSTER FT, 1971, J EXP MED, V133, P864, DOI 10.1084/jem.133.4.864; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MAROKO PR, 1977, NEW ENGL J MED, V296, P898, DOI 10.1056/NEJM197704212961603; MCCORMACK JE, 1993, J IMMUNOL, V150, P3785; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MOHAMADZADEH M, UNPUB; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; SPRENT J, 1971, CELL IMMUNOL, V2, P171, DOI 10.1016/0008-8749(71)90036-0; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SZLAVY L, 1985, ANGIOLOGY, V36, P452, DOI 10.1177/000331978503600707; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zeidler A, 1995, AUTOIMMUNITY, V21, P245, DOI 10.3109/08916939509001943	32	460	482	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					672	675		10.1126/science.278.5338.672	http://dx.doi.org/10.1126/science.278.5338.672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381175				2022-12-28	WOS:A1997YC32300051
J	LeBars, PL; Katz, MM; Berman, N; Itil, TM; Freedman, AM; Schatzberg, AF				LeBars, PL; Katz, MM; Berman, N; Itil, TM; Freedman, AM; Schatzberg, AF			A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE; CLINICAL DIAGNOSTIC-CRITERIA; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; FREE-RADICALS; RATING-SCALE; MULTICENTER; EFFICACY; TACRINE; RELIABILITY	Context.-EGb 761 is a particular extract of Ginkgo biloba used in Europe to alleviate symptoms associated with numerous cognitive disorders, Its use in dementias is based on positive results from only a few controlled clinical trials, most of which did not include standard assessments of cognition and behavior. Objective.-To assess the efficacy and safety of EGb in Alzheimer disease and multi-infarct dementia. Design.-A 52-week, randomized double-blind, placebo-controlled, parallel-group, multicenter study. Patients.-Mildly to severely demented outpatients with Alzheimer disease or multi-infarct dementia, without other significant medical conditions. Intervention.-Patients assigned randomly to treatment with EGb (120 mg/d) or placebo, Safety, compliance, and drug dispensation were monitored every 3 months with complete outcome evaluation at 12, 26, and 52 weeks. Primary Outcome Measures.-Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Geriatric Evaluation by Relative's Rating Instrument (GERRI), and Clinical Global Impression of Change (CGIC). Results.-From 309 patients included in an intent-to-treat analysis, 202 provided evaluable data for the 52-week end point analysis, In the intent-to-treat analysis, the EGb group had an ADAS-Cog score 1.4 points better than the placebo group (P=.04) and a GERRI score 0.14 points better than the placebo group (P=.004). The same patterns were observed with the evaluable data set in which 27% of patients treated with EGb achieved at least a 4-point improvement on the ADAS-Cog, compared with 14% taking placebo (P=.005); on the GERRI, 37% were considered improved with EGb, compared with 23% taking placebo (P=.003). No difference was seen in the CGIC, Regarding the safety profile of EGb, no significant differences compared with placebo were observed in the number of patients reporting adverse events or in the incidence and severity of these events. Conclusions.-EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI.	ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT PSYCHIAT, NEW YORK, NY USA; HARBOR UCLA MED CTR, TORRANCE, CA 90509 USA; NEW YORK MED COLL, DEPT PSYCHIAT, VALHALLA, NY 10595 USA; HARVARD MED CTR, BOSTON, MA USA	Montefiore Medical Center; Yeshiva University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; New York Medical College; Harvard University; Harvard Medical School	LeBars, PL (corresponding author), NYU MED CTR, NEW YORK INST MED RES, DEPT PSYCHIAT, 150 WHITE PLAINS RD, TARRYTOWN, NY 10591 USA.							AGRESTI A, 1989, PSYCHOL BULL, V105, P290, DOI 10.1037/0033-2909.105.2.290; ANDERSON DK, 1994, INT ACAD B, V7, P119; ANTHONY JC, 1982, PSYCHOL MED, V12, P397, DOI 10.1017/S0033291700046730; BALDERESCHI M, 1994, NEUROLOGY, V44, P239, DOI 10.1212/WNL.44.2.239; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; Cott J, 1995, PSYCHOPHARMACOL BULL, V31, P745; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; DAHLKE F, 1992, PSYCHOPHARMACOL BULL, V28, P425; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEFEUDIS FV, 1991, GINKGO BILOBA EXTRAC, P7; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Guy W., 1976, ECDEU ASSESSMENT MAN, P218; HOFFERBERTH B, 1994, HUM PSYCHOPHARM CLIN, V9, P215, DOI 10.1002/hup.470090308; HUGUET F, 1992, J PHARM PHARMACOL, V44, P24, DOI 10.1111/j.2042-7158.1992.tb14357.x; Itil Turan M., 1996, Am J Ther, V3, P63, DOI 10.1097/00045391-199601000-00009; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; Kanowski S, 1996, PHARMACOPSYCHIATRY, V29, P47, DOI 10.1055/s-2007-979544; KATZMAN R, 1988, AGING BRAIN, P17; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; KNOPMAN DS, 1994, NEUROLOGY, V44, P2315, DOI 10.1212/WNL.44.12.2315; KRAMERGINSBERG E, 1988, PSYCHOPHARMACOL BULL, V24, P458; Kristofikova Z, 1997, DEMENT GERIATR COGN, V8, P43; Leber P, 1996, ALZ DIS ASSOC DIS, V10, P31, DOI 10.1097/00002093-199601031-00009; Letzel H, 1996, J DRUG DEV CLIN PR, V8, P77; LOPEZ OL, 1994, NEUROLOGY, V44, P1240, DOI 10.1212/WNL.44.7.1240; Morich FJ, 1996, CLIN DRUG INVEST, V11, P185, DOI 10.2165/00044011-199611040-00001; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; OYAMA Y, 1994, BRAIN RES, V635, P125, DOI 10.1016/0006-8993(94)91431-1; PACKER L, 1995, ADV GINKGO, V4, P23; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; RICHARDSON JS, 1993, ANN NY ACAD SCI, V695, P73, DOI 10.1111/j.1749-6632.1993.tb23031.x; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; SCHWARTZ GE, 1983, PSYCHOL REP, V53, P479, DOI 10.2466/pr0.1983.53.2.479; STERN RG, 1994, AM J PSYCHIAT, V151, P390; VICTOROFF J, 1995, AM J PSYCHIAT, V152, P1476; WARBURTON DM, 1986, PRESSE MED, V15, P1595; WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016	42	764	796	0	93	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1327	1332		10.1001/jama.278.16.1327	http://dx.doi.org/10.1001/jama.278.16.1327			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343463				2022-12-28	WOS:A1997YA90500033
J	Maron, JL; Harrison, S				Maron, JL; Harrison, S			Spatial pattern formation in an insect host-parasitoid system	SCIENCE			English	Article							POPULATION-DYNAMICS; ORGYIA-VETUSTA; PERSISTENCE; DISPERSAL	Spatial models in ecology predict that populations may form patchy distributions within continuous habitats, through strong predator-prey or host-parasitoid interactions combined with limited dispersal. Empirical support of these models is provided. Parasitoids emanating from a population outbreak of tussock moths (Orgyia vetusta) suppressed the growth of nearby experimental populations of the moth, while experimental populations farther away were able to grow. This result explains the observed localized nature of tussock moth outbreaks and illustrates how population distributions can be regulated by dynamic spatial processes.	UNIV CALIF DAVIS, DIV ENVIRONM STUDIES, DAVIS, CA 95616 USA; UNIV WASHINGTON, DEPT BOT, SEATTLE, WA 98195 USA	University of California System; University of California Davis; University of Washington; University of Washington Seattle								[Anonymous], 1994, C RECORD, P29598; Brodmann PA, 1997, J ANIM ECOL, V66, P65, DOI 10.2307/5965; Comins HN, 1996, J THEOR BIOL, V183, P19, DOI 10.1006/jtbi.1996.0197; DEUTSCHMAN DH, 1993, PATCH DYNAMICS, P184; Godfray HCJ, 1997, NATURE, V386, P660, DOI 10.1038/386660a0; HANSKI I, 1997, METAPOPULATION BIOL; Harrison S, 1997, ECOL ENTOMOL, V22, P158, DOI 10.1046/j.1365-2311.1997.00053.x; HARRISON S, 1995, OECOLOGIA, V101, P309, DOI 10.1007/BF00328816; HARRISON S, 1995, OECOLOGIA, V103, P343, DOI 10.1007/BF00328623; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; KAREIVA P, 1990, PHILOS T R SOC B, V330, P175, DOI 10.1098/rstb.1990.0191; Murray J. D., 1989, MATH BIOL, DOI DOI 10.1007/978-3-662-08539-4; NEUBERT MG, 1995, THEOR POPUL BIOL, V48, P7, DOI 10.1006/tpbi.1995.1020; Roland J, 1997, NATURE, V386, P710, DOI 10.1038/386710a0; Ruxton GD, 1996, P ROY SOC B-BIOL SCI, V263, P625, DOI 10.1098/rspb.1996.0094; TURCHIN P, 1989, ECOLOGY, V70, P1008, DOI 10.2307/1941369; WILSON WG, IN PRESS P R SOC L B	18	124	132	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1619	1621		10.1126/science.278.5343.1619	http://dx.doi.org/10.1126/science.278.5343.1619			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374460				2022-12-28	WOS:A1997YJ87400039
J	Jennette, JC; Falk, RJ				Jennette, JC; Falk, RJ			Small-vessel vasculitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; RHEUMATOLOGY 1990 CRITERIA; CHURG-STRAUSS-SYNDROME; HEPATITIS-C VIRUS; SEGMENTAL NECROTIZING GLOMERULONEPHRITIS; HENOCH-SCHONLEIN PURPURA; TERM FOLLOW-UP; WEGENERS GRANULOMATOSIS; SYSTEMIC VASCULITIS; CRESCENTIC GLOMERULONEPHRITIS		UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Jennette, JC (corresponding author), UNIV N CAROLINA, DEPT PATHOL & LAB MED, CB 7525, CHAPEL HILL, NC 27599 USA.			Jennette, John Charles/0000-0002-8081-6565				AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; Agnello V, 1996, RHEUM DIS CLIN N AM, V22, P1, DOI 10.1016/S0889-857X(05)70259-3; ALARCONSEGOVIA D, 1980, CLIN RHEUM DIS, V6, P223; ALARCONSEGOVIA D, 1964, MAYO CLIN PROC, V39, P205; Arkin A, 1930, AM J PATHOL, V6, P401; BAARTDEL.EH, 1973, LANCET, V1, P892; BACON PA, 1994, J RHEUMATOL, V21, P788; BELMAN AL, 1985, PEDIATRICS, V75, P687; Bergstein J, 1996, J AM SOC NEPHROL, V7, pA0416; CARRINGTON CB, 1966, AM J MED, V41, P497, DOI 10.1016/0002-9343(66)90214-2; CHURG J, 1951, AM J PATHOL, V27, P277; Clark E, 1937, ARCH PATHOL, V24, P458; DAMICO G, 1995, AM J KIDNEY DIS, V25, P361, DOI 10.1016/0272-6386(95)90095-0; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; DAVSON J, 1948, Q J MED, V17, P175; DCruz D, 1995, BRIT J RHEUMATOL, V34, P1090; deGroot K, 1996, ARTHRITIS RHEUM, V39, P2052, DOI 10.1002/art.1780391215; DILLON MJ, 1995, RHEUM DIS CLIN N AM, V21, P1115; DOLMAN KM, 1993, LANCET, V342, P651, DOI 10.1016/0140-6736(93)91761-A; DUNA GF, 1995, RHEUM DIS CLIN N AM, V21, P949; EKENSTAM AE, 1984, ARCH DERMATOL, V120, P484; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FALK RJ, 1990, ANN INTERN MED, V113, P656, DOI 10.7326/0003-4819-113-9-656; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; GAUDIN PB, 1995, AM J CLIN PATHOL, V104, P7, DOI 10.1093/ajcp/104.1.7; GAUGHAN RK, 1990, LARYNGOSCOPE, V100, P561; GODMAN GC, 1954, AMA ARCH PATHOL, V58, P533; GOLDSCHMEDING R, 1989, J CLIN INVEST, V84, P1577, DOI 10.1172/JCI114335; GOLDSTEIN AR, 1992, LANCET, V339, P280, DOI 10.1016/0140-6736(92)91341-5; Goodpasture EW, 1919, AM J MED SCI, V158, P863, DOI 10.1097/00000441-191911000-00012; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; GOWER RG, 1978, J ALLERGY CLIN IMMUN, V62, P222, DOI 10.1016/0091-6749(78)90211-7; GROSS WL, 1993, CLIN EXP IMMUNOL, V91, P1; Guillevin L, 1996, BRIT J RHEUMATOL, V35, P958; HALL JB, 1984, AUST NZ J MED, V14, P277, DOI 10.1111/j.1445-5994.1984.tb03769.x; Henoch E., 1868, BERL KLIN WCHNSCHR, V5, P517; HENOCH EH, 1882, LECT DIS CHILDREN HD; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hogan SL, 1996, J AM SOC NEPHROL, V7, P23; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1065; JENNETTE CJ, 1994, ARCH DERMATOL, V130, P899, DOI 10.1001/archderm.130.7.899; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; JENNETTE JC, 1991, AM J KIDNEY DIS, V18, P164, DOI 10.1016/S0272-6386(12)80874-2; JENNETTE JC, 1990, BLOOD, V75, P2263; JENNETTE JC, 1995, ADV PATHOL LAB MED, V8, P363; Jones D A, 1990, N C Med J, V51, P411; KALLENBERG CGM, 1994, KIDNEY INT, V46, P1, DOI 10.1038/ki.1994.239; KISSEL JT, 1992, NEUROL CLIN, V10, P761, DOI 10.1016/S0733-8619(18)30207-X; Klinger H, 1931, FRANKFURT Z PATHOL, V42, P455; Kussmaul A., 1866, DTSCH ARCH KLIN MED, V1, P484; LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001; LANTIN JP, 1994, CLIN EXP RHEUMATOL, V12, P429; LEATHERMAN JW, 1982, AM J MED, V72, P401, DOI 10.1016/0002-9343(82)90496-X; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; LHOTE F, 1995, RHEUM DIS CLIN N AM, V21, P911; LUDEMANN J, 1990, J EXP MED, V171, P357, DOI 10.1084/jem.171.1.357; MARTINEZ JS, 1971, ANN INTERN MED, V75, P67, DOI 10.7326/0003-4819-75-1-67; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; MEHREGAN DR, 1992, J AM ACAD DERMATOL, V26, P441, DOI 10.1016/0190-9622(92)70069-R; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; Merkel PA, 1997, ANN INTERN MED, V126, P866, DOI 10.7326/0003-4819-126-11-199706010-00003; MICHEL BA, 1992, J RHEUMATOL, V19, P721; MILLS JA, 1990, ARTHRITIS RHEUM, V33, P1114; Nachman PH, 1996, J AM SOC NEPHROL, V7, P33; NILES JL, 1989, BLOOD, V74, P1888; Niles JL, 1996, ARCH INTERN MED, V156, P440, DOI 10.1001/archinte.156.4.440; NOVACK SN, 1971, NEW ENGL J MED, V284, P938, DOI 10.1056/NEJM197104292841703; Osler W, 1914, BRIT MED J, V1914, P517, DOI 10.1136/bmj.1.2775.517; Osler William, 1895, AM J MED SCI, V110, P629, DOI DOI 10.1097/00000441-189512000-00001; PANEGYRES PK, 1990, J NEUROL SCI, V100, P193, DOI 10.1016/0022-510X(90)90033-J; PARKER CW, 1975, NEW ENGL J MED, V292, P511, DOI 10.1056/NEJM197503062921006; PETTERSSON EE, 1995, CLIN NEPHROL, V43, P141; PURPURA, 1908, CURTANEOUS DIS, V1, P452; RONCO P, 1983, Q J MED, V52, P212; SANCHEZ NP, 1985, ARCH DERMATOL, V121, P220, DOI 10.1001/archderm.121.2.220; SAVAGE COS, 1985, Q J MED, V56, P467; Savage COS, 1997, LANCET, V349, P553, DOI 10.1016/S0140-6736(97)80118-3; SCHEER RL, 1964, ANN INTERN MED, V60, P1009, DOI 10.7326/0003-4819-60-6-1009; Schonlein JL, 1837, ALLGEMEINE SPECIELLE, V2, P48; SHORT AK, 1995, QJM-MON J ASSOC PHYS, V88, P775; SNELLER MC, 1995, ARTHRITIS RHEUM, V38, P608, DOI 10.1002/art.1780380505; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Stegeman CA, 1996, NEW ENGL J MED, V335, P16, DOI 10.1056/NEJM199607043350103; STORCK H, 1951, Dermatologica, V102, P197; STURGILL BC, 1965, J AMER MED ASSOC, V194, P914, DOI 10.1001/jama.194.8.914; SWERLICK RA, 1989, MED CLIN N AM, V73, P1221, DOI 10.1016/S0025-7125(16)30630-7; TalarWilliams C, 1996, ANN INTERN MED, V124, P477, DOI 10.7326/0003-4819-124-5-199603010-00003; TANEMOTO M, 1995, AM J KIDNEY DIS, V26, P774, DOI 10.1016/0272-6386(95)90441-7; VANDERWOUDE FJ, 1985, LANCET, V1, P425; Wegener F, 1939, BEITR PATHOL ANAT AL, V102, P36; WEISS MA, 1984, HUM PATHOL, V15, P943, DOI 10.1016/S0046-8177(84)80124-0; WINKELMANN RK, 1964, MEDICINE, V43, P59, DOI 10.1097/00005792-196401000-00003; WINKLEMANN RK, 1958, MAYO CLIN P, V33, P277; WOLKENSTEIN P, 1995, DRUG SAFETY, V13, P56, DOI 10.2165/00002018-199513010-00007; WRIGHT WK, 1994, PEDIATR PULM, V17, P269, DOI 10.1002/ppul.1950170411; YAMASHITA K, 1995, OPHTHALMOLOGICA, V209, P172, DOI 10.1159/000310606; ZEEK PM, 1952, AM J CLIN PATHOL, V22, P777; ZEEK PM, 1948, AM J PATHOL, V24, P889	99	932	980	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1512	1523		10.1056/NEJM199711203372106	http://dx.doi.org/10.1056/NEJM199711203372106			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366584				2022-12-28	WOS:A1997YG24900006
J	Pauwels, RA; Lofdahl, CG; Postma, DS; Tattersfield, AE; OByrne, P; Barnes, PJ; Ullman, A				Pauwels, RA; Lofdahl, CG; Postma, DS; Tattersfield, AE; OByrne, P; Barnes, PJ; Ullman, A			Effect of inhaled formoterol and budesonide on exacerbations of asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GUINEA-PIG; MILD ASTHMA; AIRWAY RESPONSIVENESS; MICROVASCULAR LEAKAGE; LUNG DEPOSITION; BETA-AGONISTS; SALMETEROL; ALBUTEROL; TOLERANCE; CORTICOSTEROIDS	Background The role of long-acting, inhaled beta(2)-agonists in treating asthma is uncertain. In a double-blind study, we evaluated the effects of adding inhaled formoterol to both lower and higher doses of the inhaled glucocorticoid budesonide. Methods After a four-week run-in period of treatment with budesonide (800 mu g twice daily), 852 patients being treated with glucocorticoids were randomly assigned to one of four treatments given twice daily by means of a dry-powder inhaler (Turbuhaler): 100 mu g of budesonide plus placebo, 100 mu g of budesonide plus 12 mu g of formoterol, 400 mu g of budesonide plus placebo, or 400 mu g of budesonide plus 12 mu g of formoterol. Terbutaline was permitted as needed. Treatment continued for one year; we compared the frequency of exacerbations of asthma, symptoms, and lung function in the four groups. A severe exacerbation was defined by the need for oral glucocorticoids or a decrease in the peak flow to more than 30 percent below the base-line value on two consecutive days. Results The rates of severe and mild exacerbations were reduced by 26 percent and 40 percent, respectively, when formoterol was added to the lower dose of budesonide. The higher dose of budesonide alone reduced the rates of severe and mild exacerbations by 49 percent and 37 percent, respectively. Patients treated with formoterol and the higher dose of budesonide had the greatest reductions - 63 percent and 62 percent, respectively. Symptoms of asthma and lung function improved with both formoterol and the higher dose of budesonide, but the improvements with formoterol were greater. Conclusions In patients who have persistent symptoms of asthma despite treatment with inhaled glucocorticoids, the addition of formoterol to budesonide therapy or the use of a higher dose of budesonide may be beneficial. The addition of formoterol to budesonide therapy improves symptoms and lung function without lessening the control of asthma. (C) 1997, Massachusetts Medical Society.	UNIV LUND HOSP, DEPT RESP MED, S-22185 LUND, SWEDEN; UNIV GRONINGEN HOSP, DIV RESP MED, GRONINGEN, NETHERLANDS; CITY HOSP, DIV RESP MED, NOTTINGHAM NG5 1PB, ENGLAND; MCMASTER UNIV, DEPT RESPIROL, HAMILTON, ON, CANADA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, LONDON, ENGLAND; ASTRO DRACO AB, CLIN RES & DEV, LUND, SWEDEN	Lund University; Skane University Hospital; University of Groningen; University of Nottingham; McMaster University; Imperial College London	Pauwels, RA (corresponding author), STATE UNIV GHENT HOSP, DEPT RESP DIS, DE PINTELAAN 185, B-9000 GHENT, BELGIUM.			O'Byrne, Paul/0000-0003-0979-281X; Barnes, Peter/0000-0002-5122-4018				ADVENIER C, 1992, BRIT J PHARMACOL, V105, P792, DOI 10.1111/j.1476-5381.1992.tb09059.x; BALUK P, 1994, AM J PHYSIOL, V266, pL461, DOI 10.1152/ajplung.1994.266.4.L461; Bhagat, 1996, CHEST, V109, P592; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; Borgstrom L, 1996, AM J RESP CRIT CARE, V153, P1636, DOI 10.1164/ajrccm.153.5.8630614; BRITTON MG, 1993, EUR RESPIR J, V6, P150; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1995, AM J RESP CRIT CARE, V152, P1485, DOI 10.1164/ajrccm.152.5.7582281; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; ERJEFALT I, 1991, AM REV RESPIR DIS, V144, P788, DOI 10.1164/ajrccm/144.4.788; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; KALLSTROM BL, 1994, BRIT J PHARMACOL, V113, P687; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; KESTEN S, 1992, ANN ALLERGY, V69, P415; KESTEN S, 1991, AM REV RESPIR DIS, V144, P622, DOI 10.1164/ajrccm/144.3_Pt_1.622; LOFDAHL CG, 1991, EUR RESPIR J, V4, P1161; *NAT HEART LUNG BL, 1995, NAT HEART LUNG BLOOD; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; ROBERTS J A, 1992, American Review of Respiratory Disease, V145, pA418; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TATTERSFIELD AE, 1993, LIFE SCI, V52, P2161, DOI 10.1016/0024-3205(93)90730-Q; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; TURNER MO, 1995, THORAX, V50, P1057, DOI 10.1136/thx.50.10.1057; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; WHELAN CJ, 1993, BRIT J PHARMACOL, V110, P613, DOI 10.1111/j.1476-5381.1993.tb13855.x; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; YATES DH, 1995, AM J RESP CRIT CARE, V152, P1170, DOI 10.1164/ajrccm.152.4.7551366	36	1226	1276	2	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1405	1411		10.1056/NEJM199711133372001	http://dx.doi.org/10.1056/NEJM199711133372001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF253	9358137				2022-12-28	WOS:A1997YF25300001
J	Hastier, P; Buckley, MJM; Raffaelli, C; Delmont, JP				Hastier, P; Buckley, MJM; Raffaelli, C; Delmont, JP			A clue in the duodenum	LANCET			English	Article							WHIPPLES-DISEASE				Hastier, P (corresponding author), CHU,HOP ARCHET II,SERV HEPATOGASTROENTEROL,F-06202 NICE,FRANCE.							ADAMS M, 1987, ANN NEUROL, V21, P104, DOI 10.1002/ana.410210121; BITTNER K, 1987, MED KLIN, V82, P421; JAMES TN, 1984, AM J MED SCI, V288, P125, DOI 10.1097/00000441-198410000-00006; PAR MM, 1962, ARCH MAL APPAR DIG, V62, P731; Schnider PJ, 1996, EUR J GASTROEN HEPAT, V8, P899	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1362	1362		10.1016/S0140-6736(97)07542-9	http://dx.doi.org/10.1016/S0140-6736(97)07542-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365451				2022-12-28	WOS:A1997YE87200011
J	Zhang, BL; Cech, TR				Zhang, BL; Cech, TR			Peptide bond formation by in vitro selected ribozymes	NATURE			English	Article							RNA; EVOLUTION; TETRAHYMENA; CATALYSIS; INVITRO; LIGANDS; DNA	An attractive solution to the problem of the origin of protein synthesis in an evolving 'RNA world' involves catalysis by nucleic acid without assistance from proteins(1,2). Indeed, even the modem ribosome has been considered to be fundamentally an RNA, machine(3), and the large ribosomal subunit can carry out peptidyl transfer in the absence of most of its protein subunits(4). Successive cycles of in vitro selection and amplification(5-7) have been used to find RNAs that perform many biochemical reactions(8-16), including transfer of an RNA-linked amino acid io their own 5'-amino-modified terminus(15). Here we demonstrate the in vitro selection of ribozymes (196 nucleotides) that perform the same pepridyl transferase reaction as the ribosome: that is, they can join amino acids by a peptide bond. Like ribosome substrates, one amino, acid (N-blocked methionine) is esterified to the 3'(2')-O of adenosine, whereas the acceptor amino acid (phenylalanine) has a free amino group. Our best characterized ribozyme recognizes the amino-acid ester substrate by binding its adenosine moiety, and is therefore capable of utilizing Leu-and Phe- as well as Met-derived substrates. Such lack of specificity with respect to the amino acid is a feature necessary for a generalized protein-synthesizing enzyme.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								AZHAYEV AV, 1977, NUCLEIC ACIDS RES, V4, P2223, DOI 10.1093/nar/4.7.2223; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; CECH TR, 1993, RNA WORLD, P239; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DAI XC, 1995, SCIENCE, V267, P237, DOI 10.1126/science.7809628; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; KRAYEVSKY AA, 1975, NUCLEIC ACIDS RES, V2, P2223, DOI 10.1093/nar/2.12.2223; Lohse PA, 1996, NATURE, V381, P442, DOI 10.1038/381442a0; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; MADEN BEH, 1968, EUR J BIOCHEM, V6, P309, DOI 10.1111/j.1432-1033.1968.tb00450.x; MERCER TFB, 1972, EUR J BIOCHEM, V28, P38; MONRO RE, 1968, P NATL ACAD SCI USA, V61, P1042, DOI 10.1073/pnas.61.3.1042; NIERHAUS KH, 1980, BIOCHEM INT, V1, P185; Noller H.F., 1993, RNA WORLD, P137; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wecker M, 1996, RNA, V2, P982; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0; Woese C, 1967, GENETIC CODE, P179	27	226	244	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					96	100		10.1038/36375	http://dx.doi.org/10.1038/36375			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363898				2022-12-28	WOS:A1997YE47700060
J	Wenger, NK				Wenger, NK			Coronary heart disease: an older woman's major health risk	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; IN-HOSPITAL MORTALITY; CARDIOVASCULAR-DISEASE; CHEST PAIN; INTERVENTION REGISTRY; POSTMENOPAUSAL WOMEN; THROMBOLYTIC THERAPY; PRIMARY PREVENTION; GENDER DIFFERENCES; SMOKING CESSATION				Wenger, NK (corresponding author), EMORY UNIV, SCH MED, DEPT MED, DIV CARDIOL, ATLANTA, GA 30303 USA.							ADAMS JN, 1995, BRIT HEART J, V73, P87; [Anonymous], 1991, JAMA, V265, P3255; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; Bell M R, 1996, Am J Card Imaging, V10, P44; BELL MR, 1995, CIRCULATION, V91, P2876, DOI 10.1161/01.CIR.91.12.2876; Boogard M, 1985, J CARDIOPULM REHABIL, V5, P379; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; *COMM FUND, 1993, SURV WOM HLTH; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HERMANSON B, 1988, NEW ENGL J MED, V319, P1365, DOI 10.1056/NEJM198811243192101; JENKINS JS, 1994, AM J CARDIOL, V73, P319, DOI 10.1016/0002-9149(94)90001-9; KANNEL WB, 1988, NUTR REV, V46, P68, DOI 10.1111/j.1753-4887.1988.tb05389.x; KAWACHI I, 1993, ANN INTERN MED, V119, P992, DOI 10.7326/0003-4819-119-10-199311150-00005; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; KING KB, 1994, J WOMENS HEALTH, V3, P347; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LACROIX AZ, 1990, CIRCULATION, V81, P437, DOI 10.1161/01.CIR.81.2.437; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; Legato MJ, 1997, J WOMENS HEALTH, V6, P189, DOI 10.1089/jwh.1997.6.189; Lehmann JB, 1996, AM J CARDIOL, V77, P641, DOI 10.1016/S0002-9149(97)89322-8; LEMAITRE RN, 1995, ARCH INTERN MED, V155, P2302, DOI 10.1001/archinte.155.21.2302; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MANOLIO TA, 1993, CIRCULATION, V88, P2163, DOI 10.1161/01.CIR.88.5.2163; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MAYNARD C, 1992, J MYOCARD ISCHEMIA, V4, P27; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; *NAT CTR HLTH STAT, 1991, HLTH US 1990 US PUBL; OCONNOR GT, 1993, CIRCULATION, V88, P2104, DOI 10.1161/01.CIR.88.5.2104; PEDERSEN TR, 1994, LANCET, V344, P1383; PEPINE CJ, 1994, AM J CARDIOL, V74, P226, DOI 10.1016/0002-9149(94)90361-1; PILOTE L, 1995, AM HEART J, V129, P1237, DOI 10.1016/0002-8703(95)90426-3; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAMAAN SA, 1995, J AM COLL CARDIOL, V26, P1403, DOI 10.1016/0735-1097(95)00360-6; Schrott HG, 1997, JAMA-J AM MED ASSOC, V277, P1281, DOI 10.1001/jama.277.16.1281; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; STONE GW, 1995, AM J CARDIOL, V75, P987, DOI 10.1016/S0002-9149(99)80709-7; Stone PH, 1996, JAMA-J AM MED ASSOC, V275, P1104, DOI 10.1001/jama.275.14.1104; SULLIVAN AK, 1994, BRIT MED J, V308, P883, DOI 10.1136/bmj.308.6933.883; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; WEINTRAUB WS, 1993, CIRCULATION, V88, P79; Weintraub WS, 1996, AM J CARDIOL, V78, P1154, DOI 10.1016/S0002-9149(96)90071-5; WEINTRAUB WS, 1994, J AM COLL CARDIOL, V24, P81, DOI 10.1016/0735-1097(94)90545-2; WELTY FK, 1994, J AM COLL CARDIOL, V23, P35, DOI 10.1016/0735-1097(94)90499-5; Wenger N K, 1996, Am J Card Imaging, V10, P42; Wenger N. K., 1997, WOMEN HEART DIS, P21; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WENGER NK, 1995, CLIN PRACTICE GUIDEL, V17; WENGER NK, 1977, J MED ASS GA, V86, P187; Woodfield SL, 1997, J AM COLL CARDIOL, V29, P35, DOI 10.1016/S0735-1097(96)00449-4	56	103	103	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1085	1090		10.1136/bmj.315.7115.1085	http://dx.doi.org/10.1136/bmj.315.7115.1085			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366743	Green Published			2022-12-28	WOS:A1997YD44500034
J	Altar, CA; Cai, N; Bliven, T; Juhasz, M; Conner, JM; Acheson, AL; Lindsay, RM; Wiegand, SJ				Altar, CA; Cai, N; Bliven, T; Juhasz, M; Conner, JM; Acheson, AL; Lindsay, RM; Wiegand, SJ			Anterograde transport of brain-derived neurotrophic factor and its role in the brain	NATURE			English	Article							PARVALBUMIN-IMMUNOREACTIVE NEURONS; NERVOUS-SYSTEM; MESSENGER-RNA; BDNF; RAT; NT-3; DIFFERENTIATION; EXPRESSION; FOREBRAIN; NT-4/5	The role of neurotrophins as target-derived proteins that promote neuron survival following their retrograde transport from the terminals to the cell bodies of neurons has been firmly established in the developing peripheral nervous system. However, neurotrophins appear to have more diverse functions, particularly in the adult central nervous system. Brain-derived neurotrophic factor (BDNF), for example, produces a variety of neuromodulatory effects in the brain that are more consistent with local actions than with long-distance retrograde signalling. Here we show that BDNF is widely distributed in nerve terminals, even in brain areas such as the striatum that lack BDNF messenger RNA, and that inhibition of axonal transport or deafferentation depletes BDNF. The number of striatal neurons that contain the calcium-binding protein parvalbumin was decreased in BDNF+/- and BDNF-/- mice in direct proportion to the loss of BDNF protein, which is consistent with anterogradely supplied BDNF having a functional role in development or maintenance. Thus the anterograde transport of BDNF from neuron cell bodies to their terminals may be important for the trafficking of BDNF in the brain.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	Altar, CA (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022					ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; ALTAR CA, 1996, NEUROPROTECTIVE APPR, P160; Conner JM, 1997, J NEUROSCI, V17, P2295; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; Fawcett JP, 1997, J BIOL CHEM, V272, P8837; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KITA H, 1990, BRAIN RES, V536, P1, DOI 10.1016/0006-8993(90)90002-S; LAPPER SR, 1992, BRAIN RES, V580, P215, DOI 10.1016/0006-8993(92)90947-8; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; *NAT RES COUNC NAT, 1996, GUID CAR US LAB AN; Radka SF, 1996, BRAIN RES, V709, P122, DOI 10.1016/0006-8993(95)01321-0; SEROOGY KB, 1993, EXP NEUROL, V124, P119, DOI 10.1006/exnr.1993.1182; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; WU K, 1997, MOL BRAIN RES, V43, P286; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Zhou XF, 1996, NEUROSCIENCE, V74, P945, DOI 10.1016/S0306-4522(96)00237-0	28	709	725	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					856	860		10.1038/39885	http://dx.doi.org/10.1038/39885			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349818				2022-12-28	WOS:A1997YC14800059
J	Kushida, CA; Efron, B; Guilleminault, C				Kushida, CA; Efron, B; Guilleminault, C			A predictive morphometric model for the obstructive sleep apnea syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						sleep apnea syndromes; models, anatomic; mouth; neck; body mass index	CLINICAL-FEATURES; AIRWAY; ABNORMALITIES; MORPHOLOGY	Background: Mathematical formulas have been used to clinically predict whether patients will develop the obstructive steep apnea syndrome (OSAS). However, these models do not take into account the disproportionate craniofacial anatomy that accompanies OSAS independently of obesity. Objective: To determine the accuracy of a morphometric model, which combines measurements of the oral cavity with body mass index and neck circumference, in predicting whether a patient has OSAS. Design: 6-month prospective study. Setting: University-based tertiary referral sleep clinic and research center. Participants: 300 consecutive patients evaluated for sleep disorders for the first time. Measurements: Body mass index, neck circumference, and oral cavity measurements were obtained, and a model value was calculated for each patient. Polysomnography was used to determine the number of abnormal respiratory events that occurred during sleep. Sleep apnea was defined as more than five episodes of apnea or hypopnea per hour of sleep. Results: The morphometric model had a sensitivity of 97.6% (95% Cl, 95% to 98.9%), a specificity of 100% (Cl, 92% to 100%), a positive predictive Value of 100% (Cl, 98.5% to 100%), and a negative predictive value of 88.5% (Cl, 77% to 96%). No significant discrepancies were revealed in tests of intermeasurer and test-retest reliability. Conclusions: The morphometric model provides a rapid, accurate, and reproducible method for predicting whether patients in an ambulatory setting have OSAS. The model may be clinically useful as a screening toot for OSAS rather than as a replacement for polysomnography.			Kushida, CA (corresponding author), STANFORD UNIV, SLEEP DISORDERS CLIN & RES CTR, 401 QUARRY RD, SUITE 3301-A, STANFORD, CA 94305 USA.				NIA NIH HHS [AG07772, AG00164-07] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007772] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Sleep Disorders Association International Classification of Sleep Disorders, 1997, INT CLASS SLEEP DIS; Clemente C., 1981, ANATOMY REGIONAL ATL, V2nd ed.; CRONBACH LJ, 1972, DEPENDABILITY BEHAV, P78; CRONBACH LJ, 1990, ESSENTIALS PSYCHOL T, P195; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; DENNISON WM, 1965, PEDIATRICS, V36, P336; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; Efron B., 1994, MONOGRAPHS STAT APPL; FERGUSON KA, 1995, CHEST, V108, P375, DOI 10.1378/chest.108.2.375; Goodman R, 1970, FACE GENETIC DISORDE; HAYDEN GD, 1977, DISORDERS RESP TRACT; HOFFSTEIN V, 1992, EUR RESPIR J, V5, P377; HOFFSTEIN V, 1993, SLEEP, V16, P118; JAMIESON A, 1986, SLEEP, V9, P469, DOI 10.1093/sleep/9.4.469; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KATZ I, 1990, AM REV RESPIR DIS, V141, P1228, DOI 10.1164/ajrccm/141.5_Pt_1.1228; KEENAN SP, 1993, SLEEP, V16, pS133, DOI 10.1093/sleep/16.suppl_8.S133; KHOSLA T, 1967, BRIT J PREV SOC MED, V21, P122; LANIADO N, 1987, SLEEP RES, V16, P378; LOWE AA, 1986, AM J ORTHOD DENTOFAC, V90, P484, DOI 10.1016/0889-5406(86)90108-3; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MATTSON DE, 1986, STATISTICS; PARTINEN M, 1988, CHEST, V93, P1199, DOI 10.1378/chest.93.6.1199; RAUSCHER H, 1993, THORAX, V48, P275, DOI 10.1136/thx.48.3.275; RIVLIN J, 1984, AM REV RESPIR DIS, V129, P355; ROJEWSKI TE, 1982, LARYNGOSCOPE, V92, P246; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; Swets J., 1982, EVALUATION DIAGNOSTI; VINER S, 1991, ANN INTERN MED, V115, P356, DOI 10.7326/0003-4819-115-5-356; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	31	180	197	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				581	+		10.7326/0003-4819-127-8_Part_1-199710150-00001	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341055				2022-12-28	WOS:A1997YB41900001
J	Ruediger, N				Ruediger, N			Work in clinical research - Without a medical degree	SCIENCE			English	Article																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					153	153						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9340744				2022-12-28	WOS:A1997XZ12400062
J	Hordijk, PL; tenKlooster, JP; vanderKammen, RA; Michiels, F; Oomen, LCJM; Collard, JG				Hordijk, PL; tenKlooster, JP; vanderKammen, RA; Michiels, F; Oomen, LCJM; Collard, JG			Inhibition of invasion of epithelial cells by Tiam1-Rac signaling	SCIENCE			English	Article							E-CADHERIN; RAS TRANSFORMATION; ADHESION; GENE; IDENTIFICATION; PROTEIN; CATENIN; CDC42; RAC1; RHO	Tiam1 encodes an exchange factor for the Rho-like guanosine triphosphatase Rac. Both Tiam1 and activated RacV12 promote invasiveness of T lymphoma cells. In epithelial Madin-Darby canine kidney (MDCK) cells, Tiam1 localized to adherens junctions. Ectopic expression of Tiam1 or RacV12 inhibited hepatocyte growth factor-induced scattering by increasing E-cadherin-mediated cell-cell adhesion accompanied by actin polymerization at cell-cell contacts. In Ras-transformed MDCK cells, expression of Tiam1 or RacV12 restored E-cadherin-mediated adhesion, resulting in phenotypic reversion and loss of invasiveness. These data suggest an invasion-suppressor role for Tiam1 and Rac in epithelial cells.	NETHERLANDS CANC INST,DIV CELL BIOL,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				ten Klooster, Jean Paul/0000-0002-4979-7482; Hordijk, Peter/0000-0002-3348-078X				BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FURLONG RA, 1992, BIOESSAYS, V14, P613, DOI 10.1002/bies.950140908; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MICHIELS F, UNPUB; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIELDY AJ, 1995, MOL CELL BIOL, V15, P110; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Webb CP, 1996, J CELL SCI, V109, P2371	27	385	400	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1464	1466		10.1126/science.278.5342.1464	http://dx.doi.org/10.1126/science.278.5342.1464			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367959				2022-12-28	WOS:A1997YG85800045
J	Walpoth, BH; WalpothAslan, BN; Mattle, HP; Radanov, BP; Schroth, G; Schaeffler, L; Fischer, AP; vonSegesser, L; Althaus, U				Walpoth, BH; WalpothAslan, BN; Mattle, HP; Radanov, BP; Schroth, G; Schaeffler, L; Fischer, AP; vonSegesser, L; Althaus, U			Outcome of survivors of accidental deep hypothermia and circulatory arrest treated with extracorporeal blood warming	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC-ARREST; CARDIOPULMONARY RESUSCITATION; EXPERIENCE	Background Cardiopulmonary bypass has been used to rewarm victims of accidental deep hypothermia. Unlike other rewarming techniques, it restores organ perfusion immediately in patients with inadequate circulation. This study evaluated the long-term outcome of survivors of accidental deep hypothermia with circulatory arrest who had been rewarmed with cardiopulmonary bypass. Methods Deep hypothermia (core temperature, <28 degrees C) with circulatory arrest was found in 46 of 234 patients with accidental hypothermia. In 32 of the 46 patients, rewarming with cardiopulmonary bypass was attempted, resulting in 15 long-term survivors. In most of these patients, deep hypothermia developed after mountaineering accidents or suicide attempts. After an average (+/-SD) of 6.7+/-4.0 years of follow-up, we obtained the patients' medical histories and performed neurologic and neuropsychological examinations, neurovascular ultrasound studies, electroencephalography, and magnetic resonance imaging of the brain. Results The average age of the patients was 25.2+/-9.9 years; seven were female and eight were male. The mean interval from discovery of the pa tient to rewarming with cardiopulmonary bypass was 141+/-50 minutes (range, 30 to 240). At follow-up there were no hypothermia-related sequelae that impaired quality of life. Neurologic and neuropsychological deficits observed in the early period after rewarming had fully or almost completely disappeared. One patient had cerebellar atrophy on magnetic resonance imaging with mild clinical signs, a condition that may have been caused by hypothermia. Other clinical abnormalities were either preexisting or due to injuries not related to hypothermia. Conclusions This clinical experience demonstrates that young, otherwise healthy people can survive accidental deep hypothermia with no or minimal cerebral impairment, even with prolonged circulatory arrest. Cardiopulmonary bypass appears to be an efficacious rewarming technique. (C) 1997, Massachusetts Medical Society.	UNIV BERN,INSELSPITAL,DEPT NEUROL,CH-3010 BERN,SWITZERLAND; UNIV BERN,INSELSPITAL,DEPT PSYCHIAT,CH-3010 BERN,SWITZERLAND; UNIV BERN,INSELSPITAL,DEPT NEURORADIOL,CH-3010 BERN,SWITZERLAND; UNIV LAUSANNE HOSP,DEPT CARDIOVASC SURG,LAUSANNE,SWITZERLAND; UNIV ZURICH,DEPT CARDIOVASC SURG,ZURICH,SWITZERLAND	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Zurich	Walpoth, BH (corresponding author), UNIV BERN,INSELSPITAL,DEPT THORAC & CARDIOVASC SURG,CH-3010 BERN,SWITZERLAND.							ALTHAUS U, 1982, ANN SURG, V195, P492, DOI 10.1097/00000658-198204000-00018; AUERBACH PS, 1990, JAMA-J AM MED ASSOC, V264, P1856, DOI 10.1001/jama.264.14.1856; BARRATTBOYES BG, 1976, ANN SURG, V184, P376; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BIGELOW WG, 1950, AM J PHYSIOL, V160, P125, DOI 10.1152/ajplegacy.1949.160.1.125; BIGGART MJ, 1990, J PEDIATR-US, V117, P179, DOI 10.1016/S0022-3476(05)80526-8; BOLTE RG, 1988, JAMA-J AM MED ASSOC, V260, P377, DOI 10.1001/jama.260.3.377; Brugger H, 1996, RESUSCITATION, V31, P11, DOI 10.1016/0300-9572(95)00913-2; DANZL DF, 1989, CRIT CARE MED, V17, P227, DOI 10.1097/00003246-198903000-00005; DANZL DF, 1994, NEW ENGL J MED, V331, P1756, DOI 10.1056/NEJM199412293312607; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; DAVIES DM, 1967, LANCET, V1, P1036; FALK M, 1994, NATURE, V368, P21, DOI 10.1038/368021a0; GENTILELLO LM, 1992, J TRAUMA, V32, P316, DOI 10.1097/00005373-199203000-00009; GREGORY JS, 1991, J TRAUMA, V31, P1247, DOI 10.1097/00005373-199109000-00008; GRIEPP EB, 1992, J CARDIAC SURG, V7, P134, DOI 10.1111/j.1540-8191.1992.tb00790.x; HARNETT RM, 1983, AVIAT SPACE ENVIR MD, V54, P425; HAUTY MG, 1987, J TRAUMA, V27, P1107, DOI 10.1097/00005373-198710000-00002; HERITY B, 1991, J EPIDEMIOL COMMUN H, V45, P19, DOI 10.1136/jech.45.1.19; KIRKLIN JW, 1993, CARDIAC SURG, V1, P61; Kornberger E, 1996, J NEUROSURG ANESTH, V8, P83, DOI 10.1097/00008506-199601000-00027; LARACH MG, 1995, LANCET, V345, P493, DOI 10.1016/S0140-6736(95)90587-1; LLOYD EL, 1986, HYPOTHERMIA COLD STR, P237; LOCHER T, 1991, SCHWEIZ MED WSCHR, V121, P1020; LONGSTRETH WT, 1983, ANN INTERN MED, V98, P588, DOI 10.7326/0003-4819-98-5-588; MAIR P, 1994, RESUSCITATION, V27, P47, DOI 10.1016/0300-9572(94)90021-3; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MESSMER BJ, 1976, J THORAC CARDIOV SUR, V72, P495; Michelet J., 1991, COLOR ATLAS MOUNTAIN, P104; MILLER JW, 1980, ANN EMERG MED, V9, P456, DOI 10.1016/S0196-0644(80)80304-0; Mills W J Jr, 1983, Alaska Med, V25, P29; PATON BC, 1983, PHARMACOL THERAPEUT, V22, P331, DOI 10.1016/0163-7258(83)90008-6; Perret E., 1973, GEHIRN VERHALTEN NEU; ROEWER N, 1985, ANASTH INTENSIV NOTF, V20, P244, DOI 10.1055/s-2007-1003118; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; Rosomoff HL, 1964, ACTA NEUROCHIR WIE S, V14, P11; SCHALLER MD, 1990, JAMA-J AM MED ASSOC, V264, P1842, DOI 10.1001/jama.264.14.1842; Steele MT, 1996, ANN EMERG MED, V27, P479, DOI 10.1016/S0196-0644(96)70237-8; VONSEGESSER LK, 1991, ANN THORAC SURG, V52, P560, DOI 10.1016/0003-4975(91)90929-K; WALPOTH BH, 1990, EUR J CARDIO-THORAC, V4, P390, DOI 10.1016/1010-7940(90)90048-5	40	278	282	3	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1500	1505		10.1056/NEJM199711203372103	http://dx.doi.org/10.1056/NEJM199711203372103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366581				2022-12-28	WOS:A1997YG24900003
J	Blumenthal, D				Blumenthal, D			The future of quality measurement and management in a transforming health care system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHYSICIANS		PARTNERS HEALTHCARE SYST,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115	Partners Healthcare System; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Blumenthal, D (corresponding author), MASSACHUSETTS GEN HOSP,HLTH POLICY RES & DEV UNIT,9TH FLOOR,50 STANIFORD ST,BOSTON,MA 02114, USA.							BERENSON RA, 1996, MARK TURM EV REL SEP; BLUMENTHAL D, 1993, JAMA-J AM MED ASSOC, V269, P2775, DOI 10.1001/jama.269.21.2775; Blumenthal D, 1996, HEALTH AFFAIR, V15, P170, DOI 10.1377/hlthaff.15.2.170; Blumenthal D, 1996, NEW ENGL J MED, V335, P1328, DOI 10.1056/NEJM199610243351721; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Gabel J, 1997, HEALTH AFFAIR, V16, P134, DOI 10.1377/hlthaff.16.3.134; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; *SAND NAT LAB, 1996, STRAT FUT ROL TECHN; Sikorski R, 1997, JAMA-J AM MED ASSOC, V277, P171; Sonnenberg FA, 1997, ARCH INTERN MED, V157, P151, DOI 10.1001/archinte.157.2.151; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209	11	41	41	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1622	1625		10.1001/jama.278.19.1622	http://dx.doi.org/10.1001/jama.278.19.1622			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YF407	9370511				2022-12-28	WOS:A1997YF40700048
J	Price, DT; Ridker, PM				Price, DT; Ridker, PM			Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective	ANNALS OF INTERNAL MEDICINE			English	Review							ACTIVATED PROTEIN-C; DEEP-VEIN-THROMBOSIS; IDIOPATHIC VENOUS THROMBOEMBOLISM; POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; ORAL-CONTRACEPTIVES; APC-RESISTANCE; MYOCARDIAL-INFARCTION; PULMONARY-EMBOLISM; INHERITED RESISTANCE	Background: A single point mutation in the gene coding for coagulation factor V results in a form of factor Va that is resistant to degradation by activated protein C and leads to a relative hypercoagulable slate. This mutation, factor V Leiden, is found in 4% to 6% of the U.S. population. Purpose: To review clinical data on factor V Leiden mutation, with emphasis on prevalence of and risks for thromboembolism and implications for screening and management. Data Sources: A MEDLINE search of the English-language literature published between 1993 and April 1997 and an extensive bibliography review. Study Selection: Case-control and prospective cohort studies were reviewed if clinical features of thromboembolic disease associated with factor V Leiden mutation or resistance to activated protein C were presented. Original research articles were reviewed if they addressed the identification of the laboratory abnormality of activated protein C or factor V Leiden mutation. Case reports and case series were reviewed when no analytic data were available. Data Extraction: Review of the identified articles. Data Synthesis: Factor V Leiden mutation is associated with three-to sixfold increases in risks for primary and recurrent venous thromboembolism, especially in patients without transient risk factors, such as surgery or trauma. Risks for venous thromboembolism in genetically affected persons are substantially higher among patients with coexistent predispositions for thrombosis, such as advanced age, use of oral contraceptives, hyperhomocystinemia, and deficiencies of protein C and protein S. Factor V Leiden mutation does not seem to increase risks for arterial thrombosis. Whether patients with the mutation would benefit from more intense or prolonged anticoagulation is unknown. Conclusions: The presence of factor V Leiden mutation predisposes patients to venous thromboembolism, but screening for this disorder is of uncertain utility. Decisions about whether to screen for the mutation will depend on the results of clinical trials designed to evaluate the benefit-to-risk ratio of long-term anticoagulation in the secondary prevention of venous thromboembolism in patients with resistance to activated protein C.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC DIS, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								Albucher JF, 1996, STROKE, V27, P766; AMUNDSEN T, 1995, ARTERIOSCL THROM VAS, V15, P1321, DOI 10.1161/01.ATV.15.9.1321; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1974, N Engl J Med, V290, P15; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BIASIUTTI FD, 1995, BLOOD COAGUL FIBRIN, V6, P456, DOI 10.1097/00001721-199507000-00013; BIENVENU T, 1991, PRESSE MED, V20, P985; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Bokarewa MI, 1996, BRIT J HAEMATOL, V92, P473, DOI 10.1046/j.1365-2141.1996.d01-1496.x; BOKAREWA MI, 1995, J LAB CLIN MED, V126, P294; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; BURKITT DP, 1972, BMJ-BRIT MED J, V2, P556, DOI 10.1136/bmj.2.5813.556; CADROY Y, 1995, THROMB HAEMOSTASIS, V73, P734; Chan LC, 1996, THROMB HAEMOSTASIS, V75, P522; COMP PC, 1986, BLOOD, V68, P881; Crowther M. A., 1995, Blood, V86, p616A; CUMMING AM, 1995, BRIT J HAEMATOL, V90, P725, DOI 10.1111/j.1365-2141.1995.tb05610.x; CUSHMAN M, 1994, THROMB HAEMOSTASIS, V72, P647; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; Dahlback B, 1996, LANCET, V347, P1346, DOI 10.1016/S0140-6736(96)91004-1; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DERONDE H, 1994, THROMB HAEMOSTASIS, V72, P880; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; EMMERICH J, 1995, LANCET, V345, P321, DOI 10.1016/S0140-6736(95)90310-0; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FARLEY TMM, 1995, LANCET, V346, P1582; Friederich PW, 1996, ANN INTERN MED, V125, P955, DOI 10.7326/0003-4819-125-12-199612150-00003; FUJIMURA H, 1995, THROMB HAEMOSTASIS, V74, P1381; GANDRILLE S, 1995, BLOOD, V86, P219, DOI 10.1182/blood.V86.1.219.bloodjournal861219; Gilmore G, 1996, THROMB HAEMOSTASIS, V75, P372; GRIFFIN JH, 1993, BLOOD, V82, P1989; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; HALBMAYER WM, 1994, THROMB HAEMOSTASIS, V72, P645; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; HENKENS CMA, 1995, THROMB HAEMOSTASIS, V73, P402; Hirsch DR, 1996, AM HEART J, V131, P1145, DOI 10.1016/S0002-8703(96)90089-7; HOLM J, 1994, LANCET, V344, P952, DOI 10.1016/S0140-6736(94)92302-7; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; KOELEMAN BPC, 1995, THROMB HAEMOSTASIS, V74, P580; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LE DT, 1995, BLOOD, V85, P1704, DOI 10.1182/blood.V85.7.1704.bloodjournal8571704; Lee EV, 1996, ANN INTERN MED, V125, P1001, DOI 10.7326/0003-4819-125-12-199612150-00012; Mandel H, 1996, NEW ENGL J MED, V334, P763, DOI 10.1056/NEJM199603213341204; Mannucci PM, 1996, THROMB HAEMOSTASIS, V75, P694; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; NACHMAN RL, 1993, ANN INTERN MED, V119, P819, DOI 10.7326/0003-4819-119-8-199310150-00008; NATCHIGALL LE, 1979, OBSTET GYNECOL, V54, P74; NATHWANI AC, 1992, BAILLIERE CLIN HAEM, V5, P383, DOI 10.1016/S0950-3536(11)80025-9; OLIVIERI O, 1995, BRIT J HAEMATOL, V91, P465, DOI 10.1111/j.1365-2141.1995.tb05323.x; PABINGER I, 1994, THROMB HAEMOSTASIS, V71, P548; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POULTER NR, 1995, LANCET, V346, P1575; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Press RD, 1996, STROKE, V27, P44, DOI 10.1161/01.STR.27.1.44; PROHASKA W, 1995, J MOL MED-JMM, V73, P521; Rai R, 1996, BRIT J HAEMATOL, V92, P489, DOI 10.1046/j.1365-2141.0000.d01-1465.x; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; Ridker PM, 1997, CIRCULATION, V95, P1777; Rintelen C, 1996, BRIT J HAEMATOL, V93, P487, DOI 10.1046/j.1365-2141.1996.5712013.x; Rintelen C, 1996, THROMB HAEMOSTASIS, V75, P229; Rosendaal FR, 1996, THROMB HAEMOSTASIS, V75, P524; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; SACHS BP, 1987, NEW ENGL J MED, V316, P667, DOI 10.1056/NEJM198703123161105; SAMANI NJ, 1994, LANCET, V344, P1709, DOI 10.1016/S0140-6736(94)90495-2; SCHAFER AI, 1985, ANN INTERN MED, V102, P814, DOI 10.7326/0003-4819-102-6-814; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SIMIONI P, 1995, STROKE, V26, P885, DOI 10.1161/01.STR.26.5.885; SIPES SL, 1990, SEMIN PERINATOL, V14, P103; STIRLING Y, 1984, THROMB HAEMOSTASIS, V52, P176; SUN X, 1994, BLOOD, V83, P3120; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TOSETTO A, 1995, THROMB HAEMOSTASIS, V73, P732; TREFFERS PE, 1983, INT J GYNECOL OBSTET, V21, P327, DOI 10.1016/0020-7292(83)90024-3; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8; ZOLLER B, 1994, J CLIN INVEST, V94, P2521, DOI 10.1172/JCI117623; ZUBER M, 1995, CEREBROVASC DIS, V5, P189	93	230	239	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					895	903		10.7326/0003-4819-127-10-199711150-00007	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382368				2022-12-28	WOS:A1997YF54500006
J	Gostin, LO				Gostin, LO			Deciding life and death in the courtroom - From Quinlan to Cruzan, Glucksberg, and Vacco - A brief history and analysis of constitutional protection of the 'right to die'	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; EUTHANASIA; END; VIEWS		GEORGETOWN JOHNS HOPKINS UNIV PROGRAM LAW & PUBL,WASHINGTON,DC	Johns Hopkins University								Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; ANNAS GJ, 1996, BRIEF BIOETHICS PROF; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; *CHOIC DYING, 1997, RIGHT DIE LAW DIG; *COUNC ETH JUD AFF, 1992, JAMA-J AM MED ASSOC, V267, P2229; DELLINGER W, 1996, BRIEF US AMICUS CURI; DUBLER NN, 1993, AM J PUBLIC HEALTH, V83, P23, DOI 10.2105/AJPH.83.1.23; Dworkin Ronald, 1997, NEW YORK REV    0327, P1; Glantz L H, 1987, Law Med Health Care, V15, P231; GOLD MR, 1996, BRIEF BIOETHICISTS A; GOSTIN L, 1991, MILBANK Q, V69, P143, DOI 10.2307/3350124; GOSTIN LO, 1993, J LAW MED ETHICS, V21, P71; HOFFMAN DA, 1996, BRIEF AMICUS CURIAE; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MARZEN TJ, 1985, DUQ L REV, V24, P1; MEISEL A, 1995, RIGHT DIE; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; New York State Task Force on Life and the Law, 1994, DEATH IS SOUGHT ASS; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; WEIR RF, 1997, PHYSICIAN ASSISTED S; WILFERT CM, 1996, NEW ENGL J MED, V335, P1676; WOLFSM, 1996, DUQUESNE LAW REV, V35, P455	28	73	73	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1523	1528		10.1001/jama.278.18.1523	http://dx.doi.org/10.1001/jama.278.18.1523			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YE445	9363974				2022-12-28	WOS:A1997YE44500038
J	Albillos, A; Calleja, JL				Albillos, A; Calleja, JL			Randomised trial of fibrin glue versus polidocanol for bleeding peptic ulcer	LANCET			English	Letter							INJECTION		CLIN PUERTA HIERRO, MADRID, SPAIN	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Albillos, A (corresponding author), UNIV ALCALA DE HENARES, HOSP RAMON Y CAJAL, DEPT MED, MADRID, SPAIN.		Panero, Jose Luis Calleja/A-5351-2010	Panero, Jose Luis Calleja/0000-0002-2265-6591				BALANZO J, 1990, ENDOSCOPY, V22, P157, DOI 10.1055/s-2007-1012828; BENEDETTI G, 1991, SURG ENDOSC-ULTRAS, V5, P28, DOI 10.1007/BF00591383; RUTGEERTS P, 1989, LANCET, V1, P1164; Rutgeerts P, 1997, LANCET, V350, P692, DOI 10.1016/S0140-6736(97)03233-9; Saeed ZA, 1996, ENDOSCOPY, V28, P288, DOI 10.1055/s-2007-1005455	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 8	1997	350	9088					1397	1398		10.1016/S0140-6736(05)65171-9	http://dx.doi.org/10.1016/S0140-6736(05)65171-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365472				2022-12-28	WOS:A1997YE87200054
J	Perera, FP				Perera, FP			Environment and cancer: Who are susceptible?	SCIENCE			English	Article							HEMOGLOBIN ADDUCT LEVELS; TRANSFERASE M1 GENOTYPE; HUMAN LUNG-CANCER; BREAST-CANCER; P53 MUTATIONS; MOLECULAR EPIDEMIOLOGY; GENETIC POLYMORPHISMS; HEREDITARY CANCER; CIGARETTE-SMOKING; RISK ASSESSMENT	Acting in concert with individual susceptibility, environmental factors such as smoking, diet, and pollutants play a role in most human cancer. However, new molecular evidence indicates that specific groups-characterized by predisposing genetic traits or ethnicity, the very young, and women-may have heightened risk from certain exposures. This is illustrated by molecular epidemiologic studies of environmental carcinogens such as polycyclic aromatic hydrocarbons and aromatic amines. Individual genetic screening for rare high-risk traits or for more common, low-penetrant susceptibility genes is problematic and not routinely recommended. However, knowledge of the full spectrum of both genetic and acquired susceptibility in the population will be instrumental in developing health and regulatory policies that increase protection of the more susceptible groups from risks of environmental carcinogens. This will necessitate revision of current risk assessment methodologies to explicitly account for individual variation in susceptibility to environmental carcinogens.			Perera, FP (corresponding author), COLUMBIA UNIV, SCH PUBL HLTH, DIV ENVIRONM HLTH SCI, 60 HAVEN AVE, B-1, NEW YORK, NY 10032 USA.							*AM CANC SOC, 1997, CANC FACTS FIG; Ambrosone CB, 1996, JAMA-J AM MED ASSOC, V276, P1494, DOI 10.1001/jama.276.18.1494; Bartsch H, 1996, ENVIRON HEALTH PERSP, V104, P569, DOI 10.2307/3432825; Bearer C, 1997, FUTURE CHILD, V5, P11; BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; CAVENEE WK, 1995, SCI AM, V272, P72, DOI 10.1038/scientificamerican0395-72; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Doll R, 1996, CARCINOGENESIS, V17, P177, DOI 10.1093/carcin/17.2.177; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; GARRETT PA, 1993, CANCER EPIDEM BIOMAR, V2, P131; GOLDMAN LR, 1995, ENVIRON HEALTH PERSP, V103, P13, DOI 10.2307/3432338; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRINBERGFUNES RA, 1994, CARCINOGENESIS, V15, P2449, DOI 10.1093/carcin/15.11.2449; GUINEE DG, 1995, CARCINOGENESIS, V16, P993, DOI 10.1093/carcin/16.5.993; Harris CC, 1996, ENVIRON HEALTH PERSP, V104, P435, DOI 10.2307/3432799; HATTIS D, 1991, ENVIRON HEALTH PERSP, V90, P229, DOI 10.2307/3430873; Hattis D, 1996, HUM ECOL RISK ASSESS, V2, P194, DOI 10.1080/10807039.1996.10387468; HAYASHI S, 1992, JPN J CANCER RES, V83, P866, DOI 10.1111/j.1349-7006.1992.tb01992.x; Hecht S. S., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P286; HEGMANN KT, 1993, EPIDEMIOLOGY, V4, P444, DOI 10.1097/00001648-199309000-00010; Kang D. H., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P107; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; Kawajiri K, 1996, CANCER RES, V56, P72; Khoury MJ, 1996, AM J PUBLIC HEALTH, V86, P1717, DOI 10.2105/AJPH.86.12.1717; KNUDSON AG, 1985, CANCER RES, V45, P1437; KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; KUCUK O, 1995, CANCER EPIDEM BIOMAR, V4, P217; Kure EH, 1996, CARCINOGENESIS, V17, P2201, DOI 10.1093/carcin/17.10.2201; Landi MT, 1996, CANCER EPIDEM BIOMAR, V5, P693; Li DH, 1996, CANCER RES, V56, P3638; Li FP, 1996, CANCER, V78, P553; Lin HJ, 1996, JAMA-J AM MED ASSOC, V276, P1511, DOI 10.1001/jama.276.18.1511; MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384; MCWILLIAMS JE, 1995, CANCER EPIDEM BIOMAR, V4, P589; MILLIKAN R, 1995, BREAST CANCER RES TR, V35, P79, DOI 10.1007/BF00694748; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; Mooney LA, 1996, J CELL BIOCHEM, P63; MOONEY LA, UNPUB; MOTT L, 1994, HANDLE CARE CHILDREN; NAKACHI K, 1991, CANCER RES, V51, P5177; *NAT AC SCI, 1993, PEST DIETS INF CHILD; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; NEBERT DW, 1995, P AM ASSOC CANC RES, V36, P665; Olden K., 1995, B SOC OCCUP ENV HLTH, P3; Olin Stephen S., 1997, Environmental Health Perspectives, V105, P117, DOI 10.2307/3433401; PERERA FP, 1982, J CHRON DIS, V35, P581, DOI 10.1016/0021-9681(82)90078-9; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; PONDER BAJ, 1991, BRIT J CANCER, V64, P203, DOI 10.1038/bjc.1991.275; REICHARDT JKV, 1995, CANCER RES, V55, P3973; RYBERG D, 1994, CANCER RES, V54, P5801; RYBERG D, 1994, CANCER RES, V54, P1551; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; TANG DL, 1995, CANCER EPIDEM BIOMAR, V4, P341; TANG DY, UNPUB; United States Environmental Protection Agency, 1994, HLTH ASS DOC 2 3 7 8; VAHAKANGAS K, 1991, CARCINOGENESIS, V12, P1389, DOI 10.1093/carcin/12.8.1389; VENITT S, 1994, CLIN CHEM, V40, P1421; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; Wei QY, 1996, CANCER RES, V56, P4103; Whyatt R. M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P250; WHYATT RM, UNPUB; Wiencke JK, 1997, CANCER EPIDEM BIOMAR, V6, P87; Xu XP, 1996, CANCER EPIDEM BIOMAR, V5, P687; YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712; YU MC, 1995, CANCER EPIDEM BIOMAR, V4, P861; Zahm SH, 1995, ENVIRON HEALTH PERSP, V103, P283, DOI 10.2307/3432326; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183; ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819; 1994, SCI JUDGMENT RISK AS	70	493	515	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1068	1073		10.1126/science.278.5340.1068	http://dx.doi.org/10.1126/science.278.5340.1068			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353182				2022-12-28	WOS:A1997YE65200034
J	Craft, N				Craft, N			Women's health - Women's health is a global issue	BRITISH MEDICAL JOURNAL			English	Article							ANGINA				Craft, N (corresponding author), GOWER PL PRACTICE,LONDON WC1E 6BN,ENGLAND.							Black D., 1980, INEQUALITIES HLTH; COOK R, 1995, HLTH HUMAN RIGHTS, V4, P350; CRAFT N, 1995, BRIT MED J, V311, P580, DOI 10.1136/bmj.311.7005.580; DAHL E, 1997, BRIT MED J, V313, P435; Doyal L., 1995, WHAT MAKES WOMEN SIC; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; *INT PLANN PAR FED, 1995, DIAL CHALL OV RESP, P42; MANSON JE, 1990, AM J MED, V89, P772, DOI 10.1016/0002-9343(90)90220-8; *MULT RISK FACT IN, 1982, JAMA-J AM MED ASSOC, V248, P1465; MURPHY ML, 1977, NEW ENGL J MED, V297, P621, DOI 10.1056/NEJM197709222971201; *OFF POP CENS SURV, 1996, POP TRENDS, V84; Rosser S., 1994, WOMENS HLTH MISSING; SMITH J, 1996, GUARDIAN        0617, P5; UN, 1995, WORLDS WOM TRENDS ST; *UN DEV PROGR, 1994, STAT WORLDS POP; *UN EC COMM AFR, 1995, GEND AFR ETH; *UNESCO, 1994, STAT YB; United Nations Development Programme, 1995, HUM DEV REP; *WHO, 1995, WOM HLTH IMPR OUR HL; *WHO, 1989, REPR HLTH AD STRAT A; *WHO, 1994, CREAT COMM GROUND AS; *WHO, 1996, VIOL WOM; *WORLD BANK, 1993, WORLD DEV REP	23	12	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1154	1157						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374895	Green Published			2022-12-28	WOS:A1997YE61500036
J	Wood, KW; Sakowicz, R; Goldstein, LSB; Cleveland, DW				Wood, KW; Sakowicz, R; Goldstein, LSB; Cleveland, DW			CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment	CELL			English	Article							KINESIN-LIKE PROTEIN; PREDICTING COILED COILS; MITOTIC SPINDLE; DIRECTIONAL INSTABILITY; MICROTUBULE DEPOLYMERIZATION; CRYSTAL-STRUCTURE; MITOSIS; MOTILITY; POSITION; DOMAIN	Mitosis requires dynamic attachment of chromosomes to spindle microtubules. This interaction is mediated largely by kinetochores. During prometaphase, forces exerted at kinetochores, in combination with polar ejection forces, drive congression of chromosomes to the metaphase plate. A major question has been whether kinetochore-associated microtubule motors play an important role in congression. Using immunodepletion from and antibody addition to Xenopus egg extracts, we show that the kinetochore-associated kinesin-like motor protein CENP-E is essential for positioning chromosomes at the metaphase plate. We further demonstrate that CENP-E powers movement toward microtubule plus ends in vitro. These findings support a model in which CENP-E functions in congression to tether kinetochores to dynamic microtubule plus ends.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego	Wood, KW (corresponding author), UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,CELL BIOL LAB,LA JOLLA,CA 92093, USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Brown KD, 1996, J CELL SCI, V109, P961; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CASSIMERIS L, 1994, J CELL SCI, V107, P285; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Duesbery NS, 1997, P NATL ACAD SCI USA, V94, P9165, DOI 10.1073/pnas.94.17.9165; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; HOWARD J, 1993, MOTILITY ASSAYS MOTO, P105; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1992, METHOD ENZYMOL, P478; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Khodjakov A, 1996, J CELL BIOL, V135, P315, DOI 10.1083/jcb.135.2.315; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cellbio.4.1.527; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1985, CHROMOSOMA, V92, P313, DOI 10.1007/BF00329815; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; ROOS UP, 1976, CHROMOSOMA, V54, P363, DOI 10.1007/BF00292816; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAWIN KE, 1991, J CELL BIOL, V112, P929; SKIBBENS RV, 1995, J CELL SCI, V108, P2537; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Waters JC, 1996, J CELL SCI, V109, P2823; Wilson PG, 1997, J CELL SCI, V110, P451; YAO X, 1997, IN PRESS J CELL BIOL; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	50	331	335	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					357	366		10.1016/S0092-8674(00)80419-5	http://dx.doi.org/10.1016/S0092-8674(00)80419-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363944	Bronze			2022-12-28	WOS:A1997YD94100009
J	Watkins, J				Watkins, J			Effectiveness of influenza vaccination policy at targeting patients at high risk of complications during winter 1994-5: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article											Watkins, J (corresponding author), GWENT HLTH AUTHOR,PONTYPOOL NP4 OYP,GWENT,WALES.							CURWEN M, 1990, BRIT MED J, V300, P896; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; KURINCZUK JJ, 1989, BRIT MED J, V299, P367, DOI 10.1136/bmj.299.6695.367; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1069	1070		10.1136/bmj.315.7115.1069	http://dx.doi.org/10.1136/bmj.315.7115.1069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366738	Green Published			2022-12-28	WOS:A1997YD44500028
J	vanWeel, C; Michels, J				vanWeel, C; Michels, J			Dying, not old age, to blame for costs of health care	LANCET			English	Article											vanWeel, C (corresponding author), UNIV NIJMEGEN,DEPT GEN PRACTICE & SOCIAL MED,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				GREENBERG I, 1997, HLTH SERV RES, V31, P723; Perls TT, 1996, ARCH INTERN MED, V156, P754, DOI 10.1001/archinte.156.7.754; RUWAARD D, 1997, VOLKSGEZONDHEID TOEK; van Noordt M, 1992, Gesundheitswesen, V54, P173; *VAND HLTH STAT NE, 1996, STAT NETH; VANWEEL C, 1996, EUR J GEN PRACT, V2, P17	6	27	27	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1159	1160		10.1016/S0140-6736(97)08312-8	http://dx.doi.org/10.1016/S0140-6736(97)08312-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343516	Green Submitted			2022-12-28	WOS:A1997YB19900044
J	Coulthard, MG; Lambert, HJ; Keir, MJ				Coulthard, MG; Lambert, HJ; Keir, MJ			Occurrence of renal scars in children after their first referral for urinary tract infection	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM, DEPT MED PHYS, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND	Newcastle University - UK	Coulthard, MG (corresponding author), ROYAL VICTORIA INFIRM, DEPT CHILD HLTH, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND.			Lambert, Heather/0000-0003-4389-4078				[Anonymous], 1991, J R Coll Physicians Lond, V25, P36; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; RICKWOOD AMK, 1992, BRIT MED J, V304, P663, DOI 10.1136/bmj.304.6828.663; VERNON S, 1994, LANCET, V4, P344; Vernon SJ, 1997, BMJ-BRIT MED J, V315, P905	5	58	60	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	1997	315	7113					918	919						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361542				2022-12-28	WOS:A1997YB07300026
J	Hines, PJ				Hines, PJ			Nota bene: Neurobiology - Unconscious odors	SCIENCE			English	Editorial Material							RECEPTORS; FAMILY											BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0	5	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					79	79		10.1126/science.278.5335.79	http://dx.doi.org/10.1126/science.278.5335.79			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9340759				2022-12-28	WOS:A1997XZ12400039
J	Boston, BA; Blaydon, KM; Varnerin, J; Cone, RD				Boston, BA; Blaydon, KM; Varnerin, J; Cone, RD			Independent and additive effects of central POMC and leptin pathways on murine obesity	SCIENCE			English	Article							AGOUTI GENE; ECTOPIC EXPRESSION; MICE; RECEPTOR; CLONING; PROTEIN	The lethal yellow (A(Y)/a) mouse has a defect in proopiomelanocortin (POMC) signaling in the brain that leads to obesity, and is resistant to the anorexigenic effects of the hormone leptin. It has been proposed that the weight-reducing effects of leptin are thus transmitted primarily by way of POMC neurons. However, the central effects of defective POMC signaling, and the absence of leptin, on weight gain in double-mutant lethal yellow (A(Y)/a) leptin-deficient (lep(ob)/lep(ob)) mice were shown to be independent and additive, Furthermore, deletion of the leptin gene restored leptin sensitivity to A(Y)/a mice. This result implies that in the A(Y)/a mouse, obesity is independent of leptin action, and resistance to leptin results from desensitization of leptin signaling.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; MERCK RES LABS,DEPT GENET & MOL BIOL,RAHWAY,NJ 07065	Oregon Health & Science University; Oregon Health & Science University; Merck & Company					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002404] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33703] Funding Source: Medline; NIDDK NIH HHS [DK/AR517330, DK02404] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; DICKIE MM, 1962, J HERED, V53, P4; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Gura T, 1997, SCIENCE, V275, P751, DOI 10.1126/science.275.5301.751; HALAAS JL, 1997, P NATL ACAD SCI USA, V944, P8878; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kesterson RA, 1997, MOL ENDOCRINOL, V11, P630, DOI 10.1210/me.11.5.630; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; PLOCHER TA, 1976, METABOLISM, V25, P593, DOI 10.1016/0026-0495(76)90013-5; SEELY RJ, IN PRESS NATURE; SHIMIZU H, 1989, AM J PHYSIOL, V256, P494; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; WOLFF GL, 1963, GENETICS, V48, P1041; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	25	205	207	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1641	1644		10.1126/science.278.5343.1641	http://dx.doi.org/10.1126/science.278.5343.1641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374468				2022-12-28	WOS:A1997YJ87400047
J	Backhaus, S; Pereverzev, SV; Loshak, A; Davis, JC; Packard, RE				Backhaus, S; Pereverzev, SV; Loshak, A; Davis, JC; Packard, RE			Direct measurement of the current-phase relation of a superfluid He-3-B weak link	SCIENCE			English	Article							FLOW	Direct measurements of the current-phase relation, I versus Delta phi, for a weak link coupling two reservoirs of B-phase superfluid helium-3 (He-3-B) were made over a wide range of temperatures. The weak link consists of a square array of 100-nanometer-diameter apertures. For temperatures T such that T/T-c greater than or equal to 0.6 (where T-c is the superfluid transition temperature), I proportional to sin(Delta phi). At lower temperatures, (Delta phi) approaches a straight line. Several remarkable phenomena heretofore inaccessible to superconducting Josephson junctions, including direct observation of quantum oscillations and continuous knowledge of Delta phi, were also observed.	RUSSIAN ACAD SCI, INST HIGH PRESSURE PHYS, MOSCOW, RUSSIA	Russian Academy of Sciences; Vereshchagin Institute of High Pressure Physics, Russian Academy of Sciences	Backhaus, S (corresponding author), UNIV CALIF BERKELEY, DEPT PHYS, BERKELEY, CA 94720 USA.		Backhaus, Scott/F-4285-2012					Anderson P.W., 1964, LECT MANY BODY PROBL, V2, P113, DOI DOI 10.1140/EPJST/E2010-01303-3; Avenel O., 1986, Proceedings of the Eleventh International Cryogenic Engineering Conference. ICEC 11, P587; AVENEL O, 1988, PHYS REV LETT, V60, P416, DOI 10.1103/PhysRevLett.60.416; AVENEL O, 1987, JPN J APPL PHYS, V26, P26; BOROVIKROMANOV AS, 1988, JETP LETT+, V47, P478; CROOKER BC, 1984, THESIS CORNELL U ITH; FEYNMAN RP, 1965, FEYNMAN LECT PHYSICS; HOOK JR, 1987, JPN J APPL PHYS 1, V26, P159, DOI 10.7567/JJAPS.26S3.159; JACOBSEN KW, 1987, J LOW TEMP PHYS, V67, P83, DOI 10.1007/BF01070651; JOSEPHSON BD, 1962, THESIS TRINITY COLLE; KOPNIN NB, 1986, JETP LETT+, V43, P700; KURKIJARVI J, 1988, PHYS REV B, V38, P11184, DOI 10.1103/PhysRevB.38.11184; MANNINEN MT, 1982, PHYS REV LETT, V48, P812, DOI 10.1103/PhysRevLett.48.812; MONIEN H, 1986, J LOW TEMP PHYS, V62, P277, DOI 10.1007/BF00683465; PACKARD RE, 1992, PHYS REV B, V46, P3540, DOI 10.1103/PhysRevB.46.3540; Pereverzev SV, 1997, NATURE, V388, P449, DOI 10.1038/41277; STEINHAUER J, 1995, THESIS U CALIFORNIA; THUNEBERG EV, 1990, PHYSICA B, V165, P755; THUNEBERG EV, 1988, EUROPHYS LETT, V7, P441, DOI 10.1209/0295-5075/7/5/011; ULLAH S, 1989, PHYS REV B, V39, P4186, DOI 10.1103/PhysRevB.39.4186; VAROQUAUX E, 1992, PHYSICA B, V178, P309, DOI 10.1016/0921-4526(92)90210-J; WIRTH FH, 1981, PHYSICA B & C, V107, P579, DOI 10.1016/0378-4363(81)90592-1	22	50	50	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	1997	278	5342					1435	1438		10.1126/science.278.5342.1435	http://dx.doi.org/10.1126/science.278.5342.1435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367950				2022-12-28	WOS:A1997YG85800036
J	Rosenberg, ES; Billingsley, JM; Caliendo, AM; Boswell, SL; Sax, PE; Kalams, SA; Walker, BD				Rosenberg, ES; Billingsley, JM; Caliendo, AM; Boswell, SL; Sax, PE; Kalams, SA; Walker, BD			Vigorous HIV-1-specific CD4(+) T cell responses associated with control of viremia	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 INFECTION; IN-VITRO; IMMUNE-RESPONSE; DEFICIENT MICE; LYMPHOCYTES; RECOGNITION; ANTIGEN; CYTOMEGALOVIRUS; IMMUNIZATION	Virus-specific CD4(+) T helper lymphocytes are critical to the maintenance of effective immunity in a number of chronic viral infections, but are characteristically undetectable in chronic human immunodeficiency virus-type 1 (HIV-1) infection. In individuals who control viremia in the absence of antiviral therapy, polyclonal, persistent, and vigorous HIV-1-specific CD4(+) T cell proliferative responses were present, resulting in the elaboration of interferon-gamma and antiviral beta chemokines. In persons with chronic infection, HIV-1-specific proliferative responses to p24 were inversely related to viral load. Strong HIV-1-specific proliferative responses were also detected following treatment of acutely infected persons with potent antiviral therapy. The HIV-1-specific helper cells are likely to be important in immunotherapeutic interventions and vaccine development.	MASSACHUSETTS GEN HOSP, PARTNERS AIDS RES CTR, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, INFECT DIS UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; FENWAY COMMUNITY HLTH CTR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV INFECT DIS, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009738, R01AI028568] Funding Source: NIH RePORTER; NIAID NIH HHS [F32-AI09738, R01-AI28568] Funding Source: Medline; PHS HHS [R01-A136550] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, pR11, DOI 10.1016/0022-1759(82)90269-1; DOLAN MJ, 1995, J INFECT DIS, V172, P79, DOI 10.1093/infdis/172.1.79; EPSTEIN JS, 1985, J INFECT DIS, V152, P727, DOI 10.1093/infdis/152.4.727; Harrer T, 1996, J IMMUNOL, V156, P2616; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; KALAMS S, UNPUB; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KROWKA JF, 1989, J CLIN INVEST, V83, P1198, DOI 10.1172/JCI114001; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAURENCE J, 1989, J CLIN INVEST, V83, P1843, DOI 10.1172/JCI114090; Lekutis C, 1997, J IMMUNOL, V158, P4471; Lekutis C, 1997, J IMMUNOL, V159, P2049; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404; PANTALEO G, 1995, NEW ENGL J MED, V69, P5838; Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874; PONTESILLI O, 1994, AIDS RES HUM RETROV, V10, P113, DOI 10.1089/aid.1994.10.113; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; ROSENBERG E, UNPUB; Schnittman SM, 1997, AIDS RES HUM RETROV, V13, P815, DOI 10.1089/aid.1997.13.815; SCHRIER RD, 1989, J IMMUNOL, V142, P1166; SCHWARTZ D, 1994, AIDS RES HUM RETROV, V10, P1703, DOI 10.1089/aid.1994.10.1703; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; Thomsen AR, 1996, J IMMUNOL, V157, P3074; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; WAHREN B, 1987, J VIROL, V61, P2017, DOI 10.1128/JVI.61.6.2017-2023.1987; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Weissman D, 1996, J EXP MED, V183, P687, DOI 10.1084/jem.183.2.687	42	1572	1603	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	1997	278	5342					1447	1450		10.1126/science.278.5342.1447	http://dx.doi.org/10.1126/science.278.5342.1447			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367954				2022-12-28	WOS:A1997YG85800040
J	StreetPerrott, FA; Huang, YS; Perrott, RA; Eglinton, G; Barker, P; BenKhelifa, L; Harkness, DD; Olago, DO				StreetPerrott, FA; Huang, YS; Perrott, RA; Eglinton, G; Barker, P; BenKhelifa, L; Harkness, DD; Olago, DO			Impact of lower atmospheric carbon dioxide on tropical mountain ecosystems	SCIENCE			English	Article							ISOTOPE FRACTIONATION; ORGANIC-MATTER; ICE CORE; SACRED-LAKE; QUATERNARY; SEDIMENTS; PLANTS; CO2; PHYTOPLANKTON; HYDROCARBONS	Carbon-isotope values of bulk organic matter from high-altitude lakes on Mount Kenya and Mount Elgon, East Africa, were 10 to 14 per mil higher during glacial times than they are today. Compound-specific isotope analyses of leaf waxes and algal biomarkers show that organisms possessing CO2-concentrating mechanisms, including C-4 grasses and freshwater algae, were primarily responsible for this large increase. Carbon limitation due to lower ambient CO2 partial pressures had a significant impact on the distribution of forest on the tropical mountains, in addition to climate. Hence, tree line elevation should not be used to infer palaeotemperatures.	UNIV BRISTOL,DEPT GEOL,BIOGEOCHEM RES CTR,BRISTOL BS8 1RJ,AVON,ENGLAND; UNIV LANCASTER,DEPT GEOG,HYDRODYNAM & SEDIMENTOL LAB,LANCASTER LA1 4YB,ENGLAND; UNIV OXFORD,SCH GEOG,OXFORD OX1 3TB,ENGLAND; NERC,RADIOCARBON LAB,GLASGOW G75 0QF,LANARK,SCOTLAND	University of Bristol; Lancaster University; University of Oxford; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Geological Survey	StreetPerrott, FA (corresponding author), UNIV COLL SWANSEA,DEPT GEOG,TROP PALAEOENVIRONM RES GRP,SWANSEA SA2 8PP,W GLAM,WALES.		Barker, Philip/J-5938-2012	Barker, Philip/0000-0002-5334-9201				AUCOUR AM, 1994, QUATERNARY RES, V41, P225, DOI 10.1006/qres.1994.1024; BARKER PD, UNPUB; BARNOLA JM, 1987, NATURE, V329, P408, DOI 10.1038/329408a0; BIRD MI, 1994, NATURE, V371, P566, DOI 10.1038/371566a0; BLAKE W JR, 1991, Journal of Paleolimnology, V6, P157; BROECKER WS, 1995, NATURE, V376, P212, DOI 10.1038/376212a0; CEPAK V, 1994, ALGOL STUD, V72, P115; Charles C, 1997, NATURE, V385, P681, DOI 10.1038/385681a0; CLIMAP (Climate: Long Range Investigation Mapping and Prediction) Project Members, 1981, GEOL SOC AM MAP CHAR, V36; Coetzee J. A, 1967, PALAEOECOL AFR, V3; Coetzee J.M., COMMUNICATION; COLE JJ, 1994, SCIENCE, V265, P1568, DOI 10.1126/science.265.5178.1568; COLLISTER JW, 1994, ORG GEOCHEM, V21, P619, DOI 10.1016/0146-6380(94)90008-6; Cranwell P., 1981, ORG GEOCHEM, V3, P79, DOI [10.1016/0146-6380(81)90002-4, DOI 10.1016/0146-6380(81)90002-4]; Deines P, 1980, HDB ENV ISOTOPE GEOC, DOI DOI 10.1016/B978-0-444-41780-0.50015-8; EHLERINGER JR, 1991, TRENDS ECOL EVOL, V6, P95, DOI 10.1016/0169-5347(91)90183-X; Estep M.F, 1982, CARNEGIE I WASHINGTO, V81, P402; Flenley J. R., 1979, PROG PHYS GEOGR, V3, P488, DOI [10.1177/030913337900300402, DOI 10.1177/030913337900300402]; Flenley JR, 1996, QUATERNARY SCI REV, V15, P549, DOI 10.1016/0277-3791(96)00017-0; FREEMAN KH, 1990, NATURE, V343, P54; GIRESSE P, 1994, PALAEOGEOGR PALAEOCL, V107, P65, DOI 10.1016/0031-0182(94)90165-1; Goericke R., 1994, STABLE ISOTOPES ECOL, P187; Hamilton A. C., 1982, ENV HIST E AFRICA; HAYES JM, 1993, MAR GEOL, V113, P111, DOI 10.1016/0025-3227(93)90153-M; HILLAIREMARCEL C, 1989, QUATERNARY SCI REV, V8, P207, DOI 10.1016/0277-3791(89)90037-1; HINGA KR, 1994, GLOBAL BIOGEOCHEM CY, V8, P91, DOI 10.1029/93GB03393; HOLLANDER DJ, 1991, GEOLOGY, V19, P929, DOI 10.1130/0091-7613(1991)019<0929:CCOCIF>2.3.CO;2; Huang Y, 1997, ORG GEOCHEM, V26, P497, DOI 10.1016/S0146-6380(97)00027-2; HUANG Y, 1995, ORGANIC GEOCHEMISTRY, P826; HUANG Y, 1995, CHEM COMMUN 1995, P385; HUANG YN, UNPUB; HUANG YS, 1995, TETRAHEDRON LETT, V36, P5973, DOI 10.1016/0040-4039(95)01156-C; Huang YS, 1996, TETRAHEDRON, V52, P6973; IDSO SB, 1989, QUATERNARY RES, V31, P433, DOI 10.1016/0033-5894(89)90051-3; IVANOVICH M, COMMUNICATION; Jolly D, 1997, SCIENCE, V276, P786, DOI 10.1126/science.276.5313.786; KEELEY JE, 1992, PLANT CELL ENVIRON, V15, P1021, DOI 10.1111/j.1365-3040.1992.tb01653.x; KRAMMER K, 1986, BACILLARIOPHYCEAE SU, V2, pR1; LAWS EA, 1995, GEOCHIM COSMOCHIM AC, V59, P1131, DOI 10.1016/0016-7037(95)00030-4; LEUENBERGER M, 1992, NATURE, V357, P488, DOI 10.1038/357488a0; Loffler H., 1964, Verhandlungen Internationalen Vereinigung Limnologie, V15, P176; McCabe B., 1985, THESIS U WAIKATO HAM; MEYERS PA, 1993, ORG GEOCHEM, V20, P867, DOI 10.1016/0146-6380(93)90100-P; MOOK WG, 1974, EARTH PLANET SC LETT, V22, P169, DOI 10.1016/0012-821X(74)90078-8; ORCUTT DM, 1975, COMP BIOCHEM PHYS B, V50, P579, DOI 10.1016/0305-0491(75)90093-0; OSMOND CB, 1982, PHYSL PLANT ECOLOGY, V2, P479, DOI DOI 10.1007/978-3-642-68150-9_16; PERROTT RA, UNPUB; PLENITZ R, 1995, J PALEOLIMNOL, V13, P21; REAVIE ED, 1995, J PALEOLIMNOL, V14, P49, DOI 10.1007/BF00682593; RIELEY G, 1993, RAPID COMMUN MASS SP, V7, P488, DOI 10.1002/rcm.1290070617; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; ROWLAND SJ, 1985, ORG GEOCHEM, V8, P207, DOI 10.1016/0146-6380(85)90028-2; ROWLAND SJ, 1990, MAR ENVIRON RES, V30, P191, DOI 10.1016/0141-1136(90)90019-K; Sarnthein M, 1988, PALEOCEANOGRAPHY, V3, P361, DOI 10.1029/PA003i003p00361; SCHIDLOWSKI M, 1985, NATURWISSENSCHAFTEN, V71, P303; Sharkey T. D., 1985, INORGANIC CARBON UPT, P389; Spaulding SA, 1997, J PALEOLIMNOL, V17, P403; STREETPERROTT FA, 1994, AMBIO, V23, P37; STREETPERROTT FA, IN PRESS STABLE ISOT; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; TALBOT MR, 1992, EARTH PLANET SC LETT, V110, P23, DOI 10.1016/0012-821X(92)90036-U; TALLING JF, 1976, J ECOL, V64, P79, DOI 10.2307/2258685; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; TIESZEN LL, 1991, J ARCHAEOL SCI, V18, P227, DOI 10.1016/0305-4403(91)90063-U; Tyson R.V., 1995, SEDIMENTARY ORGANIC, DOI [10.1007/978-94-011-0739-6, DOI 10.1007/978-94-011-0739-6, DOI 10.1007/978-94-011-0739-6_5]; VERSCHUREN D, COMMUNICATION; WAND U, 1990, GEODATISCHE GEOPHYSI, V16, P361; WEBSTER PJ, 1978, QUATERNARY RES, V10, P279, DOI 10.1016/0033-5894(78)90024-8; WOOLLER MJ, COMMUNICATION; YOUNG HJ, 1983, OECOLOGIA, V58, P373, DOI 10.1007/BF00385238	70	280	321	3	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1422	1426		10.1126/science.278.5342.1422	http://dx.doi.org/10.1126/science.278.5342.1422			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367947				2022-12-28	WOS:A1997YG85800033
J	Blumenthal, D; Campbell, EG; Weissman, JS				Blumenthal, D; Campbell, EG; Weissman, JS			The social missions of academic health centers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INDUSTRY; CARE		MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital								*AAMC DAT BOOK, 1995, STAT INF REL MED ED; Blake DA, 1996, ACAD MED, V71, P818, DOI 10.1097/00001888-199608000-00007; Blumenthal D, 1996, NEW ENGL J MED, V334, P368, DOI 10.1056/NEJM199602083340606; BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P1812, DOI 10.1056/NEJM199312093292413; BLUMENTHAL D, 1996, HLTH AFF MILLWOOD, V15, P201; *DEP HLTH HUM SERV, 1994, NIH DAT BOOK 1994 BA; GELIJNS A, 1994, HEALTH AFFAIR, V13, P28, DOI 10.1377/hlthaff.13.3.28; JONES RF, 1995, CLIN SUPPORT ACAD MI; Mechanic RE, 1996, HEALTH AFFAIR, V15, P72, DOI 10.1377/hlthaff.15.3.72; PLUMB DH, 1995, MEDICAID FUNDING GRA; *PW HLTH PROF COMM, 1995, CRIT CHALL REV HLTH; Reuter J, 1997, HEALTH AFFAIR, V16, P242, DOI 10.1377/hlthaff.16.4.242; ROSENBERG N, 1994, RES POLICY, V23, P323, DOI 10.1016/0048-7333(94)90042-6; 1995, PATENTS SURG MED PRO	14	61	62	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1550	1553		10.1056/NEJM199711203372113	http://dx.doi.org/10.1056/NEJM199711203372113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YG249	9366591				2022-12-28	WOS:A1997YG24900013
J	Rodvold, KA; Danziger, LH; Quinn, JP				Rodvold, KA; Danziger, LH; Quinn, JP			Single daily doses of aminoglycosides - Commentary	LANCET			English	Editorial Material									UNIV ILLINOIS,COLL MED,DEPT MED,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rodvold, KA (corresponding author), UNIV ILLINOIS,COLL PHARM,DEPT PHARM PRACTICE,CHICAGO,IL 60612, USA.							Ali MZ, 1997, CLIN INFECT DIS, V24, P796, DOI 10.1093/clinids/24.5.796; Bailey TC, 1997, CLIN INFECT DIS, V24, P786, DOI 10.1093/clinids/24.5.786; Bertino JS, 1997, CLIN INFECT DIS, V24, P820, DOI 10.1093/clinids/24.5.820; Freeman CD, 1997, J ANTIMICROB CHEMOTH, V39, P677, DOI 10.1093/jac/39.6.677; GILBERT DN, 1997, CLIN INFECT DIS, V21, P816; Hatala R, 1997, CLIN INFECT DIS, V24, P810, DOI 10.1093/clinids/24.5.810; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Urban A W, 1997, Curr Clin Top Infect Dis, V17, P236	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1412	1412		10.1016/S0140-6736(97)22046-5	http://dx.doi.org/10.1016/S0140-6736(97)22046-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371159				2022-12-28	WOS:A1997YF95300002
J	Munoz, V; Thompson, PA; Hofrichter, J; Eaton, WA				Munoz, V; Thompson, PA; Hofrichter, J; Eaton, WA			Folding dynamics and mechanism of beta-hairpin formation	NATURE			English	Article							SHORT LINEAR PEPTIDE; AQUEOUS-SOLUTION; PROTEIN; STABILITY; DESIGN	Protein chains coil into alpha-helices and beta-sheet structures. Knowing the timescales and mechanism of formation of these basic structural elements is essential for understanding how proteins fold(1). For the past 40 years, alpha-helix formation has been extensively investigated in synthetic and natural peptides(2-5), including by nanosecond kinetic studies(6,7). In contrast, the mechanism of formation of beta structures has not been studied experimentally. The minimal beta-structure element is the beta-hairpin, which is also the basic component of antiparallel beta-sheets. Here we use a nanosecond laser temperature-jump apparatus to study the kinetics of folding a beta-hairpin consisting of 16 amino-acid residues. Folding of the hairpin occurs in 6 mu s at room temperature, which is about 30 times slower than the rate of alpha-helix formation(6,7). We have developed a simple statistical mechanical model that provides a structural explanation for this result, Our analysis also shows that folding of a beta-hairpin captures much of the basic physics of protein folding; including stabilization by hydrogen bonding and hydrophobic interactions, two-state behaviour, and a funnel-like, partially rugged energy landscape.			Munoz, V (corresponding author), NIDDK,PHYS CHEM LAB,NIH,BLDG 5,BETHESDA,MD 20892, USA.							BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BLANCO FJ, 1993, J AM CHEM SOC, V115, P5887, DOI 10.1021/ja00066a092; BLANCO FJ, 1994, NAT STRUCT BIOL, V1, P584, DOI 10.1038/nsb0994-584; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; deAlba E, 1996, FOLD DES, V1, P133, DOI 10.1016/S1359-0278(96)00022-3; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; GRUENEWALD B, 1979, BIOPHYS CHEM, V9, P137, DOI 10.1016/0301-4622(79)87008-8; Hagen SJ, 1996, P NATL ACAD SCI USA, V93, P11615, DOI 10.1073/pnas.93.21.11615; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; Klimov DK, 1997, PHYS REV LETT, V79, P317, DOI 10.1103/PhysRevLett.79.317; KOBAYASHI N, 1993, PEPTIDE CHEMISTRY 1992, P278; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; MUNOZ V, 1995, CURR OPIN BIOTECH, V6, P382, DOI 10.1016/0958-1669(95)80066-2; PHILLIPS CM, 1995, P NATL ACAD SCI USA, V92, P7292, DOI 10.1073/pnas.92.16.7292; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; SEARLE MS, 1995, NAT STRUCT BIOL, V2, P999, DOI 10.1038/nsb1195-999; Sieber V, 1996, BIOCHEMISTRY-US, V35, P181, DOI 10.1021/bi950681o; Thompson PA, 1997, BIOCHEMISTRY-US, V36, P9200, DOI 10.1021/bi9704764; Thompson PA, 1997, TECH PROT CHEM, V8, P735, DOI 10.1016/S1080-8914(97)80072-5; Williams S, 1996, BIOCHEMISTRY-US, V35, P691, DOI 10.1021/bi952217p; ZIMM BH, 1959, P NATL ACAD SCI USA, V45, P1601, DOI 10.1073/pnas.45.11.1601	24	858	865	4	122	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					196	199		10.1038/36626	http://dx.doi.org/10.1038/36626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367160				2022-12-28	WOS:A1997YF49400060
J	Atwell, S; Ultsch, M; DeVos, AM; Wells, JA				Atwell, S; Ultsch, M; DeVos, AM; Wells, JA			Structural plasticity in a remodeled protein-protein interface	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; MONOVALENT PHAGE DISPLAY; CRYSTAL-STRUCTURE; RECEPTOR; MUTAGENESIS; RESOLUTION; COMPLEX; EPITOPE; MUTANT	Remodeling of the interface between human growth hormone (hGH) and the extracellular domain of its receptor was studied by deleting a critical tryptophan residue (at position 104) in the receptor, creating a large cavity, and selecting a pentamutant of hGH by phage display that fills the cavity and largely restores binding affinity. A 2.1 Angstrom resolution x-ray structure of the mutant complex showed that the receptor cavity was filled by selected hydrophobic mutations of hGH. Large structural rearrangements occurred in the inter face at sites that were distant from the mutations. Such plasticity may be a means for protein-protein interfaces to adapt to mutations as they coevolve.	GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; University of California System; University of California San Francisco			Wells, Jim A/O-9854-2016					ATWELL S, UNPUB; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLACKSON T, UNPUB; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; VEITER IR, 1996, PROTEIN SCI, V5, P2399; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141	25	158	174	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1125	1128		10.1126/science.278.5340.1125	http://dx.doi.org/10.1126/science.278.5340.1125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353194				2022-12-28	WOS:A1997YE65200053
J	Sidransky, D				Sidransky, D			Nucleic acid-based methods for the detection of cancer	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; RAS GENE-MUTATIONS; SQUAMOUS-CELL CARCINOMA; TELOMERASE ACTIVITY; K-RAS; REVERSE-TRANSCRIPTASE; PERIPHERAL-BLOOD; LUNG-CANCER; MICROSATELLITE ALTERATIONS; ONCOGENE MUTATIONS	Continued elucidation of the genetic changes that drive cancer progression is yielding new and potentially powerful nucleic acid-based markers of neoplastic disease. Pilot studies indicate that these markers can be used to detect cancer cells in a variety of clinical settings with unprecedented precision. Nucleic acid-based markers may prove to be valuable tools for early detection of cancer in asymptomatic individuals, for confirmation or exclusion of a cancer diagnosis that is based on suspicious but nondiagnostic clinical material, for assessment of tumor burden in cancer patients, and for assessment of response to preventive approaches applied to healthy individuals who are at high risk of developing cancer. Examples of these markers, their potential applications, and the current practical limitations on their clinical use are reviewed here.			Sidransky, D (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, DIV HEAD & NECK CANC RES, BALTIMORE, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA-88184-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Ahrendt SA, 1997, CLIN CANCER RES, V3, P1207; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOYLE JO, 1994, AM J SURG, V168, P429, DOI 10.1016/S0002-9610(05)80092-3; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; Brentnall TA, 1996, CANCER RES, V56, P1237; BROSSART P, 1995, CANCER RES, V55, P4065; CALDAS C, 1994, CANCER RES, V54, P3568; Califano J, 1996, CANCER RES, V56, P5720; CALIFANO J, UNPUB; CHEN XQ, 1996, NATURE MED, V2; DATTA YH, 1994, J CLIN ONCOL, V12, P475, DOI 10.1200/JCO.1994.12.3.475; Degani H, 1997, NAT MED, V3, P780, DOI 10.1038/nm0797-780; DeRisi J, 1996, NAT GENET, V14, P457; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; FOSS AJE, 1995, BRIT J CANCER, V72, P155, DOI 10.1038/bjc.1995.293; GERHARD M, 1994, J CLIN ONCOL, V12, P725, DOI 10.1200/JCO.1994.12.4.725; Gibbs WW, 1996, SCI AM, V275, P42, DOI 10.1038/scientificamerican0996-42; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HAYASHI N, 1994, CANCER RES, V54, P3853; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JEN J, 1994, CANCER RES, V54, P5523; Ju JY, 1996, NAT MED, V2, P246, DOI 10.1038/nm0296-246; KATZ AE, 1995, CANCER-AM CANCER SOC, V75, P1642, DOI 10.1002/1097-0142(19950401)75:7<1642::AID-CNCR2820750714>3.0.CO;2-1; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRISMANN M, 1995, J CLIN ONCOL, V13, P2769, DOI 10.1200/JCO.1995.13.11.2769; LEON SA, 1977, CANCER RES, V37, P646; MANOS M, COMMUNICATION; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MAO L, 1994, CANCER RES, V54, P1634; Marra G, 1996, GASTROENTEROL CLIN N, V25, P755, DOI 10.1016/S0889-8553(05)70273-9; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MILLS NE, 1995, J NATL CANCER I, V87, P1056, DOI 10.1093/jnci/87.14.1056; MINAMOTO T, 1995, CANCER, V75, P1520, DOI 10.1002/1097-0142(19950315)75:6+<1520::AID-CNCR2820751523>3.0.CO;2-L; Miozzo M, 1996, CANCER RES, V56, P2285; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; POWELL SM, 1987, NEW ENGL J MED, V329, P293; REDSTON MS, 1995, GASTROENTEROLOGY, V108, P383, DOI 10.1016/0016-5085(95)90064-0; Ronai Z, 1996, J CELL BIOCHEM, P172; SCHANTZ SP, 1993, J CELL BIOCHEM, P199; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SHAPIRO B, 1983, CANCER, V51, P2116, DOI 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S; Sherman ME, 1997, CANCER CYTOPATHOL, V81, P89; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SMITH B, 1991, LANCET, V338, P1227, DOI 10.1016/0140-6736(91)92100-G; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5; STROUN M, 1989, ONCOLOGY, V46, P318; Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8; TADA M, 1993, CANCER RES, V53, P2472; TOBI M, 1994, J NATL CANCER I, V86, P1007; Umbricht CB, 1997, CANCER RES, V57, P2144; VASIOUKHIN V, 1994, CANCER EPIDEM BIOMAR, V3, P67; Wagner HN, 1996, SEMIN NUCL MED, V26, P194, DOI 10.1016/S0001-2998(96)80025-0; WANG Y, 1997, J ELECTROPHORESIS, V18, P1742; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yamada O, 1996, BBA-MOL CELL RES, V1314, P260, DOI 10.1016/S0167-4889(96)00104-8; Yasumoto S, 1996, ONCOGENE, V13, P433; Yoshida K, 1997, BRIT J CANCER, V75, P548, DOI 10.1038/bjc.1997.96; Yoshida K, 1997, CANCER, V79, P362, DOI 10.1002/(SICI)1097-0142(19970115)79:2<362::AID-CNCR20>3.0.CO;2-Y; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zippelius A, 1997, J CLIN ONCOL, V15, P2701, DOI 10.1200/JCO.1997.15.7.2701	78	336	375	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1054	1058		10.1126/science.278.5340.1054	http://dx.doi.org/10.1126/science.278.5340.1054			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353179				2022-12-28	WOS:A1997YE65200031
J	Silhavy, TJ				Silhavy, TJ			Cell biology - Death by lethal injection	SCIENCE			English	Editorial Material							GENE FUSION; SECRETION; MEMBRANE				Silhavy, TJ (corresponding author), PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544, USA.			Silhavy, Thomas/0000-0001-7672-5153				Anderson DM, 1997, SCIENCE, V278, P1140, DOI 10.1126/science.278.5340.1140; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SILHAVY TJ, 1976, P NATL ACAD SCI USA, V73, P3423, DOI 10.1073/pnas.73.10.3423; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; WANDERSMAN C, 1992, TRENDS GENET, V8, P317, DOI 10.1016/0168-9525(92)90264-5	10	26	26	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1085	1086		10.1126/science.278.5340.1085	http://dx.doi.org/10.1126/science.278.5340.1085			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9381204				2022-12-28	WOS:A1997YE65200039
J	Mercurio, F; Zhu, HY; Murray, BW; Shevchenko, A; Bennett, BL; Li, JW; Young, DB; Barbosa, M; Mann, M				Mercurio, F; Zhu, HY; Murray, BW; Shevchenko, A; Bennett, BL; Li, JW; Young, DB; Barbosa, M; Mann, M			IKK-1 and IKK-2: Cytokine-activated I kappa B kinases essential for NF-kappa B activation	SCIENCE			English	Article							TRANSCRIPTION FACTORS; ALPHA PROTEOLYSIS; MASS-SPECTROMETRY; PHOSPHORYLATION; PROTEINS; UBIQUITINATION; DEGRADATION; SIGNAL; FAMILY; IDENTIFICATION	Activation of the transcription factor nuclear factor kappa B (NF-kappa B) is controlled by sequential phosphorylation, ubiquitination, and degradation of its inhibitory subunit I kappa B. A large multiprotein complex, the I kappa B kinase (IKK) signalsome, was purified from Hela cells and found to contain a cytokine-inducible I kappa B kinase activity that phosphorylates I kappa B-alpha and I kappa B-beta. Two components of the IKK signalsome, IKK-1 and IKK-2, were identified as closely related protein serine kinases containing leucine zipper and helix-loop-helix protein interaction motifs. Mutant versions of IKK-2 had pronounced effects on RelA nuclear translocation and NF-kappa B-dependent reporter activity, consistent with a critical role for the IKK kinases in the NF-kappa B signaling pathway.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	European Molecular Biology Laboratory (EMBL); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Mercurio, F (corresponding author), SIGNAL PHARMACEUT INC,5555 OBERLIN AVE,SAN DIEGO,CA 92121, USA.		Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; murray, brion/0000-0003-1591-2566				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, EMBO J, V13, P1842; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; MAININ NL, 1997, NATURE, V385, P540; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mann M, 1996, TRENDS BIOCHEM SCI, V21, P494, DOI 10.1016/S0968-0004(96)30042-X; Manning AM, 1996, DRUG DISCOV TODAY, V1, P151, DOI 10.1016/1359-6446(96)10015-5; MERCURIO F, UNPUB; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	41	1800	1876	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					860	866		10.1126/science.278.5339.860	http://dx.doi.org/10.1126/science.278.5339.860			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346484				2022-12-28	WOS:A1997YD47900046
J	Buckingham, K; Freeman, PR				Buckingham, K; Freeman, PR			Sociodemographic and morbidity indicators of need in relation to the use of community health services: observational study	BRITISH MEDICAL JOURNAL			English	Article								Objective: To examine whether the sociodemographic and morbidity characteristics of populations influence their use of the following community health services: district nursing, health visiting, chiropody, community maternity, community mental illness, and the professions allied to medicine. Design: Observational study. Setting: Nationally representative sample of provider trusts in England. Main outcome measures: Activity levels for each service calculated for enumeration districts within the catchment areas of the sample of trusts and standardised to allow for differences in age structure. Regression analysis to determine whether the standardised activity rates for each service could be predicted by a range of socio-demographic and morbidity proxies. Results: Morbidity or deprivation, or both, seemed to influence the use of services in each of the care programmes examined. Conclusions: The allocation of funds for community health services should allo iv for differences in the health and socio-demographic characteristics of health authorities.			Buckingham, K (corresponding author), UNIV PLYMOUTH,DEPT PRIMARY HLTH CARE & GEN PRACTICE,PLYMOUTH PL4 8AA,DEVON,ENGLAND.							BRENNAN M, 1996, NO NEED WEIGHT COMMU; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; *HC HLTH COMM, 1996, 2 REP ALL RES HLTH A; JUDGE K, 1994, BRIT MED J, V309, P1031, DOI 10.1136/bmj.309.6961.1031; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; *NHS EX, 1994, HCHS REV ALL WEIGHT; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050	7	15	16	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					994	996		10.1136/bmj.315.7114.994	http://dx.doi.org/10.1136/bmj.315.7114.994			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365299	Green Published			2022-12-28	WOS:A1997YC30700025
J	Kudva, YC; Young, WF				Kudva, YC; Young, WF			Lightheaded spells and hypertension	LANCET			English	Article									MAYO CLIN & MAYO FDN,DIV ENDOCRINOL & METAB,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV HYPERTENS,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV INTERNAL MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic								KAPLAN NM, 1994, CLIN HYPERTENSION, P319; MEYRIER A, 1988, AM J NEPHROL, V8, P108, DOI 10.1159/000167567; VONKNORRING J, 1981, J UROLOGY, V126, P798, DOI 10.1016/S0022-5347(17)54755-2; WATTS RA, 1987, J HUM HYPERTENS, V1, P65; YOUNG WF, 1995, MAYO CLIN PROC, V70, P757, DOI 10.4065/70.8.757	5	2	2	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1140	1140		10.1016/S0140-6736(97)08338-4	http://dx.doi.org/10.1016/S0140-6736(97)08338-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343503				2022-12-28	WOS:A1997YB19900013
J	Schott, GD				Schott, GD			Bisphosphonates for pain relief in reflex sympathetic dystrophy?	LANCET			English	Editorial Material											Schott, GD (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							Adami S, 1997, ANN RHEUM DIS, V56, P201, DOI 10.1136/ard.56.3.201; Cortet B, 1997, CLIN RHEUMATOL, V16, P51, DOI 10.1007/BF02238763; DEVOGELAER JP, 1988, J BONE MINER RES  S1, V3, pSI22; Dray A, 1996, PROG BRAIN RES, V110, P85; KOZIN F, 1992, CLIN EXP RHEUMATOL, V10, P401; MAILLEFERT JF, 1995, ANN RHEUM DIS, V54, P687, DOI 10.1136/ard.54.8.687-a; OYEN WJG, 1993, PAIN, V55, P151, DOI 10.1016/0304-3959(93)90144-E; REHMAN MTA, 1992, BONE, V13, P116; SCHOTT GD, 1995, LANCET, V345, P634, DOI 10.1016/S0140-6736(95)90528-6; SELBY PL, 1994, DIABETIC MED, V11, P28, DOI 10.1111/j.1464-5491.1994.tb00225.x; Strang P, 1996, ACTA ONCOL, V35, P50, DOI 10.3109/02841869609083968; SUDECK P, 1900, ARCH KLIN CHIR, V62, P147	12	16	76	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1117	1117		10.1016/S0140-6736(05)63785-3	http://dx.doi.org/10.1016/S0140-6736(05)63785-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343496				2022-12-28	WOS:A1997YB19900005
J	Barquet, N; Domingo, P				Barquet, N; Domingo, P			Smallpox: The triumph over the most terrible of the ministers of death	ANNALS OF INTERNAL MEDICINE			English	Article							VIRUS; STOCKS	More than 200 years ago, Edward Jenner performed an experiment that laid the foundation for the eradication of smallpox and transformed humankind's fight against disease. Smallpox afflicted humankind as no other disease had done; its persistence and diffusion were without parallel. The disease brought down at least three empires. Generations watched helplessly as their children succumbed to the disease or were disfigured or blinded by it. Attempts were made to contain smallpox by isolating its sufferers and, later, by using variolation with varying degrees of success. However, the definitive solution was not found until Jenner's work was done at the end of the 18th century. Milkmaids who had developed cowpox from contact with cow udders informed Jenner that they were protected from the human form of the disease; he listened to their folk wisdom and raised it to the status of scientific fact. Jenner did not discover vaccination, but he was the first to demonstrate that this technique offered a reliable defense against smallpox. It was also a reliable defense against other illnesses, such as poliomyelitis, measles, and neonatal tetanus, although this was not known in Jenner's lifetime.	INST CATALA SALUT, CTR ASSISTENCIA PRIMARIA GRACIA, BARCELONA 08024, SPAIN; HOSP SANTA CRUZ & SAN PABLO, DEPT INTERNAL MED, E-08025 BARCELONA, SPAIN				Domingo, Pere/AAP-7571-2021; Domingo, Pere/CAF-3577-2022	Domingo, Pere/0000-0003-1138-5770; 				BARDELL D, 1976, ASM NEWS, V42, P526; BARON J, 1827, LIFE E JENNER, V1; Baron J, 1838, LIFE E JENNER, VII; Baxby D., 1981, TRENDS IMMUNOL, V3, P26; BERNSTEIN SOLON S., 1951, JOUR MT SINAI HOSP, V18, P228; BLAKE JB, 1959, PUBLIC HLTH TOWN BOS; Blake John B, 1957, B WATERHOUSE INTRO V; BOWERS JZ, 1981, B HIST MED, V55, P17; Boylston Z., 1726, HIST ACCOUNT SMALLPO; CERNY J, 1975, CAMBRIDGE ANCIENT HI, V2, P606; COLMAN B, 1721, SOME OBSERVATIONS NE; CREIGHTON C, 1889, JENNER VACCINATOIN S; CROOKSHANK EM, 1989, HIST PATHOLOGY VACCI, V1; DIMSDALE T, 1781, TRACTS INOCULATION W; DIXON C.W, 1962, SMALLPOX; DREWITT FD, 1931, LIFE E JENNER; Duffy J., 1953, EPIDEMICS COLONIAL A; DUFFY JOHN, 1951, BULL HIST MED, V25, P324; Edwardes, 1902, CONCISE HIST SMALLPO; Fisher R. B, 1991, E JENNER 1749 1823; Franklin B., 1759, SOME ACCOUNT SUCCESS; Furman Bess, 1973, PROFILE US PUBLIC HL; Halsband R, 1956, LIFE LADY MARY WORTL; HALSEY R, 1936, PRESIDENT T JEFFERSO; HAWES IE, 1974, B WATERHOUSE; Heagerty John J., 1928, 4 CENTURIES MED HIST; Hirsch A, 1883, HDB GEOGRAPHICAL HIS, VI; Holwell John Zephaniah, 1767, ACCOUNT MANNER INOCU; Hopkins D. R., 1983, PRINCES PEASANTS SMA; Hume Edward H., 1940, CHINESE WAY MED; Jenner E, 1788, PHILOS T ROY SOC LON, V78, P219, DOI DOI 10.1098/RSTL.1788.0016; Jenner E, 1798, INQUIRY CAUSES EFFEC; JENNER E, 1896, BRIT MED J, V1, P1245; Jenner Edward, 1801, ORIGIN VACCINE INOCU; Jezek Z, 1988, HUMAN MONKEYPOX; JOKLIK WK, 1993, SCIENCE, V262, P1225, DOI 10.1126/science.8235652; Jurin J., 1722, PHILOS T ROY SOC LON, V32, P213, DOI [10.1098/rstl.1722.0038, DOI 10.1098/RSTL.1722.0038]; KAHN C, 1963, AM J DIS CHILD, V106, P597, DOI 10.1001/archpedi.1963.02080050599011; Klebs AC, 1913, B JOHNS HOPKINS HOSP, V24, P69; Kubler Paul, 1901, GESCH POCKEN IMPFUNG; Littman R J, 1973, Am J Philol, V94, P243, DOI 10.2307/293979; LITTMAN RJ, 1969, P AM PHILOLOGICAL AS, V100, P261; MACAULAY TB, 1800, HIST ENGLAND; MAHY BWJ, 1993, SCIENCE, V262, P1223, DOI 10.1126/science.8235651; Maitland C, 1722, MAITLANDS ACCOUNT IN; MAJOR RH, 1936, DIS DESTINY; Martin HA, 1881, N CAROLINA MED J, V7, P1; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P446, DOI 10.1001/jama.274.6.446; Mather C, 1722, ACCOUNT METHOD SUCCE; MAURICE J, 1995, SCIENCE, V267, P450, DOI 10.1126/science.7824942; MCCUSKER JJ, 1991, P AM ANTIQUARIAN SOC, V101, P297; MCKENDRICK GD, 1973, PRICES TXB PRACTICE, P159; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; McVail J C, 1896, Br Med J, V1, P1271; MERCER A, 1990, DIS MORTALITY POPULA, P46; Miller Genevieve, 1957, ADOPTION INOCULATION; Moore J.C., 1815, HIST SMALLPOX; Moore JC, 1817, HIST PRACTICE VACCIN; Parish HG, 1968, VICTORY VACCINES STO; PARISH HJ, 1965, HIST IMMUNICATION; Pearson George, 1802, EXAMINATION REPORT C; PILARINO G, 1714, PHILOS T ROY SOC LON, V29, P393; PLOTKIN SL, 1994, VACCINES, P1; Razzell Peter E., 1977, E JENNERS COWPOX VAC; RHAZES, 1766, VAR MORB COMM; ROSES DF, 1992, SURG GYNECOL OBSTET, V175, P365; Ruffer MA, 1911, J PATHOL BACTERIOL, V15, P1, DOI 10.1002/path.1700150102; Ruffer MA, 1921, STUDIES PALEOPATHOLO, P175; SCHMIDT JS, 1851, PROVINZIALBERICHTE, V1, P77; SCHREIBER W, 1987, INFECT INFECT DIS HI, P117; SMITH MM, 1974, T AM PHILOS SOC, V64, P1, DOI 10.2307/1006158; STARK RB, 1977, SURG GYNECOL OBSTET, V144, P425; Stearn E. W., 1945, EFFECT SMALLPOX DEST; STEARNS RAYMOND PHINEAS, 1950, BULL HIST MED, V24, P103; Thursfield Hugh, 1940, Ann Med Hist, V2, P312; Timonius E.W.J.V., 1714, PHILOS T R SOC LOND, V29, P72, DOI DOI 10.1098/RSTL.1714.0010; UNDERWOOD EA, 1949, NATURE, V163, P823, DOI 10.1038/163823a0; VOELKER R, 1993, JAMA-J AM MED ASSOC, V270, P2908, DOI 10.1001/jama.1993.03510240016005; WATERHOUSE B, 1800, PROSPECT EXTERMINA 1; Waterhouse B, 1802, PROSPECT EXTERMINA 2; Wehrle PF, 1992, TXB PEDIAT INFECT DI, P1666; *WHO, 1994, B WORLD HEALTH ORGAN, V72, P841; *WHO GLOB COMM CER, 1980, GLOB ER SMALLP FIN R; WINSLOW OE, 1974, DESTROYING ANGEL; Woodville W., 1796, HIST INOCULATION SMA; Zinsser Hans., 1935, RATS LICE HIST; 1993, LANCET, V342, P505; 1993, NATURE, V366, P711; 1969, ALLGEMEINE UNTERHALT, V39, P305	89	122	126	1	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				635	642		10.7326/0003-4819-127-8_Part_1-199710150-00010	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341063				2022-12-28	WOS:A1997YB41900009
J	Karason, K; Wallentin, L; Larsson, B; Sjostrom, L				Karason, K; Wallentin, L; Larsson, B; Sjostrom, L			Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSIVE PATIENTS; BLOOD-PRESSURE; ARTERIAL-HYPERTENSION; INSULIN-RESISTANCE; HEART; GEOMETRY; HYPERTROPHY; REDUCTION; YOUNG	Objectives: To investigate the consequences of longstanding obesity on left ventricular mass and structure and to examine the effects of weight loss on these variables, Design: Cross sectional survey and controlled intervention study. Setting: City of Gothenburg and surrounding areas, Sweden. Subjects: 41 obese patients treated with weight reducing gastric surgery, 31 obese patients treated conventionally, and 43 non-obese subjects. Main outcome measures: Changes in left ventricular mass and relative wall thickness. Results: Obese patients had higher blood pressure, greater left ventricular mass, and increased relative wall thickness than did matched non-obese control subjects. Obese subjects treated with gastric surgery had a substantial weight loss and a significant reduction in all variables when compared with conventionally treated obese subjects. Univariate and multivariate analysis of pooled data from the two groups of obese subjects showed that changes in relative wall thickness and left ventricular mass were more closely related to the change in weight than to the concomitant change in blood pressure. Conclusions: Structural heart abnormalities occurring in conjunction with obesity diminish after weight loss, The regression in these structural aberrations is better predicted by the weight loss than by the accompanying reduction in blood pressure. To prevent or improve abnormalities of heart structure in obese people, weight control should be the primary goal; it should be regarded as at least as important as regulating blood pressure.	SAHLGRENS UNIV HOSP,DEPT CLIN PHYSIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DEPT MED,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital	Karason, K (corresponding author), SAHLGRENS UNIV HOSP,DEPT CARDIOL,S-41345 GOTHENBURG,SWEDEN.			Karason, Kristjan/0000-0002-2802-1191				AGABITIROSEI E, 1989, AM J HYPERTENS, V2, P70; ALEXANDE.JK, 1972, CIRCULATION, V45, P310, DOI 10.1161/01.CIR.45.2.310; ALEXANDER JK, 1962, CARDIOVASCULAR RES C, V63, P39; ALPERT MA, 1994, AM J CARDIOL, V73, P918, DOI 10.1016/0002-9149(94)90829-X; ALPERT MA, 1985, AM J CARDIOL, V55, P783, DOI 10.1016/0002-9149(85)90156-0; BYRD BF, 1989, AM HEART J, V118, P133, DOI 10.1016/0002-8703(89)90083-5; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DEVEREUX RB, 1995, J AM COLL CARDIOL, V25, P885, DOI 10.1016/0735-1097(94)00547-4; FAGARD R, 1992, EUR HEART J, V13, P1373, DOI 10.1093/oxfordjournals.eurheartj.a060069; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HSUEH WA, 1994, ENDOCRIN METAB CLIN, V23, P405, DOI 10.1016/S0889-8529(18)30105-1; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LAUER MS, 1991, JAMA-J AM MED ASSOC, V266, P231, DOI 10.1001/jama.266.2.231; LAUER MS, 1992, J AM COLL CARDIOL, V19, P130, DOI 10.1016/0735-1097(92)90063-S; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LICATA G, 1994, AM J HYPERTENS, V7, P314, DOI 10.1093/ajh/7.4.314; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1982, LANCET, V1, P1165; MESSERLI FH, 1983, AM J MED, V74, P808, DOI 10.1016/0002-9343(83)91071-9; Reaven Gerald M., 1996, New England Journal of Medicine, V334, P374; SASSON Z, 1993, CIRCULATION, V88, P1431, DOI 10.1161/01.CIR.88.4.1431; SJOSTROM L, 1992, INT J OBESITY, V16, P465; VERDECCHIA P, 1995, J AM COLL CARDIOL, V25, P871, DOI 10.1016/0735-1097(94)00424-O; WILLIAMS GH, 1997, HEART DIS TXB CARDIO, P1887	28	119	120	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					912	916						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361540	Green Published			2022-12-28	WOS:A1997YB07300023
J	Haines, A; McMichael, AJ				Haines, A; McMichael, AJ			Climate change and health: implications for research, monitoring, and policy	BRITISH MEDICAL JOURNAL			English	Article							NINO SOUTHERN-OSCILLATION; EL-NINO; PUBLIC-HEALTH; DISEASES; MALARIA; ENSO		UCL, SCH MED, LONDON NW3 2PF, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT HLTH, LONDON WC1E 7HT, ENGLAND	University of London; University College London; UCL Medical School; University of London; London School of Hygiene & Tropical Medicine	Haines, A (corresponding author), ROYAL FREE HOSP, SCH MED, JOINT DEPT PRIMARY CARE & POPULAT SCI, LONDON NW3 2PF, ENGLAND.			Haines, Andy/0000-0002-8053-4605				ACEITUNO P, 1992, B AM METEOROL SOC, V73, P483; ALMENDARES J, 1993, LANCET, V342, P1400, DOI 10.1016/0140-6736(93)92758-L; BALBUS JM, 1996, GUIDANCE VULNERABILI; Bell W., 1997, FDN FUTURES STUDIES, V1; Bell W., 2011, FDN FUTURES STUDIES; BONGAARTS J, 1992, POPUL DEV REV, V18, P229; Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; British Medical Association, 1992, CYCL HLTH SAF; DILLEY M, 1995, DISASTERS, V19, P181, DOI 10.1111/j.1467-7717.1995.tb00338.x; EKINS P, 1995, QUEEN MAR WESTF COLL; EPSTEIN PR, 1993, LANCET, V342, P1216, DOI 10.1016/0140-6736(93)92191-U; EPSTEIN PR, 1993, LANCET, V341, P1404, DOI 10.1016/0140-6736(93)90962-G; Fleming DM, 1991, 53 ROYAL COLL GEN PR; Gilles HM, 1993, BRUCECHWATTS ESSENTI, P124; HAINES A, 1993, LANCET, V342, P1464, DOI 10.1016/0140-6736(93)92937-O; Hales S, 1996, LANCET, V348, P1664, DOI 10.1016/S0140-6736(05)65737-6; HEAD OW, 1993, GLOBAL TERRESTRIAL O; *INT CTR DIARRH DI, 1990, SPEC BIBL SER, V14; *INT PAN CLIM CHAN, 1996, 2 ASS REP INT PAN CL, P561; *INT PAN CLIM CHAN, 1996, 2 ASS REP INT PAN CL, P587; KEATING M, 1993, EARTHS SUMMITS AGEND; LaPorte RE, 1996, ANN EPIDEMIOL, V6, P162, DOI 10.1016/1047-2797(95)00133-6; Levins R., 1995, ECOSYST HEALTH, V1, P47; MARTENS WJM, 1995, GLOBAL ENVIRON CHANG, V5, P195, DOI 10.1016/0959-3780(95)00051-O; MARTIN PH, 1995, AMBIO, V24, P200; MCCULLY P, 1997, SILENCED RIVERS; McMichael AJ, 1997, BMJ-BRIT MED J, V315, P805, DOI 10.1136/bmj.315.7111.805; MCMICHAEL AJ, 1997, ENVIRON MODEL ASSESS, V2, P1; MCMICHAEL AJ, 1996, WHOEMG967; Patz JA, 1996, JAMA-J AM MED ASSOC, V275, P217, DOI 10.1001/jama.275.3.217; Patz JA, 1996, CLIMATE RES, V6, P113, DOI 10.3354/cr006113; PEARCE D, 1991, BLUEPRINT, V2; PEEL M, 1995, BRIT MED J, V311, P1651; POTTS M, 1994, J ROY SOC MED, V87, P718; ROGERS DJ, 1991, NATURE, V351, P739, DOI 10.1038/351739a0; Slaper H, 1996, NATURE, V384, P256, DOI 10.1038/384256a0; United Nations Environment Programme, 1993, HDB MONTR PROT SUBST; WHO, 1997, HLTH ENV SUST DEV; WOODWARD AJ, IN PRESS CLIMATE RES; *WORLD EN COUNC, 1996, CLIM CHANG NEG COP2	41	23	23	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					870	874		10.1136/bmj.315.7112.870	http://dx.doi.org/10.1136/bmj.315.7112.870			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353511	Green Published			2022-12-28	WOS:A1997YA00700032
J	Rich, TH; VickersRich, P; Constantine, A; Flannery, TF; Kool, L; vanKlaveren, N				Rich, TH; VickersRich, P; Constantine, A; Flannery, TF; Kool, L; vanKlaveren, N			A tribosphenic mammal from the Mesozoic of Australia	SCIENCE			English	Article							LATE CRETACEOUS MAMMALS; EUTHERIAN MAMMALS; EVOLUTION; DINOSAURS; MONGOLIA; SAHARA	A small, well-preserved dentary of a tribosphenic mammal with the most posterior premolar and all three molars in place has been found in Aptian (Early Cretaceous) rocks of southeastern Australia. In most respects, dental and mandibular anatomy of the specimen is similar to that of primitive placental mammals, With the possible exception of a single tooth reported as Eocene in age, terrestrial placentals are otherwise unknown in Australia until the Pliocene. This possible Australian placental is similar in age to Prokennalestes from the late Aptian/early Albian Khoboor Beds of Mongolia, the oldest currently accepted member of the infraclass Placentalia.	MONASH UNIV, DEPT EARTH SCI, CLAYTON, VIC 3001, AUSTRALIA; AUSTRALIAN MUSEUM, SYDNEY, NSW 2000, AUSTRALIA	Monash University; Australian Museum	Rich, TH (corresponding author), MUSEUM VICTORIA, POB 666E, MELBOURNE, VIC 3001, AUSTRALIA.							ARCHER M, 1985, NATURE, V318, P363, DOI 10.1038/318363a0; ARCHER M, 1993, MAMMAL PHYLOGENY, P75; Archer M., 1992, P15; ARCHER M, 1978, MONOTREME BIOL, P9; Bertini Reinaldo J., 1993, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V188, P71; Bonaparte J.F., 1994, Berliner Geowissenschaftliche Abhandlungen Reihe E Palaeobiologie, V13, P31; Bonaparte J.F., 1986, 4 C ARG PAL BIOESTR, V4, P63; BONAPARTE JF, 1990, NATL GEOGR RES, V6, P63; BUTLER PM, 1948, P ZOOL SOC LOND, V118, P446; BUTLER PM, 1990, BIOL REV, V65, P529, DOI 10.1111/j.1469-185X.1990.tb01237.x; Cifelli R.L., 1990, Journal of Vertebrate Paleontology, V10, P346; CIFELLI RL, 1993, MAMMAL PHYLOGENY, P205; Clemens W.A., 1986, CONTRIBUTIONS GEOLOG, V3, P55, DOI DOI 10.2113/GSR0CKY.24.SPECIAL_; Clemens W.A., 1980, PALEOBIOS, V33, P1; Clemens W.A. Jr., 1973, University of California Publications in Geological Sciences, V94, P1; Crompton A., 1971, EARLY MAMMALS, P65; EMRY RJ, 1981, J PALEONTOL, V55, P953; FLANNERY TF, 1995, NATURE, V377, P418, DOI 10.1038/377418a0; FORSTER C, COMMUNICATION; FOX RC, 1979, CAN J EARTH SCI, V16, P114, DOI 10.1139/e79-011; GODTHELP H, 1992, NATURE, V356, P514, DOI 10.1038/356514a0; GOIN FJ, 1986, 4 C ARG PAL BIOESTR, V2, P43; GRADSTEIN FM, 1994, J GEOPHYS RES-SOL EA, V99, P24051, DOI 10.1029/94JB01889; GREEN PF, 1989, 172 GEOTRACKTM; HELBY R, 1987, ASS AUSTRALASIAN PAL, V4, P1; Kielan-Jaworowska Z., 1979, P221; KIELANJAWOROWSK.Z, 1997, LETHAIA, V29, P249; KIELANJAWOROWSKA Z, 1987, NATURE, V326, P871, DOI 10.1038/326871a0; KIELANJAWOROWSKA Z, 1989, ZOOL SCR, V18, P347, DOI 10.1111/j.1463-6409.1989.tb00460.x; KRAUSE DW, 1994, NATURE, V368, P298, DOI 10.1038/368298a0; LEDOUX JC, 1966, CR ACAD SCI D NAT, V262, P1925; LILLEGRAVEN JA, 1976, J PALEONTOL, V50, P437; Lillegraven JA, 1986, AM MUS NOVIT, V2840, p1 ; MARSHALL LG, 1992, LETHAIA, V25, P361, DOI 10.1111/j.1502-3931.1992.tb01639.x; McLachlan I.R., 1979, GEOL SOC S AFR SPEC, V6, P161; MORGAN RP, 1980, MEM GEOL SURV NSW PA, V18, P1; MOUNER TE, 1986, B SOC GEOL FRANCE 8, V2, P171; Nessov Lev A., 1994, Palaeovertebrata (Montpellier), V23, P51; PRASAD GVR, 1994, J VERTEBR PALEONTOL, V14, P260, DOI 10.1080/02724634.1994.10011556; Rich T.H., 1991, VERTEBRATE PALAEONTO, P1005; Rich T.H.V., 1981, Bulletin of the American Museum of Natural History, V171, P1; Rougier G.W., 1992, Journal of Vertebrate Paleontology, V12, P188; SENSU RC, 1980, CAN J EARTH SCI, V17, P1489; SENSU RC, 1975, CAN J EARTH SCI, V12, P412; SENSU Z, 1990, LETHAIA, V23, P1; SERENO PC, 1994, SCIENCE, V266, P267, DOI 10.1126/science.266.5183.267; Sereno PC, 1996, SCIENCE, V272, P986, DOI 10.1126/science.272.5264.986; Sigogneau-Russell D, 1995, B MUSEUM NATL HIST N, V16, P291; SIGOGNEAURUSSEL.D, 1992, HSIT BIOL, V6, P185; SIGOGNEAURUSSELL D, 1992, ZOOL SCR, V21, P205, DOI 10.1111/j.1463-6409.1992.tb00322.x; SMITH AG, 1994, ATLAS MESOZOIC CENOZ, P41; SZALAY FS, 1994, EVOLUTIONARY HIST PR; WAGSTAFF BE, 1989, NATL GEOGR RES, V5, P54; WATTS CHS, 1994, AUST J ZOOL, V42, P711, DOI 10.1071/ZO9940711	54	96	104	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1438	1442		10.1126/science.278.5342.1438	http://dx.doi.org/10.1126/science.278.5342.1438			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367951				2022-12-28	WOS:A1997YG85800037
J	Settles, AM; Yonetani, A; Baron, A; Bush, DR; Cline, K; Martienssen, R				Settles, AM; Yonetani, A; Baron, A; Bush, DR; Cline, K; Martienssen, R			Sec-independent protein translocation by the maize Hcf106 protein	SCIENCE			English	Article							ESCHERICHIA-COLI; THYLAKOID MEMBRANE; SIGNAL PEPTIDE; TRANSPORT; EXPORT; PATHWAY; MUTATIONS; HOMOLOG; NUCLEAR; BINDING	The bacterial Sec and signal recognition particle (ffh-dependent) protein translocation mechanisms are conserved between prokaryotes and higher plant chloroplasts. A third translocation mechanism in chloroplasts [the proton concentration difference (Delta pH) pathway] was previously thought to be unique. The hcf106 mutation of maize disrupts the localization of proteins transported through this Delta pH pathway in isolated chloroplasts. The Hcf106 gene encodes a receptor-like thylakoid membrane protein, which shows homology to open reading frames from all completely sequenced bacterial genomes, which suggests that the Delta pH pathway has been conserved since the endosymbiotic origin of chloroplasts. Thus, the third protein translocation pathway, of which HCF106 is a component, is found in both bacteria and plants.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; EMORY UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,ATLANTA,GA 30322; UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; USDA ARS,PHOTOSYNTHESIS RES UNIT,URBANA,IL 61801; UNIV ILLINOIS,DEPT PLANT BIOL,URBANA,IL 61801	Cold Spring Harbor Laboratory; Emory University; State University System of Florida; University of Florida; United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign			Bush, Daniel R/AAG-8444-2019; Cline, Kenneth/J-6238-2013	Settles, A. Mark/0000-0002-5846-0996; Bush, Daniel/0000-0002-9160-5077				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARKAN A, 1986, EMBO J, V5, P1421, DOI 10.1002/j.1460-2075.1986.tb04378.x; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; BROCK IW, 1995, J BIOL CHEM, V270, P1657, DOI 10.1074/jbc.270.4.1657; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DAS L, 1995, PLANT CELL, V7, P287, DOI 10.1105/tpc.7.3.287; ERNST F, 1994, J BIOL CHEM, V269, P12840; ETTINGER WF, 1992, PLANT PHYSIOL, V99, P791, DOI 10.1104/pp.99.2.791; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; KNOTT TG, 1994, J BIOL CHEM, V269, P4505; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; LEE JH, 1985, J BACTERIOL, V162, P344, DOI 10.1128/JB.162.1.344-352.1985; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MANT A, 1995, J BIOL CHEM, V270, P23275, DOI 10.1074/jbc.270.40.23275; MARTIENSSEN RA, 1989, EMBO J, V8, P1633, DOI 10.1002/j.1460-2075.1989.tb03553.x; MARTIENSSEN RA, 1987, PLANT MEMBRANES STRU, P181; NAKAI M, 1994, J BIOL CHEM, V269, P31338; NG DTW, 1994, CURR OPIN CELL BIOL, V6, P510, DOI 10.1016/0955-0674(94)90069-8; NIVIERE V, 1992, J GEN MICROBIOL, V138, P2173, DOI 10.1099/00221287-138-10-2173; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; VOELKER R, 1997, GENETICS, V154, P467; YATES M, COMMUNICATION; YUAN J, 1994, J BIOL CHEM, V268, P18463; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; [No title captured]	41	225	238	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1467	1470		10.1126/science.278.5342.1467	http://dx.doi.org/10.1126/science.278.5342.1467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367960				2022-12-28	WOS:A1997YG85800046
J	Melton, LJ				Melton, LJ			The threat to medical-records research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HIP FRACTURE; EPIDEMIOLOGIC RESEARCH; PRIVACY; CONFIDENTIALITY; INFORMATION				Melton, LJ (corresponding author), MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NIAMS NIH HHS [AR-30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1991, LAW MED HLTH CARE, V19, P247; Bacon WE, 1996, OSTEOPOROSIS INT, V6, P69, DOI 10.1007/BF01626541; BEARD CM, 1990, J BONE MINER RES, V5, P691, DOI 10.1002/jbmr.5650050705; CAPRON AM, 1991, J CLIN EPIDEMIOL, V44, pS81; Codman EA, 1914, SURG GYNECOL OBSTET, V18, P491; CODMAN EA, 1914, SURG GYNECOL OBSTET, V18, P7; CORDIER LJ, 1995, EUR UNION BIOMED HLT, V6, P5; Doyal L, 1997, BMJ-BRIT MED J, V314, P1107, DOI 10.1136/bmj.314.7087.1107; FISHER ES, 1990, AM J PUBLIC HEALTH, V80, P1487, DOI 10.2105/AJPH.80.12.1487; Gabriel S E, 1997, Curr Opin Rheumatol, V9, P87, DOI 10.1097/00002281-199703000-00001; GORDIS L, 1980, SCIENCE, V207, P153, DOI 10.1126/science.7350648; Gostin LO, 1996, JAMA-J AM MED ASSOC, V275, P1921, DOI 10.1001/jama.275.24.1921; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V270, P2487; Jollis JG, 1996, MAYO CLIN PROC, V71, P1016, DOI 10.1016/S0025-6196(11)63780-4; KNOX EG, 1992, BRIT MED J, V304, P727, DOI 10.1136/bmj.304.6829.727; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Lee PR, 1997, PUBLIC HEALTH REP, V112, P114; Lowrance WW, 1997, PRIVACY HLTH RES REP; Mayo CH, 1905, NW LANCET, V25, P179; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; Melton LJ, 1996, PUBLIC HEALTH REP, V111, P146; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; *NAT COMM VIT HLTH, 1997, HLTH PRIV CONF REC; *NAT RES COUNC COM, 1997, REC PROT EL HLTH INF; Prentnieks M, 1996, Minn Med, V79, P47; RAY WA, 1990, AM J EPIDEMIOL, V131, P502, DOI 10.1093/oxfordjournals.aje.a115524; REES JL, 1982, BRIT MED J, V284, P1856, DOI 10.1136/bmj.284.6332.1856; SIEGLER M, 1982, NEW ENGL J MED, V307, P1518, DOI 10.1056/NEJM198212093072411; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; Veatch RM, 1997, NEW ENGL J MED, V336, P869, DOI 10.1056/NEJM199703203361209; WALD N, 1994, BRIT MED J, V309, P1422, DOI 10.1136/bmj.309.6966.1422; WESTRIN CG, 1994, BRIT MED J, V308, P522, DOI 10.1136/bmj.308.6927.522; WYSOWSKI DK, 1993, AM J PUBLIC HEALTH, V83, P770, DOI 10.2105/AJPH.83.5.770; YAWN B, 1997, NAT CTR HLTH STAT C; 1994, J R COLL PHYSICIANS, V28, P439; 1997, US NEWS WORLD R 0728	36	210	210	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1466	1470		10.1056/NEJM199711133372012	http://dx.doi.org/10.1056/NEJM199711133372012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF253	9380105				2022-12-28	WOS:A1997YF25300012
J	Metlay, JP; Kapoor, WN; Fine, MJ				Metlay, JP; Kapoor, WN; Fine, MJ			Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFIDENCE-INTERVALS; CLINICAL-PREDICTION; CHEST; ANTIBIOTICS; RELIABILITY; OUTPATIENTS; ADULTS	Community-acquired pneumonia is an important cause of acute respiratory symptoms (eg, cough) in the ambulatory care setting, Distinguishing pneumonia from other causes of respiratory illnesses, such as acute bronchitis and upper respiratory tract infections, has important therapeutic and prognostic implications, The reference standard for diagnosing pneumonia is chest radiography, but it is likely that many physicians rely on the patient's history and their physical examination to diagnose or exclude this disease. A review of published studies of patients suspected of having pneumonia reveals that there are no individual clinical findings, or combinations of findings, that can rule in the diagnosis of pneumonia for a patient suspected of having this illness, However, some studies have shown that the absence of any vital sign abnormalities or any abnormalities on chest auscultation substantially reduces the likelihood of pneumonia to a point where further diagnostic evaluation may be unnecessary, This article reviews the literature on the appropriate use of the history and physical examination in diagnosing community-acquired pneumonia.	MASSACHUSETTS GEN HOSP, DEPT MED, GEN INTERNAL MED UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV PITTSBURGH, DEPT MED, CTR RES HLTH CARE, DIV GEN INTERNAL MED, PITTSBURGH, PA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					BHP HRSA HHS [5 T32 PE11001-08] Funding Source: Medline	BHP HRSA HHS		Albaum MN, 1996, CHEST, V110, P343, DOI 10.1378/chest.110.2.343; Bullowa JGM, 1935, ARCH INTERN MED, V55, P558, DOI 10.1001/archinte.1935.00160220028003; CENTOR RM, 1992, MED DECIS MAKING, V12, P229, DOI 10.1177/0272989X9201200309; COCHRANE AL, 1951, LANCET, V260, P1007; DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8; EMERMAN CL, 1991, ANN EMERG MED, V20, P1215, DOI 10.1016/S0196-0644(05)81474-X; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; FLETCHER CM, 1964, METHOD INFORM MED, V3, P98, DOI 10.1055/s-0038-1636275; Forgacs P, 1969, Br J Dis Chest, V63, P1, DOI 10.1016/S0007-0971(69)80039-2; Gennis P, 1989, J Emerg Med, V7, P263, DOI 10.1016/0736-4679(89)90358-2; GILBERT VE, 1989, AM REV RESPIR DIS, V140, P1012, DOI 10.1164/ajrccm/140.4.1012; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GRAHAM NMH, 1990, EPIDEMIOL REV, V12, P149, DOI 10.1093/oxfordjournals.epirev.a036050; Hasley PB, 1996, ARCH INTERN MED, V156, P2206, DOI 10.1001/archinte.156.19.2206; HECKERLING PS, 1986, ARCH INTERN MED, V146, P1321, DOI 10.1001/archinte.146.7.1321; HECKERLING PS, 1990, ANN INTERN MED, V113, P664, DOI 10.7326/0003-4819-113-9-664; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; Mainous AG, 1996, J FAM PRACTICE, V42, P357; MELBYE H, 1992, Scandinavian Journal of Primary Health Care, V10, P226, DOI 10.3109/02813439209014066; Metlay J. P., 1997, JGIM, V12, P77; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; ORR PH, 1993, J FAM PRACTICE, V36, P507; OSMER JC, 1966, SOUTHERN MED J, V59, P75, DOI 10.1097/00007611-196601000-00014; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SCHILLING RSF, 1955, BMJ-BRIT MED J, V1, P65, DOI 10.1136/bmj.1.4905.65; SINGAL BM, 1989, ANN EMERG MED, V18, P13, DOI 10.1016/S0196-0644(89)80304-X; SMYLLIE HC, 1965, LANCET, V2, P412; SPITERI MA, 1988, LANCET, V1, P873; THACKER RE, 1982, CHEST, V81, P672, DOI 10.1378/chest.81.6.672	33	316	327	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1440	1445		10.1001/jama.278.17.1440	http://dx.doi.org/10.1001/jama.278.17.1440			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9356004				2022-12-28	WOS:A1997YC91700032
J	Nightingale, SL				Nightingale, SL			Proposed rule on women in clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-28	WOS:A1997YC91700006
J	Ryan, TM; Ciavatta, DJ; Townes, TM				Ryan, TM; Ciavatta, DJ; Townes, TM			Knockout-transgenic mouse model of sickle cell disease	SCIENCE			English	Article							BETA-GLOBIN LOCUS; YEAST ARTIFICIAL CHROMOSOME; HEMOGLOBIN-S; DEVELOPMENTAL REGULATION; DEOXYHEMOGLOBIN-S; CRYSTAL-STRUCTURE; MICE; POLYMERIZATION; THALASSEMIA; GELATION	When transgenic mice that expressed human sickle hemoglobin were mated with mice having knockout mutations of the mouse alpha-and beta-globin genes, animals were produced that synthesized only human hemoglobin in adult red blood cells. Similar to many human patients with sickle cell disease, the mice developed a severe hemolytic anemia and extensive organ pathology. Numerous sickled erythrocytes were observed in peripheral blood. Although chronically anemic, most animals survived for 2 to 9 months and were fertile. Drug and genetic therapies can now be tested in this mouse model of sickle cell disease.	UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Ryan, Thomas/0000-0002-8982-0253	NCI NIH HHS [CA13148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BRITTENHAM GM, 1985, BLOOD, V65, P183; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; CREPEAU RH, 1978, NATURE, V274, P616, DOI 10.1038/274616a0; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; EATON WA, 1987, BLOOD, V70, P1245; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12155, DOI 10.1073/pnas.89.24.12155; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; Fabry ME, 1996, J CLIN INVEST, V98, P2450, DOI 10.1172/JCI119062; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; NOGUCHI CT, 1981, BLOOD, V58, P1057; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Popp RA, 1997, BLOOD, V89, P4204, DOI 10.1182/blood.V89.11.4204; RHODA MD, 1988, BIOCHIM BIOPHYS ACTA, V952, P208, DOI 10.1016/0167-4838(88)90117-3; Roberts NA, 1997, BLOOD, V89, P713, DOI 10.1182/blood.V89.2.713; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; RYAN TM, UNPUB; SERJEANT GR, 1970, BRIT J HAEMATOL, V19, P635, DOI 10.1111/j.1365-2141.1970.tb01647.x; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; TRUDEL M, 1994, BLOOD, V84, P3189; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; Weatherall DJ, 1981, THALASSEMIA SYNDROME; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WOOD WG, 1985, NATURE, V313, P320, DOI 10.1038/313320a0; YANG BL, 1995, P NATL ACAD SCI USA, V92, P11608, DOI 10.1073/pnas.92.25.11608	34	202	211	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					873	876		10.1126/science.278.5339.873	http://dx.doi.org/10.1126/science.278.5339.873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346487				2022-12-28	WOS:A1997YD47900049
J	Lamberts, SWJ; Bruining, HA; deJong, FH				Lamberts, SWJ; Bruining, HA; deJong, FH			Corticosteroid therapy in severe illness	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE ADRENAL INSUFFICIENCY; RECENTLY INJURED PATIENTS; CRITICALLY ILL PATIENTS; PLASMA-CORTISOL LEVELS; ACUTE MEDICAL ILLNESS; SEPTIC SHOCK; ADRENOCORTICAL FUNCTION; HEMODYNAMIC IMPROVEMENT; SURGICAL STRESS; ACTH TEST		ERASMUS UNIV ROTTERDAM,DEPT MED,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT SURG,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam			De Jong, Frank H/A-9876-2011	De Jong, Frank H/0000-0003-3578-1065				ALFORD WC, 1979, J THORAC CARDIOV SUR, V78, P489; AXELROD L, 1976, MEDICINE, V55, P39, DOI 10.1097/00005792-197601000-00003; BALDWIN WA, 1993, ARCH SURG-CHICAGO, V128, P673; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BESSE JC, 1966, J PHARMACOL EXP THER, V154, P224; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; BOUACHOUR G, 1994, INTENS CARE MED, V20, P138, DOI 10.1007/BF01707669; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRIEGEL J, 1992, INTENS CARE MED, V18, P318, DOI 10.1007/BF01706486; BROMBERG JS, 1991, TRANSPLANTATION, V51, P385, DOI 10.1097/00007890-199102000-00023; CHERNOW B, 1987, ARCH INTERN MED, V147, P1273, DOI 10.1001/archinte.147.7.1273; CHOPRA MP, 1972, BRIT HEART J, V34, P992; CHRISTY NP, 1992, NEW ENGL J MED, V326, P266, DOI 10.1056/NEJM199201233260410; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CLAUSSEN MS, 1992, J TRAUMA, V32, P94, DOI 10.1097/00005373-199201000-00020; COOPER CE, 1962, J CLIN INVEST, V41, P1599, DOI 10.1172/JCI104618; CRONIN L, 1995, CRIT CARE MED, V23, P1430, DOI 10.1097/00003246-199508000-00019; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; DEJONG FH, 1984, J CLIN ENDOCR METAB, V59, P1143, DOI 10.1210/jcem-59-6-1143; DIXON RB, 1980, AM J MED, V68, P224, DOI 10.1016/0002-9343(80)90358-7; DORIN RI, 1988, CRIT CARE MED, V16, P296, DOI 10.1097/00003246-198803000-00019; DRUCKER D, 1986, CRIT CARE MED, V14, P789, DOI 10.1097/00003246-198609000-00006; DRUCKER D, 1985, CRIT CARE MED, V13, P477, DOI 10.1097/00003246-198506000-00007; ERNEST D, 1991, INTENS CARE MED, V17, P238, DOI 10.1007/BF01709885; ESTEBAN NV, 1991, J CLIN ENDOCR METAB, V72, P39, DOI 10.1210/jcem-72-1-39; ESTEP HL, 1963, J CLIN ENDOCR METAB, V23, P419, DOI 10.1210/jcem-23-5-419; FELLOWS IW, 1983, BRIT MED J, V287, P1835, DOI 10.1136/bmj.287.6408.1835; FINLAY WEI, 1982, LANCET, V1, P1414; FRASER CG, 1952, JAMA-J AM MED ASSOC, V149, P1542, DOI 10.1001/jama.1952.72930340001009; Friedman RJ, 1995, J BONE JOINT SURG AM, V77A, P1801, DOI 10.2106/00004623-199512000-00002; Glowniak JV, 1997, SURGERY, V121, P123, DOI 10.1016/S0039-6060(97)90280-4; GRABER AL, 1965, J CLIN ENDOCR METAB, V25, P11, DOI 10.1210/jcem-25-1-11; Hiebert J M, 1972, Surg Forum, V23, P69; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P82, DOI 10.1056/NEJM198401123100203; HUIZENGA N, IN PRESS J CLIN ENDO; HUME DM, 1962, SURGERY, V52, P174; IVERSEN LL, 1970, BRIT J PHARMACOL, V40, P528, DOI 10.1111/j.1476-5381.1970.tb10637.x; JANSSENS ENW, 1984, THESIS ERASMUS U ROT; JASANI MK, 1968, Q J MED, V37, P407; JASANI MK, 1967, Q J MED, V143, P261; JENSEN JK, 1966, NORD MED, V75, P978; JURNEY TH, 1987, CHEST, V92, P292, DOI 10.1378/chest.92.2.292; KALSNER S, 1969, CIRC RES, V24, P383, DOI 10.1161/01.RES.24.3.383; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; KIDESS AI, 1993, MAYO CLIN PROC, V68, P435, DOI 10.1016/S0025-6196(12)60188-8; KNOWLTON AI, 1989, J INTENSIVE CARE MED, V4, P35, DOI DOI 10.1177/088506668900400104; Koper JW, 1997, HUM GENET, V99, P663, DOI 10.1007/s004390050425; LAROCHELLE GE, 1993, AM J MED, V95, P258, DOI 10.1016/0002-9343(93)90277-V; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; LEDINGHAM IM, 1983, LANCET, V1, P1270; LEFERING R, 1995, CRIT CARE MED, V23, P1294, DOI 10.1097/00003246-199507000-00021; LINDHOLM J, 1978, J CLIN ENDOCR METAB, V47, P272, DOI 10.1210/jcem-47-2-272; LINDHOLM J, 1987, CLIN ENDOCRINOL, V26, P53, DOI 10.1111/j.1365-2265.1987.tb03638.x; MCINTOSH TK, 1981, J CLIN ENDOCR METAB, V53, P117, DOI 10.1210/jcem-53-1-117; MCKEE JI, 1983, LANCET, V1, P484; MEAKIN JW, 1960, AM J MED, V29, P459, DOI 10.1016/0002-9343(60)90042-5; MELBY JC, 1958, J CLIN INVEST, V37, P1791, DOI 10.1172/JCI103772; MELBY MJ, 1988, PHARMACOTHERAPY, V48, P69; MOHLER JL, 1985, SURG GYNECOL OBSTET, V161, P551; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; NAITO Y, 1991, J CLIN ENDOCR METAB, V73, P111, DOI 10.1210/jcem-73-1-111; NICHOLS T, 1965, J CLIN ENDOCR METAB, V25, P343, DOI 10.1210/jcem-25-3-343; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; PARKER LN, 1985, J CLIN ENDOCR METAB, V60, P947, DOI 10.1210/jcem-60-5-947; REINCKE M, 1993, J CLIN ENDOCR METAB, V77, P151, DOI 10.1210/jc.77.1.151; ROTHWELL PM, 1991, LANCET, V337, P582, DOI 10.1016/0140-6736(91)91641-7; SAINSBURY JRC, 1981, ANAESTHESIA, V36, P16, DOI 10.1111/j.1365-2044.1981.tb08594.x; SALASSA RM, 1953, JAMA-J AM MED ASSOC, V152, P1509, DOI 10.1001/jama.1953.03690160009004; SALEM M, 1994, ANN SURG, V219, P416, DOI 10.1097/00000658-199404000-00013; SAMPSON PA, 1961, LANCET, V1, P1377; SANDBERG AA, 1956, J CLIN ENDOCR METAB, V16, P1001, DOI 10.1210/jcem-16-8-1001; SCHEIN RMH, 1990, CRIT CARE MED, V18, P259, DOI 10.1097/00003246-199003000-00002; SCHNEIDER AJ, 1991, INTENS CARE MED, V17, P436, DOI 10.1007/BF01720688; SIBBALD WJ, 1977, ANN SURG, V186, P29, DOI 10.1097/00000658-197707000-00005; SONI A, 1995, AM J MED, V98, P266, DOI 10.1016/S0002-9343(99)80373-8; STONER HB, 1979, CLIN SCI, V56, P563, DOI 10.1042/cs0560563; STRECK WF, 1979, AM J MED, V66, P910, DOI 10.1016/0002-9343(79)90444-3; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; SWINGLE WW, 1959, P SOC EXP BIOL MED, V100, P617; Swingle WW, 1933, SCIENCE, V77, P58, DOI 10.1126/science.77.1985.58; TREADWELL BLJ, 1963, LANCET, V1, P355; UDELSMAN R, 1986, J CLIN INVEST, V77, P1377, DOI 10.1172/JCI112443; VERMES I, 1995, J CLIN ENDOCR METAB, V80, P1238, DOI 10.1210/jc.80.4.1238; *VET ADM SYST SEPS, 1987, NEW ENGL J MED, V317, P659; WADE CE, 1988, J CLIN ENDOCR METAB, V67, P223, DOI 10.1210/jcem-67-2-223; 1985, NEW ENGL J MED, V312, P976	89	305	320	1	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1285	1292		10.1056/NEJM199710303371807	http://dx.doi.org/10.1056/NEJM199710303371807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345079	Green Published			2022-12-28	WOS:A1997YC92000007
J	Kuusisto, J; Koivisto, K; Mykkanen, L; Helkala, EL; Vanhanen, M; Hanninen, T; Kervinen, K; Kesaniemi, YA; Riekkinen, PJ; Laakso, M				Kuusisto, J; Koivisto, K; Mykkanen, L; Helkala, EL; Vanhanen, M; Hanninen, T; Kervinen, K; Kesaniemi, YA; Riekkinen, PJ; Laakso, M			Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study	BRITISH MEDICAL JOURNAL			English	Article							DEMENTIA; RISK; HYPERINSULINEMIA; POLYMORPHISM; HYPERTENSION; DIAGNOSIS; LEVEL; BRAIN; AGE; SEX	Objective: To determine the association between features of the insulin resistance syndrome and Alzheimer's disease. Design: Cross sectional population based study. Subjects: 980 people aged 69 to 78 (349 men, 631 women). Setting: Population of Kuopio, eastern Finland. Main outcome measures: Presence of features of the insulin resistance syndrome and diagnosis of Alzheimer's disease by detailed neurological and neuropsychological evaluation. Results: 46 (4.7%) subjects were classified as having probable or possible Alzheimer's disease. In univariate analyses, apolipoprotein E4 phenotype (odds ratio; 95% confidence interval 3.24: 1.77 to 5.92), age (1.16; 1.05 to 1.29), low level of education (0.82; 0.72 to 0.93), low total cholesterol concentration (0.77; 0.59 to 1.00), high systolic blood pressure (1.01; 1.00 to 1.03), high fasting and 2 hour plasma glucose concentrations (1.11; 1.01 to 1.23 and 1.08; 1.03 to 1.13, respectively), high fasting and 2 hour insulin concentrations (1.05; 1.02 to 1.08 and 1.003; 1.00 to 1.01, respectively), and abnormal glucose tolerance (1.86; 1.23 to 2.80) were significantly associated with Alzheimer's disease. In multivariate analysis including apolipoprotein E4 phenotype, age, education, systolic blood pressure, total cholesterol concentration, fasting glucose concentration, and insulin concentration, apolipoprotein E4 phenotype, age, education, total cholesterol, and insulin were significantly associated with Alzheimer's disease. In 532 non-diabetic subjects without the e4 allele hyperinsulinaemia was associated with an increased risk for Alzheimer's disease (prevalence of disease 7.5% v 1.4% in normoinsulinaemic subjects, P = 0.0004). In contrast, in the 228 with the e4 allele hyperinsulinaemia had no effect on the risk of disease (7.0% v 7.1%, respectively). Conclusion: Features of the insulin resistance syndrome are associated with Alzheimer's disease independently of apolipoprotein E4 phenotype.	KUOPIO UNIV HOSP,DEPT MED,FIN-70211 KUOPIO,FINLAND; KUOPIO UNIV HOSP,DEPT NEUROL,FIN-70211 KUOPIO,FINLAND; OULU UNIV HOSP,DEPT INTERNAL MED,OULU,FINLAND; UNIV OULU,BIOCTR,OULU,FINLAND	Kuopio University Hospital; Kuopio University Hospital; University of Oulu; University of Oulu			Laakso, Mikko/AHB-7022-2022	Laakso, Mikko/0000-0003-1250-3425; Landin-Wilhelmsen, Kerstin/0000-0003-1998-5105				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BASKIN DG, 1987, ANNU REV PHYSIOL, V49, P335, DOI 10.1146/annurev.ph.49.030187.002003; BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EHNHOLM C, 1986, J LIPID RES, V27, P227; GROBER E, 1988, NEUROLOGY, V38, P900, DOI 10.1212/WNL.38.6.900; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; KILANDER L, 1993, ACTA NEUROL SCAND, V87, P294, DOI 10.1111/j.1600-0404.1993.tb05511.x; Koivisto K, 1992, J Geriatr Psychiatry Neurol, V5, P162; KUUSISTO J, 1993, HYPERTENSION, V22, P771, DOI 10.1161/01.HYP.22.5.771; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LAAKSO M, 1991, ARTERIOSCLER THROMB, V11, P1068, DOI 10.1161/01.ATV.11.4.1068; LANDIN K, 1993, J INTERN MED, V233, P357, DOI 10.1111/j.1365-2796.1993.tb00684.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; MYKKANEN L, 1990, DIABETES CARE, V13, P1099, DOI 10.2337/diacare.13.11.1099; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; PALOMAKI P, 1994, J CLIN EPIDEMIOL, V47, P659, DOI 10.1016/0895-4356(94)90213-5; PRINCE M, 1994, NEUROLOGY, V44, P97; Prineas R., 1982, MINNESOTA CODE MANUA; RAZAY G, 1994, AGE AGEING, V23, P396, DOI 10.1093/ageing/23.5.396; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WARRINGTON EK, 1966, BRAIN, V89, P53, DOI 10.1093/brain/89.1.53; WEINFELD FD, 1981, STROKE S1, V12, P32; *WHO, 1982, MONICA MAN CVD MNC; *WHO, 1985, WHO TECH RECP SER, V727; *WHO, 1990, MONICA MAN CVD MNC	33	346	362	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1045	1049		10.1136/bmj.315.7115.1045	http://dx.doi.org/10.1136/bmj.315.7115.1045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366728	Green Published			2022-12-28	WOS:A1997YD44500017
J	Caterina, MJ; Schumacher, MA; Tominaga, M; Rosen, TA; Levine, JD; Julius, D				Caterina, MJ; Schumacher, MA; Tominaga, M; Rosen, TA; Levine, JD; Julius, D			The capsaicin receptor: a heat-activated ion channel in the pain pathway	NATURE			English	Article							ROOT GANGLION-CELLS; SENSORY NEURONS; CHEMICAL-STRUCTURE; CATION CHANNEL; DROSOPHILA TRP; RUTHENIUM RED; CALCIUM-ENTRY; RAT; RESINIFERATOXIN; ACID	Capsaicin, the main pungent ingredient in 'hot' chilli peppers, elicits a sensation of burning pain by selectively activating sensory neurons that convey information about noxious stimuli to the central nervous system. We have used an expression cloning strategy based on calcium influx to Isolate a functional cDNA encoding a capsaicin receptor from sensory neurons. This receptor is a non-selective cation channel that is structurally related to members of the TRP family of ion channels. The cloned capsaicin receptor Is also activated by increases in temperature In the noxious range, suggesting that it functions as a transducer of painful thermal stimuli in vivo.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								AMANN R, 1990, N-S ARCH PHARMACOL, V341, P108; BERKLEY R, 1992, PEPPERS COOKBOOK; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Campbell E., 1993, CAPSAICIN STUDY PAIN, P255; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; CREM RJ, 1991, SCIENCE, V254, P1388; DEVRIES DJ, 1989, LIFE SCI, V44, P711, DOI 10.1016/0024-3205(89)90382-2; DRAY A, 1990, NEUROSCI LETT, V110, P52, DOI 10.1016/0304-3940(90)90786-9; FEIGIN AM, 1995, NEUROREPORT, V6, P2134, DOI 10.1097/00001756-199511000-00009; Fields H. L., 1987, PAIN; FORBES CA, 1988, NEUROSCI LETT S, V32, pS3; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HOLZER P, 1991, PHARMACOL REV, V43, P143; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JAMES IF, 1993, CAPSAICIN STUDY PAIN, P83; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; Kirschstein T, 1997, NEUROSCI LETT, V231, P33, DOI 10.1016/S0304-3940(97)00533-8; Kress M, 1996, NEUROSCI LETT, V211, P5, DOI 10.1016/0304-3940(96)12691-4; LIU L, 1994, P NATL ACAD SCI USA, V91, P738, DOI 10.1073/pnas.91.2.738; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Oh U, 1996, J NEUROSCI, V16, P1659; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PETERSEN M, 1993, PAIN, V54, P37, DOI 10.1016/0304-3959(93)90097-9; Reichling DB, 1997, P NATL ACAD SCI USA, V94, P7006, DOI 10.1073/pnas.94.13.7006; SATINOFF E, 1964, AM J PHYSIOL, V206, P1389, DOI 10.1152/ajplegacy.1964.206.6.1389; Scoville W.L., 1912, J AM PHARM ASSOC, V1, P453, DOI [10.1002/jps.3080010520, DOI 10.1002/JPS.3080010520]; SEGUELA P, 1993, J NEUROSCI, V13, P596; SNYDER SH, 1977, SCI AM, V236, P44, DOI 10.1038/scientificamerican0377-44; SZALLASI A, 1994, GEN PHARMACOL-VASC S, V25, P223, DOI 10.1016/0306-3623(94)90049-3; SZALLASI A, 1989, NEUROSCIENCE, V30, P515, DOI 10.1016/0306-4522(89)90269-8; Szallasi A, 1996, PAIN, V68, P195, DOI 10.1016/S0304-3959(96)03202-2; SZOLCSANYI J, 1975, ARZNEIMITTEL-FORSCH, V25, P1877; SZOLCSANYI J, 1976, ARZNEIMITTEL-FORSCH, V26, P33; Szolcsanyi J., 1993, CAPSAICIN STUDY PAIN, P1; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WINTER J, 1990, BRAIN RES, V520, P131, DOI 10.1016/0006-8993(90)91698-G; WOOD JN, 1988, J NEUROSCI, V8, P3208; WOODBURY JE, 1980, J ASSOC OFF ANA CHEM, V63, P556; YEATS JC, 1992, J PHYSIOL-LONDON, V446, pP390	49	6463	6849	83	991	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					816	824		10.1038/39807	http://dx.doi.org/10.1038/39807			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349813				2022-12-28	WOS:A1997YC14800048
J	Rieckhof, GE; Casares, F; Ryoo, HD; AbuShaar, M; Mann, RS				Rieckhof, GE; Casares, F; Ryoo, HD; AbuShaar, M; Mann, RS			Nuclear translocation of extradenticle requires homothorax, which encodes an extradenticle-related homeodomain protein	CELL			English	Article							DROSOPHILA-MELANOGASTER; HOMEOBOX GENE; HOMEOTIC TRANSFORMATION; ULTRABITHORAX PROTEINS; ECTOPIC EXPRESSION; SEGMENTAL IDENTITY; BITHORAX COMPLEX; MYELOID-LEUKEMIA; DNA-BINDING; UBX GENE	We show that homothorax (hth) is required for the Hox genes to pattern the body of the fruit fly, Drosophila melanogaster, hth is necessary for the nuclear localization of an essential HOX cofactor, Extradenticle (EXD), and encodes a homeodomain protein that shares extensive identity with the product of Meis1, a murine proto-oncogene. MEIS1 is able to rescue hth mutant phenotypes and can induce the cytoplasmic-to-nuclear translocation of EXD in cell culture and Drosophila embryos. Thus, Meis1 is a murine homolog of hth. MEIS1/HTH also specifically binds to EXD with high affinity in vitro. These data suggest a novel and evolutionarily conserved mechanism for regulating HOX activity in which a direct protein-protein interaction between EXD and HTH results in EXD's nuclear translocation.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032	Columbia University			Casares, Fernando/M-5451-2019	Casares, Fernando/0000-0002-2181-3858	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058575, R01GM054510] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054510, R01 GM058575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspland SE, 1997, DEVELOPMENT, V124, P741; BURGLIN T, 1994, GUIDEBOOK HOMEOBOX G, P26; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHAN SK, 1996, EMBO J, V15, P2477; CHEN SK, 1997, DEVELOPMENT, V124, P2007; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FEINSTEIN PG, 1995, GENETICS, V140, P573; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; HAMILTON BA, 1991, P NATL ACAD SCI USA, V88, P2731, DOI 10.1073/pnas.88.7.2731; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; KARPEN GH, 1992, GENETICS, V132, P737; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; Nakamura T, 1996, ONCOGENE, V13, P2235; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Paro R., 1996, EPIGENETIC MECH GENE, P507; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PATTATUCCI AM, 1991, GENETICS, V129, P443; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; PIRROTTA V, 1995, GENETICS, V141, P1439; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; RODER L, 1992, DEVELOPMENT, V115, P1017; SHIMELL MJ, 1994, SCIENCE, V264, P968, DOI 10.1126/science.7909957; SUN YH, 1995, GENETICS, V141, P1075; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHITE RAH, 1985, EMBO J, V4, P2035, DOI 10.1002/j.1460-2075.1985.tb03889.x; WIESCHAUS E, 1986, LOOKING EMBRYOS DROS, P199; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511	59	377	381	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					171	183		10.1016/S0092-8674(00)80400-6	http://dx.doi.org/10.1016/S0092-8674(00)80400-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346235	hybrid			2022-12-28	WOS:A1997YC35000005
J	Troemel, ER; Kimmel, BE; Bargmann, CI				Troemel, ER; Kimmel, BE; Bargmann, CI			Reprogramming chemotaxis responses: Sensory neurons define olfactory preferences in C-elegans	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NUCLEOTIDE-GATED CHANNEL; GLR-1 GLUTAMATE-RECEPTOR; CHEMOSENSORY NEURONS; ENCODES; SYSTEM; CELLS; GENES	Different olfactory cues elicit distinct behaviors such as attraction, avoidance, feeding, or mating. In the nematode C. elegans, these cues are sensed by a small number of olfactory neurons, each of which expresses several different odorant receptors. The type of behavioral response elicited by an odorant could be specified by the olfactory receptor or by the olfactory neuron in which the receptor is activated. The attractive odorant diacetyl is detected by the receptor protein ODR-10, which is normally expressed in the AWA olfactory neurons. The repulsive odorant 2-nonanone is detected by the AWB olfactory neurons. Transgenic animals that express ODR-10 in AWB rather than AWA avoid diacetyl, while maintaining qualitatively normal responses to other attractive and repulsive odorants. Animals that express ODR-10 simultaneously in AWA and AWB have a defective response to diacetyl, possibly because of conflicting olfactory inputs. Thus, an animal's preference for an odor is defined by the sensory neurons that express a given odorant receptor molecule.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PROGRAM NEUROSCI,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,GENET PROGRAM,DEPT ANAT,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Troemel, ER (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PROGRAM DEV BIOL,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.			Bargmann, Cornelia/0000-0002-8484-0618	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01393] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; Bargmann C. I., 1997, C ELEGANS, P717; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; BRENNER S, 1974, GENETICS, V77, P71; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colbert HA, 1997, LEARN MEMORY, V4, P179, DOI 10.1101/lm.4.2.179; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; COLBERT HA, 1997, IN PRESS J NEUROSCI; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MICHEL WC, 1991, J NEUROPHYSIOL, V65, P446, DOI 10.1152/jn.1991.65.3.446; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; ZECHMAN JM, 1986, J CHROMATOGR, V377, P49, DOI 10.1016/S0378-4347(00)80760-4	29	290	307	0	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					161	169		10.1016/S0092-8674(00)80399-2	http://dx.doi.org/10.1016/S0092-8674(00)80399-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346234	Bronze			2022-12-28	WOS:A1997YC35000004
J	Mechanic, LJ; Dikman, S; CunninghamRundles, C				Mechanic, LJ; Dikman, S; CunninghamRundles, C			Granulomatous disease in common variable immunodeficiency	ANNALS OF INTERNAL MEDICINE			English	Article							HYPOGAMMAGLOBULINEMIA; FAILURE	Background: Granulomatous lesions are occasionally found in the lymphoid or solid organs of patients with common variable immunodeficiency. Objective: To examine the clinical and immunologic conditions in patients with common variable immunodeficiency who have granulomas. Design: Case series. Setting: Large tertiary care medical center. Patients: 17 hypogammaglobulinaemic patients with common variable immunodeficiency whose organ or tissue biopsy samples contained noncaseating granulomas. Measurements: Results of lymphocyte function tests. Results: Eight of 17 patients had granulomas at some point before hypogammaglobulinemia was diagnosed. Sixteen of the 17 had deficient T-cell proliferation to mitogens. Although 14 patients received standard treatment with intravenous immunoglobulin, they have had substantial illness, including frequent autoimmune disease. Conclusions: Dysregulated T-cell function or macrophage activation may have been involved in formation of granulomas and increased illness in hypogammaglobulinaemic patients with common variable immunodeficiency. Delay in recognition of antibody deficiency may have contributed to the severity of illness in these patients.	MT SINAI MED CTR, MT SINAI SCH MED, DIV CLIN IMMUNOL, NEW YORK, NY 10029 USA; MT SINAI MED CTR, MT SINAI SCH MED, DIV CLIN PATHOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA 533H] Funding Source: Medline; NCRR NIH HHS [5 M01-RR-0071] Funding Source: Medline; FDA HHS [FD-R-001162-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); FDA HHS; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADELMAN DC, 1990, J ALLERGY CLIN IMMUN, V86, P512, DOI 10.1016/S0091-6749(05)80207-6; ASHERSON GL, 1980, DIAGNOSIS TREATMENT, P41; CRYSTAL RG, 1994, HARRISONS PRINCIPLES, P1683; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES S, 1981, J CLIN IMMUNOL, V1, P65, DOI 10.1007/BF00915478; Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; GILBERT S, 1993, AM REV RESPIR DIS, V148, P483, DOI 10.1164/ajrccm/148.2.483; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; JAMES DG, 1993, SARCOIDOSIS, V10, P1; JAMES DG, 1985, SARCOIDOSIS OTHER GR, P128; LAZARUS DS, 1994, BBA-MOL BASIS DIS, V1226, P12, DOI 10.1016/0925-4439(94)90052-3; Leen C L, 1985, Sarcoidosis, V2, P91; PASTORELLI G, 1989, CLIN EXP IMMUNOL, V78, P334; SAIKI O, 1982, P NATL ACAD SCI-BIOL, V79, P6008, DOI 10.1073/pnas.79.19.6008; SNELLER MC, 1990, J IMMUNOL, V144, P3762; SPICKETT GP, 1989, IMMUNOL TODAY, V10, P192, DOI 10.1016/0167-5699(89)90323-X; STAGG AJ, 1994, CLIN EXP IMMUNOL, V96, P48; World Health Organization, 1992, IMMUNODEFIC REV, P195	18	201	206	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				613	617		10.7326/0003-4819-127-8_Part_1-199710150-00005	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341059				2022-12-28	WOS:A1997YB41900005
J	Murray, E; Jolly, B; Modell, M				Murray, E; Jolly, B; Modell, M			Can students learn clinical method in general practice? A randomised crossover trial based on objective structured clinical examinations	BRITISH MEDICAL JOURNAL			English	Article							SENIOR MEDICAL-STUDENTS; OSCE STATIONS; TEST SECURITY; CURRICULUM; EDUCATION; SKILLS	Objective: To determine whether students acquired clinical skills as well in general practice as in hospital and whether there was any difference in the acquisition of specific skills in the two environments. Design: Randomised crossover trial. Subjects and setting: Annual intake of first year clinical students at one medical school. Intervention: A 10 week block of general internal medicine, one half taught in general practice, the other in hospital. Students started at random in one location and crossed over after five weeks. Outcome measures: Students' performance in two equivalent nine station objective structured clinical examinations administered at the mid and end points of the block: a direct comparison of the two groups' performance at five weeks; analysis of covariance, using their first examination scores as a covariate, to determine students' relative improvement over the second five weeks of their attachment Results: 225 students rotated through the block; all took at least one examination and 208 (92%) took both. For the first half of the year there was no significant difference in the students' acquisition of clinical skills in the two environments; later, however, students taught in general practice improved slightly more than those taught in hospital (P = 0.007). Conclusions: Students can learn clinical skills as well in general practice as in hospital; more work is needed to clarify where specific skills, knowledge, and attitudes are best learnt to allow rational planning of the undergraduate curriculum.	WHITTINGTON HOSP, ROYAL FREE HOSP, SCH MED, LONDON N19 5NF, ENGLAND; UNIV LEEDS, MED EDUC UNIT, LEEDS LS2 9NL, W YORKSHIRE, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Leeds	Murray, E (corresponding author), UCL, SCH MED, DEPT PRIMARY CARE & POPULAT SCI, MORTIMER ST, LONDON W1N 8AA, ENGLAND.		Jolly, Brian/G-2819-2010	Murray, Elizabeth/0000-0002-8932-3695				ALI J, 1995, J TRAUMA, V38, P687, DOI 10.1097/00005373-199505000-00002; *AUD COMM, 1996, WHAT DOCT ORD STUD G; BERG D, 1994, ACAD MED, V69, P758, DOI 10.1097/00001888-199409000-00023; COLLIVER JA, 1991, ACAD MED, V66, P279, DOI 10.1097/00001888-199105000-00011; CREBOLDER HFJ, 1994, ANN COMMUNITY ORIENT, V7, P121; FOLDEVI M, 1993, ANN COMMUNITY ORIENT, V6, P97; GORDON P, 1996, EXTENDING PRIMAREY C; Jolly B, 1996, ACAD MED, V71, P1023, DOI 10.1097/00001888-199610000-00001; KOKOTAILO PK, 1995, PEDIATRICS, V96, P99; MCFAUL PB, 1993, BRIT J OBSTET GYNAEC, V100, P842, DOI 10.1111/j.1471-0528.1993.tb14311.x; MURRAY E, 1995, MED EDUC, V29, P66, DOI 10.1111/j.1365-2923.1995.tb02804.x; MURRAY E, IN PRESS MED ED; Niehaus AH, 1996, ACAD MED, V71, P287, DOI 10.1097/00001888-199603000-00023; NYQIST JG, 1994, ACAD MED, V10, pS51; OSWALD N, 1995, MED EDUC, V29, P72, DOI 10.1111/j.1365-2923.1995.tb02805.x; PRICE DA, 1994, MED EDUC, V28, P239, DOI 10.1111/j.1365-2923.1994.tb02705.x; ROBINSON LA, 1994, BRIT J GEN PRACT, V44, P489; ROTHMAN AI, 1995, AUST NZ J SURG, V65, P302, DOI 10.1111/j.1445-2197.1995.tb00641.x; RUTALA PJ, 1991, ARCH INTERN MED, V151, P541, DOI 10.1001/archinte.151.3.541; SATRAN L, 1993, ACAD MED, V68, P380, DOI 10.1097/00001888-199305000-00024; SLOAN DA, 1995, ANN SURG, V222, P735, DOI 10.1097/00000658-199512000-00007; STILLMAN PL, 1991, ACAD MED, V66, pS25, DOI 10.1097/00001888-199109000-00030; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WHITEHOUSE C, 1997, TEACHING MED COMMUNI; *WORLD FED MED ED, 1994, MED ED S1, V28	25	70	70	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					920	923						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361543				2022-12-28	WOS:A1997YB07300028
J	Fox, NC; Freeborough, PA; Mekkaoui, KF; Stevens, JM; Rossor, MN				Fox, NC; Freeborough, PA; Mekkaoui, KF; Stevens, JM; Rossor, MN			Cerebral and cerebellar atrophy on serial magnetic resonance imaging in an initially symptom free subject at risk of familial prion disease	BRITISH MEDICAL JOURNAL			English	Article							CREUTZFELDT-JAKOB-DISEASE				Fox, NC (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, DEMENTIA RES GRP, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.		Rossor, Martin/C-1598-2008; Fox, Nick C/AAE-1849-2021; Fox, Nick C/B-1319-2009	Fox, Nick C/0000-0002-6660-657X; Fox, Nick C/0000-0002-6660-657X; Rossor, Martin/0000-0001-8215-3120				BARBORIAK DP, 1994, AM J ROENTGENOL, V162, P137, DOI 10.2214/ajr.162.1.8273652; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; Fox NC, 1996, LANCET, V348, P94, DOI 10.1016/S0140-6736(96)05228-2; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Zeidler M, 1996, BRIT MED J, V312, P844	5	11	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					856	857		10.1136/bmj.315.7112.856	http://dx.doi.org/10.1136/bmj.315.7112.856			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353507	Green Published			2022-12-28	WOS:A1997YA00700025
J	DeGrado, WF				DeGrado, WF			Proteins from scratch	SCIENCE			English	Editorial Material							AMINO-ACIDS; BINDING DOMAINS; COILED-COILS; DESIGN; PROPENSITIES; SEQUENCES; POLAR				DeGrado, WF (corresponding author), UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.							ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; Arnold PA, 1997, J AM CHEM SOC, V119, P3181, DOI 10.1021/ja963747r; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Coldren CD, 1997, P NATL ACAD SCI USA, V94, P6635, DOI 10.1073/pnas.94.13.6635; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; DAHIYAT BI, SCIENCE, V278, P82; Dalal S, 1997, NAT STRUCT BIOL, V4, P548, DOI 10.1038/nsb0797-548; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DESJARLAIS JR, 1995, PROTEIN SCI, V4, P2006, DOI 10.1002/pro.5560041006; Dieckmann GR, 1997, J AM CHEM SOC, V119, P6195, DOI 10.1021/ja964351i; DREXLER KE, 1981, P NATL ACAD SCI USA, V78, P5275, DOI 10.1073/pnas.78.9.5275; Gibney BR, 1996, P NATL ACAD SCI USA, V93, P15041, DOI 10.1073/pnas.93.26.15041; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; JANIN J, 1978, J MOL BIOL, V125, P37; JING X, 1997, J AM CHEM SOC, V119, P838; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; Lumb KJ, 1996, SCIENCE, V271, P1137, DOI 10.1126/science.271.5252.1137; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUNOZ V, 1994, PROTEINS, V20, P301, DOI 10.1002/prot.340200403; Pinto AL, 1997, P NATL ACAD SCI USA, V94, P5562, DOI 10.1073/pnas.94.11.5562; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Scott MP, 1997, PROTEIN SCI, V6, P340; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; Yu Y, 1996, J MOL BIOL, V255, P367, DOI 10.1006/jmbi.1996.0030	33	31	42	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					80	81		10.1126/science.278.5335.80	http://dx.doi.org/10.1126/science.278.5335.80			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9340760				2022-12-28	WOS:A1997XZ12400040
J	Ceesay, SM; Prentice, AM; Cole, TJ; Foord, F; Weaver, LT; Poskitt, EME; Whitehead, RG				Ceesay, SM; Prentice, AM; Cole, TJ; Foord, F; Weaver, LT; Poskitt, EME; Whitehead, RG			Effects on birth weight and perinatal mortality of maternal dietary supplements in rural Gambia: 5 year randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AFRICAN WOMEN; PREGNANCY; ENERGY	Objective: To test the efficacy in terms of birth weight and infant survival of a diet supplement programme in pregnant African women through a primary healthcare system. Design: 5 year controlled trial of all pregnant women in 28 villages randomised to daily supplementation with high energy groundnut biscuits (4.3MJ/day) for about 20 weeks before delivery (intervention) or after delivery (control). Setting: Rural Gambia Subjects: Chronically undernourished women (twin bearers excluded), yielding 2047 singleton live births and 35 stillbirths. Main outcome measures: Birth weight; prevalence of low birth weight (<2500 g); head circumference; birth length; gestational age; prevalence of stillbirths; neonatal and postneonatal mortality. Results: Supplementation increased weight gain in pregnancy and significantly increased birthweight, particularly during the nutritionally debilitating hungry season (June to October). Weight gain increased by 201 g (P<0.001) in the hungry season, by 94 g (P<0.01) in the harvest season (November to May), and by 136 g (P<0.001) over the whole year The odds ratio for low birthweight babies in supplemented women was 0.61 (95% confidence interval 0.47 to 0.79, P<0.001). Head circumference was significantly Increased (P<0.01), but by only 3.1 mm. Birth length and duration of gestation were not affected. Supplementation significantly reduced perinatal mortality: the odds ratio was 0.47 (0.23 to 0.99, P<0.05) for stillbirths and 0.54 (0.35 to 0.85, P<0.01) for all deaths in first week of life. Mortality after 7 days was unaffected. Conclusion: Prenatal dietary supplementation reduced retardation in intrauterine growth when effectively targeted at genuinely at-risk mothers. This was associated with a substantial reduction in the prevalence of stillbirths and in early neonatal mortality. The intervention can be successfully delivered through a primary healthcare system.	MRC, DUNN NUTR UNIT, KENEBA, GAMBIA; MRC, DUNN CLIN NUTR CTR, CAMBRIDGE CB2 2DH, ENGLAND	University of London; London School of Hygiene & Tropical Medicine			Cole, Tim J/B-7883-2008; Prentice, Andrew/AAG-1961-2019	Cole, Tim J/0000-0001-5711-8200; 				ASHWORTH A, 1985, B WORLD HEALTH ORGAN, V63, P165; Barker DJP, 1992, FETAL INFANT ORIGINS; BELSEY MA, 1993, NESTLE NUTR WORKS SE, V31, P1; CARRHILL R, 1985, DEV EXPLOITATION EMP; DOWNES B, 1991, J TROP PEDIATRICS, V37, P106, DOI 10.1093/tropej/37.3.106; Herrera M. G., 1980, Maternal nutrition during pregnancy and lactation, P252; KRAMER MS, 1993, AM J CLIN NUTR, V58, P627, DOI 10.1093/ajcn/58.5.627; KUSIN JA, 1993, P NUTR SOC, V52, P19, DOI 10.1079/PNS19930033; LAWRENCE M, 1987, AM J CLIN NUTR, V45, P1442, DOI 10.1093/ajcn/45.6.1442; Lechtig A., 1980, Maternal nutrition during pregnancy and lactation, P285; Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245; PARKIN JM, 1976, ARCH DIS CHILD, V51, P259, DOI 10.1136/adc.51.4.259; POPPITT SD, 1994, AM J OBSTET GYNECOL, V171, P118, DOI 10.1016/S0002-9378(94)70087-7; PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912, DOI 10.1093/ajcn/46.6.912; PRENTICE AM, 1983, LANCET, V1, P489; PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790, DOI 10.1093/ajcn/34.12.2790; PRENTICE AM, 1991, ACTA PAEDIATR SCAND, P67; Prentice Andrew M, 1984, ENERGY INTAKE ACTIVI, P3; RUSH D, 1989, EFFECTIVE CARE PREGN, P255; Stein Z., 1975, FAMINE HUM DEV DUTCH; SUSSER M, 1981, AM J CLIN NUTR, V34, P784, DOI 10.1093/ajcn/34.4.784	21	289	295	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	1997	315	7111					786	790						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345173	Green Published, Green Submitted			2022-12-28	WOS:A1997XY91100023
J	Roberts, CM				Roberts, CM			Connectivity and management of Caribbean coral reefs	SCIENCE			English	Article							GULF-OF-MEXICO; FLORIDA-KEYS; GENETIC-VARIATION; FISHES; CIRCULATION; RECRUITMENT; CURRENTS; PACIFIC; ISLAND; OCEAN	Surface current patterns were used to map dispersal routes of pelagic larvae from 18 coral reef sites in the Caribbean. The sites varied, both as sources and recipients of larvae, by an order of magnitude. It is likely that sites supplied copiously from ''upstream'' reef areas will be more resilient to recruitment overfishing, less susceptible to species loss, and less reliant on local management than places with little upstream reef. The mapping of connectivity patterns will enable the identification of beneficial management partnerships among nations and the design of networks of interdependent reserves.			Roberts, CM (corresponding author), UNIV YORK,DEPT ENVIRONM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.							BOEHLERT GW, 1996, REEF FISHERIES, P61; BRACKS JT, 1971, B MAR SCI, V21, P455; CAMPTON DE, 1992, FISH B-NOAA, V90, P250; COWEN RK, 1994, B MAR SCI, V54, P228; DARBYSHIRE J, 1976, CAYMAN ISLANDS NAT 3; DOHERTY PJ, 1995, ECOLOGY, V76, P2373, DOI 10.2307/2265814; DUNCAN CP, 1982, INT HYDROGR REV, V59, P67; GOLD JR, 1993, MAR BIOL, V116, P175, DOI 10.1007/BF00350007; GORDON AL, 1967, J GEOPHYS RES, V72, P6207, DOI 10.1029/JZ072i024p06207; GRANT CJ, 1980, B MAR SCI, V30, P613; HATELEY JG, 1993, B MAR SCI, V52, P993; IBARRA MM, 1986, AN I BIOL U NAC CML, V13, P31; Jackson J. B. C., 1997, CORAL REEFS, V16, P523; JOHNSON AG, 1993, FISH B US, V92, P91; JONES GP, IN PRESS 8 INT COR R; KATZ SJ, 1983, FISH B-NOAA, V81, P41; LACSON JM, 1991, MAR BIOL, V110, P353, DOI 10.1007/BF01344354; LACSON JM, 1992, MAR BIOL, V112, P327, DOI 10.1007/BF00702479; LEE TN, 1992, CONT SHELF RES, V12, P971, DOI 10.1016/0278-4343(92)90055-O; LEE TN, 1994, B MAR SCI, V54, P621; LEIS JM, 1993, B MAR SCI, V53, P362; LESSIOS HA, 1988, ANNU REV ECOL SYST, V19, P371, DOI 10.1146/annurev.es.19.110188.002103; MAUL GA, 1995, CIRCULATION INTRAAME; MCMANUS JW, 1994, AMBIO, V23, P181; MCMANUS JW, IN PRESS 8 INT COR R; Menzies R.A., 1979, Proceedings of the Gulf and Caribbean Fisheries Institute, V31, P164; MULLER-KARGER F, 1989, Memoria de la Sociedad de Ciencias Naturales La Salle, V49-50, P361; MULLERKARGER FE, 1994, CONT SHELF RES, V14, P199, DOI 10.1016/0278-4343(94)90013-2; MULLERKARGER FE, 1989, PROG OCEANOGR, V23, P23, DOI 10.1016/0079-6611(89)90024-4; Roberts C.M., 1991, Reviews in Fish Biology and Fisheries, V1, P65, DOI 10.1007/BF00042662; Roberts CM, 1997, TRENDS ECOL EVOL, V12, P35, DOI 10.1016/S0169-5347(96)20109-0; ROBERTS CM, 1995, CONSERV BIOL, V9, P815, DOI 10.1046/j.1523-1739.1995.09040815.x; ROBERTS HH, 1992, CONT SHELF RES, V12, P809, DOI 10.1016/0278-4343(92)90046-M; Robertson DR, 1996, CORAL REEFS, V15, P132; SARY Z, 1995, THESIS U W INDIES BA; SCHMITZ WJ, 1993, B MAR SCI, V53, P1048; SHULMAN MJ, 1995, EVOLUTION, V49, P897, DOI 10.1111/j.1558-5646.1995.tb02325.x; Stobutzki IC, 1997, MAR ECOL PROG SER, V149, P35, DOI 10.3354/meps149035; STOBUTZKI IC, 1994, J EXP MAR BIOL ECOL, V175, P275, DOI 10.1016/0022-0981(94)90031-0; STURGES W, 1993, J PHYS OCEANOGR, V23, P250, DOI 10.1175/1520-0485(1993)023<0250:SOWCRI>2.0.CO;2; VIDAL VMV, 1992, J GEOPHYS RES-OCEANS, V97, P2155, DOI 10.1029/91JC00486; VIDAL VMV, 1994, J GEOPHYS RES-OCEANS, V99, P7571, DOI 10.1029/93JC03334; WATLINGTON RA, 1994, INT OC COMM INT WORK	43	523	537	4	199	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1454	1457		10.1126/science.278.5342.1454	http://dx.doi.org/10.1126/science.278.5342.1454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367956				2022-12-28	WOS:A1997YG85800042
J	Forget, F; Pierrehumbert, RT				Forget, F; Pierrehumbert, RT			Warming early Mars with carbon dioxide clouds that scatter infrared radiation	SCIENCE			English	Article							ATMOSPHERE; CLIMATE; TEMPERATURES; VENUS; WET	Geomorphic evidence that Mars was warm enough to support flowing water about 3.8 billion years ago presents a continuing enigma that cannot be explained by conventional greenhouse warming mechanisms. Model calculations show that the surface of early Mars could have been warmed through a scattering variant of the greenhouse effect, resulting from the ability of the carbon dioxide ice clouds to reflect the outgoing thermal radiation back to the surface, This process could also explain how Earth avoided an early irreversible glaciation and could extend the size of the habitable zone on extrasolar planets around stars.	UNIV CHICAGO,DEPT GEOPHYS SCI,CHICAGO,IL 60637	University of Chicago	Forget, F (corresponding author), UNIV PARIS 06,CNRS,METEOROL DYNAM LAB,BOITE POSTALE 99,4 PL JUSSIEU,F-75252 PARIS 05,FRANCE.			Pierrehumbert, Raymond/0000-0002-5887-1197				CADEIRA K, 1992, NATURE, V359, P226; EMANUEL KA, 1994, Q J ROY METEOR SOC, V120, P1111, DOI 10.1256/smsqj.51901; Fanale F.P., 1992, MARS, P1135; Forget F, 1996, J GEOPHYS RES-PLANET, V101, P16865, DOI 10.1029/96JE01077; FORGET F, 1995, J GEOPHYS RES, V100, P2119; Hansen GB, 1997, J GEOPHYS RES-PLANET, V102, P21569, DOI 10.1029/97JE01875; JENSEN EJ, 1994, GEOPHYS RES LETT, V21, P2023, DOI 10.1029/94GL01358; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; KASTING JF, 1984, ICARUS, V57, P335, DOI 10.1016/0019-1035(84)90122-2; Kasting JF, 1997, SCIENCE, V276, P1213, DOI 10.1126/science.276.5316.1213; MANABE S, 1967, J ATMOS SCI, V24, P241, DOI 10.1175/1520-0469(1967)024<0241:TEOTAW>2.0.CO;2; McKay CP, 1997, ORIGINS LIFE EVOL B, V27, P263, DOI 10.1023/A:1006500116990; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; POLLACK JB, 1993, ICARUS, V103, P1, DOI 10.1006/icar.1993.1055; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217; SAMUELSON RE, 1967, ASTROPHYS J, V147, P782, DOI 10.1086/149053; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; STANSBERRY JA, 1995, 27 ANN M DIV PLAN SC; STEPHENS GL, 1990, J ATMOS SCI, V47, P1742, DOI 10.1175/1520-0469(1990)047<1742:TROTMA>2.0.CO;2; TOON OB, 1989, J GEOPHYS RES-ATMOS, V94, P16287, DOI 10.1029/JD094iD13p16287; WHITMIRE DP, 1995, J GEOPHYS RES-PLANET, V100, P5457, DOI 10.1029/94JE03080; XU KM, 1989, MON WEATHER REV, V117, P1471, DOI 10.1175/1520-0493(1989)117<1471:ITTACU>2.0.CO;2	24	336	338	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1273	1276		10.1126/science.278.5341.1273	http://dx.doi.org/10.1126/science.278.5341.1273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360920				2022-12-28	WOS:A1997YG04300039
J	Middleton, J; Neil, S; Wintle, J; ClarkLewis, I; Moore, H; Lam, C; Auer, M; Hub, E; Rot, A				Middleton, J; Neil, S; Wintle, J; ClarkLewis, I; Moore, H; Lam, C; Auer, M; Hub, E; Rot, A			Transcytosis and surface presentation of IL-8 ky venular endothelial cells	CELL			English	Article							ATTRACTANT ACTIVATION PROTEIN-1; ERYTHROCYTE CHEMOKINE RECEPTOR; RED-BLOOD-CELLS; HUMAN-NEUTROPHILS; LEUKOCYTE ADHESION; HEPARAN-SULFATE; L-SELECTIN; HUMAN-SKIN; BINDING; INTERLEUKIN-8	Chemokines have been convincingly implicated in actuating inflammatory leukocyte emigration. To affect the circulating leukocytes, tissue-derived chemokines have to traverse the endothelial cells (ECs). This was thought to be accomplished by chemokine diffusion through the intercellular gaps. On the contrary, we show by electron microscopy that the prototype chemokine IL-8 is internalized by venular ECs abluminally and transcytosed to the luminal surface. Here, it is presented to the adherent leukocytes on the EC membrane, predominantly in association with the EC projections. The intact C terminus of IL-8, the molecule's ''immobilization'' domain, is required for the EC binding, transcytosis, and consequently, the in vivo proemigratory activity of IL-8, indicating that the described subcellular interactions of IL-8 with the ECs are functionally relevant.	NOVARTIS FORSCHUNGSINST, A-1235 VIENNA, AUSTRIA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1Z3, CANADA	Novartis; University of British Columbia				Auer, Manfred/0000-0001-8920-3522; Neil, Stuart/0000-0003-3306-5831; Rot, Antal/0000-0002-9730-6166				Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1994, BLOOD, V84, P2068; CARVETH HJ, 1989, BIOCHEM BIOPH RES CO, V162, P387, DOI 10.1016/0006-291X(89)92009-3; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COLDITZ IG, 1990, J LEUKOCYTE BIOL, V48, P129, DOI 10.1002/jlb.48.2.129; COLDITZ IG, 1985, SURV SYN PATHOL RES, V4, P44; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DEWALD B, 1987, BIOCHEM PHARMACOL, V36, P2505, DOI 10.1016/0006-2952(87)90523-5; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; FINA L, 1990, BLOOD, V75, P2417; FURIE MB, 1995, AM J PATHOL, V146, P1287; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; KOHN S, 1992, LAB INVEST, V67, P596; Koopmann W, 1997, J BIOL CHEM, V272, P10103; LEONARD EJ, 1991, J INVEST DERMATOL, V96, P690, DOI 10.1111/1523-1747.ep12470612; LEY K, 1993, J IMMUNOL, V151, P6347; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OMOTO E, 1990, EXP CELL RES, V187, P85, DOI 10.1016/0014-4827(90)90120-Y; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PEDRESCU D, 1994, P NATL ACAD SCI USA, V91, P3014; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; ROT A, 1992, CYTOKINE, V4, P347, DOI 10.1016/1043-4666(92)90077-5; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; ROT A, 1992, BIOCH INFLAMMATION, P271; ROT A, 1993, IMMUNOLOGIST, V1, P145; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1994, CYTOKINE HDB, P419; Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHUBERT C, 1989, ARCH DERMATOL RES, V281, P475, DOI 10.1007/BF00510083; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steegmaier M, 1997, J CELL SCI, V110, P687; Strieter RM, 1996, J IMMUNOL, V156, P3583; SWENSSON O, 1991, J INVEST DERMATOL, V96, P682, DOI 10.1111/1523-1747.ep12470606; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WATSON CA, 1995, SCIENCE, V268, P447, DOI 10.1126/science.7716553; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WILLIAMS EW, 1978, J MICROSC-OXFORD, V112, P319, DOI 10.1111/j.1365-2818.1978.tb00082.x; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	71	587	597	3	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					385	395		10.1016/S0092-8674(00)80422-5	http://dx.doi.org/10.1016/S0092-8674(00)80422-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363947	Bronze			2022-12-28	WOS:A1997YD94100012
J	Caplan, LR; Mohr, JP; Kistler, JP; Koroshetz, W				Caplan, LR; Mohr, JP; Kistler, JP; Koroshetz, W			Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - Not a panacea for ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NEUROL INST,NEW YORK,NY 10032; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	Caplan, LR (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DEPT NEUROL,314,750 WASHINGTON ST,BOSTON,MA 02111, USA.		Mohr, J/AAO-9694-2020					Adams HP, 1996, STROKE, V27, P1711; [Anonymous], 1996, NEUROLOGY, V47, P835; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581; PESSIN MS, 1995, CEREBROVASCULAR DISEASES, P409; SLOAN MA, 1987, ARCH NEUROL-CHICAGO, V44, P748, DOI 10.1001/archneur.1987.00520190052017; YAMAGUCHI T, 1995, THROMBOLYTIC THERAPY, P111	7	147	151	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1309	1310						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345084				2022-12-28	WOS:A1997YC92000012
J	Ogg, S; Paradis, S; Gottlieb, S; Patterson, GI; Lee, L; Tissenbaum, HA; Ruvkun, G				Ogg, S; Paradis, S; Gottlieb, S; Patterson, GI; Lee, L; Tissenbaum, HA; Ruvkun, G			The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C-elegans	NATURE			English	Article							DAUER LARVA DEVELOPMENT; CAENORHABDITIS-ELEGANS; ALVEOLAR RHABDOMYOSARCOMA; INTERACTING GENES; EXPRESSION; GROWTH; TRANSLOCATION; SUPPRESSES; PROTEINS; HOMOLOG	In mammals, insulin signalling regulates glucose transport together with the expression and activity of various metabolic enzymes. In the nematode Caenorhabditis elegans, a related pathway regulates metabolism, development and longevity(1,2). Wild-type animals enter the developmentally arrested dauer stage in response to high levels of a secreted pheromone(3), accumulating large amounts of fat in their intestines and hypodermis. Mutants in DAF-2 (a homologue of the mammalian insulin receptor) and AGE-1 (a homologue of the catalytic subunit of mammalian phosphatidylinositol 3-OH kinase) arrest development at the dauer stage(3), Moreover, animals bearing weak or temperature-sensitive mutations in daf-2 and age-1 can develop reproductively, but nevertheless show increased energy storage and longevity(1,2,4,5). Here we show that null mutations in daf-16 suppress the effects of mutations in daf-2 or age-1; lack of daf-16 bypasses the need for this insulin receptor-like signalling pathway. The principal role of DAF-2/AGE-1 signalling is thus to antagonize DAF-16. daf-16 is widely expressed and encodes three members of the Fork head family of transcription factors, The DAF-2 pathway acts synergistically with the pathway activated by a nematode TGF-beta-type signal, DAF-7, suggesting that DAF-16 cooperates with nematode SMAD proteins in regulating the transcription of key metabolic and developmental control genes. The probable human orthologues of DAF-16, FKHR and AFX, may also act downstream of insulin signalling and cooperate with TGF-beta effecters in mediating metabolic regulation. These genes may be dysregulated in diabetes.	MASSACHUSETTS GEN HOSP,DEPT MOL BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DORMAN JB, 1995, GENETICS, V141, P1399; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FEDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOTTLIEB S, 1994, GENETICS, V137, P107; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; KALEBIC T, 1994, CANCER RES, V54, P5531; KAUFMANN E, 1995, J MOL BIOL, V248, P239, DOI 10.1006/jmbi.1995.0218; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; NOJIMA T, 1990, VIRCHOWS ARCH A, V417, P357, DOI 10.1007/BF01605789; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PATTERSON GI, IN PRESS GENES DEV; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle D.L., 1997, GENETIC ENV REGULATI, VII, P739; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VOWELS JJ, 1992, GENETICS, V130, P105	30	1506	1554	3	177	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					994	999		10.1038/40194	http://dx.doi.org/10.1038/40194			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353126				2022-12-28	WOS:A1997YD29900062
J	Johnston, D				Johnston, D			A missing link? LTP and learning	SCIENCE			English	Editorial Material							APLYSIA SENSORY NEURONS; CELLULAR MECHANISM; WITHDRAWAL REFLEX; POTENTIATION; CALIFORNICA; RECEPTOR; SYNAPSES				Johnston, D (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030, USA.							BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; CAREW TJ, 1981, J NEUROSCI, V1, P1426; CAREW TJ, 1983, SCIENCE, V219, P397, DOI 10.1126/science.6681571; DALE N, 1993, P NATL ACAD SCI USA, V90, P7163, DOI 10.1073/pnas.90.15.7163; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HAWKINS RD, 1984, PSYCHOL REV, V91, P375, DOI 10.1037/0033-295X.91.3.375; Jeffery KJ, 1997, HIPPOCAMPUS, V7, P95; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P215, DOI 10.1098/rspb.1994.0031; MCHUGH TJ, 1996, CELL, V87, P1329; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murphy GG, 1997, SCIENCE, V278, P467, DOI 10.1126/science.278.5337.467; Rotenberg A, 1996, CELL, V87, P1351, DOI 10.1016/S0092-8674(00)81829-2; SACTER D, 1995, NATURE, V378, P186; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; WALTERS ET, 1985, J NEUROSCI, V5, P662	20	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					401	402		10.1126/science.278.5337.401	http://dx.doi.org/10.1126/science.278.5337.401			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381142				2022-12-28	WOS:A1997YB35500027
J	Sinclair, S; James, S; Singer, M				Sinclair, S; James, S; Singer, M			Intraoperative intravascular volume optimisation and length of hospital stay after repair of proximal femoral fracture: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK SURGICAL PATIENTS; CLINICAL-TRIAL; HIP-FRACTURES; MORTALITY; SURGERY; BLOOD	Objectives: To assess whether intraoperative intravascular volume optimisation improves outcome and shortens hospital stay after repair of proximal femoral fracture. Design: Prospective, randomised controlled trial comparing conventional intraoperative fluid management with repeated colloid fluid challenges monitored by oesophageal Doppler ultrasonography to maintain maximal stroke Volume throughout die operative period. Setting: Teaching hospital, London. Subjects: 40 patients undergoing repair of proximal femoral fracture under general anaesthesia. Interventions: Patients were randomly assigned to receive either conventional intraoperative fluid management (control patients) or additional repeated colloid fluid challenges with oesophageal Doppler ultrasonography used to maintain maximal stroke volume throughout the operative period (protocol patients). Main outcome measures: Time declared medically fit for hospital discharge, duration of hospital stay (in acute bed; in acute plus long stay bed), mortality, perioperative haemodynamic changes. Results: Intraoperative intravascular fluid loading produced significantly greater changes in stroke Volume (median 15 ml (95% confidence interval 10 to 21 ml)) and cardiac output (1.2 l/min (0.1 to 2.3 l/min)) than in the conventionally managed group (-5 ml (-10 to 1 mi) and -0.4 l/min (-1.0 to 0.2 l/min)) (P < 0.001 and P < 0.05, respectively). One protocol patient and two control patients died in hospital. In the survivors, postoperative recovery was significantly faster in the protocol patients, with shorter times to being declared medically fit for discharge (median 10 (9 to 15) days v 15 (11 to 40) days, P < 0.05) and a 39% reduction in hospital stay (12 (8 to 13) days v 20 (10 to 61) days, P < 0.05). Conclusions: Proximal femoral fracture repair constitutes surgery in a high risk population. Intraoperative intravascular volume loading-to optimal stroke volume resulted in a more rapid postoperative recovery and a significantly reduced hospital stay.	UNIV LONDON UNIV COLL, SCH MED, BLOOMSBURY INST INTENS CARE MED, DIV MED, LONDON WC1E 6JJ, ENGLAND; UCL HOSP, DEPT ORTHOPAED, LONDON, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London			Singer, Mervyn/Q-6142-2019; Singer, Mervyn/J-4425-2012	Singer, Mervyn/0000-0002-1042-6350; Singer, Mervyn/0000-0002-1042-6350				*AUD COMM, 1995, UN THEY STAND COORD; BERLAUK JF, 1991, ANN SURG, V214, P289, DOI 10.1097/00000658-199109000-00011; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; MYTHEN MG, 1995, ARCH SURG-CHICAGO, V130, P423; *NCEPOD, 1996, REP NAT CONF ENQ PER; NEES JE, 1978, SURGERY, V83, P639; PARKER MJ, 1995, AGE AGEING, V24, P96, DOI 10.1093/ageing/24.2.96; PARKER MJ, 1994, INT ORTHOP, V18, P184; SCHULTZ RJ, 1985, J TRAUMA, V25, P309, DOI 10.1097/00005373-198504000-00005; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; SHOEMAKER WC, 1988, CRIT CARE MED, V16, P1117, DOI 10.1097/00003246-198811000-00007; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SINGER M, 1991, CRIT CARE MED, V19, P1132, DOI 10.1097/00003246-199109000-00007; SINGER M, 1991, CRIT CARE MED, V19, P1138, DOI 10.1097/00003246-199109000-00008; SINGER M, 1995, ANAESTHESIA PAIN INT, P819; TODD CJ, 1995, BRIT MED J, V310, P904, DOI 10.1136/bmj.310.6984.904	20	515	526	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	1997	315	7113					909	912						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361539				2022-12-28	WOS:A1997YB07300022
J	McGrath, MA				McGrath, MA			Planetary science - Io and the plasma torus	SCIENCE			English	Editorial Material											McGrath, MA (corresponding author), SPACE TELESCOPE SCI INST,3700 SAN MARTIN DR,BALTIMORE,MD 21218, USA.							Brown ME, 1997, SCIENCE, V278, P268, DOI 10.1126/science.278.5336.268; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; Galileo G., 1610, SIDEREUS NUNCIUS; HALL DT, IN PRESS ASTROPHYS J; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; NASH DB, 1986, SATELLITES; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; PEALE SJ, 1979, SCIENCE, V204; SCHNEIDER NM, 1989, NASA	9	3	3	3	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					237	238		10.1126/science.278.5336.237	http://dx.doi.org/10.1126/science.278.5336.237			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9340770				2022-12-28	WOS:A1997YA56400028
J	Chisholm, DG; Calder, I; Peterson, D; Powell, M				Chisholm, DG; Calder, I; Peterson, D; Powell, M			Drug points - Intranasal chlorhexidine resulting in anaphylactic circulatory arrest	BMJ-BRITISH MEDICAL JOURNAL			English	Letter											Chisholm, DG (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							CHEWING J, 1985, ANAESTH INTENSIVE CA, V13, P429; OHTOSHI T, 1986, CLIN ALLERGY, V16, P155, DOI 10.1111/j.1365-2222.1986.tb00759.x; OKANO M, 1989, ARCH DERMATOL, V125, P50, DOI 10.1001/archderm.125.1.50; RUSS BR, 1994, ANAESTH INTENS CARE, V22, P611, DOI 10.1177/0310057X9402200522	4	17	17	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	1997	315	7111					785	785						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345172				2022-12-28	WOS:A1997XY91100022
J	Evans, BG; Parry, JV; Mortimer, PP				Evans, BG; Parry, JV; Mortimer, PP			HIV antibody assay that gave false negative results: multicentre collaborative study	BRITISH MEDICAL JOURNAL			English	Article								Objective: to identify false negative results arising from the use of a commercial kit to detect antibody to HIV-1 and HIV-2 between July 1995 and March 1996. Design: The 56 laboratories in the United Kingdom that were using the assay were asked to retrieve and retest specimens with an alternative assay for HIV-1 and HIV-2. Details of false negative results were obtained and these serum samples further investigated. Subjects: 24 181 patients tested with the assay who were reported as being negative for HIV antibody. An additional 497 patients were confirmed as HIV positive with the assay. Results: Serum samples of 20 973 of the patients were retested, and four patients were found to have had false negative results with the kit; three further patients were found to have had false negative results in the course of other laboratory testing. The seven patients with false negative results with the kit were of diverse risk group and HIV-1 subtype. Four had evidence of recent HIV infection. Conclusion: The commercial kit had a sensitivity of 99.2% (497/501), or less if the additional three patients with false negative results were taken into account.			Evans, BG (corresponding author), PUBL HLTH LAB SERV,LONDON NW9 5EQ,ENGLAND.							MCALPINE L, 1995, J CLIN PATHOL, V48, P490, DOI 10.1136/jcp.48.5.490; PAU CP, 1994, AIDS RES HUM RETROV, V10, P1369, DOI 10.1089/aid.1994.10.1369; 1996, COMMUN DIS REP CDR W, V6, P125	3	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					772	774						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345168	Green Published			2022-12-28	WOS:A1997XY91100018
J	Bigger, JT				Bigger, JT			Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; SIGNAL-AVERAGED ELECTROCARDIOGRAM; CARDIOVERTER-DEFIBRILLATOR; DEATH; SURVIVAL; ARREST; REVASCULARIZATION; FIBRILLATION; TRIALS	Background Patients with coronary heart disease, left ventricular dysfunction, and abnormalities on signal-averaged electrocardiograms have an increased risk of sudden death. We evaluated the effect on survival of the prophylactic implantation of cardioverter-defibrillators in such patients at the time of coronary-artery bypass surgery. Methods Over the course of five years, 37 clinical centers screened all patients who were scheduled for elective coronary bypass surgery. Patients were eligible for the trial if they were less than 80 years old, had a left ventricular ejection fraction of less than 0.36, and had abnormalities on signal-averaged electrocardiograms. We identified 1422 eligible patients, enrolled 1055, and randomly assigned 900 to therapy with an implantable cardioverter-defibrillator (446 patients) or to the control group (454 patients). The primary end point of the study was overall mortality, and the two groups were compared in an intention-to-treat analysis, Results The base-line characteristics of the two groups were similar. During an average (+/-SD) follow-up Of 32+/-16 months, there were 101 deaths in the defibrillator group (71 from cardiac causes) and 95 in the control group (72 from cardiac causes). The hazard ratio for death from any cause was 1.07 (95 percent confidence interval, 0.81 to 1.42; P = 0.64). There was no statistically significant interaction between defibrillator therapy and any of 10 preselected base-line covariates. Conclusions We found no evidence of improved survival among patients with coronary heart disease, a depressed left ventricular ejection fraction, and an abnormal signal-averaged electrocardiogram in whom a defibrillator was implanted prophylactically at the time of elective coronary bypass surgery. (C) 1997, Massachusetts Medical Society.			Bigger, JT (corresponding author), COLUMBIA UNIV, DATA COORDINATING CTR, CABG PATCH TRIAL, PH 103D, 630 W 168TH ST, NEW YORK, NY 10032 USA.				NHLBI NIH HHS [HL-48120, HL-48159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL048120, U01HL048159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHNVE S, 1986, AM J CARDIOL, V58, P872, DOI 10.1016/S0002-9149(86)80002-9; AHNVE S, 1987, AM J CARDIOL, V59, pA12; BAUM RS, 1974, CIRCULATION, V50, P1231, DOI 10.1161/01.CIR.50.6.1231; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BIGGER JT, 1987, CIRCULATION, V75, P28; BIGGER JT, 1993, PROG CARDIOVASC DIS, V36, P97; BIGGER JT, IN PRESS CONTROL CLI; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Connolly SJ, 1997, LANCET, V350, P1417; COX DR, 1972, J R STAT SOC B, V34, P187; CURTIS AB, IN PRESS AM HEART J; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; Eisenberg MS, 1996, ARCH INTERN MED, V156, P1611, DOI 10.1001/archinte.156.15.1611; ELSHERIF N, 1995, J AM COLL CARDIOL, V25, P908, DOI 10.1016/0735-1097(94)00504-J; EVERY NR, 1992, J AM COLL CARDIOL, V19, P1435, DOI 10.1016/0735-1097(92)90599-I; GOTTLIEB CD, 1995, CIRCULATION S1, V92, P406; GREENE HL, 1989, AM J CARDIOL, V63, P1, DOI 10.1016/0002-9149(89)91065-5; HOLMES DR, 1986, CIRCULATION, V73, P1254, DOI 10.1161/01.CIR.73.6.1254; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; KRON IL, 1989, ANN THORAC SURG, V48, P85, DOI 10.1016/0003-4975(89)90185-9; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEVINE JH, 1991, CIRCULATION, V84, P558, DOI 10.1161/01.CIR.84.2.558; Lombardi Gary, 1994, JAMA (Journal of the American Medical Association), V271, P678, DOI 10.1001/jama.271.9.678; MARCUS FI, 1988, AM J CARDIOL, V61, P8, DOI 10.1016/0002-9149(88)91295-7; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; NISAM S, 1995, PACE, V18, P142, DOI 10.1111/j.1540-8159.1995.tb02493.x; OROURKE RA, 1992, CIRCULATION, V85, P112; PACKER M, 1985, CIRCULATION, V72, P681, DOI 10.1161/01.CIR.72.4.681; PITT B, 1992, CIRCULATION, V85, P107; SCHWARTZ PJ, 1994, CIRCULATION, V89, P2892; STEINBERG JS, 1992, AM J CARDIOL, V69, P13, DOI 10.1016/0002-9149(92)90669-P; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; *VARNAUSKAS E, 1985, CIRCULATION S5, V72, P90; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1996, J AM COLL CARDIOL, V27, P238	40	715	735	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1569	1575		10.1056/NEJM199711273372201	http://dx.doi.org/10.1056/NEJM199711273372201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371853				2022-12-28	WOS:A1997YH52100001
J	Ash, EL; Sudmeier, JL; DeFabo, EC; Bachovchin, WW				Ash, EL; Sudmeier, JL; DeFabo, EC; Bachovchin, WW			A low-barrier hydrogen bond in the catalytic triad of serine proteases? Theory versus experiment	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; ALPHA-LYTIC PROTEASE; N-15 NMR-SPECTROSCOPY; ACTIVE-SITE; HISTIDINE; MECHANISM; ACID; CONSTANTS; COMPLEXES; TRYPSIN	Cleland and Kreevoy recently advanced the idea that a special type of hydrogen bond (H-bond), termed a low-barrier hydrogen bond (LBHB), may account for the ''missing'' transition state stabilization underlying the catalytic power of many enzymes, and Frey ef al. have proposed that the H-bond between aspartic acid 102 and histidine 57 in the catalytic triad of serine proteases is an example of a catalytically important LBHB. Experimental facts are here considered regarding the aspartic acid-histidine and cis-urocanic H-bonds that are inconsistent with fundamental tenets of the LBHB hypothesis. The inconsistencies between theory and experiment in these paradigm systems cast doubt on the existence of LBHBs, as currently defined, within enzyme active sites.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; GEORGE WASHINGTON UNIV,SCH MED,DEPT DERMATOL,WASHINGTON,DC 20037	Tufts University; George Washington University			Ash, Elissa L./AAA-5982-2021; william.bachovchin@tufts.edu/AAA-3538-2022		NIGMS NIH HHS [GM27927] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027927] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASH EL, UNPUB; BACHOVCHIN WW, 1985, P NATL ACAD SCI USA, V82, P7948, DOI 10.1073/pnas.82.23.7948; BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BACHOVCHIN WW, 1988, BIOCHEMISTRY-US, V27, P7689, DOI 10.1021/bi00420a018; BACHOVCHIN WW, 1978, J AM CHEM SOC, V100, P8041, DOI 10.1021/ja00494a001; BACHOVCHIN WW, 1994, STABLE ISOTOPE APPL, P41; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Cassidy CS, 1997, BIOCHEMISTRY-US, V36, P4576, DOI 10.1021/bi962013o; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; DAY RM, 1995, THEIS TUFTS U BOSTON; FARRJONES S, 1993, J AM CHEM SOC, V115, P6813, DOI 10.1021/ja00068a044; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; FUJIWARA FY, 1974, J AM CHEM SOC, V96, P7625, DOI 10.1021/ja00832a005; FUJIWARA FY, 1974, J AM CHEM SOC, V96, P7632; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GOLUBEV NS, 1994, BIOCHEMISTRY-MOSCOW+, V59, P447; GUTHRIE JP, 1996, CHEM BIOL, V4, P259; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P15941, DOI 10.1021/bi961805f; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HORSLEY WJ, 1968, J AM CHEM SOC, V90, P3738, DOI 10.1021/ja01016a025; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P338; KETTNER CA, 1988, BIOCHEMISTRY-US, V27, P7682, DOI 10.1021/bi00420a017; LEGON AC, 1980, P ROY SOC LOND A MAT, V370, P213, DOI 10.1098/rspa.1980.0030; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; MARKLEY JL, 1996, BIOCHEMISTRY-US, V35, P1102; MARKLEY JL, 1979, BIOL APPL MAGNETIC R; MILLEN DJ, 1979, J CHEM SOC F2, V75, P592; ROBERTS JD, 1982, J AM CHEM SOC, V104, P3945, DOI 10.1021/ja00378a027; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; SAKIYAMA F, 1983, J BIOCHEM-TOKYO, V94, P1661; SANTUCCI I, 1995, THESIS FLINDERS U S; Schowen R., 1988, MECHANISTIC PRINCIPL, P119; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; Smirnov SN, 1996, J AM CHEM SOC, V118, P4094, DOI 10.1021/ja953445+; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220	37	173	174	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1128	1132		10.1126/science.278.5340.1128	http://dx.doi.org/10.1126/science.278.5340.1128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353195				2022-12-28	WOS:A1997YE65200054
J	Baines, MJ				Baines, MJ			ABC of palliative care - Nausea, vomiting, and intestinal obstruction	BRITISH MEDICAL JOURNAL			English	Review											Baines, MJ (corresponding author), ELLENOR FDN,DARTFORD,KENT,ENGLAND.								0	38	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1148	1150						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374893				2022-12-28	WOS:A1997YE61500034
J	Singer, RH; Green, MR				Singer, RH; Green, MR			Compartmentalization of eukaryotic gene expression: Causes and effects	CELL			English	Review							SPLICING FACTORS; TRANSCRIPTION; NUCLEUS; SITES		UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOL MED, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Singer, RH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA.							Bickmore WA, 1996, CELL, V84, P95, DOI 10.1016/S0092-8674(00)80996-4; BRIDGE E, 1995, J VIROL, V69, P281, DOI 10.1128/JVI.69.1.281-290.1995; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Fay FS, 1997, EXP CELL RES, V231, P27, DOI 10.1006/excr.1996.3460; Huang S, 1996, J CELL BIOL, V133, P719, DOI 10.1083/jcb.133.4.719; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; Mattern KA, 1997, J CELL BIOCHEM, V65, P42, DOI 10.1002/(SICI)1097-4644(199704)65:1<42::AID-JCB5>3.0.CO;2-Z; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; Nierras CR, 1997, CHROMOSOMA, V105, P444; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Strouboulis J, 1996, J CELL SCI, V109, P1991; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; ZHANG GH, 1994, NATURE, V372, P809	20	100	102	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					291	294		10.1016/S0092-8674(00)80411-0	http://dx.doi.org/10.1016/S0092-8674(00)80411-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363936	Bronze			2022-12-28	WOS:A1997YD94100001
J	Fischer, TM; Blazis, DEJ; Priver, NA; Carew, TJ				Fischer, TM; Blazis, DEJ; Priver, NA; Carew, TJ			Metaplasticity at identified inhibitory synapses in Aplysia	NATURE			English	Article							SIPHON WITHDRAWAL REFLEX; TERM SYNAPTIC PLASTICITY; GILL-WITHDRAWAL; GAIN-CONTROL; TAIL SHOCK; SEROTONIN; SENSITIZATION; FACILITATION; DISHABITUATION; DISSOCIATION	Synaptic plasticity is an important feature of neural networks involved in the encoding of information. In the analysis of longterm potentiation and long-term depression, several examples have emerged in which this plasticity is itself modulated(1-3). This higher-order form of plasticity has been referred to as 'metaplasticity'(4), a modification of synapses reflected as a change in the ability to induce or maintain plasticity. These observations raise the question of the possible advantage of regulating the intrinsic plastic properties of a synapse. The neural circuit mediating the siphon withdrawal reflex in Aplysia provides a useful network in which to examine this question directly. Inhibitory synapses in this circuit (from L30 neurons) exhibit a variety of forms of activity-dependent short-term synaptic enhancement which contribute to dynamic gain control in the siphon withdrawal reflex(5-9). Here we report that tail shock, an extrinsic modulatory input of known behavioural relevance, induces differential metaplasticity at this synapse, attenuating its ability to exhibit short-term synaptic enhancement after presynaptic activation (augmentation and post-tetanic potentiation), while leaving intact its capacity for enhancement during activation. This attenuation of inhibition at the synaptic level seems to mediate comparable attenuation of inhibitory modulation at both network and behavioural levels.	YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520	Yale University								Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ABRAMS TW, 1984, P NATL ACAD SCI-BIOL, V81, P7956, DOI 10.1073/pnas.81.24.7956; BLAZIS DEJ, 1993, NEURAL COMPUT, V5, P213, DOI 10.1162/neco.1993.5.2.213; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; CAREW TJ, 1983, SCIENCE, V219, P397, DOI 10.1126/science.6681571; DELANEY KR, 1994, J NEUROSCI, V14, P5885; FISCHER TM, 1995, J NEUROSCI, V15, P762; FISCHER TM, 1993, J NEUROSCI, V13, P1302; FISCHER TM, IN PRESS J NEUROPHYS; Fisher SA, 1997, TRENDS NEUROSCI, V20, P170, DOI 10.1016/S0166-2236(96)01001-6; FITZGERALD K, 1991, J NEUROSCI, V11, P2510; FROST WN, 1988, J NEUROBIOL, V19, P297, DOI 10.1002/neu.480190402; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; HAWKINS RD, 1989, J NEUROSCI, V9, P4236; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P304, DOI 10.1152/jn.1981.45.2.304; HICKIE C, 1995, J NEUROPHYSIOL, V74, P307, DOI 10.1152/jn.1995.74.1.307; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; KANEKO S, BEHAV BRAIN RES, V45, P97; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; Lieb JR, 1997, J NEUROPHYSIOL, V77, P1249, DOI 10.1152/jn.1997.77.3.1249; LIFE SCI, 1996, KANE, V60, P245; MARCUS EA, 1988, SCIENCE, V241, P210, DOI 10.1126/science.3388032; MERCER AR, 1991, SCIENCE, V254, P1811, DOI 10.1126/science.1662413; WALTERS ET, 1991, BIOL BULL, V180, P241, DOI 10.2307/1542394; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	27	65	65	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					860	865		10.1038/39892	http://dx.doi.org/10.1038/39892			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349819				2022-12-28	WOS:A1997YC14800060
J	Ikeda, S; Takei, Y; Yanagisawa, N; Matsunami, H; Hashikura, Y; Ikegami, T; Kawasaki, S				Ikeda, S; Takei, Y; Yanagisawa, N; Matsunami, H; Hashikura, Y; Ikegami, T; Kawasaki, S			Peripheral nerves regenerated in familial amyloid polyneuropathy after liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL IMPROVEMENT; SWEDISH PATIENTS	Background: Liver transplantation holds promise as a treatment for familial amyloid polyneuropathy Objective: To determine whether peripheral nerves regenerate in patients with familial amyloid polyneuropathy after liver transplantation. Design: Case report. Setting: University hospital in Matsumoto, Japan. Patient: A 34-year-old woman with familial amyloid polyneuropathy who had liver transplantation and showed marked clinical improvement 3 years after surgery. Measurements: Histopathologic examination and morphometric analysis of biopsy specimens taken from sural nerves. Results: Diffuse fiber loss and amyloid deposits were seen in a biopsy specimen of the left sural nerve obtained before liver transplantation (total number of myelinated fibers, 1326/mm(2) of the endoneurial area). In the biopsy specimen of the right sural nerve, which was obtained 3 years after transplantation. amyloid deposits remained but the number of myelinated fibers was markedly increased (total number of myelinated fibers, 4740/mm(2)). Conclusion: Peripheral nerves regenerated in a patient with familial amyloid polyneuropathy after liver transplantation.	SHINSHU UNIV, SCH MED, DEPT SURG, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University	Ikeda, S (corresponding author), SHINSHU UNIV, SCH MED, DEPT MED NEUROL, MATSUMOTO, NAGANO 390, JAPAN.							ANDO Y, 1995, LANCET, V345, P195, DOI 10.1016/S0140-6736(95)90201-5; BENSON MD, 1996, INT J EXP CLIN INVES, V3, P44; Bergethon PR, 1996, NEUROLOGY, V47, P944, DOI 10.1212/WNL.47.4.944; DYCK PJ, 1969, ARCH NEUROL-CHICAGO, V20, P490, DOI 10.1001/archneur.1969.00480110054005; ERICZON BG, 1996, NEUROMUSC DISORD S1, V6, P65; HANYU N, 1989, ANN NEUROL, V25, P340, DOI 10.1002/ana.410250405; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; HOLMGREN G, 1991, CLIN GENET, V40, P242; IKEDA S, 1997, INT J EXP CLIN INVES, V4, P18; IKEDA SI, 1987, BRAIN, V110, P315, DOI 10.1093/brain/110.2.315; JONSON E, 1996, INT J EXP CLIN INVES, V3, P124; MATSUNAMI H, 1995, TRANSPLANTATION, V60, P301, DOI 10.1097/00007890-199508000-00017; PARRILLA P, 1995, BRIT J SURG, V82, P825, DOI 10.1002/bjs.1800820634; SKINNER M, 1994, ANN INTERN MED, V120, P133, DOI 10.7326/0003-4819-120-2-199401150-00006; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; STEEN L, 1994, AMYLOID, V1, P138, DOI 10.3109/13506129409148636; SUHR OB, 1995, TRANSPLANTATION, V60, P933, DOI 10.1097/00007890-199511150-00009	17	36	36	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				618	620		10.7326/0003-4819-127-8_Part_1-199710150-00006	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341060				2022-12-28	WOS:A1997YB41900006
J	DurandZaleski, I; Colin, C; BlumBoisgard, C				DurandZaleski, I; Colin, C; BlumBoisgard, C			An attempt to save money by using mandatory practice guidelines in France	BRITISH MEDICAL JOURNAL			English	Article							MEDICINE; REALITY; IMPACT; TRIAL		UNIV LYON 1,F-69365 LYON,FRANCE; UNIV PARIS 05,PARIS,FRANCE	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Paris Cite	DurandZaleski, I (corresponding author), HOSP HENRI MONDOR,HITEQ,DEPT PUBL HLTH,51 AVE MARECHAL LATTRE DE TASSIGNY,F-94010 CRETEIL,FRANCE.							American Medical Association, 1990, ATTR GUID DEV PRACT; BENETT KJ, 1987, JAMA-J AM MED ASSOC, V257, P2451; *CAISS NAT ASS MAL, 1994, CONV NAT DEST ORG RA; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; *DEP CLIN EP BIOST, 1981, CAN MED ASSOC J, V124, P1156; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; FIELDING JE, 1993, JAMA-J AM MED ASSOC, V270, P748, DOI 10.1001/jama.270.6.748; HAINES A, 1992, BMJ-BRIT MED J, V305, P785, DOI 10.1136/bmj.305.6857.785; Kanouse D E, 1988, Int J Technol Assess Health Care, V4, P27; LALARDRIE S, 1996, ARCH PED S, V3, P261; LEFUR P, 1996, 116 CTR ET DOC EC SA; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; *SERV STAT ET SYST, 1996, ANN STAT SAN SOC; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; WOOLF SH, 1993, ARCH INTERN MED, V153, P2646, DOI 10.1001/archinte.153.23.2646; 1995, J OFFICIEL REPU 0305; 1994, PANORAMA MED, P3934; 1992, JAMA-J AM MED ASSOC, V268, P2420	21	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					943	946						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361548				2022-12-28	WOS:A1997YB07300036
J	Kauhanen, J; Kaplan, GA; Goldberg, DE; Salonen, JT				Kauhanen, J; Kaplan, GA; Goldberg, DE; Salonen, JT			Beer binging and mortality: results from the Kuopio ischaemic heart disease risk factor study, a prospective population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EASTERN FINNISH MEN; ACUTE MYOCARDIAL-INFARCTION; ALCOHOL-CONSUMPTION; PHYSICAL-ACTIVITY; CORONARY; WINE; DRINKERS	Objective: To examine the association between beer binging (regular sessions of heavy beer drinking) and mortality. Design: Prospective population based study with the baseline assessment of level of alcohol intake (dose), by type of drink and drinking pattern, previous and existing diseases, socioeconomic background, occupational status, involvement in organisations during leisure time, physical activity in leisure time, body mass index, blood pressure, serum lipids and plasma fibrinogen concentration, during an average of 7.7 years' follow up of mortality. Setting: Finland. Subjects: A population sample of 1641 men who consumed beer who were aged 42, 48, 54, or 60 years at baseline. Main outcome measures: All cause mortality, cardiovascular mortality, death due to external causes, fatal myocardial infarctions. Results: The risk of death was substantially increased in men whose usual dose of beer was 6 or more bottles per session compared with men who usually consumed less than 3 bottles, after adjustment forage and total alcohol consumption (relative risk 3.01 (95% confidence interval 1.54 to 5.90) for all deaths; 7.10 (2.01 to 25.12) for external deaths; and 6.50 (2.05 to 20.61) for fatal myocardial infarction). The association changed only slightly when smoking, occupational status, previous diseases, systolic blood pressure, low density lipoprotein and high density lipoprotein cholesterol concentration, plasma fibrinogen concentration, body mass index, marital status, leisure time physical activity, and involvement in organisations were controlled for. Conclusion: The pattern of beer binging is associated with increased risk of death, independently of the total average consumption of alcoholic drinks. The relation is not explained by known behavioural, psychosocial, or biological risk factors. Death due to injuries and other external causes is overrepresented.	UNIV KUOPIO, PUBL HLTH RES INST, FIN-70211 KUOPIO, FINLAND; UNIV MICHIGAN, SCH PUBL HLTH, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA; HUMAN POPULAT LAB, BERKELEY, CA 94704 USA	University of Eastern Finland; University of Michigan System; University of Michigan	Kauhanen, J (corresponding author), UNIV KUOPIO, DEPT PUBL HLTH & GEN PRACTICE, BOX 1627, FIN-70211 KUOPIO, FINLAND.		Kauhanen, Jussi/ABC-4064-2021; Kaplan, George/AAJ-2398-2020		NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beaglehole R, 1992, Drug Alcohol Rev, V11, P275, DOI 10.1080/09595239200185811; Cox D. R., 1984, ANAL SURVIVAL DATA; Dahlstrom, 1975, MMPI HDB RES APPL, V2; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; GAZIANO JM, 1995, BRIT MED J, V311, P3, DOI 10.1136/bmj.311.6996.3a; GREENFIELD TK, 1986, INT J ADDICT, V21, P1059, DOI 10.3109/10826088609077255; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Irgens-Jensen O, 1981, SIFA STENSILSERIE, V44; ISTVAN J, 1995, INT J EPIDEMIOL, V24, P543, DOI 10.1093/ije/24.3.543; JACKSON R, 1995, LANCET, V346, P716, DOI 10.1016/S0140-6736(95)91496-X; KAPLAN GA, 1994, EPIDEMIOLOGY, V5, P495; KAUHANEN J, 1992, BEHAV MED, V18, P121, DOI 10.1080/08964289.1992.9936962; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; *OY ALKO AB, 1995, ALC STAT YB 1994; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; Simpura J, 1987, FINNISH DRINKING HAB, V35; *WHO, 1989, INT J EPIDEMIOL S1, V18, pS38; WILSON TW, 1993, AM J EPIDEMIOL, V137, P292, DOI 10.1093/oxfordjournals.aje.a116676	28	198	202	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	1997	315	7112					846	851		10.1136/bmj.315.7112.846	http://dx.doi.org/10.1136/bmj.315.7112.846			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353504	Green Published, Green Submitted			2022-12-28	WOS:A1997YA00700022
J	Solovey, A; Lin, Y; Browne, P; Choong, S; Wayner, E; Hebbel, RP				Solovey, A; Lin, Y; Browne, P; Choong, S; Wayner, E; Hebbel, RP			Circulating activated endothelial cells in sickle cell anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDITERRANEAN SPOTTED-FEVER; VASCULAR ENDOTHELIUM; MONOCLONAL-ANTIBODY; RICKETTSIA-CONORII; STEADY-STATE; WHOLE-BLOOD; EXPRESSION; INFARCTION; DISEASE; INJURY	Background The vascular wall participates in the pathogenesis of sickle cell disease. To determine whether the endothelium is activated in this disease, we studied the number, origin, and surface phenotype of circulating endothelial cells in patients with sickle cell anemia. Methods We used immunohistochemical examination of buffy-coat smears to enumerate circulating endothelial cells, and we evaluated the surface phenotype by applying immunofluorescence microscopy to preparations of circulating endothelial cells. A panel of antibodies was used, including a specific anti-endothelial-cell antibody, P1H12. Results Mean (+/-SD) numbers of circulating endothelial cells in normal blood donors, patients with sickle cell trait, and patients with hemolytic anemias not due to hemoglobin S were 2.6+/-1.6, 3.0+/-2.6, and 2.0+/-0.8 per milliliter of whole blood, respectively. Patients with sickle cell anemia who presented with acute painful episodes had 22.8+/-18.2 circulating endothelial cells per milliliter of blood (P<0.001 for the comparison with normal donors), and patients with no such events within one month before or after blood sampling had 13.2+/-11.8 circulating endothelial cells per milliliter of blood (P=0.002 for the comparison with normal donors and P=0.019 for the comparison with patients with acute events). Serial observations of three patients showed a tendency toward higher levels of circulating endothelial cells at the onset of acute painful crises. The average viability of circulating endothelial cells was 66+/-30 percent. In patients with sickle cell anemia, regardless of clinical status, the circulating endothelial cells were predominantly microvascular in origin (CD36-positive), and most of the cells expressed four markers of endothelial-cell activation: intercellular adhesion molecule 1, vascular-cell adhesion molecule 1, E-selectin, and P-selectin. Conclusions Our studies suggest that the vascular endothelium is activated in patients with sickle cell anemia, regardless of the patients' clinical status. Adhesion proteins on activated endothelial cells may have a role in the vascular pathology of sickle cell disease. (C) 1997, Massachusetts Medical Society.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	Solovey, A (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455, USA.		Lin, Yi/K-1510-2013	Browne, Paul/0000-0001-5310-1487; Lin, Yi/0000-0002-1556-6416	NHLBI NIH HHS [HL 55174, P01 HL055552] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055174, P01HL055552] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKINOLA NO, 1992, J CLIN PATHOL, V45, P902, DOI 10.1136/jcp.45.10.902; BLEI F, 1994, BLOOD, V84, pA409; Bouvier C., 1970, THROMB DIATH HAEMO, V40, P163; BRENNER BM, 1989, J CLIN INVEST, V84, P1373, DOI 10.1172/JCI114309; DRANCOURT M, 1992, J INFECT DIS, V166, P660, DOI 10.1093/infdis/166.3.660; Embury Stephen H., 1994, P311; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FAVALORO EJ, 1993, IMMUNOL CELL BIOL, V71, P571, DOI 10.1038/icb.1993.63; GEORGE F, 1991, J IMMUNOL METHODS, V139, P65, DOI 10.1016/0022-1759(91)90352-G; GEORGE F, 1993, BLOOD, V82, P2109; GEORGE F, 1992, BLOOD S, V80, pA12; GERRITY RG, 1976, EXP MOL PATHOL, V24, P59, DOI 10.1016/0014-4800(76)90057-5; GREFTE A, 1993, J INFECT DIS, V167, P270, DOI 10.1093/infdis/167.2.270; Gupta K, 1997, EXP CELL RES, V230, P244, DOI 10.1006/excr.1996.3421; Hebbel RP, 1997, J LAB CLIN MED, V129, P288, DOI 10.1016/S0022-2143(97)90176-1; HLADOVEC J, 1978, KLIN WOCHENSCHR, V56, P1033, DOI 10.1007/BF01476669; KLUG PP, 1982, BLOOD CELLS, V8, P175; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; PERCIVALLE E, 1993, J CLIN INVEST, V92, P663, DOI 10.1172/JCI116635; PETZELBAUER P, 1993, J IMMUNOL, V151, P5062; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; RODGERS GM, 1988, FASEB J, V2, P116, DOI 10.1096/fasebj.2.2.3277885; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; RUSSELL MO, 1984, BLOOD, V63, P162; SBARBATI R, 1991, BLOOD, V77, P764; SINGHAL A, 1993, LANCET, V341, P651, DOI 10.1016/0140-6736(93)90418-G; Solovey A., 1996, Blood, V88, p648A; SOWEMIMOCOKER SO, 1989, AM J HEMATOL, V31, P263, DOI 10.1002/ajh.2830310409; STOCKMAN JA, 1972, NEW ENGL J MED, V287, P846, DOI 10.1056/NEJM197210262871703; SUGIHARA K, 1992, BLOOD, V80, P2634; SWERLICK RA, 1992, J IMMUNOL, V148, P78	32	497	535	2	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1584	1590		10.1056/NEJM199711273372203	http://dx.doi.org/10.1056/NEJM199711273372203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371854				2022-12-28	WOS:A1997YH52100003
J	Misiani, R; Mantero, G; Bellavita, P; Mori, L; Vicari, O; Marchesi, D; Primi, D				Misiani, R; Mantero, G; Bellavita, P; Mori, L; Vicari, O; Marchesi, D; Primi, D			GB virus C infection in patients with type II mixed cryoglobulinemia	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATITIS-G VIRUS; UNKNOWN ETIOLOGY; LONG-TERM; ASSOCIATION; THERAPY	Background: Hepatitis C virus (HCV) infection is present in most but not all patients with type II mixed cryoglobulinemia. Objective: To investigate the role of GB virus C (GBV-C) in type II mixed cryoglobulinemia. Design: Retrospective study of serum and cryoprecipitate samples. Setting: Tertiary care hospital in Bergamo, Italy. Patients: 58 cryoglobulinemic patients, 35 of whom were treated with interferon-alpha. Measurements: GB virus C RNA was determined by a reverse-transcription polymerase chain reaction assay done by using primers derived from the conserved GBV-C helicase region. Results: GB virus C RNA was detected in serum specimens from 23 of 58 cryoglobulinemic patients (40% [95% CI, 27% to 53%]) and 1 of 145 healthy blood donors (0.7%) (P < 0.001). Twenty of the 23 patients with GBV-C RNA were simultaneously infected with HCV. Unlike antibodies to HCV and HCV RNA, GBV-C RNA did not concentrate in cryoprecipitate in patients co-infected with GBV-C and HCV. Furthermore, the therapeutic effectiveness of interferon-alpha in patients with coinfection was related to the disappearance of HCV RNA but not GBV-C RNA from serum. None of 3 patients with GBV-C infection alone had detectable GBV-C RNA in cryoprecipitate. Conclusions: Infection with GBV-C, usually associated with HCV, is common in patients with type II mixed cryoglobulinemia but is unlikely to have a primary role in this disease.	OSPED RIUNITI BERGAMO, SERV IMMUNOEMATOL, I-24128 BERGAMO, ITALY; OSPED RIUNITI BERGAMO, DIV NEFROL & DIALISI, I-24128 BERGAMO, ITALY; SPEDALI CIVILI BRESCIA, CONSORZIO BIOTECHNOL, I-25123 BRESCIA, ITALY; OSPED RIUNITI BERGAMO, CTR TRASFUS, I-24128 BERGAMO, ITALY	Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo; Hospital Spedali Civili Brescia; Ospedali Riuniti di Bergamo								AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; Byrnes JJ, 1996, LANCET, V348, P472, DOI 10.1016/S0140-6736(05)64562-X; CACOUB P, 1994, AM J MED, V96, P124, DOI 10.1016/0002-9343(94)90132-5; DAMMACCO F, 1994, BLOOD, V84, P3336, DOI 10.1182/blood.V84.10.3336.bloodjournal84103336; DiBisceglie AM, 1996, ANN INTERN MED, V125, P772, DOI 10.7326/0003-4819-125-9-199611010-00013; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; Fiordalisi G, 1996, J INFECT DIS, V174, P181, DOI 10.1093/infdis/174.1.181; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LEVEY JM, 1994, MEDICINE, V73, P53, DOI 10.1097/00005792-199401000-00005; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MANTERO G, 1991, CLIN CHEM, V37, P422; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MISIANI R, 1994, NEW ENGL J MED, V330, P751, DOI 10.1056/NEJM199403173301104; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; WEINER SM, 1996, 9 TRIENN INT S VIR H, P167; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	20	18	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					891	894		10.7326/0003-4819-127-10-199711150-00005	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382367				2022-12-28	WOS:A1997YF54500005
J	Rosen, CJ				Rosen, CJ			A tale of two worlds in prescribing etidronate for osteoporosis	LANCET			English	Editorial Material							POSTMENOPAUSAL OSTEOPOROSIS; ALENDRONATE; FRACTURES; THERAPY; WOMEN				Rosen, CJ (corresponding author), UNIV MAINE,ST JOSEPH HOSP,MAINE CTR OSTEOPOROSIS RES & EDUC,BANGOR,ME 04401, USA.							Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; Herd RJM, 1997, AM J MED, V103, P92, DOI 10.1016/S0002-9343(97)00019-3; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; MUENIER PJ, 1997, J CLIN ENDOCR METAB, V82, P2784; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1340	1340		10.1016/S0140-6736(05)65132-X	http://dx.doi.org/10.1016/S0140-6736(05)65132-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365446				2022-12-28	WOS:A1997YE87200006
J	Grillner, S				Grillner, S			Neuroscience - Ion channels and locomotion	SCIENCE			English	Editorial Material							SPINAL-CORD; LAMPREY; NEURONS; INTERNEURONS; SIMULATION; NETWORKS				Grillner, S (corresponding author), KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,DEPT NEUROSCI,BOX 60400,S-17177 STOCKHOLM,SWEDEN.							BACSKAI BJ, 1995, NEURON, V14, P19, DOI 10.1016/0896-6273(95)90237-6; Bao JX, 1997, SCIENCE, V275, P969, DOI 10.1126/science.275.5302.969; BUCHANAN JT, 1987, SCIENCE, V236, P312, DOI 10.1126/science.3563512; Dale N, 1995, J PHYSIOL-LONDON, V489, P489, DOI 10.1113/jphysiol.1995.sp021067; DiPrisco GV, 1997, SCIENCE, V278, P1122, DOI 10.1126/science.278.5340.1122; ELMANIRA A, 1994, J NEUROPHYSIOL, V72, P1852, DOI 10.1152/jn.1994.72.4.1852; ELMANIRA A, IN PRESS J COMP NEUR; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; GRILLNER S, 1995, TRENDS NEUROSCI, V18, P270, DOI 10.1016/0166-2236(95)93914-J; HARRISWARRICK RM, 1993, CURR OPIN NEUROBIOL, V3, P952; HELLGREN J, 1992, BIOL CYBERN, V68, P1, DOI 10.1007/BF00203132; Jordan L M, 1992, Curr Opin Neurobiol, V2, P794, DOI 10.1016/0959-4388(92)90136-9; KIEHN O, 1991, TRENDS NEUROSCI, V14, P68, DOI 10.1016/0166-2236(91)90023-N; MARDNER E, 1996, PHYSIOL REV, V76, P3687; OHTA Y, 1989, J NEUROPHYSIOL, V62, P1079, DOI 10.1152/jn.1989.62.5.1079; ROBERTS A, 1995, J NEUROPHYSIOL, V73, P485, DOI 10.1152/jn.1995.73.2.485; ROVAINEN CM, 1979, PHYSIOL REV, V59, P1007, DOI 10.1152/physrev.1979.59.4.1007; SCHOTLAND J, 1995, NATURE, V374, P266, DOI 10.1038/374266a0; SELVERSTON AI, 1993, ANNU REV NEUROSCI, V16, P531, DOI 10.1146/annurev.ne.16.030193.002531; SHIK ML, 1976, PHYSIOL REV, V56, P465, DOI 10.1152/physrev.1976.56.3.465; SILLAR KT, 1994, J NEUROSCI, V14, P2636; TEGNER J, 1997, THESIS; WALLEN P, 1987, J NEUROSCI, V7, P2745; [No title captured]	24	28	28	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1087	1088		10.1126/science.278.5340.1087	http://dx.doi.org/10.1126/science.278.5340.1087			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9381205				2022-12-28	WOS:A1997YE65200040
J	Joseph, S; Weiser, B; Noller, HF				Joseph, S; Weiser, B; Noller, HF			Mapping the inside of the ribosome with an RNA helical ruler	SCIENCE			English	Article							PEPTIDYL TRANSFERASE CENTER; ESCHERICHIA-COLI RIBOSOME; SEQUENCE-SPECIFIC CLEAVAGE; ANTICODON INTERACTION SITE; P-SITE; PROTEIN-SYNTHESIS; CROSS-LINKING; 70S RIBOSOMES; 16-S RNA; 16S RNA	The structure of ribosomal RNA (rRNA) in the ribosome was probed with hydroxyl radicals generated locally from iron(II) tethered to the 5' ends of anticodon stem-loop analogs (ASLs) of transfer RNA. The ASLs, ranging in length from 4 to 33 base pairs, bound to the ribosome in a messenger RNA-dependent manner and directed cleavage to specific regions of the 16S, 23S, and 5S rRNA chains. The positions and intensities of cleavage depended on whether the ASLs were bound to the ribosomal A or P site, and on the lengths of their stems, These data predict the three-dimensional locations of the rRNA targets relative to the positions of A- and P-site transfer RNAs inside the ribosome.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, RNA, CTR MOL BIOL, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRIMACOMBE R, 1988, JMB, V199, P155; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CHAPMAN NM, 1977, J MOL BIOL, V109, P131, DOI 10.1016/S0022-2836(77)80049-1; DERIEMER LH, 1981, J LABELLED COMPD RAD, V18, P1517, DOI 10.1002/jlcr.2580181017; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; DREYER GB, 1985, P NATL ACAD SCI USA, V82, P968, DOI 10.1073/pnas.82.4.968; Fink DL, 1996, RNA, V2, P851; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GORNICKI P, 1984, J BIOL CHEM, V259, P493; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAN HY, 1994, P NATL ACAD SCI USA, V91, P4955, DOI 10.1073/pnas.91.11.4955; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; JOSEPH S, UNPUB; KIRILLOV SV, 1980, NUCLEIC ACIDS RES, V8, P183, DOI 10.1093/nar/8.1.183; KUHLBRANDT W, 1982, J MOL BIOL, V156, P431, DOI 10.1016/0022-2836(82)90259-5; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LEVIEV I, 1995, NUCLEIC ACIDS RES, V23, P1512; MERRYMAN C, UNPUB; MITCHELL P, 1993, NUCLEIC ACIDS RES, V21, P887, DOI 10.1093/nar/21.4.887; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OSSWALD M, 1995, NUCLEIC ACIDS RES, V23, P4635, DOI 10.1093/nar/23.22.4635; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; PAULSEN H, 1983, J MOL BIOL, V167, P411, DOI 10.1016/S0022-2836(83)80342-8; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P12565, DOI 10.1021/bi00165a004; POGOZELSKI WK, 1995, J AM CHEM SOC, V117, P6428, DOI 10.1021/ja00129a002; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; RINKE AJ, 1995, RNA, V1, P1018; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SANTER M, 1990, P NATL ACAD SCI USA, V87, P3700, DOI 10.1073/pnas.87.10.3700; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; SUNDARALINGAM M, 1975, P101; TAPPRICH WE, 1989, P NATL ACAD SCI USA, V86, P4927, DOI 10.1073/pnas.86.13.4927; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; TULLIUS TD, 1991, FREE RADICAL RES COM, V12-3, P521; TUSCHL T, 1994, SCIENCE, V266, P785, DOI 10.1126/science.7973630; VASSILENKO SK, 1981, J MOL BIOL, V152, P699, DOI 10.1016/0022-2836(81)90123-6; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; YUSUPOV MM, 1986, FEBS LETT, V197, P229, DOI 10.1016/0014-5793(86)80332-5	61	76	76	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1093	1098		10.1126/science.278.5340.1093	http://dx.doi.org/10.1126/science.278.5340.1093			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353184				2022-12-28	WOS:A1997YE65200043
J	Dixon, AK; Coulden, RA				Dixon, AK; Coulden, RA			Coronary artery calcification on computed tomography	LANCET			English	Editorial Material							CT SCANS; QUANTIFICATION				Dixon, AK (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND.							AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; BREEN JF, 1992, RADIOLOGY, V185, P435, DOI 10.1148/radiology.185.2.1410350; Callaway MP, 1997, BRIT J RADIOL, V70, P572, DOI 10.1259/bjr.70.834.9227248; DIXON AK, 1984, CLIN RADIOL, V35, P33, DOI 10.1016/S0009-9260(84)80228-7; ELKELES A, 1957, LANCET, V2, P714; KAUFMANN RB, 1994, RADIOLOGY, V190, P347, DOI 10.1148/radiology.190.2.8284380; MCCARTHY JH, 1974, BRIT HEART J, V36, P499; MOORE EH, 1989, RADIOLOGY, V172, P711, DOI 10.1148/radiology.172.3.2772178; Reinmuller R, 1987, DYNAMIC CARDIOVASCUL, V1, P139; Shemesh J, 1996, RADIOLOGY, V199, P665, DOI 10.1148/radiology.199.3.8637984; SHEMESH J, 1995, RADIOLOGY, V197, P779, DOI 10.1148/radiology.197.3.7480756; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175	12	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1265	1265		10.1016/S0140-6736(05)62470-1	http://dx.doi.org/10.1016/S0140-6736(05)62470-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357403				2022-12-28	WOS:A1997YD68900005
J	Sloan, M; Kreiger, N; James, B				Sloan, M; Kreiger, N; James, B			Improving response rates among doctors: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							MAIL SURVEYS; PHYSICIANS				Sloan, M (corresponding author), CANC CARE ONTARIO,DIV PREVENT ONCOL,620 UNIV AVE,TORONTO,ON M5G 2L7,CANADA.							MAHEUX B, 1989, AM J PUBLIC HEALTH, V79, P638, DOI 10.2105/AJPH.79.5.638; TOFFLER WM, 1989, AM J PUBLIC HEALTH, V79, P1434, DOI 10.2105/AJPH.79.10.1434	2	6	6	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1136	1136						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YE615	9374887				2022-12-28	WOS:A1997YE61500026
J	Sorensen, HT; Sabroe, S; Rothman, KJ; Gillman, M; Fischer, P; Sorensen, TIA				Sorensen, HT; Sabroe, S; Rothman, KJ; Gillman, M; Fischer, P; Sorensen, TIA			Relation between weight and length at birth and body mass index in young adulthood: cohort study	BRITISH MEDICAL JOURNAL			English	Article							OBESITY; GROWTH		AARHUS UNIV,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL & SOCIAL MED,DK-8000 AARHUS,DENMARK; BOSTON UNIV,SCH MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02215; HARVARD PILGRIM HLTH CARE,BOSTON,MA 02215; 5TH CONSCRIPT DIST,DK-9000 AALBORG,DENMARK; UNIV COPENHAGEN HOSP,DANISH EPIDEMIOL SCI CTR,INST PREVENT MED,DK-1399 COPENHAGEN K,DENMARK	Aarhus University; Boston University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Aarhus University; University of Copenhagen	Sorensen, HT (corresponding author), AARHUS UNIV HOSP,DEPT INTERNAL MED 5,DK-8000 AARHUS,DENMARK.		Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Rothman, Kenneth/0000-0003-2398-1705				BINKIN NJ, 1988, PEDIATRICS, V82, P828; CHARNEY E, 1976, NEW ENGL J MED, V295, P6, DOI 10.1056/NEJM197607012950102; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; PECKHAM CS, 1983, BMJ-BRIT MED J, V286, P1237, DOI 10.1136/bmj.286.6373.1237; SEIDMAN DS, 1991, AM J DIS CHILD, V145, P782	5	175	180	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1137	1137						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374888	Green Published			2022-12-28	WOS:A1997YE61500027
J	Hudson, C; Clements, D; Friday, RV; Stott, D; Woodland, HR				Hudson, C; Clements, D; Friday, RV; Stott, D; Woodland, HR			Xsox17 alpha and -beta mediate endoderm formation in Xenopus	CELL			English	Article							IN-SITU HYBRIDIZATION; MESODERM INDUCTION; TRANSCRIPTIONAL REPRESSION; TRUNCATED ACTIVIN; GROWTH-FACTORS; EXPRESSION; LAEVIS; EMBRYOS; GENES; PROTEIN	We have isolated two Xenopus relatives of murine Sox17 expressed in gastrula presumptive endoderm. Xsox17 alpha and -beta expression can be induced in animal caps by activin, but not by FGF. Ectopic expression of these genes in animal caps induces the expression of endoderm markers; this induction is blocked by overexpression of a fusion of the Xsox17 beta HMG domain to the Drosophila Engrailed repressor domain, as is induction of endoderm markers by activin and the expression of endodermal markers in whole embryos and isolated vegetal poles. These experiments, as well as the effects of the mRNAs on embryo phenotypes, suggest that the Xsox17 genes mediate an activin-induced endoderm differentiation pathway in animal caps and are involved in normal endoderm differentiation in embryos.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick			Hudson, Clare/X-7618-2019	Hudson, Clare/0000-0003-1585-8328	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BASSEZ T, 1990, DEVELOPMENT, V110, P955; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; Conlon FL, 1996, DEVELOPMENT, V122, P2427; COOK JP, 1993, BIOCONJUGATE CHEM, V4, P440, DOI 10.1021/bc00024a005; DEMARTIS A, 1994, MECH DEVELOP, V47, P19, DOI 10.1016/0925-4773(94)90092-2; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Fan MJ, 1997, DEVELOPMENT, V124, P2581; GAMER LW, 1995, DEV BIOL, V171, P240, DOI 10.1006/dbio.1995.1275; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Henry GL, 1996, DEVELOPMENT, V122, P1007; Horb ME, 1997, DEVELOPMENT, V124, P1689; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; Islam N, 1996, TRENDS GENET, V12, P459, DOI 10.1016/0168-9525(96)99990-4; JOHN A, 1995, DEVELOPMENT, V121, P1801; JONES EA, 1993, ROUX ARCH DEV BIOL, V202, P233, DOI 10.1007/BF02427884; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KNOCHEL W, 1986, J MOL EVOL, V23, P211, DOI 10.1007/BF02115578; Lemaire P, 1996, BIOESSAYS, V18, P701, DOI 10.1002/bies.950180904; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; LUKYANOV SA, 1994, BIOORG KHIM+, V20, P701; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; RICHARDSON JC, 1995, MECH DEVELOP, V52, P165, DOI 10.1016/0925-4773(95)00388-H; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Smith ST, 1996, DEVELOPMENT, V122, P3141; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; Weber H, 1996, DEVELOPMENT, V122, P1975; WILSON C, 1986, CELL, V47, P589, DOI 10.1016/0092-8674(86)90623-9; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; WYLIE CC, 1987, DEV BIOL, V119, P496, DOI 10.1016/0012-1606(87)90052-2	44	304	323	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					397	405		10.1016/S0092-8674(00)80423-7	http://dx.doi.org/10.1016/S0092-8674(00)80423-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363948	Bronze			2022-12-28	WOS:A1997YD94100013
J	Lin, VSY; Motesharei, K; Dancil, KPS; Sailor, MJ; Ghadiri, MR				Lin, VSY; Motesharei, K; Dancil, KPS; Sailor, MJ; Ghadiri, MR			A porous silicon-based optical interferometric biosensor	SCIENCE			English	Article							GENE-EXPRESSION; ARRAYS; MICROARRAY; POLYMER; SURFACE	A biosensor has been developed based on induced wavelength shifts in the Fabry-Perot fringes in the visible-light reflection spectrum of appropriately derivatized thin films of porous silicon semiconductors. Binding of molecules induced changes in the refractive index of the porous silicon. The validity and sensitivity of the system are demonstrated for small organic molecules (biotin and digoxigenin), 16-nucleotide DNA oligomers, and proteins (streptavidin and antibodies) at pico- and femtomolar analyte concentrations. The sensor is also highly effective for detecting single and multilayered molecular assemblies.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Sailor, Michael J/H-9044-2017	Sailor, Michael J/0000-0002-4809-9826	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM047165] Funding Source: NIH RePORTER; NIGMS NIH HHS [2SO6 GM47165-06, GM18309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bard A. J., 1980, ELECTROCHEMICAL METH; BARNARD SM, 1991, SCIENCE, V251, P927, DOI 10.1126/science.2000492; BRECHT A, 1995, BIOSENS BIOELECTRON, V10, P923, DOI 10.1016/0956-5663(95)99230-I; BRECHT A, 1997, FRONTIERS BIOSENSORI, V2, P1; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DOAN VV, 1992, SCIENCE, V256, P1791, DOI 10.1126/science.256.5065.1791; Ferguson JA, 1996, NAT BIOTECHNOL, V14, P1681, DOI 10.1038/nbt1296-1681; GOPEL W, 1989, SENSORS UPDATE, V1; HEMENWAY BR, 1989, APPL PHYS LETT, V55, P349, DOI 10.1063/1.101905; HICKMAN JJ, 1991, SCIENCE, V252, P688, DOI 10.1126/science.252.5006.688; Kittel C, 1986, INTRO SOLID STATE PH; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; Motohashi A, 1996, JPN J APPL PHYS 1, V35, P4253, DOI 10.1143/JJAP.35.4253; NEU DR, 1993, J PHYS CHEM-US, V97, P5713, DOI 10.1021/j100123a041; PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0; RIKLIN A, 1995, NATURE, V376, P672, DOI 10.1038/376672a0; Rossi B. B., 1957, OPTICS; ROWELL FJ, 1991, BIOCHEM SOC T, V19, P32, DOI 10.1042/bst0190032; SCHECHTER I, 1995, ANAL CHEM, V67, P3727, DOI 10.1021/ac00116a018; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHINOHARA Y, 1995, J BIOCHEM-TOKYO, V117, P1076; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0; STIEVENARD D, 1995, APPL PHYS LETT, V67, P1570, DOI 10.1063/1.114942; Watanabe K, 1996, SENSOR ACTUAT B-CHEM, V33, P194, DOI 10.1016/0925-4005(96)80097-9	25	1137	1317	9	382	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					840	843		10.1126/science.278.5339.840	http://dx.doi.org/10.1126/science.278.5339.840			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346478				2022-12-28	WOS:A1997YD47900040
J	Skinner, PJ; Koshy, BT; Cummings, CJ; Klement, IA; Helin, K; Servadio, A; Zoghbi, HY; Orr, HT				Skinner, PJ; Koshy, BT; Cummings, CJ; Klement, IA; Helin, K; Servadio, A; Zoghbi, HY; Orr, HT			Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures	NATURE			English	Article							SPINOCEREBELLAR ATAXIA; COILED BODY; TYPE-1; LOCALIZATION; ONCOPROTEIN; EXPRESSION; REPEAT; CELLS; GENE	Spinocerebellar ataxia type 1 (SCA1) is one of several neurodegenerative disorders caused by an expansion of a polyglutamine tract(1,2). It is characterized by ataxia, progressive motor deterioration, and loss of cerebellar Purkinje cells(1). To understand the pathogenesis of SCA1, we examined the subcellular localization of wild-type human ataxin-1 (the protein encoded by the SCA1 gene) and mutant ataxin-1 in the Purkinje cells of transgenic mice(3). We found that ataxin-1 localizes to the nuclei of cerebellar Purkinje cells, Normal ataxin-1 localizes to several nuclear structures similar to 0.5 mu m across, whereas the expanded ataxin-1 localizes to a single similar to 2-mu m structure, before the onset of ataxia. Mutant ataxin-1 localizes to a single nuclear structure in affected neurons of SCA1 patients. Similarly, COS-1 cells transfected with wild-type or mutant ataxin-1 show a similar pattern of nuclear localization; with expanded ataxin-1 occurring in larger structures that are fewer in number than those of normal ataxin-1. Colocalization studies show that mutant ataxin-1 causes a specific redistribution of the nuclear matrix-associated domain containing promyelocytic leukaemia protein(4-7). Nuclear matrix preparations demonstrate that ataxin-1 associates with the nuclear matrix in Purkinje and COS cells. We therefore propose that a critical aspect of SCA1 pathogenesis involves the disruption of a nuclear matrix-associated domain.	UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CELL & MOL BIOL PROGRAM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Skinner, Pamela/0000-0003-3388-1687; Orr, Harry/0000-0001-6118-741X; Zoghbi, Huda/0000-0002-0700-3349; Helin, Kristian/0000-0003-1975-6097	Telethon [38/B, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; [Anonymous], ADV NEUROL; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BISOTTO S, 1995, J CELL SCI, V108, P1873; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; CHAN EKL, 1994, NUCLEIC ACIDS RES, V22, P4462, DOI 10.1093/nar/22.21.4462; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dhordain P, 1995, ONCOGENE, V11, P2689; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MATILLA A, UNPUB P NATL ACAD SC; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; ROBITAILLE Y, 1995, ACTA NEUROPATHOL, V90, P572; ROOS RAC, 1983, J NEUROL SCI, V61, P37, DOI 10.1016/0022-510X(83)90053-9; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; STUURMAN N, 1992, J CELL SCI, V101, P773; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; TELLEZNAGEL I, 1974, J NEUROPATH EXP NEUR, V33, P308, DOI 10.1097/00005072-197404000-00008; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZOGHBI HY, 1995, SEMIN CELL BIOL, V6, P29, DOI 10.1016/1043-4682(95)90012-8	29	470	479	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	1997	389	6654					971	974		10.1038/40153	http://dx.doi.org/10.1038/40153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353120				2022-12-28	WOS:A1997YD29900056
J	Nee, S; May, RM				Nee, S; May, RM			Extinction and the loss of evolutionary history	SCIENCE			English	Article							GENETIC DIVERSITY; CONSERVATION; BIODIVERSITY; POPULATIONS; TAXONOMY	Extinction episodes, such as the anthropogenic one currently under way, result in a pruned tree of life. But what fraction of the underlying evolutionary history survives when k of n species in a taxon are lost? This is relevant both to how species loss has translated into a loss of evolutionary history and to assigning conservation priorities. Here it is shown that approximately 80 percent of the underlying tree of life can survive even when approximately 95 percent of species are lost, and that algorithms that maximize the amount of evolutionary history preserved are not much better than choosing the survivors at random. Given the political, economic, and social realities constraining conservation biology, these findings may be helpful.			Nee, S (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.							BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Courtillot V, 1996, NATURE, V381, P146, DOI 10.1038/381146a0; DONOGHUE MJ, 1985, BRYOLOGIST, V88, P172, DOI 10.2307/3243026; ERWIN DH, 1994, NATURE, V367, P231, DOI 10.1038/367231a0; ERWIN TL, 1991, SCIENCE, V253, P750, DOI 10.1126/science.253.5021.750; FAITH DP, 1994, BIOL CONSERV, V68, P69, DOI 10.1016/0006-3207(94)90548-7; GUYER C, 1993, EVOLUTION, V47, P253, DOI [10.2307/2410133, 10.1111/j.1558-5646.1993.tb01214.x]; HESSE H, 1987, GLASS BEARD GAME; HEY J, 1992, EVOLUTION, V46, P627, DOI [10.2307/2409633, 10.1111/j.1558-5646.1992.tb02071.x]; Hibbett DS, 1996, CONSERV BIOL, V10, P1321, DOI 10.1046/j.1523-1739.1996.10051321.x; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; KRAJEWSKI C, 1991, SCIENCE, V254, P918, DOI 10.1126/science.254.5034.918-a; Lawton J. H., 1995, EXTINCTION RATES; LAWTON JH, 1994, OIKOS, V71, P1; Lovelock J, 1997, PHILOS T ROY SOC B, V352, P143, DOI 10.1098/rstb.1997.0009; Martin G, 1996, NATURE, V380, P666, DOI 10.1038/380666a0; MAY RM, 1990, NATURE, V347, P129, DOI 10.1038/347129a0; Mooers AO, 1997, Q REV BIOL, V72, P31, DOI 10.1086/419657; MORITZ C, 1994, TRENDS ECOL EVOL, V9, P373, DOI 10.1016/0169-5347(94)90057-4; NEE S, 1995, PHILOS T ROY SOC B, V349, P25, DOI 10.1098/rstb.1995.0087; NEI M, 1975, EVOLUTION, V29, P1, DOI 10.2307/2407137; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Pimm SL, 1997, NATURE, V387, P231, DOI 10.1038/387231a0; PURVIS A, 1995, P ROY SOC B-BIOL SCI, V260, P329, DOI 10.1098/rspb.1995.0100; RAUP DM, 1993, EXTINCTION; SLATKIN M, 1991, GENETICS, V129, P555; STANLEY SM, 1994, SCIENCE, V266, P1340, DOI 10.1126/science.266.5189.1340; STANLEY SM, 1987, EVOLUTION, V41, P1177; TAVARE S, 1984, THEOR POPUL BIOL, V26, P119, DOI 10.1016/0040-5809(84)90027-3; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; [No title captured]	32	216	223	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					692	694		10.1126/science.278.5338.692	http://dx.doi.org/10.1126/science.278.5338.692			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381180				2022-12-28	WOS:A1997YC32300056
J	Holtz, JH; Asher, SA				Holtz, JH; Asher, SA			Polymerized colloidal crystal hydrogel films as intelligent chemical sensing materials	NATURE			English	Article							N-ISOPROPYLACRYLAMIDE; RESPONSIVE POLYMERS; PHASE-TRANSITIONS; GELS; POLY(N-ISOPROPYLACRYLAMIDE); DIFFRACTION; KINETICS; WATER; TEMPERATURE; SEPARATION	Chemical sensors' respond to the presence of a specific analyte in a variety of ways, One of the most convenient is a change in optical properties, and in particular a visually perceptible colour change. Here we report the preparation of a material that changes colour in response to a chemical signal by means of a change in diffraction (rather than absorption) properties. Our material is a crystalline colloidal array(2-12) of polymer spheres (roughly 100 nm diameter) polymerized within a hydrogel(13,14) that swells and shrinks reversibly in the presence of certain analytes (here metal ions and glucose). The crystalline colloidal array diffracts light at (visible) wavelengths determined by the lattice spacing(2-12), which gives rise to an intense colour. The hydrogel contains either a molecular-recognition group that binds the analyte selectively (crown ethers for metal ions), or a molecular-recognition agent that reacts with the analyte selectively. These recognition events cause the gel to swell owing to an increased osmotic pressure, which increases the mean separation between the colloidal spheres and so shifts the Bragg peak of the diffracted light to longer wavelengths. We anticipate that this strategy can be used to prepare 'intelligent' materials responsive to a wide range of analytes, including viruses.	UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								AASTUEN DJW, 1986, PHYS REV LETT, V57, P1733, DOI 10.1103/PhysRevLett.57.1733; ACKERSON BJ, 1981, PHYS REV LETT, V46, P123, DOI 10.1103/PhysRevLett.46.123; Asher S.A., 1986, Patent No. [US4632517A, 4632517]; Asher S.A., 1986, SPECTROSCOPY, V1, P26; ASHER SA, 1994, J AM CHEM SOC, V116, P4997, DOI 10.1021/ja00090a059; ASHER SA, 1986, Patent No. 4627689; CARLSON RJ, 1984, APPL SPECTROSC, V38, P297, DOI 10.1366/0003702844555548; CLARK NA, 1979, NATURE, V281, P57, DOI 10.1038/281057a0; DUBEY RK, 1995, TALANTA, V42, P65, DOI 10.1016/0039-9140(94)00217-G; DUSEK K, 1993, ADV POLYM SCI, V109; DUSEK K, 1993, ADV POLYM SCI, V110; FILLMORE DJ, 1979, J CHEM PHYS, V70, P1214; FLORY J, 1953, PRINCIPLES POLYM SCI; FUJISHIGE S, 1989, J PHYS CHEM-US, V93, P3311, DOI 10.1021/j100345a085; GEHRKE SH, 1986, CHEM ENG SCI, V41, P2153, DOI 10.1016/0009-2509(86)87131-7; GEHRKE SH, 1993, ADV POLYM SCI, V110, P81; GRIMSHAW PE, 1989, CHEM ENG SCI, V44, P827, DOI 10.1016/0009-2509(89)85256-X; HAKIKI A, 1994, J CHEM PHYS, V101, P9054, DOI 10.1063/1.468034; Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI DOI 10.1080/10601326808051910; HILTNER PA, 1969, J PHYS CHEM-US, V73, P2386, DOI 10.1021/j100727a049; HILTNER PA, 1971, J PHYS CHEM-US, V75, P1881, DOI 10.1021/j100681a020; HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; HURD AJ, 1982, PHYS REV A, V26, P2869, DOI 10.1103/PhysRevA.26.2869; IRIE M, 1993, ADV POLYM SCI, V110, P49; IRIE M, 1993, POLYMER, V34, P4531, DOI 10.1016/0032-3861(93)90160-C; IZATT RM, 1976, J AM CHEM SOC, V98, P7626, DOI 10.1021/ja00440a029; JANATA J, 1989, PRINCIPLES CHEM SENS; KATAOKA K, 1994, MACROMOLECULES, V27, P1061, DOI 10.1021/ma00082a028; KATAOKA K, 1995, MACROMOLECULES, V28, P3336, DOI 10.1021/ma00113a038; Khokhlov AR, 1996, MACROMOLECULES, V29, P681, DOI 10.1021/ma946426d; KOPOLOW S, 1973, MACROMOLECULES, V6, P133; KRIEGER IM, 1968, J AM CHEM SOC, V90, P3114, DOI 10.1021/ja01014a025; KUBOTA K, 1990, J PHYS CHEM-US, V94, P5154, DOI 10.1021/j100375a070; LI Y, 1990, J CHEM PHYS, V92, P1365, DOI 10.1063/1.458148; MCCURLEY MF, 1994, BIOSENS BIOELECTRON, V9, P527, DOI 10.1016/0956-5663(94)90015-9; OKANO T, 1993, ADV POLYM SCI, V110, P179; OSADA Y, 1993, PROG POLYM SCI, V18, P187, DOI 10.1016/0079-6700(93)90025-8; PETERS A, 1986, MACROMOLECULES, V19, P1952, DOI 10.1021/ma00161a029; Popov A.I., 1979, COORDINATION CHEM MA; RABA J, 1995, CRIT REV ANAL CHEM, V25, P1, DOI 10.1080/10408349508050556; RUNDQUIST PA, 1989, J CHEM PHYS, V91, P4932, DOI 10.1063/1.456734; Savage M.D., 1992, AVIDIN BIOTIN CHEM H; SCHALKHAMMER T, 1995, SENSOR ACTUAT B-CHEM, V24, P166, DOI 10.1016/0925-4005(95)85036-8; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; SHEPPARD NF, 1995, SENSOR ACTUAT B-CHEM, V28, P95, DOI 10.1016/0925-4005(94)01542-P; TANAKA T, 1978, PHYS REV LETT, V40, P820, DOI 10.1103/PhysRevLett.40.820; WANG KL, 1993, ADV POLYM SCI, V110, P67; Weissman JM, 1996, SCIENCE, V274, P959, DOI 10.1126/science.274.5289.959; YOKOI K, 1995, ANAL CHIM ACTA, V316, P363, DOI 10.1016/0003-2670(95)00375-A; ZEN JM, 1994, ANAL CHIM ACTA, V296, P77, DOI 10.1016/0003-2670(94)85152-2	50	1713	1789	59	1387	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					829	832		10.1038/39834	http://dx.doi.org/10.1038/39834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349814				2022-12-28	WOS:A1997YC14800051
J	Jones, AH				Jones, AH			Literature and medicine: Garcia Marquez' Love in the Time of Cholera	LANCET			English	Editorial Material											Jones, AH (corresponding author), UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,ASHBEL SMITH BLDG SUITE 2-210,301 UNIV BLVD,GALVESTON,TX 77555, USA.							BELLVILLADA GH, 1990, G MARQUEZ MAN HIS WO, P192; BOOKER MK, 1993, LOVE TIME CHOLERA ST, V17, P181; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; COLUMBUS CK, 1992, TWENTIETH CENT LIT, V38, P89; CONTI MS, 1996, WORLD PRESS REV  OCT, P60; DICKEY J, 1969, EYE BEATERS BLOOD VI, P31; DOWNIE RS, 1991, J MED ETHICS, V17, P93, DOI 10.1136/jme.17.2.93; DOWNIE RS, 1991, J MED ETHICS, V17, P98; FIDDIAN R, 1987, GG MARQUEZ NEW READI, P192; Garcia Marquez G., 1988, LOVE TIME CHOLERA; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; McLellan MF, 1996, LANCET, V348, P109, DOI 10.1016/S0140-6736(96)03521-0; Moore AR, 1978, MISSING MED TEXT HUM; RABUZZI KA, 1982, LIT MED, V1, P1; Tennyson Alfred, 1971, TENNYSONS POETRY, P54; Trautmann J., 1978, ROLE HUMANITIES MED, P32	16	3	6	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1169	1172		10.1016/S0140-6736(97)09249-0	http://dx.doi.org/10.1016/S0140-6736(97)09249-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	YB199	9379818				2022-12-28	WOS:A1997YB19900050
J	WeverlingRijnsburger, AWE; Blauw, GJ; Lagaay, AM; Knook, DL; Meinders, AE; Westendorp, RGJ				WeverlingRijnsburger, AWE; Blauw, GJ; Lagaay, AM; Knook, DL; Meinders, AE; Westendorp, RGJ			Total cholesterol and risk of mortality in the oldest old	LANCET			English	Article							POPULATION-BASED SURVEY; SERUM-CHOLESTEROL; MYOCARDIAL-INFARCTION; FOLLOW-UP; AGED 85; PRAVASTATIN; CANCER; TRANSPLANTATION; ASSOCIATION; MORBIDITY	Background The impact of total serum cholesterol as a risk factor for cardiovascular disease decreases with age, which casts doubt on the necessity for cholesterol-lowering therapy in the elderly. We assessed the influence of total cholesterol concentrations on specific and all-cause mortality in people aged 85 years and over. Methods In 724 participants (median age 89 years), total cholesterol concentrations were measured and mortality risks calculated over 10 years of follow-up. Three categories of total cholesterol concentrations were defined <5.0 mmol/L, 5.0-6.4 mmol/L, and greater than or equal to 6.5 mmol/L. In a subgroup of 137 participants, total cholesterol was measured again after 5 years of follow-up. Mortality risks for the three categories of total cholesterol concentrations were estimated with a Cox proportional-hazards model, adjusted for age, sex, and cardiovascular risk factors. The primary causes of death were coded according to the International Classification of Diseases (ICD-9). Findings During 10 years of follow-up from Dec 1, 1986, to Oct 1, 1996, a total of 642 participants died. Each 1 mmol/L increase in total cholesterol corresponded to a 15% decrease in mortality (risk ratio 0.85 [95% CI 0.79-0.91]). This risk estimate was similar in the subgroup of participants who had stable cholesterol concentrations over a 5-year period. The main cause of death was cardiovascular disease with a similar mortality risk in the three total cholesterol categories. Mortality from cancer and infection was significantly lower among the participants in the highest total cholesterol category than in the other categories, which largely explained the lower all-cause mortality in this category. Interpretation in people older than 85 years, high total cholesterol concentrations are associated with longevity owing to lower mortality from cancer and infection. The effects of cholesterol-lowering therapy have yet to be assessed.	LEIDEN UNIV,MED CTR,DEPT CLIN EPIDEMIOL,NL-2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	WeverlingRijnsburger, AWE (corresponding author), LEIDEN UNIV,MED CTR,DEPT GEN INTERNAL MED,SECT GERONTOL & GERIATR,POB 9600,C1-R45,NL-2300 RC LEIDEN,NETHERLANDS.		Blauw, Gerard/GWD-1079-2022; Blauw, Gerard/AAW-7904-2021					*AM ASS CLIN CHEM, 1994, GER CLIN CHEM REF VA, P312; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; Blauw GJ, 1997, STROKE, V28, P946, DOI 10.1161/01.STR.28.5.946; Corti MC, 1997, ANN INTERN MED, V126, P753, DOI 10.7326/0003-4819-126-10-199705150-00001; Crouse JR, 1997, ARCH INTERN MED, V157, P1305, DOI 10.1001/archinte.157.12.1305; DelgadoRodriguez M, 1997, INFECT CONT HOSP EP, V18, P9; DEVRIES CL, 1993, CARDIOLOGY, V82, P89, DOI 10.1159/000175861; Izaks GJ, 1997, J AM GERIATR SOC, V45, P56, DOI 10.1111/j.1532-5415.1997.tb00978.x; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Katznelson S, 1996, TRANSPLANTATION, V61, P1469, DOI 10.1097/00007890-199605270-00010; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; KROMHOUT D, 1988, ARCH INTERN MED, V148, P1051, DOI 10.1001/archinte.148.5.1051; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; LAGAAY AM, 1992, ARCH GERONTOL GERIAT, V15, P115, DOI 10.1016/0167-4943(92)90012-S; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Netea MG, 1996, J CLIN INVEST, V97, P1366, DOI 10.1172/JCI118556; OLDHAM PD, 1962, J CHRON DIS, V15, P969, DOI 10.1016/0021-9681(62)90116-9; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHATZKIN A, 1988, CANCER RES, V48, P452; SCHUIT AJ, 1993, AM J EPIDEMIOL, V137, P966, DOI 10.1093/oxfordjournals.aje.a116769; Sharp SJ, 1997, EPIDEMIOLOGY, V8, P132, DOI 10.1097/00001648-199703000-00002; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; World Health Organization, 1977, INT CLASS DIS; Zureik M, 1997, EPIDEMIOLOGY, V8, P137, DOI 10.1097/00001648-199703000-00003; 1995, LANCET, V333, P1301	27	363	378	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1119	1123		10.1016/S0140-6736(97)04430-9	http://dx.doi.org/10.1016/S0140-6736(97)04430-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343498				2022-12-28	WOS:A1997YB19900008
J	Wilding, J				Wilding, J			Science, medicine, and the future - Obesity treatment	BRITISH MEDICAL JOURNAL			English	Review							MICE				Wilding, J (corresponding author), UNIV LIVERPOOL,FAZAKERLEY DIST GEN HOSP,CLIN DEPT AINTREE,DIABET & ENDOCRINOL CLIN RES UNIT,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND.		Wilding, John/ABB-6443-2020; Wilding, John PH/A-7106-2008	Wilding, John/0000-0003-2839-8404; Wilding, John PH/0000-0003-2839-8404				BALLINGER A, 1995, CLIN SCI, V89, P375, DOI 10.1042/cs0890375; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Jung RT, 1997, BRIT MED BULL, V53, P307, DOI 10.1093/oxfordjournals.bmb.a011615; LU D, 1994, NATURE, V371, P79; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; SJOSTROM L, 1995, OBES RES, V3, P317; SKENDER ML, 1996, AM J CLIN NUTR, V96, P1115; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wang Q, 1997, DIABETES, V46, P335, DOI 10.2337/diabetes.46.3.335; Wilding J, 1997, BRIT MED BULL, V53, P286, DOI 10.1093/oxfordjournals.bmb.a011614; WING RR, 1992, AM J CLIN NUTR, V55, P545, DOI 10.1093/ajcn/55.2.545s; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	19	54	63	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					997	&		10.1136/bmj.315.7114.997	http://dx.doi.org/10.1136/bmj.315.7114.997			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365300	Green Published			2022-12-28	WOS:A1997YC30700027
J	Ganem, D				Ganem, D			KSHV and Kaposi's sarcoma: The end of the beginning?	CELL			English	Review							DNA-SEQUENCES; HERPESVIRUS; AIDS		UNIV CALIF SAN FRANCISCO,MED CTR,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Ganem, D (corresponding author), UNIV CALIF SAN FRANCISCO,MED CTR,HOWARD HUGHES MED INST,DEPT MICROBIOL,SAN FRANCISCO,CA 94143, USA.							Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BOSCHOFF C, 1995, NAT MED, V1, P1274; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; ENSOLI B, 1991, HEMATOL ONCOL CLIN N, V5, P281, DOI 10.1016/S0889-8588(18)30441-6; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; Ganem D, 1996, SEMIN VIROL, V7, P325, DOI 10.1006/smvy.1996.0040; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Koelle DM, 1997, J INFECT DIS, V176, P94, DOI 10.1086/514045; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	20	192	196	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					157	160		10.1016/S0092-8674(00)80398-0	http://dx.doi.org/10.1016/S0092-8674(00)80398-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346233	Bronze			2022-12-28	WOS:A1997YC35000003
J	Klumpp, M; Baumeister, W; Essen, LO				Klumpp, M; Baumeister, W; Essen, LO			Structure of the substrate binding domain of the thermosome, an archaeal group II chaperonin	CELL			English	Article							T-COMPLEX POLYPEPTIDE-1; CYTOSOLIC CHAPERONIN; MOLECULAR CHAPERONE; THERMOPHILIC ARCHAEBACTERIUM; CYTOPLASMIC CHAPERONIN; EUKARYOTIC CYTOSOL; CRYSTAL-STRUCTURE; BETA-ACTIN; HEAT-SHOCK; PROTEIN	The crystal structure of the substrate binding domain of the thermosome, the archaeal group II chaperonin, has been determined at 2.3 Angstrom resolution. The core resembles the apical domain of GroEL but lacks the hydrophobic residues implied in binding of substrates to group I chaperonins. Rather, a large hydrophobic surface patch is found in a novel helix-turn-helix motif, which is characteristic of all group II chaperonins including the eukaryotic TRiC/CCT complex. Models of the holochaperonin, which are consistent with cryo electron microscopy data, suggest a dual role of this helical protrusion in substrate binding and controlling access to the central cavity independent of a GroES-like cochaperonin.	MAX PLANCK INST BIOCHEM,DEPT MOL STRUCT BIOL,D-82152 PLANEGG,GERMANY; MAX PLANCK INST BIOCHEM,DEPT MEMBRANE BIOCHEM,D-82152 PLANEGG,GERMANY	Max Planck Society; Max Planck Society			Essen, Lars-Oliver/L-3862-2016	Essen, Lars-Oliver/0000-0003-4272-4026; Klumpp, Martin/0000-0003-3373-9605				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Andra S, 1996, FEBS LETT, V379, P127, DOI 10.1016/0014-5793(95)01493-4; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BRUNGER AT, 1992, XPLOR VERSION 3 1; Dobrzynski JK, 1996, BIOCHEMISTRY-US, V35, P15870, DOI 10.1021/bi961114j; ELLIS J, 1992, NATURE, V358, P191, DOI 10.1038/358191a0; ELLIS RJ, 1996, ACTA CRYSTALLOGR A, V47, P392; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; MAY ACW, 1994, PROTEIN ENG, V7, P475, DOI 10.1093/protein/7.4.475; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nitsch M, 1997, J MOL BIOL, V267, P142, DOI 10.1006/jmbi.1996.0849; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WALDMANN T, 1995, BIOL CHEM H-S, V376, P119, DOI 10.1515/bchm3.1995.376.2.119; WALDMANN T, 1995, FEBS LETT, V376, P67, DOI 10.1016/0014-5793(95)01248-8; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; Willison Keith R., 1996, P107, DOI 10.1016/B978-012237455-5/50006-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	44	137	140	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					263	270		10.1016/S0092-8674(00)80408-0	http://dx.doi.org/10.1016/S0092-8674(00)80408-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346243	Bronze			2022-12-28	WOS:A1997YC35000013
J	Gress, FG; Savides, TJ; Sandler, A; Kesler, K; Conces, D; Cummings, O; Mathur, P; Ikenberry, S; Bilderback, S; Hawes, R				Gress, FG; Savides, TJ; Sandler, A; Kesler, K; Conces, D; Cummings, O; Mathur, P; Ikenberry, S; Bilderback, S; Hawes, R			Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: A comparison study	ANNALS OF INTERNAL MEDICINE			English	Article						carcinoma, non-small-cell lung; lung neoplasms; neoplasm staging; endosonography; tomography, x-ray computed; biopsy, needle	MEDIASTINAL LYMPH-NODE; BRONCHOGENIC-CARCINOMA; DIAGNOSIS; ULTRASOUND; ENDOSONOGRAPHY; CT; OPERABILITY; METASTASIS; ESOPHAGUS; SURGERY	Background: Current methods for detecting mediastinal lymph node involvement with non-small-cell lung cancer can be inaccurate and are often invasive and expensive. Objective: To assess the utility of endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography for the detection of metastases to the posterior mediastinal lymph nodes in non-small-cell lung cancer. Design: Prospective preoperative evaluation of the diagnostic operating characteristics of these procedures. Setting: Referral-based academic medical center. Patients: 130 consecutive patients with non-small-cell lung cancer who were otherwise good surgical candidates. Interventions: All patients had initial computed tomography of the chest; those with enlarged nodes were referred for endoscopic ultrasonography. Endoscopic ultrasonography-guided fine-needle aspiration biopsy was done on suspicious contralateral posterior mediastinal or subcarinal lymph nodes identified by ultrasonography. At surgery, lymph nodes were dissected and categorized by location and underwent histopathologic evaluation. Results: 52 patients were ultimately enrolled in the study: Thirty-one had thoracotomy with mediastinal dissection, and 21 had tumors considered unresectable on the basis of preoperative evaluation. Ultrasonography without aspiration biopsy had an overall accuracy of 84% for predicting metastasis to lymph nodes; computed tomography had an accuracy of 49% (P < 0.025). Twenty-four patients had ultrasonography-guided aspiration biopsy; 14 of the 24 were ineligible for surgery because cytology showed malignancy. Results of surgical pathology correlated with negative aspiration cytology results in 9 of 10 patients; the one node with false-negative results contained a 2-mm focus of cancer. The accuracy of ultrasonography-guided aspiration biopsy in diagnosing metastasis to lymph nodes was 96%; the results of this test prompted a change in management in 95% of the patients who had the procedure. Conclusions: Endoscopic ultrasonography alone or with fine-needle aspiration biopsy adds useful diagnostic information in determining metastasis to posterior mediastinal or subcarinal lymph nodes in patients with non-small-cell lung cancer. These procedures are especially helpful in the preoperative evaluation of patients with suspicious contralateral mediastinal or ''bulky'' subcarinal nodes.	INDIANA UNIV, MED CTR, SCH MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis								AIBE T, 1986, SCAND J GASTROENTERO, V21, P164, DOI 10.3109/00365528609091879; ARONCHICK JM, 1990, RADIOL CLIN N AM, V28, P573; CARLIN BW, 1989, AM REV RESPIR DIS, V140, P1800, DOI 10.1164/ajrccm/140.6.1800; CHANG KJ, 1994, GASTROINTEST ENDOSC, V40, P694, DOI 10.1016/S0016-5107(94)70112-1; CHINCHILLI VM, 1983, BIOMETRICS, V39, P333, DOI 10.2307/2531006; CYBULSKY IJ, 1992, ANN THORAC SURG, V54, P533, DOI 10.1016/0003-4975(92)90449-E; DEVITA VT, 1993, IMPORTANT ADV ONCOLO, P259; GALLARDO JFM, 1992, AM REV RESPIR DIS, V146, P1210, DOI 10.1164/ajrccm/146.5_Pt_1.1210; GLAZER GM, 1984, AM J ROENTGENOL, V142, P1101, DOI 10.2214/ajr.142.6.1101; GLAZER GM, 1985, AM J ROENTGENOL, V144, P261, DOI 10.2214/ajr.144.2.261; HARROW E, 1991, CHEST, V100, P1592, DOI 10.1378/chest.100.6.1592; HARROW EM, 1989, CHEST, V96, P1268, DOI 10.1378/chest.96.6.1268; HATTER J, 1994, ANN THORAC SURG, V58, P1738, DOI 10.1016/0003-4975(94)91673-X; HAWES RH, 1994, ENDOSCOPY, V26, P784, DOI 10.1055/s-2007-1009106; HURTER T, 1992, THORAX, V47, P565, DOI 10.1136/thx.47.7.565; Ikenberry S, 1996, GASTROINTEST ENDOSC, V43, P605, DOI 10.1016/S0016-5107(96)81594-X; INGRAM CE, 1989, CLIN RADIOL, V40, P35, DOI 10.1016/S0009-9260(89)80015-7; JOLLY PC, 1991, J THORAC CARDIOV SUR, V102, P266; KOBAYASHI H, 1988, JPN J MED, V27, P17, DOI 10.2169/internalmedicine1962.27.17; KONDO D, 1990, CHEST, V98, P586, DOI 10.1378/chest.98.3.586; LEE N, 1992, WORLD J SURG, V16, P986, DOI 10.1007/BF02067013; LEWIS JW, 1990, ANN THORAC SURG, V49, P591, DOI 10.1016/0003-4975(90)90306-Q; MANN H, 1988, SEMIN ULTRASOUND CT, V9, P40; MARTINI N, 1980, J THORAC CARDIOV SUR, V80, P390; MARTINI N, 1987, SURG CLIN N AM, V67, P1037; MARTINI N, 1987, TREATMENT LUNG TUMOR, P111; MCKENNA RJ, 1985, CHEST, V88, P206, DOI 10.1378/chest.88.2.206; MCLOUD TC, 1992, RADIOLOGY, V182, P319, DOI 10.1148/radiology.182.2.1732943; MERAV AD, 1991, CANCER INVEST, V9, P439, DOI 10.3109/07357909109084642; Midthun David E., 1994, P147; MOUNTAIN CF, 1985, ANN THORAC SURG, V40, P60, DOI 10.1016/S0003-4975(10)61171-X; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; NARUKE T, 1988, ANN THORAC SURG, V46, P603, DOI 10.1016/S0003-4975(10)64717-0; ONO R, 1993, JPN J CLIN ONCOL, V23, P34; PALAZZO L, 1993, ENDOSCOPY, V25, P143, DOI 10.1055/s-2007-1010273; PATTERSON GA, 1987, J THORAC CARDIOV SUR, V94, P679; REX DK, 1991, GASTROINTEST ENDOSC, V37, P465, DOI 10.1016/S0016-5107(91)70781-5; ROSCH T, 1992, GASTROINTEST ENDOSC, V38, P460, DOI 10.1016/S0016-5107(92)70477-5; SANDLER AB, 1992, LUNG, V170, P249, DOI 10.1007/BF00566678; SCHENK DA, 1986, AM REV RESPIR DIS, V134, P146; SCHIEPPATI E, 1958, SURG GYNECOL OBSTET, V107, P243; SCHUDER G, 1991, THORAC CARDIOV SURG, V39, P299, DOI 10.1055/s-2007-1019991; SHIELDS TW, 1993, CLIN CHEST MED, V14, P121; STAPLES CA, 1988, RADIOLOGY, V167, P367, DOI 10.1148/radiology.167.2.3357944; SUGIMACHI K, 1990, SURGERY, V107, P366; TIO TL, 1989, GASTROENTEROLOGY, V96, P1478, DOI 10.1016/0016-5085(89)90515-5; TISI GM, 1983, AM REV RESPIR DIS, V127, P659, DOI 10.1164/arrd.1983.127.5.659; VANRAEMDONCK DE, 1992, ANN THORAC SURG, V54, P999, DOI 10.1016/0003-4975(92)90677-V; VILMANN P, 1993, ENDOSCOPY, V25, P523, DOI 10.1055/s-2007-1010389; WANG KP, 1983, AM REV RESPIR DIS, V127, P344; WANG KP, 1978, AM REV RESPIR DIS, V118, P17; WIERSEMA MJ, 1992, GASTROINTEST ENDOSC, V38, P35, DOI 10.1016/S0016-5107(92)70327-7; WIERSEMA MJ, 1993, GASTROINTEST ENDOSC, V39, P788, DOI 10.1016/S0016-5107(93)70266-7; WIERSEMA MJ, 1993, GASTROINTEST ENDOSC, V39, P429, DOI 10.1016/S0016-5107(93)70122-4	54	222	231	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				604	+		10.7326/0003-4819-127-8_Part_1-199710150-00004	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341058				2022-12-28	WOS:A1997YB41900004
J	Nunn, AJ; Mulder, DW; Kamali, A; Ruberantwari, A; KengeyaKayondo, JF; Whitworth, J				Nunn, AJ; Mulder, DW; Kamali, A; Ruberantwari, A; KengeyaKayondo, JF; Whitworth, J			Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE PROGRESSION; HOMOSEXUAL MEN; AFRICAN CITY; AIDS; IMMUNODEFICIENCY; SURVIVAL; SEX; AGE; SEROCONVERSION; HEMOPHILIACS	Objective: To assess the impact of HIV-1 infection on mortality over five years in a rural Ugandan population. Design: Longitudinal cohort study followed up annually by a house to house census and medical survey. Setting: Rural population in south west Uganda. Subjects: About 10 000 people from 15 villages who were enrolled in 1989-90 or later. Main outcome measures: Number of deaths from all causes, death rates, mortality fraction attributable to HIV-1 infection. Results: Of 9777 people resident in the study area in 1989-90, 8833 (90%) had an unambiguous result on testing for HIV-1 antibody; throughout the period of follow up adult seroprevalence was about 8%. During 35 083 person years of follow up, 459 deaths occurred, 273 in seronegative subjects and 186 in seropositive subjects, corresponding to standardised death rates of 8.1 and 129.3 per 1000 person years. Standardised death rates for adults were 10.4 (95% confidence interval 9.0 to 11.8) and 114.0 (93.2 to 134.8) per 1000 person years respectively, The mortality fraction attributable to HIV-1 infection was 41% for adults and was in excess of 70% for men aged 25-44 and women aged 20-44 years. Median survival from time of enrolment was less than three years in subjects aged 55 years or more who were infected with HIV-1. Life expectancy from birth in the total population resident at any time was estimated to be 42.5 years (41.4 years in men; 43.5 years in women), which compares with 58.3 years (56.5 years in men; 60.5 years in women) in people known to be seronegative. Conclusions: These data confirm that in a rural African population HIV-1 infection is associated with high death rates and a substantial reduction in life expectancy.	UGANDA VIRUS RES INST, MED RES PROGRAMME AIDS, ENTEBBE, UGANDA; UNIV AMSTERDAM, ACAD MED CTR, INST SOCIAL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS; MRC, AIDS PROGRAMME, ENTEBBE, UGANDA	Uganda Virus Research Institute; University of Amsterdam; Academic Medical Center Amsterdam	Nunn, AJ (corresponding author), UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON WC1E 6AU, ENGLAND.			Nunn, Andrew/0000-0002-9158-4595				ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; BLATT SP, 1995, J INFECT DIS, V171, P837, DOI 10.1093/infdis/171.4.837; BORGDORFF MW, 1995, GENITOURIN MED, V71, P212; BULTERYS M, 1993, AIDS, V7, P1269, DOI 10.1097/00002030-199309000-00019; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DONDERO TJ, 1994, LANCET, V343, P989, DOI 10.1016/S0140-6736(94)90120-1; Duesberg P, 1996, BRIT MED J, V312, P210; DUESBERG PH, 1995, LANCET, V346, P1371, DOI 10.1016/S0140-6736(95)92389-6; DUESBERG PH, 1995, GENETICA, V95, P51, DOI 10.1007/BF01435001; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; LEPRI AC, 1994, BRIT MED J, V309, P1537, DOI 10.1136/bmj.309.6968.1537; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; Low N, 1996, GENITOURIN MED, V72, P12; MANN JM, 1986, JAMA-J AM MED ASSOC, V255, P3255, DOI 10.1001/jama.255.23.3255; MARTIN JN, 1995, AM J EPIDEMIOL, V142, P1221, DOI 10.1093/oxfordjournals.aje.a117581; MELNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915, DOI 10.1001/jama.272.24.1915; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; NELSON AM, 1991, AIDS, V5, P583, DOI 10.1097/00002030-199105000-00018; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; NUNN AJ, 1994, METHOD INFORM MED, V33, P170; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; PHILLIPS AN, 1994, AIDS, V8, P831, DOI 10.1097/00002030-199406000-00017; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; Sabin CA, 1996, BMJ-BRIT MED J, V312, P207, DOI 10.1136/bmj.312.7025.207; SCHECHTER MT, 1995, J ACQ IMMUN DEF SYND, V8, P474, DOI 10.1097/00042560-199504120-00007; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011; VEUGELERS PJ, 1994, AM J EPIDEMIOL, V140, P747, DOI 10.1093/oxfordjournals.aje.a117322; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014	33	99	99	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					767	771						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345167	Green Submitted, Green Published			2022-12-28	WOS:A1997XY91100016
J	ONeill, B; Fallon, M				ONeill, B; Fallon, M			ABC of palliative care - Principles of palliative care and pain control	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,WESTERN INFIRM,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND	Beatson Oncology Centre; University of Glasgow	ONeill, B (corresponding author), BRITISH MED ASSOC,BMA HOUSE,LONDON,ENGLAND.			Fallon, Marie/0000-0001-9214-0091					0	45	45	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					801	804		10.1136/bmj.315.7111.801	http://dx.doi.org/10.1136/bmj.315.7111.801			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345176	Green Published			2022-12-28	WOS:A1997XY91100028
J	Rostoker, N; Binderbauer, MW; Monkhorst, HJ				Rostoker, N; Binderbauer, MW; Monkhorst, HJ			Colliding beam fusion reactor	SCIENCE			English	Article							TURBULENCE	Recent results with Tokamak experiments provide insights into the problem of magnetic confinement. They demonstrate how to avoid anomalous transport and thus solve the major problems of Tokamak reactors: size, the production of 14-megaelectron volt neutrons, and maintenance. An alternate confinement system, the field-reversed configuration, confines beams of protons and boron-11. For the proton-boron-11 fusion reaction, the fusion products are all charged particles for which direct conversion is feasible and neutron flux is negligible.	UNIV FLORIDA,DEPT PHYS,GAINESVILLE,FL 32611	State University System of Florida; University of Florida	Rostoker, N (corresponding author), UNIV CALIF IRVINE,DEPT PHYS & ASTRON,IRVINE,CA 92697, USA.							BERK HL, 1987, PHYS FLUIDS, V30, P3548, DOI 10.1063/1.866525; Binderbauer MW, 1996, J PLASMA PHYS, V56, P451, DOI 10.1017/S0022377800019413; Bloch F., 1950, PHYS REV, V77, P305; Budker G. I., 1976, Particle Accelerators, V7, P197; CHEN FF, 1988, INTRO PLASMA PHYSICS, V1, P190; DAWSON J, 1977, ER429SR RES I; Glanz J, 1996, SCIENCE, V274, P1600, DOI 10.1126/science.274.5293.1600; HEIDBRINK WW, 1994, NUCL FUSION, V34, P535, DOI 10.1088/0029-5515/34/4/I07; Manfredi G, 1996, PHYS REV LETT, V76, P4360, DOI 10.1103/PhysRevLett.76.4360; MOIR RW, 1973, NUCL FUSION, V13, P35, DOI 10.1088/0029-5515/13/1/005; MOMOTA H, 1992, FUSION TECHNOL, V21, P2307, DOI 10.13182/FST92-A29724; NAITOU H, 1979, J PHYS SOC JPN, V46, P258, DOI 10.1143/JPSJ.46.258; Perkins LJ, 1997, CURRENT TRENDS IN INTERNATIONAL FUSION RESEARCH, P365; POSTMA H, 1966, PHYS REV LETT, V16, P265, DOI 10.1103/PhysRevLett.16.265; ROSTOKER N, 1993, PHYS REV LETT, V70, P1818, DOI 10.1103/PhysRevLett.70.1818; ROSTOKER N, 1997, COMMENTS PLASMA PHYS, V18, P1; TUSZEWSKI M, 1988, NUCL FUSION, V28, P2033, DOI 10.1088/0029-5515/28/11/008; Yoshikawa K., 1991, FUSION TECHNOL, V19, P870	18	73	103	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1419	1422		10.1126/science.278.5342.1419	http://dx.doi.org/10.1126/science.278.5342.1419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367946				2022-12-28	WOS:A1997YG85800032
J	Schmittdiel, J; Selby, JV; Grumbach, K; Quesenberry, CP				Schmittdiel, J; Selby, JV; Grumbach, K; Quesenberry, CP			Choice of a personal physician and patient satisfaction in a health maintenance organization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED CARE	Context.-Being able to choose one's health care plan has been shown to increase subsequent patient satisfaction with the plan, but it is not known whether choosing one's own primary care physician affects patient satisfaction with the physician. Objective.-To compare satisfaction with care between members of a group-model health maintenance organization (HMO) who chose their primary care physician and members who were assigned a physician. Design.-Cross-sectional mailed survey with response rate of 71.4%. Setting.-A large group-model HMO in northern California. Main Outcome Measure.-Nine questions on satisfaction with the primary care physician. Subjects.-Random sample of HMO members 35 to 85 years of age who were impaneled with a primary care physician. Results.-Among the 10 205 survey respondents, patients who chose their personal physician (n=4748) were 16 to 20 percentage points more likely to rate their satisfaction as ''excellent'' or ''very good'' than patients who were assigned a physician (n=5457) for 9 satisfaction measures (P<.001 for each comparison). The association of choice with satisfaction was not due to physicians with higher patient satisfaction being chosen more often, or to differences in patient demographic or socioeconomic characteristics, health values, or health beliefs, or to differences in physician demographics or specialty. In a logistic regression model that adjusted for all of these characteristics, having chosen one's physician was the single predictor most strongly related to having high overall satisfaction (odds ratio, 2.18, 95% confidence interval, 1.95-2.42). Conclusion.-These results suggest that even in a setting of limited physician choice, the opportunity to select one's personal physician may influence subsequent satisfaction.	KAISER PERMANENTE MED CARE PROGRAM,DIV RES,NO CALIF REG,OAKLAND,CA 94611; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PRIMARY CARE RES CTR,SAN FRANCISCO,CA 94143	Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Grumbach, Kevin/L-9222-2016		AHRQ HHS [HS08269] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BROWN RS, 1994, HMOS AND THE ELDERLY, P13; DAVIS K, 1995, HEALTH AFFAIR, V14, P99, DOI 10.1377/hlthaff.14.2.99; ELSTAD JI, 1994, WOMEN HEALTH, V21, P1, DOI 10.1300/J013v21n04_01; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; Gopalakrishna P, 1992, J Ambul Care Mark, V5, P35; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LOPEZ L, 1995, BUSINESS HLTH    JAN, P22; McBride C A, 1994, Arch Fam Med, V3, P948, DOI 10.1001/archfami.3.11.948; MCCLELLAN AT, IN PRESS PSYCHIAT SE; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; RELMAN AS, 1993, NEW ENGL J MED, V329, P1574, DOI 10.1056/NEJM199311183292113; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; TEMKINGREENER H, 1991, HEALTH SERV RES, V26, P509; WARE JE, 1996, SF12 SCOR SF12 PHYSI; Weyrauch K F, 1996, J Am Board Fam Pract, V9, P31	16	98	98	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1596	1599		10.1001/jama.278.19.1596	http://dx.doi.org/10.1001/jama.278.19.1596			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YF407	9370506				2022-12-28	WOS:A1997YF40700041
J	Giroir, BP; Quint, PA; Barton, P; Kirsch, EA; Kitchen, L; Goldstein, B; Nelson, BJ; Wedel, NI; Carroll, SF; Scannon, PJ				Giroir, BP; Quint, PA; Barton, P; Kirsch, EA; Kitchen, L; Goldstein, B; Nelson, BJ; Wedel, NI; Carroll, SF; Scannon, PJ			Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis	LANCET			English	Article							SEPTICEMIA PROGNOSTIC SCORE; MONOCLONAL-ANTIBODY; CONTROLLED TRIAL; ENDOTOXIN; SHOCK; ACTIVATION; INFECTIONS; CYTOKINES; RBPI(23); DISEASE	Background Meningococcal sepsis remains an important cause of morbidity and mortality. We hypothesised that children with severe meningococcaemia might benefit from inhibition of the inflammatory processes thought responsible for fulminant disease. rBPI(21) is a recombinant, N-terminal fragment of human bactericidal/permeability-increasing protein, which kills meningococci and binds to and clears bacterial endotoxin, these being the primary inducers of the systemic inflammation. The aim; of this study was to determine the safety and kinetics of rBPI(21) in children with severe meningococcaemia and to make a preliminary assessment of clinical outcome, Methods In this open-label, dose-escalation, phase I/II trial in severe meningococcaemia (Glasgow meningococcal prognostic septicaemia score [GMSPS] greater than or equal to 8), 26 patients aged 1-18 years, who had received their first dose of antibiotics no more than 8 hours earlier were given rBPI(21) by infusion at total doses of 1.0, 2.0, and 4.0 mg/kg. Findings The patients bad significantly raised plasma concentrations of bacterial endotoxin and cytokines. Peak and steady state BPI concentrations were comparable with pharmacokinetic data in healthy adults. Ail complications were compatible with the expected pattern for severe meningococcal sepsis. Only one patient died. This outcome was found to compare favourably with a predicted mortality of greater than or equal to 30% by GMSPS, greater than or equal to 15% by plasma endotoxin values, greater than or equal to 28% by plasma interleukin-6 concentrations, 29-49% by severity of coagulopathy, and 20% (11/54) by comparison with recent historical patients consecutively treated in participating centres before this study. Interpretation This, the first clinical trial of rBPI(21), shows that rBPI(21) can be safely administered to children with severe meningococcaemia and that the pharmacokinetics are consistent with patterns seen in healthy adults. Predicted mortality, on the basis of GMSPS, laboratory indices of inflammation and coagulopathy, and historical controls, was for between four and eight deaths. These findings have prompted a phase III randomised trial.	LEGACY EMANUEL HOSP, DEPT PEDIAT, PORTLAND, OR USA; OREGON HLTH SCI UNIV, DEPT PEDIAT, PORTLAND, OR 97201 USA; XOMA CORP, DEPT PEDIAT, BERKELEY, CA 94710 USA	Oregon Health & Science University	Giroir, BP (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PEDIAT, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.							AMMONS WS, 1993, CIRC SHOCK, V41, P176; Bauer RJ, 1996, SHOCK, V5, P91, DOI 10.1097/00024382-199602000-00002; Betz Corradin Sally, 1994, Journal of Infectious Diseases, V169, P105; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; Brandtzaeg P, 1996, J INFECT DIS, V173, P647, DOI 10.1093/infdis/173.3.647; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRANDTZAEG P, 1995, MENINGOCOCCAL DIS, P71; Carnall D, 1996, BRIT MED J, V312, P202; Cartwright K., 1995, MENINGOCOCCAL DIS; DEWINTER RJ, 1995, CIRC SHOCK, V45, P192; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; HAVENS PL, 1989, PEDIATR INFECT DIS J, V8, P8, DOI 10.1097/00006454-198901000-00003; Horwitz AH, 1996, PROTEIN EXPRES PURIF, V8, P28, DOI 10.1006/prep.1996.0071; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Kirsch EA, 1996, PEDIATR INFECT DIS J, V15, P967, DOI 10.1097/00006454-199611000-00009; LAMBERT L, 1996, 36 INT C ANT AG CHEM, P141; LECHNER AJ, 1995, SHOCK, V4, P298, DOI 10.1097/00024382-199510000-00012; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; MCMANUS ML, 1993, CRIT CARE MED, V21, P706, DOI 10.1097/00003246-199305000-00014; OOI CE, 1987, J BIOL CHEM, V262, P14891; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; SHAH A, 1992, CRIT CARE MED, V20, P1495, DOI 10.1097/00003246-199210000-00023; SINCLAIR JF, 1987, LANCET, V2, P38; Stoffel MP, 1996, CLIN EXP IMMUNOL, V104, P54, DOI 10.1046/j.1365-2249.1996.d01-654.x; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; THOMSON A, 1992, CRIT CARE MED, V20, P1495, DOI 10.1097/00003246-199210000-00024; THOMSON APJ, 1991, CRIT CARE MED, V19, P26, DOI 10.1097/00003246-199101000-00010; VANDEUREN M, 1995, J INFECT DIS, V172, P433, DOI 10.1093/infdis/172.2.433; VONDERMOHLEN MAM, 1995, BLOOD, V85, P3437, DOI 10.1182/blood.V85.12.3437.bloodjournal85123437; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930	31	135	142	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	1997	350	9089					1439	1443		10.1016/S0140-6736(97)06468-4	http://dx.doi.org/10.1016/S0140-6736(97)06468-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371168				2022-12-28	WOS:A1997YF95300011
J	Lin, K; Dorman, JB; Rodan, A; Kenyon, C				Lin, K; Dorman, JB; Rodan, A; Kenyon, C			daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans	SCIENCE			English	Article							C-ELEGANS; INTERACTING GENES; DAUER FORMATION; LONGEVITY; SEQUENCE; AGE-1; PATHWAY; HEAD	The wild-type Caenorhabditis elegans nematode ages rapidly, undergoing development, senescence, and death in less than 3 weeks. In contrast, mutants with reduced activity of the gene daf-2 a homolog of the insulin and insulin-like growth factor receptors, age more slowly than normal and live more than twice as long, These mutants are active and fully fertile and have normal metabolic rates. The life-span extension caused by daf-2 mutations requires the activity of the gene daf-16. daf-16 appears to play a unique role in life-span regulation and encodes a member of the hepatocyte nuclear factor 3 (HNF-3)/forkhead family of transcriptional regulators, In humans, insulin down-regulates the expression of certain genes by antagonizing the activity of HNF-3, raising the possibility that aspects of this regulatory system have been conserved.			Lin, K (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Rodan, Aylin/0000-0001-9202-2378	NIA NIH HHS [AG11816] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011816, R01AG011816] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APFELD J, UNPUB; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DORMAN JB, 1995, GENETICS, V141, P1399; Finch CE, 1990, LONGEVITY SENESCENCE; Flakoll Paul, 1996, P121; FRIEDMAN DB, 1988, GENETICS, V118, P75; FROHMAN MA, 1993, METHOD ENZYMOL, V28, P341; GOTTLIEB S, 1994, GENETICS, V137, P107; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kenyon C, 1996, CELL, V84, P501, DOI 10.1016/S0092-8674(00)81024-7; KENYON C, 1997, C ELEGANS, V2, P791; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LARSEN PL, 1995, GENETICS, V139, P1567; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Murakami S, 1996, GENETICS, V143, P1207; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1996, DIABETES MELLITUS, P234; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Plasterk Ronald H.A., 1997, Cold Spring Harbor Monograph Series, V33, P97; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL, 1997, C ELEGANS, P739; Smeal T, 1997, CURR OPIN GENET DEV, V7, P281, DOI 10.1016/S0959-437X(97)80139-6; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Vanfleteren JR, 1996, J EXP ZOOL, V274, P93, DOI 10.1002/(SICI)1097-010X(19960201)274:2&lt;93::AID-JEZ2&gt;3.0.CO;2-8; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VOWELS JJ, 1992, GENETICS, V130, P105; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381	33	1188	1217	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1319	1322		10.1126/science.278.5341.1319	http://dx.doi.org/10.1126/science.278.5341.1319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360933				2022-12-28	WOS:A1997YG04300052
J	Anderson, DM; Schneewind, O				Anderson, DM; Schneewind, O			A mRNA signal for the type III secretion of Yop proteins by Yersinia enterocolitica	SCIENCE			English	Article							TARGET-CELL CONTACT; GENETIC-ANALYSIS; TRANSPOSON TN5; EXPORT; TRANSLOCATION; MACROPHAGES; EXPRESSION; BACTERIAL; CYTOSOL; DOMAINS	Pathogenic Yersinia species have a specialized secretion system (type III) to target cytotoxic Yap proteins during infection. The signals of YopE and YopN sufficient for the secretion of translational reporter fusions were mapped to the first 15 codons, No common amino acid or peptide sequence could be identified among the secretion signals. Systematic mutagenesis of the secretion signal yielded mutants defective in Yop translation; however, no point mutants could be identified that specifically abolished secretion. Frameshift mutations that completely altered the peptide sequences of these signals also failed to prevent secretion. Thus, the signal that leads to the type III secretion of Yop proteins appears to be encoded in their messenger RNA rather than the peptide sequence.	UNIV CALIF LOS ANGELES,INST MOL BIOL,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles					NIAID NIH HHS [AI 07323] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; Boland A, 1996, EMBO J, V15, P5191, DOI 10.1002/j.1460-2075.1996.tb00904.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cheng LW, 1997, MOL MICROBIOL, V24, P757, DOI 10.1046/j.1365-2958.1997.3831750.x; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; PORTNOY DA, 1981, INFECT IMMUN, V31, P775, DOI 10.1128/IAI.31.2.775-782.1981; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REISS B, 1984, EMBO J, V3, P3317, DOI 10.1002/j.1460-2075.1984.tb02297.x; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; RUSSEL M, 1994, SCIENCE, V265, P612, DOI 10.1126/science.8036510; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; Schesser K, 1996, J BACTERIOL, V178, P7227, DOI 10.1128/jb.178.24.7227-7233.1996; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	23	257	265	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1140	1143		10.1126/science.278.5340.1140	http://dx.doi.org/10.1126/science.278.5340.1140			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353199				2022-12-28	WOS:A1997YE65200058
J	Daaka, Y; Luttrell, LM; Lefkowitz, RJ				Daaka, Y; Luttrell, LM; Lefkowitz, RJ			Switching of the coupling of the beta(2)-adrenergic receptor to different G proteins by protein kinase A	NATURE			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-ADRENERGIC-RECEPTOR; MAP KINASE; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT ACTIVATION; SIGNALING PATHWAYS; PERTUSSIS-TOXIN; TYROSINE-KINASE; GAMMA-SUBUNITS; FIBROBLASTS	Many of the G-grotein-coupled receptors for hormones that bind to the cell surface can signal to the interior of the cell through several different classes of G protein(1-4). Far example, although most of the actions of the prototype beta(2)-adrenergic receptor are mediated through G(s) proteins and thr cyclic-AMP-dependent protein kinase (PKA) system(5,6), beta-adrenergis receptors can also couple to G(i) proteins(1,2). Here we investigate the mechanism that controls the specificity of this coupling. We show that in HEK293 cells, stimulation of mitogen-activated protein (MAP) kinase by the beta(2)-adrenergic receptor is mediated by the beta gamma subunits of pertussis-toxin-sensitive G proteins through a pathway involving the non-receptor tyrosine kinase c-Src and the G protein Ras, Activation of this pathway by the beta(2)-adrenergic receptor requires that the receptor be phosphorylated by PKA because it is blocked by H-89, an inhibitor of PKA. Additionally, a mutant of the receptor, which lacks the sites normally phosphorylated by PKA, can activate adenylyl cyclase(5), the enzyme that generates cAMP, but not MAP kinase. Our results demonstrate that a mechanism previously shown to mediate uncoupling of the beta(2)-adrenergic receptor from G(s) and thus heterologous desensitization(7) (PKA-mediated receptor phosphorylation), also serves to 'switch' coupling of this receptor from G(s) to G(i) and initiate a new set of signalling events.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949				ABRAMSON SN, 1988, BIOCHEM PHARMACOL, V37, P4289, DOI 10.1016/0006-2952(88)90609-0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; FAURE M, 1994, J BIOL CHEM, V269, P7851; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; HARWOOD SJ, 1996, BIOCHEM BIOPH RES CO, V224, P734; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; STRULOVICI B, 1984, SCIENCE, V225, P837, DOI 10.1126/science.6089331; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; XIAO RP, 1995, MOL PHARMACOL, V47, P322	28	1027	1045	0	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					88	91		10.1038/36362	http://dx.doi.org/10.1038/36362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363896				2022-12-28	WOS:A1997YE47700058
J	Fenczik, CA; Sethi, T; Ramos, JW; Hughes, PE; Ginsberg, MH				Fenczik, CA; Sethi, T; Ramos, JW; Hughes, PE; Ginsberg, MH			Complementation of dominant suppression implicates CD98 in integrin activation	NATURE			English	Article							OUT SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; MOLECULAR-CLONING; CELL-ADHESION; RECEPTOR; PROTEINS; BINDING; EXPRESSION; MONOCYTES; SURFACE	The integrin family of adhesion receptors are involved in cell growth, migration and tumour metastasis(1). Integrins are heterodimeric proteins composed of an alpha and a beta subunit, each with a large extracellular, a single transmembrane, and a short cytoplasmic domain. The dynamic regulation of integrin affinity for ligands in response to cellular signals is central to integrin function(2). This process is energy dependent and is mediated through integrin cytoplasmic domains(3). However, the cellular machinery regulating integrin affinity remains poorly understood. Here we describe a genetic strategy to disentangle integrin signalling pathways. Dominant suppression occurs when overexpression of isolated integrin beta(1) cytoplasmic domains blocks integrin activation. Proteins involved in integrin signalling were identified by their capacity to complement dominant suppression in an expression cloning scheme. CD98, an early T-cell activation antigen that associates with functional integrins(4), was found to regulate integrin activation. Furthermore, antibody-mediated crosslinking of CD98 stimulated beta(1) integrin-dependent cell adhesion. These data indicate that CD98 is involved in regulating integrin affinity, and validate an unbiased genetic approach to analysing integrin signalling pathways.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; UNIV EDINBURGH, SCH MED, DEPT RESP MED, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	Scripps Research Institute; University of Edinburgh			Ramos, Joe/G-4074-2010	Ramos, Joe/0000-0002-9708-2115	NCI NIH HHS [F32 CA074529, F32 CA074529-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA074529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHEN YP, 1994, J BIOL CHEM, V269, P18307; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HIRASAWA M, 1994, BRIT J CANCER, V70, P466, DOI 10.1038/bjc.1994.329; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INDIG FE, IN PRESS BIOCH J, V326; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MANNION BA, UNPUB FUNCTIONALLY A; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; OHTA H, 1994, EMBO J, V13, P2044, DOI 10.1002/j.1460-2075.1994.tb06479.x; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; [No title captured]	25	242	244	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					81	85		10.1038/36349	http://dx.doi.org/10.1038/36349			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363894				2022-12-28	WOS:A1997YE47700056
J	Braver, ER; Ferguson, SA; Greene, MA; Lund, AK				Braver, ER; Ferguson, SA; Greene, MA; Lund, AK			Reductions in deaths in frontal crashes among right front passengers in vehicles equipped with passenger air bags	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEAT-BELT USE; DRIVER FATALITIES; USE LAW; ENFORCEMENT; PUBLICITY	Context.-Virtually all new cars now are equipped with passenger air bags. Determining whether passenger air bags are saving lives is important, particularly because passenger air bags have caused some deaths among children and adults. Objective.-To assess the effectiveness of passenger air bags in reducing the risk of death in frontal crashes for right front passengers. Design.-Air bags are designed to protect occupants in frontal crashes. Using Fatality Analysis Reporting System data for calendar years 1992 through 1995, the relative frequency of right front passenger deaths in frontal vs nonfrontal fatal crashes was compared for cars with dual air bags and for cars with driver-only air bags. Main Outcome Measures.-Odds of right front passengers dying in frontal compared with nonfrontal fatal crashes were computed for 1992 through 1995 model year cars with dual air bags and for cars with driver-only air bags. Percentage reductions in right front passenger deaths in dual air bag vehicles were estimated. Results.-Right front passenger fatalities were 18% lower than expected in frontal crashes of cars with dual air bags and 11% lower in all crashes. An estimated 73 fewer than expected right front passengers died in 1992 through 1995 model cars with dual air bags during 1992 through 1995. The risk of frontal crash death for right front passengers in cars with dual air bags was reduced 14% among those reported to be using belts and 23% among belt nonusers. Children younger than 10 years in cars with dual air bags had a 34% increased risk of dying in frontal crashes. Conclusions.-Passenger air bags were associated with substantial reductions in fatalities among right front passengers in frontal crashes. However, more children are being killed than are being saved by air bags. Immediate countermeasures to reduce the dangers of air bags to children and adults are suggested.			Braver, ER (corresponding author), INSURANCE INST HIGHWAY SAFETY,1005 N GLEBE RD,ARLINGTON,VA 22201, USA.		Braver, Elisa/AAT-4631-2020					BRAVER ER, 1997, RISK DEATH CHILD PAS; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P1073; FERGUSON SA, 1996, 3 INT S SOPH CAR OCC; FERGUSON SA, 1995, DRIVER FATAILITIES 1; GREENBERG L, 1996, DOT PUBLICATION; *HIGHW LOSS DAT I, 1996, VIND 96 COMP PROGR V; *INS I HIGHW SAF, 1995, STATUS REP, V30, P2; KAHANE C, 1996, FATALITY REDUCTION A; LUND AK, 1995, J TRAUMA, V38, P469, DOI 10.1097/00005373-199504000-00001; LUND AK, 1989, J CRIM JUST, V17, P329, DOI 10.1016/0047-2352(89)90045-7; *NAT HIGHW TRAFF S, 1997, AIR BAG FACT SHEET; *NAT HIGHW TRAFF S, 1996, FAT AN REP SYST 1992; *NAT HIGHW TRAFF S, 1997, SPEC CRASH INT REP; ONEILL B, 1997, BESTS REV P C, V98, P88; WELLS JAK, 1992, J SAFETY RES, V23, P63, DOI 10.1016/0022-4375(92)90022-2; Williams AF, 1996, J SAFETY RES, V27, P33, DOI 10.1016/0022-4375(95)00027-5; WILLIAMS AF, 1987, ACCIDENT ANAL PREV, V19, P243, DOI 10.1016/0001-4575(87)90059-5; WILLIAMS CB, 1991, CURR OPIN GASTROEN, V7, P55, DOI 10.1097/00001574-199102000-00011; ZADOR PL, 1993, AM J PUBLIC HEALTH, V83, P661, DOI 10.2105/AJPH.83.5.661; 1997, FED REG         0319, V62, P12960	20	92	92	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1437	1439		10.1001/jama.278.17.1437	http://dx.doi.org/10.1001/jama.278.17.1437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC917	9356003				2022-12-28	WOS:A1997YC91700031
J	Dogterom, M; Yurke, B				Dogterom, M; Yurke, B			Measurement of the force-velocity relation for growing microtubules	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; THERMAL FLUCTUATIONS; DYNAMIC INSTABILITY; FLEXURAL RIGIDITY; VARIABLE RATES; CELL MOTILITY; MOLECULE; DEPOLYMERIZATION; DRIVEN; MOTOR	Forces generated by protein polymerization are important for various forms of cellular motility. Assembling microtubules, for instance, are believed to exert pushing forces on chromosomes during mitosis. The force that a single microtubule can generate was measured by attaching microtubules to a substrate at one end and causing them lo push against a microfabricated rigid barrier at the other end. The subsequent buckling of the microtubules was analyzed to determine both the force on each microtubule end and the growth velocity. The growth velocity decreased from 1.2 micrometers per minute at zero force to 0.2 micrometer per minute at forces of 3 to 4 piconewtons. The force-velocity relation fits well to a decaying exponential, in agreement with theoretical models, but the rate of decay is faster than predicted.	AT&T BELL LABS, LUCENT TECHNOL, MURRAY HILL, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs								[Anonymous], 1987, LINEAR AGGREGATION T; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; DOGTEROM M, UNPUB; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Elbaum M, 1996, PHYS REV LETT, V76, P4078, DOI 10.1103/PhysRevLett.76.4078; Felgner H, 1996, J CELL SCI, V109, P509; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Fygenson DK, 1997, PHYS REV E, V55, P850, DOI 10.1103/PhysRevE.55.850; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; Gittes F, 1996, BIOPHYS J, V70, P418, DOI 10.1016/S0006-3495(96)79585-1; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Holy TE, 1997, P NATL ACAD SCI USA, V94, P6228, DOI 10.1073/pnas.94.12.6228; Hotani H, 1990, Adv Biophys, V26, P135, DOI 10.1016/0065-227X(90)90010-Q; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1992, NATURE, V359, P533, DOI 10.1038/359533a0; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; INOUE S, 1967, J GEN PHYSIOL, V50, P529; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; KURZ JC, 1995, BIOCHEMISTRY-US, V34, P13374, DOI 10.1021/bi00041a014; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; SVOBODA K, 1994, CELL, V77, P733; VENLER P, 1994, J BIOL CHEM, V169, P13353; VENLER P, 1995, J BIOL CHEM, V270, P17056; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161	35	395	401	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					856	860		10.1126/science.278.5339.856	http://dx.doi.org/10.1126/science.278.5339.856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346483				2022-12-28	WOS:A1997YD47900045
J	Webb, BL; Cox, MM; Inman, RB				Webb, BL; Cox, MM; Inman, RB			Recombinational DNA repair: The RecF and RecR proteins limit the extension of RecA filaments beyond single-strand DNA gaps	CELL			English	Article							ESCHERICHIA-COLI RECF; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; BINDING-PROTEIN; NUCLEOSIDE TRIPHOSPHATE; DUPLEX DNA; EXCHANGE; PURIFICATION; COMPLEXES; PATHWAY	In the presence of both the RecF and RecR proteins, RecA filament extension from a single strand gap into adjoining duplex DNA is attenuated. RecR protein alone has no effect, and RecF protein alone has a reduced activity. The RecFR complexes bind randomly, primarily to the duplex regions of the DNA, and the extension of the RecA filament is halted at the first complex encountered. A very slow lengthening of RecA filaments observed in the presence of RecFR is virtually eliminated when RecF is replaced with an RecF mutant protein that does not hydrolyze ATP. These observations are incorporated into an expanded model for the functions of RecF, RecO, and RecR proteins in the early stages of postreplication DNA repair.			Webb, BL (corresponding author), UNIV WISCONSIN,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725, R01GM014711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07215, GM14711, GM52725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO JC, 1993, J BIOL CHEM, V268, P1424; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; Hegde SP, 1996, J BACTERIOL, V178, P184, DOI 10.1128/jb.178.1.184-190.1996; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; JAIN SK, 1994, J BIOL CHEM, V269, P20653; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kogoma T, 1997, P NATL ACAD SCI USA, V94, P3483, DOI 10.1073/pnas.94.8.3483; KOLODNER R, 1985, J BACTERIOL, V163, P1060, DOI 10.1128/JB.163.3.1060-1066.1985; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kubista M, 1996, BIOLOGICAL STRUCTURE AND DYNAMICS, VOL 1, P49; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUISIDELUCA C, 1994, J MOL BIOL, V236, P124, DOI 10.1006/jmbi.1994.1123; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; MADIRAJU MVVS, 1992, J BACTERIOL, V174, P7705, DOI 10.1128/JB.174.23.7705-7710.1992; MADIRAJU MVVS, 1991, NUCLEIC ACIDS RES, V19, P6295, DOI 10.1093/nar/19.22.6295; MAHDI AA, 1989, MOL GEN GENET, V216, P503, DOI 10.1007/BF00334397; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sandler SJ, 1996, MOL MICROBIOL, V19, P871, DOI 10.1046/j.1365-2958.1996.429959.x; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; SAWITZKE JA, 1994, J BACTERIOL, V176, P6730, DOI 10.1128/JB.176.21.6730-6737.1994; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SINDEN RR, 1978, J BACTERIOL, V136, P538, DOI 10.1128/JB.136.2.538-547.1978; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH GR, 1989, GENOME, V31, P520, DOI 10.1139/g89-100; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; TSENG YC, 1994, MUTAT RES, V315, P1; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; Webb BL, 1995, J BIOL CHEM, V270, P31397, DOI 10.1074/jbc.270.52.31397; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0	57	155	169	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					347	356		10.1016/S0092-8674(00)80418-3	http://dx.doi.org/10.1016/S0092-8674(00)80418-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363943	Bronze			2022-12-28	WOS:A1997YD94100008
J	Supp, DM; Witte, DP; Potter, SS; Brueckner, M				Supp, DM; Witte, DP; Potter, SS; Brueckner, M			Mutation of an axonemal dynein affects left right asymmetry in inversus viscerum mice	NATURE			English	Article							SITUS-INVERSUS; INSERTIONAL MUTATION; MOUSE; EXPRESSION; GENE; RAT; IDENTIFICATION; MICROTUBULES; SEQUENCES; LEGLESS	The development of characteristic visceral asymmetries along the left-right (LR) axis in an initially bilaterally symmetrical embryo is an essential feature of vertebrate patterning. The allelic mouse mutations inversus viscerum (iv)(1,2) and legless (lgl)(3,4) produce LR inversion, or situs inversus, in half of live-born homozygotes, This suggests that the iv gene product drives correct LR determination, and in its absence this process is randomized(2), These mutations provide tools for studying the development of LR-handed asymmetry and provide mouse models of human lateralization defects. At the molecular level, the normally LR asymmetric expression patterns of nodal(5) and lefty(6) are randomized in iv/iv embryos, suggesting that iv functions early in the genetic hierarchy of LR specification, Here we report the positional cloning of an axonemal dynein heavy-chain gene, left/right-dynein (lrd), that is mutated in both lgl and iv, lrd is expressed in the node of the embryo at embryonic day 7.5, consistent with its having a role in LR development(7). Our findings indicate that dynein, a microtubule-based motor, is involved in the determination of LR-handed asymmetry and provide insight into the early molecular mechanisms of this process.	YALE UNIV, SCH MED, DEPT PEDIAT CARDIOL, NEW HAVEN, CT 06520 USA; CHILDRENS HOSP RES FDN, DIV DEV BIOL, CINCINNATI, OH 45229 USA; CHILDRENS HOSP RES FDN, DIV PATHOL, CINCINNATI, OH 45229 USA	Yale University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation			Supp, Dorothy/ABQ-7999-2022	Supp, Dorothy/0000-0002-2429-6630	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024517] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD024517] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AFZELIUS B A, 1976, Science (Washington D C), V193, P317; Afzelius BA, 1995, INT J DEV BIOL, V39, P839; Andrews KL, 1996, MOL BIOL CELL, V7, P71, DOI 10.1091/mbc.7.1.71; ASAI DJ, 1995, CELL MOTIL CYTOSKEL, V32, P129, DOI 10.1002/cm.970320212; ASAI DJ, 1994, J CELL SCI, V107, P839; Bellomo D, 1996, DEV DYNAM, V205, P471, DOI 10.1002/(SICI)1097-0177(199604)205:4<471::AID-AJA10>3.0.CO;2-4; BROWN NA, 1991, CIBA F SYMP, V162, P182; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; DANOS MC, 1995, DEVELOPMENT, V121, P1467; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; Hummel K. P., 1959, Journal of Heredity, V50, P9; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Jesuthasan S, 1997, CURR BIOL, V7, P31, DOI 10.1016/S0960-9822(06)00025-X; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MCGRATH J, 1992, GENOMICS, V14, P643, DOI 10.1016/S0888-7543(05)80163-6; MCNEISH JD, 1990, J EXP ZOOL, V253, P151, DOI 10.1002/jez.1402530205; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SINGH G, 1991, GENE DEV, V5, P2245, DOI 10.1101/gad.5.12a.2245; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; TANAKA Y, 1995, J CELL SCI, V108, P1883; THEURKAUF WE, 1994, DEV BIOL, V165, P352, DOI 10.1006/dbio.1994.1258; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; Vaughan KT, 1996, GENOMICS, V36, P29, DOI 10.1006/geno.1996.0422	28	422	427	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	1997	389	6654					963	966		10.1038/40140	http://dx.doi.org/10.1038/40140			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353118	Green Accepted			2022-12-28	WOS:A1997YD29900054
J	Schiffman, SS				Schiffman, SS			Taste and smell losses in normal aging and disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							OLFACTORY DYSFUNCTION; ALZHEIMERS-DISEASE; BITTER TASTE; FOOD-INTAKE; SALT TASTE; AGE; SENSITIVITY; SODIUM; SATIETY; HUMANS	Objective.-To review the scientific literature on the alterations in the senses of taste and smell in the elderly, including causes, diagnosis, prognosis, and treatment. Data Sources.-Original reports and reviews obtained through MEDLINE searches from 1966 through June 1997 using the MeSH headings of '''taste,'' ''taste buds,'' ''qaste disorders,'' ''taste thresholds,'' ''smell,'' ''odors,'' ''aged,'' and ''aging.'' Articles frequently cited in reference lists were also included. Study Selection.-All articles were reviewed, tabulated, and summarized. Data Extraction.-Criteria for extraction included data quality and validity, statistical treatment of the data, venue of publication, and relevance to clinical care. Conclusion.-Losses of taste and smell are common in the elderly and result from normal aging, certain disease states (especially Alzheimer disease), medications, surgical interventions, and environmental exposure. Deficits in these chemical senses cannot only reduce the pleasure and comfort from food, but represent risk factors for nutritional and immune deficiencies as well as adherence to specific dietary regimens. Chemosensory decrements can lead to food poisoning or overexposure to environmentally hazardous chemicals that are otherwise detectable by taste and smell. Use of flavor-enhanced food can increase enjoyment of food and have a positive effect on food intake and immune status.			Schiffman, SS (corresponding author), DUKE UNIV, MED CTR, DEPT PSYCHIAT, BOX 3259, DURHAM, NC 27710 USA.				NATIONAL INSTITUTE ON AGING [R37AG000443, R01AG000443] Funding Source: NIH RePORTER; NIA NIH HHS [AG00443] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM AC FAM PHYS, 1995, PROC SKILLS POS PAP, P1; BARTOSHUK L, 1987, ANN NY ACAD SCI, V510, P166; Bartoshuk LM, 1996, NEUROSCI BIOBEHAV R, V20, P79, DOI 10.1016/0149-7634(95)00042-D; BEAUCHAMP GK, 1990, AM J CLIN NUTR, V51, P881, DOI 10.1093/ajcn/51.5.881; BELL IR, 1993, ARCH ENVIRON HEALTH, V48, P6, DOI 10.1080/00039896.1993.9938387; BELLISLE F, 1991, PHYSIOL BEHAV, V49, P869, DOI 10.1016/0031-9384(91)90196-U; BOOTH DA, 1985, ANN NY ACAD SCI, V443, P22, DOI 10.1111/j.1749-6632.1985.tb27061.x; BRADLEY RM, 1988, GERODONTICS, V4, P244; Breer Heinz, 1994, Seminars in Cell Biology, V5, P25, DOI 10.1006/scel.1994.1004; Breslin PAS, 1995, CHEM SENSES, V20, P609, DOI 10.1093/chemse/20.6.609; CAIN WS, 1989, ANN NY ACAD SCI, V561, P29; CAIN WS, 1991, J EXP PSYCHOL HUMAN, V17, P382, DOI 10.1037/0096-1523.17.2.382; COWART B J, 1989, Chemical Senses, V14, P692; COWART BJ, 1994, PHYSIOL BEHAV, V56, P1237, DOI 10.1016/0031-9384(94)90371-9; DOTY RL, 1991, ANN NY ACAD SCI, V640, P20; DOTY RL, 1989, ANN NEUROL, V25, P166, DOI 10.1002/ana.410250210; DOTY RL, 1984, SCIENCE, V226, P1441, DOI 10.1126/science.6505700; Drewnowski A, 1996, J AM DIET ASSOC, V96, P471, DOI 10.1016/S0002-8223(96)00131-9; DREWNOWSKI A, 1995, AM J CLIN NUTR, V61, P1206, DOI 10.1093/ajcn/61.6.1206; DUFFY VB, 1995, J AM DIET ASSOC, V95, P879, DOI 10.1016/S0002-8223(95)00244-8; EGBERT AM, 1993, POSTGRAD MED, V94, P199, DOI 10.1080/00325481.1993.11945740; ESPAT NJ, 1994, SURG ONCOL, V3, P255, DOI 10.1016/0960-7404(94)90027-2; FRANK ME, 1992, CRIT REV ORAL BIOL M, V3, P371, DOI 10.1177/10454411920030040401; Friedman M I, 1989, Bol Asoc Med P R, V81, P111; GIDUCK SA, 1987, J NUTR, V117, P1191, DOI 10.1093/jn/117.7.1191; GILMORE MM, 1989, PERCEPT PSYCHOPHYS, V46, P555, DOI 10.3758/BF03208152; GIZA BK, 1992, BRAIN RES BULL, V28, P637, DOI 10.1016/0361-9230(92)90116-F; GLENN JF, 1976, PHYSIOL BEHAV, V16, P561, DOI 10.1016/0031-9384(76)90216-X; Green BG, 1996, TRENDS FOOD SCI TECH, V7, P415, DOI 10.1016/S0924-2244(96)10043-1; Hetherington MM, 1996, NEUROSCI BIOBEHAV R, V20, P113, DOI 10.1016/0149-7634(95)00048-J; Hofer D, 1996, P NATL ACAD SCI USA, V93, P6631, DOI 10.1073/pnas.93.13.6631; KASPER J, 1982, DHHS PUBLICATION PHS; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; KLINE DW, 1994, EXP AGING RES, V20, P11, DOI 10.1080/03610739408253950; LEOPOLD DA, 1989, OTOLARYNG HEAD NECK, V100, P287, DOI 10.1177/019459988910000406; Lewis I K, 1993, Spec Care Dentist, V13, P171, DOI 10.1111/j.1754-4505.1993.tb01470.x; MATSUDA T, 1995, CHEM SENSES, V20, P283, DOI 10.1093/chemse/20.3.283; MATTES RD, 1994, J AM DIET ASSOC, V94, P50, DOI 10.1016/0002-8223(94)92041-9; *MED EC, 1995, PHYSL DESK REF; Mistretta C M, 1984, Gerodontology, V3, P131, DOI 10.1111/j.1741-2358.1984.tb00364.x; MORRISON EE, 1992, MICROSC RES TECHNIQ, V23, P49, DOI 10.1002/jemt.1070230105; MOSKOWITZ HW, 1975, SCIENCE, V190, P1217, DOI 10.1126/science.1198109; MURPHY C, 1983, J GERONTOL, V38, P217, DOI 10.1093/geronj/38.2.217; MURPHY C, 1993, CRIT REV FOOD SCI, V33, P3, DOI 10.1080/10408399309527607; NORDIN S, 1995, J GERONTOL B-PSYCHOL, V50, pP187, DOI 10.1093/geronb/50B.4.P187; Nordin S, 1996, LARYNGOSCOPE, V106, P739, DOI 10.1097/00005537-199606000-00014; PELCHAT M, 1994, APPETITE, V23, P193, DOI 10.1006/appe.1994.1046; PLATASALAMAN CR, 1992, J NEUROPHYSIOL, V67, P1552, DOI 10.1152/jn.1992.67.6.1552; PRITCHARD TC, 1991, SMELL TASTE HLTH DIS, P109; ROLLS BJ, 1993, CRIT REV FOOD SCI, V33, P39, DOI 10.1080/10408399309527610; SCHIFFMAN S, 1979, SENSORY SYSTEMS COMM, V10, P227; Schiffman S., 1991, SMELL TASTE HLTH DIS, P845; Schiffman S. S., 1993, MECH TASTE TRANSDUCT, P395; SCHIFFMAN SS, 1990, NEUROBIOL AGING, V11, P597, DOI 10.1016/0197-4580(90)90023-S; SCHIFFMAN SS, 1981, NEUROBIOL AGING, V2, P173, DOI 10.1016/0197-4580(81)90018-X; SCHIFFMAN SS, 1993, PHYSIOL BEHAV, V53, P395, DOI 10.1016/0031-9384(93)90224-4; SCHIFFMAN SS, 1983, NEW ENGL J MED, V308, P1275; SCHIFFMAN SS, 1983, NEW ENGL J MED, V308, P1337; SCHIFFMAN SS, 1990, CHEM SENSES, V15, P671, DOI 10.1093/chemse/15.6.671; SCHIFFMAN SS, 1980, NEUROBIOL AGING, V1, P81, DOI 10.1016/0197-4580(80)90028-7; SCHIFFMAN SS, 1992, BETTER NUTR 21 CENTU, P149; SCHIFFMAN SS, 1994, CHEM SENSES APPETITE, V4, P341; SCHIFFMAN SS, 1984, NUTRITION GERONTOLOG, P43; Schiffman SS, 1996, AGE NUTR, V7, P106; Schiffman SS, 1992, PENNINGTON CTR NUTRI, V2, P293; SCHIFFMAN SS, 1994, NUTR SUSTAINABLE ENV, P728; Schiffman Susan S., 1992, Chemical Senses, V17, P693; Scott T R, 1992, World Rev Nutr Diet, V67, P1; Scott T. R., 1995, Neurobiology (Budapest), V3, P281; SERBY M, 1991, AM J PSYCHIAT, V148, P357; SHAFFER SE, 1994, PHYSIOL BEHAV, V55, P979, DOI 10.1016/0031-9384(94)90377-8; SNOW JB, 1991, SMELL TASTE HLTH DIS, P463; SPIELMAN AI, 1992, SOC GEN PHY, V47, P307; STEVENS JC, 1995, CHEM SENSES, V20, P451, DOI 10.1093/chemse/20.4.451; STEVENS JC, 1982, NEUROBIOL AGING, V3, P125, DOI 10.1016/0197-4580(82)90008-2; STEVENS JC, 1985, CHEM SENSES, V10, P517, DOI 10.1093/chemse/10.4.517; Sullivan Susan L., 1994, Progress in Clinical and Biological Research, V390, P75; Teff KL, 1996, PHYSIOL BEHAV, V60, P567, DOI 10.1016/S0031-9384(96)80033-3; *US BUR CENS, 1996, STAT ABSTR US, P15; VANBUSKIRK RL, 1977, BRAIN RES, V135, P287, DOI 10.1016/0006-8993(77)91032-0; WARWICK ZS, 1993, PHYSIOL BEHAV, V53, P553, DOI 10.1016/0031-9384(93)90153-7; WARWICK ZS, 1991, PHYSIOL BEHAV, V50, P465, DOI 10.1016/0031-9384(91)90531-R; WATTENBERG BJ, 1976, STAT HIST US COLONIA, P15; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; WYSOCKI CJ, 1989, ANN NY ACAD SCI, V561, P12, DOI 10.1111/j.1749-6632.1989.tb20966.x; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171	86	344	361	1	63	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1357	1362		10.1001/jama.278.16.1357	http://dx.doi.org/10.1001/jama.278.16.1357			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343468				2022-12-28	WOS:A1997YA90500038
J	Mulley, GP				Mulley, GP			Myths of ageing	LANCET			English	Article							OLDER-PEOPLE				Mulley, GP (corresponding author), ST JAMES UNIV HOSP, ELDERLY SERV DIRECTORATE, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND.							Agate J., 1970, PRACTICE GERIATRICS; Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; Ebrahim S, 1996, BRIT MED J, V313, P610; Forbes A, 1996, BRIT MED J, V313, P352, DOI 10.1136/bmj.313.7053.352; MANN E, 1996, PSYCHIAT ELDERLY, P89; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; MANTON KG, 1995, J GERONTOL, V50, P5104; Markowe H, 1994, Health Trends, V26, P98; *MRC, 1994, HLTH UK ELD PEOPL MR; RITCHIE K, 1995, LANCET, V346, P931, DOI 10.1016/S0140-6736(95)91556-7; Starr JM, 1997, AGE AGEING, V26, P295, DOI 10.1093/ageing/26.4.295; Travers AF, 1996, BRIT MED J, V313, P482; VERHAEGHEN P, 1993, J GERONTOL, V48, pP157, DOI 10.1093/geronj/48.4.P157; WYSOCKI CJ, 1989, ANN NY ACAD SCI, V561, P12, DOI 10.1111/j.1749-6632.1989.tb20966.x; Young J, 1996, BRIT MED J, V313, P677	15	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	1997	350	9085					1160	1161		10.1016/S0140-6736(97)08296-2	http://dx.doi.org/10.1016/S0140-6736(97)08296-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343517				2022-12-28	WOS:A1997YB19900045
J	Whitehead, M; Evandrou, M; Haglund, B; Diderichsen, F				Whitehead, M; Evandrou, M; Haglund, B; Diderichsen, F			As the health divide widens in Sweden and Britain, what's happening to access to care?	BRITISH MEDICAL JOURNAL			English	Article							EQUITY		KAROLINSKA INST,DEPT PUBL HLTH SCI,S-17283 SUNDBYBERG,SWEDEN; KINGS FUND INST,LONDON W1M 0AN,ENGLAND; NATL BOARD HLTH & WELF,CTR EPIDEMIOL,STOCKHOLM,SWEDEN	Karolinska Institutet; National Board of Health & Welfare			Diderichsen, Finn/P-4654-2019	Diderichsen, Finn/0000-0002-9998-4972				ANDERSEN R, 1970, RES SERIES CTR HLTH, V27; Arber S, 1997, SOC SCI MED, V44, P773, DOI 10.1016/S0277-9536(96)00185-2; Bartley M, 1996, BRIT MED J, V313, P445; BLAXTER M, 1984, BRIT MED J, V288, P1963, DOI 10.1136/bmj.288.6435.1963; BLAXTER M, 1996, HLTH SOCIAL ORG, P32; DAHLGREN G, 1984, HALSOPOLITISKA MAL B, P40; DIDERICHSEN F, 1995, HEALTH POLICY, V32, P141, DOI 10.1016/0168-8510(95)00732-8; Diderichsen F, 1997, INT J EPIDEMIOL, V26, P782, DOI 10.1093/ije/26.4.782; DREVER F, 1996, POPUL TRENDS, V86, P15; EVANDROU M, 1992, J SOC POLICY, V21, P489, DOI 10.1017/S0047279400020158; EVANDROU M, 1996, BRIT SOC POP STUD AN; HAGLUND B, 1994, VARD PA LIKA VILLKOR, P3; Harding S, 1995, Popul Trends, P31; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; HAYNES R, 1991, SOC SCI MED, V33, P361, DOI 10.1016/0277-9536(91)90317-6; LEGRAND J, 1978, ECONOMICA, V45, P125, DOI 10.2307/2553499; LUNDBERG O, 1992, INT J HLTH SCI, V3, P167; Macintyre S., 1989, HLTH INEQUALITIES EU, P317; MAJEED FA, 1994, BMJ-BRIT MED J, V308, P1426, DOI 10.1136/bmj.308.6941.1426; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; *NAT BOARD HLTH WE, 1995, WELF PUBL HLTH SWED; ODONNELL O, 1991, J HEALTH ECON, V10, P1, DOI 10.1016/0167-6296(91)90014-E; *ONS, 1996, DAT AN ANN ABSTR STA; *ORG EC COOP DEV, 1996, HLTH DAT 1996; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; Whitehead M, 1994, EUR J PUBLIC HEALTH, V4, P1; WHITEHEAD M, 1997, BMJ, V315	28	58	60	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					1006	1009		10.1136/bmj.315.7114.1006	http://dx.doi.org/10.1136/bmj.315.7114.1006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC307	9365303	Green Published			2022-12-28	WOS:A1997YC30700030
J	denBoer, JA				denBoer, JA			Social phobia: epidemiology, recognition, and treatment	BRITISH MEDICAL JOURNAL			English	Review							PSYCHIATRIC-DISORDERS; PANIC DISORDER; ANXIETY DISORDERS; PAROXETINE; PSYCHOPHARMACOLOGY; PLACEBO; PREVALENCE; BENZODIAZEPINES; CLOMIPRAMINE; COMORBIDITY				denBoer, JA (corresponding author), ACAD HOSP GRONINGEN,DEPT BIOL PSYCHIAT,POB 3001,NL-9712 RB GRONINGEN,NETHERLANDS.							ALLSOPP LF, 1984, CURR MED RES OPIN, V9, P64, DOI 10.1185/03007998409109561; AMIES PL, 1983, BRIT J PSYCHIAT, V142, P174, DOI 10.1192/bjp.142.2.174; BEAUMONT G, 1977, J INT MED RES, V5, P116; BLACK B, 1992, J CLIN PSYCHOPHARM, V12, P293; DAVIDSON JRT, 1993, J CLIN PSYCHOPHARM, V13, P423; DAVIDSON JRT, 1994, J CLIN PSYCHIAT, V55, P28; DENBOER JA, 1994, PROG NEURO-PSYCHOPH, V18, P625, DOI 10.1016/0278-5846(94)90073-6; DENBOER JA, 1995, EUR ARCH PSY CLIN N, V244, P309, DOI 10.1007/BF02190409; DONOHUE BC, 1994, BEHAV MODIF, V18, P262, DOI 10.1177/01454455940183002; DUNBAR GC, 1993, ACTA PSYCHIAT SCAND, V87, P302, DOI 10.1111/j.1600-0447.1993.tb03376.x; DUNBAR GC, 1995, EUR NEUROPSYCHOPHARM, V5, P361; GABBARD GO, 1992, B MENNINGER CLIN, V56, pA3; GELERNTER CS, 1991, ARCH GEN PSYCHIAT, V48, P938; GORMAN JM, 1985, J CLIN PSYCHOPHARM, V5, P669; GREIST JH, 1995, J CLIN PSYCHIAT, V56, P5; GRINGRAS M, 1977, J INT MED RES, V5, P111; HEIMBERG RG, 1994, J CLIN PSYCHIAT, V55, P38; HEIMBERG RG, 1993, J CLIN PSYCHIAT, V54, P36; HWU HG, 1989, ACTA PSYCHIAT SCAND, V79, P136, DOI 10.1111/j.1600-0447.1989.tb08581.x; Jefferson JW, 1996, J CLIN PSYCHIAT, V57, P28; JEFFERSON JW, 1995, J CLIN PSYCHIAT, V56, P18; JENNER PN, 1992, INT CLIN PSYCHOPHARM, V6, P69, DOI 10.1097/00004850-199206004-00013; JUDD LL, 1994, J CLIN PSYCHIAT, V55, P5; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; LAVERDURE B, 1991, Encephale, V17, P481; LEE CK, 1990, J NERV MENT DIS, V178, P247, DOI 10.1097/00005053-199004000-00005; LEPINE JP, 1995, EUR ARCH PSY CLIN N, V244, P290, DOI 10.1007/BF02190406; LIEBOWITZ MR, 1992, ARCH GEN PSYCHIAT, V49, P290; LIEBOWITZ MR, 1993, CLIN NEUROPHARMACOL, V16, pS83; LIEBOWITZ MR, 1992, J CLIN PSYCHOPHARM, V12, P62; Mancini C, 1996, J CLIN PSYCHIAT, V57, P519, DOI 10.4088/JCP.v57n1103; MARKS IM, 1966, AM J PSYCHIAT, V123, P218, DOI 10.1176/ajp.123.2.218; MARSHALL JR, 1994, B MENNINGER CLIN, V58, pA58; MARSHALL JR, 1992, B MENNINGER CLIN, V56, pA42; MENNINGER WW, 1994, B MENNINGER CLIN, V58, pA84; MERIKANGAS KR, 1995, EUR ARCH PSY CLIN N, V244, P97; RAPAPORT MH, 1995, PSYCHOPHARMACOL BULL, V31, P125; REINHERZ HZ, 1993, J AM ACAD CHILD PSY, V32, P369, DOI 10.1097/00004583-199303000-00019; RINGOLD AL, 1994, J CLIN PSYCHIAT, V55, P363; ROSENBAUM JF, 1991, J CLIN PSYCHIAT, V52, P5; ROSENBAUM JF, 1994, B MENNINGER CLIN, V58, pA67; ROSENBAUM JF, 1994, J CLIN PSYCHIAT, V55, P10; ROYBYRNE P, 1993, PSYCHIAT CLIN N AM, V16, P719; SCHNEIER FR, 1992, ARCH GEN PSYCHIAT, V49, P282; Stein MB, 1996, J CLIN PSYCHOPHARM, V16, P218, DOI 10.1097/00004714-199606000-00005; SWINSON RP, 1992, CAN MED ASSOC J, V147, P878; Uhlenhuth EH, 1995, J AFFECT DISORDERS, V35, P153, DOI 10.1016/0165-0327(95)00064-X; VANAMERINGEN M, 1993, J CLIN PSYCHIAT, V54, P27; WACKER HR, 1992, INT J METH PSYCH RES, V2, P91; WALLEY EJ, 1994, AM FAM PHYSICIAN, V50, P1745; WALLEY EJ, 1994, AM FAM PHYSICIAN, V50, P1757	51	38	40	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					796	800						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY911	9345175				2022-12-28	WOS:A1997XY91100026
J	Cui, JQ; Shin, T; Kawano, T; Sato, H; Kondo, E; Toura, I; Kaneko, Y; Koseki, H; Kanno, M; Taniguchi, M				Cui, JQ; Shin, T; Kawano, T; Sato, H; Kondo, E; Toura, I; Kaneko, Y; Koseki, H; Kanno, M; Taniguchi, M			Requirement for V(alpha)14 NKT cells in IL-12-mediated rejection of tumors	SCIENCE			English	Article							RECEPTOR-ALPHA-CHAIN; LYMPHOCYTE MATURATION FACTOR; ANTI-MELANOMA ANTIBODY; IFN-GAMMA PRODUCTION; CLASS-I MOLECULES; BETA T-CELLS; HETERODIMERIC CYTOKINE; STIMULATORY FACTOR; LIVER METASTASIS; THYMOCYTES	A lymphocyte subpopulation, the V(alpha)14 natural killer T (NKT) cells, expresses both NK1.1 and a single invariant T cell receptor encoded by the V(alpha)14 and J(alpha)281 gene segments, Mice with a deletion of the J(alpha)281 gene segment were found to exclusively lack this subpopulation. The V(alpha)14 NKT cell-deficient mice could no longer mediate the interleukin-12 (IL-12)-induced rejection of tumors. Although the antitumor effect of IL-12 Was thought to be mediated through natural killer cells and T cells, V(alpha)14 NKT cells were found to be an essential target of IL-12, and they mediated their cytotoxicity by an NK-like effector mechanism after activation with IL-12.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOL IMMUNOL,CHUO KU,CHIBA 260,JAPAN; JAPAN SCI & TECHNOL CORP,CORE RES EVOL SCI & TECHNOL,TOKYO,JAPAN	Chiba University; Japan Science & Technology Agency (JST)			Taniguchi, Masaru/N-7932-2015; Koseki, Haruhiko/I-3825-2014	Taniguchi, Masaru/0000-0001-7821-7179; Koseki, Haruhiko/0000-0001-8424-5854; Kanno, masamoto/0000-0001-9169-3444				Akasaka T, 1996, DEVELOPMENT, V122, P1513; Ando K, 1997, J IMMUNOL, V158, P5283; BALLAS ZK, 1990, J IMMUNOL, V145, P1039; BARBERAGUILLEM E, 1989, CANCER RES, V49, P4003; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; BRUNDA MJ, 1984, INT J CANCER, V34, P421, DOI 10.1002/ijc.2910340321; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; CHEN LK, 1986, EUR J IMMUNOL, V16, P767, DOI 10.1002/eji.1830160709; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; GATELY MK, 1991, J IMMUNOL, V147, P874; GUNJI Y, 1986, JPN J CANCER RES, V77, P595; HASHIMOTO W, 1995, J IMMUNOL, V154, P4333; IMAI K, 1986, P NATL ACAD SCI USA, V83, P8708, DOI 10.1073/pnas.83.22.8708; Kataoka T, 1996, J IMMUNOL, V156, P3678; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KOPPER L, 1982, J CANCER RES CLIN, V103, P31, DOI 10.1007/BF00410303; KOSEKI H, 1990, P NATL ACAD SCI USA, V87, P5248, DOI 10.1073/pnas.87.14.5248; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; MAKINO Y, 1993, J EXP MED, V177, P1399, DOI 10.1084/jem.177.5.1399; MAKINO Y, 1995, INT IMMUNOL, V7, P1157, DOI 10.1093/intimm/7.7.1157; Makino Y, 1996, P NATL ACAD SCI USA, V93, P6516, DOI 10.1073/pnas.93.13.6516; MARASKOVSKY E, 1989, J IMMUNOL, V143, P1210; Masuda K, 1997, J IMMUNOL, V158, P2076; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NASTALA CL, 1994, J IMMUNOL, V153, P1697; NORES GA, 1987, J IMMUNOL, V139, P3171; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; SYKES M, 1990, J IMMUNOL, V145, P3209; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; Takahashi M, 1996, J IMMUNOL, V156, P2436; Taniguchi M, 1996, P NATL ACAD SCI USA, V93, P11025, DOI 10.1073/pnas.93.20.11025; Tardif M, 1996, INT J CANCER, V68, P97, DOI 10.1002/(SICI)1097-0215(19960927)68:1<97::AID-IJC17>3.0.CO;2-3; Teicher BA, 1996, INT J CANCER, V65, P80, DOI 10.1002/(SICI)1097-0215(19960103)65:1<80::AID-IJC14>3.0.CO;2-M; WAKABAYASHI S, 1981, NATURE, V294, P748, DOI 10.1038/294748a0; WAKABAYASHI S, 1984, JPN J CANCER RES, V75, P427; WEIGENT DA, 1983, BIOCHEM BIOPH RES CO, V111, P525, DOI 10.1016/0006-291X(83)90338-8; WOLF SF, 1991, J IMMUNOL, V146, P3074; ZOU JP, 1995, INT IMMUNOL, V7, P1135, DOI 10.1093/intimm/7.7.1135	45	1091	1128	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1623	1626		10.1126/science.278.5343.1623	http://dx.doi.org/10.1126/science.278.5343.1623			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374462				2022-12-28	WOS:A1997YJ87400041
J	Plautz, JD; Kaneko, M; Hall, JC; Kay, SA				Plautz, JD; Kaneko, M; Hall, JC; Kay, SA			Independent photoreceptive circadian clocks throughout Drosophila	SCIENCE			English	Article							PERIOD GENE; BEHAVIORAL RHYTHMS; MELANOGASTER; EXPRESSION; SYSTEM; MUTANTS; CELLS; LIGHT; HEAD; TIME	Transgenic Drosophila that expressed either luciferase or green fluorescent protein driven From the promoter of the clock gene period were used lo monitor the circadian clock in explanted head, thorax, and abdominal tissues. The tissues (including sensory bristles in the leg and wing) showed rhythmic bioluminescence, and the rhythms could be reset by light, The photoreceptive properties of the explanted tissues indicate that unidentified photoreceptors are likely to contribute to photic signal transduction to the clock. These results show that autonomous circadian oscillators are present throughout the body, and they suggest that individual cells in Drosophila are capable of supporting their own independent clocks.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, NATL SCI FDN, CTR BIOL TIMING, LA JOLLA, CA 92037 USA; BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA; BRANDEIS UNIV, NATL SCI FDN, CTR BIOL TIMING, WALTHAM, MA 02254 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute; Brandeis University; Brandeis University; National Science Foundation (NSF); NSF - Center for Biological Timing			Weydahl, Andi/C-6391-2008; Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878; Kaneko, Maki/0000-0002-2489-6185	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-51573] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARGAMASO SM, 1995, BIOPHYS CHEM, V56, P3, DOI 10.1016/0301-4622(95)00009-M; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; EWER J, 1992, J NEUROSCI, V12, P3321; GIEBULTOWICZ JM, 1989, SCIENCE, V245, P1098, DOI 10.1126/science.245.4922.1098; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HANDLER AM, 1979, NATURE, V279, P236, DOI 10.1038/279236a0; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; Hege DM, 1997, J BIOL RHYTHM, V12, P300, DOI 10.1177/074873049701200402; Ito K, 1997, CELL TISSUE RES, V290, P1, DOI 10.1007/s004410050901; JOHNSON RF, 1988, BRAIN RES, V460, P297, DOI 10.1016/0006-8993(88)90374-5; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MARTINEZGOMEZ M, 1994, PHYSIOL BEHAV, V55, P651, DOI 10.1016/0031-9384(94)90040-X; MCMILLAN JP, 1975, J COMP PHYSIOL, V102, P251, DOI 10.1007/BF01464359; MENAKER M, 1996, CIRCADIAN ORG OSCILL, P39; OKEEFE LP, 1987, PHYSIOL BEHAV, V41, P193, DOI 10.1016/0031-9384(87)90353-2; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Plautz JD, 1996, GENE, V173, P83, DOI 10.1016/0378-1119(95)00700-8; POWER J, 1995, J NEUROGENET, V9, P227, DOI 10.3109/01677069509084159; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Sehgal A, 1996, MOL CELL NEUROSCI, V7, P165, DOI 10.1006/mcne.1996.0013; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1982, J COMP PHYSIOL, V146, P245, DOI 10.1007/BF00610244; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TRUMAN JW, 1974, J COMP PHYSIOL, V95, P281, DOI 10.1007/BF00609702; TRUMAN JW, 1972, J COMP PHYSIOL, V81, P99, DOI 10.1007/BF00693553; VanGelder RN, 1995, CURR BIOL, V5, P1424, DOI 10.1016/S0960-9822(95)00280-6; VanGelder RN, 1996, EMBO J, V15, P1625, DOI 10.1002/j.1460-2075.1996.tb00507.x; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106	39	506	515	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1632	1635		10.1126/science.278.5343.1632	http://dx.doi.org/10.1126/science.278.5343.1632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374465				2022-12-28	WOS:A1997YJ87400044
J	Weeks, ER; Tian, YD; Urbach, JS; Ide, K; Swinney, HL; Ghil, M				Weeks, ER; Tian, YD; Urbach, JS; Ide, K; Swinney, HL; Ghil, M			Transitions between blocked and zonal flows in a rotating annulus with topography	SCIENCE			English	Article							PERSISTENT ANOMALIES; BAROCLINIC FLOWS; WEATHER REGIMES; MODEL; CIRCULATION; PREDICTABILITY; WAVES; FLUID; OSCILLATIONS; WINTER	The mid-latitude atmosphere is dominated by westerly, nearly zonal flow. Occasionally, this flow is deflected poleward by blocking anticyclones that persist for 10 days or longer. Experiments in a rotating annulus used radial pumping to generate a zonal jet under the action of the Coriolis force. In the presence of two sym metric ridges at the bottom of the annulus, the resulting flaws were nearly zonal at high forcing or blocked ai lewd forcing Intermittent switching between blocked and zonal patterns occurs because of the jet's interaction with the topography. These results shed further light on previous atmospheric observations and numerical simulations.	UNIV TEXAS,CTR NONLINEAR DYNAM,AUSTIN,TX 78712; UNIV TEXAS,DEPT PHYS,AUSTIN,TX 78712; UNIV CALIF LOS ANGELES,DEPT ATMOSPHER SCI,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Weeks, Eric R/I-8960-2019; Ide, Kayo/F-8443-2010; Ghil, Michael/O-1433-2019	Weeks, Eric R/0000-0003-1503-3633; Ghil, Michael/0000-0001-5177-7133; Urbach, Jeffrey/0000-0002-1593-520X				BENZI R, 1986, Q J ROY METEOR SOC, V112, P661, DOI 10.1002/qj.49711247306; BENZI R, 1986, ADV GEOPHYSICS, V29; BERNARDET P, 1990, J ATMOS SCI, V47, P3023, DOI 10.1175/1520-0469(1990)047<3023:LFOIAR>2.0.CO;2; CARNEVALE GF, 1991, J FLUID MECH, V233, P119, DOI 10.1017/S0022112091000411; CHARNEY JG, 1979, J ATMOS SCI, V36, P1205, DOI 10.1175/1520-0469(1979)036<1205:MFEITA>2.0.CO;2; CHARNEY JG, 1947, J METEOROL, V4, P135; CHENG XH, 1993, J ATMOS SCI, V50, P2674, DOI 10.1175/1520-0469(1993)050<2674:CAOTNH>2.0.CO;2; DOLE RM, 1983, MON WEATHER REV, V111, P1567, DOI 10.1175/1520-0493(1983)111<1567:PAOTEN>2.0.CO;2; EADY ET, 1949, TELLUS, V1, P33; Fruh WG, 1997, PHILOS T R SOC A, V355, P101, DOI 10.1098/rsta.1997.0003; Gill AE, 1982, ATMOSPHERE OCEAN DYN; Held I M, 1983, LARGE SCALE DYNAMICA, P127; HIDE R, 1975, ADV PHYS, V24, P47, DOI 10.1080/00018737500101371; Hide R., 1958, PHILOS T R SOC LON A, V250A, P442; Holton J. R., 1992, INTRO DYNAMIC METEOR; Horel JD, 1988, J CLIMATE, V1, P582, DOI 10.1175/1520-0442(1988)001<0582:OASIVO>2.0.CO;2; Itoh H, 1996, J ATMOS SCI, V53, P2217, DOI 10.1175/1520-0469(1996)053<2217:MAACII>2.0.CO;2; JONAS PR, 1981, Q J ROY METEOR SOC, V107, P775, DOI 10.1256/smsqj.45402; KALNAYRIVAS E, 1981, J ATMOS SCI, V38, P2077, DOI 10.1175/1520-0469(1981)038<2077:ASMFB>2.0.CO;2; KANEKO K, 1990, PHYSICA D, V41, P137, DOI 10.1016/0167-2789(90)90119-A; KANEKO K, 1991, PHYSICA D, V54, P5, DOI 10.1016/0167-2789(91)90103-G; KIMOTO M, 1993, J ATMOS SCI, V50, P2625, DOI 10.1175/1520-0469(1993)050<2625:MFRITN>2.0.CO;2; LAU NC, 1987, MON WEATHER REV, V115, P251, DOI 10.1175/1520-0493(1987)115<0251:FDOTSA>2.0.CO;2; LEGRAS B, 1985, J ATMOS SCI, V42, P433, DOI 10.1175/1520-0469(1985)042<0433:PABAVI>2.0.CO;2; LI GQ, 1986, J ATMOS SCI, V43, P2585, DOI 10.1175/1520-0469(1986)043<2585:AESOBF>2.0.CO;2; LORENZ E, 1967, NATURE THEORY GENERA; Marcus SL, 1996, J ATMOS SCI, V53, P1993, DOI 10.1175/1520-0469(1996)053<1993:TEDOIT>2.0.CO;2; MOLTENI F, 1993, Q J ROY METEOR SOC, V119, P269, DOI 10.1002/qj.49711951004; OCONNOR JF, 1963, MON WEA REV, V91, P209; PALMER TN, 1993, B AM METEOROL SOC, V74, P49, DOI 10.1175/1520-0477(1993)074<0049:ERAPAT>2.0.CO;2; PEDLOSKY J, 1981, J ATMOS SCI, V38, P2626, DOI 10.1175/1520-0469(1981)038<2626:RTWIBA>2.0.CO;2; Pedlosky J., 1987, GEOPHYS FLUID DYN; PERVEZ MS, 1994, EXP FLUIDS, V17, P135, DOI 10.1007/BF00190909; PRATTE JM, 1991, J FLUID MECH, V229, P87, DOI 10.1017/S0022112091002951; REINHOLD BB, 1982, MON WEATHER REV, V110, P1105, DOI 10.1175/1520-0493(1982)110<1105:DOWRQS>2.0.CO;2; Rex D. F., 1950, TELLUS, V2, P275, DOI DOI 10.1111/J.2153-3490.1950.TB00339.X; Rossby CG, 1939, J MAR RES, V2, P38, DOI 10.1357/002224039806649023; SOLOMON TH, 1993, PHYS FLUIDS A-FLUID, V5, P1971, DOI 10.1063/1.858824; SOMMERIA J, 1989, NATURE, V337, P58, DOI 10.1038/337058a0; Sommeria J., 1991, NONLINEAR TOPICS OCE, P227; STRONG C, 1995, J ATMOS SCI, V52, P2627, DOI 10.1175/1520-0469(1995)052<2627:IOIABM>2.0.CO;2; TIAN Y, 1997, THESIS U CALIFORNIA; TIAN Y, UNPUB; TRACTON MS, 1989, MON WEATHER REV, V117, P1604, DOI 10.1175/1520-0493(1989)117<1604:DERFAT>2.0.CO;2; Wallace JM, 1983, LARGE SCALE DYNAMICA, P55; Weeks E.R., 1997, THESIS U TEXAS AUSTI	46	75	77	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1598	1601		10.1126/science.278.5343.1598	http://dx.doi.org/10.1126/science.278.5343.1598			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374453				2022-12-28	WOS:A1997YJ87400032
J	Walter, E; Mockel, J				Walter, E; Mockel, J			Peliosis hepatis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV FREIBURG,INST PATHOL,D-79106 FREIBURG,GERMANY	University of Freiburg	Walter, E (corresponding author), UNIV FREIBURG,MED KLIN,HUGSTETTER STR 55,D-79106 FREIBURG,GERMANY.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1603	1603		10.1056/NEJM199711273372206	http://dx.doi.org/10.1056/NEJM199711273372206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371857				2022-12-28	WOS:A1997YH52100006
J	Rivers, JK; Roof, MI				Rivers, JK; Roof, MI			Sentinel lymph-node biopsy in melanoma: is less surgery better?	LANCET			English	Editorial Material									BRITISH COLUMBIA CANC AGCY,VANCOUVER,BC V5Z 4E8,CANADA; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG ONCOL,HOUSTON,TX 77030	British Columbia Cancer Agency; University of Texas System; UTMD Anderson Cancer Center	Rivers, JK (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DIV DERMATOL,VANCOUVER,BC V5Z 4E8,CANADA.		Rivers, Jason/K-1031-2019	Rivers, Jason/0000-0002-0131-1607				Albertini JJ, 1996, ANN SURG, V223, P217, DOI 10.1097/00000658-199602000-00016; Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; Brady MS, 1997, ARCH DERMATOL, V133, P1014, DOI 10.1001/archderm.133.8.1014; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Piepkorn M, 1997, ARCH DERMATOL, V133, P995, DOI 10.1001/archderm.133.8.995; Ross MI, 1996, SEMIN SURG ONCOL, V12, P394, DOI 10.1002/(SICI)1098-2388(199611/12)12:6<394::AID-SSU4>3.0.CO;2-5; WANG XN, 1994, ANN SURG, V220, P768, DOI 10.1097/00000658-199412000-00010	7	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1336	1337		10.1016/S0140-6736(97)22045-3	http://dx.doi.org/10.1016/S0140-6736(97)22045-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365442				2022-12-28	WOS:A1997YE87200002
J	Fearon, ER				Fearon, ER			Human cancer syndromes: Clues to the origin and nature of cancer	SCIENCE			English	Review							ENDOCRINE NEOPLASIA TYPE-2; TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; GERM-LINE MUTATIONS; BREAST-CANCER; BETA-CATENIN; RET PROTOONCOGENE; INTESTINAL NEOPLASIA; SUSCEPTIBILITY GENE; FAMILIAL MELANOMA	More than 20 different hereditary cancer syndromes have now been defined and attributed to specific germline mutations in various inherited cancer genes. Collectively, the syndromes affect about 1 percent of cancer patients. An individual who carries a mutant allele of an inherited cancer gene has a variable risk of cancer that is influenced by the particular mutation, other cellular genes, and dietary, lifestyle, and environmental factors. Though hereditary cancer syndromes are rare, their study has provided powerful insights into more common forms of cancer. Somatic mutations in sporadic cancers frequently alter the inherited cancer genes, and the functions of cell signaling pathways have been illuminated by study of the affected genes. Further investigation of inherited mutations that affect susceptibility to cancer will aid efforts to effectively prevent, detect, and treat the disease.	UNIV MICHIGAN, MED CTR, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fearon, ER (corresponding author), UNIV MICHIGAN, MED CTR,DEPT INTERNAL MED,DIV MED & MOL GENET, 4301 MSRB III, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA.							ALEXANDRIE AK, 1994, CARCINOGENESIS, V15, P1785, DOI 10.1093/carcin/15.9.1785; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bishop DT, 1997, NAT GENET, V15, P226, DOI 10.1038/ng0397-226; BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; BORST MJ, 1995, SURGERY, V117, P386, DOI 10.1016/S0039-6060(05)80057-1; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dragani TA, 1997, NAT GENET, V17, P7, DOI 10.1038/ng0997-7; EASTON DF, 1995, AM J HUM GENET, V56, P265; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; FRANCKE U, 1976, CYTOGENET CELL GENET, V16, P131, DOI 10.1159/000130573; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HAHN H, 1996, CELL, V85, P741; HAHN SA, 1995, CANCER RES, V55, P4670; HAKEM R, 1993, CELL, V74, P1009; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; Kawajiri K, 1996, CANCER RES, V56, P72; KAWAJIRI K, 1990, FEBS LETT, V263, P121; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LI FP, 1969, J NATL CANCER I, V43, P1365; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lohmann DR, 1996, AM J HUM GENET, V58, P940; Lynch HT, 1996, AM J HUM GENET, V59, P1184; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; OCONNELL P, 1989, SCIENCE, V244, P1087, DOI 10.1126/science.2543077; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ozcelik H, 1997, NAT GENET, V16, P17, DOI 10.1038/ng0597-17; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; RICCARDI VM, 1980, CANC GENET CYTOGENET, V2, P13; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SCHIMKE RN, 1974, CANCER, V34, P2077, DOI 10.1002/1097-0142(197412)34:6<2077::AID-CNCR2820340630>3.0.CO;2-A; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SWIFT M, 1976, CANCER RES, V36, P209; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu XP, 1996, CANCER EPIDEM BIOMAR, V5, P687; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	103	417	427	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1043	1050		10.1126/science.278.5340.1043	http://dx.doi.org/10.1126/science.278.5340.1043			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353177				2022-12-28	WOS:A1997YE65200029
J	Anzueto, A; Jubran, A; Ohar, JA; Piquette, CA; Rennard, SI; Colice, G; Pattishall, EN; Barrett, J; Engle, M; Perret, KA; Rubin, BK				Anzueto, A; Jubran, A; Ohar, JA; Piquette, CA; Rennard, SI; Colice, G; Pattishall, EN; Barrett, J; Engle, M; Perret, KA; Rubin, BK			Effects of aerosolized surfactant in patients with stable chronic bronchitis - A prospective randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT HUMAN DNASE; IODINATED GLYCEROL; PULMONARY-FUNCTION; CYSTIC-FIBROSIS; MUCUS; TRANSPORT; SPUTUM	Context.-Chronic bronchitis, estimated to affect more than 13 million adults in the United States, is characterized in part by retention of airway secretions, but no approved or effective therapy for airway mucus retention in patients with chronic bronchitis has been established. Surfactant reduces sputum adhesiveness, which contributes to difficulty in clearing secretions, but surfactant has not been tested in patients with chronic bronchitis. Objective.-To examine the effects of exogenous surfactant on sputum clearance and pulmonary function in patients with stable chronic bronchitis. Design.-A prospective, multicenter, randomized, double-blind, parallel-group, placebo-controlled comparison of the effects of 2 weeks of treatment with 3 doses of aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) or saline (placebo). Setting.-Four US teaching hospitals. Participants.-A total of 87 adult patients with the diagnosis of stable chronic bronchitis. Main Outcome Measures.-Pulmonary function, respiratory symptoms, and sputum properties before treatment (day 0), after 2 weeks of treatment (day 14), and 7 days after stopping treatment (day 21). Results.-A total of 66 patients were randomized to surfactant treatment and 21 to saline treatment. Patient demographic characteristics between groups were similar at baseline, In patients who received a DPPC dose of 607.5 mg/d for 2 weeks, prebronchodilator forced expiratory volume in 1 second (FEV1) increased from 1.22 L (SEM, 0.08 L) at day 0 to 1.33 L (SEM, 0.09 L) at day 21 (P=.05), an improvement of 11.4%; postbronchodilator FEV1 improved 10.4% by days 14 and 21 (P=.02); and the ratio of residual volume to total lung capacity, a measure of thoracic gas trapping, decreased 6.2% by day 21 (P=.009). In the surfactant groups, there was a dose-dependent increase in the ability of sputum to be transported by cilia in vitro. Conclusion.-Aerosolized surfactant improved pulmonary function and resulted in a dose-related improvement in sputum transport by cilia in patients with stable chronic bronchitis.	UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA; AUDIE L MURPHY MEM VET ADM MED CTR, S TEX VET HLTH CARE SYST, SAN ANTONIO, TX 78284 USA; LOYOLA UNIV, HINES, IL USA; US DEPT VET AFFAIRS, VET AFFAIRS EDWARD HINES JR HOSP, HINES, IL 60141 USA; ST LOUIS UNIV, HLTH SCI CTR, ST LOUIS, MO 63103 USA; UNIV NEBRASKA, MED CTR, OMAHA, NE USA; 3M PHARMACEUT, ST PAUL, MN USA; GLAXO WELLCOME INC, RES TRIANGLE PK, NC 27709 USA; E TENNESSEE PULM ASSOC, KNOXVILLE, TN USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Saint Louis University; University of Nebraska System; University of Nebraska Medical Center; 3M; GlaxoSmithKline								AGARWAL M, 1989, BIORHEOLOGY, V26, P977; AIKAWA T, 1989, AM REV RESPIR DIS, V140, P477, DOI 10.1164/ajrccm/140.2.477; ALLEGRA L, 1985, EUR J RESPIR DIS, V67, P71; *AM THOR SOC, 1995, AM J RESP CRIT CARE, pS77; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BONE RC, 1995, CHEST, V108; BRIDGES RB, 1986, EUR J RESPIR DIS, V69, P145; DEBLASIO F, 1993, CHEST, V104, P1032, DOI 10.1378/chest.104.4.1032; DUEHOLM M, 1992, RESP MED, V86, P89, DOI 10.1016/S0954-6111(06)80220-9; ESPINOSA FF, 1993, J APPL PHYSIOL, V75, P2028, DOI 10.1152/jappl.1993.75.5.2028; FICK RB, 1994, CLIN RES, V42, pA294; FINLEY TN, 1972, NEW ENGL J MED, V286, P223, DOI 10.1056/NEJM197202032860501; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GIROD S, 1992, EUR RESPIR J, V5, P477; Higenbottam T, 1987, Eur J Respir Dis Suppl, V153, P222; KNG M, 1996, CHRONIC OBSTRUCTIVE, P391; MORGENROTH K, 1985, RESPIRATION, V47, P225, DOI 10.1159/000194774; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OTIS DR, 1993, J APPL PHYSIOL, V75, P1323, DOI 10.1152/jappl.1993.75.3.1323; PETTY TL, 1990, CHEST, V97, P75, DOI 10.1378/chest.97.1.75; PUCHELLE E, 1982, ADV EXP MED BIOL, V144, P397; RUBIN BK, 1992, CHEST, V101, P1080, DOI 10.1378/chest.101.4.1080; RUBIN BK, 1990, J APPL PHYSIOL, V69, P424, DOI 10.1152/jappl.1990.69.2.424; Rubin BK, 1996, CHEST, V109, P348, DOI 10.1378/chest.109.2.348; RUBIN BK, 1993, J RESPIR DIS, V14, pS19; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SHIM C, 1987, CHEST, V92, P679, DOI 10.1378/chest.92.4.679; THOMASSEN MJ, 1994, AM J RESP CELL MOL, V10, P399, DOI 10.1165/ajrcmb.10.4.8136155; ZAHM JM, 1986, B EUR PHYSIOPATH RES, V22, P609; ZAR JH, 1984, BIOSTAT ANAL, P162; 1994, MMWR-MORBID MORTAL W, V43, P916	32	68	74	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1426	1431						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9356001				2022-12-28	WOS:A1997YC91700029
J	Hoffenberg, R; Lock, M; Tilney, N; Casabona, C; Daar, AS; Guttmann, RD; Kennedy, I; Nundy, S; RadcliffeRichards, J; Sells, RA				Hoffenberg, R; Lock, M; Tilney, N; Casabona, C; Daar, AS; Guttmann, RD; Kennedy, I; Nundy, S; RadcliffeRichards, J; Sells, RA			Should organs from patients in permanent vegetative state be used for transplantation?	LANCET			English	Article									ROYAL LIVERPOOL HOSP, RENAL TRANSPLANT UNIT, INT FORUM TRANSPLANT ETH, LIVERPOOL L7 8XP, MERSEYSIDE, ENGLAND; DEPT SOCIAL STUDIES MED, MONTREAL, PQ, CANADA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV DEUSTO, CATEDRA DERECHRO & GENOMA HUMANO, BILBAO, SPAIN; SULTAN QABOOS UNIV, COLL MED, DEPT SURG, AL KHOUD, OMAN; ROYAL VICTORIA HOSP, MONTREAL, PQ H3A 1A1, CANADA; ALL INDIA INST MED SCI, DEPT GASTROINTESTINAL SURG, NEW DELHI, INDIA	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; Harvard University; Brigham & Women's Hospital; University of Deusto; Sultan Qaboos University; McGill University; Royal Victoria Hospital; All India Institute of Medical Sciences (AIIMS) New Delhi				Nundy, Samiran/0000-0002-1757-3919				Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; *BRIT MED ASS ETH, 1992, DISC PAP TREATM PAT; CELESIA, 1993, ANN NEUROL, V33, P386; CRAWFORD R, 1996, BRIT MED J, V313, P5; Dyer C, 1997, BRIT MED J, V314, P996; *HL, 1994, REP SEL COMM MED ETH	8	21	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1320	1321		10.1016/S0140-6736(97)02306-4	http://dx.doi.org/10.1016/S0140-6736(97)02306-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357422				2022-12-28	WOS:A1997YD68900045
J	Medzhitov, R; Janeway, CA				Medzhitov, R; Janeway, CA			Innate immunity: The virtues of a nonclonal system of recognition	CELL			English	Review							EVOLUTION		HOWARD HUGHES MED INST,NEW HAVEN,CT 06520	Howard Hughes Medical Institute	Medzhitov, R (corresponding author), YALE UNIV,SCH MED,IMMUNOBIOL SECT,333 CEDAR ST,NEW HAVEN,CT 06520, USA.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; AUDIBERT FM, 1993, IMMUNOL TODAY, V14, P281, DOI 10.1016/0167-5699(93)90046-N; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LIU Y, 1992, P NATL ACAD SCI USA, V89, P3845, DOI 10.1073/pnas.89.9.3845; MAC ARTHUR ROBERT H., 1967; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; PIANKA ER, 1970, AM NAT, V104, P592, DOI 10.1086/282697; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8	18	1828	1935	3	130	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					295	298		10.1016/S0092-8674(00)80412-2	http://dx.doi.org/10.1016/S0092-8674(00)80412-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363937	hybrid			2022-12-28	WOS:A1997YD94100002
J	Farmer, PB				Farmer, PB			Diesel fuel and exhaust emissions: Is there a human carcinogenic risk?	LANCET			English	Editorial Material							CARBON-BLACK; EXPOSURE; ADDUCTS; RATS; DNA				Farmer, PB (corresponding author), UNIV LEICESTER,MRC,TOXICOL UNIT,LEICESTER LE1 9HN,LEICS,ENGLAND.							HEINRICH U, 1995, INHAL TOXICOL, V7, P533, DOI 10.3109/08958379509015211; *INT AG RES CANC, 1989, IARC MON, V46, P41; IPCS (International Programme on Chemical Safety), 1996, ENV HLTH CRIT, V171; LEVY LS, 1995, INDOOR ENVIRON, V4, P254; Nielsen PS, 1996, TOXICOL LETT, V86, P27, DOI 10.1016/0378-4274(96)83963-4; Nielsen PS, 1996, CARCINOGENESIS, V17, P1021, DOI 10.1093/carcin/17.5.1021; NIKULA KJ, 1995, FUND APPL TOXICOL, V25, P80, DOI 10.1006/faat.1995.1042	7	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1118	1118		10.1016/S0140-6736(05)63786-5	http://dx.doi.org/10.1016/S0140-6736(05)63786-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343497				2022-12-28	WOS:A1997YB19900006
J	Lahita, RG				Lahita, RG			Influence of age on Henoch Schonlein purpura	LANCET			English	Editorial Material											Lahita, RG (corresponding author), COLUMBIA UNIV,ST LUKES ROOSEVELT MED CTR,DEPT RHEUMATOL,NEW YORK,NY 10019, USA.							BERTHOUX FC, 1978, NEW ENGL J MED, V298, P1034; Blanco R, 1997, ARTHRITIS RHEUM, V40, P859, DOI 10.1002/art.1780400513; Escudero A, 1996, Allergol Immunopathol (Madr), V24, P22; MERRILL J, 1994, BRIT J RHEUMATOL, V33, P586; MICHEL BA, 1992, J RHEUMATOL, V19, P721; MILLS JA, 1990, ARTHRITIS RHEUM, V33, P1114; TancredeBohin E, 1997, ARCH DERMATOL, V133, P438, DOI 10.1001/archderm.133.4.438	7	23	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1116	1117		10.1016/S0140-6736(05)63784-1	http://dx.doi.org/10.1016/S0140-6736(05)63784-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343495	hybrid			2022-12-28	WOS:A1997YB19900004
J	Peverill, RE; Harper, RW; Smolich, JJ				Peverill, RE; Harper, RW; Smolich, JJ			CARS trial: warfarin and thrombin generation	LANCET			English	Letter											Peverill, RE (corresponding author), MONASH MED CTR,CARDIOL UNIT,CLAYTON,VIC 3168,AUSTRALIA.			Peverill, Roger/0000-0002-3319-5356				*COUM ASP REINF ST, 1997, LANCET, V350, P389; Feinberg WM, 1997, STROKE, V28, P1101, DOI 10.1161/01.STR.28.6.1101; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; *POST COR ART BYP, 1997, NEW ENGL J MED, V336, P153; *STROK PREV ATR FI, 1996, LANCET, V348, P633	5	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1177	1178		10.1016/S0140-6736(05)63824-X	http://dx.doi.org/10.1016/S0140-6736(05)63824-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343528				2022-12-28	WOS:A1997YB19900057
J	Williams, C; Milton, J; Strickland, P; ArdaghWalter, N; Knapp, J; Wilson, S; Trigwell, P; Feldman, E; Sims, ACP				Williams, C; Milton, J; Strickland, P; ArdaghWalter, N; Knapp, J; Wilson, S; Trigwell, P; Feldman, E; Sims, ACP			Impact of medical school teaching on preregistration house officers' confidence in assessing and managing common psychological morbidity: three centre study	BRITISH MEDICAL JOURNAL			English	Article									DEPT PSYCHIAT,NOTTINGHAM NG3 6AA,ENGLAND; NOTTINGHAM HEALTHCARE NHS TRUST,NOTTINGHAM NG3 6AA,ENGLAND; MEADOWBROOK,DEPT PSYCHOL MED,SALFORD M6 8HG,LANCS,ENGLAND; MANCHESTER ROYAL INFIRM,MANCHESTER M13 9WL,LANCS,ENGLAND; UNIV LEEDS,GEN INFIRM,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; JOHN RADCLIFFE HOSP,DEPT PSYCHOL MED,OXFORD OX3 9DU,ENGLAND	University of Manchester; Leeds General Infirmary; University of Leeds; University of Oxford	Williams, C (corresponding author), ST JAMES UNIV HOSP,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							AWAD I, 1990, BRIT J ADDICT, V85, P149; Crisp A, 1994, PSYCHOL BULL, V18, P257; *ROYAL COLL PHYS P, 1995, PSYCH CAR MED PAT RE; WILLIAMS C, 1996, PSYCHIAT B, V20, P398	4	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					917	918						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB073	9361541				2022-12-28	WOS:A1997YB07300025
J	Holgate, ST				Holgate, ST			The cellular and mediator basis of asthma in relation to natural history	LANCET			English	Article							BRONCHIAL BIOPSIES; VIRAL-INFECTIONS; NONATOPIC ASTHMA; T-LYMPHOCYTES; MESSENGER-RNA; CELLS; RESPONSES; ALLERGEN; AIRWAYS; ATOPY				Holgate, ST (corresponding author), UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, LEVEL D, CTR BLOCK, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BRADDING P, 1995, IMMUNOPHARMACOLOGY R, P53; BURASTERO SE, 1995, J IMMUNOL, V155, P5836; Casale TB, 1996, AM J RESP CELL MOL, V15, P35, DOI 10.1165/ajrcmb.15.1.8679220; Castro JE, 1996, IMMUNITY, V5, P617, DOI 10.1016/S1074-7613(00)80275-7; Church MK, 1997, J ALLERGY CLIN IMMUN, V99, P155, DOI 10.1016/S0091-6749(97)70089-7; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DENBURG JA, 1995, ALLERGY, V50, P25, DOI 10.1111/j.1398-9995.1995.tb04272.x; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Hartley JA, 1996, IMMUNOLOGY, V89, pOJ95; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HOLGATE ST, 1993, CHEST, V103, pS125; Holt PG, 1997, THORAX, V52, P1, DOI 10.1136/thx.52.1.1; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Hussell T, 1996, J GEN VIROL, V77, P2447, DOI 10.1099/0022-1317-77-10-2447; JAFFAR Z, 1996, FASEB J, V10, pA1054; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KeaneMyers A, 1997, J IMMUNOL, V158, P2042; KONIG P, 1996, ALLERGY CLIN IMMUNOL, V98, P1103; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14, DOI 10.1165/ajrcmb.16.1.8998074; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; Palmer EM, 1997, J IMMUNOL, V158, P2654; Pender SLF, 1997, J IMMUNOL, V158, P1582; RAEBURN D, 1994, EUR RESPIR J, V7, P2226, DOI 10.1183/09031936.94.07122226; ROBINSON C, 1995, IMMUNOPHARMACOLOGY R, P187; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROCHE WR, 1989, LANCET, V1, P520; Semper AE, 1996, CLIN EXP ALLERGY, V26, P485, DOI 10.1111/j.1365-2222.1996.tb00568.x; Shaheen S, 1997, BRIT MED J, V314, P987, DOI 10.1136/bmj.314.7086.987; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANCIU LA, IN PRESS J ALLERGY C; STEVENSON E, IN PRESS CLIN EXP AL; Strachan D, 1996, TOXICOL LETT, V86, P199, DOI 10.1016/0378-4274(96)03691-0; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Warner JA, 1996, ALLERGY, V51, P447, DOI 10.1111/j.1398-9995.1996.tb04650.x; WEFEL T, 1996, J INVEST DERMATL, V107, P871; WEICHMANN HE, 1995, ALLERGY, V4, P315; Wilkinson J, 1996, CLIN EXP ALLERGY, V26, P861; WILSON JW, 1993, AM REV RESPIR DIS, V148, P806, DOI 10.1164/ajrccm/148.3.806; YANAGIDA M, 1995, BLOOD, V86, P3705, DOI 10.1182/blood.V86.10.3705.bloodjournal86103705	56	64	67	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT	1997	350			2			5	9						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC511	9343097				2022-12-28	WOS:A1997YC51100003
J	Behrensmeyer, AK; Todd, NE; Potts, R; McBrinn, GE				Behrensmeyer, AK; Todd, NE; Potts, R; McBrinn, GE			Late Pliocene faunal turnover in the Turkana Basin, Kenya and Ethiopia	SCIENCE			English	Article							PLIOPLEISTOCENE	Analysis of a large sample of well-dated fossil mammals from localities in tl-e Turkana Basin of Kenya and Ethiopia revealed sampling biases that affect patterns of faunal turnover during the late Pliocene, When these biases were accounted for, results indicated that 58 to 77 percent of the mammal species were replaced between 3.0 and 1.8 million years ago (Ma), Overall diversity increased from 3.0 to 2.0 Ma but then declined. No distinct turnover pulse is seen between 2.8 and 2.5 Ma; instead, the most significant period of faunal change began after 2.5 Ma and continued through 1.8 Ma.	SMITHSONIAN INST,MUSEUM NATL HIST NAT,NHB MRC 121,EVOLUT TERR ECOSYST PROGRAM,WASHINGTON,DC 20560	Smithsonian Institution; Smithsonian National Museum of Natural History								Alroy J, 1996, PALAEOGEOGR PALAEOCL, V127, P285, DOI 10.1016/S0031-0182(96)00100-9; ALROY J, COMMUNICATION; BEDEN M, 1987, FAUNES PILO PLEISTOC, V2; Behrensmeyer A.K., 1991, TAPHONOMY RELEASING, P291, DOI [DOI 10.1007/978-1-4899-5034-5, 10.1007/978-1-4899-5034-5_6, DOI 10.1007/978-1-4899-5034-5_6]; BERNOR R, IN PRESS AFRICAN BIO; BISHOP LC, 1994, THESIS YALE U NEW HA; BOBE R, 1996, J VERTEBR PALEONTOL, V16, pA23; Bobe R., 1997, THESIS U WASHINGTON; Bonnefille R, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P299; BONNEFILLE R, 1977, SUPPLEMENTARY B ASS, V501; BONNEFILLE R, 1983, OMO GROUP ARCH INT O, P191; Brown F.H., 1988, P325; Brown FH, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P319; BROWN FH, 1991, FOSSIL UNGULATES GEO, V3, P1; CERLING T E, 1992, Global and Planetary Change, V5, P241; CERLING TE, 1988, PALAEOGEOGR PALAEOCL, V63, P335, DOI 10.1016/0031-0182(88)90104-6; COPPENS Y, 1987, FAUNES PILO PLEISTOC, V3; coPPENs Y., 1985, FAUNES PLIO PLEISTOC, V1; Damuth JD, 1997, ETE DATABASE MANUAL; Delson E., 1984, Courier Forschungsinstitut Senckenberg, V69, P199; DELSON E, 1992, CAMBRIDGE ENCY HUMAN, P220; DELSON E, 1985, COLOBINE MONKEYS THE, P11; deMenocal PB, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P262; DEMENOCAL PB, 1995, SCIENCE, V270, P53, DOI 10.1126/science.270.5233.53; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; Feibel CS, 1991, FOSSIL UNGULATES GEO, V3, P321; Grine F, 1988, EVOLUTIONARY HIST RO; Harris J.M., 1988, CONTRIBUTIONS SCI, V399, P1; HARRIS JM, 1991, FOSSIL UNGULATES GEO, V3; HARRIS JM, 1983, FOSSIL UNGULATES PRO, V2; LEAKEY MG, 1993, THEROPITHECUS, P85, DOI 10.1017/CBO9780511565540.004; Marshall CR, 1997, PALEOBIOLOGY, V23, P165, DOI 10.1017/S0094837300016766; POTTS R, 1996, HUMANITYS DESCENT CO, P114; Prentice M.L., 1988, P383; SADLER PM, 1981, J GEOL, V89, P569, DOI 10.1086/628623; Schultz, 1982, GEOLOGICAL SOC AM SP, V190, P291, DOI DOI 10.1130/SPE190-P291; Shipman P., 1988, P343; Spencer LM, 1997, J HUM EVOL, V32, P201, DOI 10.1006/jhev.1996.0102; STANLEY SM, 1992, PALEOBIOLOGY, V18, P237, DOI 10.1017/S0094837300010836; Suwa G, 1996, AM J PHYS ANTHROPOL, V101, P247, DOI 10.1002/(SICI)1096-8644(199610)101:2<247::AID-AJPA9>3.0.CO;2-Z; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; TODD NE, 1997, THESIS G WASHINGTON; TURNER A, 1995, J HUM EVOL, V24, P147; Turner Alan, 1995, Acta Zoologica Cracoviensia, V38, P45; Van Valkenburgh Blaire, 1993, P330; Vrba E., 1985, P63; Vrba E.S., 1980, P247; Vrba E.S., 1988, P405; Vrba Elizabeth S., 1995, PALEOCLIMATE EVOLUTI; Vrba ES, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P385; VRBA ES, 1992, J MAMMAL, V73, P1, DOI 10.2307/1381862; WESSELMAN H.B., 1984, CONTRIBUTIONS VERTEB, P1; White TD, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P369; WOOD B, 1994, AM J PHYS ANTHROPOL, V95, P117, DOI 10.1002/ajpa.1330950202; WOOD B, 1994, AM J PHYS ANTHR, V95; Wood B. A., 1991, HOMINID CRANIAL REMA, V4	56	179	181	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1589	1594		10.1126/science.278.5343.1589	http://dx.doi.org/10.1126/science.278.5343.1589			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YJ874	9374451				2022-12-28	WOS:A1997YJ87400030
J	Crowther, SD; Morley, J; Costello, JF				Crowther, SD; Morley, J; Costello, JF			Varied effects of regular salbutamol on airway responsiveness to inhaled spasmogens	LANCET			English	Article							ASTHMA				Crowther, SD (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT RESP MED,SACKLER INST PULM PHARMACOL,DENMARK HILL,LONDON SE5 9RS,ENGLAND.							BOULTON DW, 1996, BR J CLIN PHARM, V41, P34; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; PERRINFAYOLLE M, 1995, LANCET, V346, P1101, DOI 10.1016/S0140-6736(95)91775-6; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1450	1450		10.1016/S0140-6736(05)64212-2	http://dx.doi.org/10.1016/S0140-6736(05)64212-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371177				2022-12-28	WOS:A1997YF95300020
J	Fullarton, G; Galloway, D				Fullarton, G; Galloway, D			Randomised trial of fibrin glue versus polidocanol for bleeding peptic ulcer	LANCET			English	Letter											Fullarton, G (corresponding author), GARTNAVEL ROYAL HOSP,DEPT SURG GASTROENTEROL,GLASGOW G12 0YN,LANARK,SCOTLAND.		Calleja-Panero, Jose Luis/A-5351-2010	Calleja-Panero, Jose Luis/0000-0002-2265-6591				FULLARTON GM, 1990, ENDOSCOPY, V22, P68, DOI 10.1055/s-2007-1012795; Rutgeerts P, 1997, LANCET, V350, P692, DOI 10.1016/S0140-6736(97)03233-9	2	0	0	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1397	1397		10.1016/S0140-6736(97)26045-9	http://dx.doi.org/10.1016/S0140-6736(97)26045-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365471	Bronze			2022-12-28	WOS:A1997YE87200053
J	Ponder, B				Ponder, B			Genetic testing for cancer risk	SCIENCE			English	Article							OVARIAN-CANCER; FAMILIES; BREAST; BRCA1	Genetic testing for cancer susceptibility is already part of the clinical management of families with some of the well-defined (but uncommon) inherited cancer syndromes. In cases where the risks associated with a predisposing mutation are less certain, or where there is no clearly effective intervention to offer those with a positive result, its use is more controversial. Careful evaluation of costs and benefits, and of the efficacy of interventions in those found to be at risk, is essential and is only just beginning. An immediate challenge is to ensure that both health professionals and the public understand clearly the issues involved.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT ONCOL,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Ponder, B (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,CANC RES CAMPAIGN,HUMAN CANC GENET GRP,BOX 238,CAMBRIDGE CB2 2QQ,ENGLAND.							*AM SOC CLIN ONC, 1996, J CLIN ONCOL, V14, P1730; *AM SOC HUM GEN, 1994, AM J HUM GENET, V55, P1; *ASS BRIT INS, 1997, INF SHEET LIF INS GE; BROWN ML, 1995, J NATL CANCER I, V87, P1131, DOI 10.1093/jnci/87.15.1131; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Dunlop M, 1997, BRIT MED J, V314, P1779, DOI 10.1136/bmj.314.7097.1779; EASTON D, 1997, NAT GENET, V15, P210; EASTON DF, 1995, AM J HUM GENET, V56, P265; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; Green J, 1997, J Genet Couns, V6, P45, DOI 10.1023/A:1025611818643; Hallowell N., 1997, PSYCHOL HEALTH MED, V2, P149, DOI [10.1080/13548509708400572, DOI 10.1080/13548509708400572]; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; Kahn P, 1996, SCIENCE, V274, P496, DOI 10.1126/science.274.5287.496; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Marshall A, 1996, NAT BIOTECHNOL, V14, P1642, DOI 10.1038/nbt1296-1642; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; *NAPBC US PHS OFF, 1997, NAPBC NIH DOE ELSI W; Nelson NJ, 1996, J NATL CANCER I, V88, P70, DOI 10.1093/jnci/88.2.70-a; NOURANI HZ, 1996, AM J HUM GENET, V59, P301; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; *ONC INC, 1997, BRCA1 BRCA2 FACT SHE; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Richards M., 1996, PUBLIC UNDERST SCI, V5, P217, DOI [10.1088/0963-6625/5/3/003, DOI 10.1088/0963-6625/5/3/003]; Richards M P, 1995, J Genet Couns, V4, P219, DOI 10.1007/BF01408411; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; SMITH D, 1997, NAT MED, V3, P709; STREUWING JP, 1997, NEW ENGL J MED, V336, P1401; *TASK FORC GEN TES, LEG SOC IMPL HUM GEN; Williamson P, 1996, J ROY COLL PHYS LOND, V30, P443	39	67	68	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1050	1054		10.1126/science.278.5340.1050	http://dx.doi.org/10.1126/science.278.5340.1050			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353178				2022-12-28	WOS:A1997YE65200030
J	Greenfield, EM; Goldberg, VM				Greenfield, EM; Goldberg, VM			Genetic determination of bone density	LANCET			English	Editorial Material							OSTEOPOROSIS; ALLELES; VIEW				Greenfield, EM (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT ORTHOPAED, CLEVELAND, OH 44106 USA.							BEAMER W, 1997, J BONE MINER RES, V12, P174; EISMAN JA, 1995, J BONE MINER RES, V10, P1289; Gong YQ, 1996, AM J HUM GENET, V59, P146; Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470; Lewallen DG, 1995, AAOS INSTR COURS LEC, V44, P287; PEACOCK M, 1995, J BONE MINER RES, V10, P1294; Ralston SH, 1997, SCAND J CLIN LAB INV, V57, P114; Rogers J, 1997, ANN RHEUM DIS, V56, P85, DOI 10.1136/ard.56.2.85; Vezyroglou G, 1996, J RHEUMATOL, V23, P672	9	23	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1263	1264		10.1016/S0140-6736(05)62468-3	http://dx.doi.org/10.1016/S0140-6736(05)62468-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357401				2022-12-28	WOS:A1997YD68900003
J	Pedersen, AT; Lidegaard, O; Kreiner, S; Ottesen, B				Pedersen, AT; Lidegaard, O; Kreiner, S; Ottesen, B			Hormone replacement therapy and risk of non-fatal stroke	LANCET			English	Article							POSTMENOPAUSAL ESTROGEN; CARDIOVASCULAR-DISEASE; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; FOLLOW-UP; WOMEN; USERS; COPENHAGEN; MORTALITY; COHORT	Background The effect of postmenopausal hormone replacement therapy (HRT) on the risk of subtypes of stroke is as yet unclear. To investigate the effect of oestrogen and combined oestrogen-progestagen therapy on the risk of nonfatal haemorrhagic and thromboembolic stroke, we carried out a case-control study. Methods From the Danish National Patient Register we identified all Danish women aged 45-64 years who had a non-fatal, first-ever cerebrovascular attack during 1990-92. Two age-matched controls were randomly selected for each case from the Danish National Person Register. Important correlates of hormone use and stroke, on which information was obtained from postal questionnaires, were controlled for by multivariate analyses based on log-linear graphical models. The analyses included data on 1422 cases classified in four subtypes of stroke (160 subarachnoid haemorrhage, 95 intracerebral haemorrhage, 846 thromboembolic infarction, 321 transient ischaemic attack) and 3171 controls. Findings After adjustment for confounding variables and correction for the trend in sales of HRT preparations, no significant associations were detected between current use of unopposed oestrogen replacement therapy and non-fatal subarachnoid haemorrhage (odds ratio 0.52 [95% CI 0.23-1.22]), intracerebral haemorrhage (0.15 [0.02-1.09]), or thromboembolic infarction (1.16 [0.86-1.58]), respectively, compared with never use. Current use of combined oestrogen-progestagen replacement therapy had no significant influence on the risk of subarachnoid haemorrhage (1.22 [0.79-1.89]), intracerebral haemorrhage (1.17 [0.64-2.13]), or thromboembolic infarction (1.17 [0.92-1.47]). A significantly increased incidence of transient ischaemic attacks among former users of HRT and among current users of unopposed oestrogen may to some extent be explained by selection-HRT users being more aware of symptoms than non-users. Interpretation Unopposed oestrogen and combined oestrogen-progestagen replacement therapy have no influence on the risk of non-fatal thromboembolic or haemorrhagic stroke in women aged 45-64 years.	UNIV COPENHAGEN, INST SOCIOL, COPENHAGEN, DENMARK; HERLEV HOSP, DEPT OBSTET & GYNAECOL, DK-2730 HERLEV, DENMARK	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Pedersen, AT (corresponding author), UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT OBSTET & GYNAECOL 537, KETTEGARDS ALLEE 30, DK-2650 HVIDOVRE, DENMARK.							[Anonymous], [No title captured]; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DARROCH JN, 1980, ANN STAT, V8, P522, DOI 10.1214/aos/1176345006; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; Falkeborn M, 1996, EPIDEMIOLOGY, V7, P67, DOI 10.1097/00001648-199601000-00012; FEINBERG WM, 1994, CIRCULATION, V89, P2950, DOI 10.1161/01.CIR.89.6.2950; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; KLEIN JP, 1995, STAT MED, V14, P1265, DOI 10.1002/sim.4780141202; LINDEGAARD O, 1993, BRIT MED J, V306, P956; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PFEFFER RI, 1978, J CHRON DIS, V31, P389, DOI 10.1016/0021-9681(78)90003-6; ROSENBERG SH, 1980, WESTERN J MED, V133, P292; SALOMAA V, 1995, ARTERIOSCL THROM VAS, V15, P1549, DOI 10.1161/01.ATV.15.10.1549; SPEROFF L, 1996, EUR MENOPAUSE J, V3, P151; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; WERMUTH N, 1990, J ROY STAT SOC B MET, V52, P21; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; ZHANG XH, 1995, STROKE, V26, P1774, DOI 10.1161/01.STR.26.10.1774	33	122	122	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1277	1283		10.1016/S0140-6736(97)06005-4	http://dx.doi.org/10.1016/S0140-6736(97)06005-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357407				2022-12-28	WOS:A1997YD68900009
J	Nelsen, SF; Ismagilov, RF; Trieber, DA				Nelsen, SF; Ismagilov, RF; Trieber, DA			Adiabatic electron transfer: Comparison of modified theory with experiment	SCIENCE			English	Article							CHARGE RECOMBINATION; DISTANCE DEPENDENCE; SOLVENT DEPENDENCE; ACCEPTOR COMPOUNDS; RADICAL-CATION; BIS(HYDRAZINE); SEPARATION; MOLECULES; COMPLEXES; BRIDGES	The radical cations of properly designed bishydrazines allow comparison of observed and calculated electron transfer rate constants. These compounds have rate constants small enough to be measured by dynamic electron spin resonance spectroscopy and show charge transfer bands corresponding to vertical excitation from the energy well for the charge occurring upon one hydrazine unit to that for the electron-transferred species. Analysis of the data for all six compounds studied indicates that the shape of the adiabatic surface on which electron transfer occurs can be obtained from the charge transfer band accurately enough to successfully predict the electron transfer rate constant and that explicit tunneling corrections are not required for these compounds.			Nelsen, SF (corresponding author), UNIV WISCONSIN,DEPT CHEM,1101 UNIV AVE,MADISON,WI 53706, USA.							[Anonymous], 1967, PROG INORG CHEM, DOI DOI 10.1002/9780470166093.CH7; Barbara PF, 1996, J PHYS CHEM-US, V100, P13148, DOI 10.1021/jp9605663; BIXON M, 1994, J AM CHEM SOC, V116, P7349, DOI 10.1021/ja00095a044; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; CORTES J, 1994, J PHYS CHEM-US, V98, P2527, DOI 10.1021/j100061a006; CREUTZ C, 1983, PROG INORG CHEM, V30, P1, DOI 10.1002/9780470166314.ch1; CREUTZ C, 1994, J PHOTOCH PHOTOBIO A, V82, P47, DOI 10.1016/1010-6030(94)02013-2; DOORN SK, 1989, J AM CHEM SOC, V111, P1142, DOI 10.1021/ja00185a062; GOULD IR, 1994, J AM CHEM SOC, V116, P8188, DOI 10.1021/ja00097a028; GOULD IR, 1993, CHEM PHYS, V176, P439, DOI 10.1016/0301-0104(93)80253-6; HUSH NS, 1985, COORDIN CHEM REV, V64, P135, DOI 10.1016/0010-8545(85)80047-3; HUSH NS, 1985, CHEM PHYS LETT, V117, P8, DOI 10.1016/0009-2614(85)80394-8; JORTNER J, 1988, J CHEM PHYS, V88, P167, DOI 10.1063/1.454632; JORTNER J, 1975, J CHEM PHYS, V63, P4358; KROON J, 1993, J PHYS CHEM-US, V97, P5065, DOI 10.1021/j100121a036; KROON J, 1991, ANGEW CHEM INT EDIT, V30, P1358, DOI 10.1002/anie.199113581; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEYERS AB, 1996, CHEM REV, V96, P911; Nelsen SF, 1996, J AM CHEM SOC, V118, P2047, DOI 10.1021/ja952539g; Nelsen SF, 1997, J AM CHEM SOC, V119, P6863, DOI 10.1021/ja963415m; NELSEN SF, 1993, J AM CHEM SOC, V115, P12276, DOI 10.1021/ja00079a007; NELSEN SF, 1994, J AM CHEM SOC, V116, P1589, DOI 10.1021/ja00083a062; Nelsen SF, 1996, J AM CHEM SOC, V118, P6313, DOI 10.1021/ja960500l; NELSEN SF, IN PRESS J AM CHEM S; OEVERING H, 1987, J AM CHEM SOC, V109, P3258, DOI 10.1021/ja00245a014; OEVERING H, 1989, TETRAHEDRON, V45, P4751, DOI 10.1016/S0040-4020(01)85150-4; PADDONROW MN, 1988, J PHYS CHEM-US, V92, P6958, DOI 10.1021/j100335a024; Prassides K., 1991, MIXED VALENCY SYSTEM; SUTIN N, 1983, PROG INORG CHEM, V30, P441, DOI 10.1002/9780470166314.ch9; WARMAN JM, 1991, J PHYS CHEM-US, V95, P1979, DOI 10.1021/j100158a018; WASLELEWSKI MR, 1992, CHEM REV, V92, P435	31	121	121	3	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					846	849		10.1126/science.278.5339.846	http://dx.doi.org/10.1126/science.278.5339.846			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346480	Green Accepted			2022-12-28	WOS:A1997YD47900042
J	Luh, FY; Archer, SJ; Domaille, PJ; Smith, BO; Owen, D; Brotherton, DH; Raine, ARC; Xu, X; Brizuela, L; Brenner, SL; Laue, ED				Luh, FY; Archer, SJ; Domaille, PJ; Smith, BO; Owen, D; Brotherton, DH; Raine, ARC; Xu, X; Brizuela, L; Brenner, SL; Laue, ED			Structure of the cyclin-dependent kinase inhibitor p19(Ink4d)	NATURE			English	Article							FAMILIAL MELANOMA; LARGER PROTEINS; TUMOR; CDK4; P16(INK4); NMR; SPECTROSCOPY; ALLELES; ANKYRIN; P19	In cancer, the biochemical pathways that are dominated by the two tumour-suppressor proteins, p53 and Rb, are the most frequently disrupted. Cyclin D-dependent kinases phosphorylate Rb to control its activity and they are, in turn, specifically inhibited by the Ink4 family of cyclin-dependent kinase inhibitors (CDKIs) which cause arrest at the G1 phase of the cell cycle. Mutations in Rb, cyclin D1, its catalytic subunit Cdk4, and the CDKI p16(Ink4a), which alter the protein or its level of expression, are all strongly implicated in cancer. This suggests that the Rb 'pathway' is of particular importance(1). Here we report the structure of the p19(Ink4d) protein, determined by NMR spectroscopy(2-4). The structure indicates that most mutations to the p16(Ink4a) gene, which result in loss of function, are due to incorrectly folded and/or insoluble protein(5). We propose a model for the interaction of Ink4 proteins with D-type cyclin-Cdk4/6 complexes that might provide a basis for the design of therapeutics against cancer.	UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CTR MOL RECOGNIT, CAMBRIDGE CB2 1QW, ENGLAND; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; MITOTIX INC, CAMBRIDGE, MA 02139 USA	University of Cambridge; DuPont			; Smith, Brian/J-1899-2015	Laue, Ernest/0000-0002-7476-4148; Smith, Brian/0000-0003-3363-4168; Luh, Frederick/0000-0001-5180-8489	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Clowes Robin T., 1995, Current Opinion in Biotechnology, V6, P81, DOI 10.1016/0958-1669(95)80013-1; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Kalus W, 1997, FEBS LETT, V401, P127, DOI 10.1016/S0014-5793(96)01465-2; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Parry D, 1996, MOL CELL BIOL, V16, P3844; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith BO, 1996, J BIOMOL NMR, V8, P360, DOI 10.1007/BF00410335; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WICK ST, 1995, ONCOGENE, V11, P2013; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; YANG R, 1995, CANCER RES, V55, P2503; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734	30	89	92	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					999	1003		10.1038/40202	http://dx.doi.org/10.1038/40202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353127				2022-12-28	WOS:A1997YD29900063
J	Haarmeier, T; Thier, P; Repnow, M; Petersen, D				Haarmeier, T; Thier, P; Repnow, M; Petersen, D			False perception of motion in a patient who cannot compensate for eye movements	NATURE			English	Article							CORTICAL AREAS MT; MST	We are usually unaware of the motion of an image across our retina that results from our own movement. For instance, during slow-tracking eye movements we do not mistake the shift of the image projected onto the retina for motion of the world around us, but instead perceive a stable world. Following early suggestions by von Helmoltz(1), it is commonly believed that this spatial stability is achieved by subtracting the retinal motion signal from an internal reference signal, such as a copy of the movement command (efference copy)(2-4). Object motion is perceived only if the two differ. Although this concept is widely accepted, its anatomical underpinning remains unknown. Here we describe the case of a patient with bilateral extrastriate cortex lesions, suffering from false perception of motion due to an inability to take eye movements into account when faced with self-induced retinal image slip. This is indicated by the fact that during smooth-pursuit eye movements, he perceives motion of the stationary world at a velocity that corresponds to the velocity of his eye movement; that is, he perceives the raw retinal image slip uncorrected for his own eye movements. We suspect that this deficiency reflects damage of a distinct parieto-occipital region that disentangles self-induced and externally induced visual motion by comparing retinal signals with a reference signal encoding eye movements and possibly ego-motion in general.	UNIV TUBINGEN,DEPT NEUROL,SECT SENSORIMOTOR RES,D-72076 TUBINGEN,GERMANY; UNIV TUBINGEN,DEPT NEURORADIOL,SECT SENSORIMOTOR RES,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen				Thier, Peter/0000-0001-5909-4222				ERICKSON RG, 1991, EXP BRAIN RES, V86, P608; Filehne W., 1922, Z SINNESPHYSIOL, V53, P134; Haarmeier T, 1996, VISION RES, V36, P741, DOI 10.1016/0042-6989(95)00154-9; Haarmeier T., 1997, Society for Neuroscience Abstracts, V23, P1950; HAARMEIER T, IN PRESS J COGN NEUR; Herbst H, 1997, EVOKED POTENTIAL, V104, P82, DOI 10.1016/S0168-5597(96)95722-6; Ilg UJ, 1996, EUR J NEUROSCI, V8, P1156; KOMATSU H, 1988, J NEUROPHYSIOL, V60, P621, DOI 10.1152/jn.1988.60.2.621; KOMATSU H, 1988, J NEUROPHYSIOL, V60, P580, DOI 10.1152/jn.1988.60.2.580; LIEBERMAN HR, 1982, BEHAV RES METH INSTR, V14, P21, DOI 10.3758/BF03202110; MACK A, 1973, Q J EXP PSYCHOL, V25, P71, DOI 10.1080/14640747308400324; MCKEE SP, 1985, PERCEPT PSYCHOPHYS, V37, P286, DOI 10.3758/BF03211350; REGAN D, 1991, BRAIN, V114, P1129, DOI 10.1093/brain/114.3.1129; RIZZO M, 1995, BRAIN, V118, P1105, DOI 10.1093/brain/118.5.1105; SPERRY RW, 1950, J COMP PHYSIOL PSYCH, V43, P482, DOI 10.1037/h0055479; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; von Helmholtz H, 1962, PHYSL OPTICS, VIII; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503; WERTHEIM AH, 1994, BEHAV BRAIN SCI, V17, P293, DOI 10.1017/S0140525X00034646; ZEKI S, 1991, J NEUROSCI, V11, P641	20	107	107	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					849	852		10.1038/39872	http://dx.doi.org/10.1038/39872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349816				2022-12-28	WOS:A1997YC14800057
J	Yang, DD; Kuan, CY; Whitmarsh, AJ; Rincon, M; Zheng, TS; Davis, RJ; Rakic, P; Flavell, RA				Yang, DD; Kuan, CY; Whitmarsh, AJ; Rincon, M; Zheng, TS; Davis, RJ; Rakic, P; Flavell, RA			Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene	NATURE			English	Article							EXCITATORY AMINO-ACIDS; KAINIC ACID; NERVOUS-SYSTEM; C-JUN; BRAIN-DAMAGE; KINASE; NEUROTOXICITY; GLUTAMATE; PATHWAY; SEIZURE	Excitatory amino acids induce both acute membrane depolarization and latent cellular toxicity, which often leads to apoptosis in many neurological disorders(1,2). Recent studies indicate that glutamate toxicity may involve the c-Jun amino-terminal kinase (JNK) group of mitogen-activated protein (MAP) kinases(3-5). One member of the JNK family, Jnk3, may be required for stress-induced neuronal apoptosis, as it is Selectively expressed in the nervous system(6,7). Here we report that disruption of the gene encoding Jnk3 in mice caused the mice to be resistant to the excitotoxic glutamate-receptor agonist kainic acid: they showed a reduction in seizure activity and hippocampal neuron apoptosis was prevented. Although application of kainic add imposed the same level of noxious stress, the phosphorylation of c-Jun and the transcriptional activity of the AP-1 transcription factor complex were markedly reduced in the mutant mice. These data indicate that the observed neuroprotection is due to the extinction of a Jnk3-mediated signalling, pathway, which is an important component in the pathogenesis of glutamate neurotoxicity.	YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA; UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV VERMONT, DEPT MED, IMMUNOBIOL PROGRAM, BURLINGTON, VT 05405 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Vermont				Whitmarsh, Alan/0000-0003-1184-6610				BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; BERGER M, 1983, NEUROSCI LETT, V39, P237, DOI 10.1016/0304-3940(83)90306-3; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FERKANY JW, 1984, NATURE, V308, P561, DOI 10.1038/308561a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; KASOF GM, 1995, J NEUROSCI, V15, P4238; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Martin JH, 1996, MOL BRAIN RES, V35, P47, DOI 10.1016/0169-328X(95)00181-Q; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	30	1082	1141	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	1997	389	6653					865	870		10.1038/39899	http://dx.doi.org/10.1038/39899			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349820				2022-12-28	WOS:A1997YC14800061
J	Muhart, M; McFalls, S; Kirsner, R; Kerdel, F; Eaglstein, WH				Muhart, M; McFalls, S; Kirsner, R; Kerdel, F; Eaglstein, WH			Bioengineered skin	LANCET			English	Article									UNIV MIAMI,SCH MED,DEPT DERMATOL & CUTANEOUS SURG,MIAMI,FL 33101	University of Miami								EAGLSTEIN WH, 1995, J DERM SURG, V21, P1; McCarthy M, 1996, LANCET, V348, P466, DOI 10.1016/S0140-6736(05)64548-5; MECHCATIE E, 1995, SKIN ALLERGY NE 0804; MESZAROS L, 1995, DERMATOL TIMES  0715	4	32	35	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1142	1142		10.1016/S0140-6736(05)63788-9	http://dx.doi.org/10.1016/S0140-6736(05)63788-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343505	hybrid			2022-12-28	WOS:A1997YB19900015
J	Malagnac, F; Wendel, B; Goyon, C; Faugeron, G; Zickler, D; Rossignol, JL; NoyerWeidner, M; Vollmayr, P; Trautner, TA; Walter, J				Malagnac, F; Wendel, B; Goyon, C; Faugeron, G; Zickler, D; Rossignol, JL; NoyerWeidner, M; Vollmayr, P; Trautner, TA; Walter, J			A gene essential for de novo methylation and development in ascobolus reveals a novel type of eukaryotic DNA methyltransferase structure	CELL			English	Article							CYTOSINE METHYLTRANSFERASE; ARABIDOPSIS-THALIANA; HOST DEFENSE; IMMERSUS; CELLS; CDNA; EXPRESSION; TRANSFORMATION; PURIFICATION; INACTIVATION	Molecular mechanisms determining methylation patterns in eukaryotic genomes still remain unresolved. We have characterized, in Ascobolus, a gene for de novo methylation. This novel eukaryotic gene, masc1, encodes a protein that has all motifs of the catalytic domain of eukaryotic C5-DNA-methyltransferases but is unique in that it lacks a regulatory N-terminal domain. The disruption of masc1 has no effect on viability or methylation maintenance but prevents the de novo methylation of DNA repeats, which takes place after fertilization, through the methylation induced premeiotically (MIP) process. Crosses between parents harboring the masc1 disruption are arrested at an early stage of sexual reproduction, indicating that the activity of Masc1, the product of the gene, is crucial in this developmental process.	MAX PLANCK INST MOL GENET,ABT TRAUTNER,D-14195 BERLIN,GERMANY; UNIV PARIS 11,INST GENET & MICROBIOL,CNRS,F-91405 ORSAY,FRANCE	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Malagnac, Fabienne/0000-0003-1139-7691				Aniello F, 1996, GENE, V178, P57, DOI 10.1016/0378-1119(96)00334-4; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; COLOT V, 1995, GENETICS, V141, P1299; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; FAUGERON G, 1989, GENE, V76, P109, DOI 10.1016/0378-1119(89)90013-9; FAUGERON G, 1990, GENETICS, V124, P585; FINNEGAN EJ, 1993, NUCLEIC ACIDS RES, V21, P2383, DOI 10.1093/nar/21.10.2383; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; GOYON C, 1989, MOL CELL BIOL, V9, P2818, DOI 10.1128/MCB.9.7.2818; Goyon C, 1996, NUCLEIC ACIDS RES, V24, P3348, DOI 10.1093/nar/24.17.3348; Goyon C, 1996, MOL CELL BIOL, V16, P3054; GOYON C, 1994, J MOL BIOL, V240, P42, DOI 10.1006/jmbi.1994.1416; GRIFFITHS AJF, 1976, CAN J GENET CYTOL, V18, P35, DOI 10.1139/g76-005; GUNTHERT U, 1981, J BIOL CHEM, V256, P9340; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HAGEMANN AT, 1996, EPIGENETIC MECH GENE, P335; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KELLEHER JE, 1991, J MOL BIOL, V221, P431, DOI 10.1016/0022-2836(91)80064-2; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; Lei H, 1996, DEVELOPMENT, V122, P3195; Leonhardt H., 1993, DNA methylation: molecular biology and biological significance., P109; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; NOYERWEIDNER M, 1993, DNA METHYLATION MOL, P39; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2424; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; RHOUNIM L, 1994, CURR GENET, V26, P344, DOI 10.1007/BF00310499; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH SS, 1994, PROG NUCLEIC ACID RE, V49, P65; TAJIMA S, 1995, J BIOCHEM-TOKYO, V117, P1050, DOI 10.1093/oxfordjournals.jbchem.a124805; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	40	110	116	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					281	290		10.1016/S0092-8674(00)80410-9	http://dx.doi.org/10.1016/S0092-8674(00)80410-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346245	Bronze			2022-12-28	WOS:A1997YC35000015
J	Skowyra, D; Craig, KL; Tyers, M; Elledge, SJ; Harper, JW				Skowyra, D; Craig, KL; Tyers, M; Elledge, SJ; Harper, JW			F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex	CELL			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; G1 CYCLINS; DEGRADATION; INHIBITOR; KINASE; PROTEOLYSIS; ACTIVATION; PATHWAY; ENCODES	We have reconstituted the ubiquitination pathway for the Cdk inhibitor Sic1 using recombinant proteins. Skp1, Cdc53, and the F-box protein Cdc4 form a complex, SCFCdc4, which functions as a Sic1 ubiquitin-ligase (E3) in combination with the ubiquitin conjugating enzyme (E2) Cdc34 and E1. Cdc4 assembled with Skp1 functions as the receptor that selectively binds phosphorylated Sic1. Grr1, an F-box protein involved in Cln destruction, forms complexes with Skp1 and Cdc53 and binds phosphorylated Cln1 and Cln2, but not Sic1. Because the constituents of the SCF complex are members of protein families, SCFCdc4 in likely to serve as the prototype for a large class of E3s formed by combinatorial interactions of related family members. SCF complexes couple protein kinase signaling pathways to the control of protein abundance.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAM MOL BIOL & CANC,TORONTO,ON M5G 1X5,CANADA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Tyers, Michael/ABE-3194-2021	Harper, Jeffrey/0000-0002-6944-7236	NIA NIH HHS [AG-11085] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HENHOZ S, 1997, IN PRESS GENES DEV; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LI F, 1997, IN PRESS EMBO J; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VISINTIN R, 1997, IN PRESS SCIENCE; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	42	1017	1045	1	53	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					209	219		10.1016/S0092-8674(00)80403-1	http://dx.doi.org/10.1016/S0092-8674(00)80403-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346238	Bronze			2022-12-28	WOS:A1997YC35000008
J	Whitehead, M; Gustafsson, RA; Diderichsen, F				Whitehead, M; Gustafsson, RA; Diderichsen, F			Why is Sweden rethinking its NHS style reforms?	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; WELFARE		KAROLINSKA INST,DEPT PUBL HLTH SCI,S-17283 SUNDBYBERG,SWEDEN	Karolinska Institutet			Diderichsen, Finn/P-4654-2019	Diderichsen, Finn/0000-0002-9998-4972				BERGMAN SE, 1994, 250 SPRI SWED I DEV; Dahlgren Goran, 1994, FRAMTIDENS SJUKVARDS; DAHLSTROM A, 1995, 398 SPRI SWED I DEV; DIDERICHSEN F, 1995, HEALTH POLICY, V32, P141, DOI 10.1016/0168-8510(95)00732-8; *GOV COMM REIMB PR, 1996, FUT SCOP REIMB SYST, P91; GUSTAFSSON RA, 1995, INT J HEALTH SERV, V25, P243, DOI 10.2190/F81H-W0PL-PMWA-1J0R; Hanning M, 1996, HEALTH POLICY, V36, P17, DOI 10.1016/0168-8510(95)00791-1; *HLTH SERV MED CAR, 1994, HSU 2000 SJUKV ANDR; *HLTH SERV MED CAR, 1994, HSU 2000 INT PERSP H; JONSSON E, 1994, HAR STOCKHOLMSMODELL; Mechanic D, 1996, MILBANK Q, V74, P171, DOI 10.2307/3350245; *NAT BOARD HLTH WE, 1994, VARDG 1993, P14; *NAT BOARD HLTH WE, 1993, ADEL REF ARSR 1993, P8; *NAT BOARD HLTH WE, 1996, PLAN MARKN NYA STYRF; *STOCKH COUNT COUN, 1995, 1095 STOCKH COUNT CO; *STOCKH COUNT COUN, 1996, 19960325 STOCK COUNT; *STOCKH COUNT COUN, 1996, 2096 STOCKH COUNT CO, P2; *STOCKH COUNT COUN, 1995, FRAN PRISST TILL AVT; *STOCKH COUNT COUN, 1995, 19950327 STOCKH COUN; *STOCKH COUNT COUN, 1995, ARSR FOR STOCKH LANS, P2; *STOCKH COUNT COUN, 1993, 393 STOCKH COUNT COU; *STOCKH COUNT COUN, 1992, 19920921 STOCKH COUN; *STOCKH COUNT COUN, 1993, ARSR FOR KONC STOCKH; SVALLFORS S, 1995, ACTA SOCIOL, V38, P53, DOI 10.1177/000169939503800105; *SWED I DEV HLTH S, 1993, 339 SPRI SWED I DEV; Werko L, 1989, Lakartidningen, V86, P2505; *WHO, 1996, HLTH ALL DAT	27	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					935	939						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB073	9361546				2022-12-28	WOS:A1997YB07300033
J	Menzies, D; Bourbeau, J				Menzies, D; Bourbeau, J			Building-related illnesses	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VOLATILE ORGANIC-COMPOUNDS; INDOOR AIR-QUALITY; CARBONLESS COPY PAPER; 2 OFFICE BUILDINGS; VENTILATION SYSTEM; HYPERSENSITIVITY PNEUMONITIS; LEGIONELLA-PNEUMOPHILA; CONTROLLED EXPOSURE; PASSIVE SMOKING; VARYING LEVELS		MONTREAL CHEST INST, DEPT MED, MONTREAL, PQ, CANADA; MONTREAL CHEST INST, DEPT EPIDEMIOL & BIOSTAT, MONTREAL, PQ, CANADA	McGill University; McGill University	Menzies, D (corresponding author), MCGILL UNIV, RESP EPIDEMIOL UNIT, 1110 PINE AVE W, MONTREAL, PQ H3A 1A3, CANADA.		anand, amit/A-7222-2009; Trajman, Anete/C-7679-2016	Trajman, Anete/0000-0002-4000-4984				AHLSTROM R, 1986, Environment International, V12, P289, DOI 10.1016/0160-4120(86)90041-3; ANDERSEN I, 1973, ARCH ENVIRON HEALTH, V26, P22, DOI 10.1080/00039896.1973.10666213; ANDERSEN I, 1974, ARCH ENVIRON HEALTH, V29, P319, DOI 10.1080/00039896.1974.10666606; ARNOW PM, 1978, AM J MED, V64, P236, DOI 10.1016/0002-9343(78)90051-7; BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; BAUER RM, 1992, J CONSULT CLIN PSYCH, V60, P213, DOI 10.1037/0022-006X.60.2.213; BERNSTEIN RS, 1983, AM IND HYG ASSOC J, V44, P161, DOI 10.1080/15298668391404581; Bourbeau J, 1996, OCCUP ENVIRON MED, V53, P204, DOI 10.1136/oem.53.3.204; BROWN SK, 1994, INDOOR AIR, V4, P123, DOI 10.1111/j.1600-0668.1994.t01-2-00007.x; BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108; BURGE PS, 1985, THORAX, V40, P248, DOI 10.1136/thx.40.4.248; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; CHAPPELL SB, 1977, CAN J PUBLIC HEALTH, V68, P159; Christie  B., 1985, HUMAN FACTORS INFORM; DANIELL W, 1991, J OCCUP ENVIRON MED, V33, P681, DOI 10.1097/00043764-199106000-00007; DENNIS PJ, 1982, LANCET, V1, P949; DOELAND HJ, 1989, MUSCLE NERVE, V12, P712, DOI 10.1002/mus.880120903; FARKAS J, 1983, CONTACT DERMATITIS, V9, P79, DOI 10.1111/j.1600-0536.1983.tb04636.x; FISK WJ, 1993, INDOOR AIR, V3, P246, DOI DOI 10.1111/J.1600-0668.1993.00005.X; FRASER DW, 1977, NEW ENGL J MED, V297, P1189, DOI 10.1056/NEJM197712012972201; GRAVESEN S, 1986, ALLERGY, V41, P520, DOI 10.1111/j.1398-9995.1986.tb00337.x; GRIVEL F, 1991, ERGONOMICS, V34, P365, DOI 10.1080/00140139108967320; HARRISON J, 1992, RESP MED, V86, P225, DOI 10.1016/S0954-6111(06)80060-0; HECKERLING PS, 1987, ANN INTERN MED, V107, P174, DOI 10.7326/0003-4819-107-2-174; HODGSON MJ, 1991, J OCCUP ENVIRON MED, V33, P527; HOFFMAN RE, 1993, AM J PUBLIC HEALTH, V83, P89, DOI 10.2105/AJPH.83.1.89; HORVATH EP, 1988, JAMA-J AM MED ASSOC, V259, P701, DOI 10.1001/jama.259.5.701; HORVATH SM, 1971, ARCH ENVIRON HEALTH, V23, P343, DOI 10.1080/00039896.1971.10666019; HUGENHOLTZ P, 1992, APPL ENVIRON MICROB, V58, P3914, DOI 10.1128/AEM.58.12.3914-3920.1992; JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755, DOI 10.1093/oxfordjournals.aje.a117498; JAAKKOLA JJK, 1991, ENVIRON INT, V17, P371, DOI 10.1016/0160-4120(91)90025-L; JAAKKOLA JJK, 1995, OCCUP ENVIRON MED, V52, P709, DOI 10.1136/oem.52.11.709; JAAKKOLA JJK, 1994, AM J PUBLIC HEALTH, V84, P422, DOI 10.2105/AJPH.84.3.422; JAAKKOLA JJK, 1989, ENVIRON INT, V15, P163, DOI 10.1016/0160-4120(89)90022-6; JAAKKOLA JJK, 1995, EUR J EPIDEMIOL, V11, P213, DOI 10.1007/BF01719490; Jaakkola JJK, 1991, INDOOR AIR, V1, P111; Jarvis BB, 1996, J NAT PROD, V59, P553, DOI 10.1021/np960395t; KARASEK RA, 1988, AM J PUBLIC HEALTH, V78, P910, DOI 10.2105/AJPH.78.8.910; KAUFMANN AF, 1981, AM J EPIDEMIOL, V114, P337, DOI 10.1093/oxfordjournals.aje.a113200; KJAERGAARD SK, 1991, ATMOS ENVIRON A-GEN, V25, P1417; KLITZMAN S, 1989, SOC SCI MED, V29, P733, DOI 10.1016/0277-9536(89)90153-6; LAMARTE FP, 1988, JAMA-J AM MED ASSOC, V260, P242, DOI 10.1001/jama.260.2.242; MAIN DM, 1983, J OCCUP ENVIRON MED, V25, P896, DOI 10.1097/00043764-198312000-00013; MARKS JG, 1984, JAMA-J AM MED ASSOC, V252, P1038; Mendell MJ, 1996, EPIDEMIOLOGY, V7, P583, DOI 10.1097/00001648-199611000-00004; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; Mendell MJ., 1993, INDOOR AIR, V3, P227, DOI DOI 10.1111/J.1600-0668.1993.00003.X; Menzies D, 1997, ARCH ENVIRON HEALTH, V52, P360, DOI 10.1080/00039899709602212; Menzies D, 1996, AM J PUBLIC HEALTH, V86, P1629, DOI 10.2105/AJPH.86.11.1629; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; Molhave L., 1993, INDOOR AIR, V3, P155; MORGAN MS, 1986, J OCCUP ENVIRON MED, V28, P415, DOI 10.1097/00043764-198606000-00007; NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302; NORBACK D, 1990, SCAND J WORK ENV HEA, V16, P121, DOI 10.5271/sjweh.1808; OTTO D, 1990, NEUROTOXICOL TERATOL, V12, P649, DOI 10.1016/0892-0362(90)90079-R; PASANEN PO, 1994, INDOOR AIR, V4, P106, DOI 10.1111/j.1600-0668.1994.t01-2-00005.x; REINIKAINEN LM, 1992, ARCH ENVIRON HEALTH, V47, P8, DOI 10.1080/00039896.1992.9935938; REINIKAINEN LM, 1991, ENVIRON INT, V17, P243, DOI 10.1016/0160-4120(91)90009-F; RITCHIE IM, 1987, AM J PUBLIC HEALTH, V77, P323, DOI 10.2105/AJPH.77.3.323; ROBERTSON AS, 1985, BRIT MED J, V291, P373, DOI 10.1136/bmj.291.6492.373; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; SALVAGGIO JE, 1990, CLIN EXP ALLERGY, V20, P137, DOI 10.1111/j.1365-2222.1990.tb02658.x; SCHNEIDER T, 1986, Environment International, V12, P61, DOI 10.1016/0160-4120(86)90014-0; SKOV P, 1989, SCAND J WORK ENV HEA, V15, P286, DOI 10.5271/sjweh.1851; SKOV P, 1990, SCAND J WORK ENV HEA, V16, P363, DOI 10.5271/sjweh.1772; SMORAGIEWICZ W, 1993, INT ARCH OCC ENV HEA, V65, P113, DOI 10.1007/BF00405729; STENBERG B, 1994, INT J EPIDEMIOL, V23, P1190, DOI 10.1093/ije/23.6.1190; Stenerg B, 1993, INDOOR AIR, V3, P71, DOI [DOI 10.1111/j.1600-0668.1993.t01-2-00002.x, 10.1111/j.1600-0668.1993.t01-2-00002.x, DOI 10.11II/J.1600-0668.1993.T01-2-00002.X]; SUNDELL J, 1994, ENVIRON INT, V20, P239, DOI 10.1016/0160-4120(94)90141-4; SUNDELL J, 1994, INDOOR AIR, V4, P83, DOI 10.1111/j.1600-0668.1994.t01-2-00003.x; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339; TENCATI JR, 1983, ANN INTERN MED, V98, P320, DOI 10.7326/0003-4819-98-3-320; TURIEL I, 1983, ATMOS ENVIRON, V17, P51, DOI 10.1016/0004-6981(83)90007-0; Vanderstraeten P, 1984, INDOOR AIR 1984, V4, P335; VERBECK SJA, 1981, CONTACT DERMATITIS, V7, P354, DOI 10.1111/j.1600-0536.1981.tb04115.x; Wallace L. A., 1993, INDOOR AIR, V3, P193, DOI [10.1111/j.1600-0668.1993.t01-1-00005.x, DOI 10.1111/J.1600-0668.1993.T01-1-00005.X]; WALLACE LA, 1983, JAPCA J AIR WASTE MA, V33, P678, DOI 10.1080/00022470.1983.10465626; WEBER A, 1984, PREV MED, V13, P618, DOI 10.1016/S0091-7435(84)80012-2; WHO, 1983, IND AIR POLL EXP HLT; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOODARD ED, 1988, JAMA-J AM MED ASSOC, V259, P1965, DOI 10.1001/jama.259.13.1965; WOODWARD A, 1991, SCAND J WORK ENV HEA, V17, P293, DOI 10.5271/sjweh.1699; WYON DP, 1992, ENVIRON TECHNOL, V13, P313, DOI 10.1080/09593339209385159; Zweers T, 1992, INDOOR AIR, V2, P127, DOI DOI 10.1111/J.1600-0668.1992.00001.X; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	100	115	117	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1524	1531		10.1056/NEJM199711203372107	http://dx.doi.org/10.1056/NEJM199711203372107			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366585				2022-12-28	WOS:A1997YG24900007
J	Kuroo, M; Matsumura, Y; Aizawa, H; Kawaguchi, H; Suga, T; Utsugi, T; Ohyama, Y; Kurabayashi, M; Kaname, T; Kume, E; Iwasaki, H; Iida, A; ShirakiIida, T; Nishikawa, S; Nagai, R; Nabeshima, Y				Kuroo, M; Matsumura, Y; Aizawa, H; Kawaguchi, H; Suga, T; Utsugi, T; Ohyama, Y; Kurabayashi, M; Kaname, T; Kume, E; Iwasaki, H; Iida, A; ShirakiIida, T; Nishikawa, S; Nagai, R; Nabeshima, Y			Mutation of the mouse klotho gene leads to a syndrome resembling ageing	NATURE			English	Article							LACTASE-PHLORIZIN HYDROLASE; ELONGATION FACTOR-1-ALPHA; SUPERFAMILY; PROMOTER; MICE	A new gene, termed klotho, has been identified that is involved in the suppression of several ageing phenotypes. A defect in klotho gene expression in the mouse results in a syndrome that resembles human ageing, Including a short lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis and emphysema. The gene encodes a membrane protein that shares sequence similarity with the B-glucosidase enzymes. The klotho gene product may function as part of a signalling pathway that regulates ageing in vivo and morbidity In age-related diseases.	GUNMA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,MAEBASHI,GUMMA 371,JAPAN; UNIV TOKYO,FAC MED,DEPT ORTHOPAED SURG,BUNKYO KU,TOKYO 113,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 862,JAPAN; TANABE SEIYAKU CO LTD,LEAD OPTIMIZAT RES LAB,TODA,SAITAMA 335,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN; KYOWA HAKKO KOGYO CO LTD,PHARMACEUT RES LABS,NAGAIZUMI,SHIZUOKA 411,JAPAN; JRDC,CREST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Gunma University; University of Tokyo; Kumamoto University; Mitsubishi Tanabe Pharma Corporation; Kyowa Kirin Ltd; Kyowa Kirin Ltd; Japan Science & Technology Agency (JST); Osaka University	Kuroo, M (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV MOL GENET,4-1-1 OGAWAHIGASKI,KODAIRA,TOKYO 187,JAPAN.							Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; CHUTTANI A, 1995, HDB PHYSL, V11, P309; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; Ellis NA, 1996, NATURE, V381, P110, DOI 10.1038/381110a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; HANAOKA K, 1991, DIFFERENTIATION, V48, P183, DOI 10.1111/j.1432-0436.1991.tb00256.x; HAUSMAN PB, 1985, HDB BIOL AGING, P414; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; KANAME T, 1993, CYTOGENET CELL GENET, V64, P195, DOI 10.1159/000133573; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KUROO M, 1995, CIRC RES, V76, P148, DOI 10.1161/01.RES.76.1.148; LANSING AI, 1959, ARTERIAL WALL, P136; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MASER EJ, 1995, HDB PHYSL, V11, P3; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P155; ROBBINS SL, 1981, BASIC PATHOLOGY, P3; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sambrook J., 1989, MOL CLONING; TAKEDA T, 1991, J AM GERIATR SOC, V39, P911, DOI 10.1111/j.1532-5415.1991.tb04460.x; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOLFSON L, 1992, PRINCIPLES GERIATRIC, P75; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	26	2556	2756	2	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					45	51		10.1038/36285	http://dx.doi.org/10.1038/36285			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363890				2022-12-28	WOS:A1997YE47700045
J	Turner, R; Stratton, I; Horton, V; Manley, S; Zimmet, P; Mackay, IR; Shattock, M; Bottazzo, GF; Holman, R				Turner, R; Stratton, I; Horton, V; Manley, S; Zimmet, P; Mackay, IR; Shattock, M; Bottazzo, GF; Holman, R			UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes	LANCET			English	Article							ANTIBODIES; MELLITUS; RELATIVES; IDDM; DIAGNOSIS; ADULTS; ONSET; DISEASE; MARKERS	Background Autoantibodies to islet-cell cytoplasm (ICA) and glutamic acid decarboxylase (GADA) can occur in apparently typical, non-insulin dependent diabetes mellitus (type 2). We investigated whether the presence of either or both antibodies characterises a subtype of diabetes and provides better prediction of requirement for insulin therapy by 6 years' follow-up than clinical variables. Methods We measured ICA and GADA at diagnosis of diabetes in a representative population of 3672 white patients with type 2 diabetes, aged between 25 and 65 years. The phenotype was assessed by age of onset, body-mass index, percentage haemoglobin A(1c) (HbA(1c)), and islet beta-cell function. We investigated the need for insulin therapy among 1538 patients not assigned insulin and followed up for 6 years from diagnosis. Findings The proportion of patients with ICA and GADA decreased with increasing age at diagnosis (from 33 [21%] of 157 patients aged 25-65 to 66 [4%] of 1769 aged 55-65 for ICA; from 53 [34%] to 122 [7%] for GADA). Among patients younger than 35 at diagnosis, those with ICA or GADA had lower body-mass index than those without (mean 24.9 [SD 6.0] vs 31.7 [7.3] kg/m(2); p<0.0001 and had higher percentage of HbA(1c) (9.7 vs 8.7%, p<0.05). 94% of patients with ICA and 84% of those with GADA required insulin therapy by 6 years, compared with 14% of those without the antibodies (p<0.0001). Among patients older than 55 at diagnosis, the difference between those with and without antibodies in body-mass index was smaller (27.2 [5.4] vs 28.6 [4.8] kg/m(2), p<0.001); 44% of those with ICA, 34% of those with GADA, and 5% with neither antibody required insulin therapy by 6 years (p<0.0001). Among patients older than 45 years, body-mass index and HbA(1c) provided little predictive information for insulin requirement, whereas the positive predictive values of GADA (greater than or equal to 60 U/L) alone, or both GADA (greater than or equal to 20 U/L) and ICA (>5 U/L), for insulin therapy were 52% and 68%. Interpretation Among young adults with type 2 diabetes, the phenotype of those with ICA or GADA antibodies was similar to that of classic juvenile-onset insulin-dependent diabetes, and either phenotype or antibodies predicted insulin requirement. In older adults, the phenotype was closer to that of patients without antibodies and only the presence of antibodies predicted an increased likelihood of insulin requirement.	INT DIABET INST,MELBOURNE,VIC,AUSTRALIA; MONASH UNIV,DEPT BIOCHEM & MOL BIOL,CLAYTON,VIC 3168,AUSTRALIA; ST BARTHOLOMEWS & ROYAL LONDON MED SCH & DENT,DEPT IMMUNOL,LONDON,ENGLAND	Monash University; University of London; Queen Mary University London	Turner, R (corresponding author), RADCLIFFE INFIRM,DIABET RES LABS,UK PROSPECT DIBAET STUDY GRP,WOODSTOCK RD,OXFORD OX2 6HE,ENGLAND.		stratton, irene/AAZ-3627-2020; Mackay, Ian R/A-7228-2010; Zimmet, Paul/O-8486-2019	stratton, irene/0000-0003-1172-7865; Zimmet, Paul/0000-0003-0627-0776; Manley, Susan/0000-0002-8298-4511				BAEKKESKOV V, 1990, NATURE, V347, P152; BINGLEY PJ, 1994, DIABETES, V43, P1304, DOI 10.2337/diabetes.43.11.1304; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BONIFACIO E, 1995, DIABETOLOGIA, V38, P816, DOI 10.1007/s001250050358; BOTTAZZO GF, 1993, DIABETES, V42, P778; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; CHEN QY, 1993, PEDIATR RES, V34, P785, DOI 10.1203/00006450-199312000-00018; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; GLEICHMANN H, 1984, DIABETOLOGIA, V27, P90, DOI 10.1007/BF00275656; GOTTSATER A, 1995, DIABETES RES CLIN PR, V27, P133, DOI 10.1016/0168-8227(95)01026-A; GROOP L, 1988, DIABETES, V37, P99, DOI 10.2337/diabetes.37.1.99; GROOP LC, 1986, DIABETES, V35, P237, DOI 10.2337/diabetes.35.2.237; IRVINE WJ, 1977, LANCET, V1, P1025; KOBAYASHI T, 1993, DIABETES CARE, V16, P780, DOI 10.2337/diacare.16.5.780; KOBAYASHI T, 1987, DIABETES, V36, P510, DOI 10.2337/diabetes.36.4.510; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; NABARRO JDN, 1991, DIABETIC MED, V8, P59, DOI 10.1111/j.1464-5491.1991.tb01517.x; NISKANEN LK, 1995, DIABETES CARE, V18, P1557, DOI 10.2337/diacare.18.12.1557; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; SANJEEVI CB, 1996, DIABETOLOGIA, V39, pS301; Seissler J, 1996, DIABETOLOGIA, V39, P1351, DOI 10.1007/s001250050582; TUOMI T, 1993, DIABETES, V42, P359, DOI 10.2337/diabetes.42.2.359; *UKPDS GROUP, IN PRESS UK PROSP DI, V24; *UKPDS GROUP, 1991, DIABETOLOGIA, V34, P877; VERGE CF, 1994, DIABETOLOGIA, V37, P113; Willis JA, 1996, DIABETES RES CLIN PR, V33, P89, DOI 10.1016/0168-8227(96)01281-8; ZIMMET PZ, 1994, DIABETIC MED, V11, P299, DOI 10.1111/j.1464-5491.1994.tb00275.x; 1985, LANCET, V2, P809	30	564	612	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1288	1293		10.1016/S0140-6736(97)03062-6	http://dx.doi.org/10.1016/S0140-6736(97)03062-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357409				2022-12-28	WOS:A1997YD68900011
J	Pufahl, RA; Singer, CP; Peariso, KL; Lin, SJ; Schmidt, PJ; Fahrni, CJ; Culotta, VC; PennerHahn, JE; OHalloran, TV				Pufahl, RA; Singer, CP; Peariso, KL; Lin, SJ; Schmidt, PJ; Fahrni, CJ; Culotta, VC; PennerHahn, JE; OHalloran, TV			Metal ion chaperone function of the soluble Cu(I) receptor Atx1	SCIENCE			English	Article							WILSON-DISEASE GENE; COPPER-TRANSPORTING ATPASE; MENKES DISEASE; IRON UPTAKE; CHEMISTRY; COMPLEX; MECHANISM; PROTEINS; ENCODES; BINDING	Reactive and potentially toxic cofactors such as copper ions are imported into eukaryotic cells and incorporated into target proteins by unknown mechanisms. Atx1, a prototypical copper chaperone protein from yeast, has now been shown to act as a soluble cytoplasmic copper(l) receptor that can adopt either a two-or three-coordinate metal center in the active site. Atx1 also associated directly with the Atx1-like cytosolic domains of Ccc2, a vesicular protein defined in genetic studies as a member of the copper-trafficking pathway. The unusual structure and dynamics of Atx1 suggest a copper exchange function for this protein and related domains in the Menkes and Wilson disease proteins.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA; UNIV MICHIGAN, DEPT CHEM, ANN ARBOR, MI 48109 USA; JOHNS HOPKINS UNIV, DEPT ENVIRONM HLTH SCI, BALTIMORE, MD 21205 USA	Northwestern University; Northwestern University; University of Michigan System; University of Michigan; Johns Hopkins University			Penner-Hahn, James/GYD-3750-2022; O'Halloran, Thomas/ABE-6125-2021; Peariso, Katrina/AAQ-2090-2021; Peariso, Katrina/Y-1516-2019	Penner-Hahn, James/0000-0003-0314-1274; O'Halloran, Thomas/0000-0001-8732-5059; Peariso, Katrina/0000-0003-1616-8329	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111, R01GM050016, R29GM038047, R37GM050016, R01GM038047] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50016, R01 GM054111, GM-38047, GM-54111] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CHEESMAN BV, 1988, J AM CHEM SOC, V110, P6359, DOI 10.1021/ja00227a014; COUCOUVANIS D, 1980, INORG CHEM, V19, P2993, DOI 10.1021/ic50212a030; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DASILVA JRR, 1991, BIOL CHEM ELEMENTS, P396; Dieckmann GR, 1997, J AM CHEM SOC, V119, P6195, DOI 10.1021/ja964351i; ERIKSSON PO, 1993, J BIOMOL NMR, V3, P613; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GITSCHLER J, COMMUNICATION; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; Hausinger RP, 1996, MECH METALLOCENTER A; Hobman JL, 1997, MET IONS BIOL SYST, V34, P527; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KOCH SA, 1984, INORG CHEM, V23, P121, DOI 10.1021/ic00170a001; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIN SJ, 1997, J BIOL CHEM, V272, P9214; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PICKERING IJ, 1993, J AM CHEM SOC, V115, P9498, DOI 10.1021/ja00074a014; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; RiggsGelasco PJ, 1996, J AM CHEM SOC, V118, P2387, DOI 10.1021/ja9504496; SOLOMON EI, 1996, CHEM REV, V96, P2653; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; THORP HH, 1992, INORG CHEM, V31, P1585, DOI 10.1021/ic00035a012; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; Utschig LM, 1997, INORG CHEM, V36, P2926, DOI 10.1021/ic960571l; VALENTINE JS, 1994, BIOINORG CHEM, V1, P253; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Winge DR, 1997, J BIOL INORG CHEM, V2, P2, DOI 10.1007/s007750050100; WRIGHT JG, 1990, PROG INORG CHEM, V38, P323; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	37	582	596	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					853	856		10.1126/science.278.5339.853	http://dx.doi.org/10.1126/science.278.5339.853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346482				2022-12-28	WOS:A1997YD47900044
J	Stancovski, I; Baltimore, D				Stancovski, I; Baltimore, D			NF-kappa B activation: The I kappa B kinase revealed?	CELL			English	Review							PHOSPHORYLATION; UBIQUITINATION; DEGRADATION; PROTEINS; ALPHA				Stancovski, I (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MERCURIO F, 1997, SCIENCE, V281, P860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WORONICZ JD, 1997, SCIENCE, V281, P866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	19	451	470	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					299	302		10.1016/S0092-8674(00)80413-4	http://dx.doi.org/10.1016/S0092-8674(00)80413-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363938				2022-12-28	WOS:A1997YD94100003
J	Donaldson, GC; Keatinge, WR				Donaldson, GC; Keatinge, WR			Mortality related to cold weather in elderly people in southeast England, 1979-94	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT PHYSIOL,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London			Donaldson, Gavin/M-7992-2017	Donaldson, Gavin/0000-0002-5538-4190				DONALDSON GC, IN PRESS J EPIDEMIOL; KEATINGE WR, 1989, INT J BIOMETEOROL, V33, P71, DOI 10.1007/BF01686280; McDowall M, 1981, POPUL TRENDS, V26, P16	3	39	39	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1055	1056		10.1136/bmj.315.7115.1055	http://dx.doi.org/10.1136/bmj.315.7115.1055			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366732	Green Published			2022-12-28	WOS:A1997YD44500021
J	Hieter, P; Boguski, M				Hieter, P; Boguski, M			Functional genomics: It's all how you read it	SCIENCE			English	Editorial Material							GENE-EXPRESSION; STRATEGY		NIH,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Hieter, P (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED GENET,CTR MOL MED & THERAPEUT,VANCOUVER,BC V6T 124,CANADA.							DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1997, NAT GENET, V5, P325; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goodfellow P, 1997, NAT GENET, V16, P209, DOI 10.1038/ng0797-209; *HARV I HUM GEN, 1997, S GEN GEN THER MEAN; MCKUSICK V, IN PRESS GENOMICS; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Oliver S, 1996, TRENDS GENET, V12, P241, DOI 10.1016/0168-9525(96)30053-X; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	18	228	267	7	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					601	602		10.1126/science.278.5338.601	http://dx.doi.org/10.1126/science.278.5338.601			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381168				2022-12-28	WOS:A1997YC32300036
J	Orentlicher, D				Orentlicher, D			The Supreme Court and physician-assisted suicide - Rejecting assisted suicide but embracing euthanasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TERMINALLY ILL; CANCER		INDIANA UNIV,SCH LAW,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis								Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P206; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; Cherny N I, 1994, J Palliat Care, V10, P31; ENCK RE, 1994, MED CARE TERMINALLY, P166; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; Kamisar Yale, 1995, Univ Detroit Mercy Law Rev, V72, P735; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; Ramani S, 1996, SOUTH MED J, V89, P1101, DOI 10.1097/00007611-199611000-00017; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311	14	100	100	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1236	1239		10.1056/NEJM199710233371713	http://dx.doi.org/10.1056/NEJM199710233371713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB718	9340517				2022-12-28	WOS:A1997YB71800013
J	Resnick, NM; Marcantonio, ER				Resnick, NM; Marcantonio, ER			How should clinical care of the aged differ?	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; EFFICACY; THERAPY		HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA	Harvard University; Harvard Medical School	Resnick, NM (corresponding author), BRIGHAM & WOMENS HOSP,DIV GERONTOL,75 FRANCIS ST,BOSTON,MA 02115, USA.		Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008812, P60AG008812, P01AG004390] Funding Source: NIH RePORTER; NIA NIH HHS [AG-04390, AG-08812] Funding Source: Medline; NIDDK NIH HHS [DK-49482] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDUCCI L, 1991, J AM GERIATR SOC, V39, P1113, DOI 10.1111/j.1532-5415.1991.tb02879.x; Balducci L, 1992, Oncology (Williston Park), V6, P62; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CASSEL CK, 1997, GERIATRIC MED; Fries JF, 1981, VITALITY AGING; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; KAPOOR WN, 1997, GERIATRIC MED, P757; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LIPSITZ LA, 1983, ANN INTERN MED, V99, P92, DOI 10.7326/0003-4819-99-1-92; MOKSHAGUNDAM S, 1993, J AM GERIATR SOC, V41, P1361, DOI 10.1111/j.1532-5415.1993.tb06488.x; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; RESNICK NM, 1995, LANCET, V346, P94, DOI 10.1016/S0140-6736(95)92117-6; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SIVENIUS J, 1995, BMJ-BRIT MED J, V310, P25, DOI 10.1136/bmj.310.6971.25; Tinetti ME, 1997, GERIATRIC MED, P787	16	63	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1157	1158		10.1016/S0140-6736(05)63817-2	http://dx.doi.org/10.1016/S0140-6736(05)63817-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343515				2022-12-28	WOS:A1997YB19900043
J	KowenzLeutz, E; Herr, P; Niss, K; Leutz, A				KowenzLeutz, E; Herr, P; Niss, K; Leutz, A			The homeobox gene GBX2, a target of the myb oncogene, mediates autocrine growth and monocyte differentiation	CELL			English	Article							AVIAN LEUKEMIA VIRUSES; DNA-BINDING DOMAIN; HEMATOPOIETIC-CELLS; NF-M; MYELOID CELLS; C-MYB; TRANSCRIPTIONAL CONTROL; TRANSLOCATION PROTEIN; MOLECULAR-CLONING; PRE-B	The homeobox gene GBX2 was identified as a target gene of the v-Myb oncoprotein encoded by the avian myeloblastosis virus (AMV). GBX2 activation by c-Myb requires signal transduction emanating from the cell surface while the leukemogenic AMV v-Myb constitutively induces the GBX2 gene. Mutations in the DHA binding domain of AMV-Myb render it independent of signaling events and concomitantly abrogate the collaboration between Myb and CCAAT Enhancer Binding Proteins (C/EBP), which are involved in granulocyte differentiation. Ectopic expression of GBX2 in growth factor-dependent myeloblasts induces monocytic features and independence from exogenous cytokines, reflecting distinct features of AMV-transformed cells. Our results suggest that Myb or factors it interacts with contribute to hematopoietic lineage choice and differentiation in a signal transduction-dependent fashion.	MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BULFONE A, 1993, J NEUROSCI, V13, P3155; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; EWERT DL, 1984, J IMMUNOL, V132, P2524; FAINSOD A, 1989, FEBS LETT, V250, P381, DOI 10.1016/0014-5793(89)80760-4; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KAADEN OR, 1977, MED MICROBIOL IMMUN, V163, P157, DOI 10.1007/BF02126676; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEHRL JH, 1994, CRIT REV ONCOL HEMAT, V16, P145, DOI 10.1016/1040-8428(94)90046-9; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lipsick JS, 1996, ONCOGENE, V13, P223; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MOSCOVICI C, 1982, TRANSFORMATION HEMOP, V1; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERNECK E, 1992, MOL CELL BIOL, V12, P1728, DOI 10.1128/MCB.12.4.1728; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wolff L, 1997, BBA-REV CANCER, V1332, pF67, DOI 10.1016/S0304-419X(97)00006-1; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	48	87	88	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	1997	91	2					185	195		10.1016/S0092-8674(00)80401-8	http://dx.doi.org/10.1016/S0092-8674(00)80401-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346236	Bronze			2022-12-28	WOS:A1997YC35000006
J	Schwartz, SM; Siscovick, DS; Longstreth, WT; Psaty, BM; Beverly, RK; Raghunathan, TE; Lin, DY; Koepsell, TD				Schwartz, SM; Siscovick, DS; Longstreth, WT; Psaty, BM; Beverly, RK; Raghunathan, TE; Lin, DY; Koepsell, TD			Use of low-dose oral contraceptives and stroke in young women	ANNALS OF INTERNAL MEDICINE			English	Article						contraceptives, oral; cerebrovascular disorders; norgestrel; cerebrovascular hemorrhage; cerebral infarction	CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; PROGESTOGENS; MENOPAUSE; ESTROGEN; RISK	Background: Low-dose oral contraceptives are widely used, but there are limited data on the cerebrovascular risks associated with these medications. Objective: To determine whether use of low-dose oral contraceptives influences the risk for stroke. Design: Population-based case-control study. Setting: Women 18 to 44 years of age who resided in western Washington State between 1991 and 1995. Participants: Patients with ischemic stroke (n = 60). hemorrhagic stroke (n = 102), and other types of stroke (n = 11) and controls identified through random-digit dialing (n = 485). Measurements: Details about oral contraceptive use and other risk factors for stroke were obtained through in-person interviews. Results: The estimated incidences of hemorrhagic stroke and ischemic stroke were 6.4 and 4.3 per 100,000 women-years, respectively. Compared with women who had never used oral contraceptives (after adjustment for risk factors for stroke), current users of low-dose oral contraceptives had estimated odds ratios of 0.93 (95% Cl, 0.37 to 2.31) for hemorrhagic stroke and 0.89 (Cl, 0.27 to 2.94) for ischemic stroke. Compared with past users of oral contraceptives, current users had odds ratios of 1.41 (Cl, 0.67 to 2.96) for hemorrhagic stroke and 1.37 (Cl, 0.49 to 3.81) for ischemic stroke. For past users compared with never users, the odds ratios were 0.59 (Cl, 0.30 to 1.18) for hemorrhagic stroke and 0.57 (Cl, 0.25 to 1.32) for ischemic stroke. The odds ratio for hemorrhagic stroke in current users of low-dose oral contraceptives containing norgestrel or levonorgestrel was elevated (3.23 [Cl, 1.24 to 8.41]). Among patients with hemorrhagic stroke, the odds ratio for aneurysmal bleeding associated with current use of low-dose oral contraceptives containing norgestrel or levonorgestrel was 4.46 (Cl, 1.58 to 12.53). Conclusions: The overall risk for stroke and type of stroke was not increased among current users of low-dose oral contraceptives in the study population. Larger studies are needed to clarify both the relation of risk for stroke to past use of oral contraceptives and the possible association between current use of norgestrel-containing oral contraceptives and hemorrhagic stroke.	UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NICHD NIH HHS [HD-1-31-7] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1973, Lancet, V1, P1399; BOLOGNIA JL, 1989, MATURITAS, V11, P295, DOI 10.1016/0378-5122(89)90026-1; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; GANGAR KF, 1991, LANCET, V338, P839; GODSLAND IF, 1995, CONTRACEPTION, V52, P143, DOI 10.1016/0010-7824(95)00153-2; HARTGE P, 1984, AM J EPIDEMIOL, V120, P825, DOI 10.1093/oxfordjournals.aje.a113955; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; KAY CR, 1982, AM J OBSTET GYNECOL, V142, P762; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; MANN JI, 1975, BRIT MED J, V2, P245, DOI 10.1136/bmj.2.5965.245; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; MEADE TW, 1977, LANCET, V2, P948; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; PHILLIPS A, 1987, CONTRACEPTION, V36, P181, DOI 10.1016/0010-7824(87)90013-8; Poulter NR, 1996, LANCET, V348, P505; Poulter NR, 1996, LANCET, V348, P498; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; *ROYAL COLL GEN PR, 1977, LANCET, V2, P727; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1993, METHOD INFORM MED, V32, P222	23	93	96	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				596	+		10.7326/0003-4819-127-8_Part_1-199710150-00003	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341057				2022-12-28	WOS:A1997YB41900003
J	Davis, CL				Davis, CL			ABC of palliative care - Breathlessness, cough, and other respiratory problems	BRITISH MEDICAL JOURNAL			English	Article											Davis, CL (corresponding author), COUNTESS MOUNTBATTEN HOUSE,SOUTHAMPTON,HANTS,ENGLAND.								0	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					931	934						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361545				2022-12-28	WOS:A1997YB07300032
J	Howell, A; Dowsett, M				Howell, A; Dowsett, M			Recent advances in endocrine therapy of breast cancer	BRITISH MEDICAL JOURNAL			English	Review							PURE ANTIESTROGEN ICI-182780; TAMOXIFEN; WOMEN; POTENT		ROYAL MARSDEN HOSP, NHS TRUST, ACAD DEPT BIOCHEM, LONDON SW3 6JJ, ENGLAND	Royal Marsden NHS Foundation Trust	Howell, A (corresponding author), UNIV MANCHESTER, CHRISTIE HOSP NHS TRUST, CRC, DEPT MED ONCOL, MANCHESTER M20 4BX, LANCS, ENGLAND.			Howell, Anthony/0000-0002-6233-719X				Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BERGH J, 1997, P AN M AM SOC CLIN, V16, P156; Buzdar A, 1996, J CLIN ONCOL, V14, P2000, DOI 10.1200/JCO.1996.14.7.2000; BUZDAR A, 1997, P AN M AM SOC CLIN, V16, P156; CHANDER SK, 1991, CANCER RES, V51, P5851; COLE MP, 1971, BRIT J CANCER, V25, P270, DOI 10.1038/bjc.1971.33; COOMBES RC, 1992, EUR J CANCER, V28A, P1941; CUZICK J, 1985, LANCET, V2, P282; DEFRIEND DJ, 1994, BRIT J CANCER, V70, P204, DOI 10.1038/bjc.1994.281; DEFRIEND DJ, 1994, CANCER RES, V54, P408; DISALLE E, 1994, INT CONGR SER, V1064, P303; Dowsett M, 1996, BREAST, V5, P196, DOI 10.1016/S0960-9776(96)90093-4; DOWSETT M, 1996, EJC SUPPL, V32, P49; *EARL BREAST CANC, 1992, LANCET, V339, P1; Ellis PA, 1997, INT J CANCER, V72, P608, DOI 10.1002/(SICI)1097-0215(19970807)72:4<608::AID-IJC10>3.0.CO;2-7; GOSS P, 1997, P AN M AM SOC CLIN, V16, P155; HAYES DF, 1995, J CLIN ONCOL, V13, P2556, DOI 10.1200/JCO.1995.13.10.2556; HOWELL A, 1988, EUR J CANCER CLIN ON, V24, P1567, DOI 10.1016/0277-5379(88)90046-6; Howell A, 1996, BRIT J CANCER, V74, P300, DOI 10.1038/bjc.1996.357; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; LIPPMAN M, 1977, CANCER RES, V37, P1901; MARTY M, 1997, P AN M AM SOC CLIN, V16, P156; MILLER WR, 1990, J STEROID BIOCHEM, V37, P467, DOI 10.1016/0960-0760(90)90390-7; RAUSCHNING W, 1994, BREAST CANCER RES TR, V31, P83, DOI 10.1007/BF00689679; Sato M, 1994, J BONE MINER METAB, V12, pS9; SCHWARZEL WC, 1973, ENDOCRINOLOGY, V92, P866, DOI 10.1210/endo-92-3-866; SMITH I, 1996, EUR J CANCER, V32, P49; TOMINAGA T, 1995, 19 INT C CHEM MONTR; WAKELING AE, 1991, CANCER RES, V51, P3867	29	39	40	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					863	866		10.1136/bmj.315.7112.863	http://dx.doi.org/10.1136/bmj.315.7112.863			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353509	Green Published			2022-12-28	WOS:A1997YA00700029
J	Silverberg, SJ; Bone, HG; Marriott, TB; Locker, FG; ThysJacobs, S; Dziem, G; Kaatz, S; Sanguinetti, EL; Bilezikian, JP				Silverberg, SJ; Bone, HG; Marriott, TB; Locker, FG; ThysJacobs, S; Dziem, G; Kaatz, S; Sanguinetti, EL; Bilezikian, JP			Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MILD PRIMARY HYPERPARATHYROIDISM; POSTMENOPAUSAL WOMEN; DIPHOSPHONATE; DISODIUM; DENSITY; THERAPY	Background Surgery is the usual therapy for patients with primary hyperparathyroidism. We investigated the ability of a calcimimetic drug that inhibits parathyroid hormone secretion in vitro to decrease serum parathyroid hormone and calcium concentrations in patients with this disorder. Methods We performed a randomized, placebo-controlled study of single oral doses of 4 to 160 mg of the calcium-receptor agonist drug R-568 in 20 postmenopausal women with mild primary hyperparathyroidism. At base line, the mean (+/-SE) serum calcium concentration was 10.7+/-0.2 mg per deciliter (2.67+/-0.05 mmol per liter). Serum parathyroid hormone and calcium were measured repeatedly after each dose, and safety was assessed. Results Administration of R-568 resulted in a dose-dependent inhibition of parathyroid hormone secretion. The mean serum parathyroid hormone concentration, which was 77+/-11 pg per milliliter (18.8+/-2.7 pmol per liter; normal range, 16 to 65 pg per milliliter [3.9 to 15.9 pmol per liter]) at base line, fell by 26+/-8 percent after 20 mg of R-568 (P=0.03), by 42+/-7 percent after 80 mg (P=0.01), and by 51+/-5 percent after 160 mg (P=0.005). Serum ionized calcium concentrations fell only after the 160-mg dose, with the decrease closely following the decrease in the serum parathyroid hormone concentration. Conclusions The calcimimetic drug R-568 reduces serum parathyroid hormone and ionized calcium concentrations in postmenopausal women with primary hyperparathyroidism. (C) 1997, Massachusetts Medical Society.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; HENRY FORD HOSP,DETROIT,MI 48202; NPS PHARMACEUT,SALT LAKE CITY,UT; AMGEN INC,THOUSAND OAKS,CA	Columbia University; Henry Ford Health System; Henry Ford Hospital; Amgen	Silverberg, SJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032333] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00645] Funding Source: Medline; NIDDK NIH HHS [NIDDK 32333] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albright F, 1932, J CLIN INVEST, V11, P411, DOI 10.1172/JCI100423; BROADUS AE, 1983, J CLIN ENDOCR METAB, V56, P953, DOI 10.1210/jcem-56-5-953; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1991, J BONE MINER RES, V6, P1217; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CLARK O H, 1991, Journal of Bone and Mineral Research, V6, pS135; DOUGLAS DL, 1983, BRIT MED J, V286, P587, DOI 10.1136/bmj.286.6365.587; FOX J, 1993, J BONE MINER RES, V8, pS181; Grey AB, 1996, ANN INTERN MED, V125, P360, DOI 10.7326/0003-4819-125-5-199609010-00002; HEATH H, 1995, BONE S1, V16, pS85; Kleerekoper Michael, 1994, P471; LICATA AA, 1983, JAMA-J AM MED ASSOC, V249, P2063, DOI 10.1001/jama.249.15.2063; MARCUS R, 1984, ANN INTERN MED, V100, P633, DOI 10.7326/0003-4819-100-5-633; Nemeth Edward F., 1996, P1019; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; *NIH, 1991, J BONE MINER RES, V6, pS9; Norton Jeffrey A., 1994, P531; PARFITT A M, 1991, Journal of Bone and Mineral Research, V6, pS97; PURNELL DC, 1974, AM J MED, V56, P800, DOI 10.1016/0002-9343(74)90808-0; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; SCHMIDLI RS, 1990, CLIN ENDOCRINOL, V32, P293, DOI 10.1111/j.1365-2265.1990.tb00869.x; SELBY PL, 1986, NEW ENGL J MED, V314, P1481, DOI 10.1056/NEJM198606053142304; SHANE E, 1981, ANN INTERN MED, V95, P23, DOI 10.7326/0003-4819-95-1-23; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P723, DOI 10.1210/jc.80.3.723; Silverberg SJ, 1996, J CLIN ENDOCR METAB, V81, P2036, DOI 10.1210/jc.81.6.2036; SILVERBERG SJ, 1995, PRINCIPLES PRACTICE, P512; STEFFEY ME, 1993, J BONE MINER RES, V8, pS175; Stock John L., 1994, P519; VERNAVA AM, 1987, SURGERY, V102, P941; 1984, LANCET, V2, P727	30	217	221	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1506	1510		10.1056/NEJM199711203372104	http://dx.doi.org/10.1056/NEJM199711203372104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366582				2022-12-28	WOS:A1997YG24900004
J	Anderson, DM; Maraskovsky, E; Billingsley, WL; Dougall, WC; Tometsko, ME; Roux, ER; Teepe, MC; DuBose, RF; Cosman, D; Galibert, L				Anderson, DM; Maraskovsky, E; Billingsley, WL; Dougall, WC; Tometsko, ME; Roux, ER; Teepe, MC; DuBose, RF; Cosman, D; Galibert, L			A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; BIOLOGICAL CHARACTERIZATION; INTERLEUKIN-4 RECEPTOR; SUPERFAMILY; ACTIVATION; MURINE; PROTEINS; CLONING; CD40; LYMPHOCYTES	Dendritic cells are rare haematopoietic cells that reside in a number of organs and tissues. By capturing, processing and presenting antigens to T cells, dendritic cells are essential for immune surveillance and the regulation of specific immunity(1-4) Several members of the tumour necrosis factor receptor (TNFR) superfamily are integral to the regulation of the immune response. These structurally related proteins modulate cellular functions ranging from proliferation and differentiation to inflammation and cell survival or death(5,6). The functional activity of dendritic cells is greatly increased by signalling through the TNFR family member CD40 (refs 7, 8). Here we report the characterization of RANK (for receptor activator of NF-kappa B), a new member of the TNFR family derived from dendritic cells, and the isolation of a RANK ligand (RANKL) by direct expression screening. RANKL augments the ability of dendritic cells to stimulate naive T-cell proliferation in a mixed lymphocyte reaction, and increases the survival of RANK(+) T cells generated with interleukin-4 and transforming growth factor (TGF)-beta. Thus RANK and RANKL seem to be important regulators of interactions between T cells and dendritic cells.	IMMUNEX RES & DEV CORP, DEPT IMMUNOBIOL, SEATTLE, WA 98101 USA; IMMUNEX RES & DEV CORP, DEPT BIOINFORMAT, SEATTLE, WA 98101 USA		Anderson, DM (corresponding author), IMMUNEX RES & DEV CORP, DEPT MOL BIOL, 51 UNIV ST, SEATTLE, WA 98101 USA.			Dougall, William/0000-0001-9487-251X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; Austyn JM, 1996, J EXP MED, V183, P1287, DOI 10.1084/jem.183.4.1287; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baker SJ, 1996, ONCOGENE, V12, P1; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CAUX C, 1996, BLOOD CEL B, V7, P263; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; DEJONG R, 1994, INT IMMUNOL, V6, P631, DOI 10.1093/intimm/6.4.631; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; MADSEN M, 1980, J IMMUNOL METHODS, V33, P323, DOI 10.1016/0022-1759(80)90003-4; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; ROTHE M, 1995, SCIENCE, V269, P124; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5	30	1799	1943	4	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					175	179		10.1038/36593	http://dx.doi.org/10.1038/36593			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367155				2022-12-28	WOS:A1997YF49400055
J	BenArie, N; Bellen, HJ; Armstrong, DL; McCall, AE; Gordadze, PR; Guo, QX; Matzuk, MM; Zoghbi, HY				BenArie, N; Bellen, HJ; Armstrong, DL; McCall, AE; Gordadze, PR; Guo, QX; Matzuk, MM; Zoghbi, HY			Math1 is essential for genesis of cerebellar granule neurons	NATURE			English	Article							PRONEURAL GENE; NERVOUS-SYSTEM; MOUSE-BRAIN; MUTANT MICE; CELLS; EXPRESSION; PROTOONCOGENE; DELETION; PROTEIN; WNT-1	The cerebellum is essential for fine motor control of movement and posture, and its dysfunction disrupts balance and impairs control of speech, limb and eye movements. The developing cerebellum consists mainly of three types of neuronal cells: granule cells in the external germinal layer, Purkinje cells, and neurons of the deep nuclei(1). The molecular mechanisms that underlie the specific determination and the differentiation of each of these neuronal subtypes are unknown. Math1 (refs 2, 3), the mouse homologue of the Drosophila gene atonal(4), encodes a basic helix-loop-helix transcription factor that is specifically expressed in the precursors of the external germinal layer and their derivatives. Here we report that mice lacking Math1 fail to form granule cells and are born with a cerebellum that is devoid of an external germinal layer. To our knowledge, Math1 is the first gene to be shown to be required in vivo for the genesis of granule cells, and hence the predominant neuronal population in the cerebellum.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute			Ben-Arie, Nissim/K-4997-2012	Bellen, Hugo/0000-0001-5992-5989; Zoghbi, Huda/0000-0002-0700-3349				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; ALBRECHT U, 1997, VISUALIZATION GENE E, P23; ALTMAN J, 1996, DEV CEREBELLAR SYSTE; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HALLONET MER, 1993, EUR J NEUROSCI, V5, P1145, DOI 10.1111/j.1460-9568.1993.tb00969.x; Hatten ME, 1997, CURR OPIN NEUROBIOL, V7, P40, DOI 10.1016/S0959-4388(97)80118-3; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Heintz Nathaniel, 1993, V6, P19; His W., 1891, ABHANDLUNGEN KONI MP, V29, P1; JARMAN AP, 1995, DEVELOPMENT, V121, P2019; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; *MOUS GEN INF JACK, 1996, MOUS GEN DAT 3 1; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SMEYNE RJ, 1989, J NEUROSCI, V9, P1608; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; THOMAS KR, 1990, NATURE, V346, P845; TOHYAMA T, 1992, LAB INVEST, V66, P303; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; WURST W, 1994, DEVELOPMENT, V120, P2065; Yang XW, 1996, DEVELOPMENT, V122, P555; 1997, FRONTIERS BIOSCIENCE	29	505	520	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					169	172		10.1038/36579	http://dx.doi.org/10.1038/36579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367153				2022-12-28	WOS:A1997YF49400053
J	Inbal, B; Cohen, O; PolakCharcon, S; Kopolovic, J; Vadai, E; Eisenbach, L; Kimchi, A				Inbal, B; Cohen, O; PolakCharcon, S; Kopolovic, J; Vadai, E; Eisenbach, L; Kimchi, A			DAP kinase links the control of apoptosis to metastasis	NATURE			English	Article							LUNG-CARCINOMA; EXTRACELLULAR-MATRIX; CELLS; TUMORIGENESIS; SUPPRESSION; SELECTION; DEATH; GENE	DAP kinase is a new type of calcium/calmodulin-dependent enzyme that phosphorylates serine/threonine residues on proteins. Its structure contains ankyrin repeats and the 'death' domain, and it is associated with the cell cytoskeleton(1-3). The gene encoding DAP kinase was initially isolated as a positive mediator of apoptosis induced by interferon-gamma, by using a strategy of functional cloning(4). We have now tested whether this gene has tumour-suppressive activity We found that lung carcinoma clones, characterized by their highly aggressive metastatic behaviour and originating from two independent murine lung tumours, did not express DAP kinase, in contrast to their low-metastatic counterparts. Restoration of DAP kinase to physiological levels in high-metastatic Lewis carcinoma cells suppressed their ability to form lung metastases after intravenous injection into syngeneic mice, and delayed local tumour growth in a foreign 'microenvironment'. Conversely, in vivo selection of rare lung lesions following injection into syngeneic mice of low-metastatic Lewis carcinoma cells or of DAP kinase transfectants, was associated with loss of DAP kinase expression. In situ TUNEL staining of tumour sections revealed that DAP kinase expression from the transgene raised the incidence of apoptosis in vivo. DAP-kinase transfectants also showed increased sensitivity in vitro to apoptotic stimuli, of the sort encountered by metastasizing cells at different stages of malignancy. We propose that loss of DAP kinase expression provides a unique mechanism that links suppression of apoptosis to metastasis.	WEIZMANN INST SCI, DEPT MOL GENET, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; CHAIM SHEBA MED CTR, DEPT HISTOPATHOL, IL-52621 TEL HASHOMER, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center				Eisenbach, Lea R/0000-0002-4816-1968				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8; LAYTON MG, 1984, BRIT J CANCER, V49, P415, DOI 10.1038/bjc.1984.67; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nikiforov MA, 1996, ONCOGENE, V13, P1709; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WEISS L, 1992, CANCER METAST REV, V11, P227, DOI 10.1007/BF01307179; Xie KP, 1996, J LEUKOCYTE BIOL, V59, P797, DOI 10.1002/jlb.59.6.797; Yamauchi A, 1996, BLOOD, V87, P5127, DOI 10.1182/blood.V87.12.5127.bloodjournal87125127	30	341	362	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	1997	390	6656					180	184		10.1038/36599	http://dx.doi.org/10.1038/36599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367156				2022-12-28	WOS:A1997YF49400056
J	Asch, DA; Hershey, JC				Asch, DA; Hershey, JC			The three-salesmen conundrum in medicine	LANCET			English	Editorial Material							UNCERTAINTY; REGRET		VET AFFAIRS MED CTR,PHILADELPHIA,PA; UNIV PENN,WHARTON SCH,DEPT OPERAT & INFORMAT MANAGEMENT,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania				Asch, David/0000-0002-7970-286X				BELL DE, 1982, OPER RES, V30, P961, DOI 10.1287/opre.30.5.961; Glassman PA, 1997, ANN INTERN MED, V126, P152, DOI 10.7326/0003-4819-126-2-199701150-00011; LOOMES G, 1982, ECON J, V92, P805, DOI 10.2307/2232669	3	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1393	1394		10.1016/S0140-6736(97)04204-9	http://dx.doi.org/10.1016/S0140-6736(97)04204-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365467				2022-12-28	WOS:A1997YE87200049
J	Paszty, C; Brion, CM; Manci, E; Witkowska, HE; Stevens, ME; Mohandas, N; Rubin, EM				Paszty, C; Brion, CM; Manci, E; Witkowska, HE; Stevens, ME; Mohandas, N; Rubin, EM			Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease	SCIENCE			English	Article							BETA-S-GLOBINS; MOUSE MODEL; HIGH EXPRESSION; ALPHA-GLOBINS; GENE; THALASSEMIA; HYPOXIA; SAD	To create mice expressing exclusively human sickle hemoglobin (HbS), transgenic mice expressing human alpha-, gamma-, and beta(s)-globin were generated and bred with knockout mice that had deletions of the murine alpha- and beta-globin genes. These sickle cell mice have the major features (irreversibly sickled red cells, anemia, multiorgan pathology) found in humans with sickle cell disease and, as such, represent a useful in vivo system to accelerate the development of improved therapies for this common genetic disease.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DEPT SUBCELLULAR STRUCT, BERKELEY, CA 94720 USA; UNIV S ALABAMA, DOCTORS HOSP, CENTRALIZED PATHOL UNIT SICKLE CELL DIS, MOBILE, AL 36604 USA; CHILDRENS HOSP OAKLAND, RES INST, OAKLAND, CA 94609 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of South Alabama; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Paszty, C (corresponding author), UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, CTR HUMAN GENOME, 1 CYCLOTRON RD, MS 74-157, BERKELEY, CA 94720 USA.				NHLBI NIH HHS [N01-HB-07086, HL31579, HL20985] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB007086] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985, R01HL031579] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAUHAN PM, 1983, PATHOL ANNU, V18, P253; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P4894, DOI 10.1073/pnas.81.15.4894; DALAND GA, 1948, J LAB CLIN MED, V33, P1082; Embury SH, 1994, SICKLE CELL DIS BASI; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12155, DOI 10.1073/pnas.89.24.12155; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; Paszty C, 1997, Curr Opin Hematol, V4, P88; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; RUBIN EM, 1991, J CLIN INVEST, V87, P639, DOI 10.1172/JCI115041; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TRUDEL M, 1994, BLOOD, V84, P3189; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723	21	353	358	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					876	878		10.1126/science.278.5339.876	http://dx.doi.org/10.1126/science.278.5339.876			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346488	Green Submitted			2022-12-28	WOS:A1997YD47900050
J	Bugeja, G; Kumar, A; Banerjee, AK				Bugeja, G; Kumar, A; Banerjee, AK			Exclusion of elderly people from clinical research: a descriptive study of published reports	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BOLTON HOSP,DEPT MED ELDERLY,BOLTON BL4 0JR,ENGLAND	Royal Bolton Hospital								BELL J A, 1987, Drug Intelligence and Clinical Pharmacy, V21, P1002; MONFARDINI S, 1995, CANCER, V76, P333, DOI 10.1002/1097-0142(19950715)76:2<333::AID-CNCR2820760226>3.0.CO;2-I; WILLETTSBLOOM MC, 1992, J DIVORCE REMARRIAGE, V18, P3	3	149	150	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1059	1059		10.1136/bmj.315.7115.1059	http://dx.doi.org/10.1136/bmj.315.7115.1059			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366735	Green Published			2022-12-28	WOS:A1997YD44500025
J	Rudd, AG; Wolfe, CDA; Tilling, K; Beech, R				Rudd, AG; Wolfe, CDA; Tilling, K; Beech, R			Randomised controlled trial to evaluate early discharge scheme for patients with stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL DISCHARGE; CARE; MANAGEMENT; COMMUNITY; SERVICES; COSTS; STAY	Objective: To assess the clinical effectiveness of an early discharge policy for patients with stroke by using a community based rehabilitation team. Design: Randomised controlled trial to compare conventional care with an early discharge policy. Setting Two teaching hospitals in inner London. Subjects: 331 medically stable patients with stroke (mean age 71) who lived alone and were able to transfer independently or who lived with a resident carer and were able to transfer with help. Interventions: 167 patients received specialist community rehabilitation for up to 3 months after randomisation. 164 patients continued with conventional hospital and community care. Main outcome measures: Barthel score at 12 months. Secondary outcomes measured impairment with motoricity index, minimental state examination, and Frenchay aphasia screening test; disability with the Rivermead activity of daily living scales, hospital anxiety and depression scale, and 5 m walk; handicap with the Nottingham health profile; carer stress with caregiver strain index and patient and carer satisfaction. The main process measure was length of stay after randomisation. Results: One year after randomisation no significant differences in clinical outcomes were found apart from increased satisfaction with hospital care in the community therapy group. Length of stay after randomisation in the community therapy group was significantly reduced (12 v 18 days; P < 0.0001). Patients with impairments were more likely to receive treatment in the community therapy group. Conclusions: Early discharge with specialist community rehabilitation after stroke is feasible, as clinically effective as conventional care, and acceptable to patients. Considerable reductions in use of hospital beds are achievable.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, ST THOMAS HOSP, DIV PUBL HLTH SCI, LONDON SE1 7EH, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Rudd, AG (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, ST THOMAS HOSP, ELDERLY CARE UNIT, LONDON SE1 7EH, ENGLAND.		Tilling, Kate/AAY-1578-2021	Wolfe, Charles/0000-0001-8264-0981; Tilling, Kate/0000-0002-1010-8926				Aboderin I, 1996, J INTERN MED, V240, P173, DOI 10.1046/j.1365-2796.1996.39861000.x; ADLER MW, 1974, MED CARE, V12, P541, DOI 10.1097/00005650-197406000-00007; ADLER MW, 1978, J EPIDEMIOL COMMUN H, V32, P136, DOI 10.1136/jech.32.2.136; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Beech R, 1996, STROKE, V27, P1958, DOI 10.1161/01.STR.27.11.1958; BERGMAN L, 1995, STROKE, V26, P1830, DOI 10.1161/01.STR.26.10.1830; BROOTEN D, 1994, OBSTET GYNECOL, V84, P832; Clarke A, 1996, QUAL HEALTH CARE, V5, P172, DOI 10.1136/qshc.5.3.172; FORSTER A, 1992, BRIT MED J, V305, P1446, DOI 10.1136/bmj.305.6867.1446; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988; LINDLEY RI, 1995, AGE AGEING, V24, P525, DOI 10.1093/ageing/24.6.525; MARTIN F, 1994, AGE AGEING, V23, P228, DOI 10.1093/ageing/23.3.228; POUND P, 1995, BMJ-BRIT MED J, V311, P18, DOI 10.1136/bmj.311.6996.18; STOJCEVIC N, 1996, STROKE SERVICES RES; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544; WADE DT, 1985, LANCET, V1, P323; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; WADE DT, 1986, HOSP UPDATE, P427; WADE DT, 1994, HLTH CARE NEEDS ASSE, V1, P111; WOLFE CDA, 1993, J EPIDEMIOL COMMUN H, V47, P144, DOI 10.1136/jech.47.2.144; YOUNG J, 1994, BRIT MED J, V309, P1356, DOI 10.1136/bmj.309.6965.1356	23	141	144	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1039	1044		10.1136/bmj.315.7115.1039	http://dx.doi.org/10.1136/bmj.315.7115.1039			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366727	Green Published			2022-12-28	WOS:A1997YD44500015
J	Hughes, JB; Daily, GC; Ehrlich, PR				Hughes, JB; Daily, GC; Ehrlich, PR			Population diversity: Its extent and extinction	SCIENCE			English	Article							GENE FLOW; BIODIVERSITY	Genetically distinct populations are an important component of biodiversity. This work estimates the number of populations per area of a sample of species from literature on population differentiation and the average range area of a species from a sample of distribution maps. This yields an estimate of about 220 populations per species, or 1.1 to 6.6 billion populations globally. Assuming that population extinction is a linear function of habitat loss, approximately 1800 populations per hour (16 million annually) are being destroyed in tropical forests alone.			Hughes, JB (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.		Martiny, Jennifer/AAB-9323-2019	Martiny, Jennifer/0000-0002-2415-1247				ALLEN TB, 1983, FIELD GUIDE BIRDS N; BARROWCLOUGH GF, 1983, PERSPECTIVES ORNITHO; BROWN IL, 1980, OECOLOGIA, V47, P239, DOI 10.1007/BF00346827; Burt W., 1976, FIELD GUIDE MAMMALS, V3rd; Corbet G.B., 1992, P1; Daily GC, 1997, NATURES SERVICES SOC, DOI DOI 10.12987/9780300188479-039; EHRLICH PR, 1992, AMBIO, V21, P219; EHRLICH PR, 1993, AMBIO, V22, P64; ERWIN T L, 1982, Coleopterists Bulletin, V36, P74; *FAO UN, 1990, FOR RES ASS TROP COU; FRANCE R, 1992, AM NAT, V139, P342, DOI 10.1086/285330; Gaston K.J., 1994, RARITY, P1; Hammond P.M., 1995, GLOBAL BIODIVERSITY, P113; Hawksworth D. L, 1991, BIODIVERSITY MICROOR; KINGDON J, 1971, E AFRICAN MAMMALS A, V2; KINGDON J, 1971, E AFRICAN MAMMALS A, V3; LAVERY S, 1995, HEREDITY, V74, P531, DOI 10.1038/hdy.1995.75; Lawton J. H., 1995, EXTINCTION RATES; Lee DS, 1980, ATLAS N AM FRESHWATE; Legge JT, 1996, CONSERV BIOL, V10, P85, DOI 10.1046/j.1523-1739.1996.10010085.x; MAC ARTHUR ROBERT H., 1967; MYERS N, 1984, PRIMARY SOURCE; PAGEL MD, 1991, AM NAT, V137, P791, DOI 10.1086/285194; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; PIMM SL, 1995, P NATL ACAD SCI USA, V92, P9343, DOI 10.1073/pnas.92.20.9343; RAPPORT EH, 1982, AEROGRAPHY GEOGRAPHI; RASMUSSEN IR, 1992, OECOLOGIA, V89, P277, DOI 10.1007/BF00317228; RAVEN PH, 1985, FUTURIST, V19, P8; RAVEN PH, 1983, B ESA            SPR, P4; Ridgely R.S., 1989, BIRDS S AM, VI; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SCOTT JA, 1986, BUTTERFLIES N AM; Sinnott E. W., 1950, PRINCIPLES GENETICS; Tsukada E, 1982, BUTTERFLIES S E ASIA, VI; TSUKADA E, 1982, BUTTERFLIES S E ASIA, V4; TSUKADA E, 1982, BUTTERFLIES S E ASIA, V3; TSUKADA E, 1982, BUTTERFLIES S E ASIA, V2; Webb, 1984, BUTTERFLIES DORSET; WILSON E O, 1992; [No title captured]	40	331	354	3	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					689	692		10.1126/science.278.5338.689	http://dx.doi.org/10.1126/science.278.5338.689			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381179				2022-12-28	WOS:A1997YC32300055
J	Bandmann, O; Vaughan, J; Holmans, P; Marsden, CD; Wood, NW				Bandmann, O; Vaughan, J; Holmans, P; Marsden, CD; Wood, NW			Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease	LANCET			English	Article							POLYMERASE CHAIN-REACTION; 5'-FLANKING REGION; OXIDATIVE STRESS; GENE; POLYMORPHISM; SMOKING; SUSCEPTIBILITY; CARCINOGENS; EXPRESSION; METABOLISM	Background Epidemiological studies have identified positive family history and exposure to environmental toxins as risk factors for Parkinson's disease (PD). An inherited defect of xenobiotic metabolism could result in increased susceptibility to such toxins. We investigated the frequency of functionally relevant polymorphisms in six detoxification enzymes among patients with PD to elucidate the relation between these polymorphisms and the disease. Methods We obtained brain-tissue samples from 100 patients with apparently sporadic PD and blood samples from 100 living patients with familiar PD. For the control group, we extracted DNA from the tissue of 100 pathologically normal brains. The six enzymes analysed in these three groups were: CYP2D6, CYP2E1, NAD(P)H-menadione reductase, glutathione transferases M1 and T1, and N-acetyltransferase 2. We also investigated N-acetyltransferase 2 in 100 blood samples from patients with genetically proven Huntington's disease. We used PCR-based methods and restriction-enzyme analysis to detect polymorphisms. Findings The slow acetylator genotype for N-acetyltransferase 2 was more common in the familial PD group (69%) than in all controls (37%). Even after correction for multiple comparisons, this result remained highly significant (p=0.002) for familial PD compared with normal controls (odds ratio 3.79 [95% CI 2.08-6.90]) and compared with Huntington's disease (2.45 [1.37-4.38], p=0.004). The slow acetylator frequency for N-acetyltransferase 2 for sporadic PD was between that for Huntington's disease and familiar PD. The frequencies of all the other polymorphisms were similar in the two study groups and the normal control group. Interpretation We found an association between the slow acetylator genotype for N-acetyltransferase 2 and familial PD. Further studies are needed to investigate the biological relevance of these findings, but slow acetylation could lead to impaired ability of patients with familial PD to handle neurotoxic substances.	UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,LONDON WC1N 3BG,ENGLAND; UNIV WALES COLL MED,NEUROPSYCHIAT GENET UNIT,CARDIFF CF4 4XN,S GLAM,WALES	University of London; University College London; Cardiff University			Holmans, Peter/F-4518-2015; Wood, Nicholas W/C-2505-2009	Holmans, Peter/0000-0003-0870-9412; Wood, Nicholas W/0000-0002-9500-3348; Bandmann, Oliver/0000-0003-3149-0252				ARMSTRONG M, 1993, HUM GENET, V91, P616; ARMSTRONG M, 1992, LANCET, V339, P1017, DOI 10.1016/0140-6736(92)90537-D; Bandmann O, 1997, J NEUROL, V244, P262, DOI 10.1007/s004150050082; BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; Chen CL, 1996, PHARMACOGENETICS, V6, P187, DOI 10.1097/00008571-199604000-00005; DEXTER D, 1986, LANCET, V2, P639; DEXTER DT, 1994, ANN NEUROL, V35, P38, DOI 10.1002/ana.410350107; Diederich N, 1996, ANN NEUROL, V40, P463, DOI 10.1002/ana.410400319; Gibb W., 1989, DISORDERS MOVEMENT C, P33; HAYASHI S, 1991, J BIOCHEM-TOKYO, V110, P559, DOI 10.1093/oxfordjournals.jbchem.a123619; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; IGBOKWE E, 1993, E AFR MED J, V70, P807; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; LADERO JM, 1989, EUR J CLIN PHARMACOL, V37, P391, DOI 10.1007/BF00558506; LIN HJ, 1993, AM J HUM GENET, V52, P827; MARAGANORE DM, 1991, MOVEMENT DISORD, V6, P205, DOI 10.1002/mds.870060303; MONTOLIU C, 1995, J NEUROCHEM, V65, P2561; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; PAYAMI H, 1989, AM J HUM GENET, V45, P541; PETERS L, 1994, XENOBIOTICA, V24, P1013, DOI 10.3109/00498259409043298; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Rijk M. C., 1997, J NEUROL NEUROSUR PS, V62, P10, DOI DOI 10.1136/JNNP.62.1.10; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; ROSVOLD EA, 1995, PHARMACOGENETICS, V5, P199, DOI 10.1097/00008571-199508000-00003; SCHAPIRA AHV, 1994, MOVEMENT DISORD, V9, P125, DOI 10.1002/mds.870090202; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; Sies H, 1988, GLUTATHIONE CONJUGAT; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; SNYDER SH, 1986, NEUROLOGY, V36, P250, DOI 10.1212/WNL.36.2.250; TRAVER RD, 1992, CANCER RES, V52, P797; TSUNEOKA Y, 1993, J BIOCHEM, V114, P263, DOI 10.1093/oxfordjournals.jbchem.a124164; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; WATANABE J, 1994, J BIOCHEM-TOKYO, V116, P321, DOI 10.1093/oxfordjournals.jbchem.a124526; Wood N, 1997, J NEUROL NEUROSUR PS, V62, P305, DOI 10.1136/jnnp.62.4.305	36	108	111	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1136	1139		10.1016/S0140-6736(97)03495-8	http://dx.doi.org/10.1016/S0140-6736(97)03495-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343502				2022-12-28	WOS:A1997YB19900012
J	Law, MR; Morris, JK; Wald, NJ				Law, MR; Morris, JK; Wald, NJ			Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PASSIVE SMOKING; CIGARETTE-SMOKING; UNITED-STATES; RISK FACTOR; CARDIOVASCULAR-DISEASE; PUBLICATION BIAS; DIETARY PATTERNS; SERUM COTININE; BETA-CAROTENE; INFARCT SIZE	Objectives: To estimate the risk of ischaemic heart disease caused by exposure to environmental tobacco smoke and to explain why the associated excess risk is almost half that of smoking 20 cigarettes per day when the exposure is only about 1% that of smoking. Design: Meta-analysis of all 19 acceptable published studies of risk of ischaemic heart disease in lifelong non-smokers who live with a smoker and in those who live with a non-smoker, five large prospective studies of smoking and ischaemic heart disease, and studies of platelet aggregation and studies of diet according to exposure to tobacco smoke. Results: The relative risk of ischaemic heart disease associated with exposure to environmental tobacco smoke was 1.30 (95% confidence interval 1.22 to 1.38) at age 65. At the same age the estimated relative risk associated with smoking one cigarette per day was similar (1.39 (1.18 to 1.64)), while for 20 per day it was 1.78 (1.31 to 2.44). Two separate analyses indicated that non-smokers who live with smokers eat a diet that places them at a 6% higher risk of ischaemic heart disease, so the direct effect of environmental tobacco smoke is to increase risk by 23% (14% to 33%), since 1.30/1.06 = 1.23. Platelet aggregation provides a plausible and quantitatively consistent mechanism for the low dose effect. The increase in platelet aggregation produced experimentally by exposure to environmental tobacco smoke would be expected to have acute effects increasing the risk of ischaemic heart disease by 34%. Conclusion: Breathing other people's smoke is an important and avoidable cause of ischaemic heart disease, increasing a person's risk by a quarter.	ROYAL LONDON SCH MED, LONDON EC1M 6BQ, ENGLAND		Law, MR (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021; Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X; Pirich, Christian/0000-0002-4502-0609				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BLACHE D, 1992, ATHEROSCLEROSIS, V93, P179, DOI 10.1016/0021-9150(92)90254-E; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; CADE JE, 1991, J EPIDEMIOL COMMUN H, V45, P270, DOI 10.1136/jech.45.4.270; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; Ciruzzi M., 1996, European Heart Journal, V17, P309; CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784; DAVIS JW, 1985, CLIN PHARMACOL THER, V37, P529, DOI 10.1038/clpt.1985.83; DAVIS JW, 1989, ARCH INTERN MED, V149, P386, DOI 10.1001/archinte.149.2.386; DAVIS JW, 1982, CAN MED ASSOC J, V126, P637; DAVIS JW, 1986, BRIT J EXP PATHOL, V67, P765; DAVIS JW, 1981, ARCH INTERN MED, V141, P206, DOI 10.1001/archinte.141.2.206; DAVIS JW, 1985, J LAB CLIN MED, V105, P479; Denson KWE, 1996, LANCET, V348, P1663, DOI 10.1016/S0140-6736(05)65734-0; DIMINNO G, 1983, BLOOD, V61, P1081; DOBSON AJ, 1991, MED J AUSTRALIA, V154, P793, DOI 10.5694/j.1326-5377.1991.tb121366.x; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DOLL RICHARD, 1966, NAT CANCER INST MONOGR, V19, P205; ELWOOD PC, 1991, CIRCULATION, V83, P38, DOI 10.1161/01.CIR.83.1.38; EMMONS KM, 1995, EUR J CLIN NUTR, V49, P336; FEHILY AM, 1984, AM J CLIN NUTR, V40, P827, DOI 10.1093/ajcn/40.4.827; FITZGERALD GA, 1988, AM HEART J, V115, P267, DOI 10.1016/0002-8703(88)90648-5; FRIEDMAN GD, 1979, NEW ENGL J MED, V300, P213, DOI 10.1056/NEJM197902013000501; GARLAND C, 1985, AM J EPIDEMIOL, V121, P645, DOI 10.1093/aje/121.5.645; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; HAMMOND EC, 1958, JAMA-J AM MED ASSOC, V166, P1294, DOI 10.1001/jama.1958.02990110030007; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HE Y, 1994, BRIT MED J, V308, P380, DOI 10.1136/bmj.308.6925.380; HE Y, 1989, CHIN J PREV MED, V23, P19; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HIRAYAMA T, 1990, NZ MED J, V1, P54; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; HOWARD G, 1994, ARCH INTERN MED, V154, P1277; HUMBLE C, 1990, AM J PUBLIC HEALTH, V80, P599, DOI 10.2105/AJPH.80.5.599; Iso H, 1996, AM J EPIDEMIOL, V144, P1151, DOI 10.1093/oxfordjournals.aje.a008893; JARVINEN R, 1994, J EPIDEMIOL COMMUN H, V48, P549, DOI 10.1136/jech.48.6.549; JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335; KAHN HAROLD A., 1966, NAT CANCER INST MONOGR, V19, P1; Kawachi I, 1996, AM J EPIDEMIOL, V144, P909; Kawachi I, 1997, CIRCULATION, V95, P2374, DOI 10.1161/01.CIR.95.10.2374; KEITH RE, 1980, NUTR REP INT, V21, P907; KRITZ H, 1995, ARCH INTERN MED, V155, P1942, DOI 10.1001/archinte.155.18.1942; LARKIN FA, 1990, J AM DIET ASSOC, V90, P230; LAVECCHIA C, 1993, LANCET, V341, P505, DOI 10.1016/0140-6736(93)90271-H; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Law MR, 1997, BRIT J CANCER, V75, P1690, DOI 10.1038/bjc.1997.287; LAW MR, 1997, IN PRESS EUR J CLIN; LAYARD MW, 1995, REGUL TOXICOL PHARM, V21, P180, DOI 10.1006/rtph.1995.1022; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; LEE PN, 1992, ENV TOBACCO SMOKE MO; LEMARCHAND L, 1991, CANCER CAUSE CONTROL, V2, P11, DOI 10.1007/BF00052356; LEVOIS ME, 1995, REGUL TOXICOL PHARM, V21, P184, DOI 10.1006/rtph.1995.1023; MARGETTS BM, 1993, BMJ-BRIT MED J, V307, P1381, DOI 10.1136/bmj.307.6916.1381; MCPHILLIPS JB, 1994, J AM DIET ASSOC, V94, P287, DOI 10.1016/0002-8223(94)90370-0; MIDGETTE AS, 1993, AM J EPIDEMIOL, V137, P521, DOI 10.1093/oxfordjournals.aje.a116705; MUSCAT JE, 1995, INT J EPIDEMIOL, V24, P715, DOI 10.1093/ije/24.4.715; NUTTENS MC, 1992, J INTERN MED, V231, P349, DOI 10.1111/j.1365-2796.1992.tb00943.x; PENN A, 1993, CIRCULATION, V88, P1820, DOI 10.1161/01.CIR.88.4.1820; PENN A, 1994, CIRCULATION, V90, P1363, DOI 10.1161/01.CIR.90.3.1363; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; PRENTICE R C, 1989, Journal of the American College of Cardiology, V13, p124A; Roberts KA, 1996, CIRCULATION, V94, P2248, DOI 10.1161/01.CIR.94.9.2248; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; SANDLER DP, 1989, AM J PUBLIC HEALTH, V79, P163, DOI 10.2105/AJPH.79.2.163; SCHERER G, 1992, CLIN INVESTIGATOR, V70, P352; Schmid P, 1996, THROMB RES, V81, P451, DOI 10.1016/0049-3848(96)00017-5; SCHMIDT KG, 1984, THROMB HAEMOSTASIS, V51, P279; SIDNEY S, 1989, AM J EPIDEMIOL, V129, P1305, DOI 10.1093/oxfordjournals.aje.a115250; SMITH CB, 1993, BR J NUTR, V69, P315; Steenland K, 1996, CIRCULATION, V94, P622, DOI 10.1161/01.CIR.94.4.622; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; SUBAR AF, 1990, AM J PUBLIC HEALTH, V80, P1323, DOI 10.2105/AJPH.80.11.1323; SUN YP, 1994, CIRCULATION, V89, P2260, DOI 10.1161/01.CIR.89.5.2260; SVENDSEN KH, 1987, AM J EPIDEMIOL, V126, P783, DOI 10.1093/oxfordjournals.aje.a114715; THORNTON A, 1994, J CLIN EPIDEMIOL, V47, P1143, DOI 10.1016/0895-4356(94)90101-5; TRIBBLE DL, 1993, AM J CLIN NUTR, V58, P886, DOI 10.1093/ajcn/58.6.886; TUNSTALLPEDOE H, 1995, J EPIDEMIOL COMMUN H, V49, P139, DOI 10.1136/jech.49.2.139; WALD N, 1984, LANCET, V1, P1067; Wald NJ, 1997, BMJ-BRIT MED J, V314, P1860, DOI 10.1136/bmj.314.7098.1860; WALD NJ, 1984, LANCET, V1, P230; WALD NJ, 1981, LANCET, V2, P775; WELLS AJ, 1994, J AM COLL CARDIOL, V24, P546, DOI 10.1016/0735-1097(94)90315-8; Zhu BQ, 1996, AM HEART J, V132, P91, DOI 10.1016/S0002-8703(96)90395-6; ZHU BQ, 1993, J AM COLL CARDIOL, V21, P225, DOI 10.1016/0735-1097(93)90741-I; ZHU BQ, 1994, CIRCULATION, V89, P1282, DOI 10.1161/01.CIR.89.3.1282; Zondervan KT, 1996, INT J EPIDEMIOL, V25, P70, DOI 10.1093/ije/25.1.70	93	385	407	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	1997	315	7114					973	980		10.1136/bmj.315.7114.973	http://dx.doi.org/10.1136/bmj.315.7114.973			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365294	Green Published			2022-12-28	WOS:A1997YC30700018
J	Lovegrove, J; Valencia, O; Treasure, T; SherlawJohnson, C; Gallivan, S				Lovegrove, J; Valencia, O; Treasure, T; SherlawJohnson, C; Gallivan, S			Monitoring the results of cardiac surgery by variable life-adjusted display	LANCET			English	Article							OPEN-HEART-SURGERY; RISK STRATIFICATION	Background Conventional assessment of the outcome of cardiac surgery usually takes the form of retrospective mortality figures and, at best, indicates an average performance over time. Summary tables conceal good and bad runs, and without risk adjustment they are difficult to interpret. We developed a refinement of the cumulative sum method that weights death and survival by each patient's risk status and provides a display of surgical performance over time. Methods The variable life-adjusted (VLAD) plot shows the difference between expected and actual cumulative mortality. VLAD shows whether a surgeon's performance is above or below what might be expected. This mortality-scoring system accumulates penalties for each death and rewards for every survivor, based on the inherent risk of perioperative death of each case concerned. Findings We illustrate the results of three performance reviews, displayed as VLADs. The first shows the results of an individual surgeon for 547 consecutive cardiac-surgical cases. The overall mortality was 36% less than that predicted by the Parsonnet scoring system. The second displays the results for 5000 consecutive patients who underwent cardiopulmonary bypass between 1992 and 1996, divided into six contemporaneous series. The predicted mortality was 9% compared with 6% actual mortality. The third is a plot for a trainee surgeon and clearly shows how a period of poor performance was identified and then substantially improved, which would not have been revealed by conventional tables of summary statistics. Interpretation VLAD provides a graphical display of risk adjusted survival figures for individual surgeons or units over time and could be modified to monitor performance over a range of treatments and outcomes.	ST GEORGE HOSP, SCH MED, LONDON SW17 0RE, ENGLAND; UCL, DEPT STAT SCI, CLIN OPERAT RES UNIT, LONDON, ENGLAND	St Georges University London; University of London; University College London								DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; deLeval MR, 1997, LANCET, V349, P723, DOI 10.1016/S0140-6736(96)11327-1; LOVEGOVE J, 1997, HEART, V77, P18; NASHEF SAM, 1992, BRIT MED J, V305, P1066, DOI 10.1136/bmj.305.6861.1066; Parsonnet V., 1989, CIRCULATION S1, V779, P1; REESMOGG W, 1996, TIMES           0401; SPIEGELHALTER DJ, 1992, BRIT MED J, V305, P1500, DOI 10.1136/bmj.305.6867.1500-a; TREASURE T, 1994, LANCET, V344, P419, DOI 10.1016/S0140-6736(94)91763-9; TREASURE T, 1995, BRIT HEART J, V74, P11; Treasure T, 1997, INDEPENDENT REV ADUL; WILLIAMS SM, 1992, BRIT MED J, V304, P1359, DOI 10.1136/bmj.304.6838.1359	11	210	214	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1128	1130		10.1016/S0140-6736(97)06507-0	http://dx.doi.org/10.1016/S0140-6736(97)06507-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343500				2022-12-28	WOS:A1997YB19900010
J	Barr, FA; Puype, M; Vandekerckhove, J; Warren, G				Barr, FA; Puype, M; Vandekerckhove, J; Warren, G			GRASP65, a protein involved in the stacking of Golgi cisternae	CELL			English	Article							3-DIMENSIONAL ELECTRON-MICROSCOPY; CELL-FREE SYSTEM; VESICULAR TRANSPORT; NITRIC-OXIDE; APPARATUS; MEMBRANES; FRAGMENTS; NSF	NEM prevents mitotic reassembly of Golgi cisternae into stacked structures. The major target of NEM is a 65 kDa protein conserved from yeast to mammals. Antibodies to this protein and a recombinant form of it block cisternal stacking in a cell-free system, justifying its designation as a Golgi ReAssembly Stacking Protein (GRASP65). One of the two minor targets of NEM is GM130, previously implicated in the docking of transport vesicles and mitotic fragmentation of the Golgi stack. GRASP65 is complexed with GM130 and is tightly bound to Golgi membranes, even under mitotic conditions when both are heavily phosphorylated. These results link vesicle docking, stacking of Golgi cisternae, and the disruption of both of these interactions during mitosis.	FLANDERS INST BIOTECHNOL,DEPT BIOCHEM,B-9000 GHENT,BELGIUM	Flanders Institute for Biotechnology (VIB)	Barr, FA (corresponding author), IMPERIAL CANC RES FUND,CELL BIOL LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Barr, Francis/0000-0001-7518-253X				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMOS WB, 1968, J CELL BIOL, V38, P466, DOI 10.1083/jcb.38.2.466; Becker B, 1996, MICROBIOL REV, V60, P697, DOI 10.1128/MMBR.60.4.697-721.1996; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; CLUETT EB, 1992, J CELL SCI, V103, P773; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRANKE WW, 1972, Z ZELLFORSCH MIK ANA, V132, P365, DOI 10.1007/BF02450714; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; GOLGI C, 1898, ARCH ITAL BIOL, V30, P60; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MOLLENHAUER HH, 1966, ANN REV PLANT PHYSIO, V17, P27, DOI 10.1146/annurev.pp.17.060166.000331; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RAMBOURG A, 1993, ANAT REC, V237, P441, DOI 10.1002/ar.1092370402; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SAPPERSTEIN SK, 1996, J CELL BIOL, V132, P765; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WHALEY WG, 1976, GOLGI APPARATUS, V2	30	338	345	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					253	262		10.1016/S0092-8674(00)80407-9	http://dx.doi.org/10.1016/S0092-8674(00)80407-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346242	Bronze			2022-12-28	WOS:A1997YC35000012
J	Klein, MDS				Klein, MDS			The prison patient	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				648	649		10.7326/0003-4819-127-8_Part_1-199710150-00014	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341066				2022-12-28	WOS:A1997YB41900012
J	Law, MR; Hackshaw, AK				Law, MR; Hackshaw, AK			A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HORMONE-REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; LIFE-STYLE FACTORS; PHYSICAL-ACTIVITY; POSTMENOPAUSAL WOMEN; CALCIUM INTAKE; DIETARY CALCIUM; OLDER WOMEN; PERIMENOPAUSAL WOMEN; FOREARM FRACTURES	Objective: To determine the magnitude and importance of the relation between smoking, bone mineral density, and risk of hip fracture according to age. Design: Meta-analysis of 29 published cross sectional studies reporting the difference in bone density in 2156 smokers and 9705 non-smokers according to age, and of 19 cohort and case-control studies recording 3859 hip fractures reporting risk in smokers relative to non-smokers. Results: In premenopausal women bone density was similar in smokers and non-smokers. Postmenopausal bone loss was greater in current smokers than non-smokers, bone density diminishing by about an additional 2% for every 10 year increase in age, with a difference of 6% at age 80. In current smokers relative to non-smokers the risk of hip fracture was similar at age 50 but greater thereafter by an estimated 17% at age 60, 41% at 70, 71% at 80, and 108% at 90. These estimates of relative risk by age, derived directly from a regression analysis of the studies of smoking and hip fracture, were close to estimates using the difference in bone density between smokers and non-smokers and the association between bone density and risk of hip fracture. The estimated cumulative risk of hip fracture in women in England was 19% in smokers and 12% in non-smokers to age 85; 37% and 22% to age 90. Among all women, one hip fracture in eight is attributable to smoking. Limited data in men suggest a similar proportionate effect of smoking as in women. The association was not explained by smokers being thinner, younger at menopause, and exercising less nor by actions of smoking on oestrogen, but smoking may have a direct action on bone. Conclusions: Hip fracture in old age is a major adverse effect of smoking after the menopause. The cumulative excess bone loss over decades is substantial, increasing the lifetime risk of hip fracture by about half.	ROYAL LONDON SCH MED, LONDON EC1M 6BQ, ENGLAND		Law, MR (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL, DEPT ENVIRONM & PREVENT MED, WOLFSON INST PREVENT MED, LONDON EC1M 6BQ, ENGLAND.							BARON JA, 1995, J PHARMACOL EXP THER, V272, P151; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; Bennett N, 1995, HLTH SURVEY ENGLAND; CASSIDENTI DL, 1992, AM J OBSTET GYNECOL, V166, P1444, DOI 10.1016/0002-9378(92)91617-J; CHENG S, 1993, AGING-CLIN EXP RES, V5, P55, DOI 10.1007/BF03324127; CHENG SL, 1991, BONE MINER, V12, P123, DOI 10.1016/0169-6009(91)90041-W; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; CUMMING RG, 1994, AM J EPIDEMIOL, V139, P493, DOI 10.1093/oxfordjournals.aje.a117032; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DANIEL M, 1992, CALCIFIED TISSUE INT, V50, P300, DOI 10.1007/BF00301626; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; Egger P, 1996, J EPIDEMIOL COMMUN H, V50, P47, DOI 10.1136/jech.50.1.47; ENSRUD KE, 1994, J AM GERIATR SOC, V42, P481, DOI 10.1111/j.1532-5415.1994.tb04968.x; FEHILY AM, 1992, AM J CLIN NUTR, V56, P579, DOI 10.1093/ajcn/56.3.579; FORSEN L, 1994, J BONE MINER RES, V9, P1671; *GOV STAT SERV, 1994, HOSP EP STAT, V1; GRISSO JA, 1994, NEW ENGL J MED, V330, P1555, DOI 10.1056/NEJM199406023302202; Guthrie JR, 1996, GYNECOL ENDOCRINOL, V10, P199, DOI 10.3109/09513599609027989; Hansen M A, 1991, Osteoporos Int, V1, P95; HEMENWAY D, 1988, AM J PUBLIC HEALTH, V78, P1554, DOI 10.2105/AJPH.78.12.1554; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HOLLENBACH KA, 1993, AM J PUBLIC HEALTH, V83, P1265, DOI 10.2105/AJPH.83.9.1265; Hollo I, 1979, Aktuelle Gerontol, V9, P365; HOPPER JL, 1994, NEW ENGL J MED, V330, P387, DOI 10.1056/NEJM199402103300603; JAGLAL SB, 1993, AM J EPIDEMIOL, V138, P107, DOI 10.1093/oxfordjournals.aje.a116833; JENSEN GF, 1986, EUR J CLIN INVEST, V16, P239, DOI 10.1111/j.1365-2362.1986.tb01335.x; JENSEN J, 1988, AM J OBSTET GYNECOL, V159, P820, DOI 10.1016/S0002-9378(88)80144-3; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; JOHANSSON C, 1992, AGE AGEING, V21, P20, DOI 10.1093/ageing/21.1.20; JOHNELL O, 1984, CALCIFIED TISSUE INT, V36, P354, DOI 10.1007/BF02405345; JOHNELL O, 1995, J BONE MINER RES, V10, P1802, DOI 10.1002/jbmr.5650101125; Kiel DP, 1996, OSTEOPOROSIS INT, V6, P240, DOI 10.1007/BF01622741; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; KRALL EA, 1991, J BONE MINER RES, V6, P331; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; KREIGER N, 1986, AM J EPIDEMIOL, V123, P291, DOI 10.1093/oxfordjournals.aje.a114237; KREIGER N, 1992, INT J EPIDEMIOL, V21, P953, DOI 10.1093/ije/21.5.953; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; LAVECCHIA C, 1991, INT J EPIDEMIOL, V20, P671, DOI 10.1093/ije/20.3.671; Law MR, 1997, EUR J EPIDEMIOL, V13, P553, DOI 10.1023/A:1007389712487; LINDSAY R, 1981, OSTEOPOROSIS RECENT, P481; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MAY H, 1994, Q J MED, V87, P625; MAZESS RB, 1987, BONE MINER, V2, P211; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MCCULLOCH RG, 1990, CAN MED ASSOC J, V142, P221; MCDERMOTT MT, 1988, SOUTHERN MED J, V81, P477, DOI 10.1097/00007611-198804000-00017; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; MEYER HE, 1993, AM J EPIDEMIOL, V137, P1203, DOI 10.1093/oxfordjournals.aje.a116622; MICHAELSSON K, 1995, INT J EPIDEMIOL, V24, P771, DOI 10.1093/ije/24.4.771; NELSON HD, 1994, JAMA-J AM MED ASSOC, V272, P1825, DOI 10.1001/jama.272.23.1825; NGUYEN TV, 1994, J BONE MINER RES, V9, P1339; ORTEGOCENTENO N, 1994, CALCIFIED TISSUE INT, V55, P403, DOI 10.1007/BF00298551; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; RIEBEL GD, 1995, SPINE, V20, P2198, DOI 10.1097/00007632-199510001-00004; RUNDGREN A, 1984, MECH AGEING DEV, V28, P273, DOI 10.1016/0047-6374(84)90027-7; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SOWERS MR, 1985, AM J CLIN NUTR, V41, P1045, DOI 10.1093/ajcn/41.5.1045; SOWERS MR, 1992, J BONE MINER RES, V7, P647; VALIMAKI MJ, 1994, BMJ-BRIT MED J, V309, P230, DOI 10.1136/bmj.309.6949.230; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695	65	437	453	2	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	1997	315	7112					841	846		10.1136/bmj.315.7112.841	http://dx.doi.org/10.1136/bmj.315.7112.841			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353503	Green Published			2022-12-28	WOS:A1997YA00700021
J	Sidebotham, PP; Pearce, AV				Sidebotham, PP; Pearce, AV			Audit of child protection procedures in accident and emergency department to identify children at risk of abuse	BRITISH MEDICAL JOURNAL			English	Article									BATH & W COMMUNITY NHS TRUST,DEPT CHILD HLTH,BATH BA1 3QE,AVON,ENGLAND		Sidebotham, PP (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,AVON,ENGLAND.		Sidebotham, Peter D/E-3011-2010	Sidebotham, Peter D/0000-0003-4891-6926				*DEP HLTH, 1991, CHILD AB STUD INQ RE; PHILLIPS BM, 1992, ARCH DIS CHILD, V67, P560, DOI 10.1136/adc.67.4.560; SMITH J, 1995, AVON JOINT CHILD PRO	3	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					855	856		10.1136/bmj.315.7112.855	http://dx.doi.org/10.1136/bmj.315.7112.855			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353506	Green Published			2022-12-28	WOS:A1997YA00700024
